0Gene	Alteration_type	Alteration	Cancer	Drug	Response	Level	PMIDs	Cancervar_type	Evidence_type	Evidence_level
ABCB1	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Paclitaxel	Resistance	D	21883677	Lung	Therapeutic	D
ABCB1	MUT	I1145I	Breast Cancer		Better Outcome	B	22906996	Breast	Prognostic	B
ABCB1	MUT	I1145I	Lung Non-small Cell Carcinoma	Cisplatin,Carboplatin	Sensitivity/Response	B	22296372	Lung	Therapeutic	B
ABCB1	MUT	S893A	Breast Cancer		Better Outcome	B	22906996	Breast	Prognostic	B
ABCB1	MUT	S893T	Breast Cancer		Better Outcome	B	22906996	Breast	Prognostic	B
ABCB1	MUT	S893T	Ovarian Cancer	Paclitaxel	Sensitivity/Response	B	16467099	Ovary	Therapeutic	B
ABCC10	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Paclitaxel	Resistance	D	18445659	Lung	Therapeutic	D
ABCC3	CNV	AMPLIFICATION	Breast Cancer	Monomethyl Auristatin E,Paclitaxel	Resistance	D	18593940	Breast	Therapeutic	D
ABCG2	MUT	Q141K	Ovarian Cancer		Better Outcome	B	22112610	Ovary	Prognostic	B
ABL1	FUS	BCR-ABL A397P	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL	Acute Myeloid Leukemia	Imatinib	Resistance	D	12476305	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL	Acute Myeloid Leukemia	Imatinib	Sensitivity/Response	A	12476305	Blood;Bone_Marrow	Therapeutic	A
ABL1	FUS	BCR-ABL	Chronic Myeloid Leukemia	Imatinib	Sensitivity/Response	A	20537386	Blood;Bone_Marrow	Therapeutic	A
ABL1	FUS	BCR-ABL	Chronic Myeloid Leukemia	Nilotinib,Dasatinib	Sensitivity/Response	A	20537386	Blood;Bone_Marrow	Therapeutic	A
ABL1	FUS	BCR-ABL	Chronic Myeloid Leukemia		Positive	A	20537386	Blood;Bone_Marrow	Diagnostic	A
ABL1	FUS	BCR-ABL D276G	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL D276G	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL D276G	Chronic Myeloid Leukemia	Nilotinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Dasatinib	Reduced Sensitivity	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib	Resistance	D	15194504	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib	Resistance	D	15930265	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate,Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	C	19652056	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255K	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255V	Chronic Myeloid Leukemia	Bosutinib	Reduced Sensitivity	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	C	19652056	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E255V	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL E453A	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL E459K	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F311L	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317C	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317I	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317I	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Bosutinib	Reduced Sensitivity	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib	Reduced Sensitivity	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib	Resistance	B	18818391	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib	Resistance	B	19779040	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Ponatinib	Sensitivity/Response	B	25349473	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL F317L	Chronic Myeloid Leukemia	Ponatinib	Sensitivity/Response	D	24236021	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317S	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317V	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F317V	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	C	19652056	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359I	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Dasatinib	Reduced Sensitivity	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	C	19652056	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F359V	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL F486S	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F486S	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL F486S	Chronic Myeloid Leukemia	Nilotinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Bosutinib	Reduced Sensitivity	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Dasatinib	Reduced Sensitivity	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	B	17264298	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G250E	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G398R	Chronic Myeloid Leukemia	Dasatinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL G398R	Chronic Myeloid Leukemia	Nilotinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL H396P	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL H396R	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L248R	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L248R	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L248V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL L248V	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L248V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate,Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L248V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL L387F	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL L387F	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL L387F	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib	Sensitivity/Response	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Bosutinib	Reduced Sensitivity	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Dasatinib	Reduced Sensitivity	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib	Sensitivity/Response	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL M351T	Chronic Myeloid Leukemia	Nilotinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315A	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Acute Lymphocytic Leukemia	Dasatinib	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	21865346	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Bosutinib	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Dasatinib	Resistance	B	19779040	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib	Resistance	B	20537386	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib	Resistance	D	15194504	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib,Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate,Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL T315I	Chronic Myeloid Leukemia	Ponatinib	Sensitivity/Response	B	23190221	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Bosutinib	Reduced Sensitivity	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Resistance	C	19779040	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	B	22371878	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL V299L	Chronic Myeloid Leukemia	Nilotinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	17264298	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	C	19652056	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	B	17264298	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL Y253H	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	FUS	FOXP1-ABL1	Pediatric B-lymphoblastic Leukemia	Dasatinib	Sensitivity/Response	C	30938769	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	A344V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A350V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A365V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A366G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A380T	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A397P	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	A433T	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	any mutation	Chronic Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24382642,24131888	Blood;Bone_Marrow	Therapeutic	B
ABL1	FUS	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Imatinib, Ponatinib	Response	1	17496201, 24180494, 11287973, 24441288, 20131302, 21931113, 12200353	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	A
ABL1	FUS	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	FUS	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Asciminib	Response	3A		Blood;Bone_Marrow	Therapeutic	C
ABL1	FUS	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Nilotinib, Dasatinib, Imatinib, Bosutinib	Response	1	28095277, 28218239, 27217448, 11287973, 20525993, 29091516, 12637609, 20525995, 23502220, 11287972	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	C475V	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	D276G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	D363Y	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255K	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	E255K	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	E255K	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255K	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255K	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255V	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	E255V	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	E255V	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255V	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E255V	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E258D	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E275K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E275Q	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E279K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E292Q	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E292V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E292V	Chronic Myeloid Leukemia	Nilotinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	E355A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E355D	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E355G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E373K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E450A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E450G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E450K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E450V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E453A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E453G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E453K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E453V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E459A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E459G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E459K	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E459V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	E507G	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F311I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F311L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317C	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F317C	Chronic Myelogenous Leukemia	Nilotinib, Bosutinib	Response	2A	15930265, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F317C	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317C	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317C	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317C	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317I	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F317I	Chronic Myelogenous Leukemia	Nilotinib, Bosutinib	Response	2A	15930265, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F317I	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317I	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317I	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317L	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F317L	Chronic Myelogenous Leukemia	Nilotinib, Bosutinib	Response	2A	15930265, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F317L	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317L	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317L	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317V	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F317V	Chronic Myelogenous Leukemia	Nilotinib, Bosutinib	Response	2A	15930265, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F317V	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317V	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F317V	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359C	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F359C	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F359C	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359C	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359C	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359C	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359I	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F359I	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F359I	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359I	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359I	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359V	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	F359V	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	F359V	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359V	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F359V	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F382L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	F486S	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	G250E	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	G250R	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	G321L	lung adenocarcinoma	Dasatinib	sensitive	Preclinical	26758680	Lung	Therapeutic	D
ABL1	MUT	G321L	lung adenocarcinoma	Imatinib	sensitive	Preclinical	26758680	Lung	Therapeutic	D
ABL1	MUT	G340L	Lung Non-small Cell Carcinoma	Dasatinib,Imatinib Mesylate	Sensitivity/Response	D	26758680	Lung	Therapeutic	D
ABL1	MUT	H396A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	H396P	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	H396R	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	I242T	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	I293V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	I418S	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	I418V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	K247R	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L248V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L273M	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L298V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L324Q	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L364I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L370P	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L384M	Chronic Myeloid Leukemia	Dasatinib	Resistance	C	19779040	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	L384M	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L384M	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	L387F	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L387M	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	L387V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M237V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M244V	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M343T	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M351T	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M388L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	M472I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	N336S	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	P480L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Q252H	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	15705718	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	Q252H	Chronic Myeloid Leukemia	Dasatinib	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	Q252H	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	D	16772610	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	Q252H	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Q252H	Chronic Myeloid Leukemia	Imatinib	Sensitivity/Response	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	Q252R	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Q300R	Chronic Myeloid Leukemia	Imatinib Mesylate	Resistance	C	22371878	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	R332W	lung adenocarcinoma	Dasatinib	sensitive	Preclinical	26758680	Lung	Therapeutic	D
ABL1	MUT	R332W	lung adenocarcinoma	Imatinib	sensitive	Preclinical - Cell line xenograft	26758680	Lung	Therapeutic	D
ABL1	MUT	R351W	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	26758680	Lung	Therapeutic	D
ABL1	MUT	R351W	Lung Non-small Cell Carcinoma	Imatinib	Sensitivity/Response	D	26758680	Lung	Therapeutic	D
ABL1	MUT	S417F	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	S417Y	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	S438C	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T277A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315A	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Bosutinib	Response	2A	15071128, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	T315A	Chronic Myelogenous Leukemia	Nilotinib, Bosutinib	Response	2A	15930265, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	T315A	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315A	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315A	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Any cancer type	Axitinib	Responsive	Pre-clinical	25686603	Cancer	Therapeutic	D
ABL1	MUT	T315I	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib, Dasatinib, Imatinib, Bosutinib	Resistant	R1	17768119, 18403620	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	A
ABL1	MUT	T315I	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib	Response	1	23044928, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	A
ABL1	MUT	T315I	Chronic Myelogenous Leukemia	Nilotinib, Dasatinib, Imatinib, Bosutinib	Resistant	R1	17768119, 18403620	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic Myelogenous Leukemia	Ponatinib	Response	1	24180494, 23190221, 19878872	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic myeloid leukemia;Acute lymphoblastic leukemia	Ponatinib	Responsive	FDA guidelines	FDA	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24382642,24131888	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	T315I	Chronic myeloid leukemia	Bosutinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic myeloid leukemia	[Nilotinib,Dasatinib]	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	T315I	Chronic myeloid leukemia	Ponatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V280A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V289A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V289I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V299L	Any cancer type	Cabozantinib	Responsive	Pre-clinical	26924578	Cancer	Therapeutic	D
ABL1	MUT	V299L	Any cancer type	Crizotinib	Responsive	Pre-clinical	26924578	Cancer	Therapeutic	D
ABL1	MUT	V299L	Any cancer type	ForetinibÂ 	Responsive	Pre-clinical	26924578	Cancer	Therapeutic	D
ABL1	MUT	V299L	Any cancer type	Vandetanib	Responsive	Pre-clinical	26924578	Cancer	Therapeutic	D
ABL1	MUT	V299L	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib	Response	2A	15071128	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	V299L	Chronic Myelogenous Leukemia	Nilotinib	Response	2A	15930265, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	V299L	Chronic myeloid leukemia	Dasatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V299L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V299L	Chronic myeloid leukemia	Nilotinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V371A	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	V379I	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	W261L	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y253F	Chronic Myeloid Leukemia	Imatinib	Resistance	C	15930265	Blood;Bone_Marrow	Therapeutic	C
ABL1	MUT	Y253F	Chronic Myeloid Leukemia	Imatinib	Resistance	D	19075254	Blood;Bone_Marrow	Therapeutic	D
ABL1	MUT	Y253F	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y253H	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib, Bosutinib	Response	2A	25368968, 19075254	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ABL1	MUT	Y253H	Chronic Myelogenous Leukemia	Dasatinib, Bosutinib	Response	2A	15930265, 19779040, 28599428, 19075254	Blood;Bone_Marrow	Therapeutic	B
ABL1	MUT	Y253H	Chronic myeloid leukemia	Bosutinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y253H	Chronic myeloid leukemia	Dasatinib	Responsive	NCCN guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y253H	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y253H	Chronic myeloid leukemia	Nilotinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y320C	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y342H	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ABL1	MUT	Y393C	Chronic myeloid leukemia	Imatinib	Resistant	European LeukemiaNet guidelines	21562040	Blood;Bone_Marrow	Therapeutic	A
ACTA1	EXP	EXPRESSION	Lung Adenocarcinoma		Poor Outcome	B	26950277	Lung	Prognostic	B
ACVR1	MUT	G328E	Diffuse Intrinsic Pontine Glioma		Positive	C	24705252	Brain	Diagnostic	C
ACVR1	MUT	G328V	Diffuse Intrinsic Pontine Glioma		Positive	B	24705250	Brain	Diagnostic	B
ACVR1	MUT	G328V	Diffuse Intrinsic Pontine Glioma		Positive	B	24705254	Brain	Diagnostic	B
ACVR1	MUT	Gain-of-Function	Astrocytoma		Positive	B	24705250	Brain	Diagnostic	B
AGR2	EXP	EXPRESSION	Breast Cancer	Tamoxifen	Resistance	B	24167368	Breast	Therapeutic	B
AKT1	CNV	amp	Advanced Solid Tumor	ONC201	predicted - sensitive	Preclinical - Cell line xenograft	23390247	Other	Therapeutic	D
AKT1	MUT	E17K	Adenocarcinoma/Carcinoma in Breast/Endometrium/Prostate/Lung/Ovary/Colon/Rectum			2	12094235,22025159	Breast;Colorectal;Lung;Ovary;Prostate;Uterus	Therapeutic	C
AKT1	MUT	E17K	Advanced Solid Tumor	BAY1125976	no benefit	Phase I	;	Other	Therapeutic	C
AKT1	MUT	E17K	Advanced Solid Tumor	Capivasertib	sensitive	Phase I	26931343;	Other	Therapeutic	C
AKT1	MUT	E17K	Advanced Solid Tumor	Capivasertib	sensitive	Phase II	30429128	Other	Therapeutic	C
AKT1	MUT	E17K	anal canal cancer	BAY1125976	sensitive	Preclinical - Pdx	27699769;	Other	Therapeutic	D
AKT1	MUT	E17K	Any cancer type	[AKT inhibitor]	Responsive	Pre-clinical	21464312;17611497;23134728; ENA 2015 (abstr B109)	Cancer	Therapeutic	D
AKT1	MUT	E17K	Any cancer type	[allosteric AKT inhibitor]	Responsive	Early trials	ENA 2015 (abstract B109);28489509	Cancer	Therapeutic	C
AKT1	MUT	E17K	Any cancer type	[non-allosteric AKT inhibitor]	Responsive	Early trials	ENA 2015 (abstract B109);28489509	Cancer	Therapeutic	C
AKT1	MUT	E17K	Breast Cancer	AZD5363	Response	3A	22294718, 23394218, 28489509, 26351323	Breast	Therapeutic	C
AKT1	MUT	E17K	Breast Cancer	AZD5363	Sensitivity/Response	C	26351323	Breast	Therapeutic	C
AKT1	MUT	E17K	breast cancer	BAY1125976	sensitive	Preclinical - Pdx	27699769	Breast	Therapeutic	D
AKT1	MUT	E17K	breast cancer	Capivasertib	sensitive	Case Reports/Case Series	28489509	Breast	Therapeutic	D
AKT1	MUT	E17K	breast cancer	Capivasertib	sensitive	Preclinical	26351323	Breast	Therapeutic	D
AKT1	MUT	E17K	breast cancer	MK2206	no benefit	Phase II	31277699	Breast	Therapeutic	C
AKT1	MUT	E17K	breast papillary carcinoma	Capivasertib	sensitive	Phase I	26351323	Breast	Therapeutic	C
AKT1	MUT	E17K	Cancer	AZD-5363	Sensitivity/Response	B	28489509	Cancer	Therapeutic	B
AKT1	MUT	E17K	cancer	Uprosertib	sensitive	Preclinical	24978597	Cancer	Therapeutic	D
AKT1	MUT	E17K	cervical cancer	Capivasertib	predicted - sensitive	Case Reports/Case Series	28489509	Cervix	Therapeutic	D
AKT1	MUT	E17K	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	24265152	Skin	Therapeutic	D
AKT1	MUT	E17K	endometrial adenocarcinoma	Capivasertib	predicted - sensitive	Phase II	30429128	Uterus	Therapeutic	C
AKT1	MUT	E17K	endometrial cancer	ARQ 751	sensitive	Preclinical - Cell line xenograft	26469692	Uterus	Therapeutic	D
AKT1	MUT	E17K	Endometrial Cancer	AZD5363	Response	3A	22294718, 23394218, 28489509, 26351323	Uterus	Therapeutic	C
AKT1	MUT	E17K	endometrial cancer	Capivasertib	predicted - sensitive	Case Reports/Case Series	28489509	Uterus	Therapeutic	D
AKT1	MUT	E17K	endometrial cancer	Miransertib	sensitive	Preclinical - Cell line xenograft	26469692	Uterus	Therapeutic	D
AKT1	MUT	E17K	Endometrium	Tensirolimus	Responsive	Early trials	27016228	Uterus	Therapeutic	C
AKT1	MUT	E17K	estrogen-receptor mutation breast cancer	Capivasertib	predicted - sensitive	Phase I	28489509	Breast	Therapeutic	C
AKT1	MUT	E17K	granulosa cell tumor	Capivasertib	sensitive	Case Reports/Case Series	28489509	Ovary	Therapeutic	D
AKT1	MUT	E17K	Head an neck squamous	[PI3K pathway inhibitor]	Responsive	Case report	26763254	Head_and_Neck	Therapeutic	D
AKT1	MUT	E17K	Her2-receptor negative breast cancer	Capivasertib	predicted - sensitive	Phase II	30429128	Breast	Therapeutic	C
AKT1	MUT	E17K	Her2-receptor negative breast cancer	Ipatasertib	sensitive	Phase I	27872130	Breast	Therapeutic	C
AKT1	MUT	E17K	lung adenocarcinoma	Capivasertib	predicted - sensitive	Case Reports/Case Series	28489509	Lung	Therapeutic	D
AKT1	MUT	E17K	Melanoma	GSK2141795	Sensitivity/Response	D	24735930	Skin	Therapeutic	D
AKT1	MUT	E17K	melanoma	Uprosertib	sensitive	Preclinical - Cell culture	24735930	Skin	Therapeutic	D
AKT1	MUT	E17K	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
AKT1	MUT	E17K	meningothelial meningioma	Capivasertib	predicted - sensitive	Case Reports/Case Series	28376212	Nervous_System	Therapeutic	D
AKT1	MUT	E17K	Ovarian Cancer	AZD5363	Response	3A	22294718, 23394218, 28489509, 26351323	Ovary	Therapeutic	C
AKT1	MUT	E17K	ovarian carcinoma	Miransertib	predicted - sensitive	Case Reports/Case Series	31058421	Ovary	Therapeutic	D
AKT1	MUT	E17K	ovarian endometrial cancer	Capivasertib	sensitive	Phase I	26351323	Ovary	Therapeutic	C
AKT1	MUT	E17K	parotid gland cancer	Capivasertib	predicted - sensitive	Phase II	30429128	Other	Therapeutic	C
AKT1	MUT	E17K	triple-receptor negative breast cancer	Capivasertib	predicted - sensitive	Case Reports/Case Series	28489509	Breast	Therapeutic	D
AKT1	MUT	E17K	Uterus leiomyosarcoma	Capivasertib	predicted - sensitive	Phase II	30429128	Uterus;Soft_Tissue	Therapeutic	C
AKT1	MUT	Gain-of-Function	Advanced Solid Tumor	Triciribine	no benefit	Phase I	20644979	Other	Therapeutic	C
AKT1	MUT	Gain-of-Function	lymphoma	Doxorubicin	decreased response	Preclinical - Cell line xenograft	18708578	Lymph_Nodes	Therapeutic	D
AKT1	MUT	Gain-of-Function	lymphoma	Doxorubicin + Sirolimus	predicted - sensitive	Preclinical - Cell line xenograft	18708578	Lymph_Nodes	Therapeutic	D
AKT1	MUT	Gain-of-Function	lymphoma	Sirolimus	no benefit	Preclinical - Cell line xenograft	18708578	Lymph_Nodes	Therapeutic	D
AKT1	MUT	H238Y	Fibrous histiocytoma	Everolimus	Responsive	Case report	ASCO 2015 (abstr 11010)	Eye	Therapeutic	D
AKT1	MUT	mutant	endometrial cancer	GDC-0980	sensitive	Phase II	;	Uterus	Therapeutic	C
AKT1	MUT	mutant	endometrial cancer	Temsirolimus	predicted - sensitive	Phase II	27016228	Uterus	Therapeutic	C
AKT1	MUT	mutant	invasive bladder transitional cell carcinoma	Cisplatin + Gemcitabine + Sorafenib	predicted - resistant	Phase II	;	Bladder	Therapeutic	C
AKT1	MUT	mutant	triple-receptor negative breast cancer	Capivasertib + Paclitaxel	predicted - sensitive	Phase II	30715161	Breast	Therapeutic	C
AKT1	MUT	mutant	triple-receptor negative breast cancer	Ipatasertib + Paclitaxel	predicted - sensitive	Phase II	;	Breast	Therapeutic	C
AKT1	MUT	mutation	ovarian clear cell carcinoma	Cisplatin + Perifosine	predicted - sensitive	Preclinical - Cell culture	25519148	Ovary	Therapeutic	D
AKT1	MUT	mutation	ovarian clear cell carcinoma	Perifosine	predicted - sensitive	Preclinical - Cell line xenograft	25519148	Ovary	Therapeutic	D
AKT1	MUT	P68_C77dup	breast cancer	Capivasertib	sensitive	Preclinical - Cell culture	29247016	Breast	Therapeutic	D
AKT1	MUT	Q79K	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	24265152	Skin	Therapeutic	D
AKT1	MUT	Q79K	Melanoma	Dabrafenib	Resistance	C	24265155	Skin	Therapeutic	C
AKT1	MUT	Q79K	Melanoma	Vemurafenib	Resistance	D	24265152	Skin	Therapeutic	D
AKT1	MUT	Q79K	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
AKT1	MUT	Q79K	ovarian cancer	Capivasertib	predicted - sensitive	Case Reports/Case Series	28489509	Ovary	Therapeutic	D
AKT1	MUT	W80A	Advanced Solid Tumor	MK2206	resistant	Preclinical - Cell culture	25856301	Other	Therapeutic	D
AKT1	MUT	W80A	breast cancer	MK2206	resistant	Preclinical	25551293	Breast	Therapeutic	D
AKT1	MUT	WILDTYPE	cancer	Uprosertib	sensitive	Preclinical	23795919	Cancer	Therapeutic	D
AKT1	MUT	WILDTYPE	clear cell renal cell carcinoma	Everolimus + RX-0201	sensitive	Phase Ib/II	;	Kidney	Therapeutic	C
AKT1	MUT	WILDTYPE	ovarian cancer	Uprosertib	predicted - sensitive	Phase I	26429956	Ovary	Therapeutic	C
AKT2	CNV	amplification	Any cancer type	MK2206	Responsive	Pre-clinical	ENA 2014 (abstr 373)	Cancer	Therapeutic	D
AKT2	CNV	AMPLIFICATION	Lung Adenocarcinoma	Vandetanib,Everolimus	Sensitivity/Response	C	25982012	Lung	Therapeutic	C
AKT2	EXP	EXPRESSION	Breast Cancer	Trastuzumab	Sensitivity/Response	B	22842582	Breast	Therapeutic	B
AKT3	EXP	OVEREXPRESSION	Breast Cancer	MK-2206	Resistance	D	27297869	Breast	Therapeutic	D
AKT3	EXP	OVEREXPRESSION	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
AKT3	EXP	OVEREXPRESSION	Triple-receptor Negative Breast Cancer	AKT3 Inhibitor	Sensitivity/Response	E	24335962	Breast	Therapeutic	D
AKT3	MUT	E17K	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
ALCAM	EXP	EXPRESSION	Colorectal Cancer	5-fluorouracil	Resistance	B	24708484	Colorectal	Therapeutic	B
ALDH1A2	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma		Better Outcome	B	23635773	Head_and_Neck	Prognostic	B
ALDH1A2	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma		Better Outcome	B	26634247	Head_and_Neck	Prognostic	B
ALDH1A2	EXP	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	All-trans Retinoic Acid	Sensitivity/Response	D	26634247	Head_and_Neck	Therapeutic	D
ALK	CNV	amplification	Lung adenocarcinoma	Brigatinib	Responsive	Case report	ASCO 2017 (abstr 9065)	Lung	Therapeutic	D
ALK	CNV	amplification	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784	Lung	Therapeutic	D
ALK	CNV	amplification	Non-small cell lung	Crizotinib	Resistant	Clinical trials	22235099	Lung	Therapeutic	C
ALK	CNV	amp	neuroblastoma	CEP-28122	sensitive	Preclinical - Cell culture	22203728	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	CNV	amp	neuroblastoma	Crizotinib	sensitive	Preclinical - Cell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	CNV	amp	neuroblastoma	Lorlatinib	sensitive	Preclinical - Cell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	FUS	ALK FUSION	Anaplastic Thyroid Carcinoma	Crizotinib	Sensitivity/Response	C	24687827	Thyroid	Therapeutic	C
ALK	FUS	ALK FUSION F1245C	Cancer	Crizotinib	Resistance	D	22034911	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	C	26775591	Lung	Therapeutic	C
ALK	FUS	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	26775591	Lung	Therapeutic	C
ALK	FUS	ALK FUSION G1202R	Cancer	Alectinib	Resistance	D	25727400	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION G1202R	Cancer	Brigatinib	Resistance	D	25727400	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION G1202R	Lung Adenocarcinoma	Crizotinib	Resistance	C	22277784	Lung	Therapeutic	C
ALK	FUS	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	17-AAG	Sensitivity/Response	D	22277784	Lung	Therapeutic	D
ALK	FUS	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	Ceritinib	Resistance	D	24675041	Lung	Therapeutic	D
ALK	FUS	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	ALK FUSION G1269A	Cancer	Alectinib	Resistance	D	25727400	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION G1269A	Cancer	Brigatinib	Sensitivity/Response	D	25727400	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION G1269A	Cancer	Ceritinib	Sensitivity/Response	D	25727400	Cancer	Therapeutic	D
ALK	FUS	ALK FUSION G1269A	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	D	24675041	Lung	Therapeutic	D
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Alectinib	Resistance	C	25228534	Lung	Therapeutic	C
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Alectinib	Resistance	C	25736571	Lung	Therapeutic	C
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	C	25228534	Lung	Therapeutic	C
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	C	25736571	Lung	Therapeutic	C
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	D	24675041	Lung	Therapeutic	D
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	25228534	Lung	Therapeutic	D
ALK	FUS	ALK FUSION I1171	Lung Non-small Cell Carcinoma	TAE684	Sensitivity/Response	D	25228534	Lung	Therapeutic	D
ALK	FUS	ALK FUSIONS	Anaplastic Large Cell Lymphoma	Crizotinib	Sensitivity/Response	C	21345110	Lymph_Nodes	Therapeutic	C
ALK	FUS	ALK FUSIONS	Breast Cancer	Crizotinib	Sensitivity/Response	E	19737969	Breast	Therapeutic	D
ALK	FUS	ALK FUSIONS	Cancer	Entrectinib	Sensitivity/Response	B	28183697	Cancer	Therapeutic	B
ALK	FUS	ALK FUSIONS	Colorectal Adenocarcinoma	Crizotinib	Sensitivity/Response	E	19737969	Colorectal	Therapeutic	D
ALK	FUS	ALK FUSIONS	Diffuse Large B-cell Lymphoma	Crizotinib	Sensitivity/Response	C	24330038	Lymph_Nodes	Therapeutic	C
ALK	FUS	ALK FUSIONS	Epithelioid Inflammatory Myofibroblastic Sarcoma	Crizotinib	Sensitivity/Response	C	25028698	Soft_Tissue	Therapeutic	C
ALK	FUS	ALK FUSIONS	Inflammatory Myofibroblastic Tumor	Crizotinib	Sensitivity/Response	B	23598171	Soft_Tissue	Therapeutic	B
ALK	FUS	ALK FUSIONS	Inflammatory Myofibroblastic Tumor		Positive	C	10383129	Soft_Tissue	Diagnostic	C
ALK	FUS	ALK FUSIONS	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	25922291	Lung	Therapeutic	C
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	Sensitivity/Response	A	26708155	Lung	Therapeutic	A
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	Sensitivity/Response	B	23639470	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib	Sensitivity/Response	B	25153538	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Brigatinib	Sensitivity/Response	B	28475456	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	B	26973324	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	CH5424802	Sensitivity/Response	C	26938871	Lung	Therapeutic	C
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib,Alectinib	Sensitivity/Response	B	28586279	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	A	20979469	Lung	Therapeutic	A
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	A	23724913	Lung	Therapeutic	A
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	A	25470694	Lung	Therapeutic	A
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	21933749	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	24478318	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	26466010	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	27022118	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	IPI-504	Sensitivity/Response	C	20940188	Lung	Therapeutic	C
ALK	FUS	ALK FUSIONS	Lung Non-small Cell Carcinoma	Pemetrexed	Sensitivity/Response	B	21642865	Lung	Therapeutic	B
ALK	FUS	ALK FUSIONS	Vagina Sarcoma	Crizotinib	Sensitivity/Response	C	26942346	Other	Therapeutic	C
ALK	FUS	CLTC-ALK	Diffuse Large B-cell Lymphoma	Crizotinib	Sensitivity/Response	C	26221234	Lymph_Nodes	Therapeutic	C
ALK	FUS	CLTC-ALK	Diffuse Large B-cell Lymphoma		Poor Outcome	C	19636007	Lymph_Nodes	Prognostic	C
ALK	FUS	CLTC-ALK	Diffuse Large B-cell Lymphoma	TAE684	Sensitivity/Response	D	21494621	Lymph_Nodes	Therapeutic	D
ALK	FUS	EML4-ALK AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	23344087	Lung	Therapeutic	C
ALK	FUS	EML4-ALK AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	22235099	Lung	Therapeutic	D
ALK	FUS	EML4-ALK AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK C1156YâL1196M	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	20979473	Lung	Therapeutic	C
ALK	FUS	EML4-ALK C1156YâL1198F	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	26698910	Lung	Therapeutic	C
ALK	FUS	EML4-ALK C1156YâL1198F	Lung Non-small Cell Carcinoma	Lorlatinib	Resistance	C	26698910	Lung	Therapeutic	C
ALK	FUS	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	AUY922,Crizotinib,Ceritinib	Resistance	C	26698910	Lung	Therapeutic	C
ALK	FUS	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	24675041	Lung	Therapeutic	D
ALK	FUS	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	Lorlatinib	Sensitivity/Response	C	26698910	Lung	Therapeutic	C
ALK	FUS	EML4-ALK E20;A20	Cancer	Crizotinib	Sensitivity/Response	C	25408655	Cancer	Therapeutic	C
ALK	FUS	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	17-DMAG,Crizotinib	Sensitivity/Response	D	22912387	Lung	Therapeutic	D
ALK	FUS	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	20979469	Lung	Therapeutic	C
ALK	FUS	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	D	22912387	Lung	Therapeutic	D
ALK	FUS	EML4-ALK E2;A20	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	E	18927303	Lung	Therapeutic	D
ALK	FUS	EML4-ALK E2;A20	Renal Cell Carcinoma		Sensitivity/Response	E	22252991	Kidney	Therapeutic	D
ALK	FUS	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	2,4-pyrimidinediamine	Sensitivity/Response	D	18593892	Lung	Therapeutic	D
ALK	FUS	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	D	24675041	Lung	Therapeutic	D
ALK	FUS	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	20979469	Lung	Therapeutic	C
ALK	FUS	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	TAE684	Sensitivity/Response	D	18451166	Lung	Therapeutic	D
ALK	FUS	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	22235099	Lung	Therapeutic	C
ALK	FUS	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	23344087	Lung	Therapeutic	C
ALK	FUS	EML4-ALK I1171S	Lung Non-small Cell Carcinoma	Crizotinib,Alectinib	Resistance	C	25393796	Lung	Therapeutic	C
ALK	FUS	EML4-ALK L1152R	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	21791641	Lung	Therapeutic	C
ALK	FUS	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Alectinib (CH5424802)	Sensitivity/Response	D	21575866	Lung	Therapeutic	D
ALK	FUS	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	D	24675041	Lung	Therapeutic	D
ALK	FUS	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	B	20979473	Lung	Therapeutic	B
ALK	FUS	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK	Lung Acinar Adenocarcinoma	Erlotinib	Resistance	C	23181703	Lung	Therapeutic	C
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	17-DMAG,Crizotinib	Sensitivity/Response	D	22912387	Lung	Therapeutic	D
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	20979473	Lung	Therapeutic	B
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	20979469	Lung	Therapeutic	C
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	IPI-504,Crizotinib	Sensitivity/Response	D	21258415	Lung	Therapeutic	D
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	Lorlatinib	Sensitivity/Response	D	26554404	Lung	Therapeutic	D
ALK	FUS	EML4-ALK	Lung Non-small Cell Carcinoma	WHI-P154	Sensitivity/Response	D	17625570	Lung	Therapeutic	D
ALK	FUS	EML4-ALK S1206Y	Cancer	Ceritinib	Sensitivity/Response	D	24675041	Cancer	Therapeutic	D
ALK	FUS	EML4-ALK S1206Y	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	17-AAG	Sensitivity/Response	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	Alectinib	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	22277784	Lung	Therapeutic	C
ALK	FUS	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	TAE684	Resistance	D	22277784	Lung	Therapeutic	D
ALK	FUS	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Alectinib	Resistance	D	25228534	Lung	Therapeutic	D
ALK	FUS	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Brigatinib	Sensitivity/Response	D	25228534	Lung	Therapeutic	D
ALK	FUS	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	D	25228534	Lung	Therapeutic	D
ALK	FUS	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	25228534	Lung	Therapeutic	D
ALK	FUS	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	TAE684	Sensitivity/Response	D	25228534	Lung	Therapeutic	D
ALK	FUS	fusion	Advanced Solid Tumor	Repotrectinib	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ALK	FUS	fusion	anaplastic large cell lymphoma	Crizotinib	sensitive	Phase Ib/II	28787259	Lymph_Nodes	Therapeutic	C
ALK	FUS	fusion	colorectal cancer	Entrectinib	sensitive	Phase I	26633560	Colorectal	Therapeutic	C
ALK	FUS	fusion	inflammatory myofibroblastic tumor	Ceritinib	sensitive	Guideline	;	Soft_Tissue	Therapeutic	A
ALK	FUS	fusion	inflammatory myofibroblastic tumor	Crizotinib	sensitive	Guideline	;	Soft_Tissue	Therapeutic	A
ALK	FUS	fusion	inflammatory myofibroblastic tumor	Crizotinib	sensitive	Phase Ib/II	28787259	Soft_Tissue	Therapeutic	C
ALK	FUS	fusion	lung non-small cell carcinoma	Alectinib	sensitive	FDA approved - On Companion Diagnostic	;28586279;	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Alectinib	sensitive	Phase III	;	Lung	Therapeutic	C
ALK	FUS	fusion	lung non-small cell carcinoma	Alectinib	sensitive	Phase II	;	Lung	Therapeutic	C
ALK	FUS	fusion	lung non-small cell carcinoma	Brigatinib	sensitive	FDA approved	28475456;	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Brigatinib	sensitive	Phase Ib/II	24091716	Lung	Therapeutic	C
ALK	FUS	fusion	lung non-small cell carcinoma	Ceritinib	sensitive	FDA approved - On Companion Diagnostic	;;25754348	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Crizotinib	sensitive	FDA approved - On Companion Diagnostic	25470694;;	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Lorlatinib	sensitive	FDA approved	;;	Lung	Therapeutic	A
ALK	FUS	fusion	lung non-small cell carcinoma	Lorlatinib	sensitive	Phase I	;	Lung	Therapeutic	C
ALK	FUS	HIP1-ALK I1171N	Lung Non-small Cell Carcinoma	Crizotinib,Alectinib	Resistance	C	25393796	Lung	Therapeutic	C
ALK	FUS	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Sensitivity/Response	B	23598171	Lymph_Nodes	Therapeutic	B
ALK	FUS	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Sensitivity/Response	D	18089725	Lymph_Nodes	Therapeutic	D
ALK	FUS	NPM-ALK	Cancer	Crizotinib	Sensitivity/Response	D	25727400	Cancer	Therapeutic	D
ALK	FUS	RANBP2-ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	Sensitivity/Response	C	20979472	Soft_Tissue	Therapeutic	C
ALK	MUT	A348D	Acute myeloid leukemia	Crizotinib	Responsive	Pre-clinical	26032424	Blood;Bone_Marrow	Therapeutic	D
ALK	MUT	ALTERNATIVE TRANSCRIPT (ATI)	Skin Melanoma	Crizotinib	Sensitivity/Response	C	26444240	Skin	Therapeutic	C
ALK	MUT	C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical	21575866	Other	Therapeutic	D
ALK	MUT	C1156Y	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	C1156Y	Lung adenocarcinoma	Lorlatinib	Responsive	Pre-clinical	27401242	Lung	Therapeutic	D
ALK	MUT	C1156Y	Non-Small Cell Lung Cancer	Crizotinib	Resistant	R2	22235099, 23434628, 27045755, 26144315, 20979473, 26698910, 24675041	Lung	Therapeutic	C
ALK	MUT	C1156Y	Non-small cell lung	Crizotinib	Resistant	Case report	20979473	Lung	Therapeutic	D
ALK	MUT	D1091N	neuroblastoma	Alectinib + Doxorubicin	predicted - sensitive	Preclinical - Cell culture	28455243	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	D1091N	neuroblastoma	Alectinib	predicted - sensitive	Preclinical - Cell culture	28455243	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	D1091N	neuroblastoma	AZD3463 + Doxorubicin	sensitive	Preclinical - Cell culture	28455243	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	D1091N	neuroblastoma	AZD3463	sensitive	Preclinical - Cell culture	26786851	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	4_11del	Neuroblastoma	Brigatinib	Sensitivity/Response	D	27049722	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	E1408V	Lung adenocarcinoma	Brigatinib	Responsive	Case report	ASCO 2017 (abstr 9065)	Lung	Therapeutic	D
ALK	MUT	F1174C	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	21030459,24675041,22266870,26503946	Lung	Therapeutic	C
ALK	MUT	F1174L	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	21030459,24675041,22266870,26503946	Lung	Therapeutic	C
ALK	MUT	F1174L	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	F1174L	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26554404	Other	Therapeutic	D
ALK	MUT	F1174L	Glioma	Crizotinib	Resistant	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Inflammatory Myofibroblastic Tumor	Crizotinib	Resistance	D	21030459	Soft_Tissue	Therapeutic	D
ALK	MUT	F1174L	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	F1174L	Lung adenocarcinoma	[novel ALK inhibitor]	Responsive	Pre-clinical	24327273	Lung	Therapeutic	D
ALK	MUT	F1174L	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	21030459	Lung	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	Alectinib	Sensitivity/Response	D	21575866	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	neuroblastoma	AZD3463	sensitive	Preclinical - Cell line xenograft	26786851	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	AZD3463	Sensitivity/Response	D	26786851	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	neuroblastoma	CEP-28122	sensitive	Preclinical - Cell culture	22203728	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	Crizotinib	Resistance	D	22072639	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	neuroblastoma	Crizotinib	resistant	Preclinical - Pdxcell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	Crizotinib	Sensitivity/Response	D	21948233	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	neuroblastoma	Lorlatinib	conflicting	Preclinical - Cell culture	30322862	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	neuroblastoma	Lorlatinib	conflicting	Preclinical - Pdxcell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	Lorlatinib	Sensitivity/Response	D	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174L	Neuroblastoma	TAE684	Sensitivity/Response	D	18923525	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1174V	neuroblastoma	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1245C	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	F1245C	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26554404	Other	Therapeutic	D
ALK	MUT	F1245C	Glioma	Crizotinib	Responsive	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	F1245C	Neuroblastoma	Crizotinib	Resistance	C	23598171	Adrenal_Gland;Nervous_System	Therapeutic	C
ALK	MUT	F1245C	neuroblastoma	Crizotinib	resistant	Preclinical - Pdxcell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1245C	neuroblastoma	Lorlatinib	sensitive	Preclinical - Pdxcell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1245C	Neuroblastoma	Lorlatinib	Sensitivity/Response	D	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F1245V	neuroblastoma	Entrectinib	predicted - sensitive	Case Reports/Case Series	28183697	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	F856S	Acute myeloid leukemia	Crizotinib	Responsive	Pre-clinical	26032424	Blood;Bone_Marrow	Therapeutic	D
ALK	FUS	Fusions	Inflammatory Myofibroblastic Tumor	Crizotinib, Ceritinib	Response	2A	26020125, 24670165, 20979472, 23598171	Soft_Tissue	Therapeutic	B
ALK	FUS	Fusions	Non-Small Cell Lung Cancer	Crizotinib, Alectinib, Ceritinib	Response	1	28586279, 29596029, 29668860, 30215676, 28126333, 23724913	Lung	Therapeutic	A
ALK	MUT	G1123S	Lung adenocarcinoma	Ceritinib	Resistant	Case report	26134233	Lung	Therapeutic	D
ALK	MUT	G1128A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	G1128A	Glioma	Crizotinib	Responsive	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	G1202R	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	24736079,22277784,24675041	Lung	Therapeutic	C
ALK	MUT	G1202R	Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
ALK	MUT	G1202R	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	G1202R	Non-Small Cell Lung Cancer	Alectinib	Resistant	R2	29376144, 29650534, 27130468, 27432227, 24736079, 29373100	Lung	Therapeutic	C
ALK	MUT	G1269A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	G1269A	Lung adenocarcinoma	Ceritinib	Responsive	FDA guidelines	24670165;24327273	Lung	Therapeutic	A
ALK	MUT	G1269A	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	G1269A	Non-Small Cell Lung Cancer	Crizotinib	Resistant	R2	28434515, 22235099, 23434628, 27045755, 23344087, 24675041	Lung	Therapeutic	C
ALK	MUT	I1171N	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	I1171N	Glioma	Crizotinib	Responsive	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	I1171N	Non-Small Cell Lung Cancer	Alectinib	Resistant	R2	29376144, 23239810, 29650534, 25393798, 25393796, 27565911, 25736571	Lung	Therapeutic	C
ALK	MUT	I1171T	ganglioneuroblastoma	Ceritinib	predicted - sensitive	Case Reports/Case Series	29907598	Brain	Therapeutic	D
ALK	MUT	I1171T	Lung adenocarcinoma	Alectinib	Resistant	Case report	25228534	Lung	Therapeutic	D
ALK	MUT	I1171T	Lung adenocarcinoma	Ceritinib	Responsive	FDA guidelines	24670165;24327273	Lung	Therapeutic	A
ALK	MUT	I1171T	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	inframe insertion 1151T	Lung adenocarcinoma	Ceritinib	Responsive	FDA guidelines	24670165	Lung	Therapeutic	A
ALK	MUT	inframe insertion 1151T	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784	Lung	Therapeutic	D
ALK	MUT	L1152R	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	L1196M	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	20979473,22277784,24675041	Lung	Therapeutic	C
ALK	MUT	L1196M	Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
ALK	MUT	L1196M	Lung adenocarcinoma	Brigatinib	Responsive	Case report	ASCO 2017 (abstr 9065)	Lung	Therapeutic	D
ALK	MUT	L1196M	Lung adenocarcinoma	Ceritinib	Responsive	FDA guidelines	24670165;24327273	Lung	Therapeutic	A
ALK	MUT	L1196M	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	L1196M	Non-Small Cell Lung Cancer	Crizotinib	Resistant	R2	28434515, 22235099, 23434628, 22277784, 23344087, 27432227, 24675041	Lung	Therapeutic	C
ALK	MUT	L1196M	Non-small cell lung	Crizotinib	Resistant	Case report	20979473	Lung	Therapeutic	D
ALK	MUT	L1196Q	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	20979473,22277784,24675041	Lung	Therapeutic	C
ALK	MUT	L1198F	Lung adenocarcinoma	Crizotinib	Responsive	Case report	26698910	Lung	Therapeutic	D
ALK	MUT	mutation	Advanced Solid Tumor	Belizatinib	sensitive	Phase Ib/II	;	Other	Therapeutic	C
ALK	MUT	mutation	lung non-small cell carcinoma	Belizatinib	sensitive	Phase I	;	Lung	Therapeutic	C
ALK	MUT	mutation	Lung Non-small Cell Carcinoma	Ceritinib	Sensitivity/Response	B	24670165	Lung	Therapeutic	B
ALK	MUT	mutation	lung non-small cell carcinoma	Crizotinib + Onalespib	no benefit	Phase II	;	Lung	Therapeutic	C
ALK	MUT	mutation	lung non-small cell carcinoma	Ensartinib	sensitive	Phase Ib/II	;	Lung	Therapeutic	C
ALK	MUT	mutation	lung non-small cell carcinoma	Entrectinib	sensitive	Case Reports/Case Series	;	Lung	Therapeutic	D
ALK	MUT	mutation	neuroblastoma	Entrectinib	sensitive	Case Reports/Case Series	;	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	oncogenic mutation	Non-small cell lung	Crizotinib	Resistant	Clinical trials	22235099	Lung	Therapeutic	C
ALK	MUT	Oncogenic Mutations	Non-Small Cell Lung Cancer	Brigatinib, Lorlatinib	Response	1	30413378, 27432227, 28475456, 29074098, 29768119, 30280657	Lung	Therapeutic	A
ALK	MUT	R1192P	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
ALK	MUT	R1192P	Glioma	Crizotinib	Responsive	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell line xenograft	27049722	Other	Therapeutic	D
ALK	MUT	R1275Q	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26554404	Other	Therapeutic	D
ALK	MUT	R1275Q	Glioma	Crizotinib	Responsive	Pre-clinical	22072639	Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	neuroblastoma	CEP-28122	sensitive	Preclinical - Cell culture	22203728	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	neuroblastoma	Ceritinib	sensitive	Preclinical - Cell culture	29907598	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	neuroblastoma	Crizotinib	conflicting	Preclinical - Cell culture	29907598	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	neuroblastoma	Crizotinib	conflicting	Preclinical - Cell line xenograft	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	neuroblastoma	Crizotinib + Cyclophosphamide + Topotecan	sensitive	Preclinical - Cell line xenograft	26438783	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Neuroblastoma	Crizotinib	Sensitivity/Response	C	23598171	Adrenal_Gland;Nervous_System	Therapeutic	C
ALK	MUT	R1275Q	Neuroblastoma	Crizotinib	Sensitivity/Response	D	22072639	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Neuroblastoma in Soft Tissue/Brain/Brain, Infratentorial/Brain, Supratentorial			1	22266870,22249260,26503946	Brain;Soft_Tissue	Therapeutic	B
ALK	MUT	R1275Q	neuroblastoma	Lorlatinib	sensitive	Preclinical - Cell line xenograft	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Neuroblastoma	Lorlatinib	Sensitivity/Response	D	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Neuroblastoma	TAE684	Resistance	D	18923525	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	R1275Q	Neuroblastoma	TAE684	Sensitivity/Response	D	18923525	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	rearrange	Advanced Solid Tumor	ASP3026	sensitive	Phase I	26966027	Other	Therapeutic	C
ALK	MUT	rearrange	Advanced Solid Tumor	Entrectinib	sensitive	Phase I	28183697	Other	Therapeutic	C
ALK	MUT	rearrange	Advanced Solid Tumor	Entrectinib	sensitive	Phase I	;	Other	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Afatinib	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Alectinib	sensitive	Clinical Study - Cohort	26438117	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Alectinib	sensitive	FDA approved - On Companion Diagnostic	28586279;;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Alectinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Alectinib	sensitive	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Alectinib	sensitive	Phase II	26598747	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Atezolizumab	no benefit	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Atezolizumab	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	Clinical Study	29935304	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	Clinical Study - Cohort	26438117	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	FDA approved	;28475456	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	sensitive	Phase Ib/II	27836716	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib + Crizotinib	sensitive	Clinical Study - Cohort	25724526	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Clinical Study - Cohort	26438117	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	FDA approved - On Companion Diagnostic	25754348;;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Phase II	27432917	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	FDA approved - On Companion Diagnostic	;25470694;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Phase III	27022118	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Phase III	;	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Durvalumab	no benefit	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Durvalumab	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Ensartinib	sensitive	Clinical Study - Cohort	26438117	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Ensartinib	sensitive	Phase Ib/II	29563138	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Erlotinib	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Gefitinib	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	FDA approved	;;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Phase I	29074098	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Phase II	30413378	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Nivolumab	no benefit	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Nivolumab	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Osimertinib	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-small cell carcinoma	Pembrolizumab	no benefit	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
ALK	MUT	rearrange	lung non-small cell carcinoma	Pembrolizumab	no benefit	Guideline	;	Lung	Therapeutic	A
ALK	MUT	rearrange	lung non-squamous non-small cell carcinoma	Ceritinib	sensitive	Phase III	28126333	Lung	Therapeutic	C
ALK	MUT	S1206Y	Lung adenocarcinoma	Ceritinib	Responsive	FDA guidelines	24670165;24327273	Lung	Therapeutic	A
ALK	MUT	S1206Y	Lung adenocarcinoma	Crizotinib	Resistant	Case report	22277784;25228534	Lung	Therapeutic	D
ALK	MUT	WILDTYPE	Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
ALK	MUT	WILDTYPE	breast cancer	Cisplatin + Dalantercept	predicted - sensitive	Preclinical - Cell line xenograft	26373572	Breast	Therapeutic	D
ALK	MUT	WILDTYPE	endometrial cancer	Dalantercept	no benefit	Phase II	25888978	Uterus	Therapeutic	C
ALK	MUT	WILDTYPE	head and neck cancer	Cisplatin + Dalantercept	predicted - sensitive	Preclinical - Cell line xenograft	26373572	Head_and_Neck	Therapeutic	D
ALK	MUT	WILDTYPE	melanoma	Dalantercept + Doxorubicin	sensitive	Preclinical - Cell line xenograft	26373572	Skin	Therapeutic	D
ALK	MUT	WILDTYPE	neuroblastoma	CEP-28122	resistant	Preclinical - Cell culture	22203728	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	WILDTYPE	neuroblastoma	Lorlatinib	resistant	Preclinical - Cell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
ALK	MUT	Y1278S	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27049722	Other	Therapeutic	D
APC	MUT	any frameshift	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162	Colorectal	Therapeutic	C
APC	MUT	any missense	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162	Colorectal	Therapeutic	C
APC	MUT	any nonsense	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162	Colorectal	Therapeutic	C
APC	MUT	E1309X	colorectal cancer	TASIN-1	sensitive	Preclinical - Cell line xenograft	27798265	Colorectal	Therapeutic	D
APC	MUT	E1464fs	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	G1416X	colorectal cancer	TASIN-1	sensitive	Preclinical - Cell culture	27798265	Colorectal	Therapeutic	D
APC	MUT	I1164fs	colorectal cancer	G007-LK	sensitive	Preclinical - Patient cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	I1164fs	colorectal cancer	IWR-1	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	I1307fs	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	L1488X	colorectal cancer	TASIN-1	sensitive	Preclinical - Cell culture	27798265	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	CGP049090	sensitive	Preclinical	14749129	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	G007-LK	sensitive	Preclinical - Cell line xenograft	23539443	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	ICG-001	sensitive	Preclinical	15314234	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	iCRT-14	sensitive	Preclinical - Cell line xenograft	21393571	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	iCRT-3	sensitive	Preclinical	21393571	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	iCRT-5	sensitive	Preclinical	21393571	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	JW55	sensitive	Preclinical	22440753	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	MF tricyclic	sensitive	Preclinical	23843721	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	PKF115-584	sensitive	Preclinical	14749129	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	Sirolimus	sensitive	Preclinical	18768809;20080688	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	StAx-35	sensitive	Preclinical	23071338	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	Vandetanib	sensitive	Preclinical	20811697	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon cancer	Vinorelbine	sensitive	Preclinical	22399804	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colon carcinoma	FH535	sensitive	Preclinical	18347139	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	CCT031374	sensitive	Preclinical	20610623	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	CCT036477	sensitive	Preclinical	20610623	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	CCT070535	sensitive	Preclinical	20610623	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Celecoxib + Erlotinib	sensitive	Preclinical - Cell line xenograft	17909047	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Celecoxib	sensitive	Preclinical	17909047	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Dasatinib	sensitive	Preclinical	20473900	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Erlotinib + Ibuprofen	sensitive	Preclinical - Cell line xenograft	17909047	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	NC043	sensitive	Preclinical - Cell line xenograft	21321609	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Niclosamide	sensitive	Preclinical	21531761	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	PKF118-310	sensitive	Preclinical	14749129	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Pyrvinium	sensitive	Preclinical	20890287	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	Sulindac	sensitive	Preclinical	19755659	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	TASIN-1	sensitive	Preclinical - Cell line xenograft	27798265	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	colorectal cancer	XAV939	sensitive	Preclinical	19759537	Colorectal	Therapeutic	D
APC	MUT	LOSS-OF-FUNCTION	prostate cancer	Abiraterone	decreased response	Clinical Study	31176623	Prostate	Therapeutic	C
APC	MUT	LOSS-OF-FUNCTION	prostate cancer	Enzalutamide	decreased response	Clinical Study	31176623	Prostate	Therapeutic	C
APC	MUT	mutant	colon adenoma	TetMYB	predicted - sensitive	Preclinical	;	Colorectal	Therapeutic	D
APC	MUT	mutant	colorectal cancer	G-631	no benefit	Preclinical - Cell line xenograft	26692561	Colorectal	Therapeutic	D
APC	MUT	mutant	colorectal cancer	JW74	sensitive	Preclinical	21199802	Colorectal	Therapeutic	D
APC	MUT	mutant	colorectal cancer	K-756	predicted - sensitive	Preclinical	27196752	Colorectal	Therapeutic	D
APC	MUT	mutant	medulloblastoma	N/A	not applicable	Guideline	;	Nervous_System	Prognostic	A
APC	MUT	mutation	Colon Carcinoma	JW55	Sensitivity/Response	D	22440753	Colorectal	Therapeutic	D
APC	MUT	mutation	Colorectal Cancer	G007-LK	Sensitivity/Response	D	23539443	Colorectal	Therapeutic	D
APC	MUT	N1819fs	colorectal cancer	IWR-1	resistant	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	oncogenic mutation	Colorectal adenocarcinoma	[Tankyrase inhibitor]	Responsive	Pre-clinical	22440753;23539443	Colorectal	Therapeutic	D
APC	MUT	Q1338X	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	Q1338X	colorectal cancer	JW67	sensitive	Preclinical	21199802	Colorectal	Therapeutic	D
APC	MUT	Q1338X	colorectal cancer	JW74	sensitive	Preclinical	21199802	Colorectal	Therapeutic	D
APC	MUT	Q1338X	colorectal cancer	TASIN-1	sensitive	Preclinical - Cell culture	27798265	Colorectal	Therapeutic	D
APC	MUT	Q1429X	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	R1114X	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	R216X	colorectal cancer	G007-LK	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	R216X	colorectal cancer	IWR-1	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	R876X	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	S1465fs	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	S811X	colorectal cancer	G007-LK	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	S811X	colorectal cancer	IWR-1	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	S811X	colorectal cancer	XAV939	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	T1556fs	Adenocarcinoma in Colon/Rectum			2	23700467,17257127,21532622,21901162,20102718	Colorectal	Therapeutic	C
APC	MUT	W553X	colorectal cancer	G007-LK	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	W553X	colorectal cancer	IWR-1	sensitive	Preclinical - Cell culture	28179481	Colorectal	Therapeutic	D
APC	MUT	WILDTYPE	colorectal cancer	TASIN-1	resistant	Preclinical - Cell line xenograft	27798265	Colorectal	Therapeutic	D
ARAF	MUT	oncogenic mutation	Colorectal adenocarcinoma	[BRAF inhibitor;EGFR mAb inhibitor]	Resistant	Case report	ENA 2014 (abstr 428)	Colorectal	Therapeutic	D
ARAF	MUT	oncogenic mutation	Colorectal adenocarcinoma	[BRAF inhibitor;MEK inhibitor]	Resistant	Case report	ENA 2014 (abstr 428)	Colorectal	Therapeutic	D
ARAF	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib, Sorafenib	Response	3A	24569458, 29236635, 26566875, 30867592	Lymph_Nodes	Therapeutic	C
ARAF	MUT	Oncogenic Mutations	Non-Small Cell Lung Cancer	Sorafenib	Response	3A	24569458	Lung	Therapeutic	C
ARAF	MUT	S214C	Lung adenocarcinoma	Sorafenib	Responsive	Case report	http://www.jci.org/articles/view/72763;24569458	Lung	Therapeutic	D
ARAF	MUT	S214C	Lung Non-small Cell Carcinoma	Sorafenib	Sensitivity/Response	C	24569458	Lung	Therapeutic	C
ARAF	MUT	S214C	Lung Non-small Cell Carcinoma	Sorafenib	Sensitivity/Response	D	24569458	Lung	Therapeutic	D
ARAF	MUT	S214C	Lung Non-small Cell Carcinoma	Trametinib	Sensitivity/Response	D	24569458	Lung	Therapeutic	D
ARAF	MUT	S490T	Colorectal Cancer	Vemurafenib,Cetuximab,Irinotecan	Resistance	C	27729313	Colorectal	Therapeutic	C
AR	CNV	amplification	Prostate adenocarcinoma	Abiraterone	Resistant	Early trials	26537258	Prostate	Therapeutic	C
AR	CNV	amplification	Prostate adenocarcinoma	[AR inhibitor next gen]	Responsive	Pre-clinical	23589709;21859989	Prostate	Therapeutic	D
AREG	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Responsive	Early trials	19738126;26341080	Colorectal	Therapeutic	C
AREG	EXP	EXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	23374602	Colorectal	Therapeutic	B
AREG	EXP	EXPRESSION	Colorectal Cancer	Panitumumab	Sensitivity/Response	B	26867820	Colorectal	Therapeutic	B
AREG	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab,Docetaxel	Resistance	B	21653686	Head_and_Neck	Therapeutic	B
AREG	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	B	23344087	Lung	Therapeutic	B
AREG	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	21791641	Lung	Therapeutic	D
AR	EXP	OVEREXPRESSION	Breast Cancer	Dactolisib	Sensitivity/Response	D	24356815	Breast	Therapeutic	D
AR	EXP	overexpression	Breast adenocarcinoma	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	Responsive	Early trials	ASCO 2015 (abstr 1003)	Breast	Therapeutic	C
AR	EXP	overexpression	Prostate adenocarcinoma	Enzalutamide	Responsive	Early trials	24882673	Prostate	Therapeutic	C
ARID1A	CNV	loss	breast cancer	AZD8055 + MK2206	sensitive	Preclinical - Cell culture	27172896	Breast	Therapeutic	D
ARID1A	CNV	loss	colon cancer	unspecified PD-L1 antibody	predicted - sensitive	Preclinical - Cell line xenograft	29736026	Colorectal	Therapeutic	D
ARID1A	CNV	loss	Her2-receptor mutation breast cancer	AZD8055	resistant	Preclinical - Cell culture	27172896	Breast	Therapeutic	D
ARID1A	CNV	loss	Her2-receptor mutation breast cancer	Trastuzumab	resistant	Preclinical - Cell culture	27172896	Breast	Therapeutic	D
ARID1A	CNV	loss	ovarian cancer	unspecified PD-L1 antibody	predicted - sensitive	Preclinical	29736026	Ovary	Therapeutic	D
ARID1A	CNV	loss	ovarian clear cell carcinoma	JQ1	predicted - sensitive	Preclinical - Cell culture	29760405	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	breast cancer	Olaparib	sensitive	Preclinical	26069190	Breast	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	breast cancer	Rucaparib	sensitive	Preclinical - Cell culture	26069190	Breast	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	breast cancer	Talazoparib	conflicting	Preclinical - Cell culture	29669295	Breast	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	breast cancer	Talazoparib	conflicting	Preclinical - Cell line xenograft	26069190	Breast	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	breast cancer	Veliparib	sensitive	Preclinical - Cell culture	26069190	Breast	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	Clear Cell Renal Cell Carcinoma		Poor Outcome	B	25628030	Kidney	Prognostic	B
ARID1A	EXP	UNDEREXPRESSION	ovarian cancer	APR-246	predicted - sensitive	Preclinical - Cell line xenograft	30686770	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	ovarian cancer	Buthionine sufoximine	predicted - sensitive	Preclinical - Cell line xenograft	30686770	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	ovarian cancer	GSK126	sensitive	Preclinical - Cell culture	25686104	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	ovarian cancer	Talazoparib	sensitive	Preclinical - Cell culture	26069190	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	ovarian clear cell carcinoma	GSK525762	predicted - sensitive	Preclinical - Cell culture	29760405	Ovary	Therapeutic	D
ARID1A	EXP	UNDEREXPRESSION	Ovarian Clear Cell Carcinoma		Poor Outcome	B	22101352	Ovary	Prognostic	B
ARID1A	EXP	UNDEREXPRESSION	Stomach Cancer		Poor Outcome	D	22808142	Stomach	Prognostic	D
ARID1A	MUT	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	Dasatinib	Sensitivity/Response	D	27364904	Ovary	Therapeutic	D
ARID1A	MUT	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	GSK126	Sensitivity/Response	D	25686104	Ovary	Therapeutic	D
ARID1A	MUT	mutant	ovarian cancer	GSK126	sensitive	Preclinical - Cell line xenograft	25686104	Ovary	Therapeutic	D
ARID1A	MUT	mutant	ovarian cancer	UNC1999	sensitive	Preclinical - Cell culture	25686104	Ovary	Therapeutic	D
ARID1A	MUT	mutant	ovarian clear cell carcinoma	Dasatinib	sensitive	Preclinical - Cell line xenograft	27364904	Ovary	Therapeutic	D
ARID1A	MUT	mutant	ovarian clear cell carcinoma	VE-821	sensitive	Preclinical - Cell culture	27958275	Ovary	Therapeutic	D
ARID1A	MUT	mutant	ovarian clear cell carcinoma	VX-970	sensitive	Preclinical - Cell line xenograft	27958275	Ovary	Therapeutic	D
ARID1A	MUT	mutant	renal cell carcinoma	Bevacizumab + Everolimus	predicted - sensitive	Phase II	27601542	Kidney	Therapeutic	C
ARID1A	MUT	oncogenic mutation	Any cancer type	[ATR inhibitors]	Responsive	Pre-clinical	27958275	Cancer	Therapeutic	D
ARID1A	MUT	oncogenic mutation	Any cancer type	[PARP inhibitor]	Responsive	Pre-clinical	26069190	Cancer	Therapeutic	D
ARID1A	MUT	oncogenic mutation	Ovary	[EZH2 inhibitor]	Responsive	Pre-clinical	25686104	Ovary	Therapeutic	D
ARID1A	MUT	P1175fs	Ovarian Clear Cell Carcinoma	Dasatinib	Sensitivity/Response	D	27364904	Ovary	Therapeutic	D
ARID1A	MUT	Q1148X	ovarian clear cell carcinoma	JQ1	predicted - sensitive	Preclinical - Pdx	29760405	Ovary	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	Dasatinib	sensitive	Preclinical - Cell culture	27364904	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	Olaparib	sensitive	Preclinical	26069190	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	Rucaparib	sensitive	Preclinical - Cell culture	26069190	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	Talazoparib	sensitive	Preclinical - Cell line xenograft	26069190	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	VE-821	sensitive	Preclinical - Cell culture	27958275	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	colorectal cancer	VX-970	sensitive	Preclinical - Cell line xenograft	27958275	Colorectal	Therapeutic	D
ARID1A	MUT	Q456X	Ovarian Clear Cell Carcinoma	Dasatinib	Sensitivity/Response	D	27364904	Ovary	Therapeutic	D
ARID1A	MUT	WILDTYPE	ovarian cancer	GSK126	no benefit	Preclinical - Cell culture	25686104	Ovary	Therapeutic	D
AR	MUT	any mutation	Adenocarcinoma in Prostate			1	23759327,16107210	Prostate	Therapeutic	B
AR	CNV	copy number gain	Adenocarcinoma in Prostate			1	23759327,16107210	Prostate	Therapeutic	B
AR	MUT	F877L	Prostate adenocarcinoma	Arn-509	Resistant	Case report	23779130	Prostate	Therapeutic	D
AR	MUT	F877L	Prostate adenocarcinoma	Enzalutamide	Resistant	Case report	23779130	Prostate	Therapeutic	D
AR	MUT	F877L	Prostate Cancer	Enzalutamide,ARN-509	Resistance	D	23779130	Prostate	Therapeutic	D
AR	MUT	H875Y	Adenocarcinoma in Prostate			1	19366804,26813233	Prostate	Therapeutic	B
AR	MUT	L702H	Prostate adenocarcinoma	Abiraterone	Resistant	Early trials	26537258	Prostate	Therapeutic	C
AR	MUT	mutation	Prostate Cancer	Nilutamide,Cyproterone Acetate,Flutamide,Bicalutamide	Resistance	B	26000489	Prostate	Therapeutic	B
AR	MUT	SPLICE VARIANT 7	Prostate Cancer	Enzalutamide,Abiraterone	Resistance	B	25184630	Prostate	Therapeutic	B
AR	MUT	T878A	Adenocarcinoma in Prostate			1	19366804,26813233	Prostate	Therapeutic	B
AR	MUT	T878A	Prostate adenocarcinoma	Abiraterone	Resistant	Early trials	26537258	Prostate	Therapeutic	C
AR	MUT	T878A	Prostate adenocarcinoma	Flutamide	Resistant	Case report	2260966	Prostate	Therapeutic	D
AR	MUT	W742	Prostate Carcinoma	Bicalutamide	Resistance	D	12517791	Prostate	Therapeutic	D
ASNS	CNV	AMPLIFICATION	Ovarian Cancer	L-asparaginase	Resistance	D	17088436	Ovary	Therapeutic	D
ASS1	CNV	LOSS	Ovarian Cancer	PLATINUM	Resistance	D	19533750	Ovary	Therapeutic	D
ASS1	CNV	LOSS	Sarcoma	Chloroquine,ADI-PEG20	Sensitivity/Response	D	27735949	Soft_Tissue	Therapeutic	D
ASXL1	MUT	any mutation	Myeloproliferative Neoplasm/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Primary Myelofibrosis/Mast Cell Neoplasm in Blood/Bone Marrow			1	24695057,24549259,24220272,23645565,23640996,22436456,24496303	Blood;Bone_Marrow	Therapeutic	B
ASXL1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Poor Outcome	B	23018865	Blood;Bone_Marrow	Prognostic	B
ASXL1	MUT	LOSS-OF-FUNCTION	myelodysplastic/myeloproliferative neoplasm	N/A	not applicable	Clinical Study	20880116;26849014;23690417	Bone_Marrow	Prognostic	C
ASXL1	MUT	mutant	acute myeloid leukemia	CG-806	predicted - sensitive	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
ASXL1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
ASXL1	MUT	mutant	acute myeloid leukemia	Sunitinib	predicted - resistant	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
ASXL1	MUT	mutant	chronic myelomonocytic leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
ASXL1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	24220272;21714648	Bone_Marrow	Prognostic	C
ASXL1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
ASXL1	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
ASXL1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	22031865	Blood;Bone_Marrow	Prognostic	B
ASXL1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	25308295	Blood;Bone_Marrow	Prognostic	B
ASXL1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	25412851	Blood;Bone_Marrow	Prognostic	B
ASXL1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
ASXL1	MUT	mutation	Acute Myeloid Leukemia		Positive	B	25412851	Blood;Bone_Marrow	Diagnostic	B
ASXL1	MUT	mutation	Myelofibrosis		Poor Outcome	B	26124496	Bone_Marrow	Prognostic	B
ATM	CNV	deletion	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
ATM	CNV	deletion	Colorectal adenocarcinoma	[ATR inhibitor]	Responsive	Case report	ENA 2015 (abstr A48)	Colorectal	Therapeutic	D
ATM	CNV	deletion	Lymphoma	[DNA-PKc inhibitor]	Responsive	Pre-clinical	23761041	Lymph_Nodes	Therapeutic	D
ATM	CNV	deletion	Stomach	[PARP inhibitor]	Responsive	Early trials	ENA 2014 (abstr 8LBA)	Stomach	Therapeutic	C
ATM	CNV	loss	Advanced Solid Tumor	YU238259	sensitive	Preclinical	26116172	Other	Therapeutic	D
ATM	CNV	loss	chronic lymphocytic leukemia	AZD6482	sensitive	Preclinical	26563132	Blood;Bone_Marrow	Therapeutic	D
ATM	CNV	loss	chronic lymphocytic leukemia	AZD6738 + Ibrutinib	sensitive	Preclinical	26563132	Blood;Bone_Marrow	Therapeutic	D
ATM	CNV	loss	colorectal cancer	VX-970	sensitive	Phase I	;	Colorectal	Therapeutic	C
ATM	CNV	loss	head and neck cancer	AZD6738 + Olaparib	predicted - sensitive	Preclinical - Cell culture	;	Head_and_Neck	Therapeutic	D
ATM	CNV	loss	lung non-small cell carcinoma	AZD6738 + Cisplatin	sensitive	Preclinical	26517239	Lung	Therapeutic	D
ATM	EXP	OVEREXPRESSION	stomach cancer	Irinotecan	decreased response	Preclinical - Cell culture	27638859	Stomach	Therapeutic	D
ATM	EXP	OVEREXPRESSION	stomach cancer	Irinotecan + Veliparib	sensitive	Preclinical - Cell line xenograft	27638859	Stomach	Therapeutic	D
ATM	EXP	OVEREXPRESSION	stomach cancer	Veliparib	decreased response	Preclinical - Cell culture	27638859	Stomach	Therapeutic	D
ATM	EXP	UNDEREXPRESSION	breast cancer	Talazoparib	sensitive	Preclinical - Cell culture	23881923	Breast	Therapeutic	D
ATM	EXP	UNDEREXPRESSION	Cancer	KU-0060648,NU7441	Sensitivity/Response	D	23761041	Cancer	Therapeutic	D
ATM	EXP	UNDEREXPRESSION	Chronic Lymphocytic Leukemia		Poor Outcome	B	9788599	Blood;Bone_Marrow	Prognostic	B
ATM	EXP	UNDEREXPRESSION	Gastric Adenocarcinoma	Olaparib	Sensitivity/Response	D	24841718	Stomach	Therapeutic	D
ATM	EXP	UNDEREXPRESSION	Pancreatic Cancer		Poor Outcome	B	25423555	Pancreas	Prognostic	B
ATM	EXP	UNDEREXPRESSION	Stomach Cancer		Better Outcome	B	26282658	Stomach	Prognostic	B
ATM	EXP	UNDEREXPRESSION	stomach cancer	Olaparib + Paclitaxel	predicted - sensitive	Phase II	26282658	Stomach	Therapeutic	C
ATM	EXP	UNDEREXPRESSION	stomach cancer	Veliparib	sensitive	Preclinical - Cell line xenograft	27638859	Stomach	Therapeutic	D
ATM	MUT	A59S	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	any mutation	Chronic Lymphocytic Leukemia/Mantle Cell Lymphoma/T Cell Lymphoproliferative Disorder in Blood/Bone Marrow/Lymph Node			1	24584352,11801464,23407552,9288106	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
ATM	MUT	D2725G	lung small cell carcinoma	Temozolomide + Veliparib	predicted - sensitive	Case Reports/Case Series	29906251	Lung	Therapeutic	D
ATM	MUT	H2038Y	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	K2749I	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	L1449X	prostate adenocarcinoma	Olaparib	predicted - sensitive	Case Reports/Case Series	29304353	Prostate	Therapeutic	D
ATM	MUT	L1874F	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	L1956H	neuroblastoma	Olaparib	no benefit	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	E7449	sensitive	Preclinical	26513298	Other	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Veliparib	sensitive	Preclinical - Cell culture	21300883	Other	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	chronic lymphocytic leukemia	Olaparib	sensitive	Preclinical - Patient cell culture	20739657	Blood;Bone_Marrow	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	lymphocytic leukemia	Olaparib	sensitive	Preclinical - Patient cell culture	20739657	Blood;Bone_Marrow	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	mantle cell lymphoma	Bendamustine + Olaparib	sensitive	Preclinical - Cell culture	20739657	Lymph_Nodes	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	mantle cell lymphoma	Fludarabine + Olaparib	sensitive	Preclinical - Cell culture	20739657	Lymph_Nodes	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	mantle cell lymphoma	Olaparib	sensitive	Preclinical - Cell line xenograft	20739657	Lymph_Nodes	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	mantle cell lymphoma	Olaparib + Valproic acid	sensitive	Preclinical - Cell culture	20739657	Lymph_Nodes	Therapeutic	D
ATM	MUT	LOSS-OF-FUNCTION	prostate cancer	Olaparib	sensitive	Phase II	26510020	Prostate	Therapeutic	C
ATM	MUT	mutant	Advanced Solid Tumor	BAY1895344	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ATM	MUT	mutant	mantle cell lymphoma	Ibrutinib + Venetoclax	predicted - sensitive	Phase II	30455436	Lymph_Nodes	Therapeutic	C
ATM	MUT	mutant	prostate cancer	Olaparib	sensitive	Phase II	;	Prostate	Therapeutic	C
ATM	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	A	26837699	Blood;Bone_Marrow	Prognostic	A
ATM	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	21993670	Blood;Bone_Marrow	Prognostic	B
ATM	MUT	mutation	glioblastoma multiforme	AZD1390	sensitive	Preclinical - Cell line xenograft	;	Brain	Therapeutic	D
ATM	MUT	mutation	Glioblastoma Multiforme	Temozolomide	Sensitivity/Response	D	23960094	Brain	Therapeutic	D
ATM	MUT	mutation	Hematologic Cancer	Olaparib	Sensitivity/Response	D	20739657	Blood	Therapeutic	D
ATM	MUT	mutation	lung cancer	AZD1390	sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
ATM	MUT	mutation	Mantle Cell Lymphoma	Olaparib	Sensitivity/Response	D	20124459	Lymph_Nodes	Therapeutic	D
ATM	MUT	mutation	Melanoma	Temozolomide	Sensitivity/Response	D	23960094	Skin	Therapeutic	D
ATM	MUT	mutation	Prostate Cancer	Olaparib	Sensitivity/Response	C	26510020	Prostate	Therapeutic	C
ATM	MUT	N2875H	Prostate Cancer	Olaparib	Sensitivity/Response	C	26510020	Prostate	Therapeutic	C
ATM	MUT	oncogenic mutation	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
ATM	MUT	oncogenic mutation	Colorectal adenocarcinoma	[ATR inhibitor]	Responsive	Case report	ENA 2015 (abstr A48)	Colorectal	Therapeutic	D
ATM	MUT	oncogenic mutation	Glioma	Temozolomide	Responsive	Pre-clinical	23960094	Nervous_System	Therapeutic	D
ATM	MUT	oncogenic mutation	Lymphoma	[DNA-PKc inhibitor]	Responsive	Pre-clinical	23761041	Lymph_Nodes	Therapeutic	D
ATM	MUT	Oncogenic Mutations	All Solid Tumors	Olaparib	Response	4	26510020	Other	Therapeutic	D
ATM	MUT	oncogenic mutation	Stomach	[PARP inhibitor]	Responsive	Early trials	ENA 2014 (abstr 8LBA)	Stomach	Therapeutic	C
ATM	MUT	oncogenic mutation	Stomach;Prostate adenocarcinoma	Olaparib	Responsive	Early trials	ENA 2014 (abstr 8LBA);26510020	Prostate;Stomach	Therapeutic	C
ATM	MUT	P604S	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	P960H	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	R2691C	neuroblastoma	Olaparib	no benefit	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	S1455R	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	S333F	lung small cell carcinoma	Temozolomide + Veliparib	predicted - sensitive	Case Reports/Case Series	29906251	Lung	Therapeutic	D
ATM	MUT	S824F	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	V1841I	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATM	MUT	V2288fs	Prostate Cancer	Olaparib	Sensitivity/Response	C	26510020	Prostate	Therapeutic	C
ATM	MUT	V410A	lung small cell carcinoma	Temozolomide + Veliparib	predicted - sensitive	Case Reports/Case Series	29906251	Lung	Therapeutic	D
ATM	MUT	V519I	neuroblastoma	Olaparib	sensitive	Preclinical - Cell culture	29059438	Adrenal_Gland;Nervous_System	Therapeutic	D
ATR	CNV	deletion	Ovary;Any cancer type	Olaparib	Responsive	Pre-clinical	23548269	Cancer;Ovary	Therapeutic	D
ATR	MUT	I774fs	Endometrial Cancer		Poor Outcome	B	19470935	Uterus	Prognostic	B
ATR	MUT	oncogenic mutation	Glioma	Temozolomide	Responsive	Pre-clinical	23960094	Nervous_System	Therapeutic	D
ATR	MUT	oncogenic mutation	Ovary;Any cancer type	Olaparib	Responsive	Pre-clinical	23548269	Cancer;Ovary	Therapeutic	D
ATRX	CNV	loss	glioblastoma multiforme	Doxorubicin	sensitive	Preclinical	26936505	Brain	Therapeutic	D
ATRX	CNV	loss	glioblastoma multiforme	Irinotecan	sensitive	Preclinical	26936505	Brain	Therapeutic	D
ATRX	CNV	loss	glioblastoma multiforme	Topotecan	sensitive	Preclinical	26936505	Brain	Therapeutic	D
ATRX	EXP	UNDEREXPRESSION	Astrocytoma	Vincristine,Lomustine,Procarbazine,Temozolomide		B	23904111	Brain	Therapeutic	B
ATRX	EXP	UNDEREXPRESSION	Glioblastoma Multiforme		Poor Outcome	D	26936505	Brain	Prognostic	D
ATRX	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	E7449	sensitive	Preclinical	26513298	Other	Therapeutic	D
ATRX	MUT	mutant	malignant glioma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
AURKA	CNV	amplification	Prostate adenocarcinoma;Any cancer type	[AURK inhibitor]	Responsive	Pre-clinical	22302096;22389870	Cancer;Prostate	Therapeutic	D
AURKA	CNV	AMPLIFICATION	Esophagus Adenocarcinoma	Cisplatin,Alisertib	Sensitivity/Response	E	22302096	Esophagus	Therapeutic	D
AURKA	EXP	EXPRESSION	Esophagus Squamous Cell Carcinoma	5-fluorouracil,Cisplatin	Sensitivity/Response	B	25924824	Esophagus	Therapeutic	B
AURKA	EXP	EXPRESSION	Ovarian Carcinoma		Better Outcome	B	19157502	Ovary	Prognostic	B
AURKA	EXP	OVEREXPRESSION	Cervical Adenocarcinoma	Paclitaxel	Resistance	D	12559175	Cervix	Therapeutic	D
AURKA	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin	Resistance	B	25082261	Lung	Therapeutic	B
AURKA	EXP	OVEREXPRESSION	Ovarian Serous Carcinoma	PLATINUM	Resistance	B	27209210	Ovary	Therapeutic	B
AXL	EXP	EXPRESSION	Esophagus Squamous Cell Carcinoma		Poor Outcome	B	27172793	Esophagus	Prognostic	B
B2M	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 Ab inhibitor]	Resistant	Case report	27433843	Skin	Therapeutic	D
B2M	MUT	S14fs	Skin Melanoma	Pembrolizumab	Resistance	C	27433843	Skin	Therapeutic	C
B4GALT1	EXP	EXPRESSION	Renal Cell Carcinoma		Poor Outcome	B	27092876	Kidney	Prognostic	B
BAP1	CNV	deletion	Cutaneous melanoma	[HDAC inhibitor]	Responsive	Pre-clinical	22038994	Skin	Therapeutic	D
BAP1	CNV	deletion	Mesothelioma	[EZH2 inhibitor]	Responsive	Pre-clinical	26437366	Pleura	Therapeutic	D
BAP1	CNV	deletion	Renal;Any cancer type	[PARP inhibitor]	Responsive	Pre-clinical	22683710	Cancer;Kidney	Therapeutic	D
BAP1	EXP	EXPRESSION	Uveal Melanoma		Better Outcome	B	25147369	Eye	Prognostic	B
BAP1	MUT	ALTERNATIVE TRANSCRIPT (ATI)	Malignant Mesothelioma	GDC-0980,Olaparib	Sensitivity/Response	D	28389374	Other	Therapeutic	D
BAP1	MUT	any mutation	Clear Cell Renal Cell Carcinoma in Kidney			2	23036577,24166983,25873528,25365943	Kidney	Therapeutic	C
BAP1	MUT	mutation	Clear Cell Renal Cell Carcinoma		Poor Outcome	B	23792563	Kidney	Prognostic	B
BAP1	MUT	mutation	Clear Cell Renal Cell Carcinoma		Poor Outcome	B	23797736	Kidney	Prognostic	B
BAP1	MUT	mutation	Malignant Mesothelioma	MC1568,Mocetinostat,Vorinostat (SAHA)	Sensitivity/Response	E	25970771	Other	Therapeutic	D
BAP1	MUT	mutation	Renal Cell Carcinoma	Everolimus,Sunitinib	Resistance	B	27751729	Kidney	Therapeutic	B
BAP1	MUT	mutation	Uveal Melanoma	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Sensitivity/Response	D	22038994	Eye	Therapeutic	D
BAP1	MUT	oncogenic mutation	Cutaneous melanoma	[HDAC inhibitor]	Responsive	Pre-clinical	22038994	Skin	Therapeutic	D
BAP1	MUT	oncogenic mutation	Mesothelioma	[EZH2 inhibitor]	Responsive	Pre-clinical	26437366	Pleura	Therapeutic	D
BAP1	MUT	oncogenic mutation	Renal;Any cancer type	[PARP inhibitor]	Responsive	Pre-clinical	22683710	Cancer;Kidney	Therapeutic	D
BARD1	MUT	LOSS-OF-FUNCTION	Colorectal Cancer	Olaparib	Sensitivity/Response	D	27197561	Colorectal	Therapeutic	D
BCL2	CNV	amplification	Lymphoma	[BCL2 inhibitor]	Responsive	Pre-clinical	22649144	Lymph_Nodes	Therapeutic	D
BCL2	EXP	EXPRESSION	Diffuse Large B-cell Lymphoma		Poor Outcome	B	9207459	Lymph_Nodes	Prognostic	B
BCL2	EXP	overexpression	Multiple myeloma	Venetoclax;Bortezomib	Responsive	Early trials	ASH 2015 (Blood 2015 126:2975)	Bone_Marrow	Therapeutic	C
BCL2	FUS	IGH-BCL2	Diffuse Large B-cell Lymphoma		Positive	B	12075054	Lymph_Nodes	Diagnostic	B
BCL2L11	CNV	deletion POLYMORPHISM	Chronic Myeloid Leukemia	Imatinib	Resistance	B	22426421	Blood;Bone_Marrow	Therapeutic	B
BCL2L11	CNV	deletion POLYMORPHISM	Lung Non-small Cell Carcinoma	EGFR Inhibitor	Resistance	B	22426421	Lung	Therapeutic	B
BCL2	MUT	mutation	Follicular Lymphoma		Poor Outcome	B	25452615	Lymph_Nodes	Prognostic	B
BCL6	EXP	overexpression	Lymphoma	Onalespib	Responsive	Early trials	NCT02572453	Lymph_Nodes	Therapeutic	C
BCORL1	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	24047651,21989985,22210327	Blood;Bone_Marrow	Therapeutic	B
BCOR	MUT	any mutation	Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	24047651,22210327,22012066	Blood;Bone_Marrow	Therapeutic	B
BCOR	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
BCOR	MUT	mutation	Stomach Cancer		Better Outcome	B	27313181	Stomach	Prognostic	B
BCOR	MUT	oncogenic mutation	Stomach	Enzastaurin	Responsive	Pre-clinical	27397505	Stomach	Therapeutic	D
BCOR-RARA	FUS		acute promyelocytic leukemia	Tretinoin	predicted - sensitive	Case Reports/Case Series	25790901	Blood;Bone_Marrow	Therapeutic	D
BIRC3	MUT	TRUNCATING mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	24943832	Blood;Bone_Marrow	Prognostic	B
BIRC5	EXP	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	B	23204226	Breast	Therapeutic	B
BIRC5	MUT	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma	PLATINUM,Taxane	Sensitivity/Response	B	24961465	Lung	Therapeutic	B
BIRC7	CNV	AMPLIFICATION	Colon Cancer	Cisplatin	Resistance	D	23188704	Colorectal	Therapeutic	D
BRAF	CNV	AMPLIFICATION	Colorectal Cancer	Dabrafenib,Panitumumab	Resistance	C	25673644	Colorectal	Therapeutic	C
BRAF	FUS	AGK-BRAF	Melanoma	Sorafenib	Sensitivity/Response	C	23890088	Skin	Therapeutic	C
BRAF	FUS	AGK-BRAF	Melanoma	Vemurafenib	Resistance	D	23890088	Skin	Therapeutic	D
BRAF	FUS	AKAP9-BRAF	Thyroid Gland Papillary Carcinoma		Positive	B	15630448	Thyroid	Diagnostic	B
BRAF	FUS	BRAF-CUL1	Ovarian Serous Carcinoma	MEK Inhibitor	Sensitivity/Response	C	26324360	Ovary	Therapeutic	C
BRAF	FUS	CUX1-BRAF	Pancreatic Cancer	Vemurafenib	Sensitivity/Response	C	29320312	Pancreas	Therapeutic	C
BRAF	FUS	fusion	pilocytic astrocytoma	N/A	not applicable	Guideline	;	Brain	Diagnostic	A
BRAF	FUS	fusion	pilocytic astrocytoma	N/A	not applicable	Guideline	;	Brain	Prognostic	A
BRAF	FUS	KIAA1549-BRAF	Pilocytic Astrocytoma		Gain of Function	D	18974108	Brain	Functional	D
BRAF	FUS	KIAA1549-BRAF	Pilocytic Astrocytoma		Positive	B	23817572	Brain	Diagnostic	B
BRAF	FUS	KIAA1549-BRAF	Sarcoma	Temsirolimus,Bevacizumab,Sorafenib	Sensitivity/Response	C	24422672	Soft_Tissue	Therapeutic	C
BRAF	FUS	KIAA1549-BRAF	Skin Melanoma	Trametinib	Sensitivity/Response	C	26072686	Skin	Therapeutic	C
BRAF	FUS	PAPSS1-BRAF	Melanoma	Trametinib	Sensitivity/Response	D	24345920	Skin	Therapeutic	D
BRAF	FUS	PAPSS1-BRAF	Melanoma	Vemurafenib	Resistance	D	24345920	Skin	Therapeutic	D
BRAF	FUS	PPFIBP2-BRAF	Skin Melanoma	Trametinib	Sensitivity/Response	C	26072686	Skin	Therapeutic	C
BRAF	FUS	TRIM24-BRAF	Melanoma	Trametinib	Sensitivity/Response	D	24345920	Skin	Therapeutic	D
BRAF	FUS	TRIM24-BRAF	Skin Melanoma	Vemurafenib	Resistance	D	24345920	Skin	Therapeutic	D
BRAF	FUS	ZKSCAN1-BRAF	Melanoma	Trametinib	Sensitivity/Response	C	26314551	Skin	Therapeutic	C
BRAF	MUT	any mutation	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	codon(s) 464 any	Adenocarcinoma in Lung			2	12068308	Lung	Therapeutic	C
BRAF	MUT	codon(s) 469 any	Adenocarcinoma in Lung			2	22649091,12068308	Lung	Therapeutic	C
BRAF	MUT	codon(s) 594 any	Melanoma/Adenocarcinoma in Skin/Colon/Rectum/Lung/Lung			2	20141835	Colorectal;Lung;Skin	Therapeutic	C
BRAF	MUT	codon(s) 600 any	Adenocarcinoma in Colon/Rectum			1	12068308,28404754,14734469,27825133,24885062,22281684,17786445	Colorectal	Therapeutic	B
BRAF	MUT	codon(s) 600 any	Adenocarcinoma in Lung			2	24888229,21483012	Lung	Therapeutic	C
BRAF	MUT	codon(s) 600 any	Glial Neoplasm in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	24725538,23547069,21274720	Brain;Nervous_System	Therapeutic	C
BRAF	MUT	codon(s) 600 any	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	codon(s) 600 any	Histiocytic and Dendritic Cell Neoplasms in Bone			2	24720374,25209580,24567436	Bone	Therapeutic	C
BRAF	MUT	codon(s) 600 any	Langerhans Cell Histiocytosis in Bone			1	20519626,25150293	Bone	Therapeutic	B
BRAF	MUT	codon(s) 600 any	Melanoma in Skin			1	23770823,12068308,23415641,25426645,24331719	Skin	Therapeutic	B
BRAF	MUT	codon(s) 600 any	Papillary Carcinoma in Thyroid			1	12068308,25367656,25422487	Thyroid	Therapeutic	B
BRAF	MUT	codon(s) 601 any	Adenocarcinoma in Lung			2	22798288	Lung	Therapeutic	C
BRAF	MUT	D594A	Skin Melanoma	Sorafenib,MEK Inhibitor	Sensitivity/Response	E	20141835	Skin	Therapeutic	D
BRAF	MUT	D594E	Melanoma/Adenocarcinoma in Skin/Colon/Rectum/Lung/Lung			2	20141835	Colorectal;Lung;Skin	Therapeutic	C
BRAF	MUT	D594G	Colorectal Cancer	Cetuximab,Irinotecan	Resistance	C	26989027	Colorectal	Therapeutic	C
BRAF	MUT	D594G	Colorectal Cancer		Poor Outcome	B	27404270	Colorectal	Prognostic	B
BRAF	MUT	D594G	Cutaneous melanoma	Sorafenib	Responsive	Pre-clinical	18794803	Skin	Therapeutic	D
BRAF	MUT	D594G	melanoma	Trametinib	sensitive	Preclinical - Cell culture	28783719	Skin	Therapeutic	D
BRAF	MUT	D594G	Skin Melanoma	Sorafenib	Sensitivity/Response	D	18794803	Skin	Therapeutic	D
BRAF	MUT	D594G	Skin Melanoma	U0126	Resistance	D	18794803	Skin	Therapeutic	D
BRAF	MUT	D594K	Colorectal Cancer	Irinotecan	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	D594K	Colorectal Cancer	Oxaliplatin	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	D594N	Advanced Solid Tumor	Vemurafenib	predicted - resistant	Preclinical - Cell culture	28783719	Other	Therapeutic	D
BRAF	MUT	D594N	lung non-small cell carcinoma	RMC-4550	predicted - sensitive	Preclinical - Pdx	30104724	Lung	Therapeutic	D
BRAF	MUT	D594V	Skin Melanoma	Trametinib,Sorafenib	Sensitivity/Response	E	20141835	Skin	Therapeutic	D
BRAF	MUT	485_490del	Cancer	LY3009120	Sensitivity/Response	D	26732095	Cancer	Therapeutic	D
BRAF	MUT	exon(s) 15 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Resistance	C	22614970	Stomach	Therapeutic	C
BRAF	MUT	F247L	Advanced Solid Tumor	Dabrafenib	sensitive	Preclinical - Cell culture	28512244	Other	Therapeutic	D
BRAF	MUT	F247L	Advanced Solid Tumor	Trametinib	sensitive	Preclinical - Cell culture	28512244	Other	Therapeutic	D
BRAF	MUT	F595L	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26582644	Other	Therapeutic	D
BRAF	FUS	Fusions	Melanoma	Cobimetinib, Trametinib	Response	3A	26314551, 23890088, 24345920, 26072686	Skin	Therapeutic	C
BRAF	FUS	Fusions	Ovarian Cancer	Cobimetinib, Trametinib	Response	3A	23890088, 26324360, 24345920	Ovary	Therapeutic	C
BRAF	MUT	G464	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	G464E	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	G464R	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	G464V	Adenocarcinoma in Lung			2	12068308	Lung	Therapeutic	C
BRAF	MUT	G464V	Advanced Solid Tumor	Vemurafenib	resistant	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	G464V	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	G466E	melanoma	AZ628	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	G466E	melanoma	Dabrafenib	decreased response	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	G466E	melanoma	PLX7904	decreased response	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	G466E	melanoma	TAK-632	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	G466E	melanoma	Vemurafenib	decreased response	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	G466V	Adenocarcinoma/Non-Small Cell Lung Carcinoma/Carcinoma in Lung			2	22649091,12068308	Lung	Therapeutic	C
BRAF	MUT	G466V	Advanced Solid Tumor	Vemurafenib	no benefit	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	G466V	colorectal cancer	Cetuximab	sensitive	Preclinical - Pdx	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G466V	colorectal cancer	Irinotecan + Panitumumab	predicted - sensitive	Case Reports/Case Series	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G466V	colorectal cancer	Trametinib	sensitive	Preclinical - Pdx	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G466V	colorectal cancer	Vemurafenib	no benefit	Preclinical - Pdx	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G466V	Lung adenocarcinoma	Dasatinib	Responsive	Pre-clinical	22649091	Lung	Therapeutic	D
BRAF	MUT	G466V	lung adenocarcinoma	PLX8394	sensitive	Preclinical - Cell culture	27834212	Lung	Therapeutic	D
BRAF	MUT	G466V	lung cancer	RMC-4550	predicted - sensitive	Preclinical - Cell culture	30104724	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Preclinical - Cell culture	28947956	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	Dasatinib	sensitive	Preclinical - Cell culture	22649091	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	TAE226	sensitive	Preclinical	26090892	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	TAK-632	sensitive	Preclinical - Cell culture	27523909	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	28783719	Lung	Therapeutic	D
BRAF	MUT	G466V	lung non-small cell carcinoma	Vemurafenib	decreased response	Preclinical - Cell culture	27523909	Lung	Therapeutic	D
BRAF	MUT	G469A	Adenocarcinoma in Colon			2	12068308,28404754,14734469,27825133,24885062,22281684,17786445,21227396	Colorectal	Therapeutic	C
BRAF	MUT	G469A	Adenocarcinoma in Lung			2	22649091,12068308	Lung	Therapeutic	C
BRAF	MUT	G469A	Advanced Solid Tumor	Vemurafenib	resistant	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	G469A	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	G469A	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	G469A	head and neck cancer	Ulixertinib	sensitive	Phase I	29247021	Head_and_Neck	Therapeutic	C
BRAF	MUT	G469A	Head an neck squamous	[ERK inhibitor]	Responsive	Case report	ASCO 2017 (abstr 2508)	Head_and_Neck	Therapeutic	D
BRAF	MUT	G469A	Lung adenocarcinoma	[EGFR TK inhibitor]	Resistant	Case report	22773810	Lung	Therapeutic	D
BRAF	MUT	G469A	lung adenocarcinoma	PLX8394	sensitive	Preclinical - Cell line xenograft	27834212	Lung	Therapeutic	D
BRAF	MUT	G469A	lung cancer	RMC-4550	resistant	Preclinical - Cell culture	30104724	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Dabrafenib	sensitive	Preclinical - Cell culture	29903896	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Preclinical - Cell culture	28947956	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Encorafenib + Trametinib	sensitive	Preclinical - Cell culture	29903896	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	TAE226	sensitive	Preclinical	26090892	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	25706985	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Trametinib + Vemurafenib	conflicting	Preclinical - Cell culture	25706985	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Trametinib + Vemurafenib	conflicting	Preclinical - Cell culture	29903896	Lung	Therapeutic	D
BRAF	MUT	G469A	lung non-small cell carcinoma	Vemurafenib	resistant	Preclinical - Cell culture	25706985	Lung	Therapeutic	D
BRAF	MUT	G469A	small intestine carcinoma	Ulixertinib	sensitive	Phase I	29247021	Other	Therapeutic	C
BRAF	MUT	G469E	Cutaneous melanoma	Sorafenib	Responsive	Pre-clinical	18794803	Skin	Therapeutic	D
BRAF	MUT	G469E	Skin Melanoma	Sorafenib	Sensitivity/Response	D	18794803	Skin	Therapeutic	D
BRAF	MUT	G469E	Skin Melanoma	U0126		D	18794803	Skin	Therapeutic	D
BRAF	MUT	G469L	lung adenocarcinoma	Vemurafenib	no benefit	Case Reports/Case Series	24035431	Lung	Therapeutic	D
BRAF	MUT	G469R	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	G469V	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	G469V	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	G469V	lung non-small cell carcinoma	Sorafenib	predicted - sensitive	Case Reports/Case Series	27388325	Lung	Therapeutic	D
BRAF	MUT	G469V	melanoma	Encorafenib	no benefit	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	G596C	Lung Non-small Cell Carcinoma	Trametinib,Dabrafenib	Sensitivity/Response	D	27577079	Lung	Therapeutic	D
BRAF	MUT	G596R	Advanced Solid Tumor	Vemurafenib	no benefit	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	G596R	colorectal cancer	Dabrafenib + Trametinib	sensitive	Preclinical - Cell culture	28947956	Colorectal	Therapeutic	D
BRAF	MUT	G596R	colorectal cancer	RMC-4550	predicted - sensitive	Preclinical - Cell culture	30104724	Colorectal	Therapeutic	D
BRAF	MUT	G596R	colorectal cancer	Trametinib	sensitive	Preclinical - Cell culture	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G596R	colorectal cancer	Vemurafenib	resistant	Preclinical - Cell culture	28783719	Colorectal	Therapeutic	D
BRAF	MUT	G606E	Advanced Solid Tumor	Vemurafenib	no benefit	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	Gain-of-Function	Advanced Solid Tumor	Binimetinib + Encorafenib	sensitive	Phase Ib/II	;	Other	Therapeutic	C
BRAF	MUT	Gain-of-Function	Advanced Solid Tumor	PLX8394	sensitive	Preclinical	24422853	Other	Therapeutic	D
BRAF	MUT	Gain-of-Function	colorectal cancer	Venetoclax + VX-11e	no benefit	Preclinical - Cell culture	27974663	Colorectal	Therapeutic	D
BRAF	MUT	Gain-of-Function	colorectal cancer	VX-11e + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Colorectal	Therapeutic	D
BRAF	MUT	Gain-of-Function	lung non-small cell carcinoma	RAF709	sensitive	Preclinical - Pdx	29343524	Lung	Therapeutic	D
BRAF	MUT	Gain-of-Function	melanoma	Cobimetinib	sensitive	Preclinical - Cell line xenograft	22084396	Skin	Therapeutic	D
BRAF	MUT	Gain-of-Function	melanoma	Sorafenib	no benefit	Phase II	22394203;16880785	Skin	Therapeutic	C
BRAF	MUT	Gain-of-Function	papillary thyroid carcinoma	Vemurafenib	sensitive	Phase I	23489023	Thyroid	Therapeutic	C
BRAF	MUT	Gain-of-Function	thyroid cancer	Dabrafenib	sensitive	Guideline	;	Thyroid	Therapeutic	A
BRAF	MUT	Gain-of-Function	thyroid cancer	Vemurafenib	sensitive	Guideline	;	Thyroid	Therapeutic	A
BRAF	MUT	Gain-of-Function	thyroid cancer	Vemurafenib	sensitive	Phase I	23489023	Thyroid	Therapeutic	C
BRAF	MUT	485_485del	Any cancer type	[Pan-RAF inhibitor]	Responsive	Pre-clinical	26732095	Cancer	Therapeutic	D
BRAF	MUT	485_485del	Any cancer type	Vemurafenib	Resistant	Pre-clinical	26732095	Cancer	Therapeutic	D
BRAF	MUT	490_490del	Any cancer type	[Pan-RAF inhibitor]	Responsive	Pre-clinical	26732095	Cancer	Therapeutic	D
BRAF	MUT	490_490del	Any cancer type	Vemurafenib	Resistant	Pre-clinical	26732095	Cancer	Therapeutic	D
BRAF	MUT	intron 10 rearrangement	Melanoma	Dabrafenib,Vemurafenib	Resistance	B	24265155	Skin	Therapeutic	B
BRAF	MUT	intron 9 rearrangement	Melanoma	Dabrafenib,Vemurafenib	Resistance	B	24265155	Skin	Therapeutic	B
BRAF	MUT	K483M	Skin Melanoma	Sorafenib,MEK Inhibitor	Sensitivity/Response	E	20141835	Skin	Therapeutic	D
BRAF	MUT	K601	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	K601E	Adenocarcinoma in Lung			2	22798288	Lung	Therapeutic	C
BRAF	MUT	K601E	Advanced Solid Tumor	Trametinib	sensitive	Preclinical - Cell culture	22798288	Other	Therapeutic	D
BRAF	MUT	K601E	Advanced Solid Tumor	Vemurafenib	conflicting	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	K601E	Advanced Solid Tumor	Vemurafenib	conflicting	Preclinical - Cell culture	22798288	Other	Therapeutic	D
BRAF	MUT	K601E	Advanced Solid Tumor	Vemurafenib	conflicting	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	K601E	melanoma	Dabrafenib	no benefit	Phase I	22608338	Skin	Therapeutic	C
BRAF	MUT	K601E	melanoma	Trametinib	predicted - sensitive	Case Reports/Case Series	23248257	Skin	Therapeutic	D
BRAF	MUT	K601E	melanoma	Trametinib	predicted - sensitive	Case Reports/Case Series	28344857	Skin	Therapeutic	D
BRAF	MUT	K601E	Papillary Carcinoma/Follicular Carcinoma in Thyroid			1	26422023,22136270,2383702,25417114	Thyroid	Therapeutic	B
BRAF	MUT	K601E	Skin Melanoma	Vemurafenib,Trametinib	Sensitivity/Response	D	22798288	Skin	Therapeutic	D
BRAF	MUT	K601	Melanoma	Trametinib	Response	3A	22798288, 28344857, 24933606, 23248257, 29903896	Skin	Therapeutic	C
BRAF	MUT	K601N	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	K601N	hematologic cancer	LY3009120	sensitive	Preclinical - Cell culture	26732095	Blood	Therapeutic	D
BRAF	MUT	K601R	Cutaneous melanoma	[Trametinib]	Responsive	Case report	23248257;22805292;23248257	Skin	Therapeutic	D
BRAF	MUT	K601T	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	L485delinsLY	lung non-small cell carcinoma	LY3009120	sensitive	Preclinical	26732095	Lung	Therapeutic	D
BRAF	MUT	L485delinsLY	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical	26732095	Lung	Therapeutic	D
BRAF	MUT	L485delinsLY	lung non-small cell carcinoma	Vemurafenib	resistant	Preclinical	26732095	Lung	Therapeutic	D
BRAF	MUT	L485W	Billiary tract	[ERK inhibitor]	Responsive	Case report	ASCO 2017 (abstr 2508)	Other	Therapeutic	D
BRAF	MUT	L485W	gallbladder cancer	Ulixertinib	sensitive	Phase I	29247021;29247016	Bladder	Therapeutic	C
BRAF	MUT	L485Y	lung non-small cell carcinoma	GDC0879	resistant	Preclinical - Cell culture	19276360	Lung	Therapeutic	D
BRAF	MUT	L505H	Melanoma	Vemurafenib	Resistance	B	25515853	Skin	Therapeutic	B
BRAF	MUT	L505H	Melanoma	Vemurafenib	Resistance	D	24112705	Skin	Therapeutic	D
BRAF	MUT	L505H	melanoma	Vemurafenib	resistant	Preclinical	24283590	Skin	Therapeutic	D
BRAF	MUT	L514V	breast cancer	Dabrafenib	resistant	Preclinical - Cell culture	29880583	Breast	Therapeutic	D
BRAF	MUT	L597	All Tumors	PLX8394	Response	4	26466569, 28659148, 28783719, 30559419	Cancer	Therapeutic	D
BRAF	MUT	L597	Melanoma	Trametinib	Response	3A	22798288, 24933606, 29903896	Skin	Therapeutic	C
BRAF	MUT	L597Q	Advanced Solid Tumor	Vemurafenib	resistant	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	L597Q	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	L597Q	lung cancer	Ulixertinib	sensitive	Phase I	29247021	Lung	Therapeutic	C
BRAF	MUT	L597Q	Skin Melanoma	Trametinib	Sensitivity/Response	C	24933606	Skin	Therapeutic	C
BRAF	MUT	L597Q	Skin Melanoma	Vemurafenib,Trametinib	Sensitivity/Response	D	22798288	Skin	Therapeutic	D
BRAF	MUT	L597R	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	22798288	Other	Therapeutic	D
BRAF	MUT	L597R	Advanced Solid Tumor	Vemurafenib	sensitive	Preclinical	22798288	Other	Therapeutic	D
BRAF	MUT	L597R	Cutaneous melanoma	[BRAF inhibitor]	Responsive	Case report	23715574	Skin	Therapeutic	D
BRAF	MUT	L597R	Cutaneous melanoma	[Trametinib]	Responsive	Case report	23248257;22805292;23248257	Skin	Therapeutic	D
BRAF	MUT	L597R	Melanoma in Skin			1	23715574,22798288,23770823	Skin	Therapeutic	B
BRAF	MUT	L597R	Melanoma	Vemurafenib	Sensitivity/Response	C	23715574	Skin	Therapeutic	C
BRAF	MUT	L597R	Skin Melanoma	Vemurafenib,Trametinib	Sensitivity/Response	D	22798288	Skin	Therapeutic	D
BRAF	MUT	L597S	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	22798288	Other	Therapeutic	D
BRAF	MUT	L597S	Advanced Solid Tumor	Vemurafenib	sensitive	Preclinical	22798288	Other	Therapeutic	D
BRAF	MUT	L597S	melanoma	Binimetinib + Encorafenib	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Binimetinib	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Cobimetinib	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Dabrafenib	predicted - sensitive	Preclinical - Pdxcell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Dabrafenib + Trametinib	sensitive	Case Reports/Case Series	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Encorafenib	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	Encorafenib + Trametinib	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	LY3009120	sensitive	Preclinical - Cell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	melanoma	TAK-733	sensitive	Phase I	22798288	Skin	Therapeutic	C
BRAF	MUT	L597S	melanoma	Trametinib	predicted - sensitive	Preclinical - Pdxcell culture	29903896	Skin	Therapeutic	D
BRAF	MUT	L597S	Skin Melanoma	TAK-733	Sensitivity/Response	C	22798288	Skin	Therapeutic	C
BRAF	MUT	L597S	Skin Melanoma	Vemurafenib,Trametinib	Sensitivity/Response	D	22798288	Skin	Therapeutic	D
BRAF	MUT	L597V	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	26343582	Other	Therapeutic	D
BRAF	MUT	L597V	Melanoma in Skin			1	23715574,22798288,23770823	Skin	Therapeutic	B
BRAF	MUT	L597V	Skin Melanoma	Trametinib	Sensitivity/Response	C	22805292	Skin	Therapeutic	C
BRAF	MUT	mutant	Advanced Solid Tumor	BGB-283	sensitive	Phase I	;	Other	Therapeutic	C
BRAF	MUT	mutant	Advanced Solid Tumor	CC-90003	no benefit	Phase I	;	Other	Therapeutic	C
BRAF	MUT	mutant	Advanced Solid Tumor	Dabrafenib	sensitive	Phase I	22608338	Other	Therapeutic	C
BRAF	MUT	mutant	Advanced Solid Tumor	KO-947	predicted - sensitive	Preclinical - Pdx	;	Other	Therapeutic	D
BRAF	MUT	mutant	Advanced Solid Tumor	LXH 254	predicted - sensitive	Case Reports/Case Series	;	Other	Therapeutic	D
BRAF	MUT	mutant	Advanced Solid Tumor	MLN2480	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
BRAF	MUT	mutant	Advanced Solid Tumor	Obatoclax	sensitive	Preclinical	22460902	Other	Therapeutic	D
BRAF	MUT	mutant	Advanced Solid Tumor	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Cell line xenograft	26140595	Other	Therapeutic	D
BRAF	MUT	mutant	Advanced Solid Tumor	RAF709	sensitive	Phase I	29343524	Other	Therapeutic	C
BRAF	MUT	mutant	Advanced Solid Tumor	XL147	decreased response	Preclinical	25637314	Other	Therapeutic	D
BRAF	MUT	mutant	cervix carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Cervix	Therapeutic	D
BRAF	MUT	mutant	colon cancer	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Cell line xenograft	26140595	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colon cancer	Selumetinib	predicted - sensitive	Preclinical - Cell culture	27655129	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Alpelisib + Cetuximab + Encorafenib	sensitive	Phase Ib/II	;28363909	Colorectal	Therapeutic	C
BRAF	MUT	mutant	colorectal cancer	AZ628 + Selumetinib	sensitive	Preclinical - Cell culture	26351322	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Belvarafenib	sensitive	Preclinical - Cell line xenograft	;	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Binimetinib	predicted - sensitive	Phase I	28152546	Colorectal	Therapeutic	C
BRAF	MUT	mutant	colorectal cancer	Cetuximab + Encorafenib	sensitive	Phase Ib/II	28363909	Colorectal	Therapeutic	C
BRAF	MUT	mutant	colorectal cancer	Cetuximab + LSN3074753	sensitive	Preclinical - Pdx	28611205	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Dabrafenib + Panitumumab + Trametinib	predicted - sensitive	Phase Ib/II	27770002	Colorectal	Therapeutic	C
BRAF	MUT	mutant	colorectal cancer	KO-947	predicted - sensitive	Preclinical - Pdx	;	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	LSN3074753	predicted - sensitive	Preclinical - Pdx	28611205	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	MLN2480	sensitive	Preclinical	;	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	PLX4720	decreased response	Preclinical - Cell culture	26351322	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Regorafenib	no benefit	Phase II	30120161	Colorectal	Therapeutic	C
BRAF	MUT	mutant	colorectal cancer	SYM004	predicted - resistant	Preclinical - Pdx	29423521	Colorectal	Therapeutic	D
BRAF	MUT	mutant	colorectal cancer	Trametinib	resistant	Preclinical	26343583	Colorectal	Therapeutic	D
BRAF	MUT	mutant	lung adenocarcinoma	Trametinib	sensitive	Preclinical	26343583	Lung	Therapeutic	D
BRAF	MUT	mutant	lung non-small cell carcinoma	Dabrafenib + Trametinib	predicted - sensitive	Preclinical - Cell culture	28947956	Lung	Therapeutic	D
BRAF	MUT	mutant	lung non-small cell carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Lung	Therapeutic	D
BRAF	MUT	mutant	lung non-small cell carcinoma	unspecified PD-1 antibody	predicted - sensitive	Clinical Study - Cohort	;	Lung	Therapeutic	C
BRAF	MUT	mutant	lung non-small cell carcinoma	unspecified PD-L1 antibody	predicted - sensitive	Clinical Study - Cohort	;	Lung	Therapeutic	C
BRAF	MUT	mutant	melanoma	Belvarafenib	predicted - sensitive	Phase I	;	Skin	Therapeutic	C
BRAF	MUT	mutant	melanoma	BI-847325	predicted - sensitive	Preclinical - Cell line xenograft	25873592	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Binimetinib + Buparlisib	sensitive	Preclinical - Cell culture	27307593	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Buparlisib + Encorafenib	sensitive	Preclinical - Cell culture	27307593	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Buparlisib	sensitive	Preclinical - Cell line xenograft	27307593	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	E6201 + LY294002	sensitive	Preclinical	23039341	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	E6201	sensitive	Preclinical	23039341	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Encorafenib	sensitive	Phase I	28611198	Skin	Therapeutic	C
BRAF	MUT	mutant	melanoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	MLN2480	sensitive	Phase I	;	Skin	Therapeutic	C
BRAF	MUT	mutant	melanoma	MLN2480	sensitive	Preclinical	;	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Palbociclib + Trametinib	sensitive	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	PET-16 + Vemurafenib	sensitive	Preclinical - Cell line xenograft	26984758	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	PLX8394	sensitive	Preclinical	24422853	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	S63845 + Trametinib	sensitive	Preclinical - Cell culture	27760111	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	S63845 + Vemurafenib	sensitive	Preclinical - Cell culture	27760111	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Selumetinib	sensitive	Phase II	22048237	Skin	Therapeutic	C
BRAF	MUT	mutant	melanoma	ST-162	predicted - sensitive	Preclinical - Cell line xenograft	28775144	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Tubastatin A	sensitive	Preclinical	25957812	Skin	Therapeutic	D
BRAF	MUT	mutant	melanoma	Ulixertinib	predicted - sensitive	Phase I	29247021	Skin	Therapeutic	C
BRAF	MUT	mutant	melanoma	Vemurafenib + Voruciclib	sensitive	Phase I	;	Skin	Therapeutic	C
BRAF	MUT	mutant	multiple myeloma	Trametinib	sensitive	Preclinical	26343583	Bone_Marrow	Therapeutic	D
BRAF	MUT	mutant	pancreatic adenocarcinoma	Trametinib	sensitive	Preclinical	26343583	Pancreas	Therapeutic	D
BRAF	MUT	mutant	pancreatic cancer	KO-947	predicted - sensitive	Preclinical - Pdx	;	Pancreas	Therapeutic	D
BRAF	MUT	mutant	stomach carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Stomach	Therapeutic	D
BRAF	MUT	mutant	thyroid cancer	Belvarafenib	sensitive	Preclinical - Cell culture	;	Thyroid	Therapeutic	D
BRAF	MUT	mutant	thyroid cancer	Selumetinib	sensitive	Phase I	23406027	Thyroid	Therapeutic	C
BRAF	MUT	mutation	Cancer	Trametinib	Sensitivity/Response	D	22169769	Cancer	Therapeutic	D
BRAF	MUT	mutation	Colorectal Cancer	Bevacizumab	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	D	22586653	Colorectal	Therapeutic	D
BRAF	MUT	mutation	Colorectal Cancer	Irinotecan	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	mutation	Colorectal Cancer	Oxaliplatin	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	mutation	Colorectal Cancer		Poor Outcome	B	19603024	Colorectal	Prognostic	B
BRAF	MUT	mutation	Colorectal Cancer		Poor Outcome	B	21641636	Colorectal	Prognostic	B
BRAF	MUT	mutation	Colorectal Cancer		Poor Outcome	B	24112392	Colorectal	Prognostic	B
BRAF	MUT	486_490del	ovarian cancer	Dabrafenib	predicted - resistant	Preclinical	26732095	Ovary	Therapeutic	D
BRAF	MUT	486_490del	ovarian cancer	LY3009120	sensitive	Preclinical	26732095	Ovary	Therapeutic	D
BRAF	MUT	486_490del	ovarian cancer	Trametinib	sensitive	Preclinical	26732095	Ovary	Therapeutic	D
BRAF	MUT	486_490del	ovarian cancer	Vemurafenib	resistant	Preclinical	26732095	Ovary	Therapeutic	D
BRAF	MUT	486_490del	pancreatic ductal adenocarcinoma	Trametinib	predicted - sensitive	Case Reports/Case Series	29903880	Pancreas	Therapeutic	D
BRAF	MUT	N486delinsNK	Advanced Solid Tumor	Cobimetinib	predicted - sensitive	Preclinical - Cell culture	30867592	Other	Therapeutic	D
BRAF	MUT	N486delinsNK	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
BRAF	MUT	N581D	lung non-small cell carcinoma	RMC-4550	predicted - sensitive	Preclinical - Pdx	30104724	Lung	Therapeutic	D
BRAF	MUT	N581S	Advanced Solid Tumor	Vemurafenib	no benefit	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	N581S	lung adenocarcinoma	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Patient cell culture	26140595	Lung	Therapeutic	D
BRAF	MUT	N581S	Melanoma in Skin			1	20141835,22817889,23875803,17724477,19624854	Skin	Therapeutic	B
BRAF	MUT	N581Y	colon cancer	GDC0879	resistant	Preclinical - Cell culture	19276360	Colorectal	Therapeutic	D
BRAF	MUT	Non-V600	Colorectal Cancer		Better Outcome	B	28486044	Colorectal	Prognostic	B
BRAF	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib	Response	3A	29236635, 30867592	Lymph_Nodes	Therapeutic	C
BRAF	MUT	P731T	Advanced Solid Tumor	Vemurafenib	no benefit	Clinical Study - Cohort	29320312	Other	Therapeutic	C
BRAF	MUT	T599delinsTT	Glial Neoplasm in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	21190184	Brain;Nervous_System	Therapeutic	C
BRAF	MUT	47_380del	melanoma	Dabrafenib + Trametinib	predicted - resistant	Case Reports/Case Series	29171936	Skin	Therapeutic	D
BRAF	MUT	V487delinsVA	pancreatic cancer	Dabrafenib	resistant	Preclinical	26732095	Pancreas	Therapeutic	D
BRAF	MUT	V487delinsVA	pancreatic cancer	LY3009120	sensitive	Preclinical	26732095	Pancreas	Therapeutic	D
BRAF	MUT	V487delinsVA	pancreatic cancer	Trametinib	sensitive	Preclinical	26732095	Pancreas	Therapeutic	D
BRAF	MUT	V487delinsVA	pancreatic cancer	Vemurafenib	resistant	Preclinical - Cell line xenograft	26732095	Pancreas	Therapeutic	D
BRAF	MUT	V504_R506dup	Advanced Solid Tumor	Sorafenib	resistant	Preclinical - Cell culture	30575814	Other	Therapeutic	D
BRAF	MUT	V504_R506dup	Advanced Solid Tumor	Trametinib	resistant	Preclinical - Cell culture	30575814	Other	Therapeutic	D
BRAF	MUT	V504_R506dup	Advanced Solid Tumor	Vemurafenib	resistant	Preclinical - Cell culture	30575814	Other	Therapeutic	D
BRAF	MUT	V600	Cholangiocarcinoma	Vemurafenib	Sensitivity/Response	B	26287849	Bile_Duct	Therapeutic	B
BRAF	MUT	V600	Colorectal adenocarcinoma	[BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor]	Responsive	Early trials	28363909	Colorectal	Therapeutic	C
BRAF	MUT	V600	Colorectal adenocarcinoma	Irinotecan;Vemurafenib;Cetuximab	Responsive	Early trials	27729313	Colorectal	Therapeutic	C
BRAF	MUT	V600	Colorectal adenocarcinoma	Panitumumab;Dabrafenib;BYL719	Responsive	Early trials	ENA 2014 (abstr 11LBA)	Colorectal	Therapeutic	C
BRAF	MUT	V600	Colorectal Cancer	Cetuximab,Encorafenib,Alpelisib	Sensitivity/Response	B	28363909	Colorectal	Therapeutic	B
BRAF	MUT	V600	Colorectal Cancer	Cetuximab,Encorafenib	Sensitivity/Response	B	28363909	Colorectal	Therapeutic	B
BRAF	MUT	V600	Colorectal Cancer	Cetuximab,Irinotecan,Vemurafenib	Sensitivity/Response	B	147167	Colorectal	Therapeutic	B
BRAF	MUT	V600	Colorectal Cancer	Panitumumab	Resistance	B	23325582	Colorectal	Therapeutic	B
BRAF	MUT	V600	Colorectal Cancer	Trametinib,Dabrafenib	Sensitivity/Response	B	26392102	Colorectal	Therapeutic	B
BRAF	MUT	V600	Colorectal Cancer	Vemurafenib + Panitumumab, Panitumumab + Dabrafenib + Trametinib	Response	3A	19884556, 29431699, 20619739, 25589621, 19001320, 22448344	Colorectal	Therapeutic	C
BRAF	MUT	V600	Colorectal Cancer	Vemurafenib	Resistance	B	26287849	Colorectal	Therapeutic	B
BRAF	MUT	V600D	Cutaneous melanoma	Vemurafenib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
BRAF	MUT	V600D	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600D	melanoma	AZ628	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600D	melanoma	CCT196969	sensitive	Preclinical	25500121;17210691	Skin	Therapeutic	D
BRAF	MUT	V600D	melanoma	CCT241161	sensitive	Preclinical	25500121;17210691	Skin	Therapeutic	D
BRAF	MUT	V600D	melanoma	Dabrafenib	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600D	Melanoma	Dabrafenib	Sensitivity/Response	B	23463675	Skin	Therapeutic	B
BRAF	MUT	V600D	melanoma	PLX7904	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600D	melanoma	TAK-632	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600D	melanoma	Vemurafenib	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600D	Melanoma	Vemurafenib	Sensitivity/Response	D	18287029	Skin	Therapeutic	D
BRAF	MUT	V600D	Melanoma	Vemurafenib	Sensitivity/Response	D	20551065	Skin	Therapeutic	D
BRAF	MUT	V600D	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600D	pilocytic astrocytoma	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	28784858	Brain	Therapeutic	D
BRAF	MUT	V600E	Adenocarcinoma in Colon/Rectum			1	12068308,28404754,14734469,27825133,24885062,22281684,17786445	Colorectal	Therapeutic	B
BRAF	MUT	V600E	Adenocarcinoma in Lung			2	24888229,21483012	Lung	Therapeutic	C
BRAF	MUT	V600E	Advanced Solid Tumor	BGB-283	sensitive	Preclinical - Cell culture	26208524	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	CI-1040	sensitive	Preclinical	20538618	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Cell culture	26140595	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	PLX4720	sensitive	Preclinical	20538618	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	PLX8394	sensitive	Preclinical	24422853	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	RAF265	sensitive	Preclinical	20538618	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	SB590885	sensitive	Preclinical	20538618	Other	Therapeutic	D
BRAF	MUT	V600E	Advanced Solid Tumor	Vemurafenib	sensitive	Phase II	29320312	Other	Therapeutic	C
BRAF	MUT	V600E AMPLIFICATION	Colorectal Cancer	Selumetinib	Resistance	E	21098728	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib	Response	1	29072975	Thyroid	Therapeutic	A
BRAF	MUT	V600E	Anaplastic Thyroid Carcinoma	Trametinib,Dabrafenib	Sensitivity/Response	B	29072975	Thyroid	Therapeutic	B
BRAF	MUT	V600E	Anaplastic Thyroid Carcinoma	Vemurafenib,Pertuzumab	Sensitivity/Response	C	29320312	Thyroid	Therapeutic	C
BRAF	MUT	V600E	Anaplastic Thyroid Carcinoma	Vemurafenib	Sensitivity/Response	B	26287849	Thyroid	Therapeutic	B
BRAF	MUT	V600E	Cancer	Cobimetinib	Sensitivity/Response	D	23934108	Cancer	Therapeutic	D
BRAF	MUT	V600E	Cholangiocarcinoma	Dabrafenib,Trametinib DMSO	Sensitivity/Response	C	25435907	Bile_Duct	Therapeutic	C
BRAF	MUT	V600E	Cholangiocarcinoma	Irinotecan,Panitumumab,Vemurafenib	Sensitivity/Response	C	26687137	Bile_Duct	Therapeutic	C
BRAF	MUT	V600E	Cholangiocarcinoma	Trametinib DMSO,Dabrafenib	Sensitivity/Response	C	28078132	Bile_Duct	Therapeutic	C
BRAF	MUT	V600E	Cholangiocarcinoma	Trametinib DMSO,Dabrafenib	Sensitivity/Response	C	28480077	Bile_Duct	Therapeutic	C
BRAF	MUT	V600E	colon cancer	Binimetinib + Cetuximab + Encorafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Binimetinib + Encorafenib + Panitumumab	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Cetuximab + Dabrafenib + Trametinib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Cetuximab + Irinotecan + Vemurafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Cetuximab + Sorafenib	predicted - sensitive	Case Reports/Case Series	23792568	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	Dabrafenib + Panitumumab + Trametinib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	GDC0879	sensitive	Preclinical - Cell line xenograft	19276360	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	Gedatolisib	sensitive	Preclinical	24042735;21325073	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	Irinotecan + Panitumumab + Vemurafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	Navitoclax + Trametinib	sensitive	Preclinical	25665005	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	Navitoclax + Vemurafenib	sensitive	Preclinical	25665005	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	colon cancer	PD-0325901	sensitive	Preclinical - Cell line xenograft	16273091	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon cancer	PLX4720	sensitive	Preclinical - Cell line xenograft	18287029	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon carcinoma	RXDX-105	sensitive	Preclinical - Cell line xenograft	22319199	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon neuroendocrine neoplasm	Binimetinib	no benefit	Case Reports/Case Series	30181415	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colon neuroendocrine neoplasm	Dabrafenib	predicted - sensitive	Case Reports/Case Series	30181415	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal adenocarcinoma	Cetuximab	Resistant	Late trials	20619739;21163703;23325582	Colorectal	Therapeutic	C
BRAF	MUT	V600E	Colorectal adenocarcinoma	Dabrafenib;Trametinib	Responsive	Early trials	26392102;ASCO 2015 (abstr 8006)	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal adenocarcinoma	DEL-22379	sensitive	Preclinical - Pdx	26267534	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal adenocarcinoma	Panitumumab;Dabrafenib;Trametinib	Responsive	Early trials	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	Colorectal	Therapeutic	C
BRAF	MUT	V600E	Colorectal adenocarcinoma	Panitumumab	Resistant	Late trials	20619739;21163703;23325582	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Afatinib + BI 882370	sensitive	Preclinical	26916115	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Alpelisib + Cetuximab + Encorafenib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Bevacizumab	Resistance	B	19571295	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	BGB-283 + Cetuximab	sensitive	Preclinical - Cell line xenograft	26208524	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	BGB-283	sensitive	Preclinical - Pdxcell culture	26208524	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	BI 882370 + Cetuximab	sensitive	Preclinical	26916115	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	BI 882370 + Trametinib	sensitive	Preclinical	26916115	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Binimetinib + Cetuximab + Encorafenib	predicted - sensitive	Phase III	30892987	Colorectal	Therapeutic	C
BRAF	MUT	V600E	Colorectal Cancer	Capecitabine,Vemurafenib,Bevacizumab	Sensitivity/Response	D	22180495	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	CCT196969	sensitive	Preclinical - Cell culture	25500121;15294323	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	CCT241161	sensitive	Preclinical	25500121;15294323	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Dabrafenib + SCH772984	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Dabrafenib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Dabrafenib + Trametinib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Encorafenib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Cetuximab,Gefitinib,Vemurafenib	Sensitivity/Response	D	22281684	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + PLX4720	sensitive	Preclinical - Cell line xenograft	22281684	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Cetuximab	Resistance	B	20619739	Colorectal	Therapeutic	B
BRAF	MUT	V600E	Colorectal Cancer	Cetuximab	Resistance	B	25666295	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	Cetuximab + SCH772984	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Selumetinib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Vemurafenib	sensitive	Case Reports/Case Series	24523613	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cetuximab + Vemurafenib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Cobimetinib + Vemurafenib	sensitive	Preclinical - Cell line xenograft	28649441	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Dabrafenib + Panitumumab	sensitive	Phase I	29431699	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Dabrafenib + Panitumumab	sensitive	Phase Ib/II	;	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Dabrafenib + Panitumumab + Trametinib	predicted - sensitive	Phase I	29431699	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Dabrafenib + SCH772984	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Dabrafenib	sensitive	Preclinical	24885690	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Dabrafenib + Trametinib	sensitive	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Dactolisib,GDC-0879	Sensitivity/Response	D	23549875	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	DT01 + Fluorouracil + Oxaliplatin	sensitive	Preclinical - Cell line xenograft	26637369	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	EBI-907	sensitive	Preclinical - Cell line xenograft	26810733	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Encorafenib + Binimetinib + Cetuximab, Panitumumab + Dabrafenib + Trametinib	Response	2A	29431699	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	Encorafenib	sensitive	Phase I	;	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Erlotinib + Vemurafenib	sensitive	Preclinical - Cell line xenograft	22448344	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Everolimus + Pimasertib	sensitive	Preclinical - Cell culture	23629727	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Gefitinib + Vemurafenib	sensitive	Preclinical	22448344	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	INU-152	sensitive	Preclinical - Cell line xenograft	28645859	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Irinotecan	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	Lapatinib + Panobinostat	sensitive	Preclinical	21464044	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	LSN3074753	predicted - sensitive	Preclinical - Pdx	28611205	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer		Negative	B	27302369	Colorectal	Prognostic	B
BRAF	MUT	V600E	Colorectal Cancer	Oxaliplatin	Resistance	B	19603024	Colorectal	Therapeutic	B
BRAF	MUT	V600E	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	19001320	Colorectal	Therapeutic	B
BRAF	MUT	V600E	Colorectal Cancer	Panitumumab,Trametinib,Dabrafenib	Sensitivity/Response	B	29431699	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	Panitumumab + Trametinib	no benefit	Phase I	29431699	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Panitumumab + Vemurafenib	sensitive	Phase I	25589621	Colorectal	Therapeutic	C
BRAF	MUT	V600E	Colorectal Cancer	Panitumumab,Vemurafenib	Sensitivity/Response	C	27325282	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	PD-0325901	sensitive	Preclinical	26267534	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Pimasertib + Regorafenib	sensitive	Preclinical - Cell culture	23629727	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Pimasertib	sensitive	Preclinical - Cell culture	23629727	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Pimasertib + Sorafenib	sensitive	Preclinical - Cell culture	23629727	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	PLX4720,GDC0941	Sensitivity/Response	D	23845441	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	PLX4720,Nutlin-3	Sensitivity/Response	D	23812671	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	PLX4720 + TAK-632	sensitive	Preclinical - Cell line xenograft	27523909	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	PLX7904	sensitive	Preclinical - Cell line xenograft	26466569	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer		Poor Outcome	B	20008640	Colorectal	Prognostic	B
BRAF	MUT	V600E	Colorectal Cancer		Poor Outcome	B	21502544	Colorectal	Prognostic	B
BRAF	MUT	V600E	Colorectal Cancer		Poor Outcome	B	24594804	Colorectal	Prognostic	B
BRAF	MUT	V600E	Colorectal Cancer		Poor Outcome	B	27404270	Colorectal	Prognostic	B
BRAF	MUT	V600E	colorectal cancer	Refametinib	sensitive	Preclinical	19706763	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Regorafenib	sensitive	Preclinical - Cell line xenograft	21170960	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	SCH772984	sensitive	Preclinical	26267534	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Selumetinib	sensitive	Preclinical - Cell line xenograft	23942066	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	SHP099	resistant	Preclinical - Cell culture	27362227	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Sorafenib,Panitumumab	Sensitivity/Response	D	19001320	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Sorafenib	sensitive	Preclinical	24885690	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	TAK-632	sensitive	Preclinical - Cell culture	27523909	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Trametinib	sensitive	Preclinical	25309914	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Ulixertinib	sensitive	Preclinical - Cell line xenograft	28939558	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Vemurafenib,Cetuximab,Irinotecan	Sensitivity/Response	B	27729313	Colorectal	Therapeutic	B
BRAF	MUT	V600E	colorectal cancer	Vemurafenib	no benefit	Phase II	26460303	Colorectal	Therapeutic	C
BRAF	MUT	V600E	colorectal cancer	Vemurafenib	no benefit	Preclinical - Cell culture	27312529	Colorectal	Therapeutic	D
BRAF	MUT	V600E	colorectal cancer	Vemurafenib	no benefit	Preclinical - Cell line xenograft	22281684	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Colorectal Cancer	Vemurafenib	Sensitivity/Response	C	29320312	Colorectal	Therapeutic	C
BRAF	MUT	V600E	Colorectal Cancer	Vemurafenib	Sensitivity/Response	D	22180495	Colorectal	Therapeutic	D
BRAF	MUT	V600E	Cutaneous melanoma	[BRAF inhibitor;CDK2/4 inhibitor]	Responsive	Pre-clinical	22997239	Skin	Therapeutic	D
BRAF	MUT	V600E	Cutaneous melanoma	[BRAF inhibitor;HSP90 inhibitor]	Responsive	Pre-clinical	22351686	Skin	Therapeutic	D
BRAF	MUT	V600E	Cutaneous melanoma	[BRAF inhibitor;PI3K pathway inhibitor]	Responsive	Pre-clinical	22389471;21156289	Skin	Therapeutic	D
BRAF	MUT	V600E	Cutaneous melanoma	Dabrafenib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600E	Cutaneous melanoma	Dabrafenib;Trametinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600E	Cutaneous melanoma	[ERK inhibitor]	Responsive	Pre-clinical	23614898;22997239	Skin	Therapeutic	D
BRAF	MUT	V600E	Cutaneous melanoma	[Pan-RAF inhibitor]	Responsive	Early trials	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	Skin	Therapeutic	C
BRAF	MUT	V600E	Cutaneous melanoma	Trametinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600E	Cutaneous melanoma	Vemurafenib;Cobimetinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600E	Cutaneous melanoma	Vemurafenib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600E	ganglioglioma	Dabrafenib	predicted - sensitive	Case Reports/Case Series	29880583	Brain	Therapeutic	D
BRAF	MUT	V600E	Ganglioglioma	Vemurafenib	Sensitivity/Response	C	25524464	Brain	Therapeutic	C
BRAF	MUT	V600E	Gastrointestinal Neuroendocrine Tumor	Vemurafenib,Trametinib,Dabrafenib	Sensitivity/Response	C	27048246	Stomach	Therapeutic	C
BRAF	MUT	V600E	Gastrointestinal stromal	Dabrafenib	Responsive	Case report	23470635;22608338	Stomach	Therapeutic	D
BRAF	MUT	V600E	Glial Neoplasm in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	24725538,23547069,21274720	Brain;Nervous_System	Therapeutic	C
BRAF	MUT	V600E	glioblastoma multiforme	BI2536 + PLX4720	sensitive	Preclinical - Cell line xenograft	26573800	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	BI2536	sensitive	Preclinical - Cell culture	26573800	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	Cobimetinib + Vemurafenib	predicted - sensitive	Case Reports/Case Series	31217909	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	29632053	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	31217909	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	PD-0325901	decreased response	Preclinical - Cell culture	26573800	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	PLX4720	decreased response	Preclinical - Cell line xenograft	26573800	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	Ulixertinib	sensitive	Phase I	29247021	Brain	Therapeutic	C
BRAF	MUT	V600E	glioblastoma multiforme	Vemurafenib	predicted - sensitive	Case Reports/Case Series	31217909	Brain	Therapeutic	D
BRAF	MUT	V600E	glioblastoma multiforme	Vemurafenib	predicted - sensitive	Case Reports/Case Series	31386052	Brain	Therapeutic	D
BRAF	MUT	V600E	Glioma	[BRAF inhibitor]	Responsive	Pre-clinical	22038996;22586120	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600E	hairy cell leukemia	N/A	not applicable	Guideline	29118233	Blood;Bone_Marrow	Diagnostic	A
BRAF	MUT	V600E	Hairy Cell Leukemia		Positive	B	21663470	Blood;Bone_Marrow	Diagnostic	B
BRAF	MUT	V600E	Hairy Cell Leukemia	Vemurafenib	Response	2A	26352686	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600E	hairy cell leukemia	Vemurafenib	sensitive	Phase II	26352686	Blood;Bone_Marrow	Therapeutic	C
BRAF	MUT	V600E	Hairy Cell Leukemia	Vemurafenib	Sensitivity/Response	B	26352686	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600E	Histiocytic and Dendritic Cell Neoplasms in Bone			2	24720374,25209580,24567436	Bone	Therapeutic	C
BRAF	MUT	V600E/K AMPLIFICATION	Melanoma	Dabrafenib,Vemurafenib	Resistance	B	24265155	Skin	Therapeutic	B
BRAF	MUT	V600E	Langerhans Cell Histiocytosis in Bone			1	20519626,25150293	Bone	Therapeutic	B
BRAF	MUT	V600E	Laryngeal Squamous Cell Carcinoma	Vemurafenib	Sensitivity/Response	C	29320312	Esophagus	Therapeutic	C
BRAF	MUT	V600E	larynx cancer	Vemurafenib	predicted - sensitive	Case Reports/Case Series	29320312	Esophagus	Therapeutic	D
BRAF	MUT	V600E	Lung adenocarcinoma	Dabrafenib;Trametinib	Responsive	FDA guidelines	27283860	Lung	Therapeutic	A
BRAF	MUT	V600E	Lung adenocarcinoma	[EGFR TK inhibitor]	Resistant	Case report	22773810	Lung	Therapeutic	D
BRAF	MUT	V600E	Lung adenocarcinoma	[ERK inhibitor]	Responsive	Early trials	ASCO 2017 (abstr 2508)	Lung	Therapeutic	C
BRAF	MUT	V600E	Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma	Vemurafenib	Responsive	Case report	22743296;22621641;23612012	Blood;Bone_Marrow;Lung	Therapeutic	D
BRAF	MUT	V600E	Lung adenocarcinoma;Thyroid	Dabrafenib	Responsive	Early trials	23524406;22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);20818844;23489023;27080216	Lung;Thyroid	Therapeutic	C
BRAF	MUT	V600E	lung cancer	Ulixertinib	sensitive	Phase I	29247021	Lung	Therapeutic	C
BRAF	MUT	V600E	lung carcinoma	Dasatinib	resistant	Preclinical	22649091	Lung	Therapeutic	D
BRAF	MUT	V600E	Lung Non-small Cell Carcinoma	Dabrafenib	Resistance	C	23524406	Lung	Therapeutic	C
BRAF	MUT	V600E	lung non-small cell carcinoma	Dabrafenib	sensitive	Guideline	;	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Dabrafenib	sensitive	Phase II	27080216	Lung	Therapeutic	C
BRAF	MUT	V600E	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	27283860;27080216;28919011	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	;	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Navitoclax + Trametinib	sensitive	Preclinical	25665005	Lung	Therapeutic	D
BRAF	MUT	V600E	lung non-small cell carcinoma	Navitoclax + Vemurafenib	sensitive	Preclinical	25665005	Lung	Therapeutic	D
BRAF	MUT	V600E	Lung Non-small Cell Carcinoma	Trametinib,Dabrafenib	Sensitivity/Response	A	27283860	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Trametinib + TW-37	sensitive	Preclinical	25665005	Lung	Therapeutic	D
BRAF	MUT	V600E	lung non-small cell carcinoma	TW-37 + Vemurafenib	sensitive	Preclinical	25665005	Lung	Therapeutic	D
BRAF	MUT	V600E	lung non-small cell carcinoma	Vemurafenib	sensitive	Case Reports/Case Series	23733758	Lung	Therapeutic	D
BRAF	MUT	V600E	lung non-small cell carcinoma	Vemurafenib	sensitive	Guideline	;	Lung	Therapeutic	A
BRAF	MUT	V600E	lung non-small cell carcinoma	Vemurafenib	sensitive	Phase II	29320312	Lung	Therapeutic	C
BRAF	MUT	V600E	Lung Non-small Cell Carcinoma	Vemurafenib	Sensitivity/Response	B	29320312	Lung	Therapeutic	B
BRAF	MUT	V600E	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
BRAF	MUT	V600E	Malignant astrocytoma	PLX4720	Responsive	Pre-clinical	PMC3638050	Brain	Therapeutic	D
BRAF	MUT	V600E	Malignant astrocytoma	Vemurafenib	Responsive	Early trials	22586120	Brain	Therapeutic	C
BRAF	MUT	V600E	malignant glioma	Everolimus + PLX4720	predicted - sensitive	Preclinical - Cell culture	27217440	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	malignant glioma	Everolimus + Selumetinib	predicted - sensitive	Preclinical - Cell line xenograft	27217440	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	malignant glioma	PLX4720 + Selumetinib	predicted - sensitive	Preclinical - Cell line xenograft	27217440	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	malignant glioma	Vemurafenib	predicted - sensitive	Phase II	30351999	Nervous_System	Therapeutic	C
BRAF	MUT	V600E	melanoma	Alpelisib + PLX4720	sensitive	Preclinical - Cell line xenograft	27924459	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	ASN003	sensitive	Preclinical - Cell line xenograft	;	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	AZ628	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	BGB-283	sensitive	Phase I	;	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	BGB-283	sensitive	Preclinical - Cell culture	26208524	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	BI-69A11	sensitive	Preclinical	20531415;26603897	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	BI-847325	sensitive	Preclinical - Cell line xenograft	25873592	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	BI 882370 + Trametinib	sensitive	Preclinical	26916115	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	29573941;;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	29573941;;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	;30219628;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	;;;30219628	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	Guideline	30959471;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib + Encorafenib	sensitive	Guideline	30959471;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Binimetinib	sensitive	Phase II	23414587	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	CCT196969	sensitive	Preclinical - Pdx	25500121	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	CCT241161	sensitive	Preclinical - Pdx	25500121	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Cediranib + PLX4720 + Selumetinib	sensitive	Preclinical	26461489	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Cediranib + PLX4720	sensitive	Preclinical - Cell line xenograft	26461489	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Cobimetinib	sensitive	Phase I	27424159	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	Cobimetinib + Vemurafenib	sensitive	FDA approved - On Companion Diagnostic	27480103;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Cobimetinib + Vemurafenib	sensitive	FDA approved - On Companion Diagnostic	;;27480103	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Cobimetinib + Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Cobimetinib + Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600E	Melanoma	Cobimetinib,Vemurafenib	Sensitivity/Response	B	25265494	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	Dabrafenib + GSK2126458	sensitive	Preclinical	22389471	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Dabrafenib + SCH772984 + Trametinib	decreased response	Preclinical - Cell culture	28714990	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Dabrafenib	sensitive	FDA approved - On Companion Diagnostic	;;22735384	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;;25399551	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;;25399551	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;28891408;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	Phase II	28268064	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	Dabrafenib + Trametinib	sensitive	Preclinical	22389471	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	B	24583796	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	Dasatinib	sensitive	Preclinical	23242808	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	DEL-22379	sensitive	Preclinical - Cell line xenograft	26267534	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	DETD-35	sensitive	Preclinical - Cell line xenograft	27048951	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	DETD-35 + Vemurafenib	sensitive	Preclinical - Cell line xenograft	27048951	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Doxorubicin + PLX4720	sensitive	Preclinical - Cell line xenograft	27924459	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	E6201	sensitive	Preclinical	24448821	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	EBI-907	sensitive	Preclinical - Cell line xenograft	26810733	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Encorafenib + Ribociclib	sensitive	Phase Ib/II	28351928	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	Encorafenib	sensitive	Preclinical - Cell line xenograft	;	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Erlotinib + PLX4720	sensitive	Preclinical - Cell line xenograft	27924459	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Ganetespib + TAK-733	sensitive	Preclinical - Cell line xenograft	24398428	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	GDC0879	sensitive	Preclinical - Pdxcell culture	19276360	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Gefitinib + PLX4720	sensitive	Preclinical	23242808	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	GSK2126458	sensitive	Preclinical	22389471	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	GSK2126458 + Trametinib	sensitive	Preclinical	22389471	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Imatinib + PLX4720	sensitive	Preclinical - Cell line xenograft	27924459	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma in Skin			1	12068308,23415641,25426645,24331719	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	INU-152	sensitive	Preclinical - Cell line xenograft	28645859	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	LY3009120	sensitive	Preclinical	26343583	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Navitoclax + PLX4720	sensitive	Preclinical - Cell line xenograft	24983357	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Navitoclax + Trametinib	sensitive	Preclinical	25665005	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Navitoclax + Vemurafenib	sensitive	Preclinical	25665005	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Nivolumab	decreased response	Clinical Study - Cohort	30630828	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	PAC-1 + Trametinib + Vemurafenib	sensitive	Preclinical - Cell culture	27297867	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PAC-1 + Vemurafenib	sensitive	Preclinical - Cell line xenograft	27297867	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Palbociclib	no benefit	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Palbociclib + PD-0325901	sensitive	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PD-0325901	conflicting	Preclinical - Cell culture	26267534	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PD-0325901	conflicting	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Pembrolizumab	decreased response	Clinical Study	30630828	Skin	Therapeutic	C
BRAF	MUT	V600E	Melanoma	Pictilisib	Sensitivity/Response	C	25370471	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	PLX4720 + Selumetinib	sensitive	Preclinical	26461489	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PLX4720	sensitive	Preclinical - Cell line xenograft	18287029	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PLX4720 + Tivozanib	sensitive	Preclinical	26461489	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PLX4720 + Vorinostat	sensitive	Preclinical - Cell line xenograft	27924459	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	PLX7904	sensitive	Preclinical - Cell culture	26466569	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma		Poor Outcome	B	24388723	Skin	Prognostic	B
BRAF	MUT	V600E	melanoma	RAF265	predicted - sensitive	Phase I	28719152	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	RAF709	sensitive	Preclinical - Cell culture	29343524	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Refametinib	sensitive	Preclinical - Cell line xenograft	19706763	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	RMC-4550	resistant	Preclinical - Cell culture	30104724	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	RO4987655	sensitive	Preclinical - Cell culture	26438159	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	RO5126766	sensitive	Preclinical - Cell culture	26438159	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	RXDX-105	sensitive	Preclinical - Cell line xenograft	22319199	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	S3I-201	sensitive	Preclinical	23242808	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Saracatinib	sensitive	Preclinical	23242808	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SB590885	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SBI-0640726	sensitive	Preclinical	20531415;26603897	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SBI-0640756	sensitive	Preclinical	20531415;26603897	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SBI-0640756 + Vemurafenib	sensitive	Preclinical - Cell line xenograft	26603897	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SBI-755199	sensitive	Preclinical	26603897	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	SCH772984	sensitive	Preclinical	26267534	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma	Selumetinib,Dactolisib	Sensitivity/Response	D	26678033	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Selumetinib	sensitive	Phase II	22048237	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	SHP099	no benefit	Preclinical	27362227	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Sorafenib	no benefit	Phase II	22394203;16880785	Skin	Therapeutic	C
BRAF	MUT	V600E	melanoma	TAK-632	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	23020132	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	25265492	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	28891408	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	Trametinib	sensitive	FDA approved - On Companion Diagnostic	22663011;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Trametinib	sensitive	FDA approved - On Companion Diagnostic	22663011;;	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Trametinib	sensitive	Phase I	22805292	Skin	Therapeutic	C
BRAF	MUT	V600E	Melanoma	Trametinib	Sensitivity/Response	B	22663011	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	Trametinib + TW-37	sensitive	Preclinical	25665005	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	TW-37 + Vemurafenib	sensitive	Preclinical	25665005	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Ulixertinib	sensitive	Preclinical - Cell line xenograft	28939558	Skin	Therapeutic	D
BRAF	MUT	V600E	Melanoma	Vemurafenib, Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib, Encorafenib + Binimetinib	Response	1	29573941, 22735384, 28961848, 25265494, 25287827, 25399551, 22608338, 23051966, 28891408, 27480103, 22663011, 25265492, 24508103, 29361468, 28991513, 23020132	Skin	Therapeutic	A
BRAF	MUT	V600E	Melanoma	Vemurafenib	Resistance	D	24576830	Skin	Therapeutic	D
BRAF	MUT	V600E	melanoma	Vemurafenib	sensitive	FDA approved - On Companion Diagnostic	28961848;21639808	Skin	Therapeutic	A
BRAF	MUT	V600E	melanoma	Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600E	Melanoma	Vemurafenib	Sensitivity/Response	B	20818844	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Vemurafenib	Sensitivity/Response	B	23569304	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Vemurafenib	Sensitivity/Response	B	24508103	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Vemurafenib	Sensitivity/Response	B	25524477	Skin	Therapeutic	B
BRAF	MUT	V600E	Melanoma	Vemurafenib	Sensitivity/Response	B	26557775	Skin	Therapeutic	B
BRAF	MUT	V600E	melanoma	Vemurafenib + XL888	predicted - sensitive	Phase I	29674508	Skin	Therapeutic	C
BRAF	MUT	V600E	Multiple Myeloma	Vemurafenib	Sensitivity/Response	C	24997557	Bone_Marrow	Therapeutic	C
BRAF	MUT	V600E	Myeloma		Poor Outcome	B	23612012	Bone_Marrow	Prognostic	B
BRAF	MUT	V600E	Neuroendocrine	Dabrafenib;Trametinib	Responsive	Case report	27048246	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	neuroendocrine tumor	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	27048246	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	neuroendocrine tumor	Trametinib + Vemurafenib	predicted - sensitive	Case Reports/Case Series	27048246	Nervous_System	Therapeutic	D
BRAF	MUT	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib	Response	1	27283860, 28919011	Lung	Therapeutic	A
BRAF	MUT	V600E	Non-small cell lung	Dabrafenib	Responsive	NCCN guidelines	NCCN	Lung	Therapeutic	A
BRAF	MUT	V600E	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600E	ovarian cancer	CI-1040	sensitive	Preclinical - Cell line xenograft	19018267	Ovary	Therapeutic	D
BRAF	MUT	V600E	ovarian cancer	Vemurafenib	predicted - sensitive	Phase II	29320312	Ovary	Therapeutic	C
BRAF	MUT	V600E	Ovarian Cancer	Vemurafenib	Sensitivity/Response	B	29320312	Ovary	Therapeutic	B
BRAF	MUT	V600E	Ovarian Cystadenocarcinoma	Vemurafenib	Sensitivity/Response	C	26490654	Ovary	Therapeutic	C
BRAF	MUT	V600E	Ovary	[BRAF inhibitor]	Responsive	Case report	22608338	Ovary	Therapeutic	D
BRAF	MUT	V600E	Ovary	[MEK inhibitor]	Responsive	Pre-clinical	19018267	Ovary	Therapeutic	D
BRAF	MUT	V600E	Papillary Carcinoma in Thyroid			1	12068308,25367656,25422487	Thyroid	Therapeutic	B
BRAF	MUT	V600E	papillary thyroid carcinoma	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	31085763	Thyroid	Therapeutic	D
BRAF	MUT	V600E	papillary thyroid carcinoma	RO5126766	sensitive	Preclinical	27669459	Thyroid	Therapeutic	D
BRAF	MUT	V600E	Pediatric glioma	Selumetinib	Responsive	Early trials	NCT01089101	Nervous_System	Therapeutic	C
BRAF	MUT	V600E	pilocytic astrocytoma	Dabrafenib	predicted - sensitive	Case Reports/Case Series	28784858	Brain	Therapeutic	D
BRAF	MUT	V600E	pleomorphic xanthoastrocytoma	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	29632053	Brain	Therapeutic	D
BRAF	MUT	V600E	pleomorphic xanthoastrocytoma	Vemurafenib	predicted - sensitive	Case Reports/Case Series	31386052	Brain	Therapeutic	D
BRAF	MUT	V600E	pleomorphic xanthoastrocytoma	Vemurafenib	predicted - sensitive	Phase II	30351999	Brain	Therapeutic	C
BRAF	MUT	V600	Erdheim-Chester Disease	Vemurafenib	Response	1	26287849, 29188284	Blood	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Binimetinib + Cetuximab + Encorafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Binimetinib + Encorafenib + Panitumumab	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Cetuximab + Dabrafenib + Trametinib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Cetuximab + Irinotecan + Vemurafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Dabrafenib + Panitumumab + Trametinib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Irinotecan + Panitumumab + Vemurafenib	sensitive	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	rectum cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
BRAF	MUT	V600E	renal cell carcinoma	Vemurafenib	predicted - sensitive	Case Reports/Case Series	26918217	Kidney	Therapeutic	D
BRAF	MUT	V600E	salivary gland carcinoma	Dabrafenib + Trametinib	predicted - sensitive	Case Reports/Case Series	30323086	Esophagus	Therapeutic	D
BRAF	MUT	V600E	Skin Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	B	25399551	Skin	Therapeutic	B
BRAF	MUT	V600E	skin melanoma	Ganetespib	sensitive	Preclinical - Cell line xenograft	24398428	Skin	Therapeutic	D
BRAF	MUT	V600E	Skin Melanoma	Vemurafenib	Sensitivity/Response	A	21639808	Skin	Therapeutic	A
BRAF	MUT	V600E	Skin Melanoma	Vemurafenib	Sensitivity/Response	B	22356324	Skin	Therapeutic	B
BRAF	MUT	V600E	Thyroid	[BRAF inhibitor;MEK inhibitor]	Responsive	Early trials	ASCO 2013 (abstr 9029)	Thyroid	Therapeutic	C
BRAF	MUT	V600E	thyroid cancer	BGB-283	sensitive	Phase I	;	Thyroid	Therapeutic	C
BRAF	MUT	V600E	thyroid cancer	CLM3	sensitive	Preclinical	24423321	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Dasatinib + SCH772984	sensitive	Preclinical - Cell culture	27222538	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Dasatinib + Selumetinib	sensitive	Preclinical - Cell culture	27222538	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Dasatinib + Trametinib	sensitive	Preclinical - Cell culture	27222538	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Lapatinib + Vemurafenib	sensitive	Preclinical	23365119	Thyroid	Therapeutic	D
BRAF	MUT	V600E	Thyroid Cancer		Positive	B	21594703	Thyroid	Diagnostic	B
BRAF	MUT	V600E	thyroid cancer	Selumetinib	sensitive	Preclinical - Cell line xenograft	27222538	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	TAK-632	sensitive	Preclinical - Cell culture	27523909	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Trametinib	predicted - sensitive	Preclinical - Cell culture	27222538	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Vemurafenib	conflicting	Case Reports/Case Series	29320312	Thyroid	Therapeutic	D
BRAF	MUT	V600E	thyroid cancer	Vemurafenib	conflicting	Preclinical - Cell culture	27523909	Thyroid	Therapeutic	D
BRAF	MUT	V600E	Thyroid carcinoma	Vemurafenib	Responsive	Early trials	22608338;20818844;23489023	Thyroid	Therapeutic	C
BRAF	MUT	V600E	thyroid gland anaplastic carcinoma	Dabrafenib + Trametinib	sensitive	Clinical Study	27697975	Thyroid	Therapeutic	C
BRAF	MUT	V600E	thyroid gland anaplastic carcinoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	29072975;;	Thyroid	Therapeutic	A
BRAF	MUT	V600E	thyroid gland anaplastic carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	;	Thyroid	Therapeutic	A
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	18682506	Thyroid	Prognostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	21594703	Thyroid	Prognostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	21882184	Thyroid	Prognostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	24396464	Thyroid	Prognostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	25024077	Thyroid	Prognostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma		Positive	B	24570209	Thyroid	Diagnostic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	Sensitivity/Response	B	27460442	Thyroid	Therapeutic	B
BRAF	MUT	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	Sensitivity/Response	C	24987354	Thyroid	Therapeutic	C
BRAF	MUT	V600E	Thyroid	[MEK inhibitor]	Responsive	Early trials	22241789	Thyroid	Therapeutic	C
BRAF	MUT	V600G	Cutaneous melanoma	Vemurafenib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
BRAF	MUT	V600G	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600K	Cutaneous melanoma	Dabrafenib;Trametinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600K	Cutaneous melanoma	Trametinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600K	Cutaneous melanoma	Vemurafenib;Cobimetinib	Responsive	FDA guidelines	FDA	Skin	Therapeutic	A
BRAF	MUT	V600K	Cutaneous melanoma	Vemurafenib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
BRAF	MUT	V600K	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600K	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
BRAF	MUT	V600K	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	29573941;;;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	29573941;;;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	;30219628;;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	FDA approved - On Companion Diagnostic	;;;30219628	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	Guideline	30959471;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Binimetinib + Encorafenib	sensitive	Guideline	30959471;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Cobimetinib + Vemurafenib	sensitive	FDA approved - On Companion Diagnostic	;27480103;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Cobimetinib + Vemurafenib	sensitive	FDA approved - On Companion Diagnostic	;;27480103	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Cobimetinib + Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Cobimetinib + Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Dabrafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600K	Melanoma	Dabrafenib	Sensitivity/Response	B	21343559	Skin	Therapeutic	B
BRAF	MUT	V600K	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;25399551;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;;25399551	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Dabrafenib + Trametinib	sensitive	FDA approved - On Companion Diagnostic	;28891408;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Dabrafenib + Trametinib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600K	Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	B	28891408	Skin	Therapeutic	B
BRAF	MUT	V600K	Melanoma	Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Trametinib, Encorafenib + Binimetinib	Response	1	29573941, 28891408, 27480103, 22663011, 25265492, 25265494, 25287827, 29361468, 28991513, 23020132, 25399551	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	GSK2126458	sensitive	Preclinical	22389471	Skin	Therapeutic	D
BRAF	MUT	V600K	melanoma	Nivolumab	predicted - sensitive	Clinical Study - Cohort	30630828	Skin	Therapeutic	C
BRAF	MUT	V600K	melanoma	Pembrolizumab	predicted - sensitive	Clinical Study - Cohort	30630828	Skin	Therapeutic	C
BRAF	MUT	V600K	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	25265494	Skin	Therapeutic	B
BRAF	MUT	V600K	melanoma	Trametinib	sensitive	FDA approved - On Companion Diagnostic	22663011;;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Trametinib	sensitive	FDA approved - On Companion Diagnostic	22663011;;	Skin	Therapeutic	A
BRAF	MUT	V600K	melanoma	Trametinib	sensitive	Phase I	22805292	Skin	Therapeutic	C
BRAF	MUT	V600K	Melanoma	Trametinib	Sensitivity/Response	B	22663011	Skin	Therapeutic	B
BRAF	MUT	V600K	melanoma	Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600K	Melanoma	Vemurafenib	Sensitivity/Response	B	24508103	Skin	Therapeutic	B
BRAF	MUT	V600K	Melanoma	Vemurafenib	Sensitivity/Response	B	25524477	Skin	Therapeutic	B
BRAF	MUT	V600K	Melanoma	Vemurafenib	Sensitivity/Response	C	26989536	Skin	Therapeutic	C
BRAF	MUT	V600K	melanoma	Vemurafenib + XL888	predicted - sensitive	Phase I	29674508	Skin	Therapeutic	C
BRAF	MUT	V600K	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600K	Skin Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	B	25399551	Skin	Therapeutic	B
BRAF	MUT	V600	Langerhans-Cell Histiocytosis	Vemurafenib	Sensitivity/Response	B	26287849	Other	Therapeutic	B
BRAF	MUT	V600	Lung Non-small Cell Carcinoma	Vemurafenib	Sensitivity/Response	B	26287849	Lung	Therapeutic	B
BRAF	MUT	V600M	Cutaneous melanoma	Vemurafenib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
BRAF	MUT	V600	Melanoma	BAY 86-9766	Resistance	C	23434733	Skin	Therapeutic	C
BRAF	MUT	V600	Melanoma	Cobimetinib,Vemurafenib	Sensitivity/Response	B	25037139	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Cobimetinib,Vemurafenib	Sensitivity/Response	B	25265494	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Dabrafenib	Sensitivity/Response	B	22608338	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	B	23020132	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma		Positive	B	21166657	Skin	Diagnostic	B
BRAF	MUT	V600	Melanoma	RO4987655	Sensitivity/Response	B	24947927	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	25265492	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Trametinib,Dabrafenib	Sensitivity/Response	B	28891408	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Trametinib	Sensitivity/Response	B	22663011	Skin	Therapeutic	B
BRAF	MUT	V600	Melanoma	Vemurafenib,Cobimetinib	Sensitivity/Response	A	27480103	Skin	Therapeutic	A
BRAF	MUT	V600M	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600R	Cutaneous melanoma	Dabrafenib	Responsive	Early trials	23237741	Skin	Therapeutic	C
BRAF	MUT	V600R	Cutaneous melanoma	[Trametinib]	Responsive	Case report	23248257;22805292;23248257	Skin	Therapeutic	D
BRAF	MUT	V600R	Cutaneous melanoma	Vemurafenib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
BRAF	MUT	V600R	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	24495477,23009221,22230299,23088640,22639828,24428489	Blood;Bone_Marrow	Therapeutic	B
BRAF	MUT	V600R	melanoma	AZ628	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600R	melanoma	Dabrafenib	sensitive	Case Reports/Case Series	27255157	Skin	Therapeutic	D
BRAF	MUT	V600R	melanoma	Dabrafenib	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600R	melanoma	PLX7904	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600R	melanoma	TAK-632	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600R	melanoma	Vemurafenib	sensitive	Preclinical - Cell culture	27523909	Skin	Therapeutic	D
BRAF	MUT	V600R	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Responsive	NCCN guidelines	26287849	Blood;Lung;Other	Therapeutic	A
BRAF	MUT	V600	Skin Melanoma	Dabrafenib,Trametinib	Sensitivity/Response	A	25399551	Skin	Therapeutic	A
BRAF	MUT	V600X	cholangiocarcinoma	Vemurafenib	sensitive	Phase II	26287849	Bile_Duct	Therapeutic	C
BRAF	MUT	V600X	colorectal cancer	Cetuximab + Irinotecan + Vemurafenib	sensitive	Phase Ib/II	;	Colorectal	Therapeutic	C
BRAF	MUT	V600X	colorectal cancer	Cetuximab + Vemurafenib	sensitive	Phase II	26287849	Colorectal	Therapeutic	C
BRAF	MUT	V600X	colorectal cancer	Dabrafenib + Trametinib	sensitive	Phase Ib/II	;26392102	Colorectal	Therapeutic	C
BRAF	MUT	V600X	colorectal cancer	Vemurafenib	no benefit	Phase II	26287849	Colorectal	Therapeutic	C
BRAF	MUT	V600X	lung non-small cell carcinoma	Dabrafenib + Trametinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
BRAF	MUT	V600X	melanoma	AMG 232 + Dabrafenib + Trametinib	sensitive	Phase I	;	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	ASN003	sensitive	Preclinical - Pdx	;	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Atezolizumab + Cobimetinib + Vemurafenib	sensitive	Phase Ib/II	;31171876	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	Atezolizumab + Vemurafenib	sensitive	Phase Ib/II	31171876	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	Binimetinib	sensitive	Phase II	23414587	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	Buparlisib + Selumetinib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Buparlisib + Trametinib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Buparlisib + Vemurafenib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Cobimetinib + Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600X	melanoma	Cobimetinib + Vemurafenib	sensitive	Phase III	27480103	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	Dabrafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600X	melanoma	Dabrafenib + Trametinib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600X	melanoma	Dabrafenib + Trametinib	sensitive	Phase Ib/II	26811525	Skin	Therapeutic	C
BRAF	MUT	V600X	melanoma	MK2206 + Trametinib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	MK2206 + Vemurafenib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Selumetinib + Vemurafenib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Trametinib + Vemurafenib	sensitive	Preclinical - Cell culture	24265152	Skin	Therapeutic	D
BRAF	MUT	V600X	melanoma	Vemurafenib	sensitive	Guideline	;	Skin	Therapeutic	A
BRAF	MUT	V600X	thyroid cancer	Vemurafenib	predicted - sensitive	Phase II	26287849	Thyroid	Therapeutic	C
BRAF	MUT	Val599Ins	Papillary Carcinoma in Thyroid			1	16501605	Thyroid	Therapeutic	B
BRAF	MUT	WILDTYPE	Advanced Solid Tumor	BGB-283	resistant	Preclinical - Cell culture	26208524	Other	Therapeutic	D
BRAF	MUT	WILDTYPE	lung non-small cell carcinoma	GDC0879	resistant	Preclinical - Pdxcell culture	19276360	Lung	Therapeutic	D
BRAF	MUT	WILDTYPE	malignant glioma	Everolimus + Selumetinib	predicted - sensitive	Preclinical - Cell culture	27217440	Nervous_System	Therapeutic	D
BRAF	MUT	WILDTYPE	melanoma	GDC0879	resistant	Preclinical - Pdxcell culture	19276360	Skin	Therapeutic	D
BRAF	MUT	WILDTYPE	melanoma	Nivolumab	predicted - sensitive	Phase III	30422243	Skin	Therapeutic	C
BRAF	MUT	WILDTYPE	melanoma	Palbociclib	sensitive	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
BRAF	MUT	WILDTYPE	melanoma	Palbociclib + Trametinib	decreased response	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
BRAF	MUT	WILDTYPE	melanoma	PLX4720	resistant	Preclinical - Cell line xenograft	18287029	Skin	Therapeutic	D
BRAF	MUT	WILDTYPE	melanoma	RAF265	predicted - sensitive	Phase I	28719152	Skin	Therapeutic	C
BRAF	MUT	WILDTYPE	melanoma	RAF265	predicted - sensitive	Preclinical	22351689	Skin	Therapeutic	D
BRAF	MUT	WILDTYPE	Melanoma	RO4987655	Sensitivity/Response	B	24947927	Skin	Therapeutic	B
BRAF	MUT	WILDTYPE	melanoma	Selumetinib	no benefit	Phase II	22048237	Skin	Therapeutic	C
BRAF	MUT	WILDTYPE	melanoma	Trametinib	sensitive	Phase I	22805292	Skin	Therapeutic	C
BRAF	MUT	WILDTYPE	thyroid cancer	CLM3	sensitive	Preclinical	24423321	Thyroid	Therapeutic	D
BRAF	MUT	Y472C	Lung adenocarcinoma	Dasatinib	Responsive	Case report	22649091	Lung	Therapeutic	D
BRAF	MUT	Y472C	lung non-small cell carcinoma	Dasatinib	sensitive	Preclinical - Cell culture	22649091	Lung	Therapeutic	D
BRCA1	CNV	deletion	Ovary	[PARP inhibitor]	Responsive	Pre-clinical	22392482	Ovary	Therapeutic	D
BRCA1	EXP	EXPRESSION	Malignant Mesothelioma	Vinorelbine	Sensitivity/Response	D	22190288	Other	Therapeutic	D
BRCA1	EXP	UNDEREXPRESSION	Ovarian Cancer	PLATINUM,Taxane	Sensitivity/Response	B	21920589	Ovary	Therapeutic	B
BRCA1	MUT	C61G	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	C64Y	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	D1692N	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	E1559K	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	LOSS-OF-FUNCTION	Breast Cancer	CX-5461,CX-3543	Sensitivity/Response	D	28211448	Breast	Therapeutic	D
BRCA1	MUT	LOSS-OF-FUNCTION	Breast Cancer	Talazoparib	Sensitivity/Response	B	28242752	Breast	Therapeutic	B
BRCA1	MUT	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	Olaparib	Sensitivity/Response	B	28578601	Breast	Therapeutic	B
BRCA1	MUT	LOSS-OF-FUNCTION	Ovarian Cancer	Olaparib	Sensitivity/Response	B	23346317	Ovary	Therapeutic	B
BRCA1	MUT	LOSS-OF-FUNCTION	Ovarian Cancer	Talazoparib	Sensitivity/Response	B	28242752	Ovary	Therapeutic	B
BRCA1	MUT	LOSS-OF-FUNCTION	Pancreatic Cancer	Olaparib	Sensitivity/Response	B	25366685	Pancreas	Therapeutic	B
BRCA1	MUT	LOSS-OF-FUNCTION	Prostate Cancer	Olaparib	Sensitivity/Response	C	26510020	Prostate	Therapeutic	C
BRCA1	MUT	LOSS-OF-FUNCTION	Prostate Cancer		Poor Outcome	B	23569316	Prostate	Prognostic	B
BRCA1	MUT	M1I	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	M1V	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	mutation	Breast Cancer	Olaparib	Sensitivity/Response	B	28792849	Breast	Therapeutic	B
BRCA1	MUT	mutation	Cancer	Olaparib	Sensitivity/Response	A	19553641	Cancer	Therapeutic	A
BRCA1	MUT	mutation	Epithelial Ovarian Cancer		Better Outcome	B	22274685	Ovary	Prognostic	B
BRCA1	MUT	mutation	Ovarian Cancer		Better Outcome	B	26740259	Ovary	Prognostic	B
BRCA1	MUT	mutation	Ovarian Cancer	Cediranib,Olaparib	Sensitivity/Response	B	25218906	Ovary	Therapeutic	B
BRCA1	MUT	mutation	Ovarian Cancer	Olaparib	Sensitivity/Response	B	21862407	Ovary	Therapeutic	B
BRCA1	MUT	mutation	Ovarian Cancer	Rucaparib	Sensitivity/Response	B	27908594	Ovary	Therapeutic	B
BRCA1	MUT	mutation	Ovarian Carcinoma	PLATINUM	Sensitivity/Response	B	24240112	Ovary	Therapeutic	B
BRCA1	MUT	mutation	Pancreatic Cancer	Olaparib	Sensitivity/Response	B	25366685	Pancreas	Therapeutic	B
BRCA1	MUT	mutation	Pancreatic Cancer	Oxaliplatinum,Cisplatinum	Sensitivity/Response	B	25072261	Pancreas	Therapeutic	B
BRCA1	MUT	mutation	Pancreatic Cancer	Veliparib,Gemcitabine,Cisplatin	Sensitivity/Response	B	29338080	Pancreas	Therapeutic	B
BRCA1	MUT	mutation	Triple-receptor Negative Breast Cancer	Carboplatin,Cisplatin	Sensitivity/Response	B	25847936	Breast	Therapeutic	B
BRCA1	MUT	mutation	Triple-receptor Negative Breast Cancer	Olaparib	Resistance	B	21862407	Breast	Therapeutic	B
BRCA1	MUT	oncogenic mutation	Any cancer type	[WEE1 inhibitor]	Responsive	Case report	25964244	Cancer	Therapeutic	D
BRCA1	MUT	oncogenic mutation	Breast adenocarcinoma	[Olaparib]	Responsive	Early trials	20609467;25366685	Breast	Therapeutic	C
BRCA1	MUT	oncogenic mutation	Breast adenocarcinoma	Platinum Agent	Responsive	Early trials	25847936	Breast	Therapeutic	C
BRCA1	MUT	oncogenic mutation	Breast adenocarcinoma	Veliparib;Cisplatin	Responsive	Early trials	26801247	Breast	Therapeutic	C
BRCA1	MUT	oncogenic mutation	Ovary	Olaparib	Responsive	FDA guidelines	FDA	Ovary	Therapeutic	A
BRCA1	MUT	oncogenic mutation	Ovary	[PARP inhibitor;Chemotherapy]	Responsive	Early trials	22307137;ASCO 2012 (abstr 1009)	Ovary	Therapeutic	C
BRCA1	MUT	oncogenic mutation	Ovary	Platinum Agent	Responsive	Late trials	22406760;22711857	Ovary	Therapeutic	C
BRCA1	MUT	oncogenic mutation	Ovary	Rucaparib	Responsive	FDA guidelines	FDA	Ovary	Therapeutic	A
BRCA1	MUT	oncogenic mutation	Pancreas	[PARP inhibitor]	Responsive	Case report	25366685;25719666;19553641;25366685	Pancreas	Therapeutic	D
BRCA1	MUT	oncogenic mutation	Prostate adenocarcinoma	Olaparib	Responsive	Early trials	26510020	Prostate	Therapeutic	C
BRCA1	MUT	Oncogenic Mutations	Breast Cancer	Talazoparib, Olaparib	Response	2A	30110579, 30563931, 28578601	Breast	Therapeutic	B
BRCA1	MUT	Oncogenic Mutations	Ovarian Cancer	Olaparib	Response	2A	25366685, 30285518, 30345884, 24882434	Ovary	Therapeutic	B
BRCA1	MUT	Oncogenic Mutations	Ovarian Cancer	Rucaparib, Niraparib	Response	1	27717299, 30425037, 28882436, 28916367, 30948273	Ovary	Therapeutic	A
BRCA1	MUT	Oncogenic Mutations	Peritoneal Serous Carcinoma	Olaparib	Response	2A	25366685, 30285518, 30345884, 24882434	Pleura	Therapeutic	B
BRCA1	MUT	Oncogenic Mutations	Peritoneal Serous Carcinoma	Rucaparib, Niraparib	Response	1	27717299, 30425037, 28882436, 28916367, 30948273	Pleura	Therapeutic	A
BRCA1	MUT	Q1467X	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	R1443X	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	R1495M	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	R71G	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	R71K	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA1	MUT	W1815X	Ovarian Cancer	Olaparib	Sensitivity/Response	D	23415752	Ovary	Therapeutic	D
BRCA2	CNV	deletion	Ovary	[Olaparib]	Responsive	Pre-clinical	22392482	Ovary	Therapeutic	D
BRCA2	MUT	D3095E	Breast Cancer		Positive	C	18951446	Breast	Diagnostic	C
BRCA2	MUT	LOSS-OF-FUNCTION	Breast Cancer	CX-5461,CX-3543	Sensitivity/Response	D	28211448	Breast	Therapeutic	D
BRCA2	MUT	LOSS-OF-FUNCTION	Breast Cancer	Talazoparib	Sensitivity/Response	B	28242752	Breast	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	Olaparib	Sensitivity/Response	B	28578601	Breast	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Ovarian Cancer	Olaparib	Sensitivity/Response	B	23346317	Ovary	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Ovarian Cancer	Talazoparib	Sensitivity/Response	B	28242752	Ovary	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Pancreatic Cancer	Mitomycin C	Sensitivity/Response	D	16243825	Pancreas	Therapeutic	D
BRCA2	MUT	LOSS-OF-FUNCTION	Pancreatic Cancer	Olaparib	Sensitivity/Response	B	25366685	Pancreas	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Prostate Cancer	Olaparib	Sensitivity/Response	B	26510020	Prostate	Therapeutic	B
BRCA2	MUT	LOSS-OF-FUNCTION	Prostate Cancer		Poor Outcome	B	23569316	Prostate	Prognostic	B
BRCA2	MUT	M1I	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	M1R	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	mutation	Breast Cancer	Olaparib	Sensitivity/Response	B	28792849	Breast	Therapeutic	B
BRCA2	MUT	mutation	Cancer	Olaparib	Sensitivity/Response	A	19553641	Cancer	Therapeutic	A
BRCA2	MUT	mutation	Epithelial Ovarian Cancer		Better Outcome	B	22274685	Ovary	Prognostic	B
BRCA2	MUT	mutation	Ovarian Cancer		Better Outcome	B	26740259	Ovary	Prognostic	B
BRCA2	MUT	mutation	Ovarian Cancer	Cediranib,Olaparib	Sensitivity/Response	B	25218906	Ovary	Therapeutic	B
BRCA2	MUT	mutation	Ovarian Cancer	Olaparib	Sensitivity/Response	B	21862407	Ovary	Therapeutic	B
BRCA2	MUT	mutation	Ovarian Carcinoma	PLATINUM	Sensitivity/Response	B	24240112	Ovary	Therapeutic	B
BRCA2	MUT	mutation	Pancreatic Cancer	Gemcitabine,Veliparib,Cisplatin	Sensitivity/Response	B	29338080	Pancreas	Therapeutic	B
BRCA2	MUT	mutation	Pancreatic Cancer	Iniparib	Sensitivity/Response	C	21508395	Pancreas	Therapeutic	C
BRCA2	MUT	mutation	Pancreatic Cancer	Olaparib	Sensitivity/Response	B	25366685	Pancreas	Therapeutic	B
BRCA2	MUT	mutation	Pancreatic Cancer	PLATINUM	Sensitivity/Response	B	25072261	Pancreas	Therapeutic	B
BRCA2	MUT	mutation	Triple-receptor Negative Breast Cancer	Carboplatin,Cisplatin	Sensitivity/Response	B	25847936	Breast	Therapeutic	B
BRCA2	MUT	oncogenic mutation	Breast adenocarcinoma	[Olaparib]	Responsive	Early trials	20609467	Breast	Therapeutic	C
BRCA2	MUT	oncogenic mutation	Breast adenocarcinoma	Platinum Agent	Responsive	Early trials	25847936	Breast	Therapeutic	C
BRCA2	MUT	oncogenic mutation	Breast adenocarcinoma	Veliparib;Cisplatin	Responsive	Early trials	26801247	Breast	Therapeutic	C
BRCA2	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 Ab inhibitor]	Responsive	Case report	26997480	Skin	Therapeutic	D
BRCA2	MUT	oncogenic mutation	Ovary	Olaparib	Responsive	FDA guidelines	FDA	Ovary	Therapeutic	A
BRCA2	MUT	oncogenic mutation	Ovary	[PARP inhibitor;Chemotherapy]	Responsive	Early trials	22307137;ASCO 2012 (abstr 1009)	Ovary	Therapeutic	C
BRCA2	MUT	oncogenic mutation	Ovary	Platinum Agent	Responsive	Late trials	22406760;22711857	Ovary	Therapeutic	C
BRCA2	MUT	oncogenic mutation	Ovary	Rucaparib	Responsive	FDA guidelines	FDA	Ovary	Therapeutic	A
BRCA2	MUT	oncogenic mutation	Pancreas	Platinum Agent	Responsive	Case report	25719666	Pancreas	Therapeutic	D
BRCA2	MUT	oncogenic mutation	Prostate adenocarcinoma	Olaparib	Responsive	Early trials	26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	Prostate	Therapeutic	C
BRCA2	MUT	Oncogenic Mutations	Breast Cancer	Talazoparib, Olaparib	Response	2A	30110579, 30563931, 28578601	Breast	Therapeutic	B
BRCA2	MUT	Oncogenic Mutations	Ovarian Cancer	Olaparib	Response	2A	25366685, 30285518, 30345884, 24882434	Ovary	Therapeutic	B
BRCA2	MUT	Oncogenic Mutations	Ovarian Cancer	Rucaparib, Niraparib	Response	1	27717299, 30425037, 28882436, 28916367, 30948273	Ovary	Therapeutic	A
BRCA2	MUT	Oncogenic Mutations	Peritoneal Serous Carcinoma	Olaparib	Response	2A	25366685, 30285518, 30345884, 24882434	Pleura	Therapeutic	B
BRCA2	MUT	Oncogenic Mutations	Peritoneal Serous Carcinoma	Rucaparib, Niraparib	Response	1	27717299, 30425037, 28882436, 28916367, 30948273	Pleura	Therapeutic	A
BRCA2	MUT	R2336H	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	R2336P	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	V159M	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	V211I	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCA2	MUT	V211L	Ovarian Cancer	Rucaparib	Sensitivity/Response	C	27908594	Ovary	Therapeutic	C
BRCC3	MUT	any mutation	Myelodysplastic Syndrome in Blood/Bone Marrow			2	24220272,confex	Blood;Bone_Marrow	Therapeutic	C
BRD4	FUS	BRD4-NUTM1	NUT Midline Carcinoma	JQ1	Sensitivity/Response	D	20871596	Other	Therapeutic	D
BTK	MUT	C481	Mantle cell lymphoma	Ibrutinib	Resistant	Case report	25082755	Lymph_Nodes	Therapeutic	D
BTK	MUT	C481S	Chronic Lymphocytic Leukemia	Ibrutinib	Resistance	B	24869598	Blood;Bone_Marrow	Therapeutic	B
BTK	MUT	C481S	Chronic Lymphocytic Leukemia	Ibrutinib	Resistance	B	26182309	Blood;Bone_Marrow	Therapeutic	B
BTK	MUT	C481S	Chronic lymphocytic leukemia	Ibrutinib	Resistant	Early trials	24869598;27199251	Blood;Bone_Marrow	Therapeutic	C
BTK	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	28418267	Blood;Bone_Marrow	Prognostic	B
BTK	MUT	T316A	Chronic Lymphocytic Leukemia	Ibrutinib	Resistance	C	27626698	Blood;Bone_Marrow	Therapeutic	C
CA9	EXP	overexpression	Renal	Sunitinib	Responsive	Pre-clinical	24086736	Kidney	Therapeutic	D
CALR	MUT	exon(s) 9 frameshift	Chronic Myeloproliferative Disease	Pegylated IFN-alpha-2a	Sensitivity/Response	B	26486786	Blood;Bone_Marrow	Therapeutic	B
CALR	MUT	exon(s) 9 frameshift	Myelofibrosis		Better Outcome	A	25037629	Bone_Marrow	Prognostic	A
CALR	MUT	exon(s) 9 frameshift	Myelofibrosis		Better Outcome	B	24496303	Bone_Marrow	Prognostic	B
CALR	MUT	exon(s) 9 frameshift	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/MDS with Ring Sideroblasts/Myelodysplastic Syndrome in Blood/Bone Marrow			1	26486739,24325359,24402162,24496303,24791854	Blood;Bone_Marrow	Therapeutic	B
CALR	MUT	K385fs	hematologic cancer	Ruxolitinib	sensitive	Preclinical - Cell culture	26668133	Blood	Therapeutic	D
CALR	MUT	L367fs	hematologic cancer	Ruxolitinib	sensitive	Preclinical - Cell culture	26668133	Blood	Therapeutic	D
CALR	MUT	L367fs	hematologic cancer	Ruxolitinib + Temsirolimus	sensitive	Preclinical - Cell culture	26668133	Blood	Therapeutic	D
CALR	MUT	L367fs	myelofibrosis	Fedratinib	predicted - sensitive	Case Reports/Case Series	24645956	Bone_Marrow	Therapeutic	D
CALR	MUT	L367fs	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
CALR	MUT	mutant	bone marrow cancer	Alpha 2 Interferon	predicted - sensitive	Clinical Study - Cohort	26486786	Bone_Marrow	Therapeutic	C
CALR	MUT	mutant	bone marrow cancer	N/A	not applicable	Clinical Study	26697989;25873496;26449662;26071474	Bone_Marrow	Diagnostic	C
CALR	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
CALR	MUT	mutation	Essential Thrombocythemia		Positive	A	27069254	Blood	Diagnostic	A
CASP8	EXP	EXPRESSION	Ewing Sarcoma Of Bone	Conatumumab	Sensitivity/Response	D	26291055	Bone	Therapeutic	D
CASP8	MUT	D302H	Neuroblastoma		Poor Outcome	B	25502557	Adrenal_Gland;Nervous_System	Prognostic	B
CBFB	FUS	CBFB-MYH11	Acute Myeloid Leukemia		Better Outcome	B	22180162	Blood;Bone_Marrow	Prognostic	B
CBLB	EXP	UNDEREXPRESSION	stomach cancer	Fluorouracil	decreased response	Preclinical	24351824	Stomach	Therapeutic	D
CBLB	MUT	any mutation	Chronic Myeloid Leukemia/Acute Myeloid Leukemia in Blood/Bone Marrow			1	22072526,21346257	Blood;Bone_Marrow	Therapeutic	B
CBLC	EXP	EXPRESSION	Cancer	Olaparib	Resistance	D	25883215	Cancer	Therapeutic	D
CBLC	EXP	UNDEREXPRESSION	breast cancer	Olaparib	predicted - sensitive	Preclinical	25883215	Breast	Therapeutic	D
CBLC	EXP	UNDEREXPRESSION	osteosarcoma	Olaparib	predicted - sensitive	Preclinical	25883215	Bone	Therapeutic	D
CBL	MUT	any mutation	Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	23010802,22929312,22799433,22733026,rez,19901108	Blood;Bone_Marrow	Therapeutic	B
CBL	MUT	C384R	Myelodisplasic proliferative syndrome	Dasatinib	Responsive	Pre-clinical	23696637	Bone_Marrow	Therapeutic	D
CBL	MUT	C384R	Myelodisplasic proliferative syndrome	[JAK inhibitor]	Responsive	Pre-clinical	23696637	Bone_Marrow	Therapeutic	D
CBL	MUT	mutant	bone marrow cancer	Quizartinib	sensitive	Preclinical	22990016	Bone_Marrow	Therapeutic	D
CBL	MUT	mutant	myelodysplastic/myeloproliferative neoplasm	N/A	not applicable	Clinical Study	26230957;19901108;23690417	Bone_Marrow	Prognostic	C
CBL	MUT	Y371H	Myelodisplasic proliferative syndrome	Dasatinib	Responsive	Pre-clinical	23696637	Bone_Marrow	Therapeutic	D
CBL	MUT	Y371H	Myelodisplasic proliferative syndrome	[JAK inhibitor]	Responsive	Pre-clinical	23696637	Bone_Marrow	Therapeutic	D
CCND1	CNV	amplification	Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CCND1	CNV	amplification	Cutaneous melanoma	[CDK4/6 inhibitor]	Responsive	Case report	ASCO 2014 (abstr 2528)	Skin	Therapeutic	D
CCND1	CNV	amplification	Medulloblastoma	[SMO inhibitor]	Resistant	Pre-clinical	24951114	Nervous_System	Therapeutic	D
CCND1	CNV	AMPLIFICATION	Breast Cancer	Palbociclib (PD0332991)	Sensitivity/Response	D	19874578	Breast	Therapeutic	D
CCND1	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma		Poor Outcome	B	17070615	Lung	Prognostic	B
CCND1	CNV	AMPLIFICATION	Skin Melanoma	Sorafenib,Paclitaxel,Carboplatin	Sensitivity/Response	B	26307133	Skin	Therapeutic	B
CCND1	EXP	EXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	17070615	Lung	Prognostic	B
CCND1	EXP	OVEREXPRESSION	Breast Cancer		Poor Outcome	B	15961768	Breast	Prognostic	B
CCND1	EXP	OVEREXPRESSION	Breast Cancer		Positive	B	15961768	Breast	Diagnostic	B
CCND1	EXP	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Tamoxifen	Resistance	B	15138475	Breast	Therapeutic	B
CCND1	EXP	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	16309541	Head_and_Neck	Prognostic	B
CCND1	EXP	OVEREXPRESSION	Mantle Cell Lymphoma	Palbociclib (PD0332991)	Sensitivity/Response	D	16690963	Lymph_Nodes	Therapeutic	D
CCND1	EXP	OVEREXPRESSION	Mantle Cell Lymphoma		Poor Outcome	B	17891190	Lymph_Nodes	Prognostic	B
CCND2	CNV	amplification	Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CCND2	CNV	amplification	Lung	Palbociclib	Responsive	Early trials	NCT02154490	Lung	Therapeutic	C
CCND2	EXP	OVEREXPRESSION	Stomach Cancer		Poor Outcome	D	10547574	Stomach	Prognostic	D
CCND2	MUT	PROMOTER DEMETHYLATION	Stomach Cancer		Negative	D	14612939	Stomach	Diagnostic	D
CCND3	CNV	amplification	Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CCND3	CNV	LOSS	T-cell Leukemia	Palbociclib (PD0332991)	Sensitivity/Response	D	23079656	Blood;Bone_Marrow	Therapeutic	D
CCNE1	CNV	amplification	Any cancer type	[CDK2 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CCNE1	CNV	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Palbociclib (PD0332991)	Resistance	D	27020857	Breast	Therapeutic	D
CCNE1	CNV	AMPLIFICATION	Ovarian Carcinoma		Poor Outcome	B	20336784	Ovary	Prognostic	B
CCNE1	CNV	AMPLIFICATION	Ovarian Serous Cystadenocarcinoma	Dinaciclib,MK-2206	Sensitivity/Response	D	27663592	Ovary	Therapeutic	D
CCNE1	EXP	OVEREXPRESSION	Breast Cancer		Poor Outcome	B	12432043	Breast	Prognostic	B
CCNE1	EXP	OVEREXPRESSION	Gastric Adenosquamous Carcinoma		Poor Outcome	B	10224221	Stomach	Prognostic	B
CCNE1	EXP	OVEREXPRESSION	Ovarian Cancer	BMS-387032 (SNS-032)	Sensitivity/Response	D	26204491	Ovary	Therapeutic	D
CD274	CNV	amplification	Any cancer type	[PDL1 inhibitor]	Responsive	Pre-clinical	25079317	Cancer	Therapeutic	D
CD274	CNV	amplification	Basal cell carcinoma	[PD1 Ab inhibitor]	Responsive	Case report	27942391	Skin	Therapeutic	D
CD274	EXP	EXPRESSION	Breast Cancer		Poor Outcome	B	28079291	Breast	Prognostic	B
CD274	EXP	EXPRESSION	Breast Cancer		Poor Outcome	B	28430626	Breast	Prognostic	B
CD274	EXP	EXPRESSION	Cancer		Better Outcome	B	28453554	Cancer	Prognostic	B
CD274	EXP	EXPRESSION	Cancer	Nivolumab	Sensitivity/Response	B	22658127	Cancer	Therapeutic	B
CD274	EXP	EXPRESSION	Cancer		Poor Outcome	B	28471952	Cancer	Prognostic	B
CD274	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Radiation	Resistance	B	28476872	Head_and_Neck	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Atezolizumab,Nivolumab,Pembrolizumab,Avelumab	Sensitivity/Response	B	26918451	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Atezolizumab	Sensitivity/Response	B	26970723	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Durvalumab,Avelumab,Atezolizumab,Nivolumab,Pembrolizumab	Sensitivity/Response	B	28472902	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Nivolumab,Pembrolizumab	Sensitivity/Response	B	26086854	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Pembrolizumab	Sensitivity/Response	B	25891174	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Pembrolizumab	Sensitivity/Response	B	27718847	Lung	Therapeutic	B
CD274	EXP	EXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	26771872	Lung	Prognostic	B
CD274	EXP	EXPRESSION	Lung Squamous Cell Carcinoma		Better Outcome	B	26313362	Lung	Prognostic	B
CD274	EXP	EXPRESSION	Melanoma	Nivolumab,Pembrolizumab	Sensitivity/Response	B	26086854	Skin	Therapeutic	B
CD274	EXP	EXPRESSION	Ovarian Serous Carcinoma		Better Outcome	B	26625204	Ovary	Prognostic	B
CD274	EXP	EXPRESSION	Stomach Carcinoma		Better Outcome	B	27009855	Stomach	Prognostic	B
CD274	EXP	EXPRESSION	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	27086918	Thyroid	Prognostic	B
CD274	EXP	overexpression	Bladder	Pembrolizumab	Responsive	Early trials	NCT01848834	Bladder	Therapeutic	C
CD274	EXP	overexpression	Cutaneous melanoma;Renal;Any cancer type	Atezolizumab	Responsive	Early trials	NCT01375842;doi: 10.1093/annonc/mdu337.2	Cancer;Kidney;Skin	Therapeutic	C
CD274	EXP	overexpression	Renal	Nivolumab	Responsive	Early trials	25452452	Kidney	Therapeutic	C
CD44	EXP	ISOFORM EXPRESSION	Cancer	RG7356	Sensitivity/Response	D	25762343	Cancer	Therapeutic	D
CD69	EXP	undexpression	Chronic lymphocytic leukemia	Bendamustine	Responsive	Pre-clinical	26701728	Blood;Bone_Marrow	Therapeutic	D
CD79B	MUT	any mutation	Diffuse Large B Cell Lymphoma in Blood/Bone Marrow/Lymph Node			1	24253023,23285191,20054396	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
CDH1	EXP	OVEREXPRESSION	lung non-small cell carcinoma	BI2536	resistant	Preclinical	26597303	Lung	Therapeutic	D
CDH1	EXP	OVEREXPRESSION	lung non-small cell carcinoma	Volasertib	resistant	Preclinical	26597303	Lung	Therapeutic	D
CDH1	EXP	OVEREXPRESSION	pancreatic ductal adenocarcinoma	Erlotinib + Selumetinib	sensitive	Phase II	26251290	Pancreas	Therapeutic	C
CDH1	MUT	any indel	Invasive Lobular Carcinoma in Breast			2	25848941,26182300,24366306,25979631,26451490	Breast	Therapeutic	C
CDH1	MUT	any mutation	Adenocarcinoma in Stomach			2	26182300,23341533,25979631	Stomach	Therapeutic	C
CDH1	MUT	any mutation	Invasive Lobular Carcinoma in Breast			2	25848941,26182300,24366306,25979631,26451490	Breast	Therapeutic	C
CDH1	MUT	mutant	stomach cancer	N/A	not applicable	Clinical Study	26380059;26182300	Stomach	Diagnostic	C
CDH1	MUT	mutation	Stomach Carcinoma		Poor Outcome	E	27313181	Stomach	Prognostic	D
CDH1	MUT	oncogenic mutation	Breast adenocarcinoma	Bicalutamide	Responsive	Pre-clinical	27397505	Breast	Therapeutic	D
CDK12	CNV	amplification	Ovary	[PARP inhibitors]	Responsive	Pre-clinical	24240700;24554720	Ovary	Therapeutic	D
CDK12	MUT	LOSS-OF-FUNCTION	Ovarian Serous Carcinoma	Olaparib	Sensitivity/Response	D	24240700	Ovary	Therapeutic	D
CDK12	MUT	oncogenic mutation	Ovary	[PARP inhibitors]	Responsive	Pre-clinical	24240700;24554720	Ovary	Therapeutic	D
CDK12	MUT	Truncating Mutations	All Solid Tumors	Pembrolizumab, Nivolumab, Cemiplimab	Response	4	29906450	Other	Therapeutic	D
CDK4	CNV	amplification	Liposarcoma;Lymphoma;Any cancer type	LEE011	Responsive	Early trials	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Cancer;Lymph_Nodes;Soft_Tissue	Therapeutic	C
CDK4	CNV	AMPLIFICATION	Liposarcoma	Palbociclib	Sensitivity/Response	B	23569312	Soft_Tissue	Therapeutic	B
CDK4	CNV	AMPLIFICATION	Liposarcoma	Palbociclib	Sensitivity/Response	B	27124835	Soft_Tissue	Therapeutic	B
CDK4	EXP	EXPRESSION	Estrogen-receptor Positive Breast Cancer	Alpelisib	Sensitivity/Response	D	25002028	Breast	Therapeutic	D
CDK4	EXP	EXPRESSION	Sarcoma	Palbociclib	Sensitivity/Response	D	26528855	Soft_Tissue	Therapeutic	D
CDK4	CNV	Amplification	Dedifferentiated Liposarcoma	Abemaciclib, Palbociclib	Response	2A	23569312, 27124835	Soft_Tissue	Therapeutic	B
CDK4	CNV	Amplification	Well-Differentiated Liposarcoma	Abemaciclib, Palbociclib	Response	2A	23569312, 27124835	Soft_Tissue	Therapeutic	B
CDK4	MUT	oncogenic mutation	Liposarcoma;Lymphoma;Any cancer type	LEE011	Responsive	Early trials	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Cancer;Lymph_Nodes;Soft_Tissue	Therapeutic	C
CDK4	MUT	R24C	Skin Melanoma	Palbociclib (PD0332991)	Sensitivity/Response	D	24495407	Skin	Therapeutic	D
CDK6	CNV	amplification	Any cancer type	[CDK6 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CDK6	CNV	amplification	Liposarcoma;Lymphoma;Any cancer type	LEE011	Responsive	Early trials	NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102	Cancer;Lymph_Nodes;Soft_Tissue	Therapeutic	C
CDK6	EXP	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Fulvestrant,Palbociclib (PD0332991)	Sensitivity/Response	D	27252418	Breast	Therapeutic	D
CDK6	EXP	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Fulvestrant	Resistance	B	27252418	Breast	Therapeutic	B
CDK6	MUT	oncogenic mutation	Liposarcoma;Lymphoma;Any cancer type	LEE011	Responsive	Early trials	NCT02187783;NCT01237236	Cancer;Lymph_Nodes;Soft_Tissue	Therapeutic	C
CDKN1A	CNV	deletion	Any cancer type	[CDK2/4 inhibitor]	Responsive	Pre-clinical	22471707;22997239	Cancer	Therapeutic	D
CDKN1A	EXP	EXPRESSION	Colorectal Cancer	5-fluorouracil	Resistance	B	24708484	Colorectal	Therapeutic	B
CDKN1A	MUT	oncogenic mutation	Any cancer type	[CDK2/4 inhibitor]	Responsive	Pre-clinical	22471707;22997239	Cancer	Therapeutic	D
CDKN1B	CNV	deletion	Any cancer type	[CDK2/4 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CDKN1B	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	5-fluorouracil,Cisplatin	Sensitivity/Response	B	24239278	Head_and_Neck	Therapeutic	B
CDKN1B	MUT	CYTOPLASMIC MISLOCALIZATION	Breast Cancer	Lapatinib	Resistance	D	25587029	Breast	Therapeutic	D
CDKN1B	MUT	oncogenic mutation	Any cancer type	[CDK2/4 inhibitor]	Responsive	Pre-clinical	22471707	Cancer	Therapeutic	D
CDKN2A	CNV	deletion	Any cancer type	Ilorasertib	Responsive	Early trials	NCT02478320	Cancer	Therapeutic	C
CDKN2A	CNV	deletion	Cutaneous melanoma	[CDK4/6 inhibitor]	Responsive	Case report	ASCO 2013 (abstr 2500)	Skin	Therapeutic	D
CDKN2A	CNV	deletion	Glioma;Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707;22586120;22711607	Cancer;Nervous_System	Therapeutic	D
CDKN2A	CNV	del	glioblastoma multiforme	Palbociclib	sensitive	Preclinical - Pdxcell culture	22711607	Brain	Therapeutic	D
CDKN2A	CNV	del	lung cancer	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Cell line xenograft	26140595	Lung	Therapeutic	D
CDKN2A	CNV	loss	Advanced Solid Tumor	PF-00477736 + PF3644022	predicted - sensitive	Preclinical - Cell culture	26140595	Other	Therapeutic	D
CDKN2A	CNV	loss	brain glioblastoma multiforme	Milciclib	sensitive	Preclinical - Cell line xenograft	23347136	Brain	Therapeutic	D
CDKN2A	CNV	loss	chordoma	Abemaciclib	sensitive	Preclinical - Cell culture	26183925	Bone;Soft_Tissue	Therapeutic	D
CDKN2A	CNV	loss	chordoma	Palbociclib	sensitive	Preclinical - Cell culture	26183925	Bone;Soft_Tissue	Therapeutic	D
CDKN2A	CNV	LOSS	Dermatofibrosarcoma Protuberans	Palbociclib	Sensitivity/Response	D	25852058	Soft_Tissue	Therapeutic	D
CDKN2A	CNV	LOSS	Ewing Sarcoma	Linsitinib,Palbociclib	Sensitivity/Response	D	27286459	Bone	Therapeutic	D
CDKN2A	CNV	LOSS	Her2-receptor Negative Breast Cancer	Palbociclib (PD0332991),Letrozole	Sensitivity/Response	C	26715889	Breast	Therapeutic	C
CDKN2A	CNV	loss	lung non-small cell carcinoma	Palbociclib	sensitive	Phase II	;	Lung	Therapeutic	C
CDKN2A	CNV	loss	melanoma	Alvocidib	sensitive	Preclinical	12777976	Skin	Therapeutic	D
CDKN2A	CNV	loss	melanoma	Palbociclib	resistant	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
CDKN2A	CNV	loss	melanoma	Trametinib	sensitive	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
CDKN2A	CNV	loss	neuroendocrine tumor	ZK 304709	sensitive	Preclinical	18829975	Nervous_System	Therapeutic	D
CDKN2A	CNV	LOSS	Ovarian Cancer	Palbociclib (PD0332991)	Sensitivity/Response	D	21278246	Ovary	Therapeutic	D
CDKN2A	CNV	loss	pancreatic cancer	Gemcitabine + Palbociclib	decreased response	Preclinical	25156567	Pancreas	Therapeutic	D
CDKN2A	CNV	loss	pancreatic cancer	GSK461364 + Palbociclib	decreased response	Preclinical	25156567	Pancreas	Therapeutic	D
CDKN2A	CNV	loss	pancreatic cancer	HMN-214 + Palbociclib	decreased response	Preclinical	25156567	Pancreas	Therapeutic	D
CDKN2A	CNV	loss	pancreatic cancer	Palbociclib + Rigosertib	decreased response	Preclinical	25156567	Pancreas	Therapeutic	D
CDKN2A	CNV	LOSS	Renal Cell Carcinoma	Palbociclib (PD0332991)	Sensitivity/Response	D	23898052	Kidney	Therapeutic	D
CDKN2A	CNV	loss	renal cell carcinoma	Palbociclib	sensitive	Preclinical	23898052	Kidney	Therapeutic	D
CDKN2A	CNV	LOSS	Skin Melanoma	Flavopiridol	Sensitivity/Response	D	12777976	Skin	Therapeutic	D
CDKN2A	CNV	LOSS	Skin Melanoma	Palbociclib (PD0332991)	Sensitivity/Response	D	24495407	Skin	Therapeutic	D
CDKN2A	MUT	any mutation	Adenocarcinoma in Stomach			2	25079317,26380006	Stomach	Therapeutic	C
CDKN2A	MUT	any mutation	Adenocarcinoma/Squamous Cell Carcinoma in Colon/Rectum			2	22025288,17662938,23703248	Colorectal	Therapeutic	C
CDKN2A	MUT	any mutation	Cholangiocarcinoma/Adenocarcinoma in Liver/Ampulla (Pancreaticobiliary Duct)			2	25332972,25536104	Liver;Pancreas	Therapeutic	C
CDKN2A	MUT	any mutation	Hepatocellular Carcinoma in Liver			2	24473361,24798001	Liver	Therapeutic	C
CDKN2A	MUT	any mutation	Melanoma in Skin			2	23875803,22817889,PharmGKB	Skin	Therapeutic	C
CDKN2A	CNV	copy number loss	Adenocarcinoma in Stomach			2	25079317,26380006	Stomach	Therapeutic	C
CDKN2A	CNV	copy number loss	Glioblastoma in Brain			1	19058223	Brain	Therapeutic	B
CDKN2A	CNV	copy number loss	Hepatocellular Carcinoma in Liver			2	24473361,24798001	Liver	Therapeutic	C
CDKN2A	CNV	copy number loss	Melanoma in Skin			2	23875803,22817889,PharmGKB	Skin	Therapeutic	C
CDKN2A	MUT	mutant	lung non-small cell carcinoma	Palbociclib	sensitive	Phase II	;	Lung	Therapeutic	C
CDKN2A	MUT	oncogenic mutation	Any cancer type	Ilorasertib	Responsive	Early trials	NCT02478320	Cancer	Therapeutic	C
CDKN2A	MUT	oncogenic mutation	Cutaneous melanoma	[CDK4/6 inhibitor]	Responsive	Case report	ASCO 2013 (abstr 2500)	Skin	Therapeutic	D
CDKN2A	MUT	oncogenic mutation	Glioma;Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707;22586120;22711607	Cancer;Nervous_System	Therapeutic	D
CDKN2A	MUT	Oncogenic Mutations	All Solid Tumors	Abemaciclib, Palbociclib, Ribociclib	Response	4	19874578, 25941111, 24495407, 29232554, 28283584	Other	Therapeutic	D
CDKN2A	MUT	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Afatinib	Resistance	B	25892145	Head_and_Neck	Therapeutic	B
CDKN2A	MUT	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma		Better Outcome	B	24799460	Head_and_Neck	Prognostic	B
CDKN2A	MUT	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma		Better Outcome	B	25267748	Head_and_Neck	Prognostic	B
CDKN2A	MUT	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Panitumumab	Resistance	B	23746666	Head_and_Neck	Therapeutic	B
CDKN2A	MUT	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Panitumumab	Sensitivity/Response	B	23746666	Head_and_Neck	Therapeutic	B
CDKN2A	MUT	p16 EXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	22619677	Lung	Prognostic	B
CDKN2A	MUT	p16 EXPRESSION	Oropharynx Cancer		Better Outcome	A	20530316	Esophagus	Prognostic	A
CDKN2A	MUT	PROMOTER HYPERMETHYLATION	Lung Non-small Cell Carcinoma		Poor Outcome	B	23111194	Lung	Prognostic	B
CDKN2A	MUT	R80X	stomach carcinoma	Palbociclib	sensitive	Preclinical - Cell line xenograft	26380006;20952405	Stomach	Therapeutic	D
CDKN2B	CNV	deletion	Glioma;Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707;22711607	Cancer;Nervous_System	Therapeutic	D
CDKN2B	CNV	LOSS	Ewing Sarcoma	Palbociclib,Linsitinib	Sensitivity/Response	D	27286459	Bone	Therapeutic	D
CDKN2B	CNV	LOSS	Renal Cell Carcinoma	Palbociclib (PD0332991)	Sensitivity/Response	D	23898052	Kidney	Therapeutic	D
CDKN2B	CNV	copy number loss	Glioblastoma in Brain			1	19058223	Brain	Therapeutic	B
CDKN2B	MUT	oncogenic mutation	Glioma;Any cancer type	[CDK4/6 inhibitor]	Responsive	Pre-clinical	22471707;22711607	Cancer;Nervous_System	Therapeutic	D
CDKN2B	OTH	METHYLATION	Acute Promyelocytic Leukemia		Poor Outcome	B	16307009	Blood;Bone_Marrow	Prognostic	B
CDKN2C	CNV	deletion	Glioma;Any cancer type	[CDK2 inhibitor]	Responsive	Pre-clinical	22471707;22997239;22711607	Cancer;Nervous_System	Therapeutic	D
CDKN2C	MUT	oncogenic mutation	Glioma;Any cancer type	[CDK2 inhibitor]	Responsive	Pre-clinical	22471707;22997239;22711607	Cancer;Nervous_System	Therapeutic	D
CDX2	EXP	EXPRESSION	Colorectal Cancer		Better Outcome	B	26789870	Colorectal	Prognostic	B
CEBPA	BIA	BIALLELIC INACTIVATION	Acute Myeloid Leukemia		Better Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	any mutation	Acute Myeloid Leukemia in Blood/Bone Marrow			1	24801015,24711548,22150310	Blood;Bone_Marrow	Therapeutic	B
CEBPA	MUT	mutant	acute myeloid leukemia	AZD1480	predicted - sensitive	Preclinical - Patient cell culture	27034432	Blood;Bone_Marrow	Therapeutic	D
CEBPA	MUT	mutant	acute myeloid leukemia	Momelotinib	predicted - sensitive	Preclinical - Patient cell culture	27034432	Blood;Bone_Marrow	Therapeutic	D
CEBPA	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	22915647;26601784;19171880;20038735	Blood;Bone_Marrow	Prognostic	C
CEBPA	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
CEBPA	MUT	mutant	acute myeloid leukemia	Ruxolitinib	predicted - sensitive	Preclinical - Patient cell culture	27034432	Blood;Bone_Marrow	Therapeutic	D
CEBPA	MUT	mutant	acute myeloid leukemia	Tofacitinib	predicted - sensitive	Preclinical - Patient cell culture	27034432	Blood;Bone_Marrow	Therapeutic	D
CEBPA	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	14726504	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	18450602	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	19304957	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	19965647	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	25014773	Blood;Bone_Marrow	Prognostic	B
CEBPA	MUT	N-TERMINAL FRAME SHIFT	Acute Myeloid Leukemia	OICR-9429	Sensitivity/Response	D	26167872	Blood;Bone_Marrow	Therapeutic	D
CFLAR	EXP	EXPRESSION	Prostate Cancer	Bicalutamide	Resistance	D	22623731	Prostate	Therapeutic	D
CHD1	MUT	any indel	Adenocarcinoma in Prostate			2	22139082,23622249,25726356	Prostate	Therapeutic	C
CHD1	MUT	any mutation	Adenocarcinoma in Prostate			2	22139082,23622249,25726356	Prostate	Therapeutic	C
CHEK1	EXP	OVEREXPRESSION	Lung Small Cell Carcinoma	Olaparib,Prexasertib,Cisplatin	Sensitivity/Response	D	28490518	Lung	Therapeutic	D
CHEK2	CNV	deletion	Prostate adenocarcinoma	Olaparib	Responsive	Early trials	AACR 2015 (abstr CT322)	Prostate	Therapeutic	C
CHEK2	MUT	oncogenic mutation	Prostate adenocarcinoma	Olaparib	Responsive	Early trials	26510020;AACR 2015 (abstr CT322)	Prostate	Therapeutic	C
CNOT3	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			2	23263491	Blood;Bone_Marrow	Therapeutic	C
CRBN	EXP	undexpression	Myeloma	Lenalidomide	Resistant	Case report	21860026	Bone_Marrow	Therapeutic	D
CRBN	EXP	undexpression	Myeloma	Pomalidomide	Resistant	Case report	21860026	Bone_Marrow	Therapeutic	D
CRBN	MUT	mutation	Multiple Myeloma	Lenalidomide,Pomalidomide	Resistance	C	23480694	Bone_Marrow	Therapeutic	C
CRBN	MUT	oncogenic mutation	Myeloma	Lenalidomide	Resistant	Case report	25108355	Bone_Marrow	Therapeutic	D
CRBN	MUT	oncogenic mutation	Myeloma	Pomalidomide	Resistant	Case report	25108355	Bone_Marrow	Therapeutic	D
CRBN	MUT	Q100X	Myeloma	Lenalidomide	Resistant	Case report	23480694	Bone_Marrow	Therapeutic	D
CRBN	MUT	Q100X	Myeloma	Pomalidomide	Resistant	Case report	23480694	Bone_Marrow	Therapeutic	D
CRBN	MUT	R283K	Myeloma	Lenalidomide	Resistant	Case report	23480694	Bone_Marrow	Therapeutic	D
CRBN	MUT	R283K	Myeloma	Pomalidomide	Resistant	Case report	23480694	Bone_Marrow	Therapeutic	D
CREBBP	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma in Blood/Bone Marrow/Lymph Node			1	22388726,24662245,14528273,21390130	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
CRLF2	FUS	CRLF2-IGH fusion	Adult B-Lymphoblastic Leukemia		Poor Outcome	B	20018760	Blood;Bone_Marrow	Prognostic	B
CRLF2	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24787007,19907440,20018760	Blood;Bone_Marrow	Therapeutic	B
CSF1R	EXP	OVEREXPRESSION	tenosynovial giant cell tumor	Pexidartinib	sensitive	Phase I	26222558	Soft_Tissue	Therapeutic	C
CSF1R	FUS	MEF2D-CSF1R	Acute Lymphocytic Leukemia	Imatinib,GW-2580	Sensitivity/Response	D	24186003	Blood;Bone_Marrow	Therapeutic	D
CSF1R	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			2	2142747,2406720,8321048,1385636,17360941,24186003,22197934	Blood;Bone_Marrow	Therapeutic	C
CSF1R	MUT	mutation	chronic myelomonocytic leukemia	NMS-P088	predicted - sensitive	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
CSF1R	MUT	mutation	Hodgkins lymphoma	N/A	not applicable	Clinical Study	24619759;26066800;22955918	Lymph_Nodes	Prognostic	C
CSF1R	MUT	mutation	Hodgkins lymphoma	Sorafenib	sensitive	Preclinical	21517818	Lymph_Nodes	Therapeutic	D
CSF1R	MUT	Y571D	Myelodisplasic proliferative syndrome	Imatinib	Responsive	Pre-clinical	18971950	Bone_Marrow	Therapeutic	D
CSF1R	MUT	Y571D	myeloid leukemia	Imatinib	sensitive	Preclinical	18971950	Blood;Bone_Marrow	Therapeutic	D
CSF3R	MUT	any frameshift	Myeloproliferative Neoplasm/Chronic Neutrophilic Leukemia/Atypical Chronic Myeloid Leukemia in Blood/Bone Marrow			1	23604229,23656643,19620628	Blood;Bone_Marrow	Therapeutic	B
CSF3R	MUT	any nonsense	Myeloproliferative Neoplasm/Chronic Neutrophilic Leukemia/Atypical Chronic Myeloid Leukemia in Blood/Bone Marrow			1	23604229,23656643,19620628	Blood;Bone_Marrow	Therapeutic	B
CSF3R	MUT	frameshift variant D771	Atypical chronic myeloid leukemia	Dasatinib	Responsive	Pre-clinical	23656643	Blood;Bone_Marrow	Therapeutic	D
CSF3R	MUT	frameshift variant S783	Atypical chronic myeloid leukemia	Dasatinib	Responsive	Pre-clinical	23656643	Blood;Bone_Marrow	Therapeutic	D
CSF3R	MUT	mutation	Atypical Chronic Myeloid Leukemia		Positive	B	23656643	Blood;Bone_Marrow	Diagnostic	B
CSF3R	MUT	mutation	Chronic Neutrophilic Leukemia		Positive	B	23656643	Blood;Bone_Marrow	Diagnostic	B
CSF3R	MUT	N610H	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical - Cell culture	30348809	Other	Therapeutic	D
CSF3R	MUT	N610H	Advanced Solid Tumor	Trametinib	predicted - sensitive	Preclinical - Cell culture	30348809	Other	Therapeutic	D
CSF3R	MUT	N610S	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical - Cell culture	30348809	Other	Therapeutic	D
CSF3R	MUT	N610S	Advanced Solid Tumor	Trametinib	predicted - sensitive	Preclinical - Cell culture	30348809	Other	Therapeutic	D
CSF3R	MUT	Q741X	Advanced Solid Tumor	Ibrutinib + Ruxolitinib	sensitive	Preclinical - Cell culture	29977015	Other	Therapeutic	D
CSF3R	MUT	Q741X	Advanced Solid Tumor	Ibrutinib	sensitive	Preclinical - Cell culture	29977015	Other	Therapeutic	D
CSF3R	MUT	Q741X	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical - Cell culture	29977015	Other	Therapeutic	D
CSF3R	MUT	T618I	Advanced Solid Tumor	Ibrutinib + Ruxolitinib	sensitive	Preclinical - Cell culture	29977015	Other	Therapeutic	D
CSF3R	MUT	T618I	Advanced Solid Tumor	Ibrutinib	sensitive	Preclinical - Cell culture	29977015	Other	Therapeutic	D
CSF3R	MUT	T618I	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical - Cell culture	26475333;29977015	Other	Therapeutic	D
CSF3R	MUT	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	Sensitivity/Response	C	25180155	Blood;Bone_Marrow	Therapeutic	C
CSF3R	MUT	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	Sensitivity/Response	D	24081659	Blood;Bone_Marrow	Therapeutic	D
CSF3R	MUT	T618I	Myeloproliferative Neoplasm/Chronic Neutrophilic Leukemia/Atypical Chronic Myeloid Leukemia in Blood/Bone Marrow			1	23604229,23656643,19620628	Blood;Bone_Marrow	Therapeutic	B
CSF3R	MUT	T640N	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical	26475333	Other	Therapeutic	D
CTCF	MUT	any mutation	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma/Myelodysplastic Syndrome in Blood/Bone Marrow			1	24056718,22976956,21390130	Blood;Bone_Marrow	Therapeutic	B
CTLA4	FUS	CTLA4-CD28	Sezary's Disease	Ipilimumab	Sensitivity/Response	C	25802883	Lymph_Nodes	Therapeutic	C
CTNNB1	CNV	amp	acute myeloid leukemia	CWP232291	predicted - sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
CTNNB1	EXP	OVEREXPRESSION	colon cancer	NVP-TNKS656 + Triciribine	predicted - sensitive	Preclinical - Pdx	26224873	Colorectal	Therapeutic	D
CTNNB1	MUT	ACTIVATING mutation	Melanoma	PD-L1 Antibody,CTLA-4 Antibody	Resistance	D	25970248	Skin	Therapeutic	D
CTNNB1	MUT	any mutation	Adenocarcinoma in Colon/Rectum			2	10416591,18992635,12912937,22610277,15659508	Colorectal	Therapeutic	C
CTNNB1	MUT	any mutation	Craniopharyngioma in Brain/Spinal Cord/Brain, Supratentorial/Brain, Infratentorial			2	24413733	Brain;Nervous_System	Therapeutic	C
CTNNB1	MUT	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any	Craniopharyngioma in Brain/Spinal Cord/Brain, Supratentorial/Brain, Infratentorial			2	24413733	Brain;Nervous_System	Therapeutic	C
CTNNB1	MUT	codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	codon(s) 41, 45 any	Adenocarcinoma in Colon/Rectum			2	10416591,18992635,12912937,22610277,15659508	Colorectal	Therapeutic	C
CTNNB1	MUT	codon(s) 41, 45 any	Fibromatosis in Chest Wall			2	22211293,28717319,25341748,22766794	Pleura	Therapeutic	C
CTNNB1	MUT	codon(s) 41, 45 any	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	D32V	Endometrium	Everolimus;Letrozole	Responsive	Early trials	25624430	Uterus	Therapeutic	C
CTNNB1	MUT	D32V	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	G34E	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	Gain-of-Function	desmoid tumor	Imatinib	sensitive	Clinical Study - Cohort	26861905	Other	Therapeutic	C
CTNNB1	MUT	Gain-of-Function	hepatocellular carcinoma	unspecified CTLA4 antibody	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
CTNNB1	MUT	Gain-of-Function	hepatocellular carcinoma	unspecified CTLA4 antibody + unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
CTNNB1	MUT	Gain-of-Function	hepatocellular carcinoma	unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
CTNNB1	MUT	Gain-of-Function	hepatocellular carcinoma	unspecified PD-L1 antibody	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
CTNNB1	MUT	H36Y	Endometrium	Everolimus;Letrozole	Responsive	Early trials	25624430	Uterus	Therapeutic	C
CTNNB1	MUT	mutant	colorectal cancer	BC21	sensitive	Preclinical	22224445	Colorectal	Therapeutic	D
CTNNB1	MUT	mutant	endometrial cancer	Temsirolimus	predicted - sensitive	Phase II	27016228	Uterus	Therapeutic	C
CTNNB1	MUT	mutant	hepatocellular carcinoma	PMED-1	sensitive	Preclinical	24819961	Liver	Therapeutic	D
CTNNB1	MUT	mutant	medulloblastoma	N/A	not applicable	Guideline	;	Nervous_System	Prognostic	A
CTNNB1	MUT	oncogenic mutation	Colorectal adenocarcinoma	[Tankyrase inhibitor]	Resistant	Pre-clinical	23539443	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	BAY1161909	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	BAY1217389	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	MPI-0479605	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	Mps1-IN-1	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	Mps-BAY2b	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	NMS-P715	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S33Y	colorectal adenocarcinoma	NTRC 0066-0	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S37C	Endometrium	Everolimus;Letrozole	Responsive	Early trials	25624430	Uterus	Therapeutic	C
CTNNB1	MUT	S37C	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	S37F	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	S37Y	Craniopharyngioma in Brain/Spinal Cord/Brain, Supratentorial/Brain, Infratentorial			2	24413733	Brain;Nervous_System	Therapeutic	C
CTNNB1	MUT	S37Y	Endometrium	Everolimus;Letrozole	Responsive	Early trials	25624430	Uterus	Therapeutic	C
CTNNB1	MUT	S37Y	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	45_45del	colon carcinoma	BAY1161909	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	BAY1217389	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	MPI-0479605	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	Mps1-IN-1	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	Mps-BAY2b	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	NMS-P715	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colon carcinoma	NTRC 0066-0	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	45_45del	colorectal adenocarcinoma	BAY1161909	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	BAY1217389	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	MPI-0479605	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	Mps1-IN-1	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	Mps-BAY2b	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	NMS-P715	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	colorectal adenocarcinoma	NTRC 0066-0	predicted - sensitive	Preclinical - Cell culture	28751540	Colorectal	Therapeutic	D
CTNNB1	MUT	S45F	Desmoid Fibromatosis		Poor Outcome	B	18832571	Other	Prognostic	B
CTNNB1	MUT	S45F	Desmoid Fibromatosis		Positive	B	18832571	Other	Diagnostic	B
CTNNB1	MUT	S45F	Desmoid Fibromatosis		Positive	B	22766794	Other	Diagnostic	B
CTNNB1	MUT	S45F	desmoid tumor	Imatinib	sensitive	Clinical Study - Cohort	26861905	Other	Therapeutic	C
CTNNB1	MUT	S45P	Desmoid Fibromatosis		Better Outcome	B	18832571	Other	Prognostic	B
CTNNB1	MUT	S45P	Desmoid Fibromatosis		Positive	B	18832571	Other	Diagnostic	B
CTNNB1	MUT	S45P	Desmoid Fibromatosis		Positive	B	22766794	Other	Diagnostic	B
CTNNB1	MUT	S45P	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23490077,24429522,23867056,28699254,18757411,12824925	Blood;Bone_Marrow	Therapeutic	B
CTNNB1	MUT	T41A	Desmoid Fibromatosis		Better Outcome	B	18832571	Other	Prognostic	B
CTNNB1	MUT	T41A	Desmoid Fibromatosis		Positive	B	18832571	Other	Diagnostic	B
CTNNB1	MUT	T41A	Desmoid Fibromatosis		Positive	B	22766794	Other	Diagnostic	B
CTNNB1	MUT	T41A	desmoid tumor	Imatinib	sensitive	Clinical Study - Cohort	26861905	Other	Therapeutic	C
CTNNB1	MUT	T41A	lung cancer	BAY1161909	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	BAY1217389	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	MPI-0479605	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	Mps1-IN-1	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	Mps-BAY2b	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	NMS-P715	predicted - sensitive	Preclinical - Cell culture	28751540	Lung	Therapeutic	D
CTNNB1	MUT	T41A	lung cancer	NTRC 0066-0	predicted - sensitive	Preclinical - Cell line xenograft	28751540	Lung	Therapeutic	D
CUX1	MUT	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Lymphocytic Leukemia/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			2	23212519,24316979,21674579	Blood;Bone_Marrow	Therapeutic	C
CXCR4	EXP	EXPRESSION	Gastric Adenocarcinoma	Docetaxel	Resistance	B	20651371	Stomach	Therapeutic	B
CXCR4	MUT	any mutation	Lymphoplasmacytic Lymphoma in Blood/Bone Marrow			1	24366360,18436740,26490317,24553177,25853747	Blood;Bone_Marrow	Therapeutic	B
CYP17A1	EXP	expression	Prostate adenocarcinoma	Abiraterone	Responsive	Early trials	22184395	Prostate	Therapeutic	C
CYP17A1	EXP	expression	Prostate adenocarcinoma	Enzalutamide	Responsive	Early trials	24882673	Prostate	Therapeutic	C
DCC	EXP	EXPRESSION	Colorectal Cancer		Better Outcome	B	8929264	Colorectal	Prognostic	B
DDIT3	FUS	EWSR1-DDIT3	Myxoid Liposarcoma		Positive	C	8637704	Soft_Tissue	Diagnostic	C
DDIT3	FUS	FUS-DDIT3	Myxoid Liposarcoma		Positive	A	1568170	Soft_Tissue	Diagnostic	A
DDR2	CNV	amp EML4-ALK	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
DDR2	EXP	OVEREXPRESSION	head and neck squamous cell carcinoma	Dasatinib	sensitive	Preclinical - Cell culture	27434411	Head_and_Neck	Therapeutic	D
DDR2	MUT	G253C	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G253C	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G253C	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G253C	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	G253C	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	G505S	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G505S	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G505S	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G505S	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	G505S	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	G774V	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G774V	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G774V	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	G774V	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	G774V	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	Gain-of-Function	lung non-small cell carcinoma	Lucitanib	sensitive	Preclinical	24696502	Lung	Therapeutic	D
DDR2	MUT	I638F	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	I638F	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	I638F	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	I638F	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	I638F	lung squamous cell carcinoma	Dasatinib	sensitive	Preclinical - Cell line xenograft	22328973	Lung	Therapeutic	D
DDR2	MUT	I638F	lung squamous cell carcinoma	Ponatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
DDR2	MUT	I638F	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	L239R	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L239R	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L239R	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L239R	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	L239R	lung squamous cell carcinoma	Dasatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
DDR2	MUT	L239R	lung squamous cell carcinoma	Ponatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
DDR2	MUT	L239R	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	L63V	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L63V	Advanced Solid Tumor	Nilotinib + Saracatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L63V	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22328973	Other	Therapeutic	D
DDR2	MUT	L63V	Lung Non-small Cell Carcinoma	Dasatinib	Sensitivity/Response	D	22328973	Lung	Therapeutic	D
DDR2	MUT	L63V	lung squamous cell carcinoma	Dasatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
DDR2	MUT	L63V	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	22328973	Lung	Therapeutic	D
DDR2	MUT	mutant	lung squamous cell carcinoma	Dasatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
DDR2	MUT	S768R	Lung Non-small Cell Carcinoma	Dasatinib,Erlotinib	Sensitivity/Response	C	22328973	Lung	Therapeutic	C
DDR2	MUT	S768R	lung squamous cell carcinoma	Dasatinib + Erlotinib	predicted - sensitive	Case Reports/Case Series	22328973	Lung	Therapeutic	D
DDR2	MUT	S768R	lung squamous cell carcinoma	Dasatinib	predicted - sensitive	Case Reports/Case Series	23932362	Lung	Therapeutic	D
DDR2	MUT	S768R	Lung squamous cell	Dasatinib	Responsive	Case report	22328973	Lung	Therapeutic	D
DDR2	MUT	S768R	Lung squamous cell	Erlotinib	Responsive	Case report	22328973	Lung	Therapeutic	D
DDX43	EXP	OVEREXPRESSION	Uveal Melanoma	Trametinib,Selumetinib,PD0325901	Resistance	D	24899684	Eye	Therapeutic	D
DEFA1	EXP	EXPRESSION	Prostate Cancer	Docetaxel	Sensitivity/Response	B	26261420	Prostate	Therapeutic	B
DICER1	MUT	E1705K	Malignant Sertoli-Leydig Cell Tumor		Positive	B	26428316	Ovary	Diagnostic	B
DKK1	MUT	NUCLEAR EXPRESSION	Colorectal Cancer	Irinotecan,L-Folinic Acid,5-fluorouracil,Oxaliplatin	Resistance	B	25788273	Colorectal	Therapeutic	B
DNAJB1-PRKACA	MUT	rearrangement	Hepatocellular Carcinoma in Liver			1	24578576,25557953	Liver	Therapeutic	B
DNMT1	EXP	EXPRESSION	Gastric Adenocarcinoma	Cisplatin	Resistance	B	21458988	Stomach	Therapeutic	B
DNMT1	EXP	EXPRESSION	Ovarian Cancer	Decitabine	Sensitivity/Response	D	25968887	Ovary	Therapeutic	D
DNMT3A	MUT	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	23645565,27881874,21399634,21415852,22829153,21670448,23603912,21828135	Blood;Bone_Marrow	Therapeutic	B
DNMT3A	MUT	mutant	acute myeloid leukemia	Decitabine	predicted - sensitive	Clinical Study - Cohort	27418649	Blood;Bone_Marrow	Therapeutic	C
DNMT3A	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	22490330;21881046;21670448	Blood;Bone_Marrow	Prognostic	C
DNMT3A	MUT	mutant	acute myeloid leukemia	Pinometostat	sensitive	Preclinical - Cell line xenograft	27335278	Blood;Bone_Marrow	Therapeutic	D
DNMT3A	MUT	mutation	Acute Myeloid Leukemia	Decitabine	Sensitivity/Response	B	22124213	Blood;Bone_Marrow	Therapeutic	B
DNMT3A	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	22490330	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	27288520	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	mutation	Cancer	Pembrolizumab,Atezolizumab,Nivolumab	Resistance	B	28351930	Cancer	Therapeutic	B
DNMT3A	MUT	mutation	Myelodysplastic Syndrome		Poor Outcome	B	21415852	Bone_Marrow	Prognostic	B
DNMT3A	MUT	mutation	T-cell Acute Lymphoblastic Leukemia		Poor Outcome	B	23341344	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	oncogenic mutation	Acute myeloid leukemia	Daunorubicin	Responsive	FDA guidelines	22417203	Blood;Bone_Marrow	Therapeutic	A
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Better Outcome	B	23632886	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia	Idarubicin	Sensitivity/Response	B	22081665	Blood;Bone_Marrow	Therapeutic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Negative	B	23632886	Blood;Bone_Marrow	Diagnostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	A	23632886	Blood;Bone_Marrow	Prognostic	A
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	B	21067377	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	B	22291079	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	B	22490330	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	B	23632886	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Poor Outcome	B	24512939	Blood;Bone_Marrow	Prognostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Positive	B	21067377	Blood;Bone_Marrow	Diagnostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Positive	B	22081665	Blood;Bone_Marrow	Diagnostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Positive	B	22490330	Blood;Bone_Marrow	Diagnostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Positive	B	23632886	Blood;Bone_Marrow	Diagnostic	B
DNMT3A	MUT	R882	Acute Myeloid Leukemia		Positive	B	24512939	Blood;Bone_Marrow	Diagnostic	B
DPYD	MUT	DPYD*13 HOMOZYGOSITY	Cancer	5-FU,Tegafur,Capecitabine	Adverse Response	A	23988873	Cancer	Therapeutic	A
DPYD	MUT	DPYD*2A HOMOZYGOSITY	Cancer	Tegafur,Capecitabine,5-FU	Adverse Response	A	23988873	Cancer	Therapeutic	A
DUSP6	EXP	EXPRESSION	Cancer	Trametinib	Sensitivity/Response	D	22169769	Cancer	Therapeutic	D
DUX4	FUS	DUX4 FUSIONS	Acute Lymphocytic Leukemia		Better Outcome	C	27019113	Blood;Bone_Marrow	Prognostic	C
DUX4	FUS	DUX4 FUSIONS	Acute Lymphocytic Leukemia		Positive	D	27019113	Blood;Bone_Marrow	Diagnostic	D
EED	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	22237106,22733077	Blood;Bone_Marrow	Therapeutic	B
EGF	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab	Resistance	D	25677871	Head_and_Neck	Therapeutic	D
EGFR	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Responsive	Late trials	18794099;17664472	Colorectal	Therapeutic	C
EGFR	CNV	amplification	Endometrium	Gefitinib	Responsive	Late trials	24950987	Uterus	Therapeutic	C
EGFR	CNV	amplification	Head an neck squamous	[EGFR inhibitor]	Responsive	Case report	26763254	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	Advanced Solid Tumor	Depatuxizumab mafodotin	sensitive	Phase Ib/II	29533458	Other	Therapeutic	C
EGFR	CNV	amp	Advanced Solid Tumor	Depatuxizumab mafodotin	sensitive	Phase I	;	Other	Therapeutic	C
EGFR	CNV	amp	Advanced Solid Tumor	MM-151	predicted - sensitive	Preclinical	25911688	Other	Therapeutic	D
EGFR	CNV	amp	colorectal cancer	Panitumumab	sensitive	Phase III	17664472	Colorectal	Therapeutic	C
EGFR	CNV	amp	esophagus adenocarcinoma	AMG 337	predicted - resistant	Case Reports/Case Series	26432108	Esophagus	Therapeutic	D
EGFR	CNV	amp	esophagus squamous cell carcinoma	Afatinib	resistant	Preclinical - Cell culture	27207775	Esophagus	Therapeutic	D
EGFR	CNV	amp	esophagus squamous cell carcinoma	Cetuximab	resistant	Preclinical - Cell culture	27207775	Esophagus	Therapeutic	D
EGFR	CNV	amp	esophagus squamous cell carcinoma	Erlotinib	resistant	Preclinical - Cell culture	27207775	Esophagus	Therapeutic	D
EGFR	CNV	amp	esophagus squamous cell carcinoma	SHP099	sensitive	Preclinical - Cell line xenograft	27362227	Esophagus	Therapeutic	D
EGFR	CNV	amp	gastric adenocarcinoma	ABT-806	predicted - sensitive	Clinical Study - Cohort	29449271	Stomach	Therapeutic	C
EGFR	CNV	amp	gastric adenocarcinoma	Cetuximab	predicted - sensitive	Clinical Study - Cohort	29449271	Stomach	Therapeutic	C
EGFR	CNV	amp	gastroesophageal junction adenocarcinoma	ABT-806	predicted - sensitive	Clinical Study - Cohort	29449271	Esophagus	Therapeutic	C
EGFR	CNV	amp	gastroesophageal junction adenocarcinoma	Cetuximab	predicted - sensitive	Clinical Study - Cohort	29449271	Esophagus	Therapeutic	C
EGFR	CNV	amp	gastrointestinal system cancer	Cetuximab	sensitive	Preclinical - Pdx	24141978	Stomach	Therapeutic	D
EGFR	CNV	amp	glioblastoma multiforme	Dacomitinib	sensitive	Preclinical - Pdxcell culture	25939761	Brain	Therapeutic	D
EGFR	CNV	amp	glioblastoma multiforme	Depatuxizumab mafodotin	sensitive	Phase I	;29075855	Brain	Therapeutic	C
EGFR	CNV	amp	glioblastoma multiforme	Temozolomide + Vandetanib	no benefit	Phase II	25910950	Brain	Therapeutic	C
EGFR	CNV	amp	head and neck cancer	unspecified EGFR antibody	sensitive	Preclinical - Cell culture	27196767	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck cancer	unspecified EGFR antibody + unspecified ERBB3 antibody	sensitive	Preclinical - Cell culture	27196767	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck cancer	unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody	sensitive	Preclinical - Cell culture	27196767	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck cancer	unspecified EGFR antibody + unspecified IGF-1R antibody	sensitive	Preclinical - Cell culture	27196767	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck squamous cell carcinoma	Afatinib	sensitive	Preclinical - Cell line xenograft	25559287	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck squamous cell carcinoma	Cetuximab	resistant	Preclinical - Cell culture	27207775	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck squamous cell carcinoma	Depatuxizumab mafodotin	sensitive	Preclinical - Cell line xenograft	26846818	Head_and_Neck	Therapeutic	D
EGFR	CNV	amp	head and neck squamous cell carcinoma	Erlotinib	resistant	Preclinical - Cell culture	27207775	Head_and_Neck	Therapeutic	D
EGFR	CNV	AMPLIFICATION	Barrett's Adenocarcinoma		Poor Outcome	B	20840671	Esophagus	Prognostic	B
EGFR	CNV	AMPLIFICATION	Cervical Squamous Cell Carcinoma		Poor Outcome	B	21730982	Cervix	Prognostic	B
EGFR	CNV	AMPLIFICATION	Colorectal Cancer	Cetuximab,Panitumumab	Sensitivity/Response	B	24653627	Colorectal	Therapeutic	B
EGFR	CNV	AMPLIFICATION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	18794099	Colorectal	Therapeutic	B
EGFR	CNV	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	16943533	Head_and_Neck	Prognostic	B
EGFR	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	EGFR Inhibitor	Sensitivity/Response	B	20826716	Lung	Therapeutic	B
EGFR	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	Resistance	D	28202511	Lung	Therapeutic	D
EGFR	CNV	amp	lung non-small cell carcinoma	Docetaxel + Vandetanib	predicted - sensitive	Phase III	25057173	Lung	Therapeutic	C
EGFR	CNV	amp	lung non-small cell carcinoma	Ganetespib	sensitive	Preclinical - Cell culture	25077897	Lung	Therapeutic	D
EGFR	CNV	amp	malignant glioma	Erlotinib + Temsirolimus	no benefit	Phase Ib/II	24470557	Nervous_System	Therapeutic	C
EGFR	CNV	amp	penile cancer	ABT-806	sensitive	Phase I	25895099	Other	Therapeutic	C
EGFR	CNV	amp	triple-receptor negative breast cancer	Depatuxizumab mafodotin	sensitive	Phase Ib/II	29533458	Breast	Therapeutic	C
EGFR	CNV	amp	triple-receptor negative breast cancer	Depatuxizumab mafodotin	sensitive	Preclinical	26846818	Breast	Therapeutic	D
EGFR	CNV	amp	triple-receptor negative breast cancer	Erlotinib + PF-431396	sensitive	Preclinical - Cell culture	27793840	Breast	Therapeutic	D
EGFR	CNV	amp	triple-receptor negative breast cancer	Gefitinib + PF-431396	sensitive	Preclinical - Cell culture	27793840	Breast	Therapeutic	D
EGFR	CNV	amp	triple-receptor negative breast cancer	Gefitinib + PF-573228	sensitive	Preclinical - Cell culture	27793840	Breast	Therapeutic	D
EGFR	CNV	amp	triple-receptor negative breast cancer	SHP099	sensitive	Preclinical - Cell culture	27362227	Breast	Therapeutic	D
EGFR	CNV	amp	urinary bladder cancer	Afatinib	no benefit	Phase II	27044931	Bladder	Therapeutic	C
EGFR	CNV	COPY NUMBER VARIATION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	17538160	Head_and_Neck	Prognostic	B
EGFR	CNV	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Sensitivity/Response	B	27664271	Lung	Therapeutic	B
EGFR	CNV	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	20826716	Lung	Therapeutic	B
EGFR	CNV	exon19 del	Advanced Solid Tumor	BGB-283	sensitive	Preclinical - Cell culture	26208524	Other	Therapeutic	D
EGFR	CNV	exon19 del	Advanced Solid Tumor	DZD9008	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
EGFR	CNV	exon19 del	Advanced Solid Tumor	Lazertinib	sensitive	Preclinical - Cell culture	30670498	Other	Therapeutic	D
EGFR	CNV	exon19 del	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	CNV	exon19 del	lung adenocarcinoma	Gefitinib + Golvatinib	sensitive	Preclinical - Cell line xenograft	22789825	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung adenocarcinoma	JNJ-61186372	sensitive	Preclinical - Pdx	27216193	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung adenocarcinoma	Osimertinib	sensitive	Case Reports/Case Series	29596911	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung cancer	AZD3759	sensitive	Preclinical - Cell line xenograft	27928026	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung cancer	Dasatinib + Osimertinib	sensitive	Preclinical - Cell culture	28416483	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung cancer	Osimertinib + Selumetinib	sensitive	Preclinical - Cell culture	28416483	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Afatinib	sensitive	FDA approved - On Companion Diagnostic	;;23816960	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Afatinib	sensitive	Phase II	27083334	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Alectinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Brigatinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Cabozantinib + Erlotinib	predicted - sensitive	Phase II	30915273	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Ceritinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Dacomitinib	sensitive	FDA approved - On Companion Diagnostic	;28958502;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Erlotinib + GLPG0634	predicted - sensitive	Preclinical - Cell culture	28729401	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Erlotinib	sensitive	FDA approved - On Companion Diagnostic	24868098;;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Erlotinib	sensitive	Phase II	26720423	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Erlotinib	sensitive	Preclinical - Cell culture	30962319	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Gefitinib + K-756	sensitive	Preclinical	27196752	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Gefitinib + Pemetrexed	sensitive	Phase II	30268482	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Gefitinib	sensitive	Clinical Study - Cohort	24736073	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Gefitinib	sensitive	FDA approved - On Companion Diagnostic	;;19692680	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Ibrutinib	sensitive	Preclinical - Cell line xenograft	26375053	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Icotinib	sensitive	Clinical Study - Cohort	30791921	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Icotinib	sensitive	Clinical Study - Meta-analysis	24533047	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	JNJ-61186372	sensitive	Preclinical - Cell line xenograft	27216193	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Lazertinib	sensitive	Preclinical - Pdxcell culture	30670498	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Nazartinib	sensitive	Preclinical - Pdxcell culture	26825170	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Nimotuzumab	predicted - sensitive	Preclinical - Cell culture	30962319	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	OBX1-012	sensitive	Preclinical - Cell line xenograft	29754184	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	FDA approved - On Companion Diagnostic	29151359;;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	Phase I	25923549	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	Phase III	30659024	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Cell culture	30962319	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Cell line xenograft	27435396	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Panitumumab	predicted - sensitive	Preclinical - Cell culture	30962319	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Rociletinib	no benefit	Preclinical - Cell line xenograft	27435396	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	SHR-A1307	sensitive	Preclinical - Cell line xenograft	30962319	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	TAE226	sensitive	Preclinical - Cell line xenograft	26090892	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	TAS-121	sensitive	Case Reports/Case Series	30872380	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	TH-4000	sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	TUL-001	predicted - sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-small cell carcinoma	unspecified CTLA4 antibody + unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	unspecified PD-L1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	CNV	exon19 del	lung non-small cell carcinoma	Vandetanib	sensitive	Preclinical - Cell line xenograft	19447865	Lung	Therapeutic	D
EGFR	CNV	exon19 del	lung non-squamous non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-squamous non-small cell carcinoma	Erlotinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	lung non-squamous non-small cell carcinoma	Gefitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	CNV	exon19 del	spindle cell carcinoma	Gefitinib	no benefit	Case Reports/Case Series	30555702	Skin	Therapeutic	D
EGFR	EXP	EXPRESSION	Chordoma	Lapatinib	Sensitivity/Response	B	23559153	Bone;Soft_Tissue	Therapeutic	B
EGFR	EXP	EXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	14993230	Colorectal	Therapeutic	B
EGFR	EXP	EXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	18003960	Colorectal	Therapeutic	B
EGFR	EXP	EXPRESSION	Colorectal Cancer	Panitumumab	Sensitivity/Response	B	17470858	Colorectal	Therapeutic	B
EGFR	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	12748244	Lung	Therapeutic	B
EGFR	EXP	OVEREXPRESSION	Advanced Solid Tumor	Depatuxizumab mafodotin	predicted - sensitive	Phase Ib/II	29533458	Other	Therapeutic	C
EGFR	EXP	OVEREXPRESSION	esophageal cancer	Theliatinib	sensitive	Preclinical - Pdx	28881608	Esophagus	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	Esophagus Squamous Cell Carcinoma		Poor Outcome	B	26459251	Esophagus	Prognostic	B
EGFR	EXP	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	9625170	Head_and_Neck	Prognostic	B
EGFR	EXP	OVEREXPRESSION	lung cancer	BGB-283	sensitive	Preclinical - Cell culture	26208524	Lung	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	EGFR Inhibitor	Sensitivity/Response	B	22056021	Lung	Therapeutic	B
EGFR	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	EGFR Inhibitor	Sensitivity/Response	B	26439803	Lung	Therapeutic	B
EGFR	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	16707605	Lung	Therapeutic	B
EGFR	EXP	OVEREXPRESSION	lung squamous cell carcinoma	Depatuxizumab mafodotin	sensitive	Preclinical - Cell line xenograft	26846818	Lung	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	squamous cell carcinoma	BGB-283	sensitive	Preclinical - Cell line xenograft	26208524	Skin	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	squamous cell carcinoma	GA201	sensitive	Preclinical	23209031	Skin	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	squamous cell carcinoma	TAK-285	sensitive	Preclinical - Cell line xenograft	23983820	Skin	Therapeutic	D
EGFR	EXP	OVEREXPRESSION	stomach cancer	GC1118	predicted - sensitive	Phase I	31164456	Stomach	Therapeutic	C
EGFR	EXP	OVEREXPRESSION	Supratentorial Glioblastoma Multiforme		Poor Outcome	B	14583498	Brain	Prognostic	B
EGFR	EXP	overexpression	Colorectal adenocarcinoma	Cetuximab	Responsive	FDA guidelines	FDA	Colorectal	Therapeutic	A
EGFR	EXP	overexpression	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
EGFR-FGFR1	FUS	EGFR L858R	lung non-small cell carcinoma	Osimertinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	E746_A750del EML4-ALK	lung non-small cell carcinoma	Osimertinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	Afatinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	Naquotinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	Osimertinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	E746_S752delinsV MET-UBE2H	lung adenocarcinoma	Crizotinib	predicted - sensitive	Case Reports/Case Series	30244854	Lung	Therapeutic	D
EGFR	FUS	E746_S752delinsV MET-UBE2H	lung adenocarcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	30244854	Lung	Therapeutic	D
EGFR	FUS	L747_A750delinsP FGFR3-TACC3	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	L747_P753delinsS EML4-ALK	lung non-small cell carcinoma	Afatinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	L747_T751delinsP EML4-ALK	lung non-small cell carcinoma	Afatinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	L858R EML4-ALK	lung non-small cell carcinoma	Afatinib	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	FUS	L858R FGFR3-TACC3	lung non-small cell carcinoma	Afatinib + Cetuximab	predicted - resistant	Case Reports/Case Series	29883838	Lung	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A1118T	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A216T	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A216T	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A216T	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A216T	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A216T	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289D	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289D	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289D	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	22203214,22588883,17177598	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	A289T	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289T	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289T	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289T	lung non-small cell carcinoma	Icotinib	predicted - sensitive	Case Reports/Case Series	;	Lung	Therapeutic	D
EGFR	MUT	A289V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289V	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289V	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	17177598	Other	Therapeutic	D
EGFR	MUT	A289V	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289V	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A289V	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	22203214,22588883,17177598	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	A289V	Glioma	Erlotinib	Responsive	Pre-clinical	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	A289V	Glioma	Lapatinib	Response	4	18334972, 20459769, 22588883	Nervous_System	Therapeutic	D
EGFR	MUT	A289V	lung non-small cell carcinoma	Icotinib	predicted - sensitive	Case Reports/Case Series	30572543	Lung	Therapeutic	D
EGFR	MUT	A289V	lung non-small cell carcinoma	Icotinib	predicted - sensitive	Case Reports/Case Series	;	Lung	Therapeutic	D
EGFR	MUT	A289V	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	A702S	lung non-small cell carcinoma	Afatinib	no benefit	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	A702T	lung non-small cell carcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	A702V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	30952700	Other	Therapeutic	D
EGFR	MUT	A702V	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	30952700	Other	Therapeutic	D
EGFR	MUT	A702V	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	30952700	Other	Therapeutic	D
EGFR	MUT	A750P	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	28336552, 19625781, 25179728, 15737014	Lung	Therapeutic	A
EGFR	MUT	A750V	lung non-small cell carcinoma	Afatinib	no benefit	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	A763V	lung non-small cell carcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	15897572	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29483211;29467275	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29483211;29467275	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Luminespib	sensitive	Preclinical - Cell culture	30154228	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	29748209	Other	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Afatinib	sensitive	Preclinical	24353160	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	28089594	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Preclinical - Cell culture	24353160	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	24353160	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Gefitinib	sensitive	Case Reports/Case Series	28089594	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Gefitinib	sensitive	Preclinical	24353160	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Preclinical - Cell culture	30154228	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Cell culture	29483211	Lung	Therapeutic	D
EGFR	MUT	A763delinsAFQEA	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	23371856, 24353160, 23969006	Lung	Therapeutic	A
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Afatinib	conflicting	Preclinical - Cell culture	29141884;24353160	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Afatinib	conflicting	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Dacomitinib	resistant	Preclinical - Cell culture	28363995	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29483211	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Nazartinib	sensitive	Preclinical - Cell culture	26825170	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29483211	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767_V769dup	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	29748209	Other	Therapeutic	D
EGFR	MUT	A767_V769dupASV	Lung Adenocarcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	A767_V769dup	lung adenocarcinoma	Poziotinib	sensitive	Preclinical - Patient cell culture	29686424	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung cancer	Afatinib	predicted - resistant	Preclinical - Pdxcell culture	;	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung cancer	Tarloxotinib	sensitive	Preclinical - Pdxcell culture	;	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung cancer	TAS6417	sensitive	Preclinical - Pdxcell culture	29748209	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Afatinib	conflicting	Case Reports/Case Series	31043566	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Afatinib	conflicting	Preclinical - Cell culture	29483211	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Afatinib	conflicting	Preclinical - Pdx	29483211	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Erlotinib	resistant	Phase I	24353160	Lung	Therapeutic	C
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Gefitinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Osimertinib	sensitive	Case Reports/Case Series	31208370	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Pdx	29483211	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Pdxcell culture	29483211	Lung	Therapeutic	D
EGFR	MUT	A767_V769dup	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	A767V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767V	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A767V	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A859T	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A859T	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A859T	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A864T	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	19147750	Lung	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871G	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871T	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871T	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871T	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	A871T	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	CNV	Amplification	Glioma	Lapatinib	Response	4	18334972, 20459769, 22588883	Nervous_System	Therapeutic	D
EGFR	MUT	any mutation	Acute Myeloid Leukemia in Blood/Bone Marrow			2	24522247	Blood;Bone_Marrow	Therapeutic	C
EGFR	MUT	any mutation	Adenocarcinoma in Colon/Rectum			2	24379565,15625347,21403829,22026926,23358982,25293556,26101090	Colorectal	Therapeutic	C
EGFR	MUT	any mutation	Adenocarcinoma in Lung			1	28785538	Lung	Therapeutic	B
EGFR	MUT	any mutation	Adenocarcinoma in Stomach			2	24744582,23320047,18199332,19636422	Stomach	Therapeutic	C
EGFR	MUT	any mutation	Papillary Carcinoma/Follicular Carcinoma in Thyroid			2	26878173,16822827,21422425	Thyroid	Therapeutic	C
EGFR	MUT	C797G	Non-Small Cell Lung Cancer	Osimertinib	Resistant	R2	29713646, 27086175	Lung	Therapeutic	C
EGFR	MUT	C797S	Advanced Solid Tumor	Afatinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	C797S	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	C797S	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	C797S	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	C797S	Lung Adenocarcinoma	Osimertinib	Resistance	C	26181354	Lung	Therapeutic	C
EGFR	MUT	C797S	Lung Non-small Cell Carcinoma	Osimertinib	Resistance	B	25939061	Lung	Therapeutic	B
EGFR	MUT	C797S	Lung	Osimertinib	Resistant	Early trials	25939061	Lung	Therapeutic	C
EGFR	MUT	C797S	Non-Small Cell Lung Cancer	Osimertinib	Resistant	R2	26749488, 28625641, 26181354, 25939061	Lung	Therapeutic	C
EGFR	MUT	C797Y	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	codon(s) 289, 596, 598 any	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	22203214,22588883,17177598	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	codon(s) 761 any	Adenocarcinoma in Lung			1	PharmGKB,20966921	Lung	Therapeutic	B
EGFR	MUT	codon(s) 790 any	Adenocarcinoma in Lung			1	28219202,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	codon(s) 861 any	Adenocarcinoma in Lung			1	25668120,28219202,PharmGKB,24419415	Lung	Therapeutic	B
EGFR	CNV	copy number gain	Adenocarcinoma in Gastroesophageal Junction/Esophagus/Stomach			1	19636422	Esophagus;Stomach	Therapeutic	B
EGFR	CNV	copy number gain	Glioblastoma in Brain/Brain, Infratentorial/Brain, Supratentorial			2	19954019	Brain	Therapeutic	C
EGFR	CNV	copy number gain	Urothelial Carcinoma in Bladder			1	25158272	Bladder	Therapeutic	B
EGFR	MUT	D761delinsDEAFQ	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	D761delinsDEAFQ	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	D761delinsDEAFQ	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	D761N	Adenocarcinoma in Lung			1	PharmGKB,20966921	Lung	Therapeutic	B
EGFR	MUT	D761Y	Adenocarcinoma in Lung			1	PharmGKB,20966921	Lung	Therapeutic	B
EGFR	MUT	D761Y	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Resistance	C	17085664	Lung	Therapeutic	C
EGFR	MUT	D761Y	Non-Small Cell Lung Cancer	Gefitinib	Resistant	R2	28424065, 17085664, 17192902, 22052230	Lung	Therapeutic	C
EGFR	MUT	D761Y	Non-Small Cell Lung Cancer	Osimertinib	Response	4	28424065, 17085664	Lung	Therapeutic	D
EGFR	MUT	D761Y	Non-small cell lung	[EGFR inhibitor 1st gen]	Resistant	Case report	19680293	Lung	Therapeutic	D
EGFR	MUT	D770delinsDGY	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical - Cell culture	28363995	Other	Therapeutic	D
EGFR	MUT	D770delinsDGY	Advanced Solid Tumor	Neratinib	resistant	Preclinical - Cell culture	28363995	Other	Therapeutic	D
EGFR	MUT	D770delinsDGY	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	D770delinsDG	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	29748209	Other	Therapeutic	D
EGFR	MUT	D770delinsDGF	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	D770delinsDGL	Lung Adenocarcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	D770delinsDG	lung non-small cell carcinoma	Osimertinib	predicted - sensitive	Case Reports/Case Series	31208370	Lung	Therapeutic	D
EGFR	MUT	D770delinsDG	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	D770delinsDGT	Lung Adenocarcinoma	Erlotinib	Resistance	C	23371856	Lung	Therapeutic	C
EGFR	MUT	D770delinsDGV	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	D770delinsDGY	Lung Adenocarcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	D770delinsDNPY	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	D770delinsDSVD	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	24353160	Lung	Therapeutic	D
EGFR	MUT	D770delinsDSVD	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	D770_P772dup	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	D770_P772dup	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	E690K	Endometrium	Lapatinib	Responsive	Case report	22885469	Uterus	Therapeutic	D
EGFR	MUT	E709A	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709A	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709A	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709A	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709A	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709G	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709G	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709G	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709G	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709K	Adenocarcinoma in Lung			1	18372921,25960661,16205628,15623594	Lung	Therapeutic	B
EGFR	MUT	E709K	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Gefitinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Osimertinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Advanced Solid Tumor	Rociletinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709K	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	18372921,22203214,22588883,17177598,28219202	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	E709K	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	28336552, 23566546, 18000506, 25179728, 25130612, 23749122, 15710947	Lung	Therapeutic	A
EGFR	MUT	E709delinsED	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			1	22982663,26206867,PharmGKB,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Gefitinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Osimertinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	Advanced Solid Tumor	Rociletinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	E709delinsED	lung adenocarcinoma	Afatinib	sensitive	Case Reports/Case Series	30413663	Lung	Therapeutic	D
EGFR	MUT	E709delinsED	lung adenocarcinoma	Afatinib	sensitive	Phase I	26206867	Lung	Therapeutic	C
EGFR	MUT	E709delinsED	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	E709delinsED	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	21531810, 28336552, 26206867	Lung	Therapeutic	A
EGFR	MUT	E709V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709V	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709V	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709V	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E709X	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	E709X	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	E734Q	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	20942962	Other	Therapeutic	D
EGFR	MUT	E734Q	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	746_750del	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EGFR	MUT	746_750del	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical - Cell culture	15604279	Other	Therapeutic	D
EGFR	MUT	746_750del	Adenocarcinoma in Lung			1	28219202,PharmGKB,22848739,17429853,25611025	Lung	Therapeutic	B
EGFR	MUT	E746delinsEIle	Adenocarcinoma in Lung			1	28219202,PharmGKB,22848739,17429853,25611025	Lung	Therapeutic	B
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEIP	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	746_750del	lung adenocarcinoma	Abivertinib	sensitive	Preclinical - Cell line xenograft	27573423	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung adenocarcinoma	Gefitinib	predicted - sensitive	Clinical Study	18981003	Lung	Therapeutic	C
EGFR	MUT	746_750del	lung cancer	TAS6417	sensitive	Preclinical - Cell culture	29748209	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung carcinoma	BGB-283	sensitive	Preclinical - Cell line xenograft	26208524	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Afatinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Cisplatin + ER2	sensitive	Preclinical - Cell line xenograft	27040853	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	MUT	746_750del	lung non-small cell carcinoma	ER2	sensitive	Preclinical - Cell line xenograft	27040853	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Erlotinib + Ganetespib	sensitive	Preclinical - Cell line xenograft	25077897	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Erlotinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Gedatolisib	sensitive	Preclinical	21325073;16731747	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Lapatinib	resistant	Preclinical	18199554	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Trametinib + WZ4002	sensitive	Preclinical - Cell line xenograft	26036643	Lung	Therapeutic	D
EGFR	MUT	746_750del	lung non-small cell carcinoma	Vandetanib	sensitive	Preclinical - Cell culture	15604279	Lung	Therapeutic	D
EGFR	MUT	E746G	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	26773740	Lung	Therapeutic	C
EGFR	MUT	E746G	Lung	Erlotinib	Responsive	Case report	26773740	Lung	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEVS	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E746delinsEV	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E749Q	lung adenocarcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	28162944	Lung	Therapeutic	D
EGFR	MUT	E749Q	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	E865K	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E865K	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E865K	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	E868G	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	20942962	Other	Therapeutic	D
EGFR	MUT	E868G	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	858_858_del	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	B	22285168	Lung	Therapeutic	B
EGFR	MUT	858_858_del	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Sensitivity/Response	B	21531810	Lung	Therapeutic	B
EGFR	MUT	858_858_del	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	24755888	Lung	Therapeutic	C
EGFR	MUT	exon(s) 18 OVEREXPRESSION	Lung Non-small Cell Carcinoma	Bevacizumab,Erlotinib	Sensitivity/Response	B	24039832	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	22452895	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	23816960	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	24439929	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	25589191	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	27566387	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 deletion	Lung Adenocarcinoma	Gefitinib	Sensitivity/Response	B	22370314	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	A	23982599	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	25862853	Lung	Therapeutic	D
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	26515464	Lung	Therapeutic	D
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Dacomitinib,Erlotinib	Sensitivity/Response	B	26768165	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	A	24868098	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	B	22285168	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	16818686	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	18509184	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	D	16730237	Lung	Therapeutic	D
EGFR	MUT	exon(s) 19 deletion	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Osimertinib, Dacomitinib, Gefitinib	Response	1	28958502, 23816960, 30659024, 20022809, 21670455, 29151359, 22452895, 25589191, 22285168, 29864379, 19692680, 27987585, 22370314, 20573926	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 deletion	Lung	Osimertinib	Responsive	Early trials	NCT02465060	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 deletion	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 deletion	Non-small cell lung	Erlotinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 deletion	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	28336552, 22190593	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 insertion	Lung	Afatinib	Responsive	Late trials	22753918;25589191	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 insertion	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 insertion	Lung	Erlotinib	Responsive	Early trials	22190593	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 insertion	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	exon(s) 19 insertion	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	exon(s) 19 insertion	lung non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	lung non-small cell carcinoma	Erlotinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	lung non-small cell carcinoma	Gefitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 insertion	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	exon(s) 19 any	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	AP32788	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	Dacomitinib	resistant	Preclinical	18089823;21764376	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	DZD9008	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	Nazartinib	predicted - sensitive	Preclinical - Cell culture	26825170	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	Osimertinib	resistant	Preclinical	24893891	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	Rociletinib	resistant	Preclinical	24065731	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Lung Adenocarcinoma	Afatinib	Resistance	B	26051236	Lung	Therapeutic	B
EGFR	MUT	exon(s) 20 insertion	Lung Adenocarcinoma	Erlotinib	Resistance	C	22895145	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Resistant	R1	23371856, 24065731, 19536777, 24353160, 21764376, 18676761, 24893891, 23328547, 1867676, 15897572, 17686547	Lung	Therapeutic	A
EGFR	MUT	exon(s) 20 insertion	Non-Small Cell Lung Cancer	Poziotinib	Response	3A	27188206, 29686424	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	Lung	[EGFR inhibitor 1st gen]	Resistant	Late trials	21764376;26773740;26051236	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	Lung	[HSP90 inhibitor]	Responsive	Case report	ASCO 2014 (abstr 8015)	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	Lung	Osimertinib	Responsive	Pre-clinical	26515464	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung cancer	Tarloxotinib	predicted - sensitive	Preclinical - Pdxcell culture	;	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Afatinib	resistant	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Afatinib	resistant	Phase II	26051236	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Afatinib	resistant	Preclinical	24353160	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Erlotinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Erlotinib	resistant	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Gefitinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Gefitinib	resistant	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Case Reports/Case Series	30154228	Lung	Therapeutic	D
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29162564;	Lung	Therapeutic	C
EGFR	MUT	exon(s) 4 deletion	Epithelial Ovarian Cancer	Cisplatin	Resistance	D	23764753	Ovary	Therapeutic	D
EGFR	MUT	exon(s) 18, 19, 20, 21 any	Adenocarcinoma in Lung			1	28219202,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	exon(s) 18 deletion	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			1	22982663,26206867,PharmGKB,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	exon(s) 18 indel	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			1	22982663,26206867,PharmGKB,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	exon(s) 19 deletion	Adenocarcinoma in Lung			1	28219202,PharmGKB,22848739,17429853,25611025	Lung	Therapeutic	B
EGFR	MUT	exon(s) 20 insertion	Adenocarcinoma in Lung			1	23371856,26096453	Lung	Therapeutic	B
EGFR	MUT	exon(s) 20 insertion	Glioblastoma in Brain/Spinal Cord/Brain, Supratentorial/Brain, Infratentorial			2	23371856,26096453	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	G465E	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465E	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465E	colorectal cancer	Panitumumab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465R	Colorectal adenocarcinoma	Cetuximab	Resistant	Case report	22270724;26059438;25623215;22270724;26888827	Colorectal	Therapeutic	D
EGFR	MUT	G465R	Colorectal adenocarcinoma	Cetuximab	Resistant	Pre-clinical	25623215	Colorectal	Therapeutic	D
EGFR	MUT	G465R	Colorectal adenocarcinoma	Panitumumab	Resistant	Case report	26059438	Colorectal	Therapeutic	D
EGFR	MUT	G465R	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	C	26888827	Colorectal	Therapeutic	C
EGFR	MUT	G465R	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465R	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465R	colorectal cancer	Panitumumab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	G465R	colorectal cancer	SYM004	sensitive	Case Reports/Case Series	26888827	Colorectal	Therapeutic	D
EGFR	MUT	G465R	colorectal cancer	SYM004	sensitive	Preclinical - Cell line xenograft	26888827	Colorectal	Therapeutic	D
EGFR	MUT	G465R	Colorectal Cancer	Sym004	Sensitivity/Response	C	26888827	Colorectal	Therapeutic	C
EGFR	MUT	G598V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G598V	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G598V	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G598V	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G598V	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	22203214,22588883,17177598	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	G598V	Glioma	Erlotinib	Responsive	Pre-clinical	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	G696_P1033dup	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	26286086	Other	Therapeutic	D
EGFR	MUT	G696_P1033dup	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	26286086	Other	Therapeutic	D
EGFR	MUT	G696_P1033dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical	26286086	Other	Therapeutic	D
EGFR	MUT	G696_P1033dup	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26286086	Lung	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	AP32788	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Gefitinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Osimertinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Advanced Solid Tumor	Rociletinib	decreased response	Preclinical	26206867	Other	Therapeutic	D
EGFR	MUT	G719A	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	G719A	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	G719A	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	G719A	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	G719A	lung non-small cell carcinoma	Afatinib	sensitive	Phase III	24790411	Lung	Therapeutic	C
EGFR	MUT	G719A	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase III	24857124	Lung	Therapeutic	C
EGFR	MUT	G719A	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719A	lung non-small cell carcinoma	Gefitinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719A	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	20038723	Lung	Therapeutic	C
EGFR	MUT	G719A	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719A	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719A	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719A	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719C	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G719C	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G719C	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	G719C	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	G719C	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	G719C	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	G719C	lung non-small cell carcinoma	Afatinib	sensitive	Phase III	24790411	Lung	Therapeutic	C
EGFR	MUT	G719C	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase III	24857124	Lung	Therapeutic	C
EGFR	MUT	G719C	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719C	lung non-small cell carcinoma	Gefitinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719C	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719C	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719C	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719C	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719D	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	G719D	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	G719D	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	G719D	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	G719D	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	G719D	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719D	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719D	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719D	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	B	26773740	Lung	Therapeutic	B
EGFR	MUT	G719	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Sensitivity/Response	B	21531810	Lung	Therapeutic	B
EGFR	MUT	G719	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	21531810, 28336552, 15118073, 26051236, 21670455, 16011858, 24285021, 20573926	Lung	Therapeutic	A
EGFR	MUT	G719	Non-small cell lung	Erlotinib	Responsive	NCCN guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	G719S	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G719S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G719S	colorectal cancer	Afatinib	sensitive	Preclinical - Cell line xenograft	30872380	Colorectal	Therapeutic	D
EGFR	MUT	G719S	Colorectal Cancer	Cetuximab	Sensitivity/Response	D	24894453	Colorectal	Therapeutic	D
EGFR	MUT	G719S	colorectal cancer	TAS-121	sensitive	Preclinical - Cell line xenograft	30872380	Colorectal	Therapeutic	D
EGFR	MUT	G719S	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	G719S	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	G719S	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	G719S	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	G719S	lung non-small cell carcinoma	Afatinib	sensitive	Phase III	23344264;24790411	Lung	Therapeutic	C
EGFR	MUT	G719S	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase III	24857124	Lung	Therapeutic	C
EGFR	MUT	G719S	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Sensitivity/Response	B	26124334	Lung	Therapeutic	B
EGFR	MUT	G719S	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719S	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	19147750	Lung	Therapeutic	D
EGFR	MUT	G719S	lung non-small cell carcinoma	Gefitinib	sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719S	lung non-small cell carcinoma	Gefitinib	sensitive	Preclinical	17349580	Lung	Therapeutic	D
EGFR	MUT	G719S	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	D	15118125	Lung	Therapeutic	D
EGFR	MUT	G719S	lung non-small cell carcinoma	TAS-121	sensitive	Case Reports/Case Series	30872380	Lung	Therapeutic	D
EGFR	MUT	G719S	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719S	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719S	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719S	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	G719X	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	G719X	lung non-small cell carcinoma	Afatinib	sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	G719X	lung non-small cell carcinoma	Afatinib	sensitive	FDA approved - On Companion Diagnostic	;;26051236	Lung	Therapeutic	A
EGFR	MUT	G719X	lung non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	G719X	lung non-small cell carcinoma	Afatinib	sensitive	Phase III	24790411	Lung	Therapeutic	C
EGFR	MUT	G719X	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	G719X	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719X	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	G719X	lung non-small cell carcinoma	Gefitinib	sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	G719X	lung non-small cell carcinoma	Gefitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	G719X	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	G719X	lung non-small cell carcinoma	Neratinib	sensitive	Phase II	20479403	Lung	Therapeutic	C
EGFR	MUT	G719X	lung non-small cell carcinoma	Osimertinib	decreased response	Phase Ib/II	29285266	Lung	Therapeutic	C
EGFR	MUT	G724S	Adenocarcinoma/Squamous Cell Carcinoma in Lung			1	PharmGKB,PharmGKB,25611025,23371856,25521405	Lung	Therapeutic	B
EGFR	MUT	G724S	Colorectal Cancer	Cetuximab	Sensitivity/Response	D	24894453	Colorectal	Therapeutic	D
EGFR	MUT	G735S	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G735S	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G735S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G779S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G863S	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	G873E	Advanced Solid Tumor	Afatinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G873E	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G873E	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G873E	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G874D	lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	G874S	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G874S	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	G874S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	Gain-of-Function	Advanced Solid Tumor	ABT-806	predicted - sensitive	Phase I	25895099	Other	Therapeutic	C
EGFR	MUT	Gain-of-Function	Advanced Solid Tumor	AP32788	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	Gain-of-Function	glioblastoma multiforme	BMS-754807 + Dacomitinib	sensitive	Preclinical - Cell culture	26561558	Brain	Therapeutic	D
EGFR	MUT	Gain-of-Function	glioblastoma multiforme	Gefitinib + Linsitinib	sensitive	Preclinical	26561558	Brain	Therapeutic	D
EGFR	MUT	Gain-of-Function	glioblastoma multiforme	WSD0922	predicted - sensitive	Preclinical - Cell line xenograft	;	Brain	Therapeutic	D
EGFR	MUT	Gain-of-Function	head and neck squamous cell carcinoma	WSD0922	predicted - sensitive	Preclinical - Pdx	;	Head_and_Neck	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung adenocarcinoma	Bevacizumab + Erlotinib	sensitive	Phase II	28408243	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Afatinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Afatinib	sensitive	Phase II	28169392	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Alectinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Amlexanox + Selumetinib	sensitive	Preclinical - Cell line xenograft	27287717	Lung	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Atezolizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Bevacizumab + Erlotinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Brigatinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Camrelizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Carboplatin + Gefitinib + Pemetrexed	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Ceritinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase II	25456362	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase III	;29864379	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib + Glesatinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib + Luminespib	no benefit	Phase Ib/II	25870087	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib + MK2206	no benefit	Phase II	26106072	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib	sensitive	Phase II	26720423	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Erlotinib	sensitive	Phase III	26324372	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Gefitinib + Pemetrexed	sensitive	Phase II	30268482	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Gefitinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Gefitinib	sensitive	Phase III	19692680	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Gefitinib	sensitive	Phase III	;	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	15118073	Lung	Therapeutic	B
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	MTI-31	predicted - sensitive	Preclinical - Cell line xenograft	30796032	Lung	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Naquotinib	predicted - sensitive	Phase III	31070709	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Naquotinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Neratinib	decreased response	Phase I	20479403	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Nivolumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Pembrolizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Rociletinib	sensitive	Preclinical - Cell line xenograft	24065731	Lung	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	Sapitinib	sensitive	Preclinical - Cell line xenograft	20145185	Lung	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	WSD0922	predicted - sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	MUT	Gain-of-Function	lung non-small cell carcinoma	XL647	sensitive	Phase II	22722787	Lung	Therapeutic	C
EGFR	MUT	Gain-of-Function	lung squamous cell carcinoma	WSD0922	predicted - sensitive	Preclinical - Pdx	;	Lung	Therapeutic	D
EGFR	MUT	H304Y	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H304Y	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H304Y	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773dup	Advanced Solid Tumor	Afatinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773dup	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773dup	Advanced Solid Tumor	Luminespib	sensitive	Preclinical - Cell culture	30154228	Other	Therapeutic	D
EGFR	MUT	H773dup	lung non-small cell carcinoma	Afatinib	resistant	Preclinical	24353160	Lung	Therapeutic	D
EGFR	MUT	H773dup	lung non-small cell carcinoma	Erlotinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	H773dup	lung non-small cell carcinoma	Gefitinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	H773dup	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	H773L	Adenocarcinoma in Lung			2	28219202,24285021	Lung	Therapeutic	C
EGFR	MUT	H773L	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773L	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773L	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773L	lung non-small cell carcinoma	EKI-285	resistant	Preclinical - Cell culture	17974985	Lung	Therapeutic	D
EGFR	MUT	H773delinsHLM	lung adenocarcinoma	Bevacizumab + Gefitinib	predicted - sensitive	Case Reports/Case Series	29858019	Lung	Therapeutic	D
EGFR	MUT	H773delinsHLM	lung adenocarcinoma	Bevacizumab + Osimertinib	predicted - sensitive	Case Reports/Case Series	29858019	Lung	Therapeutic	D
EGFR	MUT	H773delinsHLM	lung adenocarcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	29858019	Lung	Therapeutic	D
EGFR	MUT	H773delinsHAH	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	H773delinsHH	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	24353160	Lung	Therapeutic	D
EGFR	MUT	H773delinsHNPH	Lung Adenocarcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	H773Y	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773Y	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773Y	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773Y	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H773Y	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H835L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H835L	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H835L	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H835L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	H835L	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	I491M	Colorectal adenocarcinoma	Cetuximab	Resistant	Pre-clinical	25623215	Colorectal	Therapeutic	D
EGFR	MUT	I491M	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	I491M	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	I491M	colorectal cancer	Panitumumab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	I740_K745dup	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	22190593	Lung	Therapeutic	D
EGFR	MUT	I744M	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	I744M	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	6_273del	Glioblastoma	Rindopepimut	Responsive	Late trials	NCT01480479	Brain	Therapeutic	C
EGFR	MUT	inframe insertion 769-770	Lung	Erlotinib	Responsive	Case report	26773740;23328547	Lung	Therapeutic	D
EGFR	MUT	K467T	Advanced Solid Tumor	SYM004	predicted - sensitive	Preclinical - Cell culture	26888827	Other	Therapeutic	D
EGFR	MUT	K467T	Colorectal adenocarcinoma	Cetuximab	Resistant	Case report	22270724;26059438;25623215;22270724;26888827	Colorectal	Therapeutic	D
EGFR	MUT	K467T	Colorectal Cancer	Cetuximab	Resistance	D	26888827	Colorectal	Therapeutic	D
EGFR	MUT	K467T	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	K467T	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	K467T	colorectal cancer	Panitumumab	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	K467T	Colorectal Cancer	Sym004,Panitumumab	Sensitivity/Response	D	26888827	Colorectal	Therapeutic	D
EGFR	MUT	K714R	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K714R	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K739_I744dup	lung adenocarcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	22190593	Lung	Therapeutic	D
EGFR	MUT	K739_I744dup	lung non-small cell carcinoma	Gefitinib	predicted - sensitive	Case Reports/Case Series	28089594	Lung	Therapeutic	D
EGFR	MUT	K745delinsKIPVAIK	Adenocarcinoma/Pleomorphic Carcinoma in Lung			1	22190593,25279299,24736087,24419426	Lung	Therapeutic	B
EGFR	MUT	K745delinsKTPVAIK	lung adenocarcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	22190593	Lung	Therapeutic	D
EGFR	MUT	K745delinsKVPVAIK	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K745delinsKVPVAIK	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K745delinsKVPVAIK	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K757R	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	26773740	Lung	Therapeutic	C
EGFR	MUT	K757R	Lung	Erlotinib	Responsive	Case report	26773740	Lung	Therapeutic	D
EGFR	MUT	K860I	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	K860I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	28336552, 26286086	Lung	Therapeutic	A
EGFR	MUT	L62R	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L62R	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L62R	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L62R	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703I	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703I	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703I	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703P	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703P	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L703P	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L718	Lung	Osimertinib	Resistant	Early trials	ASCO 2017 (abstr 2572)	Lung	Therapeutic	C
EGFR	MUT	L718Q	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L718Q	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L718Q	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L718Q	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L718Q	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L718Q	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_750del	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	bronchiolo-alveolar adenocarcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	15737014	Lung	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLQ	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	AEE788	sensitive	Preclinical	19147750	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical	19147750	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	19147750	Lung	Therapeutic	D
EGFR	MUT	L747P	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			1	PharmGKB,PharmGKB,22797155,21531810,26339441,18508816	Lung	Therapeutic	B
EGFR	MUT	L747P	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	30746257	Lung	Therapeutic	D
EGFR	MUT	L747P	lung adenocarcinoma	Bevacizumab + Erlotinib	no benefit	Case Reports/Case Series	29673089	Lung	Therapeutic	D
EGFR	MUT	L747P	lung adenocarcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	27499993	Lung	Therapeutic	D
EGFR	MUT	L747P	lung adenocarcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	29673089	Lung	Therapeutic	D
EGFR	MUT	L747P	lung adenocarcinoma	Osimertinib	predicted - resistant	Case Reports/Case Series	29673089	Lung	Therapeutic	D
EGFR	MUT	L747P	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	L747P	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	28336552, 22190593	Lung	Therapeutic	A
EGFR	MUT	747_752del	lung adenocarcinoma	Gefitinib	predicted - sensitive	Case Reports/Case Series	18981003	Lung	Therapeutic	D
EGFR	MUT	L747S	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747S	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747S	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	L747S	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	L747S	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	L747S	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	L747S	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L747S	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L747S	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L747S	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	747_751del	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_751del	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_751del	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_751del	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	747_751del	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLP	lung adenocarcinoma	Gefitinib	predicted - sensitive	Clinical Study	18981003	Lung	Therapeutic	C
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L747delinsLS	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L792	Lung	Osimertinib	Resistant	Early trials	ASCO 2017 (abstr 2572)	Lung	Therapeutic	C
EGFR	MUT	L798I	Lung adenocarcinoma	Rociletinib	Resistant	Case report	27283993	Lung	Therapeutic	D
EGFR	MUT	L833F	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833F	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833F	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833F	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	L833V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833V	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833V	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833V	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833V	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L833V	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	21949883, 23912954, 25130612, 20808254, 21422421	Lung	Therapeutic	A
EGFR	MUT	L838P	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	L838V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L838V	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L838V	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	19147750	Lung	Therapeutic	D
EGFR	MUT	L844V	Advanced Solid Tumor	Afatinib	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L844V	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L844V	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	25948633	Other	Therapeutic	D
EGFR	MUT	L858M	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	L858R	Adenocarcinoma in Lung			1	28219202,PharmGKB,22263058,25611025	Lung	Therapeutic	B
EGFR	MUT	L858R	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	AV-412	sensitive	Preclinical	17888033	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	BGB-283	sensitive	Preclinical - Cell culture	26208524	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	DZD9008	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	EAI045	sensitive	Preclinical - Cell culture	27251290	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	17085664	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	25573954	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	25573954	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Lazertinib	sensitive	Preclinical - Cell culture	30670498	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	17085664	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	PF-00477736 + PF3644022	no benefit	Preclinical - Cell culture	26140595	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	TAE226	sensitive	Preclinical	26090892	Other	Therapeutic	D
EGFR	MUT	L858R	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	L858R	Cancer	Erlotinib,Gefitinib,AEE788	Sensitivity/Response	D	19147750	Cancer	Therapeutic	D
EGFR	MUT	L858R	Cancer	Erlotinib	Sensitivity/Response	D	17877814	Cancer	Therapeutic	D
EGFR	MUT	L858R	Hematologic Cancer	Cetuximab		D	24893891	Blood	Therapeutic	D
EGFR	MUT	L858R	lung adenocarcinoma	Afatinib + Cetuximab	sensitive	Preclinical	26341921	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	22452895	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	23816960	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	B	24439929	Lung	Therapeutic	B
EGFR	MUT	L858R	lung adenocarcinoma	Cetuximab	sensitive	Preclinical	24063894	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Adenocarcinoma	Cetuximab	Sensitivity/Response	D	27102076	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	27032107	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	D	27102076	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Adenocarcinoma	Gefitinib	Sensitivity/Response	B	22370314	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Adenocarcinoma	Gefitinib	Sensitivity/Response	C	15329413	Lung	Therapeutic	C
EGFR	MUT	L858R	lung adenocarcinoma	Icotinib	predicted - sensitive	Case Reports/Case Series	31301016	Lung	Therapeutic	D
EGFR	MUT	L858R	lung adenocarcinoma	Osimertinib	predicted - sensitive	Case Reports/Case Series	31301016	Lung	Therapeutic	D
EGFR	MUT	L858R	lung adenocarcinoma	Osimertinib + Selumetinib	sensitive	Preclinical	25870145	Lung	Therapeutic	D
EGFR	MUT	L858R	lung adenocarcinoma	Rociletinib	sensitive	Preclinical	24065731	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	L858R	lung cancer	AZD3759	sensitive	Case Reports/Case Series	27928026	Lung	Therapeutic	D
EGFR	MUT	L858R	lung cancer	AZD3759	sensitive	Preclinical - Cell line xenograft	27928026	Lung	Therapeutic	D
EGFR	MUT	L858R	lung cancer	Buparlisib + Osimertinib	sensitive	Preclinical - Cell culture	28416483	Lung	Therapeutic	D
EGFR	MUT	L858R	lung cancer	Dasatinib + Selumetinib	sensitive	Preclinical - Cell culture	28416483	Lung	Therapeutic	D
EGFR	MUT	L858R	lung cancer	Osimertinib + Selumetinib	sensitive	Preclinical - Cell culture	28416483	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Afatinib	sensitive	FDA approved - On Companion Diagnostic	23816960;;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Afatinib	sensitive	Phase II	27083334	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	A	23982599	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	26515464	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Alectinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma		Better Outcome	B	24662454	Lung	Prognostic	B
EGFR	MUT	L858R	lung non-small cell carcinoma	Brigatinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Cabozantinib	predicted - sensitive	Phase II	30915273	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Canertinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Ceritinib	no benefit	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	22235099	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Dacomitinib	sensitive	FDA approved - On Companion Diagnostic	;28958502;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Dacomitinib	sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Dacomitinib	Sensitivity/Response	B	26768165	Lung	Therapeutic	B
EGFR	MUT	L858R	lung non-small cell carcinoma	EAI045	no benefit	Preclinical - Cell culture	27251290	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Erlotinib	sensitive	FDA approved - On Companion Diagnostic	24868098;;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Erlotinib	sensitive	Phase II	26720423	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	A	24868098	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	B	22285168	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	C	15329413	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	21132006	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	24353160	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	27612423	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	24457318	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	24736073	Lung	Therapeutic	B
EGFR	MUT	L858R	lung non-small cell carcinoma	Gefitinib + Pemetrexed	sensitive	Phase II	30268482	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Gefitinib	sensitive	Clinical Study - Meta-analysis	24533047	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Gefitinib	sensitive	FDA approved - On Companion Diagnostic	19692680;;	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	18509184	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	20038723	Lung	Therapeutic	B
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	D	15118125	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	D	24893891	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Ibrutinib	sensitive	Preclinical - Cell culture	26375053	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Icotinib	sensitive	Clinical Study - Cohort	30791921	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Icotinib	sensitive	Clinical Study - Meta-analysis	24533047	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Lapatinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Lazertinib	sensitive	Preclinical - Patient cell culture	30670498	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Nazartinib	sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	Neratinib	Sensitivity/Response	D	16818618	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	Osimertinib	sensitive	FDA approved - On Companion Diagnostic	29151359;;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-small cell carcinoma	Osimertinib	sensitive	Phase I	25923549	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Osimertinib	sensitive	Phase III	30659024	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Non-small Cell Carcinoma	PF 00299804	Sensitivity/Response	D	18089823	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	TAE226	sensitive	Preclinical	26090892	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	TAS-121	sensitive	Case Reports/Case Series	30872380	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-small cell carcinoma	unspecified CTLA4 antibody + unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	unspecified PD-L1 antibody	decreased response	Clinical Study - Cohort	31086949	Lung	Therapeutic	C
EGFR	MUT	L858R	lung non-small cell carcinoma	Vandetanib	sensitive	Preclinical - Cell culture	19447865	Lung	Therapeutic	D
EGFR	MUT	L858R	lung non-squamous non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-squamous non-small cell carcinoma	Erlotinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	lung non-squamous non-small cell carcinoma	Gefitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L858R	Lung	Osimertinib	Responsive	Early trials	NCT02465060	Lung	Therapeutic	C
EGFR	MUT	L858R	Lung Small Cell Carcinoma	Erlotinib		D	24893891	Lung	Therapeutic	D
EGFR	MUT	L858R	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	L858R	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L858R	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Osimertinib, Dacomitinib, Gefitinib	Response	1	28958502, 23816960, 30659024, 20022809, 21670455, 29151359, 22452895, 25589191, 22285168, 29864379, 19692680, 27987585, 22370314, 20573926	Lung	Therapeutic	A
EGFR	MUT	L858R	Non-small cell lung	Erlotinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L858R	Non-small cell lung	Erlotinib	Responsive	NCCN guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	L858R	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	21531810	Lung	Therapeutic	B
EGFR	MUT	L861	Non-Small Cell Lung Cancer	Afatinib, Erlotinib, Gefitinib	Response	1	21531810, 28336552, 26051236	Lung	Therapeutic	A
EGFR	MUT	L861	Non-small cell lung	Erlotinib	Responsive	NCCN guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	L861P	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	L861P	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	L861P	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	L861P	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	L861P	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861P	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861P	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861P	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Adenocarcinoma in Lung			1	25668120,28219202,PharmGKB,24419415	Lung	Therapeutic	B
EGFR	MUT	L861Q	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L861Q	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L861Q	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L861Q	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	L861Q	esophagus squamous cell carcinoma	Afatinib	sensitive	Preclinical - Cell line xenograft	27207775	Esophagus	Therapeutic	D
EGFR	MUT	L861Q	esophagus squamous cell carcinoma	Cetuximab	resistant	Preclinical	27207775	Esophagus	Therapeutic	D
EGFR	MUT	L861Q	esophagus squamous cell carcinoma	Erlotinib	resistant	Preclinical - Cell culture	27207775	Esophagus	Therapeutic	D
EGFR	MUT	L861Q	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	L861Q	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	L861Q	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	L861Q	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	L861Q	lung non-small cell carcinoma	Afatinib	sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	L861Q	lung non-small cell carcinoma	Afatinib	sensitive	FDA approved - On Companion Diagnostic	;;26051236	Lung	Therapeutic	A
EGFR	MUT	L861Q	lung non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L861Q	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L861Q	lung non-small cell carcinoma	Erlotinib	sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	L861Q	lung non-small cell carcinoma	Erlotinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L861Q	lung non-small cell carcinoma	Gefitinib	sensitive	Clinical Study	23344264	Lung	Therapeutic	C
EGFR	MUT	L861Q	lung non-small cell carcinoma	Gefitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L861Q	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	L861Q	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	L861Q	lung non-small cell carcinoma	Lazertinib	predicted - sensitive	Preclinical - Patient cell culture	30670498	Lung	Therapeutic	D
EGFR	MUT	L861Q	lung non-small cell carcinoma	Osimertinib	predicted - sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	L861Q	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	L861Q	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861Q	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861R	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L861R	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	L861R	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	L861R	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	L861R	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	L861R	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	L861R	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	L861R	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861R	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861R	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	L861R	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	M277E	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell line xenograft	28979142	Other	Therapeutic	D
EGFR	MUT	M277E	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	28979142	Lung	Therapeutic	A
EGFR	MUT	M766delinsMAI	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	24353160	Lung	Therapeutic	D
EGFR	MUT	mutant	lung adenocarcinoma	Poziotinib	sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	MUT	mutant	lung cancer	Rociletinib	sensitive	Preclinical - Cell line xenograft	24065731	Lung	Therapeutic	D
EGFR	MUT	mutant	lung non-small cell carcinoma	Afatinib + Bevacizumab	predicted - sensitive	Phase II	30192383	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Clinical Study	26354527	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Atezolizumab	decreased response	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	BMS-690514	predicted - sensitive	Phase II	23490650	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Brigatinib	sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Cabozantinib + Erlotinib	predicted - sensitive	Phase II	30915273	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Docetaxel + Vandetanib	predicted - sensitive	Phase III	25057173	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	DS-1205b + Erlotinib	predicted - sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	MUT	mutant	lung non-small cell carcinoma	DS-1205b + Osimertinib	predicted - sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
EGFR	MUT	mutant	lung non-small cell carcinoma	Durvalumab	decreased response	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Erlotinib + S63845	sensitive	Preclinical - Cell culture	27760111	Lung	Therapeutic	D
EGFR	MUT	mutant	lung non-small cell carcinoma	Lapatinib	no benefit	Phase II	20215545	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Naquotinib	sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	NGI-1	predicted - sensitive	Preclinical - Cell culture	27694802	Lung	Therapeutic	D
EGFR	MUT	mutant	lung non-small cell carcinoma	Nivolumab	decreased response	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Osimertinib + Selumetinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	mutant	lung non-small cell carcinoma	Pelitinib	sensitive	Phase I	16364494	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Pembrolizumab	decreased response	Clinical Study - Cohort	27225694	Lung	Therapeutic	C
EGFR	MUT	mutant	lung non-small cell carcinoma	Sorafenib	sensitive	Phase III	26743856	Lung	Therapeutic	C
EGFR	MUT	mutant	urethra adenocarcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	29320312	Bladder	Therapeutic	D
EGFR	MUT	mutation	Advanced Solid Tumor	ABBV-221	predicted - sensitive	Phase I	;	Other	Therapeutic	C
EGFR	MUT	mutation	Advanced Solid Tumor	AC480	predicted - sensitive	Phase I	21576284	Other	Therapeutic	C
EGFR	MUT	mutation	Advanced Solid Tumor	AFM24	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	mutation	Advanced Solid Tumor	AVID100	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	mutation	Advanced Solid Tumor	EGFRBi-armed autologous activated T cells	sensitive	Preclinical - Cell culture	16397041	Other	Therapeutic	D
EGFR	MUT	mutation	Advanced Solid Tumor	Pelitinib	no benefit	Phase I	16710023	Other	Therapeutic	C
EGFR	MUT	mutation	Advanced Solid Tumor	S-222611	predicted - sensitive	Phase I	25434923	Other	Therapeutic	C
EGFR	MUT	mutation	biliary tract cancer	anti-EGFR CAR T	predicted - sensitive	Phase I	29138340	Bile_Duct	Therapeutic	C
EGFR	MUT	mutation	chordoma	Lapatinib	sensitive	Guideline	;	Bone;Soft_Tissue	Therapeutic	A
EGFR	MUT	mutation	colorectal cancer	GC1118	predicted - sensitive	Preclinical - Cell line xenograft	26586721	Colorectal	Therapeutic	D
EGFR	MUT	mutation	colorectal cancer	MM-151	predicted - sensitive	Phase I	;	Colorectal	Therapeutic	C
EGFR	MUT	mutation	colorectal cancer	SYM004	sensitive	Phase I	25962717	Colorectal	Therapeutic	C
EGFR	MUT	mutation	esophageal cancer	Theliatinib	sensitive	Preclinical - Pdx	28881608	Esophagus	Therapeutic	D
EGFR	MUT	mutation	head and neck cancer	ABBV-221	predicted - sensitive	Phase I	;	Head_and_Neck	Therapeutic	C
EGFR	MUT	mutation	kidney cancer	S-222611	sensitive	Preclinical - Cell line xenograft	24837299	Kidney	Therapeutic	D
EGFR	MUT	mutation	Lung Adenocarcinoma		Better Outcome	B	21969500	Lung	Prognostic	B
EGFR	MUT	mutation	Lung Adenocarcinoma		Better Outcome	B	22810899	Lung	Prognostic	B
EGFR	MUT	mutation	Lung Cancer	Gefitinib	Sensitivity/Response	B	17409929	Lung	Therapeutic	B
EGFR	MUT	mutation	lung non-small cell carcinoma	ABBV-221	sensitive	Preclinical - Cell line xenograft	29483208	Lung	Therapeutic	D
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	B	27083334	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	C	22452896	Lung	Therapeutic	C
EGFR	MUT	mutation	lung non-small cell carcinoma	Erlotinib	conflicting	Phase III	26324372	Lung	Therapeutic	C
EGFR	MUT	mutation	lung non-small cell carcinoma	Erlotinib	conflicting	Preclinical - Pdx	30962319	Lung	Therapeutic	D
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	B	15329413	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	C	21969500	Lung	Therapeutic	C
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	21258250	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	15329413	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	20022809	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	B	20038723	Lung	Therapeutic	B
EGFR	MUT	mutation	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	19692680	Lung	Therapeutic	C
EGFR	MUT	mutation	lung non-small cell carcinoma	Radiotherapy + SYM004	predicted - sensitive	Preclinical - Cell line xenograft	24130052	Lung	Therapeutic	D
EGFR	MUT	mutation	lung non-small cell carcinoma	SHR-A1307	sensitive	Preclinical - Pdx	30962319	Lung	Therapeutic	D
EGFR	MUT	mutation	lung non-small cell carcinoma	SYM004	predicted - sensitive	Preclinical - Cell line xenograft	24204198	Lung	Therapeutic	D
EGFR	MUT	mutation	pancreatic adenocarcinoma	EGFRBi-armed autologous activated T cells	sensitive	Preclinical - Cell line xenograft	16397041	Pancreas	Therapeutic	D
EGFR	MUT	mutation	Peritoneal Mesothelioma	Hyperthermic Intraperitoneal Chemotherapy,Cytoreductive Surgery	Sensitivity/Response	B	20942962	Other	Therapeutic	B
EGFR	MUT	mutation	stomach cancer	Irinotecan + Nimotuzumab	predicted - sensitive	Phase II	25185971	Stomach	Therapeutic	C
EGFR	MUT	N771delinsNFH	lung adenocarcinoma	Poziotinib	sensitive	Preclinical - Patient cell culture	29686424	Lung	Therapeutic	D
EGFR	MUT	N771dup	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	N771dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	N771dup	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	N771dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	N771dup	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	N771_H773dup	Advanced Solid Tumor	Nazartinib	sensitive	Preclinical - Cell culture	26825170	Other	Therapeutic	D
EGFR	MUT	N771_H773dup	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
EGFR	MUT	N771_H773dup	Advanced Solid Tumor	TAS6417	sensitive	Preclinical - Cell line xenograft	29748209	Other	Therapeutic	D
EGFR	MUT	N771_H773dup	head and neck squamous cell carcinoma	Erlotinib	resistant	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	N771_H773dup	head and neck squamous cell carcinoma	Gefitinib	resistant	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	N771_H773dup	head and neck squamous cell carcinoma	Neratinib	sensitive	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	N771_H773dup	lung adenocarcinoma	Afatinib	sensitive	Preclinical - Patient cell culture	28363995	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung adenocarcinoma	Dacomitinib	sensitive	Preclinical - Patient cell culture	28363995	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung cancer	Afatinib	predicted - resistant	Preclinical - Pdxcell culture	;	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung cancer	Tarloxotinib	sensitive	Preclinical - Pdxcell culture	;	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung cancer	TAS6417	predicted - sensitive	Preclinical - Pdx	29748209	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung non-small cell carcinoma	Nazartinib	sensitive	Preclinical - Pdx	26825170	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Pdx	29483211	Lung	Therapeutic	D
EGFR	MUT	N771_H773dup	lung non-small cell carcinoma	Poziotinib	sensitive	Preclinical - Pdx	29686424	Lung	Therapeutic	D
EGFR	MUT	N771delinsNL	lung non-small cell carcinoma	Osimertinib	predicted - sensitive	Case Reports/Case Series	31208370	Lung	Therapeutic	D
EGFR	MUT	N826S	Advanced Solid Tumor	AEE788	resistant	Preclinical - Cell culture	19147750	Other	Therapeutic	D
EGFR	MUT	N826S	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	19147750	Other	Therapeutic	D
EGFR	MUT	N826S	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	19147750	Other	Therapeutic	D
EGFR	MUT	N826S	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	19147750	Lung	Therapeutic	D
EGFR	MUT	P546S	Head an neck	Cetuximab	Responsive	Case report	23578570	Head_and_Neck	Therapeutic	D
EGFR	MUT	P596L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P596L	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P596L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P596L	Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			2	22203214,22588883,17177598	Brain;Nervous_System	Therapeutic	C
EGFR	MUT	P699L	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	P741L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P741L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P741L	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P753S	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P753S	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P753S	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P753S	Head an neck	Cetuximab;Sirolimus	Responsive	Case report	24934779	Head_and_Neck	Therapeutic	D
EGFR	MUT	P753S	Skin Squamous Cell Carcinoma	Cetuximab,Rapamycin (Sirolimus)	Sensitivity/Response	C	24934779	Skin	Therapeutic	C
EGFR	MUT	P753S	Squamous Cell Carcinoma in Skin			2	28765916	Skin	Therapeutic	C
EGFR	MUT	P772_H773dup	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	29748209	Other	Therapeutic	D
EGFR	MUT	P772_H773dup	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Luminespib	sensitive	Preclinical - Cell culture	30154228	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Naquotinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	OBX1-012	predicted - resistant	Preclinical - Cell culture	29754184	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
EGFR	MUT	P772delinsPGNP	lung cancer	Poziotinib	sensitive	Preclinical	29686424	Lung	Therapeutic	D
EGFR	MUT	P772delinsPGNP	lung non-small cell carcinoma	Poziotinib	sensitive	Preclinical	;	Lung	Therapeutic	D
EGFR	MUT	P772delinsPPNP	lung adenocarcinoma	Afatinib	sensitive	Preclinical - Patient cell culture	28363995	Lung	Therapeutic	D
EGFR	MUT	P772delinsPPNP	lung adenocarcinoma	Dacomitinib	sensitive	Preclinical - Patient cell culture	28363995	Lung	Therapeutic	D
EGFR	MUT	P772delinsPYNP	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	P772delinsPPHV	Lung Adenocarcinoma	Erlotinib	Resistance	C	24353160	Lung	Therapeutic	C
EGFR	MUT	P848L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P848L	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P848L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P848L	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	P848L	lung non-small cell carcinoma	Erlotinib	predicted - resistant	Case Reports/Case Series	31175009	Lung	Therapeutic	D
EGFR	MUT	R108K	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R108K	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical	29141884	Other	Therapeutic	D
EGFR	MUT	R108K	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	17177598	Other	Therapeutic	D
EGFR	MUT	R108K	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R108K	Glioma	Erlotinib	Responsive	Pre-clinical	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	R108K	Glioma	Lapatinib	Response	4	18334972, 20459769, 22588883	Nervous_System	Therapeutic	D
EGFR	MUT	R108K	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	R222C	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R222C	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R252C	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R451C	Advanced Solid Tumor	SYM004	predicted - sensitive	Preclinical - Cell culture	26888827	Other	Therapeutic	D
EGFR	MUT	R451C	Colorectal adenocarcinoma	Cetuximab	Resistant	Case report	22270724;26059438;25623215;22270724;26888827	Colorectal	Therapeutic	D
EGFR	MUT	R451C	colorectal cancer	Cetuximab	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	R451C	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	R451C	colorectal cancer	Panitumumab	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	R451C	Colorectal Cancer	Sym004,Panitumumab,Cetuximab	Sensitivity/Response	D	26888827	Colorectal	Therapeutic	D
EGFR	MUT	R776C	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776C	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776C	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776C	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776C	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	19147750	Lung	Therapeutic	D
EGFR	MUT	R776G	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776G	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776G	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	Adenocarcinoma in Colon/Rectum			2	24379565,15625347,21403829,22026926,23358982,25293556,26101090	Colorectal	Therapeutic	C
EGFR	MUT	R776H	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R776H	lung non-small cell carcinoma	Afatinib	no benefit	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	R831H	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831H	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	20942962	Other	Therapeutic	D
EGFR	MUT	R831H	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831H	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	R831L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831L	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831L	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	R831L	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	exon(s) 18, 19, 20, 21 any	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	21531810	Lung	Therapeutic	B
EGFR	MUT	S1153I	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S1153I	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S1153I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S306L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S306L	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S306L	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S306L	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S306L	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S464L	Colorectal adenocarcinoma	Cetuximab	Resistant	Pre-clinical	25623215	Colorectal	Therapeutic	D
EGFR	MUT	S464L	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S464L	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S464L	colorectal cancer	Panitumumab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S492R	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S492R	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S492R	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S492R	Colorectal adenocarcinoma	Cetuximab	Resistant	Case report	22270724;26059438;25623215;22270724;26888827	Colorectal	Therapeutic	D
EGFR	MUT	S492R	Colorectal adenocarcinoma	[novel EGFR mAb inhibitor]	Responsive	Early trials	25962717	Colorectal	Therapeutic	C
EGFR	MUT	S492R	Colorectal adenocarcinoma	Panitumumab	Responsive	Case report	22270724	Colorectal	Therapeutic	D
EGFR	MUT	S492R	Colorectal Cancer	Cetuximab	Resistance	C	22270724	Colorectal	Therapeutic	C
EGFR	MUT	S492R	Colorectal Cancer	Cetuximab	Resistance	D	26888827	Colorectal	Therapeutic	D
EGFR	MUT	S492R	colorectal cancer	Cetuximab	resistant	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S492R	colorectal cancer	MM-151	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S492R	colorectal cancer	Panitumumab	sensitive	Preclinical	26843189	Colorectal	Therapeutic	D
EGFR	MUT	S492R	Colorectal Cancer	Panitumumab	Sensitivity/Response	C	22270724	Colorectal	Therapeutic	C
EGFR	MUT	S492R	Colorectal Cancer	Sym004,Panitumumab	Sensitivity/Response	D	26888827	Colorectal	Therapeutic	D
EGFR	MUT	S492R	colorectal cancer	SYM004	sensitive	Phase I	25962717	Colorectal	Therapeutic	C
EGFR	MUT	S492R	lung squamous cell carcinoma	Necitumumab	predicted - sensitive	Preclinical - Cell culture	29158469	Lung	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720F	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S720	Lung Adenocarcinoma	Erlotinib	Resistance	C	26773740	Lung	Therapeutic	C
EGFR	MUT	752_759del	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	752_759del	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	752_759del	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	752_759del	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	752_759del	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	752_759del	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Afatinib	resistant	Preclinical	24353160;29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Dacomitinib	resistant	Preclinical - Cell culture	28363995	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29483211	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Luminespib	sensitive	Preclinical - Cell culture	30154228	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Nazartinib	sensitive	Preclinical - Cell culture	26825170	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29483211	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	29748209	Other	Therapeutic	D
EGFR	MUT	S768_D770dup	head and neck squamous cell carcinoma	Erlotinib	resistant	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	S768_D770dup	head and neck squamous cell carcinoma	Gefitinib	resistant	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	S768_D770dup	head and neck squamous cell carcinoma	Neratinib	sensitive	Preclinical	25931286	Head_and_Neck	Therapeutic	D
EGFR	MUT	S768_D770dup	lung cancer	Tarloxotinib	sensitive	Preclinical - Patient cell culture	;	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung cancer	TAS6417	sensitive	Preclinical - Cell line xenograft	29748209	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Afatinib	resistant	Preclinical - Cell line xenograft	29483211	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Erlotinib	resistant	Case Reports/Case Series	24353160	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Osimertinib	sensitive	Case Reports/Case Series	31208370	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Osimertinib	sensitive	Preclinical - Cell line xenograft	29483211	Lung	Therapeutic	D
EGFR	MUT	S768_D770dup	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	S768I	Adenocarcinoma/Squamous Cell Carcinoma in Lung			1	PharmGKB,PharmGKB,25611025,23371856,25521405	Lung	Therapeutic	B
EGFR	MUT	S768I	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768I	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical - Cell culture	19147750	Other	Therapeutic	D
EGFR	MUT	S768I	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768I	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	S768I	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	S768I	Lung Adenocarcinoma	Erlotinib	Resistance	C	22895145	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung Adenocarcinoma	Erlotinib	Resistance	D	19147750	Lung	Therapeutic	D
EGFR	MUT	S768I	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	25521405	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung Adenocarcinoma	Gefitinib	Sensitivity/Response	C	20522446	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung	Afatinib;Cetuximab	Responsive	Early trials	ESMO 2012 (abstr 1289)	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung	[EGFR TK inhibitor]	Responsive	Late trials	22753918	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	S768I	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	S768I	lung non-small cell carcinoma	Afatinib	sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	S768I	lung non-small cell carcinoma	Afatinib	sensitive	FDA approved - On Companion Diagnostic	;;26051236	Lung	Therapeutic	A
EGFR	MUT	S768I	lung non-small cell carcinoma	Afatinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	S768I	lung non-small cell carcinoma	Dacomitinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	S768I	lung non-small cell carcinoma	Erlotinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	S768I	lung non-small cell carcinoma	Gefitinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	S768I	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	S768I	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	S768I	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Phase II	29686424	Lung	Therapeutic	C
EGFR	MUT	S768I	Non-small cell lung	Afatinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	S768I	Non-small cell lung	Afatinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	S768I	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Response	1	17285735, 28336552, 25521405, 26051236	Lung	Therapeutic	A
EGFR	MUT	S768I	Non-small cell lung	Erlotinib	Responsive	NCCN guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	S768I	Non-small cell lung	Gefitinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	S768I	Non-small cell lung	Gefitinib	Responsive	NCCN guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	S768delinsSIL	lung adenocarcinoma	Gefitinib	predicted - resistant	Case Reports/Case Series	17045698	Lung	Therapeutic	D
EGFR	MUT	T263P	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical	17177598	Other	Therapeutic	D
EGFR	MUT	T263P	Glioma	Erlotinib	Responsive	Pre-clinical	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	T263P	Glioma	Lapatinib	Response	4	18334972, 20459769, 22588883	Nervous_System	Therapeutic	D
EGFR	MUT	T263P	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	34_289del	Advanced Solid Tumor	Cetuximab	decreased response	Preclinical - Cell culture	27216155	Other	Therapeutic	D
EGFR	MUT	34_289del	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	27216155	Other	Therapeutic	D
EGFR	MUT	34_289del	neuroblastoma	Erlotinib	sensitive	Preclinical - Cell culture	27216155	Adrenal_Gland;Nervous_System	Therapeutic	D
EGFR	MUT	34_289del	neuroblastoma	Etoposide	resistant	Preclinical - Cell culture	27216155	Adrenal_Gland;Nervous_System	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751delinsTN	Advanced Solid Tumor	Rociletinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T751I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T785A	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	T790M	Adenocarcinoma/Squamous Cell Carcinoma in Stomach			2	24744582,23320047,18199332,19636422,22263058,24736066,24736080	Stomach	Therapeutic	C
EGFR	MUT	T790M	Advanced Solid Tumor	AV-412	sensitive	Preclinical	17888033	Other	Therapeutic	D
EGFR	MUT	T790M	Advanced Solid Tumor	TAS6417	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EGFR	MUT	T790M	Cancer	Erlotinib		D	19147750	Cancer	Therapeutic	D
EGFR	MUT	T790M	lung adenocarcinoma	Afatinib	resistant	Clinical Study - Cohort	26862733	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Adenocarcinoma	Erlotinib,Gefitinib	Resistance	B	23470965	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Adenocarcinoma	Osimertinib	Sensitivity/Response	C	26181354	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Adenocarcinoma	Osimertinib	Sensitivity/Response	C	26269204	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung	Afatinib;Cetuximab	Responsive	Early trials	25074459	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung	Afatinib;Nimotuzumab	Responsive	Early trials	26667485	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung	Afatinib	Resistant	NCCN/CAP guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	T790M	lung cancer	CUDC-101	sensitive	Preclinical	20388807	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung Cancer	Gefitinib,AEE788	Resistance	D	18227510	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung	[EGFR inhibitor 3rd gen]	Responsive	Early trials	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung	Erlotinib	Resistant	NCCN/CAP guidelines	NCCN	Lung	Therapeutic	A
EGFR	MUT	T790M	Lung	[HSP90 inhibitor]	Responsive	Early trials	ESMO 2012 (abstr 4380)	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung	[MEK inhibitor (alone, in combination)]	Responsive	Pre-clinical	23102728	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Abivertinib	sensitive	Case Reports/Case Series	27573423	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Abivertinib	sensitive	Phase I	29626621	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Afatinib	predicted - resistant	Clinical Study	26354527	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Afatinib	predicted - resistant	Phase II	26051236	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Afatinib	Resistance	B	24035188	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Afatinib	Sensitivity/Response	D	21732342	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Alflutinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Amlexanox + Selumetinib	sensitive	Preclinical - Cell line xenograft	27287717	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	BEZ235 + Selumetinib	sensitive	Preclinical - Cell line xenograft	24939055	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	BEZ235	sensitive	Preclinical	24939055	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Brigatinib	no benefit	Phase Ib/II	27836716	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Cabozantinib + Erlotinib	predicted - sensitive	Phase II	30915273	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Canertinib	Sensitivity/Response	D	18408761	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Dacomitinib	Resistance	B	21430269	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Dacomitinib	Sensitivity/Response	D	18089823	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Epitinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Erlotinib,Afatinib,Gefitinib	Resistance	B	27304188	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	A	25668228	Lung	Therapeutic	A
EGFR	MUT	T790M	lung non-small cell carcinoma	Erlotinib	resistant	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Gefitinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	B	15728811	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	C	15737014	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	C	17020982	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study - Cohort	27468240	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Lapatinib	Resistance	D	18408761	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Naquotinib	sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Nazartinib	sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Neratinib	Sensitivity/Response	D	16818618	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Olmutinib	sensitive	Phase II	;	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	FDA approved - On Companion Diagnostic	;;;	Lung	Therapeutic	A
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	30715168;30285222	Lung	Therapeutic	A
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Phase I	24410791	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Phase I	25923549	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Phase II	29293889	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Osimertinib	sensitive	Phase III	27959700	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Sensitivity/Response	A	26729184	Lung	Therapeutic	A
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Sensitivity/Response	A	27959700	Lung	Therapeutic	A
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Sensitivity/Response	B	25923549	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Sensitivity/Response	B	26720284	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Sensitivity/Response	D	24893891	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Pemetrexed,Erlotinib	Sensitivity/Response	C	24636847	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma		Poor Outcome	B	24623981	Lung	Prognostic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma		Poor Outcome	B	24729716	Lung	Prognostic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	Sensitivity/Response	D	26515464	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Rociletinib	sensitive	Phase Ib/II	25923550	Lung	Therapeutic	C
EGFR	MUT	T790M	lung non-small cell carcinoma	Rociletinib	sensitive	Phase I	;	Lung	Therapeutic	C
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Rociletinib	Sensitivity/Response	B	25923550	Lung	Therapeutic	B
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Rociletinib	Sensitivity/Response	D	24065731	Lung	Therapeutic	D
EGFR	MUT	T790M	lung non-small cell carcinoma	Selumetinib	decreased response	Preclinical	24939055	Lung	Therapeutic	D
EGFR	MUT	T790M	Lung Non-small Cell Carcinoma	Staurosporine	Sensitivity/Response	E	24658966	Lung	Therapeutic	D
EGFR	MUT	T790M	Non-Small Cell Lung Cancer	Erlotinib, Afatinib, Gefitinib	Resistant	R1	24478319, 26051236, 23816963	Lung	Therapeutic	A
EGFR	MUT	T790M	Non-Small Cell Lung Cancer	Osimertinib	Response	1	25923549, 30059262, 27751847, 29151359	Lung	Therapeutic	A
EGFR	MUT	T790M	Non-small cell lung	[EGFR inhibitor 1st gen]	Resistant	Late trials	19680293	Lung	Therapeutic	C
EGFR	MUT	T790M	Non-small cell lung	[EGFR inhibitor 2nd gen]	Resistant	Late trials	22452896	Lung	Therapeutic	C
EGFR	MUT	T790M	Non-small cell lung	Osimertinib	Responsive	FDA guidelines	FDA	Lung	Therapeutic	A
EGFR	MUT	T790M	Non-small cell lung	[Rociletinib,HM61713]	Responsive	Late trials	NCT02322281	Lung	Therapeutic	C
EGFR	MUT	T854A	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T854A	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T854A	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T854A	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	T854A	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V292L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V292L	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V292L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V742A	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	D	19147750	Lung	Therapeutic	D
EGFR	MUT	V765M	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V765M	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V765M	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V765M	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769delinsVASV	Lung Adenocarcinoma	Erlotinib	Sensitivity/Response	C	26773740	Lung	Therapeutic	C
EGFR	MUT	V769delinsVASV	lung non-small cell carcinoma	Luminespib	predicted - sensitive	Phase II	30351341	Lung	Therapeutic	C
EGFR	MUT	V769L	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769L	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769L	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769L	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769L	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769L	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26354527	Lung	Therapeutic	D
EGFR	MUT	V769M	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769M	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769M	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769M	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V769M	lung non-small cell carcinoma	Icotinib	decreased response	Clinical Study	;	Lung	Therapeutic	C
EGFR	MUT	V774A	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	V774M	Adenocarcinoma in Lung			2	28219202,PMC3868323	Lung	Therapeutic	C
EGFR	MUT	V774M	Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V774M	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V774M	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V774M	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V786M	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V786M	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V802I	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V802I	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V802I	Advanced Solid Tumor	Erlotinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V802I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V802I	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834I	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	V834L	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834L	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834L	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834L	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834M	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834M	Advanced Solid Tumor	Gefitinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V834M	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V843I	Advanced Solid Tumor	Afatinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V843I	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V843I	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V843I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V843I	Advanced Solid Tumor	Rociletinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V851I	Advanced Solid Tumor	Cetuximab	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V851I	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V851I	Advanced Solid Tumor	Gefitinib	resistant	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V851I	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	29141884	Other	Therapeutic	D
EGFR	MUT	V851I	Lung Non-small Cell Carcinoma	Erlotinib	Sensitivity/Response	C	21531810	Lung	Therapeutic	C
EGFR	MUT	VIII	Brain Glioma	Nimotuzumab	Sensitivity/Response	D	26778701	Brain	Therapeutic	D
EGFR	MUT	VIII	Glioblastoma Multiforme	Afatinib	Sensitivity/Response	C	26423602	Brain	Therapeutic	C
EGFR	MUT	VIII	Glioblastoma Multiforme	EGFR Inhibitor	Sensitivity/Response	B	16282176	Brain	Therapeutic	B
EGFR	MUT	VIII	Glioblastoma Multiforme	Gefitinib,Erlotinib	Sensitivity/Response	B	16282176	Brain	Therapeutic	B
EGFR	MUT	VIII	Glioblastoma Multiforme	Rindopepimut	Sensitivity/Response	B	25586468	Brain	Therapeutic	B
EGFR	MUT	VIII	Head And Neck Squamous Cell Carcinoma	Cetuximab,Docetaxel	Resistance	B	21653686	Head_and_Neck	Therapeutic	B
EGFR	MUT	VIII	Malignant Glioma	Erlotinib	Sensitivity/Response	D	17177598	Nervous_System	Therapeutic	D
EGFR	MUT	W731L	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR	MUT	WILDTYPE	Advanced Solid Tumor	EAI045	resistant	Preclinical - Cell culture	27251290	Other	Therapeutic	D
EGFR	MUT	WILDTYPE	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical - Cell culture	25573954	Other	Therapeutic	D
EGFR	MUT	WILDTYPE	Advanced Solid Tumor	Gefitinib	decreased response	Preclinical - Cell culture	25573954	Other	Therapeutic	D
EGFR	MUT	WILDTYPE	colon cancer	Decitabine + Gefitinib	sensitive	Preclinical	24874286	Colorectal	Therapeutic	D
EGFR	MUT	WILDTYPE	glioblastoma multiforme	Dacomitinib	no benefit	Preclinical - Pdxcell culture	25939761	Brain	Therapeutic	D
EGFR	MUT	WILDTYPE	lung carcinoma	Brigatinib	resistant	Preclinical - Cell culture	27780853	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Atezolizumab	predicted - sensitive	Clinical Study - Meta-analysis	29270615	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Cabozantinib + Erlotinib	unknown	Phase II	27825638	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Cabozantinib	unknown	Phase II	27825638	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Cisplatin + ER2	sensitive	Preclinical - Cell line xenograft	27040853	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Docetaxel	predicted - sensitive	Guideline	;	Lung	Therapeutic	A
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	ER2	sensitive	Preclinical - Cell line xenograft	27040853	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Erlotinib + Ganetespib	sensitive	Preclinical - Cell line xenograft	25077897	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Erlotinib + MK2206	sensitive	Phase II	26106072	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Gefitinib + K-756	sensitive	Preclinical	27196752	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Gefitinib	no benefit	Phase III	23980091	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	Lung Non-small Cell Carcinoma	Gefitinib	Sensitivity/Response	C	19692680	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Icotinib	sensitive	Phase III	23372346;2394835;24438614;25261231	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Nivolumab	predicted - sensitive	Clinical Study - Meta-analysis	29270615	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Pembrolizumab	predicted - sensitive	Clinical Study - Meta-analysis	29270615	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	Sorafenib	sensitive	Phase II	24166906	Lung	Therapeutic	C
EGFR	MUT	WILDTYPE	lung non-small cell carcinoma	TAE226	decreased response	Preclinical	26090892	Lung	Therapeutic	D
EGFR	MUT	WILDTYPE	squamous cell carcinoma	Abivertinib	no benefit	Preclinical - Cell line xenograft	27573423	Skin	Therapeutic	D
EGFR	MUT	Y1092 PHOSPHORYLATION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Sensitivity/Response	B	22901364	Lung	Therapeutic	B
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Afatinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Dacomitinib	resistant	Preclinical - Cell culture	28363995	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Luminespib	sensitive	Preclinical - Cell culture	30154228	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Naquotinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	29467275	Other	Therapeutic	D
EGFR	MUT	Y764delinsYHH	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	D	24353160	Lung	Therapeutic	D
EGFR	MUT	Y801H	Malignant Mesothelioma	Erlotinib	Sensitivity/Response	D	20942962	Other	Therapeutic	D
EGFR-PURB	FUS		lung adenocarcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	27102076	Lung	Therapeutic	D
EGFR-RAD51	FUS		Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	27102076	Other	Therapeutic	D
EGFR-RAD51	FUS		Advanced Solid Tumor	Cetuximab	sensitive	Preclinical - Cell culture	27102076	Other	Therapeutic	D
EGFR-RAD51	FUS		Advanced Solid Tumor	Osimertinib	predicted - sensitive	Preclinical - Cell culture	27102076	Other	Therapeutic	D
EGFR-RAD51	FUS		lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	29472054	Lung	Therapeutic	D
EGFR-RAD51	FUS		lung adenocarcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	27102076	Lung	Therapeutic	D
EGFR-RAD51	FUS		lung adenocarcinoma	Icotinib	predicted - sensitive	Case Reports/Case Series	31064887	Lung	Therapeutic	D
EGFR-RAD51	FUS		lung non-small cell carcinoma	Erlotinib	predicted - sensitive	Case Reports/Case Series	29290255	Lung	Therapeutic	D
EGFR-SEPTIN14	FUS		glioblastoma multiforme	Erlotinib	sensitive	Preclinical - Cell line xenograft	23917401	Brain	Therapeutic	D
EGFR-SEPTIN14	FUS		glioblastoma multiforme	Lapatinib	sensitive	Preclinical - Cell line xenograft	23917401	Brain	Therapeutic	D
EIF1AX	MUT	mutation	Uveal Melanoma		Better Outcome	C	23793026	Eye	Prognostic	C
EIF4EBP1	MUT	PHOSPHORYLATION	Colorectal Cancer	WYE354,Dactolisib,PP242	Resistance	D	22262166	Colorectal	Therapeutic	D
EIF4EBP1	MUT	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	Sensitivity/Response	D	23340172	Stomach	Therapeutic	D
EML4-ALK	CNV	EGFR amp	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	CNV	FGFR1 amp	lung non-small cell carcinoma	Brigatinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	CNV	GNAS amp	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	CNV	HRAS amp	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	30002191	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Ensartinib	sensitive	Preclinical - Cell culture	30002191	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell line xenograft	30093503	Other	Therapeutic	D
EML4-ALK	FUS		Advanced Solid Tumor	WX-0593	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	21575866	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	24675041	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	21613408	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Ensartinib	sensitive	Preclinical	21613408	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26939704	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	WX-0593	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	lung non-small cell carcinoma	Ceritinib	conflicting	Case Reports/Case Series	26698910	Lung	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	lung non-small cell carcinoma	Ceritinib	conflicting	Preclinical - Cell line xenograft	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	26698910	Lung	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	lung non-small cell carcinoma	Lorlatinib	sensitive	Case Reports/Case Series	26698910	Lung	Therapeutic	D
EML4-ALK	FUS	ALK C1156Y	lung non-small cell carcinoma	Luminespib	no benefit	Case Reports/Case Series	26698910	Lung	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK D1203N	Advanced Solid Tumor	TAE684	resistant	Preclinical - Cell culture	21948233	Other	Therapeutic	D
EML4-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK E1210K	lung non-small cell carcinoma	Crizotinib	resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	27432227;26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	27432227;26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174C	lung non-small cell carcinoma	Ceritinib	resistant	Case Reports/Case Series	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Crizotinib	conflicting	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Crizotinib	conflicting	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26144315	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK F1174V	lung non-small cell carcinoma	Alectinib	predicted - sensitive	Case Reports/Case Series	26464158	Lung	Therapeutic	D
EML4-ALK	FUS	ALK F1174V	lung non-small cell carcinoma	Crizotinib	resistant	Clinical Study	24736079	Lung	Therapeutic	C
EML4-ALK	FUS	ALK F1245C	lung non-small cell carcinoma	Ceritinib	sensitive	Case Reports/Case Series	26775591	Lung	Therapeutic	D
EML4-ALK	FUS	ALK F1245C	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	26775591	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1202del	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202del	Advanced Solid Tumor	Brigatinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202del	Advanced Solid Tumor	Ceritinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202del	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202del	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell line xenograft	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	22277784	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Entrectinib	resistant	Preclinical - Cell culture	26939704	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell line xenograft	30093503;	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	lung cancer	Lorlatinib	conflicting	Preclinical - Cell culture	26698910	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	lung cancer	Lorlatinib	conflicting	Preclinical - Cell line xenograft	26144315	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	lung non-small cell carcinoma	Alectinib	predicted - resistant	Case Reports/Case Series	24736079	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	lung non-small cell carcinoma	Ceritinib	resistant	Case Reports/Case Series	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1202R	lung non-small cell carcinoma	Ceritinib	resistant	Preclinical - Cell culture	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	26698910;27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	22235099	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Entrectinib	decreased response	Preclinical - Cell culture	26939704	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Alectinib	sensitive	Case Reports/Case Series	26849637	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Alectinib	sensitive	Preclinical - Cell line xenograft	26849637;23344087	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Ceritinib	sensitive	Preclinical - Cell culture	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Crizotinib	resistant	Case Reports/Case Series	22235099	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Crizotinib	resistant	Preclinical - Cell culture	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK G1269A	lung non-small cell carcinoma	Lorlatinib	sensitive	Preclinical - Patient cell culture	26144315	Lung	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171N	lung non-small cell carcinoma	Alectinib	predicted - resistant	Case Reports/Case Series	25393798	Lung	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	AZD3463	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	27432227;27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	27009859;27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171S	lung non-small cell carcinoma	Alectinib	predicted - resistant	Case Reports/Case Series	25393796	Lung	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25228534;27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Brigatinib	decreased response	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	Advanced Solid Tumor	TAE684	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	lung non-small cell carcinoma	Crizotinib	predicted - resistant	Case Reports/Case Series	25393798	Lung	Therapeutic	D
EML4-ALK	FUS	ALK I1171T	lung non-small cell carcinoma	Lorlatinib	sensitive	Preclinical - Patient cell culture	26144315	Lung	Therapeutic	D
EML4-ALK	FUS	ALK L1152P	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152P	Advanced Solid Tumor	Ceritinib	decreased response	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152P	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	21791641	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26144315	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1152R	lung non-small cell carcinoma	Crizotinib	resistant	Case Reports/Case Series	21791641	Lung	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell line xenograft	21575866	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell line xenograft	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	22277784	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ensartinib	sensitive	Preclinical	21613408	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26939704	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Lorlatinib	conflicting	Preclinical - Cell culture	26698910;27432227	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	Advanced Solid Tumor	WX-0593	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	lung non-small cell carcinoma	Brigatinib	sensitive	Preclinical - Cell culture	21502504	Lung	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	lung non-small cell carcinoma	Ceritinib	sensitive	Preclinical - Cell line xenograft	24675041	Lung	Therapeutic	D
EML4-ALK	FUS	ALK L1196M	lung non-small cell carcinoma	Lorlatinib	sensitive	Preclinical - Cell line xenograft	26144315	Lung	Therapeutic	D
EML4-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	27432227;26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Lorlatinib	decreased response	Preclinical - Cell culture	26698910	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198P	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	21948233	Other	Therapeutic	D
EML4-ALK	FUS	ALK L1198P	Advanced Solid Tumor	TAE684	resistant	Preclinical - Cell culture	21948233	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206F	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	24675041	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
EML4-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	26144315	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151dup	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell line xenograft	24887559	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151dup	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151dup	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	22277784	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151dup	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27780853	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	Advanced Solid Tumor	TAE684	sensitive	Preclinical - Cell culture	25228534	Other	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	lung non-small cell carcinoma	Alectinib	resistant	Preclinical - Cell culture	25228534	Lung	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	lung non-small cell carcinoma	Crizotinib	resistant	Preclinical - Cell culture	25228534	Lung	Therapeutic	D
EML4-ALK	FUS	ALK V1180L	lung non-small cell carcinoma	Lorlatinib	sensitive	Preclinical - Cell culture	26144315	Lung	Therapeutic	D
EML4-ALK	FUS		inflammatory myofibroblastic tumor	Crizotinib	predicted - sensitive	Case Reports/Case Series	26808369	Soft_Tissue	Therapeutic	D
EML4-ALK	FUS		lung cancer	X-376	sensitive	Preclinical - Cell line xenograft	21613408	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Afatinib + Alectinib	sensitive	Preclinical - Cell line xenograft	26682573	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Alectinib	sensitive	Preclinical - Cell line xenograft	21575866	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Brigatinib	sensitive	Preclinical - Cell line xenograft	27780853	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	CEP-28122	sensitive	Preclinical - Cell line xenograft	22203728	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Ceritinib	sensitive	Preclinical - Cell culture	25173427	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Crizotinib + GLPG0634	predicted - sensitive	Preclinical - Cell culture	28729401	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Crizotinib	sensitive	Clinical Study - Cohort	27354483	Lung	Therapeutic	C
EML4-ALK	FUS		lung non-small cell carcinoma	Crizotinib	sensitive	Phase I	20979469	Lung	Therapeutic	C
EML4-ALK	FUS		lung non-small cell carcinoma	Ensartinib + Sirolimus	sensitive	Preclinical	21613408	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Entrectinib	sensitive	Preclinical - Cell line xenograft	26939704	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	Lorlatinib	sensitive	Preclinical - Cell line xenograft	26144315	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	MTI-31	sensitive	Preclinical - Cell line xenograft	30796032	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	TAE226	sensitive	Preclinical	26090892	Lung	Therapeutic	D
EML4-ALK	FUS		lung non-small cell carcinoma	WX-0593	sensitive	Preclinical - Pdx	;	Lung	Therapeutic	D
EML4-ALK	FUS		neuroblastoma	Crizotinib	resistant	Preclinical - Cell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
EML4-ALK	FUS		neuroblastoma	Lorlatinib	sensitive	Preclinical - Cell culture	26554404	Adrenal_Gland;Nervous_System	Therapeutic	D
EML4-ALK	FUS	NOTCH1 D1533A	lung non-small cell carcinoma	Ceritinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	FUS	NOTCH1 D1538A	lung non-small cell carcinoma	Brigatinib	predicted - resistant	Case Reports/Case Series	29636358	Lung	Therapeutic	D
EML4-ALK	FUS	SRC pos	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	;	Other	Therapeutic	D
EML4-ALK	FUS	SRC pos	lung cancer	Crizotinib	resistant	Preclinical - Cell culture	;	Lung	Therapeutic	D
EML4-ALK	FUS	SRC pos	lung cancer	Repotrectinib	sensitive	Preclinical - Cell culture	;	Lung	Therapeutic	D
EML4-NTRK3	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	30279230	Other	Therapeutic	D
EP300	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma in Blood/Bone Marrow/Lymph Node			2	22237106,14528273	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
EPHA2	CNV	amplification	Any cancer type	Dasatinib	Responsive	Pre-clinical	18047674;19010823;19861960	Cancer	Therapeutic	D
EPHA2	MUT	G391R	Lung squamous cell	Dasatinib	Responsive	Pre-clinical	20360610	Lung	Therapeutic	D
EPHA2	MUT	G391R	Lung squamous cell	[MTOR inhibitor]	Responsive	Pre-clinical	20360610	Lung	Therapeutic	D
EPHA3	CNV	amplification	Any cancer type	[EPHA3 inhibitor]	Responsive	Pre-clinical	25125683	Cancer	Therapeutic	D
EPHB4	EXP	EXPRESSION	Colorectal Cancer	Bevacizumab	Resistance	B	23579861	Colorectal	Therapeutic	B
ERBB2	CNV	amplification	Billiary tract	Lapatinib	Responsive	Early trials	26022204	Other	Therapeutic	C
ERBB2	CNV	amplification	Billiary tract	Pertuzumab	Responsive	Early trials	26022204	Other	Therapeutic	C
ERBB2	CNV	amplification	Billiary tract	Trastuzumab	Responsive	Early trials	26022204	Other	Therapeutic	C
ERBB2	CNV	amplification	Bladder	Afatinib	Responsive	Case report	27044931	Bladder	Therapeutic	D
ERBB2	CNV	amplification	Breast adenocarcinoma	Ado-Trastuzumab Emtansine	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	CNV	amplification	Breast adenocarcinoma	Afatinib	Responsive	Late trials	20142587;22418700;23632474	Breast	Therapeutic	C
ERBB2	CNV	amplification	Breast adenocarcinoma	[ERBB2 inhibitor;CDK4/6 inhibitor]	Responsive	Pre-clinical	26977878	Breast	Therapeutic	D
ERBB2	CNV	amplification	Breast adenocarcinoma	Lapatinib	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	CNV	amplification	Breast adenocarcinoma	Neratinib	Responsive	Late trials	20142587;22418700;23632474	Breast	Therapeutic	C
ERBB2	CNV	amplification	Breast adenocarcinoma	Pertuzumab	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	CNV	amplification	Breast adenocarcinoma	Trastuzumab;Everolimus;Chemotherapy	Responsive	Early trials	21107682;20975068	Breast	Therapeutic	C
ERBB2	CNV	amplification	Breast adenocarcinoma	Trastuzumab;HSP90 inhibitor	Responsive	Early trials	21558407	Breast	Therapeutic	C
ERBB2	CNV	amplification	Breast adenocarcinoma	Trastuzumab	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	CNV	amplification	Colorectal adenocarcinoma	Ado-Trastuzumab Emtansine	Responsive	Case report	http://ascopubs.org/doi/full/10.1200/PO.16.00055	Colorectal	Therapeutic	D
ERBB2	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Early trials	22586653;23348520	Colorectal	Therapeutic	C
ERBB2	CNV	amplification	Colorectal adenocarcinoma	Trastuzumab;Lapatinib	Responsive	Late trials	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	Colorectal	Therapeutic	C
ERBB2	CNV	amplification	Endometrium	Trastuzumab;Lapatinib	Responsive	Pre-clinical	25294905	Uterus	Therapeutic	D
ERBB2	CNV	amplification	Head an neck	Trastuzumab	Responsive	Case report	21380780	Head_and_Neck	Therapeutic	D
ERBB2	CNV	amplification	Lung adenocarcinoma	[EGFR inhibitor]	Resistant	Pre-clinical	22956644	Lung	Therapeutic	D
ERBB2	CNV	amplification	Lung adenocarcinoma	Osimertinib	Resistant	Case report	27252416	Lung	Therapeutic	D
ERBB2	CNV	amplification	Lung adenocarcinoma	Rociletinib	Resistant	Case report	27252416	Lung	Therapeutic	D
ERBB2	CNV	amplification	Ovary	Trastuzumab	Responsive	Early trials	20003286;12525520	Ovary	Therapeutic	C
ERBB2	CNV	amplification	Stomach	Afatinib	Responsive	Case report	AACR 2014 (abstr CT228)	Stomach	Therapeutic	D
ERBB2	CNV	amplification	Stomach;Gastroesophageal junction adenocarcinoma	Trastuzumab	Responsive	FDA guidelines	FDA	Esophagus;Stomach	Therapeutic	A
ERBB2	CNV	amplification	Stomach	Lapatinib;Chemotherapy	Responsive	Early trials	25694417;NCT02015169	Stomach	Therapeutic	C
ERBB2	CNV	amplification	Stomach	Pertuzumab	Responsive	Early trials	24960402	Stomach	Therapeutic	C
ERBB2	CNV	amp	acral lentiginous melanoma	Ado-trastuzumab emtansine	sensitive	Case Reports/Case Series	30093446	Blood	Therapeutic	D
ERBB2	CNV	amp	Advanced Solid Tumor	Ado-trastuzumab emtansine	predicted - sensitive	Phase II	;	Other	Therapeutic	C
ERBB2	CNV	amp	Advanced Solid Tumor	Afatinib	sensitive	Phase II	23775486	Other	Therapeutic	C
ERBB2	CNV	amp	Advanced Solid Tumor	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Other	Therapeutic	C
ERBB2	CNV	amp	biliary tract cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Bile_Duct	Therapeutic	C
ERBB2	CNV	amp	breast cancer	Afatinib	sensitive	Preclinical	26545934	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Buparlisib	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	CH5132799	sensitive	Preclinical	21558396	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Dacomitinib	sensitive	Preclinical	22761403	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Lapatinib	decreased response	Preclinical - Cell culture	27197158	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Lapatinib + S63845	sensitive	Preclinical - Cell culture	27760111	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Lapatinib + Torkinib	sensitive	Preclinical - Cell culture	27197158	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	LJM716 + Neratinib	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	LJM716 + Trastuzumab	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Neratinib + Pertuzumab	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Neratinib + Temsirolimus	predicted - sensitive	Phase I	24323026	Breast	Therapeutic	C
ERBB2	CNV	amp	breast cancer	Pertuzumab + Trastuzumab	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
ERBB2	CNV	amp	breast cancer	Torkinib	sensitive	Preclinical - Cell culture	27197158	Breast	Therapeutic	D
ERBB2	CNV	amp	colorectal adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Case Reports/Case Series	28040715	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Cetuximab + Lapatinib	sensitive	Preclinical - Pdx	22586653	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Cetuximab	resistant	Clinical Study - Cohort	21900593	Colorectal	Therapeutic	C
ERBB2	CNV	amp	colorectal cancer	Cetuximab	resistant	Clinical Study - Cohort	30952821	Colorectal	Therapeutic	C
ERBB2	CNV	amp	colorectal cancer	Lapatinib	decreased response	Preclinical - Pdx	26296355	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Lapatinib + Pertuzumab	sensitive	Preclinical - Pdx	22586653	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Lapatinib + Trastuzumab	sensitive	Preclinical - Pdx	26296355	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Panitumumab	decreased response	Clinical Study - Cohort	30952821	Colorectal	Therapeutic	C
ERBB2	CNV	amp	colorectal cancer	Pertuzumab	no benefit	Preclinical - Pdx	22586653	Colorectal	Therapeutic	D
ERBB2	CNV	amp	colorectal cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Colorectal	Therapeutic	C
ERBB2	CNV	amp	colorectal cancer	Trastuzumab	resistant	Preclinical	26296355	Colorectal	Therapeutic	D
ERBB2	CNV	amp	duodenum adenocarcinoma	Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab	predicted - sensitive	Case Reports/Case Series	28784859	Other	Therapeutic	D
ERBB2	CNV	amp	esophageal cancer	Ibrutinib	sensitive	Preclinical - Cell culture	28830912	Esophagus	Therapeutic	D
ERBB2	CNV	amp	esophagus adenocarcinoma	Lapatinib	no benefit	Phase III	26628478	Esophagus	Therapeutic	C
ERBB2	CNV	amp	gastric adenocarcinoma	Capecitabine + Lapatinib + Oxaliplatin	predicted - sensitive	Phase II	29409051	Stomach	Therapeutic	C
ERBB2	CNV	amp	gastric adenocarcinoma	Lapatinib	no benefit	Phase III	26628478	Stomach	Therapeutic	C
ERBB2	CNV	amp	gastric adenocarcinoma	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	;20728210;	Stomach	Therapeutic	A
ERBB2	CNV	amp	gastroesophageal junction adenocarcinoma	Lapatinib	no benefit	Phase III	26628478	Esophagus	Therapeutic	C
ERBB2	CNV	amp	gastroesophageal junction adenocarcinoma	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	20728210;;	Esophagus	Therapeutic	A
ERBB2	CNV	amp	gastrointestinal system cancer	Dacomitinib	sensitive	Preclinical	18606718	Stomach	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	FDA approved - On Companion Diagnostic	24879797;23020162	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	FDA approved - On Companion Diagnostic	;;30516102	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	BGB-283	predicted - sensitive	Preclinical - Cell culture	26208524	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	CDX-3379	sensitive	Preclinical	26880266	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	CDX-3379 + Trastuzumab	sensitive	Preclinical	26880266	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Docetaxel + Pertuzumab + Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	23801166;;	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	KRIBB11 + MK2206	predicted - sensitive	Preclinical - Cell culture	28598816	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Lapatinib + S63845	sensitive	Preclinical - Cell culture	28768804	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Neratinib	sensitive	FDA approved	26874901;	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Neratinib	sensitive	Guideline	;31236598	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Palbociclib + Trastuzumab	sensitive	Preclinical	19874578	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Pertuzumab + Trastuzumab	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	S63845 + Trastuzumab	sensitive	Preclinical - Pdxcell culture	28768804	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	TAS0728	sensitive	Preclinical - Cell line xenograft	30787176	Breast	Therapeutic	D
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	trastuzumab and hyaluronidase-oysk injection	sensitive	FDA approved - On Companion Diagnostic	;;22884505	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Trastuzumab	sensitive	Clinical Study - Meta-analysis	24691421	Breast	Therapeutic	C
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	;;	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Trastuzumab	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	CNV	amp	Her2-receptor mutation breast cancer	Trastuzumab + Vinorelbine	sensitive	Guideline	30032243;	Breast	Therapeutic	A
ERBB2	CNV	AMPLIFICATION	Biliary Tract Cancer	Trastuzumab,Pertuzumab	Sensitivity/Response	B	29320312	Bile_Duct	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Bladder Carcinoma	Pertuzumab,Trastuzumab	Sensitivity/Response	B	29320312	Bladder	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Breast Cancer	AKTi-1/2	Sensitivity/Response	D	18725974	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Breast Cancer	Neratinib	Sensitivity/Response	B	20142587	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Breast Cancer	PP242	Sensitivity/Response	D	21358673	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Breast Cancer	Trastuzumab,Lapatinib	Sensitivity/Response	D	16091755	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Colorectal Cancer	Cetuximab	Resistance	B	22586653	Colorectal	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Colorectal Cancer	Cetuximab	Resistance	B	28223103	Colorectal	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Colorectal Cancer	Lapatinib,Trastuzumab	Sensitivity/Response	B	27108243	Colorectal	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	23348520	Colorectal	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Colorectal Cancer	Trastuzumab,Pertuzumab	Sensitivity/Response	B	29320312	Colorectal	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Gastric Adenocarcinoma	Lapatinib	Sensitivity/Response	B	24868024	Stomach	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab	Sensitivity/Response	A	20728210	Stomach	Therapeutic	A
ERBB2	CNV	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab	Sensitivity/Response	B	20728210	Stomach	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	A66	Sensitivity/Response	D	22802530	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib	Sensitivity/Response	B	22418700	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib	Sensitivity/Response	B	26596672	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Trastuzumab,Lapatinib	Sensitivity/Response	B	25537159	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Trastuzumab	Sensitivity/Response	B	25370464	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Capecitabine,Lapatinib	Sensitivity/Response	B	17192538	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Capecitabine,Trastuzumab	Sensitivity/Response	B	19289619	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Docetaxel,Trastuzumab,Pertuzumab	Sensitivity/Response	B	22149875	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Sensitivity/Response	B	20124187	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Sensitivity/Response	B	22493419	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Neratinib	Sensitivity/Response	B	26874901	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Palbociclib (PD0332991),Trastuzumab	Sensitivity/Response	D	19874578	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pictilisib	Sensitivity/Response	D	22802530	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Docetaxel,Pertuzumab	Sensitivity/Response	B	25693012	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Sensitivity/Response	B	21172893	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Sensitivity/Response	B	23020162	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Sensitivity/Response	B	23382472	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Sensitivity/Response	B	24793816	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Sensitivity/Response	B	22257673	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Pilaralisib	Sensitivity/Response	D	23204226	Breast	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	Sensitivity/Response	A	16236737	Breast	Therapeutic	A
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	Sensitivity/Response	B	11248153	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab	Sensitivity/Response	B	15911866	Breast	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Lung Adenocarcinoma	Erlotinib,Gefitinib	Resistance	C	23470965	Lung	Therapeutic	C
ERBB2	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine	Sensitivity/Response	D	24898067	Lung	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Lung Small Cell Carcinoma	Irinotecan,Trastuzumab	Sensitivity/Response	C	25601188	Lung	Therapeutic	C
ERBB2	CNV	AMPLIFICATION	Pancreatic Adenocarcinoma	Afatinib	Sensitivity/Response	D	26668065	Pancreas	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Pancreatic Cancer	Trastuzumab,Pertuzumab	Sensitivity/Response	B	29320312	Pancreas	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Salivary Gland Carcinoma	Pertuzumab,Trastuzumab	Sensitivity/Response	B	29320312	Esophagus	Therapeutic	B
ERBB2	CNV	AMPLIFICATION	Scrotum Paget's Disease	Trastuzumab	Sensitivity/Response	C	25692060	Other	Therapeutic	C
ERBB2	CNV	AMPLIFICATION	Uterine Corpus Endometrial Carcinoma	Afatinib	Sensitivity/Response	D	25268372	Bladder	Therapeutic	D
ERBB2	CNV	AMPLIFICATION	Uterine Corpus Serous Adenocarcinoma		Poor Outcome	B	15746676	Bladder	Prognostic	B
ERBB2	CNV	AMPLIFICATION	Uterine Corpus Serous Adenocarcinoma	Trastuzumab	Sensitivity/Response	C	18555254	Bladder	Therapeutic	C
ERBB2	CNV	amp	lung adenocarcinoma	Dacomitinib	no benefit	Phase II	25899785	Lung	Therapeutic	C
ERBB2	CNV	amp	lung cancer	TAS0728	predicted - sensitive	Preclinical - Cell culture	30787176	Lung	Therapeutic	D
ERBB2	CNV	amp	lung non-small cell carcinoma	Afatinib	sensitive	Preclinical - Cell line xenograft	26545934	Lung	Therapeutic	D
ERBB2	CNV	amp	lung non-small cell carcinoma	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Lung	Therapeutic	C
ERBB2	CNV	amp	lung squamous cell carcinoma	Gefitinib	resistant	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	CNV	amp	ovarian cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Ovary	Therapeutic	C
ERBB2	CNV	amp	pancreatic cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Pancreas	Therapeutic	C
ERBB2	CNV	amp	parotid gland cancer	Ado-trastuzumab emtansine	predicted - sensitive	Phase II	;	Other	Therapeutic	C
ERBB2	CNV	amp	salivary gland cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Esophagus	Therapeutic	C
ERBB2	CNV	amp	scrotum Pagets disease	Ado-trastuzumab emtansine	predicted - sensitive	Phase II	;	Other	Therapeutic	C
ERBB2	CNV	amp	stomach cancer	Afatinib + Trastuzumab	predicted - sensitive	Case Reports/Case Series	30463996	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	BMS-690514	sensitive	Preclinical	21531814	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	Fluorouracil + Oxaliplatin + Trastuzumab	predicted - sensitive	Case Reports/Case Series	30463996	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	Lapatinib	sensitive	Preclinical	20179222	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	Lapatinib + Trastuzumab	sensitive	Preclinical - Cell line xenograft	26296355	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	Poziotinib	sensitive	Preclinical	21306821	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	TAS0728	sensitive	Preclinical - Cell line xenograft	30787176	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach cancer	Trastuzumab	sensitive	Preclinical - Cell line xenograft	26296355	Stomach	Therapeutic	D
ERBB2	CNV	amp	stomach carcinoma	Debio 1347	no benefit	Preclinical - Cell line xenograft	26438159	Stomach	Therapeutic	D
ERBB2	CNV	amp	urinary bladder cancer	Afatinib	sensitive	Phase II	27044931	Bladder	Therapeutic	C
ERBB2	CNV	amp	urinary bladder cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Bladder	Therapeutic	C
ERBB2	CNV	amp	uterine cancer	Pertuzumab + Trastuzumab	no benefit	Phase II	29320312	Uterus	Therapeutic	C
ERBB2	CNV	amp	uterine corpus serous adenocarcinoma	Neratinib	sensitive	Preclinical - Cell culture	26333383	Uterus	Therapeutic	D
ERBB2	CNV	amp	uterine corpus serous adenocarcinoma	Neratinib + Taselisib	sensitive	Preclinical - Cell culture	26333383	Uterus	Therapeutic	D
ERBB2	CNV	amp	uterine corpus serous adenocarcinoma	SYD985	sensitive	Preclinical	27256376	Uterus	Therapeutic	D
ERBB2	CNV	amp	uterine corpus serous adenocarcinoma	Taselisib	sensitive	Preclinical - Cell culture	26333383	Uterus	Therapeutic	D
ERBB2	CNV	amp	vulva squamous cell carcinoma	Depatuxizumab mafodotin	sensitive	Preclinical - Cell line xenograft	26846818	Other	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Advanced Solid Tumor	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Other	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	biliary tract cancer	HER2 CAR-T cells	predicted - sensitive	Phase I	28710747	Bile_Duct	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	biliary tract cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Bile_Duct	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	breast cancer	AV-412	sensitive	Preclinical - Cell line xenograft	17888033	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	breast cancer	KU004	sensitive	Preclinical	26437915	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	breast cancer	MM-302 + Trastuzumab	sensitive	Preclinical - Cell line xenograft	26759238	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	carcinoma	MGAH22	predicted - sensitive	Phase I	28119295	Cancer	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	cholangiocarcinoma	HER2 CAR-T cells	predicted - sensitive	Phase I	28710747	Bile_Duct	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	colorectal cancer	Cetuximab	resistant	Clinical Study - Cohort	30952821	Colorectal	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	colorectal cancer	Cetuximab	resistant	Preclinical - Cell line xenograft	26296355	Colorectal	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	colorectal cancer	Panitumumab	decreased response	Clinical Study - Cohort	30952821	Colorectal	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	colorectal cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Colorectal	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	esophagus adenocarcinoma	Trastuzumab	sensitive	Guideline	;	Esophagus	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	gastric adenocarcinoma	Capecitabine + Lapatinib + Oxaliplatin	predicted - sensitive	Phase II	29409051	Stomach	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	gastric adenocarcinoma	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	20728210;;	Stomach	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	gastric adenocarcinoma	Trastuzumab	sensitive	Guideline	;	Stomach	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	gastric adenocarcinoma	VS-5584	sensitive	Preclinical - Cell line xenograft	23270925	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	gastroesophageal junction adenocarcinoma	S-222611	sensitive	Phase I	;	Esophagus	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	gastroesophageal junction adenocarcinoma	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	20728210;;	Esophagus	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	gastroesophageal junction adenocarcinoma	Trastuzumab	sensitive	Guideline	;	Esophagus	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Lapatinib	Sensitivity/Response	C	28061634	Head_and_Neck	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	FDA approved - On Companion Diagnostic	24879797;23020162	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	FDA approved - On Companion Diagnostic	;;30516102	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	ADXS31-164	sensitive	Preclinical	20725099	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	CUDC-101	sensitive	Phase I	25107918	Breast	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Docetaxel + Pertuzumab + Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	;23801166;	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Lapatinib	sensitive	Preclinical - Cell culture	27450453	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Lapatinib + Trastuzumab	sensitive	Guideline	30032243;31236598	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	MGAH22	predicted - sensitive	Phase Ib/II	;	Breast	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	NAX014	sensitive	Preclinical	26168818	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Neratinib	sensitive	FDA approved	26874901;	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Neratinib	sensitive	Guideline	31236598;	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Pertuzumab + Trastuzumab	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	PF-05280014	sensitive	Preclinical	25001079	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	TAK-285	sensitive	Preclinical - Cell line xenograft	23983820	Breast	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	trastuzumab and hyaluronidase-oysk injection	sensitive	FDA approved - On Companion Diagnostic	;;22884505	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Trastuzumab	sensitive	FDA approved - On Companion Diagnostic	;;	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Trastuzumab	sensitive	Guideline	31236598;30032243	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor mutation breast cancer	Trastuzumab + Vinorelbine	sensitive	Guideline	30032243;	Breast	Therapeutic	A
ERBB2	EXP	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Ado-trastuzumab Emtansine	Sensitivity/Response	B	28526536	Breast	Therapeutic	B
ERBB2	EXP	OVEREXPRESSION	lung non-small cell carcinoma	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Lung	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	ovarian cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Ovary	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	pancreatic cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Pancreas	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	pancreatic carcinoma	HER2 CAR-T cells	predicted - sensitive	Phase I	28710747	Pancreas	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	Salivary Gland Cancer	Paclitaxel,Trastuzumab	Sensitivity/Response	C	23826550	Esophagus	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	salivary gland cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Esophagus	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	Salivary Gland Cancer	Trastuzumab,Capecitabin,Zoledronic Acid	Sensitivity/Response	C	20504363	Esophagus	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Ado-trastuzumab emtansine	sensitive	Preclinical - Cell line xenograft	21458915	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	BMS-690514	sensitive	Preclinical	21531814	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	CDX-3379	sensitive	Preclinical	18441328	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Dacomitinib	sensitive	Phase II	;	Stomach	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Dacomitinib	sensitive	Preclinical	22135232	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	HER2 CAR-T cells	sensitive	Preclinical - Cell line xenograft	28284008	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	KU004	sensitive	Preclinical	26437915	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Lapatinib	sensitive	Preclinical	18774637	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	MM-111 + Paclitaxel + Trastuzumab	sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	MM-302	predicted - sensitive	Preclinical	;	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	MM-302 + Trastuzumab	sensitive	Preclinical - Cell line xenograft	26759238	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	S-222611	sensitive	Phase I	;	Stomach	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	stomach cancer	TAK-285	sensitive	Preclinical	18441328;25594012	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	TAK-285	sensitive	Preclinical - Cell line xenograft	23983820	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Trastuzumab + Varlitinib	sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Tucatinib	sensitive	Preclinical - Cell culture	;	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	stomach cancer	Varlitinib	sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
ERBB2	EXP	OVEREXPRESSION	urinary bladder cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Bladder	Therapeutic	C
ERBB2	EXP	OVEREXPRESSION	uterine cancer	Pertuzumab + Trastuzumab	no benefit	Phase II	29320312	Uterus	Therapeutic	C
ERBB2	EXP	overexpression	Breast adenocarcinoma	Ado-Trastuzumab Emtansine	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	EXP	overexpression	Breast adenocarcinoma	Lapatinib	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	EXP	overexpression	Breast adenocarcinoma	Pertuzumab	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	EXP	overexpression	Breast adenocarcinoma	Trastuzumab	Responsive	FDA guidelines	FDA	Breast	Therapeutic	A
ERBB2	EXP	overexpression	Solid tumors	MK2206;Trastuzumab	Responsive	Early trials	ASCO 2013 (abstr 2605);26104654	Other	Therapeutic	C
ERBB2	EXP	overexpression	Stomach;Gastroesophageal junction adenocarcinoma	Trastuzumab	Responsive	FDA guidelines	FDA	Esophagus;Stomach	Therapeutic	A
ERBB2	MUT	A775delinsAYVMA	Advanced Solid Tumor	JQ1 + Osimertinib	sensitive	Preclinical	29298799	Other	Therapeutic	D
ERBB2	MUT	A775delinsAYVMA	lung adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Case Reports/Case Series	29989854	Lung	Therapeutic	D
ERBB2	CNV	Amplification	Breast Cancer	Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab, Ado-Trastuzumab Emtansine, Lapatinib, Neratinib, Trastuzumab	Response	1	30860945, 22149875, 16236738, 19060928, 19786658, 22153890, 26874901, 30516102, 29320312, 22257673, 23020162, 29146401, 16091755, 23602601, 30274983, 17192538	Breast	Therapeutic	A
ERBB2	CNV	Amplification	Esophagogastric Cancer	Trastuzumab	Response	1	20728210	Esophagus	Therapeutic	A
ERBB2	CNV	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Carboplatin-Taxol Regimen + Trastuzumab	Response	2A	29584549	Uterus	Therapeutic	B
ERBB2	MUT	C311R	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	C311R	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	C334S	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	D769H	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	D769H	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	Breast Cancer	Lapatinib,Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769H	colorectal cancer	Neratinib	predicted - resistant	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	D769H	Her2-receptor negative breast cancer	Neratinib	no benefit	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	D769N	cervical cancer	Neratinib	no benefit	Phase II	29420467	Cervix	Therapeutic	C
ERBB2	MUT	D769Y	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	D769Y	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	D769Y	gastroesophageal junction adenocarcinoma	Neratinib	predicted - resistant	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	D769Y	urinary bladder cancer	Neratinib	predicted - resistant	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	D821N	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	755_759del	Breast Cancer	Lapatinib,Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	E321G	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	E717K	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E717K	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E719G	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E719G	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E812K	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E812K	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	E812K	lung adenocarcinoma	Poziotinib	predicted - sensitive	Phase II	30149884	Lung	Therapeutic	C
ERBB2	MUT	exon(s) 20 insertion	Advanced Solid Tumor	AP32788	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
ERBB2	MUT	exon(s) 20 insertion	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	exon(s) 20 insertion	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26964772	Lung	Therapeutic	D
ERBB2	MUT	exon(s) 20 insertion	lung adenocarcinoma	Dacomitinib	predicted - sensitive	Phase II	25899785	Lung	Therapeutic	C
ERBB2	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	28167203	Lung	Therapeutic	D
ERBB2	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	exon(s) 20 insertion	lung non-small cell carcinoma	Trastuzumab	predicted - sensitive	Case Reports/Case Series	28167203	Lung	Therapeutic	D
ERBB2	MUT	exon(s) 20 any	lung non-small cell carcinoma	Pyrotinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
ERBB2	MUT	exon(s) 20 insertion	Adenosarcoma in Lung			2	22761469,16818618,9425908	Lung	Therapeutic	C
ERBB2	MUT	G292R	urinary bladder cancer	Neratinib	predicted - resistant	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	G309A	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309A	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309A	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309A	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309A	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309A	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G309E	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	G309E	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Gefitinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Neratinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Pertuzumab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	Advanced Solid Tumor	Trastuzumab	sensitive	Preclinical	30449325	Other	Therapeutic	D
ERBB2	MUT	G660D	lung cancer	Afatinib	sensitive	Case Reports/Case Series	29146616	Lung	Therapeutic	D
ERBB2	MUT	G660D	lung cancer	Afatinib	sensitive	Case Reports/Case Series	30449325	Lung	Therapeutic	D
ERBB2	MUT	G660D	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G660D	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Gefitinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Neratinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Pertuzumab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G660R	Advanced Solid Tumor	Trastuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	G776delinsGLC	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGLC	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Adenocarcinoma in Lung			2	22761469,16818618	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Afatinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	AZ5104	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Erlotinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Ganetespib	predicted - sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Lapatinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Luminespib	predicted - sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Neratinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Pyrotinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	Advanced Solid Tumor	Tucatinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Case Reports/Case Series	29989854	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung adenocarcinoma	Poziotinib	predicted - sensitive	Phase II	30149884	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Afatinib	conflicting	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Afatinib	conflicting	Preclinical - Cell line xenograft	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Dacomitinib	no benefit	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Erlotinib	no benefit	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Gefitinib	resistant	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Lapatinib	no benefit	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVV	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
ERBB2	MUT	G776L	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	22325357	Lung	Therapeutic	C
ERBB2	MUT	G776L	Lung adenocarcinoma	Trastuzumab	Responsive	Case report	16775247	Lung	Therapeutic	D
ERBB2	MUT	G776delinsGVGC	lung non-small cell carcinoma	Neratinib	predicted - resistant	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGYVMA	Advanced Solid Tumor	Canertinib	sensitive	Preclinical	16843263	Other	Therapeutic	D
ERBB2	MUT	G776V	Advanced Solid Tumor	AP32788	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
ERBB2	MUT	G778A	colorectal cancer	Neratinib	predicted - resistant	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Afatinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	AZ5104	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical - Cell culture	28363995	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Lapatinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Neratinib	conflicting	Preclinical - Cell culture	28363995	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Neratinib	conflicting	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Osimertinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	Advanced Solid Tumor	Tucatinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	G778_P780dup	breast cancer	Lapatinib	resistant	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G778_P780dup	breast cancer	Neratinib	sensitive	Phase II	28679771	Breast	Therapeutic	C
ERBB2	MUT	G778_P780dup	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G778_P780dup	breast cancer	Trastuzumab	resistant	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	G778_P780dup	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	G778_P780dup	lung adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Case Reports/Case Series	29989854	Lung	Therapeutic	D
ERBB2	MUT	G778_P780dup	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	26964772	Lung	Therapeutic	D
ERBB2	MUT	G778_P780dup	lung adenocarcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	28363995	Lung	Therapeutic	D
ERBB2	MUT	G778_P780DUP	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	22325357	Lung	Therapeutic	C
ERBB2	MUT	G778_P780dup	lung adenocarcinoma	Dacomitinib	sensitive	Phase II	25899785	Lung	Therapeutic	C
ERBB2	MUT	G778_P780dup	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G778_P780dup	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	G778_P780dup	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	G778_P780DUP	Lung Non-small Cell Carcinoma	Dacomitinib	Sensitivity/Response	C	25899785	Lung	Therapeutic	C
ERBB2	MUT	G778_P780dup	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	G778delinsGCPG	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical - Cell culture	28363995	Other	Therapeutic	D
ERBB2	MUT	Gain-of-Function	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	Gain-of-Function	Advanced Solid Tumor	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Other	Therapeutic	C
ERBB2	MUT	Gain-of-Function	biliary tract cancer	Pertuzumab + Trastuzumab	predicted - sensitive	Case Reports/Case Series	29320312	Bile_Duct	Therapeutic	D
ERBB2	MUT	Gain-of-Function	breast cancer	Neratinib	sensitive	Phase II	;	Breast	Therapeutic	C
ERBB2	MUT	Gain-of-Function	estrogen-receptor mutation breast cancer	Vistusertib	predicted - sensitive	Phase I	25805799	Breast	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Phase II	29989854	Lung	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung non-small cell carcinoma	Atezolizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung non-small cell carcinoma	Camrelizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung non-small cell carcinoma	Nivolumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung non-small cell carcinoma	Pembrolizumab	decreased response	Clinical Study - Cohort	31085721	Lung	Therapeutic	C
ERBB2	MUT	Gain-of-Function	lung non-small cell carcinoma	Pertuzumab + Trastuzumab	predicted - sensitive	Phase II	29320312	Lung	Therapeutic	C
ERBB2	MUT	H878Y	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	H878Y	Advanced Solid Tumor	Lapatinib	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	H878Y	Hepatocellular Carcinoma	Lapatinib	Sensitivity/Response	D	22046346	Liver	Therapeutic	D
ERBB2	MUT	755_759del	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	inframe insertion 780GSP	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	inframe insertion 781GSP	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	inframe insertion 781GSP	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	A775delinsAYVMA	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	A775delinsAYVMA	Lung	Ado-Trastuzumab Emtansine	Responsive	Early trials	ASCO 2017 (abstr 8510)	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGVC	Lung	Ado-Trastuzumab Emtansine	Responsive	Early trials	ASCO 2017 (abstr 8510)	Lung	Therapeutic	C
ERBB2	MUT	G776delinsGYVMA	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	P780delinsPGSP	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	K753E	Breast adenocarcinoma	Lapatinib	Resistant	Pre-clinical	27697991	Breast	Therapeutic	D
ERBB2	MUT	K753E	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	27697991	Breast	Therapeutic	D
ERBB2	MUT	K753E	breast cancer	Lapatinib	resistant	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	K753E	breast cancer	Neratinib	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	K753E	breast cancer	Trastuzumab	resistant	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	K831N	colorectal cancer	Neratinib	predicted - resistant	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	KINASE DOMAIN mutation	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	22325357	Lung	Therapeutic	C
ERBB2	MUT	KINASE DOMAIN mutation	Lung Adenocarcinoma	Trastuzumab	Sensitivity/Response	C	26598547	Lung	Therapeutic	C
ERBB2	MUT	L663P	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Gefitinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Neratinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Pertuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L663P	Advanced Solid Tumor	Trastuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	L726F	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	L726F	Advanced Solid Tumor	XL647	sensitive	Preclinical - Cell culture	18413839	Other	Therapeutic	D
ERBB2	MUT	L726F	breast cancer	Lapatinib	resistant	Preclinical	25435280	Breast	Therapeutic	D
ERBB2	MUT	L726I	breast cancer	Gefitinib	resistant	Preclinical	17638894	Breast	Therapeutic	D
ERBB2	MUT	L755A	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	L755	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	L755delinsLS	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	L755P	Advanced Solid Tumor	AEE788	resistant	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755P	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755P	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755P	Advanced Solid Tumor	WZ4002	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755P	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	L755S	Adenocarcinoma/Invasive Ductal Carcinoma in Breast			2	23630663,22046346,23220880,16397024	Breast	Therapeutic	C
ERBB2	MUT	L755S	Advanced Solid Tumor	AEE788	resistant	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755S	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755S	Advanced Solid Tumor	Lapatinib	resistant	Preclinical - Cell culture	22046346	Other	Therapeutic	D
ERBB2	MUT	L755S	Advanced Solid Tumor	WZ4002	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	L755S	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	L755S	biliary tract cancer	Neratinib	no benefit	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	L755S	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	L755S	Breast Cancer	Lapatinib	Resistance	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	L755S	breast cancer	Neratinib	sensitive	Preclinical - Cell culture	23220880	Breast	Therapeutic	D
ERBB2	MUT	L755S	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	L755S	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colon cancer	Neratinib	sensitive	Phase II	28679771	Colorectal	Therapeutic	C
ERBB2	MUT	L755S	colon cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colon cancer	Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colorectal cancer	Afatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colorectal cancer	Cetuximab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colorectal cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	colorectal cancer	Panitumumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L755S	Her2-receptor mutation breast cancer	Lapatinib	resistant	Preclinical - Cell culture	28487443	Breast	Therapeutic	D
ERBB2	MUT	L755S	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	L755S	lung non-small cell carcinoma	Neratinib	predicted - sensitive	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	755_759del	breast cancer	Gefitinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	755_759del	breast cancer	Lapatinib	resistant	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	755_759del	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	L755W	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	L768S	breast cancer	Lapatinib	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	L768S	breast cancer	Neratinib	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	L768S	breast cancer	Trastuzumab	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	L785F	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	L785F	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	L786V	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	L841V	colorectal cancer	Neratinib	predicted - resistant	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	L841V	Her2-receptor negative breast cancer	Neratinib	no benefit	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	L866M	Colon Cancer	Neratinib,Lapatinib,Trastuzumab	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colon cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colon cancer	Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colorectal cancer	Afatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colorectal cancer	Cetuximab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colorectal cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L866M	colorectal cancer	Panitumumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	L869R	Breast adenocarcinoma	Neratinib	Responsive	Case report	28274957	Breast	Therapeutic	D
ERBB2	MUT	L869R	breast cancer	Afatinib	sensitive	Preclinical - Cell culture	28274957	Breast	Therapeutic	D
ERBB2	MUT	L869R	breast cancer	Lapatinib	resistant	Preclinical - Cell line xenograft	27900369	Breast	Therapeutic	D
ERBB2	MUT	L869R	breast cancer	Neratinib	sensitive	Phase II	28679771	Breast	Therapeutic	C
ERBB2	MUT	L869R	breast cancer	Neratinib	sensitive	Preclinical - Cell culture	28274957	Breast	Therapeutic	D
ERBB2	MUT	L869R	colorectal adenocarcinoma	Lapatinib + Trastuzumab	predicted - resistant	Case Reports/Case Series	29941010	Colorectal	Therapeutic	D
ERBB2	MUT	L869R	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	L869R	lung adenocarcinoma	Lapatinib	predicted - resistant	Case Reports/Case Series	27900369	Lung	Therapeutic	D
ERBB2	MUT	L915M	Advanced Solid Tumor	XL647	sensitive	Preclinical - Cell culture	18413839	Other	Therapeutic	D
ERBB2	MUT	M774delinsMWLV	Advanced Solid Tumor	Dacomitinib	sensitive	Preclinical - Cell culture	28363995	Other	Therapeutic	D
ERBB2	MUT	M774delinsMWLV	lung adenocarcinoma	Dacomitinib	sensitive	Phase II	25899785	Lung	Therapeutic	C
ERBB2	MUT	M774DELINSWLV	Lung Non-small Cell Carcinoma	Dacomitinib	Sensitivity/Response	C	25899785	Lung	Therapeutic	C
ERBB2	MUT	mutant	biliary tract cancer	Neratinib	predicted - sensitive	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	mutant	breast cancer	Neratinib	predicted - sensitive	Phase II	28679771	Breast	Therapeutic	C
ERBB2	MUT	mutant	cervical cancer	Neratinib	predicted - sensitive	Phase II	29420467	Cervix	Therapeutic	C
ERBB2	MUT	mutant	colorectal cancer	Neratinib	no benefit	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	mutant	endometrial cancer	Neratinib	no benefit	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	mutant	gastroesophageal junction adenocarcinoma	Neratinib	no benefit	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	mutant	Her2-receptor mutation breast cancer	Neratinib	sensitive	Phase II	;	Breast	Therapeutic	C
ERBB2	MUT	mutant	Her2-receptor negative breast cancer	Neratinib	sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	mutant	invasive bladder transitional cell carcinoma	Cisplatin + Gemcitabine + Sorafenib	predicted - sensitive	Phase II	;	Bladder	Therapeutic	C
ERBB2	MUT	mutant	lung adenocarcinoma	Afatinib	sensitive	Phase II	22325357	Lung	Therapeutic	C
ERBB2	MUT	mutant	lung cancer	Neratinib	sensitive	Phase I	24323026	Lung	Therapeutic	C
ERBB2	MUT	mutant	lung non-small cell carcinoma	Ado-trastuzumab emtansine	sensitive	Guideline	;	Lung	Therapeutic	A
ERBB2	MUT	mutant	lung non-small cell carcinoma	Afatinib	no benefit	Guideline	;	Lung	Therapeutic	A
ERBB2	MUT	mutant	lung non-small cell carcinoma	AV-412	sensitive	Preclinical	19459856	Lung	Therapeutic	D
ERBB2	MUT	mutant	lung non-small cell carcinoma	Neratinib	sensitive	Phase I	24323026	Lung	Therapeutic	C
ERBB2	MUT	mutant	lung non-small cell carcinoma	Neratinib	sensitive	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	mutant	lung non-small cell carcinoma	Pyrotinib	sensitive	Phase II	;	Lung	Therapeutic	C
ERBB2	MUT	mutant	lung non-small cell carcinoma	Trastuzumab	no benefit	Guideline	;	Lung	Therapeutic	A
ERBB2	MUT	mutant	lung non-small cell carcinoma	Trastuzumab + Vinorelbine	predicted - sensitive	Case Reports/Case Series	28167203	Lung	Therapeutic	D
ERBB2	MUT	mutant	lung squamous cell carcinoma	Afatinib	predicted - sensitive	Phase III	29902295	Lung	Therapeutic	C
ERBB2	MUT	mutant	ovarian cancer	Neratinib	no benefit	Phase II	29420467	Ovary	Therapeutic	C
ERBB2	MUT	mutant	urinary bladder cancer	Neratinib	no benefit	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	mutation	Advanced Solid Tumor	AC480	predicted - sensitive	Phase I	21576284	Other	Therapeutic	C
ERBB2	MUT	mutation	Advanced Solid Tumor	DS-8201a	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ERBB2	MUT	mutation	Advanced Solid Tumor	GBR1302	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ERBB2	MUT	mutation	Advanced Solid Tumor	MT-5111	predicted - sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
ERBB2	MUT	mutation	Advanced Solid Tumor	S-222611	predicted - sensitive	Phase I	;25434923	Other	Therapeutic	C
ERBB2	MUT	mutation	Advanced Solid Tumor	ZW25	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ERBB2	MUT	mutation	Bladder Carcinoma	PLATINUM	Sensitivity/Response	C	25636205	Bladder	Therapeutic	C
ERBB2	MUT	mutation	breast adenocarcinoma	DS-8201a	sensitive	Preclinical - Cell culture	27026201	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast cancer	ADCT-502	sensitive	Preclinical - Pdx	;	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast cancer	Ado-trastuzumab emtansine + Tucatinib	sensitive	Phase Ib/II	29955792	Breast	Therapeutic	C
ERBB2	MUT	mutation	breast cancer	ARX-788	sensitive	Preclinical - Cell line xenograft	;	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast cancer	DS-8201a	sensitive	Preclinical - Pdxcell culture	27026201	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast cancer	MI130004	sensitive	Preclinical - Cell line xenograft	29440297	Breast	Therapeutic	D
ERBB2	MUT	mutation	Breast Cancer	Neratinib	Sensitivity/Response	B	28679771	Breast	Therapeutic	B
ERBB2	MUT	mutation	breast cancer	SYD985	predicted - sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	breast cancer	Withacnistin	sensitive	Preclinical	24983364	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast cancer	XMT-1522	sensitive	Preclinical - Pdxcell culture	;	Breast	Therapeutic	D
ERBB2	MUT	mutation	breast carcinoma	SYD985	sensitive	Preclinical - Pdxcell culture	25589493	Breast	Therapeutic	D
ERBB2	MUT	mutation	colorectal cancer	DS-8201a	predicted - sensitive	Phase I	;	Colorectal	Therapeutic	C
ERBB2	MUT	mutation	colorectal cancer	ZW25	no benefit	Phase I	;	Colorectal	Therapeutic	C
ERBB2	MUT	mutation	ductal carcinoma in situ	HER2-pulsed DC1 vaccine	predicted - sensitive	Phase Ib/II	27965306	Breast	Therapeutic	C
ERBB2	MUT	mutation	esophageal cancer	Afatinib	predicted - sensitive	Phase II	30463996	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	esophageal cancer	Afatinib + Trastuzumab	predicted - sensitive	Phase II	30463996	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	esophageal cancer	ZW25	predicted - sensitive	Phase I	;	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	gastric adenocarcinoma	Afatinib	predicted - sensitive	Phase II	30463996	Stomach	Therapeutic	C
ERBB2	MUT	mutation	gastric adenocarcinoma	Afatinib + Trastuzumab	predicted - sensitive	Phase II	30463996	Stomach	Therapeutic	C
ERBB2	MUT	mutation	gastric adenosquamous carcinoma	Ado-trastuzumab emtansine	no benefit	Phase III	;	Stomach	Therapeutic	C
ERBB2	MUT	mutation	gastroesophageal adenocarcinoma	GBR1302	predicted - sensitive	Case Reports/Case Series	;	Esophagus	Therapeutic	D
ERBB2	MUT	mutation	gastroesophageal junction adenocarcinoma	Ado-trastuzumab emtansine	no benefit	Phase III	;	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	gastroesophageal junction adenocarcinoma	Afatinib	predicted - sensitive	Phase II	30463996	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	gastroesophageal junction adenocarcinoma	Afatinib + Trastuzumab	predicted - sensitive	Phase II	30463996	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	gastroesophageal junction adenocarcinoma	MM-111 + Paclitaxel + Trastuzumab	no benefit	Phase II	;	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	glioblastoma multiforme	HER2 CAR-T cells	sensitive	Phase I	28426845	Brain	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	ABP 980	predicted - sensitive	Phase III	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine + Docetaxel + Pertuzumab	sensitive	Phase Ib/II	27052654	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine + Docetaxel	sensitive	Phase Ib/II	27052654	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine	sensitive	Phase III	26920887	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Ado-trastuzumab emtansine + Tucatinib	predicted - sensitive	Phase Ib/II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Afatinib + Trastuzumab	sensitive	Phase I	25370464	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Buparlisib + Trastuzumab	sensitive	Phase I	24470511	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Capecitabine + Neratinib	sensitive	Phase II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Capecitabine + Trastuzumab	sensitive	Phase II	17679724	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Capecitabine + Trastuzumab + Tucatinib	predicted - sensitive	Phase Ib/II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Capecitabine + Tucatinib	predicted - sensitive	Phase Ib/II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab	sensitive	Guideline	;	Breast	Therapeutic	A
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Carboplatin + Docetaxel + Trastuzumab	sensitive	Guideline	;	Breast	Therapeutic	A
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	CDX-3379	sensitive	Preclinical	26880266	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Copanlisib	sensitive	Preclinical	24170767	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	CT-P6	sensitive	Phase III	28592386	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab	sensitive	Guideline	;	Breast	Therapeutic	A
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab	sensitive	Guideline	;	Breast	Therapeutic	A
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Entinostat + Lapatinib	sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Entinostat + Lapatinib + Trastuzumab	sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Everolimus + Trastuzumab + Vinorelbine	sensitive	Phase III	24742739	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	GBR1302	predicted - sensitive	Case Reports/Case Series	;	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	HER2 BATs	sensitive	Preclinical - Cell culture	11359672	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	HER2 Vaccine	predicted - sensitive	Phase II	23585514	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Hertuzumab-vc-MMAE	sensitive	Preclinical - Cell culture	27509865	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Ibrutinib	predicted - sensitive	Preclinical - Cell line xenograft	27256378	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Lapatinib + MK2206	sensitive	Phase I	27026198	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Lapatinib + Palbociclib	sensitive	Preclinical	25221644	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Lapatinib + Trastuzumab	sensitive	Clinical Study - Meta-analysis	27140927	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Lapatinib + Trastuzumab	sensitive	Phase II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	MEDI4276	predicted - sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Metformin	predicted - sensitive	Phase III	28375706	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	MGAH22	predicted - sensitive	Phase I	28119295	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	MM-302	sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	MYL-1401O + Paclitaxel	sensitive	Phase III	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Neratinib + Paclitaxel	sensitive	Phase II	27078022	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Neratinib	sensitive	Phase II	23953056	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Oxaliplatin + Trastuzumab	sensitive	Preclinical	24300914	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Oxaliplatin + Trastuzumab + TS-1	sensitive	Phase II	24982373	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Paclitaxel + Pertuzumab + Trastuzumab	sensitive	Guideline	;	Breast	Therapeutic	A
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Pertuzumab + Trastuzumab	sensitive	Phase III	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Poziotinib	predicted - sensitive	Phase II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Pyrotinib	sensitive	Phase I	;28498781	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	SB3	predicted - sensitive	Phase III	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Sunitinib + Trastuzumab	sensitive	Phase II	24606768	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Trastuzumab + Tucatinib	predicted - sensitive	Phase Ib/II	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Trodusquemine	sensitive	Preclinical - Cell line xenograft	24845231	Breast	Therapeutic	D
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Tucatinib	sensitive	Phase I	28053022	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	Varlitinib	sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	Her2-receptor mutation breast cancer	ZW25	predicted - sensitive	Phase I	;	Breast	Therapeutic	C
ERBB2	MUT	mutation	inflammatory breast carcinoma	Afatinib	predicted - sensitive	Phase II	27923043	Breast	Therapeutic	C
ERBB2	MUT	mutation	Lung Non-small Cell Carcinoma	Trastuzumab,Pertuzumab	Sensitivity/Response	B	29320312	Lung	Therapeutic	B
ERBB2	MUT	mutation	ovarian cancer	ARX-788	sensitive	Preclinical - Cell line xenograft	;	Ovary	Therapeutic	D
ERBB2	MUT	mutation	ovarian cancer	Hertuzumab-vc-MMAE	sensitive	Preclinical - Cell line xenograft	27509865	Ovary	Therapeutic	D
ERBB2	MUT	mutation	ovarian cancer	MI130004	sensitive	Preclinical - Cell line xenograft	29440297	Ovary	Therapeutic	D
ERBB2	MUT	mutation	ovarian cancer	PRS-343	sensitive	Preclinical - Cell line xenograft	;	Ovary	Therapeutic	D
ERBB2	MUT	mutation	ovarian carcinoma	SYD985	sensitive	Preclinical - Cell culture	25589493	Ovary	Therapeutic	D
ERBB2	MUT	mutation	pancreatic cancer	DS-8201a	sensitive	Preclinical - Cell line xenograft	27026201	Pancreas	Therapeutic	D
ERBB2	MUT	mutation	salivary gland cancer	DS-8201a	predicted - sensitive	Phase I	;	Esophagus	Therapeutic	C
ERBB2	MUT	mutation	sarcoma	HER2 CAR-T cells	predicted - sensitive	Phase Ib/II	25800760	Soft_Tissue	Therapeutic	C
ERBB2	MUT	mutation	stomach cancer	ARX-788	sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach cancer	DS-8201a	sensitive	Preclinical - Pdxcell culture	27026201	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach cancer	HER2 Vaccine	sensitive	Preclinical - Patient cell culture	9754653	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach cancer	Lapatinib + Paclitaxel	sensitive	Phase III	24868024	Stomach	Therapeutic	C
ERBB2	MUT	mutation	stomach cancer	MEDI4276	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
ERBB2	MUT	mutation	stomach cancer	MGAH22	predicted - sensitive	Phase I	28119295	Stomach	Therapeutic	C
ERBB2	MUT	mutation	stomach cancer	MI130004	sensitive	Preclinical - Cell line xenograft	29440297	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach cancer	Oxaliplatin + Trastuzumab	sensitive	Preclinical	24300914	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach cancer	ZW25	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
ERBB2	MUT	mutation	stomach carcinoma	SYD985	sensitive	Preclinical - Cell culture	25589493	Stomach	Therapeutic	D
ERBB2	MUT	mutation	stomach carcinoma	Tucatinib	sensitive	Preclinical - Cell culture	;	Stomach	Therapeutic	D
ERBB2	MUT	mutation	transitional cell carcinoma	lapuleucel-T	no benefit	Phase II	;	Bladder	Therapeutic	C
ERBB2	MUT	mutation	uterine corpus serous adenocarcinoma	SYD985	sensitive	Preclinical - Cell line xenograft	27256376	Uterus	Therapeutic	D
ERBB2	MUT	N813D	lung adenocarcinoma	Afatinib	predicted - sensitive	Phase II	30149884	Lung	Therapeutic	C
ERBB2	MUT	N857S	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	N857S	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	N857S	Ovarian Cancer	Lapatinib	Sensitivity/Response	D	22046346	Ovary	Therapeutic	D
ERBB2	MUT	oncogenic mutation	Lung adenocarcinoma	Neratinib	Responsive	Early trials	ESMO 2014 (abstr LBA39_PR)	Lung	Therapeutic	C
ERBB2	MUT	oncogenic mutation	Lung adenocarcinoma	Tensirolimus	Responsive	Early trials	ESMO 2014 (abstr LBA39_PR)	Lung	Therapeutic	C
ERBB2	MUT	oncogenic mutation	Non-small cell lung	Dacomitinib	Responsive	Early trials	25899785	Lung	Therapeutic	C
ERBB2	MUT	Oncogenic Mutations	Breast Cancer	Neratinib	Response	3A	23220880, 29420467	Breast	Therapeutic	C
ERBB2	MUT	Oncogenic Mutations	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine, Neratinib	Response	3A	23220880, 30206164, 29989854, 29420467	Lung	Therapeutic	C
ERBB2	MUT	761_761del	endometrial cancer	Neratinib	predicted - resistant	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	P780INS	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	P780INS	Lung Adenocarcinoma	Dacomitinib	Sensitivity/Response	C	25899785	Lung	Therapeutic	C
ERBB2	MUT	P780L	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	P780L	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	[Afatinib,Lapatinib,Neratinib]	Responsive	Early trials	26598547	Lung	Therapeutic	C
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	Afatinib	Responsive	Early trials	26598547;ASCO 2017 (abstr 9071)	Lung	Therapeutic	C
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	Lapatinib	Responsive	Early trials	26598547;ASCO 2017 (abstr 9071)	Lung	Therapeutic	C
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	Neratinib	Responsive	Early trials	26598547;ASCO 2017 (abstr 9071)	Lung	Therapeutic	C
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	Trastuzumab	Responsive	Early trials	26598547;ASCO 2017 (abstr 9071)	Lung	Therapeutic	C
ERBB2	MUT	proximal exon 20	Lung adenocarcinoma	[Trastuzumab]	Responsive	Early trials	26598547	Lung	Therapeutic	C
ERBB2	MUT	Q709L	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Gefitinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Pertuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	Q709L	Advanced Solid Tumor	Trastuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Gefitinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Neratinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	Advanced Solid Tumor	Trastuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	R678Q	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R678Q	Breast Cancer	Neratinib,Lapatinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	R678Q	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R678Q	colorectal cancer	Neratinib	predicted - resistant	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	R678Q	endometrial cancer	Neratinib	no benefit	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	R678Q	gastroesophageal junction adenocarcinoma	Neratinib	predicted - resistant	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	R784G	colorectal cancer	Cetuximab	predicted - resistant	Case Reports/Case Series	30549033	Colorectal	Therapeutic	D
ERBB2	MUT	R896C	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	R896C	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R896C	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R896C	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R896C	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	R896C	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	R896C	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	S310	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	S310F	Adenocarcinoma/Urothelial Carcinoma in Breast/Lung/Bladder/Ureter/Kidney			1	23630663	Bladder;Breast;Kidney;Lung	Therapeutic	B
ERBB2	MUT	S310F	Advanced Solid Tumor	Lapatinib	sensitive	Preclinical	22908275	Other	Therapeutic	D
ERBB2	MUT	S310F	Advanced Solid Tumor	Neratinib	sensitive	Preclinical	22908275	Other	Therapeutic	D
ERBB2	MUT	S310F	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	S310F	biliary tract cancer	Neratinib	no benefit	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	S310F	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	S310F	cervical cancer	Neratinib	predicted - sensitive	Phase II	29420467	Cervix	Therapeutic	C
ERBB2	MUT	S310F	colon cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	colon cancer	Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	colorectal cancer	Afatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	colorectal cancer	Cetuximab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	colorectal cancer	Neratinib	conflicting	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	S310F	colorectal cancer	Neratinib	conflicting	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	colorectal cancer	Panitumumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310F	endometrial cancer	Neratinib	no benefit	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	S310F	gastroesophageal junction adenocarcinoma	Neratinib	no benefit	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	S310F	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	S310F	Lung	Ado-Trastuzumab Emtansine	Responsive	Early trials	ASCO 2017 (abstr 8510)	Lung	Therapeutic	C
ERBB2	MUT	S310F	lung non-small cell carcinoma	Neratinib	predicted - resistant	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	S310F	urinary bladder cancer	Afatinib	sensitive	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S310F	urinary bladder cancer	Lapatinib	sensitive	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S310F	urinary bladder cancer	Neratinib	no benefit	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	S310F	urinary bladder cancer	Selumetinib	decreased response	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S310F	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	Adenocarcinoma/Urothelial Carcinoma in Breast/Lung/Bladder/Ureter/Kidney			1	24192927,23630663	Bladder;Breast;Kidney;Lung	Therapeutic	B
ERBB2	MUT	S310Y	Any cancer type	Trastuzumab	Responsive	Pre-clinical	22908275	Cancer	Therapeutic	D
ERBB2	MUT	S310Y	Breast adenocarcinoma;Any cancer type	Trastuzumab	Responsive	Pre-clinical	23220880;22908275	Breast;Cancer	Therapeutic	D
ERBB2	MUT	S310Y	cervical cancer	Neratinib	predicted - resistant	Phase II	29420467	Cervix	Therapeutic	C
ERBB2	MUT	S310Y	colorectal cancer	Cetuximab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	colorectal cancer	Lapatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	colorectal cancer	Lapatinib + Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	colorectal cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	colorectal cancer	Neratinib + Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	colorectal cancer	Trastuzumab	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	S310Y	endometrial cancer	Neratinib	no benefit	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	S310Y	gastroesophageal junction adenocarcinoma	Neratinib	predicted - resistant	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	S310Y	lung squamous cell carcinoma	Afatinib	predicted - sensitive	Case Reports/Case Series	30584328	Lung	Therapeutic	D
ERBB2	MUT	S310Y	urinary bladder cancer	Neratinib	no benefit	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	S653C	urinary bladder cancer	Afatinib	sensitive	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S653C	urinary bladder cancer	Lapatinib	sensitive	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S653C	urinary bladder cancer	Selumetinib	decreased response	Preclinical	24971884	Bladder	Therapeutic	D
ERBB2	MUT	S783P	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	S783P	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	SERUM LEVELS	Breast Cancer	Lapatinib	Sensitivity/Response	B	26811533	Breast	Therapeutic	B
ERBB2	MUT	SERUM LEVELS	Breast Cancer		Poor Outcome	B	26811533	Breast	Prognostic	B
ERBB2	MUT	T733I	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	T733I	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	T733I	biliary tract cancer	Neratinib	no benefit	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	T798I	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	25238247	Other	Therapeutic	D
ERBB2	MUT	T798I	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	T798I	Breast adenocarcinoma	Afatinib	Responsive	Pre-clinical	28274957	Breast	Therapeutic	D
ERBB2	MUT	T798I	Breast adenocarcinoma	Neratinib	Resistant	Case report	28274957	Breast	Therapeutic	D
ERBB2	MUT	T798I	lung cancer	Lapatinib	resistant	Preclinical	25238247	Lung	Therapeutic	D
ERBB2	MUT	T798M	Advanced Solid Tumor	AEE788	resistant	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T798M	Advanced Solid Tumor	EKI-285	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T798M	Advanced Solid Tumor	Lapatinib	resistant	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T798M	Advanced Solid Tumor	WZ4002	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Afatinib	sensitive	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Buparlisib	sensitive	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Cetuximab + Lapatinib	sensitive	Preclinical - Cell line xenograft	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Cetuximab	resistant	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	CI-1040	resistant	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Lapatinib + Trastuzumab	sensitive	Preclinical - Cell line xenograft	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	Trastuzumab + XL147	sensitive	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	breast cancer	XL147	sensitive	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T798M	Her2-receptor mutation breast cancer	Lapatinib	resistant	Preclinical	23948973	Breast	Therapeutic	D
ERBB2	MUT	T862A	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T862A	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	T862A	Stomach Carcinoma	Lapatinib	Sensitivity/Response	D	22046346	Stomach	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Afatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Cetuximab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Erlotinib	no benefit	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Gefitinib	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Lapatinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Neratinib	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Pertuzumab	predicted - resistant	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	Advanced Solid Tumor	Trastuzumab	predicted - sensitive	Preclinical - Cell culture	30449325	Other	Therapeutic	D
ERBB2	MUT	V659E	biliary tract cancer	Neratinib	no benefit	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	V659E	Breast adenocarcinoma;Lung adenocarcinoma	Lapatinib	Responsive	Case report	23950206	Breast;Lung	Therapeutic	D
ERBB2	MUT	V659E	breast cancer	23814 + Tivozanib	sensitive	Preclinical	25995436	Breast	Therapeutic	D
ERBB2	MUT	V659E	lung adenocarcinoma	Ado-trastuzumab emtansine	predicted - sensitive	Case Reports/Case Series	29989854	Lung	Therapeutic	D
ERBB2	MUT	V659E	Lung	Ado-Trastuzumab Emtansine	Responsive	Early trials	ASCO 2017 (abstr 8510)	Lung	Therapeutic	C
ERBB2	MUT	V659E	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	V659E	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	V659E	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	V697L	Advanced Solid Tumor	Neratinib	predicted - sensitive	Phase II	29247016	Other	Therapeutic	C
ERBB2	MUT	V697L	endometrial cancer	Neratinib	predicted - resistant	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	V697L	triple-receptor negative breast cancer	Neratinib	sensitive	Phase II	29247016	Breast	Therapeutic	C
ERBB2	MUT	V773A	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	V773A	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	V773A	Head And Neck Squamous Cell Carcinoma	Lapatinib	Sensitivity/Response	D	22046346	Head_and_Neck	Therapeutic	D
ERBB2	MUT	V773L	breast cancer	Lapatinib	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	V773L	breast cancer	Neratinib	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	V773L	breast cancer	Trastuzumab	sensitive	Preclinical - Cell culture	27697991	Breast	Therapeutic	D
ERBB2	MUT	V777	Any cancer type	Neratinib	Responsive	Early trials	AACR 2017 (abstr CT001)	Cancer	Therapeutic	C
ERBB2	MUT	V777L	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	V777L	Advanced Solid Tumor	Lapatinib	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	V777L	biliary tract cancer	Neratinib	no benefit	Phase II	29420467	Bile_Duct	Therapeutic	C
ERBB2	MUT	V777L	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V777L	colon cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colon cancer	Trastuzumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colorectal cancer	Afatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colorectal cancer	Cetuximab	resistant	Preclinical - Pdx	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colorectal cancer	Neratinib	conflicting	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	V777L	colorectal cancer	Neratinib	conflicting	Preclinical - Cell line xenograft	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colorectal cancer	Neratinib + Trastuzumab	sensitive	Preclinical - Cell line xenograft	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	colorectal cancer	Panitumumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V777L	endometrial cancer	Neratinib	no benefit	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	V777L	gastroesophageal junction adenocarcinoma	Neratinib	predicted - resistant	Phase II	29420467	Esophagus	Therapeutic	C
ERBB2	MUT	V777L	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	V777L	urinary bladder cancer	Neratinib	no benefit	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	V839G	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	V842I	Adenocarcinoma in Breast			2	23220880	Breast	Therapeutic	C
ERBB2	MUT	V842I	Adenocarcinoma in Colon/Rectum/Pancreas			2	26320869	Colorectal;Pancreas	Therapeutic	C
ERBB2	MUT	V842I	Breast adenocarcinoma	Lapatinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	Breast adenocarcinoma	Neratinib	Responsive	Pre-clinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	breast cancer	Lapatinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	breast cancer	Neratinib	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	Breast Cancer	Neratinib	Sensitivity/Response	D	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	breast cancer	Trastuzumab	sensitive	Preclinical	23220880	Breast	Therapeutic	D
ERBB2	MUT	V842I	colon cancer	Neratinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	Colon Cancer	Trastuzumab,Lapatinib,Neratinib	Sensitivity/Response	D	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	colon cancer	Trastuzumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	colorectal cancer	Afatinib	sensitive	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	colorectal cancer	Cetuximab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	colorectal cancer	Neratinib	conflicting	Phase II	29420467	Colorectal	Therapeutic	C
ERBB2	MUT	V842I	colorectal cancer	Neratinib	conflicting	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	colorectal cancer	Panitumumab	resistant	Preclinical	26243863	Colorectal	Therapeutic	D
ERBB2	MUT	V842I	endometrial cancer	Neratinib	predicted - resistant	Phase II	29420467	Uterus	Therapeutic	C
ERBB2	MUT	WILDTYPE	Advanced Solid Tumor	AEE788	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	WILDTYPE	Advanced Solid Tumor	Lapatinib	sensitive	Preclinical	22046346	Other	Therapeutic	D
ERBB2	MUT	WILDTYPE	Advanced Solid Tumor	Osimertinib	sensitive	Preclinical	29298799	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Afatinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	AZ5104	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Dacomitinib	decreased response	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Erlotinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Ganetespib	predicted - sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Lapatinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Luminespib	predicted - sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Neratinib	sensitive	Preclinical - Cell culture	28363995	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Osimertinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Poziotinib	sensitive	Preclinical - Cell culture	29686424	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Pyrotinib	sensitive	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Advanced Solid Tumor	Tucatinib	resistant	Preclinical - Cell culture	30527195	Other	Therapeutic	D
ERBB2	MUT	Y772_A775dup	Her2-receptor negative breast cancer	Neratinib	predicted - sensitive	Phase II	29420467	Breast	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung adenocarcinoma	Afatinib	conflicting	Case Reports/Case Series	26964772	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775DUP	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	22325357	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775DUP	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	26559459	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung adenocarcinoma	Poziotinib	predicted - sensitive	Phase II	30149884	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775DUP	Lung Adenocarcinoma	Trastuzumab Emtansine	Sensitivity/Response	C	25789838	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung cancer	Afatinib	sensitive	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775dup	lung cancer	Gefitinib	no benefit	Preclinical	26545934	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775dup	lung cancer	Poziotinib	sensitive	Preclinical	29686424	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775DUP	Lung Carcinoma	Afatinib	Sensitivity/Response	D	19122144	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775dup	lung non-small cell carcinoma	Afatinib	predicted - sensitive	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775DUP	Lung Non-small Cell Carcinoma	Afatinib,Rapamycin (Sirolimus)	Sensitivity/Response	D	19122144	Lung	Therapeutic	D
ERBB2	MUT	Y772_A775dup	lung non-small cell carcinoma	Dacomitinib	no benefit	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung non-small cell carcinoma	Erlotinib	no benefit	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung non-small cell carcinoma	Neratinib	no benefit	Phase II	29420467	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	lung non-small cell carcinoma	Poziotinib	predicted - sensitive	Clinical Study	30527195	Lung	Therapeutic	C
ERBB2	MUT	Y772_A775dup	urinary bladder cancer	Neratinib	predicted - resistant	Phase II	29420467	Bladder	Therapeutic	C
ERBB2	MUT	Y803N	Advanced Solid Tumor	Lapatinib	decreased response	Preclinical	18413839	Other	Therapeutic	D
ERBB2	MUT	Y803N	Advanced Solid Tumor	XL647	sensitive	Preclinical	18413839	Other	Therapeutic	D
ERBB3	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Early trials	25520391	Colorectal	Therapeutic	C
ERBB3	EXP	EXPRESSION	Pancreatic Ductal Adenocarcinoma	Pertuzumab,9F7-F11	Sensitivity/Response	D	25216528	Pancreas	Therapeutic	D
ERBB3	EXP	OVEREXPRESSION	Cancer	Gefitinib,Selumetinib,CP724714	Resistance	D	24685132	Cancer	Therapeutic	D
ERBB3	EXP	OVEREXPRESSION	Cancer	Selumetinib,Afatinib	Sensitivity/Response	D	24685132	Cancer	Therapeutic	D
ERBB3	EXP	OVEREXPRESSION	Colorectal Cancer	Cetuximab	Resistance	B	25520391	Colorectal	Therapeutic	B
ERBB3	MUT	G284R	Any cancer type	[ERBB3 mAb inhibitor]	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	G284R	Any cancer type	Lapatinib	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	G284R	Any cancer type	Pertuzumab	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	G284R	Any cancer type	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	G284R	Any cancer type	Trastuzumab	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	G284R	Bladder	Afatinib	Responsive	Case report	ASCO 2015 (abstr e15516)	Bladder	Therapeutic	D
ERBB3	MUT	G284R	Bladder	Afatinib	Responsive	Case report	27044931	Bladder	Therapeutic	D
ERBB3	MUT	G284R	Urothelial Carcinoma	Afatinib	Sensitivity/Response	B	27044931	Bladder	Therapeutic	B
ERBB3	MUT	P262H	Any cancer type	[ERBB3 mAb inhibitor]	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	P262H	Any cancer type	Lapatinib	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	P262H	Any cancer type	Pertuzumab	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	P262H	Any cancer type	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	P262H	Any cancer type	Trastuzumab	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	Q809R	Any cancer type	Lapatinib	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	Q809R	Any cancer type	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	Q809R	Any cancer type	Trastuzumab	Responsive	Pre-clinical	23680147	Cancer	Therapeutic	D
ERBB3	MUT	R103G	Bladder	Afatinib	Responsive	Case report	ASCO 2015 (abstr e15516)	Bladder	Therapeutic	D
ERBB3	MUT	R103G	Bladder	Afatinib	Responsive	Case report	27044931	Bladder	Therapeutic	D
ERBB3	MUT	R103G	Urothelial Carcinoma	Afatinib	Sensitivity/Response	B	27044931	Bladder	Therapeutic	B
ERBB3	MUT	V104M	Bladder	Afatinib	Responsive	Case report	27044931	Bladder	Therapeutic	D
ERBB3	MUT	V104M	Urothelial Carcinoma	Afatinib	Sensitivity/Response	B	27044931	Bladder	Therapeutic	B
ERBB3	MUT	V855A	Lung Non-small Cell Carcinoma	Pertuzumab,Afatinib	Sensitivity/Response	D	26689995	Lung	Therapeutic	D
ERBB4	EXP	EXPRESSION	Breast Cancer	Lapatinib	Resistance	D	25590338	Breast	Therapeutic	D
ERBB4	EXP	EXPRESSION	Breast Cancer	Trastuzumab	Resistance	D	25153719	Breast	Therapeutic	D
ERBB4	MUT	E317K	Cutaneous melanoma	Lapatinib	Responsive	Pre-clinical	19718025	Skin	Therapeutic	D
ERBB4	MUT	E317K	melanoma	Lapatinib	sensitive	Preclinical - Cell culture	19718025	Skin	Therapeutic	D
ERBB4	MUT	E452K	Cutaneous melanoma	Lapatinib	Responsive	Pre-clinical	19718025	Skin	Therapeutic	D
ERBB4	MUT	E452K	melanoma	Lapatinib	sensitive	Preclinical - Cell culture	19718025	Skin	Therapeutic	D
ERBB4	MUT	E563K	melanoma	Lapatinib	sensitive	Preclinical - Cell culture	19718025	Skin	Therapeutic	D
ERBB4	MUT	E872K	Cutaneous melanoma	Lapatinib	Responsive	Pre-clinical	19718025	Skin	Therapeutic	D
ERBB4	MUT	G1109C	head and neck squamous cell carcinoma	Afatinib	sensitive	Preclinical - Cell line xenograft	27207775	Head_and_Neck	Therapeutic	D
ERBB4	MUT	G1109C	head and neck squamous cell carcinoma	Cetuximab	no benefit	Preclinical - Cell culture	27207775	Head_and_Neck	Therapeutic	D
ERBB4	MUT	G1109C	head and neck squamous cell carcinoma	Erlotinib	no benefit	Preclinical - Cell culture	27207775	Head_and_Neck	Therapeutic	D
ERBB4	MUT	H809G	Breast adenocarcinoma	[Lapatinib]	Resistant	Case report	26530965	Breast	Therapeutic	D
ERBB4	MUT	mutant	lung squamous cell carcinoma	Afatinib	predicted - sensitive	Phase III	29902295	Lung	Therapeutic	C
ERBB4	MUT	mutation	Melanoma	Lapatinib	Sensitivity/Response	D	19718025	Skin	Therapeutic	D
ERBB4	MUT	NUCLEAR TRANSLOCATION	Breast Cancer	Trastuzumab	Resistance	D	25153719	Breast	Therapeutic	D
ERBB4	MUT	R393W	Cutaneous melanoma	Lapatinib	Responsive	Pre-clinical	19718025	Skin	Therapeutic	D
ERBB4	MUT	R393W	melanoma	Lapatinib	sensitive	Preclinical - Cell culture	19718025	Skin	Therapeutic	D
ERBB4	MUT	R544W	Cutaneous melanoma	Lapatinib	Responsive	Pre-clinical	19718025	Skin	Therapeutic	D
ERBB4	MUT	R544W	melanoma	Lapatinib	sensitive	Preclinical	19718025	Skin	Therapeutic	D
ERCC1	CNV	deletion	Lung	Cisplatin	Responsive	Pre-clinical	23275151;23934192	Lung	Therapeutic	D
ERCC1	CNV	deletion	Lung	[PARP inhibitor]	Responsive	Pre-clinical	23934192	Lung	Therapeutic	D
ERCC1	EXP	EXPRESSION	Bladder Carcinoma		Better Outcome	B	26162296	Bladder	Prognostic	B
ERCC1	EXP	overexpression	Bladder	Cisplatin	Resistant	Pre-clinical	20846399;21177407	Bladder	Therapeutic	D
ERCC1	MUT	oncogenic mutation	Lung	Cisplatin	Responsive	Pre-clinical	23275151;23934192	Lung	Therapeutic	D
ERCC1	MUT	oncogenic mutation	Lung	[PARP inhibitor]	Responsive	Pre-clinical	23934192	Lung	Therapeutic	D
ERCC2	MUT	K751Q	Lung Non-small Cell Carcinoma	Paclitaxel,Carboplatin	Sensitivity/Response	B	19470925	Lung	Therapeutic	B
ERCC2	MUT	K751Q	Osteosarcoma	Cisplatin	Resistance	B	19434073	Bone	Therapeutic	B
ERCC2	MUT	oncogenic mutation	Bladder	Cisplatin	Responsive	Early trials	25096233	Bladder	Therapeutic	C
ERCC2	MUT	Oncogenic Mutations	Bladder Cancer	Cisplatin	Response	3A	12208738, 25096233, 29980530, 27310333	Bladder	Therapeutic	C
ERCC4	MUT	oncogenic mutation	Ovary	Cisplatin	Responsive	Pre-clinical	25634215	Ovary	Therapeutic	D
ERCC6	MUT	oncogenic mutation	Ovary	Cisplatin	Responsive	Pre-clinical	25634215	Ovary	Therapeutic	D
EREG	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Responsive	Early trials	19738126;26341080	Colorectal	Therapeutic	C
EREG	EXP	EXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	23374602	Colorectal	Therapeutic	B
EREG	EXP	EXPRESSION	Colorectal Cancer	Panitumumab	Sensitivity/Response	B	26867820	Colorectal	Therapeutic	B
EREG	EXP	EXPRESSION	Lung Adenocarcinoma		Poor Outcome	E	26894620	Lung	Prognostic	D
ERG	FUS	EWSR1-ERG	Ewing Sarcoma		Positive	B	23706910	Bone	Diagnostic	B
ERG	FUS	TMPRSS2-ERG	Prostate Carcinoma		Positive	B	16254181	Prostate	Diagnostic	B
ERG-TMPRSS2	MUT	rearrangement	Adenocarcinoma in Prostate			2	24239470,16254181,17971772,20651988	Prostate	Therapeutic	C
ERRFI1	MUT	E384X	Cholangiocarcinoma	Erlotinib	Sensitivity/Response	C	24550739	Bile_Duct	Therapeutic	C
ESR1	EXP	OVEREXPRESSION	Breast Cancer	Letrozole,Palbociclib (PD0332991)	Sensitivity/Response	B	25524798	Breast	Therapeutic	B
ESR1	MUT	codon(s) 537 missense	Breast adenocarcinoma	[GDC-0810]	Responsive	Case report	AACR 2015 (abstr CT231)	Breast	Therapeutic	D
ESR1	MUT	codon(s) 537 missense	Breast adenocarcinoma	Tamoxifen	Resistant	Early trials	24185512;24185510;24398047	Breast	Therapeutic	C
ESR1	MUT	codon(s) 538 missense	Breast adenocarcinoma	[GDC-0810]	Responsive	Case report	AACR 2015 (abstr CT231)	Breast	Therapeutic	D
ESR1	MUT	codon(s) 538 missense	Breast adenocarcinoma	Tamoxifen	Resistant	Early trials	24185512;24185510;24398047	Breast	Therapeutic	C
ESR1	MUT	D538G	Breast Cancer	Hormone Therapy	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	D538G	Breast Cancer	Tamoxifen,Fulvestrant	Sensitivity/Response	D	24185510	Breast	Therapeutic	D
ESR1	MUT	E380Q	Breast adenocarcinoma	[GDC-0810]	Responsive	Case report	AACR 2015 (abstr CT231)	Breast	Therapeutic	D
ESR1	MUT	E380Q	Breast adenocarcinoma	Tamoxifen	Resistant	Early trials	24185512;24185510;24398047	Breast	Therapeutic	C
ESR1	MUT	L536	Breast adenocarcinoma	[GDC-0810]	Responsive	Case report	AACR 2015 (abstr CT231)	Breast	Therapeutic	D
ESR1	MUT	L536	Breast adenocarcinoma	Tamoxifen	Resistant	Early trials	24185512;24185510;24398047	Breast	Therapeutic	C
ESR1	MUT	L536Q	Breast Cancer	Hormone Therapy	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	L536Q	Breast Cancer	Tamoxifen,Fulvestrant	Sensitivity/Response	D	24185510	Breast	Therapeutic	D
ESR1	MUT	oncogenic mutation	Breast adenocarcinoma	Exemestane	Resistant	Late trials	27269946	Breast	Therapeutic	C
ESR1	MUT	oncogenic mutation	Breast adenocarcinoma	Fluvestrant	Responsive	Late trials	27269946	Breast	Therapeutic	C
ESR1	MUT	Oncogenic Mutations	Breast Cancer	AZD9496, Fulvestrant	Response	3A	27986707, 27269946	Breast	Therapeutic	C
ESR1	MUT	P535H	Breast adenocarcinoma	[GDC-0810]	Responsive	Case report	AACR 2015 (abstr CT231)	Breast	Therapeutic	D
ESR1	MUT	P535H	Breast adenocarcinoma	Tamoxifen	Resistant	Early trials	24185512;24185510;24398047	Breast	Therapeutic	C
ESR1	MUT	S463P	Estrogen-receptor Positive Breast Cancer	Aromatase Inhibitor	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	Y537C	Breast Cancer	Hormone Therapy	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	Y537C	Breast Cancer	Tamoxifen,Fulvestrant	Sensitivity/Response	D	24185510	Breast	Therapeutic	D
ESR1	MUT	Y537N	Breast Cancer	Hormone Therapy	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	Y537N	Breast Cancer	Tamoxifen,Fulvestrant	Sensitivity/Response	D	24185510	Breast	Therapeutic	D
ESR1	MUT	Y537S	Breast adenocarcinoma	Fulvestrant	Resistant	Pre-clinical	27986707	Breast	Therapeutic	D
ESR1	MUT	Y537S	Breast Cancer	Hormone Therapy	Resistance	D	24185512	Breast	Therapeutic	D
ESR1	MUT	Y537S	Breast Cancer	Tamoxifen,Fulvestrant	Sensitivity/Response	D	24185510	Breast	Therapeutic	D
ETV4	EXP	OVEREXPRESSION	Prostate Cancer		Poor Outcome	B	25544710	Prostate	Prognostic	B
ETV6-ABL1	FUS		chronic myeloid leukemia	Imatinib	predicted - resistant	Case Reports/Case Series	24053143	Blood;Bone_Marrow	Therapeutic	D
ETV6-ABL1	FUS		chronic myeloid leukemia	Nilotinib	predicted - sensitive	Case Reports/Case Series	24053143	Blood;Bone_Marrow	Therapeutic	D
ETV6-ALK	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26939704	Other	Therapeutic	D
ETV6-FGFR1	FUS		Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	27401245	Other	Therapeutic	D
ETV6-FGFR3	FUS		Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	27401245	Other	Therapeutic	D
ETV6-FGFR4	FUS		Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	27401245	Other	Therapeutic	D
ETV6-JAK2	FUS		hematologic cancer	NS-018	sensitive	Preclinical - Cell culture	22829185	Blood	Therapeutic	D
ETV6-JAK2	FUS	JAK2 N909K	hematologic cancer	Pyridone 6	resistant	Preclinical	22916261	Blood	Therapeutic	D
ETV6-JAK2	FUS	JAK2 R975G	hematologic cancer	Pyridone 6	resistant	Preclinical	22916261	Blood	Therapeutic	D
ETV6-JAK2	FUS	JAK2 V881A	hematologic cancer	Pyridone 6	resistant	Preclinical	22916261	Blood	Therapeutic	D
ETV6-JAK3	FUS		hematologic cancer	NS-018	predicted - resistant	Preclinical - Cell culture	22829185	Blood	Therapeutic	D
ETV6	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	21435002,22162831,23704090	Blood;Bone_Marrow	Therapeutic	B
ETV6	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	21877899;26769228;21714648	Bone_Marrow	Prognostic	C
ETV6	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
ETV6-NTRK1	FUS		Advanced Solid Tumor	Entrectinib	predicted - sensitive	Preclinical - Cell culture	26884591	Other	Therapeutic	D
ETV6-NTRK2	FUS		acute myeloid leukemia	Larotrectinib	sensitive	Case Reports/Case Series	29920189	Blood;Bone_Marrow	Therapeutic	D
ETV6-NTRK2	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26884591	Other	Therapeutic	D
ETV6-NTRK2	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26939704	Other	Therapeutic	D
ETV6-NTRK2	FUS		Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell culture	30093503	Other	Therapeutic	D
ETV6-NTRK3	FUS		acute myeloid leukemia	CH7057288	sensitive	Preclinical - Cell line xenograft	30242093	Blood;Bone_Marrow	Therapeutic	D
ETV6-NTRK3	FUS		acute myeloid leukemia	Crizotinib	sensitive	Preclinical - Cell line xenograft	23811600	Blood;Bone_Marrow	Therapeutic	D
ETV6-NTRK3	FUS		acute myeloid leukemia	Larotrectinib	sensitive	Preclinical	26216294	Blood;Bone_Marrow	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	Altiratinib	sensitive	Preclinical	;	Other	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	BMS-536924	sensitive	Preclinical	21804605	Other	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26884591	Other	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell culture	26939704	Other	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	Larotrectinib	sensitive	Phase II	29466156	Other	Therapeutic	C
ETV6-NTRK3	FUS		Advanced Solid Tumor	Lestaurtinib	sensitive	Preclinical	16258068	Other	Therapeutic	D
ETV6-NTRK3	FUS		Advanced Solid Tumor	Repotrectinib	sensitive	Preclinical - Cell culture	30093503	Other	Therapeutic	D
ETV6-NTRK3	FUS		breast cancer	BMS-754807	sensitive	Preclinical - Cell line xenograft	21148487	Breast	Therapeutic	D
ETV6-NTRK3	FUS		cancer	Midostaurin	sensitive	Preclinical	23131561	Cancer	Therapeutic	D
ETV6-NTRK3	FUS		congenital fibrosarcoma	Larotrectinib	sensitive	Case Reports/Case Series	28578312	Soft_Tissue	Therapeutic	D
ETV6-NTRK3	FUS		congenital fibrosarcoma	Larotrectinib	sensitive	Phase I	27093299	Soft_Tissue	Therapeutic	C
ETV6-NTRK3	FUS		congenital fibrosarcoma	Larotrectinib	sensitive	Phase Ib/II	29606586	Soft_Tissue	Therapeutic	C
ETV6-NTRK3	FUS		congenital fibrosarcoma	N/A	not applicable	Guideline	;	Soft_Tissue	Diagnostic	A
ETV6-NTRK3	FUS		fibrosarcoma	Entrectinib	predicted - sensitive	Phase I	;	Soft_Tissue	Therapeutic	C
ETV6-NTRK3	FUS		gastrointestinal stromal tumor	Larotrectinib	predicted - sensitive	Phase I	29466156;	Stomach	Therapeutic	C
ETV6-NTRK3	FUS		head and neck squamous cell carcinoma	Merestinib	sensitive	Preclinical - Pdx	29568395	Head_and_Neck	Therapeutic	D
ETV6-NTRK3	FUS		melanoma	DS-6051a	sensitive	Preclinical - Cell culture	27477320	Skin	Therapeutic	D
ETV6-NTRK3	FUS		salivary gland cancer	Crizotinib	predicted - sensitive	Case Reports/Case Series	26884591	Esophagus	Therapeutic	D
ETV6-NTRK3	FUS		salivary gland cancer	Entrectinib	predicted - sensitive	Case Reports/Case Series	26884591	Esophagus	Therapeutic	D
ETV6-NTRK3	FUS		small intestine neuroendocrine neoplasm	Entrectinib	predicted - sensitive	Case Reports/Case Series	29118225	Other	Therapeutic	D
ETV6-PDGFRA	FUS		chronic leukemia	Imatinib	predicted - sensitive	Case Reports/Case Series	17555450	Blood;Bone_Marrow	Therapeutic	D
ETV6-ROS1	FUS		Advanced Solid Tumor	Entrectinib	sensitive	Preclinical - Cell line xenograft	26939704	Other	Therapeutic	D
ETV6-RUNX1	FUS		acute lymphocytic leukemia	N/A	not applicable	Clinical Study	26711002;15704129;8609706	Blood;Bone_Marrow	Diagnostic	C
ETV6-RUNX1	FUS		acute lymphocytic leukemia	N/A	not applicable	Clinical Study	8609706;10086740;11432885	Blood;Bone_Marrow	Prognostic	C
ETV6-SYK	FUS		Advanced Solid Tumor	HMPL-523	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
EWSR1	FUS	EWSR1-FLI1	Ewing Sarcoma Of Bone		Positive	B	16258512	Bone	Diagnostic	B
EWSR1	FUS	EWSR1-FLI1	Ewing Sarcoma Of Bone		Positive	B	3163261	Bone	Diagnostic	B
EWSR1	FUS	EWSR1-FLI1	Ewing Sarcoma Of Bone		Positive	B	9741544	Bone	Diagnostic	B
EZH2	EXP	OVEREXPRESSION	Cancer		Poor Outcome	B	26683709	Cancer	Prognostic	B
EZH2	EXP	OVEREXPRESSION	lung non-small cell carcinoma	JQEZ5	sensitive	Preclinical	27312177	Lung	Therapeutic	D
EZH2	EXP	OVEREXPRESSION	medulloblastoma	MC3629	predicted - sensitive	Preclinical - Cell line xenograft	28978137	Nervous_System	Therapeutic	D
EZH2	MUT	A677	Lymphoma	[EPZ-005687,EPZ-6438]	Responsive	Pre-clinical	23023262;24563539	Lymph_Nodes	Therapeutic	D
EZH2	MUT	any mutation	Diffuse Large B Cell Lymphoma/Follicular Lymphoma/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia/Primary Myelofibrosis/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24097338,23486531,24549259,18314608,22040993,22237151	Blood;Bone_Marrow	Therapeutic	B
EZH2	MUT	INTRON 6 mutation	Colorectal Cancer		Poor Outcome	B	21926398	Colorectal	Prognostic	B
EZH2	MUT	mutant	diffuse large B-cell lymphoma	A-395	sensitive	Preclinical - Cell line xenograft	28135237	Lymph_Nodes	Therapeutic	D
EZH2	MUT	mutant	essential thrombocythemia	N/A	not applicable	Guideline	;	Blood	Prognostic	A
EZH2	MUT	mutant	myelodysplastic/myeloproliferative neoplasm	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
EZH2	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
EZH2	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
EZH2	MUT	mutation	diffuse large B-cell lymphoma	Tazemetostat	predicted - sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
EZH2	MUT	mutation	Follicular Lymphoma		Better Outcome	B	26256760	Lymph_Nodes	Prognostic	B
EZH2	MUT	mutation	follicular lymphoma	Tazemetostat	predicted - sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
EZH2	MUT	mutation	Myelodysplastic Syndrome		Poor Outcome	B	20601954	Bone_Marrow	Prognostic	B
EZH2	MUT	mutation	non-Hodgkin lymphoma	Tazemetostat	predicted - sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
EZH2	MUT	T678delinsTKK	acute myeloid leukemia	Tazemetostat	resistant	Preclinical - Cell culture	28231254	Blood;Bone_Marrow	Therapeutic	D
EZH2	MUT	WILDTYPE	melanoma	GSK126	predicted - sensitive	Preclinical - Cell culture	26936398	Skin	Therapeutic	D
EZH2	MUT	Y111D	Advanced Solid Tumor	GSK126	resistant	Preclinical - Cell culture	26360609	Other	Therapeutic	D
EZH2	MUT	Y111D	Advanced Solid Tumor	Tazemetostat	resistant	Preclinical - Cell culture	26360609	Other	Therapeutic	D
EZH2	MUT	Y641F	lymphoma	EPZ005687	sensitive	Preclinical - Cell culture	23023262	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641H	melanoma	GSK126	predicted - sensitive	Preclinical - Cell culture	26936398	Skin	Therapeutic	D
EZH2	MUT	Y641	Lymphoma	[EPZ-005687,EPZ-6438]	Responsive	Pre-clinical	23023262;24563539	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	ACY-957 + Doxorubicin	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	ACY-957 + DZNeP	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	ACY-957 + GSK126	sensitive	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	ACY-957	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	DZNeP	predicted - sensitive	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	EED226 + EI1	sensitive	Preclinical - Cell culture	28135235	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	EED226	sensitive	Preclinical - Cell line xenograft	28135235	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	GSK126	no benefit	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	UNC1999	sensitive	Preclinical	23614352	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	diffuse large B-cell lymphoma	Vorinostat	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641N	melanoma	GSK126	predicted - sensitive	Preclinical - Cell culture	26936398	Skin	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	ACY-957 + DZNeP	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	ACY-957 + GSK126	sensitive	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	ACY-957	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	DZNeP	decreased response	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	GSK126	decreased response	Preclinical - Cell culture	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	diffuse large B-cell lymphoma	Vorinostat	sensitive	Preclinical	25605023	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y641S	melanoma	GSK126	predicted - sensitive	Preclinical - Cell culture	26936398	Skin	Therapeutic	D
EZH2	MUT	Y646	Diffuse Large B-cell Lymphoma		Positive	B	20081860	Lymph_Nodes	Diagnostic	B
EZH2	MUT	Y646F	diffuse large B-cell lymphoma	EED226	sensitive	Preclinical - Cell culture	28135235	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y646F	lymphoma	Tazemetostat	sensitive	Preclinical	24563539	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y646	Follicular Lymphoma		Positive	B	20081860	Lymph_Nodes	Diagnostic	B
EZH2	MUT	Y646H	non-Hodgkin lymphoma	Tazemetostat	sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
EZH2	MUT	Y646N	diffuse large B-cell lymphoma	EED226	sensitive	Preclinical - Cell culture	28135235	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y646N	melanoma	GSK126	sensitive	Preclinical - Cell culture	26304929	Skin	Therapeutic	D
EZH2	MUT	Y646S	diffuse large B-cell lymphoma	EED226	sensitive	Preclinical - Cell culture	28135235	Lymph_Nodes	Therapeutic	D
EZH2	MUT	Y646	Skin Melanoma	GSK126	Sensitivity/Response	D	26304929	Skin	Therapeutic	D
FANCA	CNV	deletion	Prostate adenocarcinoma	Olaparib	Responsive	Case report	26510020	Prostate	Therapeutic	D
FANCA	MUT	oncogenic mutation	Prostate adenocarcinoma	Olaparib	Responsive	Case report	26510020	Prostate	Therapeutic	D
FANCC	CNV	deletion	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
FANCC	MUT	LOSS-OF-FUNCTION	Pancreatic Cancer	Melphalan,Chlorambucil,Cisplatin,Gemcitabine,Mitomycin C	Sensitivity/Response	D	16243825	Pancreas	Therapeutic	D
FANCC	MUT	oncogenic mutation	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
FANCL	MUT	any mutation	Myelodysplastic Syndrome in Blood/Bone Marrow			1	22720145,23613520,24220272	Blood;Bone_Marrow	Therapeutic	B
FAT1	MUT	oncogenic mutation	Head an neck squamous	[BET inhibitor]	Responsive	Pre-clinical	27397505	Head_and_Neck	Therapeutic	D
FBXW7	CNV	deletion	Any cancer type	[Tubulin inhibitor]	Resistant	Pre-clinical	21368834	Cancer	Therapeutic	D
FBXW7	CNV	deletion	Colorectal adenocarcinoma	Sirolimus	Responsive	Pre-clinical	23558291	Colorectal	Therapeutic	D
FBXW7	CNV	del	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FBXW7	CNV	loss	colon cancer	Sirolimus	sensitive	Preclinical	23558291	Colorectal	Therapeutic	D
FBXW7	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma/B Lymphoblastic Leukemia/Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	24166518,18485478,17646409,19109228,19794083,24113472,22150006	Blood;Bone_Marrow	Therapeutic	B
FBXW7	MUT	E192A	fibrolamellar carcinoma	Sirolimus	predicted - sensitive	Phase I	24586741	Liver	Therapeutic	C
FBXW7	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	AR-42	sensitive	Preclinical	23274910	Other	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Belinostat	sensitive	Preclinical	23274910	Other	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Docetaxel	resistant	Preclinical	23274910	Other	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Entinostat	sensitive	Preclinical	23274910	Other	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	breast cancer	Sirolimus	sensitive	Preclinical - Cell line xenograft	18787170	Breast	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	Cancer	Rapamycin (Sirolimus)	Sensitivity/Response	D	18787170	Cancer	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	hematologic cancer	AR-42	sensitive	Preclinical	23274910	Blood	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	hematologic cancer	Belinostat	sensitive	Preclinical	23274910	Blood	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	hematologic cancer	Entinostat	sensitive	Preclinical	23274910	Blood	Therapeutic	D
FBXW7	MUT	LOSS-OF-FUNCTION	Renal Cell Carcinoma	Everolimus	Sensitivity/Response	E	24253377	Kidney	Therapeutic	D
FBXW7	MUT	mutant	Her2-receptor negative breast cancer	LY3039478	predicted - sensitive	Phase I	30060061	Breast	Therapeutic	C
FBXW7	MUT	mutation	Cancer	MTOR Inhibitors	Sensitivity/Response	B	24586741	Cancer	Therapeutic	B
FBXW7	MUT	mutation	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	26508446	Colorectal	Therapeutic	B
FBXW7	MUT	oncogenic mutation	Acute lymphoblastic leukemia	[Steroid]	Responsive	Late trials	20861909	Blood;Bone_Marrow	Therapeutic	C
FBXW7	MUT	oncogenic mutation	Any cancer type	[Tubulin inhibitor]	Resistant	Pre-clinical	21368834	Cancer	Therapeutic	D
FBXW7	MUT	R465C	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FBXW7	MUT	R465H	lung adenocarcinoma	Temsirolimus	sensitive	Case Reports/Case Series	24360397	Lung	Therapeutic	D
FBXW7	MUT	R465H	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FBXW7	MUT	R479Q	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FBXW7	MUT	R505C	colorectal cancer	Regorafenib	resistant	Preclinical - Cell culture	27399335	Colorectal	Therapeutic	D
FBXW7	MUT	R505C	head and neck squamous cell carcinoma	Vorinostat	sensitive	Preclinical	23274910	Head_and_Neck	Therapeutic	D
FBXW7	MUT	R505C	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FBXW7	MUT	R505L	T-cell adult acute lymphocytic leukemia	MRK-003	resistant	Preclinical	17646409	Blood;Bone_Marrow	Therapeutic	D
FCGR2B	MUT	I232T	Breast Cancer		Poor Outcome	B	24989892	Breast	Prognostic	B
FGF13	MUT	CYTOPLASMIC EXPRESSION	Prostate Cancer		Poor Outcome	B	26891277	Prostate	Prognostic	B
FGF2	EXP	EXPRESSION	Acute Myeloid Leukemia	Quizartinib (AC220)	Resistance	D	27671675	Blood;Bone_Marrow	Therapeutic	D
FGF3	CNV	amplification	Breast adenocarcinoma	Dovitinib	Responsive	Early trials	23658459	Breast	Therapeutic	C
FGF3	CNV	amplification	Breast adenocarcinoma	Lucitanib	Responsive	Early trials	25193991	Breast	Therapeutic	C
FGF3	CNV	AMPLIFICATION	Breast Cancer	Dovitinib	Sensitivity/Response	B	23658459	Breast	Therapeutic	B
FGF4	CNV	amplification	Breast adenocarcinoma	Dovitinib	Responsive	Early trials	23658459	Breast	Therapeutic	C
FGF4	CNV	amplification	Breast adenocarcinoma	Lucitanib	Responsive	Early trials	25193991	Breast	Therapeutic	C
FGFR1	CNV	amplification	Breast adenocarcinoma	[Lucitanib]	Responsive	Early trials	25193991	Breast	Therapeutic	C
FGFR1	CNV	amplification	Endometrium	[FGFR inhibitor]	Responsive	Case report	ASCO 2017 (abstr 2500)	Uterus	Therapeutic	D
FGFR1	CNV	amplification	Head an neck	[FGFR inhibitor]	Responsive	Pre-clinical	23418312	Head_and_Neck	Therapeutic	D
FGFR1	CNV	amplification	Lung squamous cell	[FGFR inhibitor]	Responsive	Case report	27870574	Lung	Therapeutic	D
FGFR1	CNV	amplification	Lung squamous cell	[FGFR inhibitor]	Responsive	Early trials	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	Lung	Therapeutic	C
FGFR1	CNV	amp	adrenocortical carcinoma	Derazantinib	sensitive	Phase I	28972963	Adrenal_Gland	Therapeutic	C
FGFR1	CNV	amp	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR1	CNV	amp	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR1	CNV	amp	breast cancer	AZD4547	no benefit	Phase II	27179038	Breast	Therapeutic	C
FGFR1	CNV	amp	breast cancer	BGJ398	sensitive	Phase I	27870574	Breast	Therapeutic	C
FGFR1	CNV	amp	breast cancer	Ponatinib	sensitive	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Alpelisib	resistant	Preclinical - Cell culture	27126994	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Brivanib	no benefit	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Cediranib	sensitive	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Dovitinib	sensitive	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	E7090	sensitive	Preclinical - Cell culture	7506125;27535969	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Lucitanib	sensitive	Preclinical - Cell culture	27126994	Breast	Therapeutic	D
FGFR1	CNV	amp	estrogen-receptor mutation breast cancer	Nintedanib	sensitive	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	CNV	amp	Ewing sarcoma	Ponatinib	predicted - sensitive	Preclinical - Cell culture	26179511	Bone	Therapeutic	D
FGFR1	CNV	amp	Her2-receptor mutation breast cancer	Dovitinib	sensitive	Phase I	23658459	Breast	Therapeutic	C
FGFR1	CNV	amp	Her2-receptor negative breast cancer	Pazopanib	predicted - sensitive	Case Reports/Case Series	29223982	Breast	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Breast Cancer	4-hydroxytamoxifen	Resistance	D	20179196	Breast	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Breast Cancer	AZD4547	Sensitivity/Response	C	27179038	Breast	Therapeutic	C
FGFR1	CNV	AMPLIFICATION	Breast Cancer	Dovitinib	Sensitivity/Response	B	23658459	Breast	Therapeutic	B
FGFR1	CNV	AMPLIFICATION	Cancer		Poor Outcome	B	25171497	Cancer	Prognostic	B
FGFR1	CNV	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Ponatinib	Sensitivity/Response	D	22238366	Breast	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Ewing Sarcoma Of Bone	Ponatinib	Sensitivity/Response	D	26179511	Bone	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma		Better Outcome	B	23806793	Lung	Prognostic	B
FGFR1	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Dovitinib	Sensitivity/Response	B	27315356	Lung	Therapeutic	B
FGFR1	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	PD173074	Sensitivity/Response	D	21666749	Lung	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Lung Squamous Cell Carcinoma	BGJ398	Sensitivity/Response	B	27870574	Lung	Therapeutic	B
FGFR1	CNV	AMPLIFICATION	Lung Squamous Cell Carcinoma	PD173074	Sensitivity/Response	D	21160078	Lung	Therapeutic	D
FGFR1	CNV	AMPLIFICATION	Lung Squamous Cell Carcinoma		Poor Outcome	B	23182986	Lung	Prognostic	B
FGFR1	CNV	AMPLIFICATION	Lung Squamous Cell Carcinoma		Poor Outcome	B	25086725	Lung	Prognostic	B
FGFR1	CNV	amp	lung adenocarcinoma	PRN1371	sensitive	Preclinical - Pdx	28978721	Lung	Therapeutic	D
FGFR1	CNV	amp	lung cancer	AZD4547	sensitive	Preclinical	23082000	Lung	Therapeutic	D
FGFR1	CNV	amp	lung cancer	Brivanib	no benefit	Preclinical	22238366	Lung	Therapeutic	D
FGFR1	CNV	amp	lung cancer	Erdafitinib	predicted - sensitive	Preclinical - Cell line xenograft	28341788	Lung	Therapeutic	D
FGFR1	CNV	amp	lung cancer	GSK3052230	sensitive	Preclinical - Cell line xenograft	23536011	Lung	Therapeutic	D
FGFR1	CNV	amp	lung cancer	PD173074	sensitive	Preclinical - Cell culture	30140389	Lung	Therapeutic	D
FGFR1	CNV	amp	lung carcinoma	Lucitanib	sensitive	Preclinical - Cell line xenograft	27988457	Lung	Therapeutic	D
FGFR1	CNV	amp	lung large cell carcinoma	AZD4547	sensitive	Preclinical	23082000	Lung	Therapeutic	D
FGFR1	CNV	amp	lung large cell carcinoma	ODM-203	sensitive	Preclinical - Cell line xenograft	30301864	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	AZD4547	sensitive	Preclinical - Pdx	23082000	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	BGJ398	sensitive	Preclinical - Cell culture	28630215	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	BGJ398 + Trametinib	sensitive	Preclinical - Cell culture	28630215	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	Debio 1347	sensitive	Preclinical	25169980	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	E7090	sensitive	Preclinical - Cell line xenograft	27535969	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	GSK3052230	sensitive	Preclinical - Cell line xenograft	23536011	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	NGI-1	predicted - sensitive	Preclinical - Cell culture	27694802	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	PRN1371	sensitive	Preclinical - Pdx	28978721	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung non-small cell carcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	AZD4547 + Buparlisib	sensitive	Preclinical - Cell culture	28108151	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	AZD4547	sensitive	Preclinical	23082000	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	Cisplatin + Etoposide + GSK3052230	sensitive	Preclinical - Cell line xenograft	23536011	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	Debio 1347	sensitive	Preclinical	25169980	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	E7090	sensitive	Preclinical - Cell culture	27535969	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	GSK3052230	sensitive	Preclinical - Cell line xenograft	23536011	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung small cell carcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	AZD4547 + Buparlisib	sensitive	Preclinical - Cell culture	28108151	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	AZD4547	no benefit	Phase I	28615371	Lung	Therapeutic	C
FGFR1	CNV	amp	lung squamous cell carcinoma	BGJ398	sensitive	Phase I	27870574	Lung	Therapeutic	C
FGFR1	CNV	amp	lung squamous cell carcinoma	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	Dovitinib	no benefit	Phase II	27315356	Lung	Therapeutic	C
FGFR1	CNV	amp	lung squamous cell carcinoma	Ponatinib	sensitive	Preclinical	22238366	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	lung squamous cell carcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Lung	Therapeutic	D
FGFR1	CNV	amp	synovial sarcoma	AZD4547	sensitive	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	CNV	amp	synovial sarcoma	BGJ398	sensitive	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	CNV	amp	synovial sarcoma	PD173074	sensitive	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	CNV	amp	transitional cell carcinoma	AZD4547 + Buparlisib	sensitive	Preclinical - Cell culture	28108151	Bladder	Therapeutic	D
FGFR1	EXP	EXPRESSION	Bladder Carcinoma	Dovitinib,PD173074	Sensitivity/Response	D	21119661	Bladder	Therapeutic	D
FGFR1	EXP	EXPRESSION	Breast Cancer		Poor Outcome	B	26673008	Breast	Prognostic	B
FGFR1	EXP	EXPRESSION	Colorectal Cancer	BGJ398	Sensitivity/Response	D	24135816	Colorectal	Therapeutic	D
FGFR1	EXP	EXPRESSION	Gastric Adenocarcinoma	BGJ398	Sensitivity/Response	D	26637881	Stomach	Therapeutic	D
FGFR1	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	BGJ398	Sensitivity/Response	D	26015511	Head_and_Neck	Therapeutic	D
FGFR1	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	16454808	Head_and_Neck	Prognostic	B
FGFR1	EXP	EXPRESSION	Lung Cancer	Ponatinib	Sensitivity/Response	D	24771645	Lung	Therapeutic	D
FGFR1	EXP	EXPRESSION	Sarcoma	AZD4547,BGJ398,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Sensitivity/Response	D	27535980	Soft_Tissue	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Other	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	head and neck squamous cell carcinoma	BGJ398	sensitive	Preclinical	26015511	Head_and_Neck	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	thyroid cancer	Lenvatinib	sensitive	Preclinical	25295214	Thyroid	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	Uterus leiomyosarcoma	AZD4547	sensitive	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	Uterus leiomyosarcoma	BGJ398	sensitive	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	EXP	OVEREXPRESSION	Uterus leiomyosarcoma	PD173074	sensitive	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	FUS	FGFR1 FUSIONS	Chronic Myelomonocytic Leukemia		Negative	A	27069254	Blood;Bone_Marrow	Diagnostic	A
FGFR1	FUS	FGFR1 FUSIONS	Hematologic Cancer		Positive	A	27069254	Blood	Diagnostic	A
FGFR1	FUS	FGFR1OP2-FGFR1	Acute Myeloid Leukemia	Ponatinib	Sensitivity/Response	D	21482694	Blood;Bone_Marrow	Therapeutic	D
FGFR1	FUS	fusion	acute myeloid leukemia	Dovitinib	sensitive	Preclinical	17698633	Blood;Bone_Marrow	Therapeutic	D
FGFR1	FUS	fusion	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR1	FUS	fusion	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR1	FUS	fusion	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical	17698633	Other	Therapeutic	D
FGFR1	FUS	fusion	hematologic cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Blood	Therapeutic	D
FGFR1	FUS	ZNF198-FGFR1	Chronic Myeloproliferative Disease	Midostaurin	Sensitivity/Response	C	15448205	Blood;Bone_Marrow	Therapeutic	C
FGFR1	CNV	Amplification	Lung Squamous Cell Carcinoma	AZD4547, BGJ398, Erdafitinib, Debio1347	Response	3A	27870574, 23082000, 30745300	Lung	Therapeutic	C
FGFR1	CNV	copy number gain	Adenocarcinoma in Pancreas			2	23808822	Pancreas	Therapeutic	C
FGFR1	CNV	copy number gain	Invasive Ductal Carcinoma in Breast			1	20179196,25400686	Breast	Therapeutic	B
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Brivanib	no benefit	Preclinical	22238366	Other	Therapeutic	D
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Cediranib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Debio 1347	sensitive	Phase I	;	Other	Therapeutic	C
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Erdafitinib	sensitive	Phase I	26324363	Other	Therapeutic	C
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Nintedanib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR1	MUT	Gain-of-Function	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR1	MUT	Gain-of-Function	breast cancer	FIIN-1	sensitive	Preclinical	20338520	Breast	Therapeutic	D
FGFR1	MUT	mutant	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR1	MUT	mutant	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR1	MUT	mutant	Advanced Solid Tumor	Pemigatinib	sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
FGFR1	MUT	mutant	transitional cell carcinoma	Erdafitinib	predicted - sensitive	Phase II	;	Bladder	Therapeutic	C
FGFR1	MUT	mutation	head and neck squamous cell carcinoma	AZD4547 + Vistusertib	sensitive	Preclinical - Cell culture	26359452	Head_and_Neck	Therapeutic	D
FGFR1	MUT	mutation	hemangioma	Rogaratinib	predicted - sensitive	Phase I	;	Bone;Skin	Therapeutic	C
FGFR1	MUT	mutation	leiomyosarcoma	AZD4547	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	leiomyosarcoma	BGJ398	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	leiomyosarcoma	PD173074	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	lung adenocarcinoma	AZD4547 + AZD8055	sensitive	Preclinical - Cell culture	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	lung adenocarcinoma	AZD4547 + Sirolimus	sensitive	Preclinical - Cell culture	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	lung adenocarcinoma	AZD4547 + Vistusertib	sensitive	Preclinical - Cell line xenograft	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	lung large cell carcinoma	AZD4547 + AZD8055	sensitive	Preclinical - Cell culture	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	lung large cell carcinoma	AZD4547 + Sirolimus	sensitive	Preclinical - Cell culture	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	lung large cell carcinoma	AZD4547 + Vistusertib	sensitive	Preclinical - Cell line xenograft	26359452	Lung	Therapeutic	D
FGFR1	MUT	mutation	salivary gland adenoid cystic carcinoma	Rogaratinib	predicted - sensitive	Phase I	;	Esophagus	Therapeutic	C
FGFR1	MUT	mutation	synovial sarcoma	AZD4547	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	synovial sarcoma	BGJ398	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	synovial sarcoma	PD173074	decreased response	Preclinical - Cell culture	27535980	Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	Uterus leiomyosarcoma	AZD4547	decreased response	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	Uterus leiomyosarcoma	BGJ398	decreased response	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	MUT	mutation	Uterus leiomyosarcoma	PD173074	decreased response	Preclinical - Cell culture	27535980	Uterus;Soft_Tissue	Therapeutic	D
FGFR1	MUT	N546K	Ewing Sarcoma Of Bone	Ponatinib	Sensitivity/Response	E	26179511	Bone	Therapeutic	D
FGFR1	MUT	Oncogenic Mutations	All Solid Tumors	AZD4547, Erdafitinib, BGJ398, Debio1347	Response	4	26438159, 25169980, 27870574, 23082000, 31340094, 30745300	Other	Therapeutic	D
FGFR1	MUT	rearrange	leukemia	AZD4547	sensitive	Preclinical - Cell line xenograft	27550940	Blood;Bone_Marrow	Therapeutic	D
FGFR1	MUT	rearrange	lung small cell carcinoma	AZD4547	sensitive	Preclinical - Cell culture	27550940	Lung	Therapeutic	D
FGFR1	MUT	rearrange	myeloproliferative neoplasm	Dovitinib	sensitive	Preclinical	17698633	Blood;Bone_Marrow	Therapeutic	D
FGFR1	MUT	V561M	Advanced Solid Tumor	FIIN-1	sensitive	Preclinical	20338520	Other	Therapeutic	D
FGFR1	MUT	V561M	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR1	MUT	V561M	lung non-small cell carcinoma	AZD4547	resistant	Preclinical - Cell culture	30257990	Lung	Therapeutic	D
FGFR1	MUT	WILDTYPE	breast cancer	Ponatinib	resistant	Preclinical	22238366	Breast	Therapeutic	D
FGFR1	MUT	WILDTYPE	lung cancer	AZD4547	decreased response	Preclinical	23082000	Lung	Therapeutic	D
FGFR1-TACC1	FUS		malignant glioma	AZD4547	sensitive	Preclinical - Cell culture	22837387	Nervous_System	Therapeutic	D
FGFR1-TACC1	FUS		malignant glioma	BGJ398	sensitive	Preclinical - Cell culture	22837387	Nervous_System	Therapeutic	D
FGFR1-TACC1	FUS		malignant glioma	PD173074	sensitive	Preclinical - Cell culture	22837387	Nervous_System	Therapeutic	D
FGFR2-AFF3	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR2-AHCYL1	FUS		Advanced Solid Tumor	BGJ398	sensitive	Preclinical	24122810	Other	Therapeutic	D
FGFR2-AHCYL1	FUS		Advanced Solid Tumor	PD173074	sensitive	Preclinical	24122810	Other	Therapeutic	D
FGFR2-BICC1	FUS		Advanced Solid Tumor	BGJ398	sensitive	Preclinical	24122810	Other	Therapeutic	D
FGFR2-BICC1	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR2-BICC1	FUS		Advanced Solid Tumor	PD173074	sensitive	Preclinical	24122810	Other	Therapeutic	D
FGFR2-BICC1	FUS	FGFR2-CASP7	transitional cell carcinoma	Erdafitinib	predicted - sensitive	Case Reports/Case Series	26324363	Bladder	Therapeutic	D
FGFR2-BICC1	FUS	FGFR2-OFD1	endometrial cancer	Erdafitinib	predicted - sensitive	Case Reports/Case Series	26324363	Uterus	Therapeutic	D
FGFR2-CASP7	FUS		Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Other	Therapeutic	D
FGFR2-CASP7	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR2-CCDC6	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR2-CCDC6	FUS	FGFR3-TACC3	adrenal carcinoma	Erdafitinib	predicted - sensitive	Case Reports/Case Series	26324363	Adrenal_Gland	Therapeutic	D
FGFR2-CCDC6	FUS		liver cancer	PRN1371	sensitive	Preclinical - Pdx	28978721	Liver	Therapeutic	D
FGFR2	CNV	amplification	Breast adenocarcinoma	[FGFR inhibitor]	Responsive	Case report	25193991	Breast	Therapeutic	D
FGFR2	CNV	amplification	Stomach	[FGFR inhibitor]	Responsive	Early trials	ASCO 2015 (abstr 2508)	Stomach	Therapeutic	C
FGFR2	CNV	amp	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR2	CNV	amp	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR2	CNV	amp	breast cancer	AZD4547	sensitive	Preclinical - Cell culture	27550940	Breast	Therapeutic	D
FGFR2	CNV	amp	breast cancer	BGJ398	sensitive	Phase I	27870574	Breast	Therapeutic	C
FGFR2	CNV	amp	breast cancer	Debio 1347	sensitive	Case Reports/Case Series	30745300	Breast	Therapeutic	D
FGFR2	CNV	amp	breast cancer	Debio 1347	sensitive	Preclinical	25169980	Breast	Therapeutic	D
FGFR2	CNV	amp	breast cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Breast	Therapeutic	D
FGFR2	CNV	amp	breast cancer	Dovitinib	sensitive	Preclinical - Pdxcell culture	23658459	Breast	Therapeutic	D
FGFR2	CNV	amp	breast cancer	Ponatinib	sensitive	Preclinical	22238366	Breast	Therapeutic	D
FGFR2	CNV	amp -COL14A1	colon cancer	Derazantinib	sensitive	Preclinical - Cell line xenograft	27627808	Colorectal	Therapeutic	D
FGFR2	CNV	amp -COL14A1	colorectal adenocarcinoma	PRN1371	sensitive	Preclinical - Cell culture	28978721	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	AZD4547	sensitive	Preclinical - Cell culture	27550940	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	BGJ398	sensitive	Preclinical - Cell culture	27401245	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	Brivanib	no benefit	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	Cediranib	sensitive	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	Dovitinib	sensitive	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	Nintedanib	sensitive	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colon cancer	Ponatinib	sensitive	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colorectal adenocarcinoma	RO4987655	decreased response	Preclinical - Cell culture	26438159	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colorectal adenocarcinoma	RO5126766	predicted - sensitive	Preclinical - Cell culture	26438159	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colorectal adenocarcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colorectal cancer	Debio 1347	sensitive	Preclinical	25169980	Colorectal	Therapeutic	D
FGFR2	CNV	amp	colorectal cancer	Erdafitinib	sensitive	Preclinical - Cell line xenograft	28341788	Colorectal	Therapeutic	D
FGFR2	CNV	amp	endometrial cancer	AZD4547	sensitive	Preclinical - Cell line xenograft	27550940	Uterus	Therapeutic	D
FGFR2	CNV	amp	estrogen-receptor negative breast cancer	Brivanib	no benefit	Preclinical	22238366	Breast	Therapeutic	D
FGFR2	CNV	amp -GAB2	breast cancer	PRN1371	sensitive	Preclinical - Pdx	28978721	Breast	Therapeutic	D
FGFR2	CNV	amp	gastric adenocarcinoma	AZD4547	no benefit	Phase II	29177434	Stomach	Therapeutic	C
FGFR2	CNV	amp	gastric signet ring cell adenocarcinoma	M-COPA	sensitive	Preclinical - Cell culture	27197184	Stomach	Therapeutic	D
FGFR2	CNV	amp	Her2-receptor mutation breast cancer	Dovitinib	sensitive	Phase I	23658459	Breast	Therapeutic	C
FGFR2	CNV	AMPLIFICATION	Breast Cancer	Dovitinib	Sensitivity/Response	B	23658459	Breast	Therapeutic	B
FGFR2	CNV	AMPLIFICATION	Stomach Carcinoma	AZD4547	Sensitivity/Response	B	27179038	Stomach	Therapeutic	B
FGFR2	CNV	amp	lung non-small cell carcinoma	PRN1371	sensitive	Preclinical - Pdx	28978721	Lung	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	BGJ398	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	BGJ398 + Trabectedin	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	Dovitinib	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	Dovitinib + Trabectedin	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	PD173074	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	myxoid liposarcoma	PD173074 + Trabectedin	sensitive	Preclinical	26036639	Soft_Tissue	Therapeutic	D
FGFR2	CNV	amp	ovarian cancer	BAY1187982	sensitive	Preclinical - Pdx	27543601	Ovary	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	AZD4547	sensitive	Phase II	27179038	Stomach	Therapeutic	C
FGFR2	CNV	amp	stomach cancer	AZD4547	sensitive	Preclinical	22869148	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	BGJ398	sensitive	Preclinical	26036639	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Brivanib	no benefit	Preclinical	22238366	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Cediranib	sensitive	Preclinical	22238366	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Debio 1347	sensitive	Preclinical - Cell line xenograft	25169980	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Dovitinib	sensitive	Preclinical	22238366	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	E7090	sensitive	Preclinical - Cell line xenograft	27535969	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Erdafitinib	sensitive	Preclinical - Cell line xenograft	28341788	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	FIIN-1	sensitive	Preclinical	20338520	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Futibatinib	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
FGFR2	CNV	amp	stomach cancer	ODM-203	sensitive	Preclinical - Cell line xenograft	30301864	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	PD173074	sensitive	Preclinical - Cell culture	26036639	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	PD173074	sensitive	Preclinical - Cell culture	27179038	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Ponatinib	sensitive	Preclinical - Cell line xenograft	22238366	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	PRN1109	predicted - sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach cancer	Selumetinib	resistant	Preclinical	19755509	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach carcinoma	Debio 1347	sensitive	Preclinical - Cell line xenograft	26438159	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach carcinoma	PRN1371	sensitive	Preclinical - Cell line xenograft	28978721	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Stomach	Therapeutic	D
FGFR2	CNV	amp	stomach carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Stomach	Therapeutic	D
FGFR2	CNV	amp	uterine cancer	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Uterus	Therapeutic	D
FGFR2-DDX21	FUS		cholangiocarcinoma	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Bile_Duct	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell line xenograft	27627808	Other	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	breast cancer	AZ8010	sensitive	Preclinical	22869148	Breast	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	breast cancer	AZD4547	sensitive	Preclinical	22869148	Breast	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	breast cancer	PD173074	sensitive	Preclinical	22869148	Breast	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	colorectal cancer	BAY1187982	sensitive	Preclinical - Cell line xenograft	27543601	Colorectal	Therapeutic	D
FGFR2	EXP	OVEREXPRESSION	endometrial cancer	AZD4547	resistant	Preclinical - Cell culture	26294741	Uterus	Therapeutic	D
FGFR2	EXP	UNDEREXPRESSION	breast cancer	BAY1187982	resistant	Preclinical - Cell culture	27543601	Breast	Therapeutic	D
FGFR2-FAM76A	FUS		ovarian cancer	BGJ398	sensitive	Preclinical - Patient cell culture	24563622	Ovary	Therapeutic	D
FGFR2	FUS	- CIT	Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Other	Therapeutic	D
FGFR2	FUS	FGFR2-AHCYL1	Cholangiocarcinoma	BGJ398,PD173074	Sensitivity/Response	D	24122810	Bile_Duct	Therapeutic	D
FGFR2	FUS	FGFR2-AHCYL1	Cholangiocarcinoma		Positive	B	24122810	Bile_Duct	Diagnostic	B
FGFR2	FUS	FGFR2-BICC1	Cholangiocarcinoma	PD173074,BGJ398	Sensitivity/Response	D	24122810	Bile_Duct	Therapeutic	D
FGFR2	FUS	FGFR2-BICC1	Cholangiocarcinoma		Positive	B	24122810	Bile_Duct	Diagnostic	B
FGFR2	FUS	FGFR2-BICC1	Endometrial Cancer	JNJ-42756493	Sensitivity/Response	C	26324363	Uterus	Therapeutic	C
FGFR2	FUS	FGFR2-BICC1	Urothelial Carcinoma	JNJ-42756493	Sensitivity/Response	C	26324363	Bladder	Therapeutic	C
FGFR2	FUS	FGFR2 fusions	Cholangiocarcinoma	BGJ398	Sensitivity/Response	B	29182496	Bile_Duct	Therapeutic	B
FGFR2	FUS	FGFR2-MGEA5	Cholangiocarcinoma	Ponatinib	Sensitivity/Response	C	24550739	Bile_Duct	Therapeutic	C
FGFR2	FUS	FGFR2-TACC3	Cholangiocarcinoma	Ponatinib,Pazopanib	Sensitivity/Response	C	24550739	Bile_Duct	Therapeutic	C
FGFR2	FUS	fusion	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR2	FUS	fusion	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR2	FUS	fusion	biliary tract cancer	Futibatinib	predicted - sensitive	Phase I	;	Bile_Duct	Therapeutic	C
FGFR2	FUS	FUSION	Cancer	JNJ-42756493	Sensitivity/Response	B	26324363	Cancer	Therapeutic	B
FGFR2	FUS	fusion	cholangiocarcinoma	BGJ398	sensitive	Phase I	27870574	Bile_Duct	Therapeutic	C
FGFR2	FUS	FUSION	Cholangiocarcinoma	BGJ-398	Sensitivity/Response	C	27870574	Bile_Duct	Therapeutic	C
FGFR2	FUS	fusion	cholangiocarcinoma	Futibatinib	predicted - sensitive	Phase I	;	Bile_Duct	Therapeutic	C
FGFR2	FUS	fusion	intrahepatic cholangiocarcinoma	Derazantinib	sensitive	Phase I	;28972963	Bile_Duct	Therapeutic	C
FGFR2	FUS	- TACC3	Advanced Solid Tumor	BGJ398	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	FUS	- TACC3	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	FUS	V564F -BICC1	cholangiocarcinoma	BGJ398	predicted - resistant	Case Reports/Case Series	28034880	Bile_Duct	Therapeutic	D
FGFR2-INA	FUS		colon cancer	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Colorectal	Therapeutic	D
FGFR2-INA	FUS		intrahepatic cholangiocarcinoma	Debio 1347	sensitive	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-KIAA1217	FUS		cholangiocarcinoma	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Bile_Duct	Therapeutic	D
FGFR2-KIAA1217	FUS		intrahepatic cholangiocarcinoma	Futibatinib	sensitive	Preclinical - Pdx	31109923	Bile_Duct	Therapeutic	D
FGFR2	MUT	any mutation	Adenocarcinoma in Endometrium			2	26324363,25981814,25981814,25019571,20836672	Uterus	Therapeutic	C
FGFR2	MUT	E566G	Advanced Solid Tumor	Dovitinib	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	E566G	Advanced Solid Tumor	PD173074	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	E566G	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	E566G	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	E566G	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	F276C	intrahepatic cholangiocarcinoma	BGJ398	predicted - sensitive	Phase I	;	Bile_Duct	Therapeutic	C
FGFR2	MUT	FGFR2 mutation	Cholangiocarcinoma	BGJ398	Sensitivity/Response	B	29182496	Bile_Duct	Therapeutic	B
FGFR2	FUS	Fusions	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	27870574, 24122810, 30745300	Bladder	Therapeutic	C
FGFR2	FUS	Fusions	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR2	FUS	Fusions	Cholangiocarcinoma	AZD4547, BGJ398, Debio1347	Response	3A	29182496, 24122810, 30745300	Bile_Duct	Therapeutic	C
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Brivanib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Cediranib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Debio 1347	sensitive	Phase I	;	Other	Therapeutic	C
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Erdafitinib	sensitive	Phase I	26324363	Other	Therapeutic	C
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Nintedanib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR2	MUT	Gain-of-Function	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR2	MUT	Gain-of-Function	endometrial cancer	Dovitinib	sensitive	Preclinical - Cell line xenograft	23443805	Uterus	Therapeutic	D
FGFR2	MUT	Gain-of-Function	stomach carcinoma	S-49076	sensitive	Preclinical - Cell line xenograft	23804704	Stomach	Therapeutic	D
FGFR2	MUT	I548V	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	I548V	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	I548V	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	I548V	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	I548V	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	inframe insertion A266	Lung	[FGFR inhibitor]	Responsive	Pre-clinical	26048680	Lung	Therapeutic	D
FGFR2	MUT	inframe insertion S267	Lung	[FGFR inhibitor]	Responsive	Pre-clinical	26048680	Lung	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	BGJ398	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	Cediranib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	Dovitinib	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	Lenvatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	Pazopanib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	23908597	Other	Therapeutic	D
FGFR2	MUT	K660E	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721;	Other	Therapeutic	D
FGFR2	MUT	K660E	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	K660E	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	BGJ398	sensitive	Preclinical - Cell line xenograft	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	Cediranib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	Lenvatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	Pazopanib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	K660N	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721;	Other	Therapeutic	D
FGFR2	MUT	K660N	Lung squamous cell	[FGFR inhibitor]	Responsive	Pre-clinical	23786770;25035393	Lung	Therapeutic	D
FGFR2	MUT	L618M	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	L618M	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	L618M	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	L618M	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	L618M	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	M536I	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M536I	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M536I	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M536I	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	M536I	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	M538I	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M538I	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M538I	Advanced Solid Tumor	Ponatinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	M538I	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	M538I	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	mutant	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR2	MUT	mutant	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR2	MUT	mutant	Advanced Solid Tumor	Pemigatinib	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
FGFR2	MUT	mutant	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - Has Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR2	MUT	mutant	bladder urothelial carcinoma	Erdafitinib	sensitive	Guideline	;	Bladder	Therapeutic	A
FGFR2	MUT	mutant	cholangiocarcinoma	BGJ398	sensitive	Phase I	27870574	Bile_Duct	Therapeutic	C
FGFR2	MUT	mutant	endometrial cancer	BGJ398	sensitive	Preclinical	23443805	Uterus	Therapeutic	D
FGFR2	MUT	mutant	endometrial cancer	PRN1371	sensitive	Preclinical - Cell culture	;	Uterus	Therapeutic	D
FGFR2	MUT	mutant	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - Has Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR2	MUT	mutant	transitional cell carcinoma	Erdafitinib	sensitive	Guideline	;	Bladder	Therapeutic	A
FGFR2	MUT	mutation	Advanced Solid Tumor	BAY1187982	sensitive	Preclinical - Pdxcell culture	27543601	Other	Therapeutic	D
FGFR2	MUT	mutation	breast cancer	BAY1187982	sensitive	Preclinical - Pdxcell culture	27543601	Breast	Therapeutic	D
FGFR2	MUT	mutation	breast cancer	Rogaratinib	predicted - sensitive	Phase I	;	Breast	Therapeutic	C
FGFR2	MUT	mutation	Cholangiocarcinoma	BGJ-398	Sensitivity/Response	C	27870574	Bile_Duct	Therapeutic	C
FGFR2	MUT	mutation	Endometrial Cancer	Ponatinib	Sensitivity/Response	D	26574622	Uterus	Therapeutic	D
FGFR2	MUT	mutation	stomach cancer	BAY1187982	sensitive	Preclinical - Pdxcell culture	27543601	Stomach	Therapeutic	D
FGFR2	MUT	N549K	endometrial adenocarcinoma	PRN1371	sensitive	Preclinical - Cell culture	28978721	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Brivanib	no benefit	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Cediranib	sensitive	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Debio 1347	sensitive	Preclinical	25169980	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Dovitinib	decreased response	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Nintedanib	resistant	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial cancer	Ponatinib	sensitive	Preclinical - Cell line xenograft	22238366	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial carcinoma	FIIN-1	sensitive	Preclinical	20338520	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	N549K	endometrial carcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	N550	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	N550	Endometrium	Ponatinib	Responsive	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	N550H	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550H	Advanced Solid Tumor	PD173074	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550H	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550K	Advanced Solid Tumor	Dovitinib	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550K	Advanced Solid Tumor	PD173074	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550K	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550K	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR2	MUT	N550K	endometrial cancer	AZD4547	decreased response	Preclinical - Cell culture	26294741	Uterus	Therapeutic	D
FGFR2	MUT	N550K	Endometrial Cancer	PD173074	Sensitivity/Response	D	18757403	Uterus	Therapeutic	D
FGFR2	MUT	N550K	Endometrium	[FGFR inhibitor]	Responsive	Pre-clinical	18552176;22238366;23002168	Uterus	Therapeutic	D
FGFR2	MUT	N550S	Advanced Solid Tumor	Dovitinib	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550S	Advanced Solid Tumor	PD173074	decreased response	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	N550S	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	Oncogenic Mutations	All Solid Tumors	AZD4547, Erdafitinib, BGJ398, Debio1347	Response	4	26438159, 25169980, 27870574, 23082000, 31340094, 30745300	Other	Therapeutic	D
FGFR2	MUT	P253R	head and neck squamous cell carcinoma	Pazopanib	predicted - sensitive	Case Reports/Case Series	23786770	Head_and_Neck	Therapeutic	D
FGFR2	MUT	P253R	Invasive Ductal Carcinoma/Lobular Carcinoma in Breast			2	19706770,22273505,18552176,17529967,PharmGKB	Breast	Therapeutic	C
FGFR2	MUT	rearrange	cholangiocarcinoma	Futibatinib	predicted - sensitive	Phase I	;	Bile_Duct	Therapeutic	C
FGFR2	MUT	rearrange	cholangiocarcinoma	Pemigatinib	resistant	Phase II	;	Bile_Duct	Therapeutic	C
FGFR2	MUT	S252W	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	AZD4547	decreased response	Preclinical - Cell culture	26294741	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Brivanib	sensitive	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Cediranib	sensitive	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Debio 1347	sensitive	Preclinical - Cell line xenograft	25169980	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Dovitinib	decreased response	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	E7090	sensitive	Preclinical - Cell culture	18552176;27535969	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Nintedanib	sensitive	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial cancer	Ponatinib	sensitive	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial carcinoma	GSK3052230	sensitive	Preclinical - Cell line xenograft	23536011	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial carcinoma	RO4987655	decreased response	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial carcinoma	RO5126766	sensitive	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	S252W	endometrial carcinoma	Selumetinib	decreased response	Preclinical - Cell culture	26438159	Uterus	Therapeutic	D
FGFR2	MUT	S252W	Endometrium	[FGFR inhibitor]	Responsive	Pre-clinical	18552176;22238366;23002168	Uterus	Therapeutic	D
FGFR2	MUT	S267_D273dup	Advanced Solid Tumor	BGJ398	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	MUT	S267_D273dup	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	MUT	S320C	Lung squamous cell	[FGFR inhibitor]	Responsive	Pre-clinical	23786770;25035393	Lung	Therapeutic	D
FGFR2	MUT	V564F	Advanced Solid Tumor	AZD4547	resistant	Preclinical - Cell line xenograft	25169980	Other	Therapeutic	D
FGFR2	MUT	V564F	Advanced Solid Tumor	BGJ398	resistant	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR2	MUT	V564F	Advanced Solid Tumor	Debio 1347	sensitive	Preclinical - Cell line xenograft	25169980	Other	Therapeutic	D
FGFR2	MUT	V564I	Advanced Solid Tumor	Debio 1347	resistant	Preclinical - Cell culture	25169980	Other	Therapeutic	D
FGFR2	MUT	V564L	Advanced Solid Tumor	Debio 1347	resistant	Preclinical - Cell culture	25169980	Other	Therapeutic	D
FGFR2	MUT	V565I	Advanced Solid Tumor	Dovitinib	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	V565I	Advanced Solid Tumor	PD173074	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	V565I	Advanced Solid Tumor	Ponatinib	resistant	Preclinical	23908597	Other	Therapeutic	D
FGFR2	MUT	V565I	Endometrium	Dovitinib	Resistant	Pre-clinical	23908597	Uterus	Therapeutic	D
FGFR2	MUT	V565I	Endometrium	[FGFR inhibitor]	Responsive	Pre-clinical	ENA 2014 (abstr 381)	Uterus	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	BGJ398	sensitive	Preclinical - Cell line xenograft	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	Cediranib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	Lenvatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	Pazopanib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR2	MUT	W290C	Lung squamous cell	[FGFR inhibitor]	Responsive	Pre-clinical	23786770;25035393	Lung	Therapeutic	D
FGFR2	MUT	W290delinsWC	Advanced Solid Tumor	BGJ398	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	MUT	W290delinsWC	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	26048680	Other	Therapeutic	D
FGFR2	MUT	WILDTYPE	Advanced Solid Tumor	AZ6089	predicted - sensitive	Preclinical	22869148	Other	Therapeutic	D
FGFR2	MUT	WILDTYPE	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	;	Other	Therapeutic	D
FGFR2	MUT	WILDTYPE	breast cancer	Ponatinib	resistant	Preclinical	22238366	Breast	Therapeutic	D
FGFR2	MUT	WILDTYPE	colon cancer	Ponatinib	resistant	Preclinical	22238366	Colorectal	Therapeutic	D
FGFR2	MUT	WILDTYPE	endometrial cancer	AZD4547	resistant	Preclinical - Cell culture	26294741	Uterus	Therapeutic	D
FGFR2	MUT	WILDTYPE	endometrial cancer	Ponatinib	resistant	Preclinical	22238366	Uterus	Therapeutic	D
FGFR2	MUT	WILDTYPE	endometrial carcinoma	FIIN-1	resistant	Preclinical	20338520	Uterus	Therapeutic	D
FGFR2	MUT	WILDTYPE	stomach cancer	Ponatinib	resistant	Preclinical	22238366	Stomach	Therapeutic	D
FGFR2-NRAP	FUS	FGFR2 N550K	intrahepatic cholangiocarcinoma	Futibatinib	resistant	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-NRAP	FUS		intrahepatic cholangiocarcinoma	BGJ398	sensitive	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-NRAP	FUS		intrahepatic cholangiocarcinoma	Futibatinib	sensitive	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-OFD1	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR2-ROCK1	FUS		cholangiocarcinoma	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Bile_Duct	Therapeutic	D
FGFR2-SORBS1	FUS	FGFR2 V565F	intrahepatic cholangiocarcinoma	Futibatinib	resistant	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-SORBS1	FUS		intrahepatic cholangiocarcinoma	BGJ398	sensitive	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-TNS1	FUS		triple-receptor negative breast cancer	BGJ398 + Buparlisib	sensitive	Preclinical - Cell line xenograft	29203461	Breast	Therapeutic	D
FGFR2-TNS1	FUS		triple-receptor negative breast cancer	BGJ398	sensitive	Preclinical - Cell line xenograft	29203461	Breast	Therapeutic	D
FGFR2-TNS1	FUS		triple-receptor negative breast cancer	Buparlisib	no benefit	Preclinical - Cell line xenograft	29203461	Breast	Therapeutic	D
FGFR2-ZMYM4	FUS	FGFR2 V563L	intrahepatic cholangiocarcinoma	Futibatinib	resistant	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR2-ZMYM4	FUS		intrahepatic cholangiocarcinoma	BGJ398	sensitive	Case Reports/Case Series	31109923	Bile_Duct	Therapeutic	D
FGFR3-BAIAP2L1	FUS		Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Other	Therapeutic	D
FGFR3-BAIAP2L1	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	28416604	Other	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	ASP5878	sensitive	Preclinical - Cell culture	;	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	AZD4547	sensitive	Preclinical - Cell culture	25589496	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	BGJ398	sensitive	Preclinical - Cell culture	25589496	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	Cediranib	sensitive	Preclinical - Cell culture	25589496	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	Debio 1347	sensitive	Preclinical - Cell culture	25169980	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	Debio 1347	sensitive	Preclinical - Cell line xenograft	25589496	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	Dovitinib	sensitive	Preclinical - Cell culture	25589496	Bladder	Therapeutic	D
FGFR3-BAIAP2L1	FUS		urinary bladder cancer	PD173074	sensitive	Preclinical - Cell culture	25589496	Bladder	Therapeutic	D
FGFR3	CNV	amp	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR3	CNV	amp	Advanced Solid Tumor	BGJ398	predicted - sensitive	Phase I	;	Other	Therapeutic	C
FGFR3	CNV	amp	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR3	CNV	amp	Advanced Solid Tumor	Ponatinib	predicted - sensitive	Preclinical	;	Other	Therapeutic	D
FGFR3	CNV	amp	lung non-small cell carcinoma	PRN1371	sensitive	Preclinical - Pdx	28978721	Lung	Therapeutic	D
FGFR3	CNV	amp	urinary system cancer	AZD4547	sensitive	Preclinical - Cell culture	27401245	Bladder	Therapeutic	D
FGFR3	CNV	amp	urinary system cancer	BGJ398	sensitive	Preclinical - Cell culture	27401245	Bladder	Therapeutic	D
FGFR3	EXP	EXPRESSION	Bladder Carcinoma	Dovitinib,PD173074,SU-5402	Sensitivity/Response	D	21119661	Bladder	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	Advanced Solid Tumor	LY2874455	sensitive	Preclinical	21900693	Other	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	glioblastoma multiforme	U0126	sensitive	Preclinical	23298836	Brain	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	head and neck squamous cell carcinoma	Rogaratinib	sensitive	Preclinical	;	Head_and_Neck	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	multiple myeloma	MFGR1877S	sensitive	Phase I	;	Bone_Marrow	Therapeutic	C
FGFR3	EXP	OVEREXPRESSION	transitional cell carcinoma	AZ8010	sensitive	Preclinical	22869148	Bladder	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	transitional cell carcinoma	AZD4547	sensitive	Preclinical	22869148	Bladder	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	urinary bladder cancer	BEZ235 + Sorafenib	sensitive	Preclinical - Pdx	26270481	Bladder	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	urinary bladder cancer	BGJ398	sensitive	Preclinical - Pdx	26270481	Bladder	Therapeutic	D
FGFR3	EXP	OVEREXPRESSION	urinary bladder cancer	Dovitinib	sensitive	Phase II	;	Bladder	Therapeutic	C
FGFR3	EXP	OVEREXPRESSION	urinary bladder cancer	SU5402	sensitive	Preclinical	21119661	Bladder	Therapeutic	D
FGFR3	FUS	FGFR3-BAIAP2L1	Bladder Carcinoma	PD173074	Sensitivity/Response	D	23558953	Bladder	Therapeutic	D
FGFR3	FUS	FGFR3-TACC3	Cancer	JNJ-42756493	Sensitivity/Response	B	26324363	Cancer	Therapeutic	B
FGFR3	FUS	FGFR3-TACC3	Urothelial Carcinoma	BGJ398	Sensitivity/Response	B	29848605	Bladder	Therapeutic	B
FGFR3	FUS	fusion	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR3	FUS	fusion	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR3	FUS	fusion	Advanced Solid Tumor	Futibatinib	predicted - sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
FGFR3	FUS	fusion	transitional cell carcinoma	B-701 + Docetaxel	predicted - sensitive	Phase Ib/II	;	Bladder	Therapeutic	C
FGFR3	FUS	fusion	transitional cell carcinoma	BGJ398	sensitive	Phase I	;	Bladder	Therapeutic	C
FGFR3	FUS	fusion	urinary bladder cancer	AZD4547	sensitive	Preclinical - Cell culture	27550940	Bladder	Therapeutic	D
FGFR3	MUT	D764H	head and neck squamous cell carcinoma	BGJ398	no benefit	Preclinical - Cell culture	27053219	Head_and_Neck	Therapeutic	D
FGFR3	MUT	D788N	head and neck squamous cell carcinoma	BGJ398	no benefit	Preclinical - Cell culture	27053219	Head_and_Neck	Therapeutic	D
FGFR3	MUT	F386L	myeloid neoplasm	Debio 1347	sensitive	Preclinical	25169980	Blood;Bone_Marrow	Therapeutic	D
FGFR3	FUS	Fusions	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	29848605, 22837387, 30745300	Bladder	Therapeutic	C
FGFR3	FUS	Fusions	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR3	MUT	G370C	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	21119661, 29848605, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	G370C	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR3	MUT	G370C	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	G370C	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	G372C	Advanced Solid Tumor	R3Mab	sensitive	Preclinical - Cell culture	19381019	Other	Therapeutic	D
FGFR3	MUT	G380R	Bladder Cancer	AZD4547, BGJ398, Erdafitinib, Debio1347	Response	3A	21119661, 29848605, 26324363, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	G691R	Lung adenocarcinoma	[FGFR inhibitor]	Responsive	Pre-clinical	27998968	Lung	Therapeutic	D
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Brivanib	no benefit	Preclinical	22238366	Other	Therapeutic	D
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Cediranib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Debio 1347	sensitive	Phase I	;	Other	Therapeutic	C
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Erdafitinib	sensitive	Phase I	26324363	Other	Therapeutic	C
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Nintedanib	decreased response	Preclinical	22238366	Other	Therapeutic	D
FGFR3	MUT	Gain-of-Function	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	22238366	Other	Therapeutic	D
FGFR3	MUT	Gain-of-Function	urinary bladder cancer	S-49076	predicted - sensitive	Preclinical	23804704	Bladder	Therapeutic	D
FGFR3	MUT	K650	Bladder Cancer	AZD4547, BGJ398, Erdafitinib, Debio1347	Response	3A	21119661, 29848605, 26324363, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	K650E	Advanced Solid Tumor	AZD4547	decreased response	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	BGJ398	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	Debio 1347	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	FIIN-2	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	LY2874455	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	PD98059	sensitive	Preclinical	14534538	Other	Therapeutic	D
FGFR3	MUT	K650E	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	K650E	myeloid neoplasm	Debio 1347	sensitive	Preclinical	25169980	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	K650E	myeloid neoplasm	SSR128129E	no benefit	Preclinical	23597562	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	K650E	myeloid neoplasm	SU5402	sensitive	Preclinical - Cell culture	23597562	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	K650M	Advanced Solid Tumor	PRN1371	sensitive	Preclinical - Cell culture	28978721	Other	Therapeutic	D
FGFR3	MUT	K650	Myeloma	Bortezomib	Responsive	Pre-clinical	19331127;21273588	Bone_Marrow	Therapeutic	D
FGFR3	MUT	K650	Myeloma	[FGFR inhibitor]	Responsive	Pre-clinical	16091734;20439987;22869148	Bone_Marrow	Therapeutic	D
FGFR3	MUT	K652E	Advanced Solid Tumor	R3Mab	sensitive	Preclinical - Cell culture	19381019	Other	Therapeutic	D
FGFR3	MUT	K652E	urinary bladder cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Bladder	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	AZD4547	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	BGJ398	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	Debio 1347	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	FIIN-2	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	LY2874455	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	L608V	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	mutant	Advanced Solid Tumor	AZD4547	predicted - sensitive	Phase II	;	Other	Therapeutic	C
FGFR3	MUT	mutant	Advanced Solid Tumor	BGJ398	sensitive	Preclinical	23002168	Other	Therapeutic	D
FGFR3	MUT	mutant	Advanced Solid Tumor	Debio 1347	predicted - sensitive	Phase I	30745300	Other	Therapeutic	C
FGFR3	MUT	mutant	Advanced Solid Tumor	Pemigatinib	sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
FGFR3	MUT	mutant	bladder urothelial carcinoma	BGJ398	sensitive	Phase I	27870574	Bladder	Therapeutic	C
FGFR3	MUT	mutant	bladder urothelial carcinoma	Dovitinib	sensitive	Phase II	27932416	Bladder	Therapeutic	C
FGFR3	MUT	mutant	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - Has Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	mutant	bladder urothelial carcinoma	Erdafitinib	sensitive	Guideline	;	Bladder	Therapeutic	A
FGFR3	MUT	mutant	transitional cell carcinoma	B-701 + Docetaxel	predicted - sensitive	Phase Ib/II	;	Bladder	Therapeutic	C
FGFR3	MUT	mutant	transitional cell carcinoma	BGJ398	sensitive	Clinical Study	29848605	Bladder	Therapeutic	C
FGFR3	MUT	mutant	transitional cell carcinoma	BGJ398	sensitive	Phase I	;	Bladder	Therapeutic	C
FGFR3	MUT	mutant	transitional cell carcinoma	Erdafitinib	sensitive	Case Reports/Case Series	26324363	Bladder	Therapeutic	D
FGFR3	MUT	mutant	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - Has Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	mutant	transitional cell carcinoma	Erdafitinib	sensitive	Guideline	;	Bladder	Therapeutic	A
FGFR3	MUT	mutant	urinary bladder cancer	AZD4547	sensitive	Preclinical - Cell culture	27550940	Bladder	Therapeutic	D
FGFR3	MUT	mutation	Bladder Carcinoma	BGJ-398	Sensitivity/Response	B	27870574	Bladder	Therapeutic	B
FGFR3	MUT	mutation	head and neck squamous cell carcinoma	Rogaratinib	predicted - sensitive	Phase I	;	Head_and_Neck	Therapeutic	C
FGFR3	MUT	mutation	lung adenocarcinoma	Rogaratinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
FGFR3	MUT	mutation	lung squamous cell carcinoma	Rogaratinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
FGFR3	MUT	mutation	stomach cancer	Rogaratinib	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
FGFR3	MUT	N540K	Advanced Solid Tumor	AZD4547	resistant	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	BGJ398	resistant	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	Debio 1347	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	FIIN-2	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	LY2874455	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	N540K	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	oncogenic mutation	Bladder	[FGFR inhibitor]	Responsive	Early trials	27870574	Bladder	Therapeutic	C
FGFR3	MUT	Oncogenic Mutations	All Solid Tumors	AZD4547, Erdafitinib, BGJ398, Debio1347	Response	4	26438159, 21119661, 29848605, 26324363, 25169980, 27870574, 23082000, 31340094, 30745300	Other	Therapeutic	D
FGFR3	MUT	R248C	Advanced Solid Tumor	BGJ398	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	R248C	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	R248C	Advanced Solid Tumor	Pazopanib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	R248C	Advanced Solid Tumor	R3Mab	sensitive	Preclinical - Cell culture	19381019	Other	Therapeutic	D
FGFR3	MUT	R248C	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	21119661, 29848605, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	R248C	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR3	MUT	R248C	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	R248C	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	31340094;;	Bladder	Therapeutic	A
FGFR3	MUT	rearrange	myeloid neoplasm	AZD4547	sensitive	Preclinical - Cell line xenograft	27550940	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	rearrange	myeloid neoplasm	PRN1371	sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	S131L	head and neck squamous cell carcinoma	BGJ398	decreased response	Preclinical - Cell culture	27053219	Head_and_Neck	Therapeutic	D
FGFR3	MUT	S249C	Advanced Solid Tumor	BGJ398	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	S249C	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	S249C	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	23786770	Other	Therapeutic	D
FGFR3	MUT	S249C	Advanced Solid Tumor	R3Mab	sensitive	Preclinical - Cell culture	19381019	Other	Therapeutic	D
FGFR3	MUT	S249C	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	21119661, 29848605, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	S249C	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR3	MUT	S249C	bladder carcinoma	R3Mab	sensitive	Preclinical - Cell line xenograft	19381019	Bladder	Therapeutic	D
FGFR3	MUT	S249C	bladder urothelial carcinoma	Dovitinib	sensitive	Phase II	27932416	Bladder	Therapeutic	C
FGFR3	MUT	S249C	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	S249C	Lung adenocarcinoma	[FGFR inhibitor]	Responsive	Pre-clinical	27998968	Lung	Therapeutic	D
FGFR3	MUT	S249C	renal pelvis transitional cell carcinoma	Pazopanib	predicted - sensitive	Clinical Study	27271022	Kidney	Therapeutic	C
FGFR3	MUT	S249C	renal pelvis transitional cell carcinoma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Kidney	Therapeutic	D
FGFR3	MUT	S249C	renal pelvis transitional cell carcinoma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Kidney	Therapeutic	D
FGFR3	MUT	S249C	renal pelvis transitional cell carcinoma	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Kidney	Therapeutic	D
FGFR3	MUT	S249C	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	S249C	urinary bladder cancer	ASP5878	sensitive	Preclinical - Cell line xenograft	;	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Brivanib	no benefit	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Cediranib	sensitive	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Debio 1347	sensitive	Preclinical - Cell line xenograft	25169980	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Dovitinib	sensitive	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Nintedanib	resistant	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary bladder cancer	Ponatinib	sensitive	Preclinical - Cell line xenograft	22238366	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary system cancer	AZD4547	sensitive	Preclinical - Cell line xenograft	27401245	Bladder	Therapeutic	D
FGFR3	MUT	S249C	urinary system cancer	BGJ398	sensitive	Preclinical - Cell culture	27401245	Bladder	Therapeutic	D
FGFR3	MUT	S249C	Urothelial Carcinoma	Pazopanib	Sensitivity/Response	C	25766722	Bladder	Therapeutic	C
FGFR3	MUT	S371C	Bladder Cancer	AZD4547, BGJ398, Erdafitinib, Debio1347	Response	3A	21119661, 29848605, 26324363, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	V555L	Advanced Solid Tumor	BGJ398	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555L	transitional cell carcinoma	BGJ398	resistant	Case Reports/Case Series	29848605	Bladder	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	AZD4547	resistant	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	BGJ398	resistant	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	Debio 1347	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	Dovitinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	FIIN-2	decreased response	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	LY2874455	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell culture	28034880	Other	Therapeutic	D
FGFR3	MUT	V555M	Myeloma	[FGFR inhibitor]	Resistant	Pre-clinical	22869148	Bone_Marrow	Therapeutic	D
FGFR3	MUT	V555M	transitional cell carcinoma	BGJ398	resistant	Case Reports/Case Series	29848605	Bladder	Therapeutic	D
FGFR3	MUT	WILDTYPE	bladder carcinoma	R3Mab	sensitive	Preclinical - Cell line xenograft	19381019	Bladder	Therapeutic	D
FGFR3	MUT	WILDTYPE	myeloid neoplasm	SSR128129E	sensitive	Preclinical	23597562	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	WILDTYPE	myeloid neoplasm	SU5402	sensitive	Preclinical - Cell culture	23597562	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	WILDTYPE	urinary bladder cancer	Ponatinib	resistant	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	Y373C	Bladder Cancer	AZD4547, BGJ398, Debio1347	Response	3A	21119661, 29848605, 27870574, 30745300	Bladder	Therapeutic	C
FGFR3	MUT	Y373C	Bladder Cancer	Erdafitinib	Response	1	26324363, 31340094	Bladder	Therapeutic	A
FGFR3	MUT	Y373C	bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	Y373C	Carcinoma/Urothelial Carcinoma in Bladder			2	21072204,22869148,11429702	Bladder	Therapeutic	C
FGFR3	MUT	Y373C	multiple myeloma	E7090	sensitive	Preclinical - Cell culture	19901323;27535969	Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	myeloid neoplasm	Debio 1347	sensitive	Preclinical	25169980	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	myeloid neoplasm	RO4987655	no benefit	Preclinical - Cell culture	26438159	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	myeloid neoplasm	RO5126766	no benefit	Preclinical - Cell culture	26438159	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	myeloid neoplasm	Selumetinib	no benefit	Preclinical - Cell culture	26438159	Blood;Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	Myeloma	Bortezomib	Resistant	Pre-clinical	19331127;21273588	Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	Myeloma	[FGFR inhibitor]	Responsive	Pre-clinical	16091734;20439987;22869148	Bone_Marrow	Therapeutic	D
FGFR3	MUT	Y373C	transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3	MUT	Y375C	Advanced Solid Tumor	R3Mab	sensitive	Preclinical - Cell culture	19381019	Other	Therapeutic	D
FGFR3	MUT	Y375C	Bladder Carcinoma		Positive	B	20542753	Bladder	Diagnostic	B
FGFR3	MUT	Y375C	urinary bladder cancer	Brivanib	no benefit	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	Y375C	urinary bladder cancer	Cediranib	resistant	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	Y375C	urinary bladder cancer	Dovitinib	sensitive	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	Y375C	urinary bladder cancer	Nintedanib	resistant	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3	MUT	Y375C	urinary bladder cancer	Ponatinib	sensitive	Preclinical	22238366	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		Advanced Solid Tumor	AZD4547	sensitive	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3-TACC3	FUS		Advanced Solid Tumor	Erdafitinib	sensitive	Preclinical - Cell culture	26992226	Other	Therapeutic	D
FGFR3-TACC3	FUS		bladder transitional cell papilloma	RO4987655	no benefit	Preclinical - Cell culture	26438159	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		bladder transitional cell papilloma	RO5126766	no benefit	Preclinical - Cell culture	26438159	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		bladder urothelial carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3-TACC3	FUS		bladder urothelial carcinoma	PRN1371	sensitive	Preclinical - Cell line xenograft	28978721	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		cervical squamous cell carcinoma	AZD4547	predicted - sensitive	Phase II	;	Cervix	Therapeutic	C
FGFR3-TACC3	FUS		gallbladder cancer	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		glioblastoma multiforme	Erdafitinib	predicted - sensitive	Case Reports/Case Series	25609060	Brain	Therapeutic	D
FGFR3-TACC3	FUS		glioblastoma multiforme	Erdafitinib	predicted - sensitive	Case Reports/Case Series	26324363	Brain	Therapeutic	D
FGFR3-TACC3	FUS		glioblastoma multiforme	U0126	sensitive	Preclinical	23298836	Brain	Therapeutic	D
FGFR3-TACC3	FUS		lung adenocarcinoma	BGJ398	sensitive	Preclinical	25294908	Lung	Therapeutic	D
FGFR3-TACC3	FUS		lung adenocarcinoma	Ponatinib	sensitive	Preclinical	25294908	Lung	Therapeutic	D
FGFR3-TACC3	FUS		lung non-small cell carcinoma	Erdafitinib	sensitive	Preclinical - Pdx	28341788	Lung	Therapeutic	D
FGFR3-TACC3	FUS		malignant glioma	AZD4547	sensitive	Preclinical - Cell culture	22837387	Nervous_System	Therapeutic	D
FGFR3-TACC3	FUS		malignant glioma	BGJ398	sensitive	Preclinical - Cell culture	22837387	Nervous_System	Therapeutic	D
FGFR3-TACC3	FUS		malignant glioma	Erdafitinib	sensitive	Preclinical - Cell line xenograft	25609060	Nervous_System	Therapeutic	D
FGFR3-TACC3	FUS		malignant glioma	PD173074	sensitive	Preclinical - Cell line xenograft	22837387	Nervous_System	Therapeutic	D
FGFR3-TACC3	FUS		oligodendroglioma	PRN1371	sensitive	Preclinical - Pdx	28978721	Nervous_System	Therapeutic	D
FGFR3-TACC3	FUS		transitional cell carcinoma	Alpelisib + BGJ398	predicted - sensitive	Phase I	;	Bladder	Therapeutic	C
FGFR3-TACC3	FUS		transitional cell carcinoma	AZD4547 + Buparlisib	sensitive	Preclinical - Cell line xenograft	28108151	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		transitional cell carcinoma	AZD4547	predicted - sensitive	Phase II	;	Bladder	Therapeutic	C
FGFR3-TACC3	FUS		transitional cell carcinoma	Debio 1347	predicted - sensitive	Case Reports/Case Series	30745300	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		transitional cell carcinoma	Erdafitinib	sensitive	Case Reports/Case Series	26324363	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		transitional cell carcinoma	Erdafitinib	sensitive	FDA approved - On Companion Diagnostic	;31340094;	Bladder	Therapeutic	A
FGFR3-TACC3	FUS		urinary bladder cancer	ASP5878	sensitive	Preclinical - Cell line xenograft	;	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	AZ8010	sensitive	Preclinical	22869148;23175443	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Debio 1347	sensitive	Preclinical - Cell line xenograft	25169980	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Dovitinib	sensitive	Preclinical	23175443;24325461	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	E7090	sensitive	Preclinical - Cell line xenograft	27535969	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Erdafitinib	predicted - sensitive	Case Reports/Case Series	28416604	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	FIIN-1	sensitive	Preclinical	23175443;20338520	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	LY2874455	sensitive	Preclinical	21900693;23175443	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	ODM-203	sensitive	Preclinical - Cell line xenograft	30301864	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Pazopanib	sensitive	Preclinical	23558953	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	PRN1109	sensitive	Preclinical - Cell line xenograft	;	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	R3Mab	sensitive	Preclinical - Cell line xenograft	25326231	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	S-49076	predicted - sensitive	Preclinical	23175443;23804704	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	Selumetinib	no benefit	Preclinical	26438159	Bladder	Therapeutic	D
FGFR3-TACC3	FUS		urinary bladder cancer	SU5402	sensitive	Preclinical	21119661;23175443	Bladder	Therapeutic	D
FGFR4	MUT	N535	Rhabdomyosarcoma	[FGFR inhibitor]	Responsive	Pre-clinical	19809159;24124571	Other	Therapeutic	D
FGFR4	MUT	V550	Rhabdomyosarcoma	[FGFR inhibitor]	Responsive	Pre-clinical	19809159;24124571	Other	Therapeutic	D
FLCN	CNV	deletion	Thyroid	Everolimus	Responsive	Case report	25295501	Thyroid	Therapeutic	D
FLCN	MUT	any mutation	Renal Cell Carcinoma in Kidney			1	15956655,19959076	Kidney	Therapeutic	B
FLCN	MUT	oncogenic mutation	Renal	Everolimus	Responsive	Case report	23995526	Kidney	Therapeutic	D
FLI1	FUS	EWSR1-FLI1	Ewing Sarcoma		Positive	B	23706910	Bone	Diagnostic	B
FLI1	FUS	EWSR1-FLI1 Type 1	Ewing Sarcoma		Positive	B	9552022	Bone	Prognostic	B
FLI1	FUS	EWSR1-FLI1 Fusion	Ewing Sarcoma of Soft Tissue	TK216	Response	4	19584866	Soft_Tissue	Therapeutic	D
FLI1	FUS	EWSR1-FLI1 Fusion	Ewing Sarcoma	TK216	Response	4	19584866	Bone	Therapeutic	D
FLT1	EXP	overexpression	Renal	Sunitinib	Responsive	Pre-clinical	24086736;21478036	Kidney	Therapeutic	D
FLT3	CNV	amp	colorectal cancer	Sorafenib	predicted - sensitive	Case Reports/Case Series	25848357	Colorectal	Therapeutic	D
FLT3	CNV	ITD	Acute Myeloid Leukemia	AG1296	Sensitivity/Response	D	12357354	Blood;Bone_Marrow	Therapeutic	D
FLT3	CNV	ITD	Acute Myeloid Leukemia	All-trans Retinoic Acid	Resistance	B	19965647	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Daunorubicin	Resistance	D	15626738	Blood;Bone_Marrow	Therapeutic	D
FLT3	CNV	ITD	Acute Myeloid Leukemia	Lestaurtinib (CEP-701)	Sensitivity/Response	B	14726387	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Ponatinib	Sensitivity/Response	D	21482694	Blood;Bone_Marrow	Therapeutic	D
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	A	24801015	Blood;Bone_Marrow	Prognostic	A
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	11290608	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	11585760	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	16455956	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	17957027	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	21067377	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	21537333	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	24855211	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia		Positive	B	11290608	Blood;Bone_Marrow	Diagnostic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Selumetinib	Resistance	B	24178622	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Sorafenib	Sensitivity/Response	B	18230792	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Sorafenib	Sensitivity/Response	B	22368270	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Myeloid Leukemia	Sorafenib	Sensitivity/Response	C	23969938	Blood;Bone_Marrow	Therapeutic	C
FLT3	CNV	ITD	Acute Myeloid Leukemia	SU5614	Resistance	D	15626738	Blood;Bone_Marrow	Therapeutic	D
FLT3	CNV	ITD	Acute Promyelocytic Leukemia	Anthracycline,All-trans Retinoic Acid	Resistance	B	24981688	Blood;Bone_Marrow	Therapeutic	B
FLT3	CNV	ITD	Acute Promyelocytic Leukemia		Poor Outcome	B	21461300	Blood;Bone_Marrow	Prognostic	B
FLT3	CNV	ITD	Leukemia	Sunitinib,Sorafenib	Sensitivity/Response	D	21482694	Blood;Bone_Marrow	Therapeutic	D
FLT3	EXP	OVEREXPRESSION	Adult B-Lymphoblastic Leukemia	Sunitinib	Sensitivity/Response	C	27181063	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	codon(s) 676 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	codon(s) 691 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	codon(s) 697 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	codon(s) 835 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	codon(s) 839 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	codon(s) 842 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835A	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835	Acute myeloid leukemia	Lestaurtinib	Responsive	Case report	16857985	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835	Acute myeloid leukemia	Midostaurin	Responsive	Case report	20733134	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835	Acute myeloid leukemia	Ponatinib	Resistant	Pre-clinical	23430109	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835	Acute Myeloid Leukemia	Quizartinib (AC220),Ponatinib	Resistance	D	23430109	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835	Acute myeloid leukemia	Quizartinib	Resistant	Pre-clinical	22504184;23878140	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835	Acute Myeloid Leukemia	Sorafenib,Quizartinib (AC220)	Resistance	B	22504184	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835	Acute Myeloid Leukemia	Sorafenib	Resistance	B	22368270	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835	Acute Myeloid Leukemia	SU5614	Resistance	D	19318574	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835E	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835G	acute myeloid leukemia	E6201	sensitive	Preclinical - Cell culture	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835G	leukemia	E6201	sensitive	Preclinical	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835H	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835H	acute myeloid leukemia	Crenolanib	sensitive	Preclinical	24623852	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835H	Acute Myeloid Leukemia	Sorafenib	Resistance	C	23969938	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	D835H	Acute Myeloid Leukemia	Sorafenib	Resistance	D	23969938	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835HY	Acute Myeloid Leukemia	Sorafenib	Resistance	D	23969938	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835N	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835V	Acute Myeloid Leukemia	AG1296,AS602868	Sensitivity/Response	D	17330097	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835V	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	D835V	Acute Myeloid Leukemia	Cytarabine,SU11248	Sensitivity/Response	D	15304385	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835V	Acute Myeloid Leukemia	Daunorubicin,SU11248	Sensitivity/Response	D	15304385	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835V	Acute Myeloid Leukemia	Sunitinib	Sensitivity/Response	C	15459012	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	D835V	Acute Myeloid Leukemia	Tandutinib	Resistance	D	15256420	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835V	Advanced Solid Tumor	MRX-2843	sensitive	Preclinical - Cell culture	27158668	Other	Therapeutic	D
FLT3	MUT	D835V	Advanced Solid Tumor	Pexidartinib	resistant	Preclinical	25847190	Other	Therapeutic	D
FLT3	MUT	D835X	acute myeloid leukemia	Crenolanib	sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	D835X	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	FDA approved - On Companion Diagnostic	;28644114;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	D835X	acute myeloid leukemia	Gilteritinib	sensitive	FDA approved - On Companion Diagnostic	;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	D835X	acute myeloid leukemia	Selinexor + Sorafenib	sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	D835Y	acute myeloid leukemia	E6201	sensitive	Preclinical - Cell culture	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835Y	acute promyelocytic leukemia	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin	predicted - sensitive	Case Reports/Case Series	27626069	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835Y	acute promyelocytic leukemia	Tretinoin	predicted - resistant	Case Reports/Case Series	27626069	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835Y	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	12124173	Other	Therapeutic	D
FLT3	MUT	D835Y	Advanced Solid Tumor	MRX-2843	sensitive	Preclinical - Cell culture	27158668	Other	Therapeutic	D
FLT3	MUT	D835Y	Advanced Solid Tumor	Pexidartinib	resistant	Preclinical	25847190	Other	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Avapritinib	resistant	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Crenolanib	sensitive	Preclinical - Cell culture	30651561	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Crenolanib + Trametinib	sensitive	Preclinical - Cell culture	30651561	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	G-749	sensitive	Preclinical - Cell culture	22864397	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Gilteritinib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Midostaurin	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Quizartinib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	hematologic cancer	Sorafenib	resistant	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	D835Y	leukemia	CG-806	predicted - sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	D835Y	leukemia	E6201	sensitive	Preclinical	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	E598delinsEGLVQVTGSSDNEYFYVDFREYE	acute myeloid leukemia	Tandutinib	sensitive	Preclinical	12124172	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	E612delinsEGYVDFREYEYDLKWEFRPRENLEF	acute myeloid leukemia	Tandutinib	sensitive	Preclinical	12124172	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Altiratinib	sensitive	Preclinical - Cell culture	26285778	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Avapritinib	resistant	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Azacitidine + Quizartinib	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Azacitidine + Sorafenib	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	CG-806	sensitive	Preclinical - Cell line xenograft	;;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Crenolanib	sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Crenolanib	sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	FDA approved - On Companion Diagnostic	28644114;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Cytarabine + Daunorubicin + Quizartinib	predicted - sensitive	Phase I	29139135	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Cytarabine + G-749	sensitive	Preclinical - Cell culture	24532805	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Cytarabine + Quizartinib	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Decitabine + Sorafenib	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	E6201	sensitive	Preclinical - Cell culture	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	ENMD-2076	sensitive	Phase I	27406088	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Entospletinib	predicted - sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	FF-10101	sensitive	Preclinical - Pdxcell culture	29187377	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	G-749	sensitive	Preclinical - Cell line xenograft	24532805	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Gilteritinib	sensitive	FDA approved - On Companion Diagnostic	;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Gilteritinib	sensitive	Phase Ib/II	28645776	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	GTP-14564	sensitive	Preclinical - Cell culture	12815052	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Ibrutinib	predicted - sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Ki23819	sensitive	Preclinical - Cell culture	15815726	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	KW-2449	predicted - sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Midostaurin	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	MRX-2843	sensitive	Preclinical - Cell line xenograft	27158668	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Pacritinib	predicted - sensitive	Preclinical - Cell line xenograft	22829080	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Ponatinib	sensitive	Phase I	23691988	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Ponatinib	sensitive	Preclinical - Patient cell culture	21482694	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Quizartinib	sensitive	Phase I	26920889	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Quizartinib	sensitive	Phase II	29859851	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Quizartinib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Rebastinib	no benefit	Phase I	27927766	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Selinexor + Sorafenib	sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Semaxanib	sensitive	Preclinical - Cell culture	12351406	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	SHP099	predicted - sensitive	Preclinical - Pdx	27362227	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Sorafenib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	Sorafenib	sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	acute myeloid leukemia	UNC1666	sensitive	Preclinical - Cell culture	25762638	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	Advanced Solid Tumor	Cabozantinib	predicted - sensitive	Preclinical - Cell culture	21926191	Other	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	12124173	Other	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	Advanced Solid Tumor	Pexidartinib	sensitive	Preclinical	25847190	Other	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Avapritinib	decreased response	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Gilteritinib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	GTP-14564	sensitive	Preclinical - Cell culture	12815052	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Midostaurin	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Quizartinib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	hematologic cancer	Sorafenib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	leukemia	E6201	sensitive	Preclinical - Cell line xenograft	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	leukemia	FN-1501	sensitive	Preclinical - Cell line xenograft	29357250	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	leukemia	GMI-1359	predicted - sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	leukemia	GMI-1359 + Sorafenib	predicted - sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	leukemia	Pexidartinib	sensitive	Preclinical - Cell line xenograft	25847190	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	exon(s) 14 insertion	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	exon(s) 15 insertion	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	F691	Acute myeloid leukemia	[novel FLT3 inhibitor]	Responsive	Pre-clinical	25847190	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	F691	Acute myeloid leukemia	Quizartinib	Resistant	Pre-clinical	22504184;23878140	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Crenolanib	sensitive	Phase II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Cytarabine + Daunorubicin + Sunitinib	sensitive	Phase Ib/II	25818407	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Palbociclib + Quizartinib	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Palbociclib	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Palbociclib + SGI-1776	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Palbociclib + Tandutinib	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	Palbociclib + TCS 359	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	TCS 359	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	acute myeloid leukemia	VS-5584	sensitive	Preclinical - Cell line xenograft	23270925	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Gain-of-Function	leukemia	Pexidartinib	sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	836_836del	cancer	Midostaurin	sensitive	Preclinical - Cell culture	17827387	Cancer	Therapeutic	D
FLT3	MUT	836_836del	cancer	Tandutinib	sensitive	Preclinical - Cell culture	15256420	Cancer	Therapeutic	D
FLT3	MUT	I836X	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	FDA approved - On Companion Diagnostic	;;28644114	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	I836X	acute myeloid leukemia	Gilteritinib	sensitive	FDA approved - On Companion Diagnostic	;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	Internal tandem duplication	Acute Myeloid Leukemia	Crenolanib, Sorafenib, Quizartinib	Response	3A	18230792, 22368270, 24227820, 29859851, 29875101	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	Internal tandem duplication	Acute Myeloid Leukemia	Gilteritinib	Response	1	28645776, 28516360	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	K429E	hematologic cancer	Crenolanib	resistant	Preclinical - Cell culture	30651561	Blood	Therapeutic	D
FLT3	MUT	L611delinsLCSSDNEYFYVDFREYEYDLKWEFPRENL	acute myeloid leukemia	Tandutinib	sensitive	Preclinical	12124172	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	mutant	acute myeloid leukemia	Azacitidine + Midostaurin	sensitive	Phase Ib/II	25530214	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	Crenolanib	sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	FDA approved - Has Companion Diagnostic	28644114;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	mutant	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	Phase Ib/II	22627678	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	Cytarabine + Venetoclax	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	E6201	sensitive	Preclinical	26822154	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	mutant	acute myeloid leukemia	Gilteritinib	sensitive	FDA approved - Has Companion Diagnostic	;;	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	mutant	acute myeloid leukemia	Gilteritinib	sensitive	Phase Ib/II	;28645776	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	Selinexor + Sorafenib	sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	mutant	acute myeloid leukemia	TG02	sensitive	Preclinical - Cell line xenograft	21860433	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	mutant	acute myeloid leukemia	UNC2025	sensitive	Preclinical	25068800	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	mutation	acute myeloid leukemia	AGS62P1	not applicable	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	mutation	Acute Myeloid Leukemia	Midostaurin	Sensitivity/Response	A	28546144	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	N676	Acute myeloid leukemia	Crenolanib	Responsive	Pre-clinical	24619500	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	N676	Acute myeloid leukemia	Midostaurin	Responsive	Pre-clinical	24619500	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	N676	Acute myeloid leukemia	Quizartinib	Resistant	Pre-clinical	22504184;23878140	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy	Response	1	28644114	Blood;Bone_Marrow	Therapeutic	A
FLT3	MUT	R595_L601dup	acute myeloid leukemia	Tandutinib	sensitive	Preclinical	12124172	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	R834Q	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	18068628	Other	Therapeutic	D
FLT3	MUT	R834Q	Advanced Solid Tumor	PD98059	sensitive	Preclinical	18068628	Other	Therapeutic	D
FLT3	MUT	S451F	Advanced Solid Tumor	Midostaurin	decreased response	Preclinical - Cell culture	18068628	Other	Therapeutic	D
FLT3	MUT	T227M	Renal Cell Carcinoma	Sunitinib	Adverse Response	B	19667267	Kidney	Therapeutic	B
FLT3	MUT	TKD mutation	Acute Myeloid Leukemia		Better Outcome	B	17965322	Blood;Bone_Marrow	Prognostic	B
FLT3	MUT	TKD mutation	Acute Myeloid Leukemia	Midostaurin	Sensitivity/Response	B	20733134	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	TKD mutation	Acute Myeloid Leukemia		Poor Outcome	B	17940205	Blood;Bone_Marrow	Prognostic	B
FLT3	MUT	TKD mutation	Acute Myeloid Leukemia	Sorafenib	Resistance	B	18230792	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	TKD mutation	Acute Myeloid Leukemia	Sorafenib	Resistance	B	22368270	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	V592G	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	18068628	Other	Therapeutic	D
FLT3	MUT	WILDTYPE	acute myeloid leukemia	CG-806	predicted - sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	WILDTYPE	acute myeloid leukemia	Cytarabine + Daunorubicin + Midostaurin	sensitive	Phase Ib/II	22627678	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	WILDTYPE	acute myeloid leukemia	Palbociclib	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	WILDTYPE	acute myeloid leukemia	Palbociclib + TCS 359	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	WILDTYPE	acute myeloid leukemia	TCS 359	sensitive	Preclinical	27099147	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	WILDTYPE	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	12124173	Other	Therapeutic	D
FLT3	MUT	Y572C	Advanced Solid Tumor	Midostaurin	sensitive	Preclinical - Cell culture	18068628	Other	Therapeutic	D
FLT3	MUT	Y572C	hematologic cancer	Crenolanib	sensitive	Preclinical - Cell culture	30651561	Blood	Therapeutic	D
FLT3	MUT	Y599delinsYGLYVDFREYEY	acute myeloid leukemia	Tandutinib	sensitive	Preclinical	12124172	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y599delinsYSTDNEYFYVDFREYEY	acute myeloid leukemia	Azacitidine + Sorafenib	predicted - sensitive	Phase II	23613521	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	Y599delinsYSTDNEYFYVDFREYEY	acute myeloid leukemia	E6201	predicted - sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y599delinsYSTDNEYFYVDFREYEY	acute myeloid leukemia	FLX925	predicted - sensitive	Preclinical	;	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y599delinsYSTDNEYFYVDFREYEY	acute myeloid leukemia	Quizartinib	predicted - sensitive	Phase I	24002496	Blood;Bone_Marrow	Therapeutic	C
FLT3	MUT	Y842	Acute myeloid leukemia	Ponatinib	Resistant	Pre-clinical	23430109	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y842	Acute myeloid leukemia	Quizartinib	Resistant	Pre-clinical	22504184;23878140	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y842C	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	27016502,9324277,9737679,11290608,12070009,24682858,24487413,23929217,23359050,22261446,14670924,18024407,25060518,22875611,23430109	Blood;Bone_Marrow	Therapeutic	B
FLT3	MUT	Y842C	acute myeloid leukemia	Imatinib	resistant	Preclinical	15345593	Blood;Bone_Marrow	Therapeutic	D
FLT3	MUT	Y842C	acute myeloid leukemia	Midostaurin	sensitive	Preclinical - Cell culture	15345593	Blood;Bone_Marrow	Therapeutic	D
FOS	EXP	OVEREXPRESSION	Colon Adenocarcinoma	Irbesartan	Sensitivity/Response	C	27022066	Colorectal	Therapeutic	C
FOS	FUS	TRUNCATING FUSION	Bone Epithelioid Hemangioma		Positive	C	26173738	Bone	Diagnostic	C
FOXA1	CNV	amplification	Colorectal adenocarcinoma	[BCL2 inhibitor]	Responsive	Pre-clinical	27397505	Colorectal	Therapeutic	D
FOXL2	MUT	C134W	granulosa cell tumor	N/A	not applicable	Preclinical	26791928;22240241	Ovary	Diagnostic	D
FOXL2	MUT	C134W	Ovarian Granulosa Cell Tumor		Positive	B	20693978	Ovary	Diagnostic	B
FOXL2	MUT	C134W	Ovarian Sex Cord-stromal Tumours		Positive	A	26033501	Ovary	Diagnostic	A
FOXO1	FUS	PAX3-FOXO1	Alveolar Rhabdomyosarcoma		Positive	B	12039929	Soft_Tissue	Diagnostic	B
FOXO1	FUS	PAX7-FOXO1 fusion	Alveolar Rhabdomyosarcoma		Positive	B	12039929	Soft_Tissue	Diagnostic	B
FOXP1	CNV	AMPLIFICATION	Diffuse Large B-cell Lymphoma		Positive	B	18765795	Lymph_Nodes	Diagnostic	B
FOXP3	EXP	EXPRESSION	Breast Cancer	Epirubicin	Sensitivity/Response	B	22431701	Breast	Therapeutic	B
FRS2	CNV	amplification	Liposarcoma	[FGFR inhibitor]	Responsive	Pre-clinical	23393200	Soft_Tissue	Therapeutic	D
GAS6	EXP	EXPRESSION	Oral Squamous Cell Carcinoma		Poor Outcome	B	26207647	Esophagus	Prognostic	B
GAS6	EXP	EXPRESSION	Prostate Cancer	Docetaxel	Resistance	D	27153245	Prostate	Therapeutic	D
GATA1	EXP	OVEREXPRESSION	megakaryocytic leukemia	Cytarabine	decreased response	Preclinical - Cell culture	23874683	Blood;Bone_Marrow	Therapeutic	D
GATA1	EXP	OVEREXPRESSION	megakaryocytic leukemia	Daunorubicin	decreased response	Preclinical - Cell culture	23874683	Blood;Bone_Marrow	Therapeutic	D
GATA1	MUT	any mutation	Acute Myeloid Leukemia in Blood/Bone Marrow			1	24056718,22937757	Blood;Bone_Marrow	Therapeutic	B
GATA1	MUT	mutant	megakaryocytic leukemia	N/A	not applicable	Clinical Study	14636651;12586620;25266042	Blood;Bone_Marrow	Diagnostic	C
GATA2	EXP	EXPRESSION	Lung Adenocarcinoma	Bortezomib,Fasudil	Sensitivity/Response	D	22541434	Lung	Therapeutic	D
GATA2	MUT	any mutation	Acute Myeloid Leukemia/Chronic Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	24371770,24467820,24077845,24033149,22814295,22649106	Blood;Bone_Marrow	Therapeutic	B
GATA2	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	22533337;22271902;22147895;21892162	Blood;Bone_Marrow	Prognostic	C
GATA3	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	22237106	Blood;Bone_Marrow	Therapeutic	B
GATA3	MUT	oncogenic mutation	Breast adenocarcinoma	[Aromatase ihibitor]	Responsive	Pre-clinical	24758297	Breast	Therapeutic	D
GLI1	FUS	ACTB-GLI1	Pericytoma		Positive	B	15555571	Soft_Tissue	Diagnostic	B
GLI2	CNV	amplification	Medulloblastoma	[SMO inhibitor]	Resistant	Pre-clinical	24951114	Nervous_System	Therapeutic	D
GNA11	MUT	any mutation	Melanoma in Eye			1	26601868,22808163,22733540,24938562,27498141	Eye	Therapeutic	B
GNA11	MUT	mutant	uveal melanoma	AEB071 + Binimetinib	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNA11	MUT	mutant	uveal melanoma	AEB071 + CGM097	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNA11	MUT	mutant	uveal melanoma	AEB071 + Everolimus	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNA11	MUT	mutant	uveal melanoma	Dacarbazine + Selumetinib	no benefit	Phase III	29528792	Eye	Therapeutic	C
GNA11	MUT	mutant	uveal melanoma	Selumetinib	no benefit	Phase II	24938562	Eye	Therapeutic	C
GNA11	MUT	mutant	uveal melanoma	Trametinib	no benefit	Phase I	22805292	Eye	Therapeutic	C
GNA11	MUT	mutation	Uveal Melanoma	Cabozantinib	Sensitivity/Response	B	28103611	Eye	Therapeutic	B
GNA11	MUT	mutation	Uveal Melanoma	JQ1	Sensitivity/Response	D	26397223	Eye	Therapeutic	D
GNA11	MUT	mutation	Uveal Melanoma	PD0325901,AEB071	Sensitivity/Response	D	24141786	Eye	Therapeutic	D
GNA11	MUT	mutation	Uveal Melanoma	Trametinib	Sensitivity/Response	C	22805292	Eye	Therapeutic	C
GNA11	MUT	Q209L	Cutaneous melanoma	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	22733540;22808163	Skin	Therapeutic	D
GNA11	MUT	Q209L	Cutaneous melanoma	Selumetinib	Responsive	Early trials	ASCO 2013 (abstr CRA9003)	Skin	Therapeutic	C
GNA11	MUT	Q209L	Cutaneous melanoma	Vorinostat	Responsive	Pre-clinical	NCT01587352	Skin	Therapeutic	D
GNA11	MUT	Q209L	uveal melanoma	AEB071 + Binimetinib	sensitive	Preclinical - Cell line xenograft	24141786	Eye	Therapeutic	D
GNA11	MUT	Q209L	uveal melanoma	FR900359	sensitive	Preclinical - Cell culture	30567972	Eye	Therapeutic	D
GNA11	MUT	Q209L	uveal melanoma	Selumetinib	predicted - sensitive	Case Reports/Case Series	24938562	Eye	Therapeutic	D
GNA11	MUT	Q209L	uveal melanoma	TAK-733	sensitive	Preclinical - Cell culture	22515704	Eye	Therapeutic	D
GNA11	MUT	Q209L	uveal melanoma	Trametinib	sensitive	Preclinical - Cell culture	22733540	Eye	Therapeutic	D
GNA11	MUT	Q209P	Cutaneous melanoma	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	22733540;22808163	Skin	Therapeutic	D
GNA11	MUT	Q209P	Cutaneous melanoma	Selumetinib	Responsive	Early trials	ASCO 2013 (abstr CRA9003)	Skin	Therapeutic	C
GNA11	MUT	Q209P	Cutaneous melanoma	Vorinostat	Responsive	Pre-clinical	NCT01587352	Skin	Therapeutic	D
GNAQ	MUT	exon(s) 5 any	uveal melanoma	Selumetinib	no benefit	Phase II	24938562	Eye	Therapeutic	C
GNAQ	MUT	mutant	uveal cancer	Trametinib	no benefit	Phase I	22805292	Eye	Therapeutic	C
GNAQ	MUT	mutant	uveal melanoma	AEB071 + Binimetinib	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNAQ	MUT	mutant	uveal melanoma	AEB071 + CGM097	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNAQ	MUT	mutant	uveal melanoma	AEB071 + Everolimus	predicted - sensitive	Preclinical - Pdxcell culture	27507190	Eye	Therapeutic	D
GNAQ	MUT	mutant	uveal melanoma	Dacarbazine + Selumetinib	no benefit	Phase III	29528792	Eye	Therapeutic	C
GNAQ	MUT	mutation	Uveal Melanoma	Cabozantinib	Sensitivity/Response	B	28103611	Eye	Therapeutic	B
GNAQ	MUT	mutation	Uveal Melanoma	JQ1	Sensitivity/Response	D	26397223	Eye	Therapeutic	D
GNAQ	MUT	mutation	Uveal Melanoma	PD0325901,AEB071	Sensitivity/Response	D	24141786	Eye	Therapeutic	D
GNAQ	MUT	mutation	Uveal Melanoma	Trametinib	Sensitivity/Response	B	22805292	Eye	Therapeutic	B
GNAQ	MUT	Q209	Cutaneous melanoma	[HDAC inhibitor]	Responsive	Pre-clinical	NCT01587352	Skin	Therapeutic	D
GNAQ	MUT	Q209	Cutaneous melanoma	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	22733540;22808163	Skin	Therapeutic	D
GNAQ	MUT	Q209	Cutaneous melanoma	[PKC inhibitor]	Responsive	Pre-clinical	22653968;22253748	Skin	Therapeutic	D
GNAQ	MUT	Q209	Cutaneous melanoma	Selumetinib	Responsive	Early trials	ASCO 2013 (abstr CRA9003)	Skin	Therapeutic	C
GNAQ	MUT	Q209L	uveal melanoma	AEB071 + PD-0325901	sensitive	Preclinical - Cell culture	24141786	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	AEB071	sensitive	Preclinical - Cell line xenograft	24141786	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	Enzastaurin	sensitive	Preclinical - Cell culture	22253748	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	FR900359	sensitive	Preclinical - Cell culture	30567972	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	GSK2126458 + Trametinib	sensitive	Preclinical - Cell culture	22733540	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	NAV-2729	sensitive	Preclinical - Cell line xenograft	27265506	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	Selumetinib	sensitive	Preclinical - Cell culture	22550165	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	TAK-733	sensitive	Preclinical - Cell culture	22515704	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	Trametinib	sensitive	Preclinical - Cell culture	22733540	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	U0126	sensitive	Preclinical - Cell culture	19078957	Eye	Therapeutic	D
GNAQ	MUT	Q209L	uveal melanoma	Verteporfin	sensitive	Preclinical - Cell line xenograft	27308390	Eye	Therapeutic	D
GNAQ	MUT	Q209P	Skin Melanoma	PLX4720	Resistance	D	24504448	Skin	Therapeutic	D
GNAQ	MUT	Q209P	Skin Melanoma	Vemurafenib	Resistance	C	24504448	Skin	Therapeutic	C
GNAQ	MUT	Q209P	uveal melanoma	AEB071	sensitive	Preclinical - Cell culture	22653968	Eye	Therapeutic	D
GNAQ	MUT	Q209P	uveal melanoma	Enzastaurin	sensitive	Preclinical - Cell culture	22253748	Eye	Therapeutic	D
GNAQ	MUT	Q209P	uveal melanoma	FR900359	sensitive	Preclinical - Cell culture	30567972	Eye	Therapeutic	D
GNAQ	MUT	Q209P	uveal melanoma	Selumetinib	sensitive	Preclinical - Cell culture	22550165	Eye	Therapeutic	D
GNAQ	MUT	Q209P	uveal melanoma	TAK-733	sensitive	Preclinical - Cell culture	22515704	Eye	Therapeutic	D
GNAQ	MUT	Q209	Uveal Melanoma	BAY 86-9766	Sensitivity/Response	C	23434733	Eye	Therapeutic	C
GNAS	MUT	any mutation	Intraductal Papillary Mucinous Neoplasm/Adenocarcinoma in Pancreas			2	21775669,24525507,25656048,24938521,22355676	Pancreas	Therapeutic	C
GNAS	MUT	any mutation	Myelodysplastic Syndrome in Blood/Bone Marrow			1	21714648,15331575	Blood;Bone_Marrow	Therapeutic	B
GNAS	MUT	codon(s) 201, 844 any	Adenocarcinoma in Lung/Kidney			2	[abstract]	Kidney;Lung	Therapeutic	C
GNAS	MUT	codon(s) 201, 844 any	Intraductal Papillary Mucinous Neoplasm/Adenocarcinoma in Pancreas			2	21775669,24525507,25656048,24938521,22355676	Pancreas	Therapeutic	C
GNAS	MUT	codon(s) 201, 844 any	Myelodysplastic Syndrome in Blood/Bone Marrow			1	21714648,15331575	Blood;Bone_Marrow	Therapeutic	B
GNAS	MUT	Q227L	Adenocarcinoma in Lung			2	24857785,15522316,15246564,2549064	Lung	Therapeutic	C
GNAS	MUT	R201	Any cancer type	[JAK inhibitor]	Responsive	Pre-clinical	21835143	Cancer	Therapeutic	D
GNAS	MUT	R201C	Colorectal Cancer	Vemurafenib,Cetuximab,Irinotecan	Resistance	C	27729313	Colorectal	Therapeutic	C
GNAS	MUT	R201H	Follicular Thyroid Carcinoma	Radioactive Iodine	Sensitivity/Response	C	26788326	Thyroid	Therapeutic	C
GNAS	MUT	R201	Pseudomyxoma Peritonei		Poor Outcome	B	27154293	Other	Prognostic	B
GNAS	MUT	T393C	Bladder Urothelial Carcinoma		Better Outcome	B	15824158	Bladder	Prognostic	B
GNAS	MUT	T393C	Breast Carcinoma		Poor Outcome	B	17186357	Breast	Prognostic	B
GNAS	MUT	T393C	Chronic Lymphocytic Leukemia		Better Outcome	B	17020971	Blood;Bone_Marrow	Prognostic	B
GNAS	MUT	T393C	Clear Cell Renal Cell Carcinoma		Better Outcome	B	16467086	Kidney	Prognostic	B
GNAS	MUT	T393C	Colorectal Cancer		Better Outcome	B	16033819	Colorectal	Prognostic	B
GNAS	MUT	T393C	Esophageal Cancer	Cisplatin,5-fluorouracil	Resistance	B	19274060	Esophagus	Therapeutic	B
GNAS	MUT	T393C	Intrahepatic Cholangiocarcinoma		Poor Outcome	B	17356712	Intrahepatic;Bile_Duct	Prognostic	B
GNAS	MUT	T393C	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Resistance	B	24758907	Lung	Therapeutic	B
GNAS	MUT	T393C	Melanoma		Better Outcome	B	21156401	Skin	Prognostic	B
GNB1	MUT	codon(s) 57 missense	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23443460	Blood;Bone_Marrow	Therapeutic	B
GSTP1	CNV	deletion	Ovarian Carcinoma	Cisplatin,Carboplatin,Paclitaxel	Sensitivity/Response	D	25010864	Ovary	Therapeutic	D
GSTP1	MUT	I105V	Colorectal Cancer	Folfox Protocol	Sensitivity/Response	B	19922504	Colorectal	Therapeutic	B
HAVCR2	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD-1 Inhibitor	Resistance	C	26883990	Lung	Therapeutic	C
HAVCR2	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD-1 Inhibitor,TIM-3 Inhibitor	Sensitivity/Response	D	26883990	Lung	Therapeutic	D
HGF	EXP	EXPRESSION	Glioblastoma Multiforme	SGX523	Sensitivity/Response	D	22203985	Brain	Therapeutic	D
HGF	EXP	overexpression	Urinary tract carcinoma	Cabozantinib	Responsive	Pre-clinical	25534569	Bladder	Therapeutic	D
HIF1A	EXP	OVEREXPRESSION	Colorectal Cancer		Poor Outcome	B	20363910	Colorectal	Prognostic	B
HIF1A	EXP	OVEREXPRESSION	Sarcoma		Poor Outcome	B	17103226	Soft_Tissue	Prognostic	B
HIF1A	EXP	overexpression	Renal	Sunitinib	Responsive	Pre-clinical	24086736	Kidney	Therapeutic	D
HIF1A	MUT	3' UTR Polymorphism	Pancreatic Adenocarcinoma		Poor Outcome	B	26872370	Pancreas	Prognostic	B
HLA-C	CNV	COPY-NEUTRAL LOSS OF HETEROZYGOSITY	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes	Resistance	C	27959684	Colorectal	Therapeutic	C
HLA-DRA	EXP	EXPRESSION	Skin Melanoma	Nivolumab,Pembrolizumab,Atezolizumab	Sensitivity/Response	B	26822383	Skin	Therapeutic	B
HMOX1	EXP	EXPRESSION	Renal Cell Carcinoma	Sunitinib,Sorafenib	Resistance	B	26309414	Kidney	Therapeutic	B
HNF1A	MUT	LOSS-OF-FUNCTION	hepatocellular adenoma	N/A	not applicable	Clinical Study	25076298;25434466;26961851	Liver	Diagnostic	C
HRAS	MUT	codon(s) 12, 13, 61 any	Cholangiocarcinoma in Breast			2	27572273,10700175	Breast	Therapeutic	C
HRAS	MUT	codon(s) 12, 13, 61 any	Melanoma in Skin			2	23599145,22515291,1427748,23414587	Skin	Therapeutic	C
HRAS	MUT	codon(s) 12, 13, 61 any	Papillary Carcinoma/Follicular Carcinoma in Thyroid			1	22515291,25132659	Thyroid	Therapeutic	B
HRAS	MUT	codon(s) 12, 13, 61 any	Squamous Cell Carcinoma in Anus/Vulva/Oral Cavity/Pharynx			2	21798893,25631445,25072932	Esophagus;Other	Therapeutic	C
HRAS	MUT	codon(s) 12, 13, 61 any	Urothelial Carcinoma in Bladder			2	23599145,22515291,1427748,23414587,26778714	Bladder	Therapeutic	C
HRAS	MUT	G12V	Advanced Solid Tumor	Binimetinib + Everolimus	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Binimetinib	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Cetuximab	resistant	Preclinical	22797062	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Everolimus	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Panitumumab	resistant	Preclinical	22797062	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Pz-1	sensitive	Preclinical - Cell line xenograft	26126987	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	Rigosertib	sensitive	Preclinical - Cell culture	27104980	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	SR9009	predicted - sensitive	Preclinical - Cell culture	29320480	Other	Therapeutic	D
HRAS	MUT	G12V	Advanced Solid Tumor	SR9011	predicted - sensitive	Preclinical - Cell culture	29320480	Other	Therapeutic	D
HRAS	MUT	G12V	malignant glioma	SF1126	sensitive	Preclinical - Cell line xenograft	25425962	Nervous_System	Therapeutic	D
HRAS	MUT	G12V	melanoma	CI-1040	sensitive	Preclinical	26267534	Skin	Therapeutic	D
HRAS	MUT	G12V	urinary bladder cancer	Binimetinib + Everolimus	sensitive	Preclinical - Cell culture	26544513	Bladder	Therapeutic	D
HRAS	MUT	G12V	urinary bladder cancer	Everolimus + Selumetinib	sensitive	Preclinical - Cell culture	26544513	Bladder	Therapeutic	D
HRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Resistance	D	26561417	Colorectal	Therapeutic	D
HRAS	MUT	G13D	Colorectal Cancer	EGFR Inhibitor	Resistance	C	26561417	Colorectal	Therapeutic	C
HRAS	MUT	G13D	Skin Squamous Cell Carcinoma	Vemurafenib	Resistance	C	22256804	Skin	Therapeutic	C
HRAS	MUT	G13R	thyroid cancer	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
HRAS	MUT	LOSS-OF-FUNCTION	thyroid cancer	BEZ235	sensitive	Preclinical	21831957	Thyroid	Therapeutic	D
HRAS	MUT	mutant	Advanced Solid Tumor	Binimetinib	predicted - sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	mutant	Advanced Solid Tumor	Everolimus	predicted - sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	mutant	Advanced Solid Tumor	Selumetinib	predicted - sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	mutant	breast cancer	PI-273	decreased response	Preclinical - Cell culture	28827373	Breast	Therapeutic	D
HRAS	MUT	mutant	endometrial cancer	Trametinib	sensitive	Preclinical	26343583	Uterus	Therapeutic	D
HRAS	MUT	mutant	ovarian cancer	Alpelisib + Binimetinib	predicted - sensitive	Phase Ib/II	;	Ovary	Therapeutic	C
HRAS	MUT	mutant	thyroid medullary carcinoma	Cabozantinib	sensitive	Phase III	27525386	Thyroid	Therapeutic	C
HRAS	MUT	mutant	transitional cell carcinoma	Trametinib	resistant	Preclinical	26343583	Bladder	Therapeutic	D
HRAS	MUT	mutant	urinary bladder cancer	Metformin	sensitive	Preclinical	26921394	Bladder	Therapeutic	D
HRAS	MUT	mutation	Cancer	Binimetinib (MEK162),PD0325901,Everolimus,Selumetinib,AZD8055	Sensitivity/Response	D	26544513	Cancer	Therapeutic	D
HRAS	MUT	oncogenic mutation	Acute myeloid leukemia	[MEK inhibitor +/- MTOR inhibitor]	Responsive	Pre-clinical	22399013;22507781	Blood;Bone_Marrow	Therapeutic	D
HRAS	MUT	oncogenic mutation	Any cancer type	Tipifarnib	Responsive	Early trials	NCT02383927	Cancer	Therapeutic	C
HRAS	MUT	oncogenic mutation	Cervix	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	15950068	Cervix	Therapeutic	D
HRAS	MUT	oncogenic mutation	Cervix squamous cell	[MTOR inhibitor]	Responsive	Pre-clinical	22345164	Cervix	Therapeutic	D
HRAS	MUT	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	Tipifarnib	Response	3A	12497061, 24240680	Head_and_Neck	Therapeutic	C
HRAS	MUT	Q61K	Squamous Cell Carcinoma in Anus/Vulva/Oral Cavity/Pharynx			2	21798893,25631445,25072932	Esophagus;Other	Therapeutic	C
HRAS	MUT	Q61L	Advanced Solid Tumor	Binimetinib + Everolimus	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	Q61L	Advanced Solid Tumor	Binimetinib	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	Q61L	Advanced Solid Tumor	Everolimus	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	Q61L	bladder carcinoma	NS1	sensitive	Preclinical - Cell culture	27820802	Bladder	Therapeutic	D
HRAS	MUT	Q61L	head and neck squamous cell carcinoma	Sirolimus + Trametinib	sensitive	Preclinical - Cell line xenograft	26882569	Head_and_Neck	Therapeutic	D
HRAS	MUT	Q61L	lung squamous cell carcinoma	AZD8055 + Binimetinib	sensitive	Preclinical - Cell culture	26544513	Lung	Therapeutic	D
HRAS	MUT	Q61L	lung squamous cell carcinoma	Binimetinib + Everolimus	sensitive	Preclinical - Cell culture	26544513	Lung	Therapeutic	D
HRAS	MUT	Q61L	lung squamous cell carcinoma	Buparlisib	no benefit	Preclinical - Cell culture	26544513	Lung	Therapeutic	D
HRAS	MUT	Q61L	lung squamous cell carcinoma	Everolimus + Selumetinib	sensitive	Preclinical - Cell line xenograft	26544513	Lung	Therapeutic	D
HRAS	MUT	Q61L	lung squamous cell carcinoma	Selumetinib	sensitive	Preclinical - Cell line xenograft	26544513	Lung	Therapeutic	D
HRAS	MUT	Q61L	skin squamous cell carcinoma	PLX7904	no benefit	Preclinical - Cell line xenograft	26466569	Skin	Therapeutic	D
HRAS	MUT	Q61R	Advanced Solid Tumor	Binimetinib	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	Q61R	Advanced Solid Tumor	Everolimus	sensitive	Preclinical - Cell culture	26544513	Other	Therapeutic	D
HRAS	MUT	Q61R	Cholangiocarcinoma in Breast			2	27572273,10700175	Breast	Therapeutic	C
HRAS	MUT	Q61R	Squamous Cell Carcinoma in Anus/Vulva/Oral Cavity/Pharynx			2	21798893,25631445,25072932	Esophagus;Other	Therapeutic	C
HRAS	MUT	WILDTYPE	cancer	FTI-277	predicted - sensitive	Preclinical	8620483	Cancer	Therapeutic	D
HRAS	MUT	WILDTYPE	melanoma	E6201	sensitive	Preclinical	23039341	Skin	Therapeutic	D
HSPA5	EXP	EXPRESSION	Colorectal Cancer	5-fluorouracil	Sensitivity/Response	B	23456958	Colorectal	Therapeutic	B
HSPB1	EXP	EXPRESSION	Pancreatic Ductal Adenocarcinoma	Gemcitabine	Sensitivity/Response	D	22004109	Pancreas	Therapeutic	D
HSPH1	MUT	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	Cisplatin,5-fluorouracil	Sensitivity/Response	D	26943774	Stomach	Therapeutic	D
HSPH1	MUT	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Poor Outcome	B	26943774	Stomach	Prognostic	B
HSPH1	MUT	17_17del	Colorectal Cancer	Oxaliplatin,5-fluorouracil	Sensitivity/Response	B	24512910	Colorectal	Therapeutic	B
IDH1	MUT	codon(s) 132 any	Adenocarcinoma in Breast			2	23630074,26015937,22417203,24760710,22180306,22071650	Breast	Therapeutic	C
IDH1	MUT	codon(s) 132 any	Adenocarcinoma in Lung			2	23630074,26015937,22417203,22180306,22071650	Lung	Therapeutic	C
IDH1	MUT	codon(s) 132 any	Cholangiocarcinoma in Liver			2	23630074,26015937,22417203,24760710,22180306,22071650	Liver	Therapeutic	C
IDH1	MUT	codon(s) 132 any	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,22417203,24760710,22180306,22071650,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH1	MUT	codon(s) 132 any	Melanoma in Skin			2	19777641	Skin	Therapeutic	C
IDH1	MUT	codon(s) 132 any	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	23954893,PharmGKB,20107228,20410924,20368538,20368543,20376084,20376086,20494930,28710830,20567020,22615103,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH1	MUT	mutant	acute myeloid leukemia	Azacitidine	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	mutant	acute myeloid leukemia	Cytarabine + Venetoclax	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
IDH1	MUT	mutant	acute myeloid leukemia	Decitabine	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	mutant	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - Has Companion Diagnostic	;;29860938	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	mutant	acute myeloid leukemia	Ivosidenib	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	mutant	acute myeloid leukemia	LY3410738	predicted - sensitive	Preclinical - Pdxcell culture	;	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	22616558;23226625	Blood;Bone_Marrow	Prognostic	C
IDH1	MUT	mutant	acute myeloid leukemia	Venetoclax	predicted - sensitive	Phase II	27520294	Blood;Bone_Marrow	Therapeutic	C
IDH1	MUT	mutant	astrocytoma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH1	MUT	mutant	cholangiocarcinoma	Ivosidenib	sensitive	Phase I	;	Bile_Duct	Therapeutic	C
IDH1	MUT	mutant	chondrosarcoma	Dasatinib	resistant	Preclinical	27231123	Bone	Therapeutic	D
IDH1	MUT	mutant	glioblastoma multiforme	Bevacizumab + Lomustine	predicted - sensitive	Phase II	26762204	Brain	Therapeutic	C
IDH1	MUT	mutant	glioblastoma multiforme	N/A	not applicable	Clinical Study	20560678;23904262;26945349	Brain	Prognostic	C
IDH1	MUT	mutant	glioblastoma multiforme	N/A	not applicable	Guideline	;	Brain	Diagnostic	A
IDH1	MUT	mutant	grade III astrocytoma	N/A	not applicable	Guideline	;	Brain	Diagnostic	A
IDH1	MUT	mutant	lung adenocarcinoma	Dasatinib	resistant	Preclinical	27231123	Lung	Therapeutic	D
IDH1	MUT	mutant	malignant glioma	Ivosidenib	sensitive	Phase I	;	Nervous_System	Therapeutic	C
IDH1	MUT	mutant	malignant glioma	N/A	not applicable	Clinical Study	23894344;23817809;26220714	Nervous_System	Prognostic	C
IDH1	MUT	mutant	malignant glioma	N/A	not applicable	Guideline	23041832;19755387;19915484	Nervous_System	Diagnostic	A
IDH1	MUT	mutant	malignant glioma	N/A	not applicable	Guideline	;	Nervous_System	Prognostic	A
IDH1	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
IDH1	MUT	mutant	oligodendroglioma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH1	MUT	mutation	Brain Glioma		Better Outcome	B	26061751	Brain	Prognostic	B
IDH1	MUT	mutation	Brain Glioma	Olaparib	Sensitivity/Response	D	28148839	Brain	Therapeutic	D
IDH1	MUT	oncogenic mutation	Acute myeloid leukemia	[BCL2 inhibitor]	Responsive	Pre-clinical	25599133	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	oncogenic mutation	Acute myeloid leukemia	[IDH1 inhibitor]	Responsive	Early trials	ENA 2014 (abstr 1LBA)	Blood;Bone_Marrow	Therapeutic	C
IDH1	MUT	oncogenic mutation	Acute myeloid leukemia	Venetoclax	Responsive	Early trials	27520294	Blood;Bone_Marrow	Therapeutic	C
IDH1	MUT	oncogenic mutation	Cholangiocarcinoma	Dasatinib	Responsive	Early trials	NCT02428855	Bile_Duct	Therapeutic	C
IDH1	MUT	oncogenic mutation	Glioma	AG-120	Responsive	Early trials	NCT02073994;23558169	Nervous_System	Therapeutic	C
IDH1	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	Ivosidenib	Response	1	23393090, 23558169, 29860938	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132	Acute Myeloid Leukemia		Positive	B	20376086	Blood;Bone_Marrow	Diagnostic	B
IDH1	MUT	R132	Any cancer type	[PARP inhibitor]	Responsive	Pre-clinical	28148839	Cancer	Therapeutic	D
IDH1	MUT	R132	Astrocytoma		Better Outcome	B	19228619	Brain	Prognostic	B
IDH1	MUT	R132	Astrocytoma		Better Outcome	B	19933982	Brain	Prognostic	B
IDH1	MUT	R132	Billiary tract	Dasatinib	Responsive	Pre-clinical	27231123	Other	Therapeutic	D
IDH1	MUT	R132C	Acute Myeloid Leukemia	AG-120	Sensitivity/Response	B	25583779	Blood;Bone_Marrow	Therapeutic	B
IDH1	MUT	R132C	acute myeloid leukemia	BAY1436032	sensitive	Preclinical - Pdxcell culture	28232670	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132C	Acute Myeloid Leukemia	BPTES	Sensitivity/Response	D	24333121	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132C	Acute Myeloid Leukemia	GSK321	Sensitivity/Response	D	26436839	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132C	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	;;;29860938	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132C	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	;29860938;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132C	Acute Myeloid Leukemia		Positive	B	20538800	Blood;Bone_Marrow	Diagnostic	B
IDH1	MUT	R132C	Adenocarcinoma in Breast			2	23630074,26015937,22417203,24760710,22180306,22071650	Breast	Therapeutic	C
IDH1	MUT	R132C	Brain Glioma	Temozolomide	Sensitivity/Response	B	20975057	Brain	Therapeutic	B
IDH1	MUT	R132C	Cholangiocarcinoma in Liver			2	23630074,26015937,22417203,24760710,22180306,22071650	Liver	Therapeutic	C
IDH1	MUT	R132C	fibrosarcoma	AG-881	predicted - sensitive	Preclinical - Cell line xenograft	;	Soft_Tissue	Therapeutic	D
IDH1	MUT	R132C	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,22417203,24760710,22180306,22071650,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH1	MUT	R132C	Glioblastoma Multiforme	Cetuximab	Sensitivity/Response	B	22199315	Brain	Therapeutic	B
IDH1	MUT	R132C	intrahepatic cholangiocarcinoma	Dasatinib	sensitive	Preclinical	27231123	Bile_Duct	Therapeutic	D
IDH1	MUT	R132C	intrahepatic cholangiocarcinoma	Saracatinib	sensitive	Preclinical	27231123	Bile_Duct	Therapeutic	D
IDH1	MUT	R132C	malignant glioma	AGI-5198	sensitive	Preclinical	23558169	Nervous_System	Therapeutic	D
IDH1	MUT	R132C	Malignant Glioma	AGI-5198	Sensitivity/Response	D	23558169	Nervous_System	Therapeutic	D
IDH1	MUT	R132C	Malignant Glioma	Bevacizumab	Sensitivity/Response	B	22199315	Nervous_System	Therapeutic	B
IDH1	MUT	R132C	malignant glioma	Talazoparib	sensitive	Preclinical - Patient cell culture	28148839	Nervous_System	Therapeutic	D
IDH1	MUT	R132C	Melanoma in Skin			2	21356389,19777641	Skin	Therapeutic	C
IDH1	MUT	R132C	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	23954893,PharmGKB,20107228,20410924,20368538,20368543,20376084,20376086,20494930,28710830,20567020,22615103,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH1	MUT	R132C	sarcoma	AGI-5198 + Olaparib	decreased response	Preclinical - Cell culture	28148839	Soft_Tissue	Therapeutic	D
IDH1	MUT	R132C	sarcoma	AGI-5198 + Talazoparib	decreased response	Preclinical - Cell culture	28148839	Soft_Tissue	Therapeutic	D
IDH1	MUT	R132C	sarcoma	Olaparib	sensitive	Preclinical - Cell line xenograft	28148839	Soft_Tissue	Therapeutic	D
IDH1	MUT	R132G	acute myeloid leukemia	BAY1436032	sensitive	Preclinical - Patient cell culture	28232670	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132G	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	;29860938;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132	Glioblastoma Multiforme		Better Outcome	B	19228619	Brain	Prognostic	B
IDH1	MUT	R132	Glioblastoma Multiforme		Better Outcome	B	20127344	Brain	Prognostic	B
IDH1	MUT	R132H	acute myeloid leukemia	BAY1436032	sensitive	Preclinical - Patient cell culture	28232670	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132H	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	29860938;;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132H	Adenocarcinoma in Breast			2	23630074,26015937,22417203,24760710,22180306,22071650	Breast	Therapeutic	C
IDH1	MUT	R132H	Advanced Solid Tumor	AGI-5198 + Talazoparib	decreased response	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	Cisplatin + Talazoparib	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	Niraparib	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	Olaparib	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	Rucaparib	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	Talazoparib	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Advanced Solid Tumor	VX-970	sensitive	Preclinical - Cell culture	28148839	Other	Therapeutic	D
IDH1	MUT	R132H	Anaplastic Oligodendroglioma	AGI-5198	Sensitivity/Response	D	23558169	Brain	Therapeutic	D
IDH1	MUT	R132H	Cholangiocarcinoma in Liver			2	23630074,26015937,22417203,24760710,22180306,22071650	Liver	Therapeutic	C
IDH1	MUT	R132H	colon carcinoma	Olaparib	sensitive	Preclinical - Cell culture	28148839	Colorectal	Therapeutic	D
IDH1	MUT	R132H	colon carcinoma	Talazoparib	sensitive	Preclinical - Cell culture	28148839	Colorectal	Therapeutic	D
IDH1	MUT	R132H	colorectal cancer	AGI-5198 + Metformin	resistant	Preclinical	26363012	Colorectal	Therapeutic	D
IDH1	MUT	R132H	colorectal cancer	AGI-5198 + Radiotherapy	resistant	Preclinical	26363012	Colorectal	Therapeutic	D
IDH1	MUT	R132H	colorectal cancer	Metformin	sensitive	Preclinical	26363012	Colorectal	Therapeutic	D
IDH1	MUT	R132H	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,22417203,24760710,22180306,22071650,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH1	MUT	R132H	glioblastoma multiforme	Temozolomide + Vandetanib	sensitive	Phase II	25910950	Brain	Therapeutic	C
IDH1	MUT	R132H	grade III astrocytoma	Azacitidine	sensitive	Preclinical	24077805	Brain	Therapeutic	D
IDH1	MUT	R132H	malignant glioma	AG-881	predicted - sensitive	Preclinical - Cell line xenograft	;	Nervous_System	Therapeutic	D
IDH1	MUT	R132H	malignant glioma	AGI-5198	sensitive	Preclinical - Cell line xenograft	23558169	Nervous_System	Therapeutic	D
IDH1	MUT	R132H	malignant glioma	BPTES	sensitive	Preclinical - Cell culture	21045145	Nervous_System	Therapeutic	D
IDH1	MUT	R132H	malignant glioma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH1	MUT	R132H	malignant glioma	Talazoparib	sensitive	Preclinical - Patient cell culture	28148839	Nervous_System	Therapeutic	D
IDH1	MUT	R132H	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	23954893,PharmGKB,20107228,20410924,20368538,20368543,20376084,20376086,20494930,28710830,20567020,22615103,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH1	MUT	R132H	oligodendroglioma	Decitabine	sensitive	Preclinical - Pdxcell culture	24077826	Nervous_System	Therapeutic	D
IDH1	MUT	R132L	acute myeloid leukemia	BAY1436032	sensitive	Preclinical - Patient cell culture	28232670	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132L	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	29860938;;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132L	Adenocarcinoma in Breast			2	23630074,26015937,22417203,24760710,22180306,22071650	Breast	Therapeutic	C
IDH1	MUT	R132L	Adenocarcinoma in Lung			2	23630074,26015937,22417203,22180306,22071650	Lung	Therapeutic	C
IDH1	MUT	R132L	Cholangiocarcinoma in Liver			2	23630074,26015937,22417203,24760710,22180306,22071650	Liver	Therapeutic	C
IDH1	MUT	R132L	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,22417203,24760710,22180306,22071650,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH1	MUT	R132L	Malignant Glioma	Bevacizumab	Sensitivity/Response	B	22199315	Nervous_System	Therapeutic	B
IDH1	MUT	R132L	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	23954893,PharmGKB,20107228,20410924,20368538,20368543,20376084,20376086,20494930,28710830,20567020,22615103,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH1	MUT	R132	Myelodysplastic Syndrome		Poor Outcome	B	20494930	Bone_Marrow	Prognostic	B
IDH1	MUT	R132S	acute myeloid leukemia	BAY1436032	sensitive	Preclinical - Patient cell culture	28232670	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132S	acute myeloid leukemia	Ivosidenib	sensitive	FDA approved - On Companion Diagnostic	;29860938;	Blood;Bone_Marrow	Therapeutic	A
IDH1	MUT	R132S	intrahepatic cholangiocarcinoma	Dasatinib	sensitive	Preclinical	27231123	Bile_Duct	Therapeutic	D
IDH1	MUT	R132S	intrahepatic cholangiocarcinoma	Saracatinib	sensitive	Preclinical	27231123	Bile_Duct	Therapeutic	D
IDH1	MUT	R132S	Malignant Glioma	Bevacizumab	Sensitivity/Response	B	22199315	Nervous_System	Therapeutic	B
IDH1	MUT	R132X	acute myeloid leukemia	CG-806	predicted - sensitive	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
IDH1	MUT	R132X	acute myeloid leukemia	IDH305	sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
IDH2	MUT	any mutation	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma in Lung			2	15976377,22980975,24065765,27064021	Lung	Therapeutic	C
IDH2	MUT	codon(s) 140, 172 any	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma in Lung			2	15976377,22980975,24065765,27064021	Lung	Therapeutic	C
IDH2	MUT	codon(s) 140, 172 any	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,24760710,22180306,22071650,26015937,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH2	MUT	codon(s) 140, 172 any	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	24065765,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	codon(s) 140 missense	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	24065765,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	codon(s) 172 missense	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	24065765,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	D76fs	acute myeloid leukemia	Venetoclax	sensitive	Phase II	27520294	Blood;Bone_Marrow	Therapeutic	C
IDH2	MUT	mutant	acute myeloid leukemia	Azacitidine	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	mutant	acute myeloid leukemia	Cytarabine + Venetoclax	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
IDH2	MUT	mutant	acute myeloid leukemia	Decitabine	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	mutant	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - Has Companion Diagnostic	28588020;;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	mutant	acute myeloid leukemia	Enasidenib	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	mutant	acute myeloid leukemia	Venetoclax	predicted - sensitive	Phase II	27520294	Blood;Bone_Marrow	Therapeutic	C
IDH2	MUT	mutant	astrocytoma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH2	MUT	mutant	essential thrombocythemia	N/A	not applicable	Guideline	;	Blood	Prognostic	A
IDH2	MUT	mutant	glioblastoma multiforme	N/A	not applicable	Guideline	;	Brain	Diagnostic	A
IDH2	MUT	mutant	grade III astrocytoma	N/A	not applicable	Guideline	;	Brain	Diagnostic	A
IDH2	MUT	mutant	hematologic cancer	Enasidenib	sensitive	Phase I	;	Blood	Therapeutic	C
IDH2	MUT	mutant	malignant glioma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH2	MUT	mutant	malignant glioma	N/A	not applicable	Guideline	;	Nervous_System	Prognostic	A
IDH2	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
IDH2	MUT	mutant	oligodendroglioma	N/A	not applicable	Guideline	;	Nervous_System	Diagnostic	A
IDH2	MUT	mutation	Acute Myeloid Leukemia	Enasidenib	Sensitivity/Response	B	28588020	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	mutation	Acute Myeloid Leukemia	Enasidenib	Sensitivity/Response	D	28193778	Blood;Bone_Marrow	Therapeutic	D
IDH2	MUT	mutation	Brain Glioma		Better Outcome	B	26061751	Brain	Prognostic	B
IDH2	MUT	oncogenic mutation	Acute myeloid leukemia	Venetoclax	Responsive	Early trials	27520294	Blood;Bone_Marrow	Therapeutic	C
IDH2	MUT	oncogenic mutation	Cholangiocarcinoma	Dasatinib	Responsive	Early trials	NCT02428855	Bile_Duct	Therapeutic	C
IDH2	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	Enasidenib	Response	1	28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R140	Acute Myeloid Leukemia		Better Outcome	B	21596855	Blood;Bone_Marrow	Prognostic	B
IDH2	MUT	R140G	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	;;28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R140K	Hematologic malignancies	AG-221	Responsive	Early trials	AACR 2014 (abstr CT103)	Blood	Therapeutic	C
IDH2	MUT	R140L	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	;;28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R140Q	acute myeloid leukemia	AGI-6780	sensitive	Preclinical	23558173	Blood;Bone_Marrow	Therapeutic	D
IDH2	MUT	R140Q	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	;;28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R140Q	acute myeloid leukemia	Enasidenib	sensitive	Preclinical - Pdxcell culture	28193778	Blood;Bone_Marrow	Therapeutic	D
IDH2	MUT	R140Q	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma in Lung			2	15976377,22980975,24065765,27064021	Lung	Therapeutic	C
IDH2	MUT	R140Q	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,24760710,22180306,22071650,26015937,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH2	MUT	R140Q	glioblastoma multiforme	Enasidenib	predicted - sensitive	Preclinical - Cell line xenograft	28193778	Brain	Therapeutic	D
IDH2	MUT	R140Q	malignant glioma	AG-881	predicted - sensitive	Preclinical - Cell line xenograft	;	Nervous_System	Therapeutic	D
IDH2	MUT	R140Q	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
IDH2	MUT	R140Q	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	24065765,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	R140W	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	;;28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172	Acute Myeloid Leukemia		Better Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
IDH2	MUT	R172	Astrocytoma		Better Outcome	B	19228619	Brain	Prognostic	B
IDH2	MUT	R172	Billiary tract	Dasatinib	Responsive	Pre-clinical	27231123	Other	Therapeutic	D
IDH2	MUT	R172G	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	28588020;;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172	Glioblastoma Multiforme		Better Outcome	B	19228619	Brain	Prognostic	B
IDH2	MUT	R172K	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	;;28588020	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172K	acute myeloid leukemia	Enasidenib	sensitive	Preclinical - Patient cell culture	28193778	Blood;Bone_Marrow	Therapeutic	D
IDH2	MUT	R172K	Acute Myeloid Leukemia		Poor Outcome	B	21596855	Blood;Bone_Marrow	Prognostic	B
IDH2	MUT	R172K	colorectal cancer	Enasidenib	predicted - sensitive	Preclinical - Cell culture	28193778	Colorectal	Therapeutic	D
IDH2	MUT	R172K	Glial Neoplasm/Glioblastoma in Spinal Cord/Brain/Brain, Supratentorial/Brain, Infratentorial			1	23630074,26015937,24760710,22180306,22071650,26015937,23160425,23630074,26015937	Brain;Nervous_System	Therapeutic	B
IDH2	MUT	R172K	glioblastoma multiforme	Enasidenib	predicted - sensitive	Preclinical - Cell culture	28193778	Brain	Therapeutic	D
IDH2	MUT	R172K	Hematologic malignancies	AG-221	Responsive	Early trials	AACR 2014 (abstr CT103)	Blood	Therapeutic	C
IDH2	MUT	R172K	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis in Blood/Bone Marrow			1	24065765,24699305,27064021	Blood;Bone_Marrow	Therapeutic	B
IDH2	MUT	R172M	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	28588020;;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172	Peripheral T-cell Lymphoma		Positive	B	22215888	Lymph_Nodes	Diagnostic	B
IDH2	MUT	R172S	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	28588020;;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172W	acute myeloid leukemia	Enasidenib	sensitive	FDA approved - On Companion Diagnostic	28588020;;	Blood;Bone_Marrow	Therapeutic	A
IDH2	MUT	R172X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
IGF1R	CNV	amplification	Lung adenocarcinoma	Erlotinib	Resistant	Pre-clinical	24458568	Lung	Therapeutic	D
IGF1R	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	D	23619944	Lung	Therapeutic	D
IGF1R	MUT	NUCLEAR EXPRESSION	Sarcoma	IGF1R Monoclonal Antibody	Sensitivity/Response	B	22682017	Soft_Tissue	Therapeutic	B
IGF2	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Early trials	25632036	Colorectal	Therapeutic	C
IGF2	EXP	OVEREXPRESSION	Prostate Cancer	OSI-906 (Linsitinib),Docetaxel,Cabazitaxel	Sensitivity/Response	D	25670080	Prostate	Therapeutic	D
IGF2	EXP	OVEREXPRESSION	Prostate Cancer	OSI-906 (Linsitinib)	N/A	D	25670080	Prostate	Therapeutic	D
IKZF1	CNV	del	acute lymphocytic leukemia	N/A	not applicable	Clinical Study	25335741;26194343;27067989	Blood;Bone_Marrow	Prognostic	C
IKZF1	CNV	deletion	Acute Lymphocytic Leukemia		Poor Outcome	B	19770381	Blood;Bone_Marrow	Prognostic	B
IKZF1	CNV	deletion	Acute Lymphocytic Leukemia		Poor Outcome	B	20445578	Blood;Bone_Marrow	Prognostic	B
IKZF1	CNV	deletion	Precursor B Lymphoblastic Lymphoma/leukemia		Poor Outcome	B	22699455	Blood;Bone_Marrow;Lymph_Nodes	Prognostic	B
IKZF1	CNV	deletion	Precursor B Lymphoblastic Lymphoma/leukemia		Poor Outcome	B	24366361	Blood;Bone_Marrow;Lymph_Nodes	Prognostic	B
IKZF1	CNV	deletion	Precursor B Lymphoblastic Lymphoma/leukemia		Poor Outcome	B	24740809	Blood;Bone_Marrow;Lymph_Nodes	Prognostic	B
IKZF1	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	25335741,24366361,24497567,24323986,24323991	Blood;Bone_Marrow	Therapeutic	B
IKZF1	MUT	WILDTYPE	multiple myeloma	Lenalidomide	sensitive	Preclinical	24292625	Bone_Marrow	Therapeutic	D
IKZF2	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			2	23334668	Blood;Bone_Marrow	Therapeutic	C
IKZF3	MUT	any mutation	Chronic Myeloid Leukemia in Blood/Bone Marrow			2	24212482,24072100,23334668	Blood;Bone_Marrow	Therapeutic	C
IL7R	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	21536738,24787007,21892159,23069254	Blood;Bone_Marrow	Therapeutic	B
INPP4B	CNV	deletion	Breast adenocarcinoma	[PI3K pathway inhibitor]	Responsive	Pre-clinical	23551093	Breast	Therapeutic	D
INPP4B	MUT	oncogenic mutation	Breast adenocarcinoma	[PI3K pathway inhibitor]	Responsive	Pre-clinical	23551093	Breast	Therapeutic	D
JAK1	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Enzastaurin	Sensitivity/Response	D	22333600	Lung	Therapeutic	D
JAK1	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma/Acute Myeloid Leukemia in Blood/Bone Marrow			1	18362173,20417861,28395559,22237106,21880637,21393331,20167706,19470474,18160671	Blood;Bone_Marrow	Therapeutic	B
JAK1	MUT	oncogenic mutation	Colorectal adenocarcinoma	[PD1 inhibitor]	Resistant	Case report	27903500	Colorectal	Therapeutic	D
JAK1	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 inhibitor]	Resistant	Case report	27433843	Skin	Therapeutic	D
JAK1	MUT	Q503X	Skin Melanoma	Pembrolizumab	Resistance	C	27433843	Skin	Therapeutic	C
JAK1	MUT	S646F	Acute lymphoblastic leukemia	Ruxolitinib	Responsive	Pre-clinical	22955920;18805579	Blood;Bone_Marrow	Therapeutic	D
JAK1	MUT	R683	Acute lymphoblastic leukemia	Ruxolitinib	Responsive	Pre-clinical	22955920;18805579	Blood;Bone_Marrow	Therapeutic	D
JAK1	MUT	S703I	Hepatocellular Carcinoma	Ruxolitinib	Sensitivity/Response	D	26701727	Liver	Therapeutic	D
JAK2	CNV	amplification	Breast adenocarcinoma	[JAK inhibitor]	Responsive	Pre-clinical	27075627	Breast	Therapeutic	D
JAK2	CNV	amp	triple-receptor negative breast cancer	NVP-BSK805 + Paclitaxel	sensitive	Preclinical - Pdx	27075627	Breast	Therapeutic	D
JAK2	CNV	amp	triple-receptor negative breast cancer	NVP-BSK805	sensitive	Preclinical - Pdx	27075627	Breast	Therapeutic	D
JAK2	EXP	OVEREXPRESSION	Advanced Solid Tumor	BEZ235 + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	EXP	OVEREXPRESSION	Advanced Solid Tumor	Pictilisib + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	EXP	OVEREXPRESSION	Advanced Solid Tumor	Ruxolitinib + TGX-221	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	EXP	OVEREXPRESSION	Advanced Solid Tumor	Ruxolitinib + ZSTK474	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	NVP-BSK805 + Paclitaxel	sensitive	Preclinical - Pdx	27075627	Breast	Therapeutic	D
JAK2	FUS	PCM1-JAK2	Hematologic Cancer		Positive	A	27069254	Blood	Diagnostic	A
JAK2	MUT	codon(s) 683 missense	B Lymphoblastic Leukemia/Lymphoma in Bone Marrow/Blood			1	20656333,16426581,21674578,18927438,20018760	Blood;Bone_Marrow	Therapeutic	B
JAK2	MUT	exon(s) 12 splice	Skin Melanoma	Pembrolizumab	Resistance	C	27433843	Skin	Therapeutic	C
JAK2	MUT	exon(s) 12 deletion	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/Polycythemia Vera in Blood/Bone Marrow			1	20656333,16426581,21674578,18927438,20018760	Blood;Bone_Marrow	Therapeutic	B
JAK2	MUT	exon(s) 12 insertion	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/Polycythemia Vera in Blood/Bone Marrow			1	20656333,16426581,21674578,18927438,20018760	Blood;Bone_Marrow	Therapeutic	B
JAK2	MUT	F547 SPLICE SITE mutation	Melanoma	Pembrolizumab	Resistance	C	27433843	Skin	Therapeutic	C
JAK2	MUT	F694L	Pediatric B-cell Acute Lymphoblastic Leukemia	Ruxolitinib	Sensitivity/Response	C	27860260	Blood;Bone_Marrow	Therapeutic	C
JAK2	MUT	LOSS-OF-FUNCTION	melanoma	Pembrolizumab	predicted - resistant	Case Reports/Case Series	27433843	Skin	Therapeutic	D
JAK2	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 inhibitor]	Resistant	Case report	27433843	Skin	Therapeutic	D
JAK2	FUS	PCM1-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	Ruxolitinib	Response	3A	22899477, 25207766, 26202607, 23630205, 22875628, 25515960, 23400675, 25260694	Blood;Bone_Marrow	Therapeutic	C
JAK2	MUT	R867Q	hematologic cancer	AZ960	decreased response	Preclinical	24398328	Blood	Therapeutic	D
JAK2	MUT	R867Q	hematologic cancer	Fedratinib	decreased response	Preclinical - Cell culture	24398328	Blood	Therapeutic	D
JAK2	MUT	R867Q	hematologic cancer	Luminespib	decreased response	Preclinical	24398328	Blood	Therapeutic	D
JAK2	MUT	R867Q	hematologic cancer	Momelotinib	decreased response	Preclinical	24398328	Blood	Therapeutic	D
JAK2	MUT	R867Q	hematologic cancer	Ruxolitinib	decreased response	Preclinical	24398328	Blood	Therapeutic	D
JAK2	MUT	R938Q	B-cell childhood acute lymphoblastic leukemia	Ruxolitinib	resistant	Preclinical - Patient cell culture	29025600	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	acute myeloid leukemia	A-1155463	sensitive	Preclinical	25787766	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	acute myeloid leukemia	Go6976	sensitive	Preclinical	16956345	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	Acute myeloid leukemia	[JAK inhibitor (alone, in combination)]	Responsive	Pre-clinical	22829971	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	acute myeloid leukemia	RP6530 + Ruxolitinib	sensitive	Preclinical	;	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	Acute myeloid leukemia	Ruxolitinib	Responsive	Early trials	22422826	Blood;Bone_Marrow	Therapeutic	C
JAK2	MUT	V617F	Advanced Solid Tumor	BEZ235 + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	MUT	V617F	Advanced Solid Tumor	Pictilisib + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	MUT	V617F	Advanced Solid Tumor	Ruxolitinib + TGX-221	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	MUT	V617F	Advanced Solid Tumor	Ruxolitinib + ZSTK474	sensitive	Preclinical	24251790	Other	Therapeutic	D
JAK2	MUT	V617F	bone marrow cancer	AZD1208	decreased response	Preclinical	26472029	Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	bone marrow cancer	AZD1208 + Ruxolitinib	sensitive	Preclinical	26472029	Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	bone marrow cancer	CHZ868	sensitive	Preclinical	26175413	Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	Bone Marrow Cancer		Positive	B	19287384	Bone	Diagnostic	B
JAK2	MUT	V617F	bone marrow cancer	Ruxolitinib + SGI-1776	sensitive	Preclinical	26472029	Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	bone marrow cancer	SGI-1776	decreased response	Preclinical	26472029	Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	Chronic Myeloid Leukemia		Positive	B	16081687	Blood;Bone_Marrow	Diagnostic	B
JAK2	MUT	V617F	essential thrombocythemia	BMS-911543	sensitive	Preclinical - Cell culture	22015772	Blood	Therapeutic	D
JAK2	MUT	V617F	hematologic cancer	BMS-911543	sensitive	Preclinical - Cell culture	22015772	Blood	Therapeutic	D
JAK2	MUT	V617F	hematologic cancer	NS-018	sensitive	Preclinical	22829185	Blood	Therapeutic	D
JAK2	MUT	V617F	hematologic cancer	SHP099	sensitive	Preclinical - Cell culture	27362227	Blood	Therapeutic	D
JAK2	MUT	V617F	Lymphoid Leukemia		Negative	B	16081687	Blood;Bone_Marrow	Diagnostic	B
JAK2	MUT	V617F	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
JAK2	MUT	V617F	Myelofibrosis	Ruxolitinib	Responsive	FDA guidelines	FDA	Bone_Marrow	Therapeutic	A
JAK2	MUT	V617F	myeloid leukemia	Imatinib	resistant	Preclinical - Cell culture	21224473	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	myeloproliferative neoplasm	BMS-911543	sensitive	Preclinical - Cell culture	22015772	Blood;Bone_Marrow	Therapeutic	D
JAK2	MUT	V617F	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/Polycythemia Vera in Blood/Bone Marrow			1	20656333,16426581,21674578,18927438,20018760	Blood;Bone_Marrow	Therapeutic	B
JAK2	MUT	V617F	myeloproliferative neoplasm	LY2784544	predicted - sensitive	Phase I	28934680	Blood;Bone_Marrow	Therapeutic	C
JAK2	MUT	V617F	Polycythemia Vera	Pegylated IFN-alpha-2a	Sensitivity/Response	B	16709929	Blood	Therapeutic	B
JAK2	MUT	V617F	Polycythemia Vera	TG101348	Sensitivity/Response	D	18394554	Blood	Therapeutic	D
JAK2	MUT	Y931C	cancer	Ruxolitinib	resistant	Preclinical	21393331	Cancer	Therapeutic	D
JAK3	MUT	A572V	acute myeloid leukemia	NS-018	predicted - resistant	Preclinical - Cell culture	22829185	Blood;Bone_Marrow	Therapeutic	D
JAK3	MUT	A572V	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	21821710	Other	Therapeutic	D
JAK3	MUT	A572V	Lymphoma	[JAK inhibitor]	Responsive	Pre-clinical	22705984	Lymph_Nodes	Therapeutic	D
JAK3	MUT	A572V	mature T-cell and NK-cell lymphoma	Tofacitinib	sensitive	Preclinical	22705984	Lymph_Nodes	Therapeutic	D
JAK3	MUT	A573V	hematologic cancer	Tofacitinib	sensitive	Preclinical - Cell culture	29046866	Blood	Therapeutic	D
JAK3	MUT	A573V	Lymphoma	[JAK inhibitor]	Responsive	Pre-clinical	22705984	Lymph_Nodes	Therapeutic	D
JAK3	MUT	any mutation	T Cell Lymphoproliferative Disorder/NK Cell Lymphoproliferative Disorder/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24048415,24153015,23832011,23689514,21821710,22425895,22237106,21599579,21537335,22122069	Blood;Bone_Marrow	Therapeutic	B
JAK3	MUT	E183G	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	21821710	Other	Therapeutic	D
JAK3	MUT	G589D	hematologic cancer	Tofacitinib	sensitive	Preclinical - Cell culture	28284718	Blood	Therapeutic	D
JAK3	MUT	H583Y	hematologic cancer	Tofacitinib	sensitive	Preclinical - Cell culture	28284718	Blood	Therapeutic	D
JAK3	MUT	I87T	Advanced Solid Tumor	JANEX-1	sensitive	Preclinical - Cell culture	18397343	Other	Therapeutic	D
JAK3	MUT	I87T	Megakaryoblastic leukemia	[JAK inhibitor]	Responsive	Pre-clinical	18397343	Blood;Bone_Marrow	Therapeutic	D
JAK3	MUT	L156P	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	21821710	Other	Therapeutic	D
JAK3	MUT	L857P	Advanced Solid Tumor	NIBR3049	sensitive	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	L857P	Advanced Solid Tumor	Ruxolitinib	decreased response	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	L857P	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	M511I	hematologic cancer	Tofacitinib	sensitive	Preclinical - Cell culture	29046866	Blood	Therapeutic	D
JAK3	MUT	Q501H	Megakaryoblastic leukemia	[JAK inhibitor]	Responsive	Pre-clinical	18397343	Blood;Bone_Marrow	Therapeutic	D
JAK3	MUT	R172Q	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	21821710	Other	Therapeutic	D
JAK3	MUT	R657Q	Megakaryoblastic leukemia	[JAK inhibitor]	Responsive	Pre-clinical	18397343	Blood;Bone_Marrow	Therapeutic	D
JAK3	MUT	V674A	Advanced Solid Tumor	NIBR3049	decreased response	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	V674A	Advanced Solid Tumor	Ruxolitinib	sensitive	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	V674A	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical - Cell culture	26446793	Other	Therapeutic	D
JAK3	MUT	V722I	Advanced Solid Tumor	Tofacitinib	sensitive	Preclinical	25146434	Other	Therapeutic	D
JUN	EXP	OVEREXPRESSION	Colorectal Adenocarcinoma	Irbesartan	Sensitivity/Response	C	27022066	Colorectal	Therapeutic	C
KCNJ5	MUT	L168R	Adrenal adenoma	Amiloride	Responsive	Pre-clinical	24506072	Adrenal_Gland	Therapeutic	D
KCNJ5	MUT	L168R	Adrenal adenoma	Verapamil	Responsive	Pre-clinical	24506072	Adrenal_Gland	Therapeutic	D
KDM5C	MUT	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma in Kidney			2	25365943,23036577,20054297	Kidney	Therapeutic	C
KDM6A	CNV	loss	bladder urothelial carcinoma	GSK126	sensitive	Preclinical - Cell culture	28228601	Bladder	Therapeutic	D
KDM6A	CNV	loss	bladder urothelial carcinoma	GSK343	sensitive	Preclinical - Cell line xenograft	28228601	Bladder	Therapeutic	D
KDM6A	CNV	loss	bladder urothelial carcinoma	GSK503	sensitive	Preclinical - Pdx	28228601	Bladder	Therapeutic	D
KDM6A	CNV	loss	bladder urothelial carcinoma	Tazemetostat	sensitive	Preclinical - Cell culture	28228601	Bladder	Therapeutic	D
KDM6A	CNV	loss	multiple myeloma	GSK126	sensitive	Preclinical - Cell line xenograft	29045832	Bone_Marrow	Therapeutic	D
KDM6A	CNV	loss	multiple myeloma	GSK343	sensitive	Preclinical - Cell culture	29045832	Bone_Marrow	Therapeutic	D
KDM6A	MUT	Oncogenic Mutations	Bladder Cancer	Tazemetostat	Response	4	24123378, 28228601, 29045832, 29059780	Bladder	Therapeutic	D
KDR	CNV	amp	lung non-small cell carcinoma	Vandetanib	no benefit	Phase III	26578684	Lung	Therapeutic	C
KDR	EXP	OVEREXPRESSION	breast cancer	Sunitinib	predicted - resistant	Preclinical	28011623	Breast	Therapeutic	D
KDR	MUT	A1065T	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	19723655	Other	Therapeutic	D
KDR	MUT	A1065T	Angiosarcoma	Sorafenib,Sunitinib	Sensitivity/Response	D	19723655	Soft_Tissue	Therapeutic	D
KDR	MUT	A1065T	Any cancer type	[VEGFR inhibitor]	Responsive	Pre-clinical	24569783	Cancer	Therapeutic	D
KDR	MUT	D717V	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	19723655	Other	Therapeutic	D
KDR	MUT	D717V	Angiosarcoma	Sunitinib,Sorafenib	Sensitivity/Response	D	19723655	Soft_Tissue	Therapeutic	D
KDR	MUT	Gain-of-Function	Advanced Solid Tumor	Lucitanib	predicted - sensitive	Phase I	25193991	Other	Therapeutic	C
KDR	MUT	Gain-of-Function	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	19723655	Other	Therapeutic	D
KDR	MUT	Gain-of-Function	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	19723655	Other	Therapeutic	D
KDR	MUT	Gain-of-Function	bladder urothelial carcinoma	Sunitinib	predicted - sensitive	Phase II	20142593	Bladder	Therapeutic	C
KDR	MUT	L840F	colorectal cancer	Regorafenib	resistant	Preclinical - Pdx	29588308	Colorectal	Therapeutic	D
KDR	MUT	L840F	colorectal cancer	Sorafenib	resistant	Preclinical - Pdx	29588308	Colorectal	Therapeutic	D
KDR	MUT	mutation	Advanced Solid Tumor	Anti-VEGFR2 CAR CD8 lymphocytes	predicted - sensitive	Preclinical	20978347	Other	Therapeutic	D
KDR	MUT	mutation	Advanced Solid Tumor	Tanibirumab	predicted - sensitive	Phase I	28391576	Other	Therapeutic	C
KDR	MUT	mutation	melanoma	Anti-VEGFR2 CAR CD8 lymphocytes	predicted - sensitive	Preclinical	23633494	Skin	Therapeutic	D
KDR	MUT	mutation	pancreatic cancer	TAS-115	sensitive	Preclinical	24140932	Pancreas	Therapeutic	D
KDR	MUT	Q472H	melanoma	unspecified VEGFR2 antibody	sensitive	Preclinical	26631613	Skin	Therapeutic	D
KDR	MUT	R1032Q	colorectal cancer	Cabozantinib	sensitive	Preclinical - Cell culture	29588308	Colorectal	Therapeutic	D
KDR	MUT	R1032Q	colorectal cancer	Lenvatinib	sensitive	Preclinical - Cell culture	29588308	Colorectal	Therapeutic	D
KDR	MUT	R961W	Colorectal Adenocarcinoma	Regorafenib	Sensitivity/Response	C	27004155	Colorectal	Therapeutic	C
KDR	MUT	WILDTYPE	Advanced Solid Tumor	Pz-1	predicted - sensitive	Preclinical	26126987	Other	Therapeutic	D
KDR	MUT	WILDTYPE	Advanced Solid Tumor	Ramucirumab	predicted - sensitive	Phase I	20048182	Other	Therapeutic	C
KDR	MUT	WILDTYPE	pancreatic cancer	Gemcitabine + VEGFR2-169	sensitive	Phase I	19930156	Pancreas	Therapeutic	C
KIAA1524	EXP	EXPRESSION	Pancreatic Ductal Adenocarcinoma		Poor Outcome	B	26894380	Pancreas	Prognostic	B
KIAA1524	EXP	UNDEREXPRESSION	Pancreatic Ductal Adenocarcinoma	Gemcitabine	Sensitivity/Response	D	26894380	Pancreas	Therapeutic	D
KIF23	EXP	EXPRESSION	Hepatocellular Carcinoma		Better Outcome	B	26674738	Liver	Prognostic	B
KIT	CNV	AMPLIFICATION	Mucosal Melanoma	Imatinib	Resistance	B	23775962	Skin	Therapeutic	B
KIT	CNV	exon11 del	gastrointestinal stromal tumor	AZD3229	predicted - sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
KIT	CNV	exon11 del	gastrointestinal stromal tumor	Imatinib	predicted - sensitive	Phase III	28334365	Stomach	Therapeutic	C
KIT	EXP	EXPRESSION	Endometrial Cancer	Imatinib	Sensitivity/Response	C	16487996	Uterus	Therapeutic	C
KIT	EXP	EXPRESSION	Endometrial Cancer	Imatinib	Sensitivity/Response	C	18607592	Uterus	Therapeutic	C
KIT	EXP	EXPRESSION	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	B	18955451	Stomach	Therapeutic	B
KIT	EXP	OVEREXPRESSION	Advanced Solid Tumor	Derazantinib	sensitive	Preclinical - Cell culture	27627808	Other	Therapeutic	D
KIT	EXP	OVEREXPRESSION	seminoma	Imatinib	sensitive	Case Reports/Case Series	18751412	Testis	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Avapritinib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Gilteritinib	decreased response	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Midostaurin	decreased response	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Quizartinib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	FUS	N822K RUNX1-RUNX1T1	acute myeloid leukemia	Sorafenib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Dasatinib	Responsive	Case report	19671763	Skin	Therapeutic	D
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Imatinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Imatinib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Nilotinib	Responsive	Early trials	22068222;25695690	Skin	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Sunitinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	Imatinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	Regorafenib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	Sunitinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Dasatinib	Responsive	Case report	19671763	Skin	Therapeutic	D
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Imatinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Imatinib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Nilotinib	Responsive	Early trials	22068222;25695690	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Sunitinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 missense	Gastrointestinal stromal	Imatinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 13 missense	Gastrointestinal stromal	Regorafenib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 13 missense	Gastrointestinal stromal	Sunitinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 14, 17 missense	Cutaneous melanoma	Dasatinib	Responsive	Case report	19671763	Skin	Therapeutic	D
KIT	MUT	exon(s) 14, 17 missense	Cutaneous melanoma	Imatinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 14, 17 missense	Cutaneous melanoma	Imatinib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
KIT	MUT	exon(s) 14, 17 missense	Cutaneous melanoma	Nilotinib	Responsive	Early trials	22068222;25695690	Skin	Therapeutic	C
KIT	MUT	exon(s) 14, 17 missense	Cutaneous melanoma	Sunitinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 14, 17 missense	Gastrointestinal stromal	Imatinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 14, 17 missense	Gastrointestinal stromal	Regorafenib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 14, 17 missense	Gastrointestinal stromal	Sunitinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	3' UTR mutation	Acral Lentiginous Melanoma		Positive	B	21119596	Skin	Diagnostic	B
KIT	MUT	exon(s) 9 missense	Gastrointestinal stromal	Imatinib	Resistant	Late trials	18955458;18955451;16624552	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Cutaneous melanoma	Sorafenib	Responsive	Case report	18936790;20372153	Skin	Therapeutic	D
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	Ponatinib	Responsive	Early trials	ASCO 2015 (abstr 10517);25239608;ASCO 2015 (abstr 10535)	Stomach	Therapeutic	C
KIT	MUT	exon(s) 13 missense	Cutaneous melanoma	Sorafenib	Responsive	Case report	18936790;20372153	Skin	Therapeutic	D
KIT	MUT	exon(s) 13 missense	Gastrointestinal stromal	Imatinib	Resistant	Late trials	18955458;18955451;16624552	Stomach	Therapeutic	C
KIT	MUT	exon(s) 14 missense	Gastrointestinal stromal	Imatinib	Resistant	Late trials	18955458;18955451;16624552	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 missense	Cutaneous melanoma	Sorafenib	Responsive	Case report	18936790;20372153	Skin	Therapeutic	D
KIT	MUT	exon(s) 17 missense	Gastrointestinal stromal	Ponatinib	Responsive	Early trials	ASCO 2015 (abstr 10517);25239608;ASCO 2015 (abstr 10535)	Stomach	Therapeutic	C
KIT	MUT	exon(s) 18 missense	Cutaneous melanoma	Sorafenib	Responsive	Case report	18936790;20372153	Skin	Therapeutic	D
KIT	MUT	exon(s) 18 missense	Gastrointestinal stromal	Ponatinib	Responsive	Early trials	ASCO 2015 (abstr 10517);25239608;ASCO 2015 (abstr 10535)	Stomach	Therapeutic	C
KIT	MUT	A502_Y503dup	Advanced Solid Tumor	Flumatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	A502_Y503dup	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	A502_Y503dup	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	A502_Y503dup	gastrointestinal stromal tumor	Cabozantinib	sensitive	Preclinical - Pdx	27777285	Stomach	Therapeutic	D
KIT	MUT	A502_Y503dup	gastrointestinal stromal tumor	Imatinib	resistant	Preclinical - Pdx	27777285	Stomach	Therapeutic	D
KIT	MUT	A502_Y503dup	gastrointestinal stromal tumor	Regorafenib	predicted - sensitive	Preclinical - Pdx	29100343	Stomach	Therapeutic	D
KIT	MUT	A502delinsAAY	Gastrointestinal Stromal Tumor	Sunitinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	A829P	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	A829P	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	A829P	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	A829P	Gastrointestinal stromal	Ponatinib	Responsive	Pre-clinical	25239608	Stomach	Therapeutic	D
KIT	MUT	A829P	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	A829P	melanoma	Dasatinib	sensitive	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	A829P	melanoma	Imatinib	resistant	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	A829P	melanoma	Nilotinib	sensitive	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	A829P	melanoma	Sunitinib	resistant	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	any mutation	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	any mutation	Adenocarcinoma in Colon/Rectum			2	14551311,20652953,12453327,11280787	Colorectal	Therapeutic	C
KIT	MUT	any mutation	Thymic Carcinoma in Thymus			2	18448188,22357254,15201427,21969494	Thymus	Therapeutic	C
KIT	MUT	C443S	mucosal melanoma	Imatinib	sensitive	Case Reports/Case Series	25003536	Skin	Therapeutic	D
KIT	MUT	C809G	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	579_579del	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	14645423	Stomach	Therapeutic	C
KIT	MUT	579_579del	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	579_579del	thymic carcinoma	Imatinib	sensitive	Case Reports/Case Series	24419427	Thymus	Therapeutic	D
KIT	MUT	D816E	Gastrointestinal Stromal Tumor	Sunitinib,Imatinib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	D816F	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	16397263	Other	Therapeutic	D
KIT	MUT	D816F	Any cancer type	Dasatinib	Responsive	Pre-clinical	16397263	Cancer	Therapeutic	D
KIT	MUT	D816	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	D816	Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis	Imatinib	Resistant	FDA guidelines	FDA	Blood;Bone_Marrow;Other;Stomach	Therapeutic	A
KIT	MUT	D816H	Advanced Solid Tumor	AZD3229	predicted - sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
KIT	MUT	D816H	Advanced Solid Tumor	Flumatinib	predicted - sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816H	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	D816H	Advanced Solid Tumor	Regorafenib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	D816H	Advanced Solid Tumor	Sunitinib	predicted - sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816H	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	D816	Mastocytosis	Avapritinib	Response	3A	29233825, 30274985	Other	Therapeutic	C
KIT	MUT	D816	Melanoma	Imatinib	Response	2A	23775962, 21642685	Skin	Therapeutic	B
KIT	MUT	D816	Thymic Tumor	Sunitinib, Sorafenib	Response	2A	14991904, 25592632, 19461405, 20571495	Thymus	Therapeutic	B
KIT	MUT	D816V	acute myeloid leukemia	Avapritinib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	acute myeloid leukemia	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	acute myeloid leukemia	Cytarabine + Dasatinib	sensitive	Case Reports/Case Series	18986703	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	Acute myeloid leukemia	Dasatinib	Responsive	Case report	18986703	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	acute myeloid leukemia	Gilteritinib	predicted - sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	D816V	acute myeloid leukemia	Midostaurin	sensitive	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	Acute Myeloid Leukemia		Poor Outcome	B	16384925	Blood;Bone_Marrow	Prognostic	B
KIT	MUT	D816V	acute myeloid leukemia	Quizartinib	resistant	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	acute myeloid leukemia	Sorafenib	resistant	Preclinical - Cell culture	31309543	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	BPR1J373	predicted - sensitive	Preclinical - Cell culture	27512117	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Cabozantinib	resistant	Preclinical	24205792	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Flumatinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Imatinib	resistant	Preclinical	15790786	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Nilotinib	decreased response	Preclinical	20442311	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Ponatinib	resistant	Preclinical	22301675	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Quizartinib	resistant	Preclinical	23497317	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Sunitinib	resistant	Preclinical	19164557	Other	Therapeutic	D
KIT	MUT	D816V	Advanced Solid Tumor	Sunitinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816V	Any cancer type	Dasatinib	Responsive	Pre-clinical	16397263	Cancer	Therapeutic	D
KIT	MUT	D816V	Cancer	Dasatinib,Imatinib	Resistance	C	25317746	Cancer	Therapeutic	C
KIT	MUT	D816V	Cancer	Imatinib	Resistance	D	14645423	Cancer	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Avapritinib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Crenolanib	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	FF-10101	sensitive	Preclinical - Cell culture	29187377	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Gilteritinib	predicted - sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Imatinib	resistant	Preclinical	12481435	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Midostaurin	sensitive	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Quizartinib	resistant	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Sorafenib	resistant	Preclinical - Cell culture	17229632	Blood	Therapeutic	D
KIT	MUT	D816V	hematologic cancer	Sorafenib	resistant	Preclinical - Cell culture	31309543	Blood	Therapeutic	D
KIT	MUT	D816V	Indication other than cancer	Imatinib	resistant	FDA contraindicated	;;	Other	Therapeutic	A
KIT	MUT	D816V	mast cell neoplasm	Avapritinib	predicted - sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
KIT	MUT	D816V	Systemic mastocytosis	Dasatinib	Responsive	Early trials	18559612	Other	Therapeutic	C
KIT	MUT	D816V	Systemic Mastocytosis	Midostaurin	Sensitivity/Response	B	27355533	Other	Therapeutic	B
KIT	MUT	D816V	Systemic Mastocytosis		Poor Outcome	B	26464169	Other	Prognostic	B
KIT	MUT	D816Y	Advanced Solid Tumor	Flumatinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816Y	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	16397263	Other	Therapeutic	D
KIT	MUT	D816Y	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816Y	Advanced Solid Tumor	Sunitinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	D816Y	Any cancer type	Dasatinib	Responsive	Pre-clinical	16397263	Cancer	Therapeutic	D
KIT	MUT	D816Y	mast cell neoplasm	Avapritinib	sensitive	Preclinical	29093181	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D816Y	mast cell neoplasm	DCC-2618	sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	D820A	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	D820E	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	D820E	thymic carcinoma	Sorafenib	predicted - sensitive	Case Reports/Case Series	19461405	Thymus	Therapeutic	D
KIT	MUT	D820E	Thymic	Sorafenib	Responsive	Case report	19461405	Thymus	Therapeutic	D
KIT	MUT	D820G	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	D820N	gastrointestinal stromal tumor	Imatinib	predicted - resistant	Case Reports/Case Series	18628470	Stomach	Therapeutic	D
KIT	MUT	D820V	gastrointestinal stromal tumor	Avapritinib	sensitive	Phase I	29093181	Stomach	Therapeutic	C
KIT	MUT	D820Y	Cutaneous melanoma	Imatinib	Responsive	Case report	23775962	Skin	Therapeutic	D
KIT	MUT	D820Y	Cutaneous melanoma	Nilotinib	Responsive	Case report	25695690	Skin	Therapeutic	D
KIT	MUT	D820Y	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	C	22614970	Stomach	Therapeutic	C
KIT	MUT	D820Y	melanoma	Dasatinib	sensitive	Preclinical - Cell culture	29035277	Skin	Therapeutic	D
KIT	MUT	D820Y	Melanoma	Imatinib	Resistance	C	21642685	Skin	Therapeutic	C
KIT	MUT	D820Y	melanoma	Imatinib	resistant	Preclinical - Cell culture	29035277	Skin	Therapeutic	D
KIT	MUT	D820Y	melanoma	SEL201	sensitive	Preclinical - Cell line xenograft	29035277	Skin	Therapeutic	D
KIT	MUT	D820Y	melanoma	Sorafenib	predicted - sensitive	Case Reports/Case Series	20372153	Skin	Therapeutic	D
KIT	MUT	D820Y	Melanoma	Sunitinib		D	19035443	Skin	Therapeutic	D
KIT	MUT	E554K	Gastrointestinal Stromal Tumor in Stomach/Small Intestine			1	28801876	Other;Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Dasatinib	predicted - sensitive	Phase II	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	DCC-2618	predicted - sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib + MK2206	sensitive	Preclinical - Cell line xenograft	27370604	Stomach	Therapeutic	D
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib + PKF118-310	sensitive	Preclinical - Cell culture	28611108	Stomach	Therapeutic	D
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib	sensitive	Guideline	30188977;	Stomach	Therapeutic	A
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib	sensitive	Guideline	;	Stomach	Therapeutic	A
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib	sensitive	Phase III	26687836	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib	sensitive	Phase III	28196207	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Imatinib + XAV939	sensitive	Preclinical - Cell culture	28611108	Stomach	Therapeutic	D
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Nilotinib	sensitive	Phase III	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Pexidartinib + PLX9486	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	PLX9486	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Ponatinib	predicted - sensitive	Phase II	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Regorafenib	sensitive	Phase II	27371698	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	gastrointestinal stromal tumor	Sunitinib	decreased response	Clinical Study - Cohort	26772734	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 any	melanoma	Imatinib	predicted - sensitive	Case Reports/Case Series	20372153	Skin	Therapeutic	D
KIT	MUT	exon(s) 11 any	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	exon(s) 11 any	melanoma	Nilotinib	sensitive	Phase II	28843487	Skin	Therapeutic	C
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	B	14645423	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	B	18955451	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor		Poor Outcome	B	10485475	Stomach	Prognostic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor		Positive	B	10485475	Stomach	Diagnostic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	B	22614970	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	B	23177515	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	B	27371698	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	B	18955458	Stomach	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Melanoma	Imatinib	Sensitivity/Response	B	23775962	Skin	Therapeutic	B
KIT	MUT	exon(s) 11 mutation	Melanoma	Sunitinib	Sensitivity/Response	C	22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 any	gastrointestinal stromal tumor	Imatinib + MK2206	sensitive	Preclinical - Cell culture	27370604	Stomach	Therapeutic	D
KIT	MUT	exon(s) 13 any	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 any	melanoma	Nilotinib	sensitive	Phase II	28843487	Skin	Therapeutic	C
KIT	MUT	exon(s) 13 mutation	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	14645423	Stomach	Therapeutic	C
KIT	MUT	exon(s) 14 mutation	Gastrointestinal Stromal Tumor		Poor Outcome	B	16551858	Stomach	Prognostic	B
KIT	MUT	exon(s) 17 any	Advanced Solid Tumor	Avapritinib	sensitive	Preclinical	29093181	Other	Therapeutic	D
KIT	MUT	exon(s) 17 any	gastrointestinal stromal tumor	Avapritinib	sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 any	gastrointestinal stromal tumor	Pexidartinib + PLX9486	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 any	gastrointestinal stromal tumor	PLX9486	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 mutation	Gastrointestinal Stromal Tumor	Imatinib, Sunitinib	Resistant	R2	22301675, 23840364, 25239608, 18955458	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Response	1	23177515	Stomach	Therapeutic	A
KIT	MUT	exon(s) 17 mutation	Gastrointestinal Stromal Tumor	Sorafenib	Response	2A	23140824, 22270258	Stomach	Therapeutic	B
KIT	MUT	exon(s) 17 mutation	Melanoma	Imatinib	Response	2A	23775962, 21642685	Skin	Therapeutic	B
KIT	MUT	exon(s) 17 mutation	Thymic Tumor	Sunitinib, Sorafenib	Response	2A	14991904, 25592632, 19461405, 20571495	Thymus	Therapeutic	B
KIT	MUT	exon(s) 9 any	Advanced Solid Tumor	Imatinib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	exon(s) 9 any	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	exon(s) 9 any	Advanced Solid Tumor	Regorafenib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	exon(s) 9 any	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	exon(s) 9 any	gastrointestinal stromal tumor	Imatinib	sensitive	Guideline	30188977;	Stomach	Therapeutic	A
KIT	MUT	exon(s) 9 any	gastrointestinal stromal tumor	Imatinib	sensitive	Guideline	;	Stomach	Therapeutic	A
KIT	MUT	exon(s) 9 any	gastrointestinal stromal tumor	Sunitinib	predicted - sensitive	Clinical Study - Cohort	26772734	Stomach	Therapeutic	C
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Imatinib	Reduced Sensitivity	B	18955451	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	B	14645423	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	B	16624552	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Reduced Sensitivity	B	22614970	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Reduced Sensitivity	C	27371698	Stomach	Therapeutic	C
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	B	23177515	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Sunitinib	Sensitivity/Response	B	18955458	Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 mutation	Gastrointestinal Stromal Tumor	Sunitinib	Sensitivity/Response	B	22439647	Stomach	Therapeutic	B
KIT	MUT	exon(s) 10 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	exon(s) 11 any	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	exon(s) 11 any	Gastrointestinal Stromal Tumor in Stomach/Small Intestine			1	24093165,PharmGKB,23127174,26040420	Other;Stomach	Therapeutic	B
KIT	MUT	exon(s) 17 any	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	exon(s) 17 any	Melanoma in Anus			1	16908931,18980976,19718013,28779754	Other	Therapeutic	B
KIT	MUT	exon(s) 8 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	exon(s) 9 insertion	Gastrointestinal Stromal Tumor in Stomach/Small Intestine/Rectum			1	26276366,28524779,24127596	Colorectal;Other;Stomach	Therapeutic	B
KIT	MUT	exon(s) 9 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm in Blood/Bone Marrow			1	24487413,24281161,24443360,24359244,7691885,7512180,7479840,9714703,11074560,12481435,12569358,12701114,15070706,16183119,16741248,17065430,24226631,24164801,23053179	Blood;Bone_Marrow	Therapeutic	B
KIT	MUT	Gain-of-Function	Advanced Solid Tumor	PLX9486	sensitive	Preclinical	;	Other	Therapeutic	D
KIT	MUT	Gain-of-Function	gastrointestinal stromal tumor	Cabozantinib	sensitive	Preclinical	25836719	Stomach	Therapeutic	D
KIT	MUT	Gain-of-Function	gastrointestinal stromal tumor	N/A	not applicable	Guideline	;	Stomach	Diagnostic	A
KIT	MUT	Gain-of-Function	gastrointestinal stromal tumor	Pexidartinib	sensitive	Preclinical - Cell line xenograft	24583793	Stomach	Therapeutic	D
KIT	MUT	Gain-of-Function	melanoma	Imatinib	sensitive	Guideline	;	Skin	Therapeutic	A
KIT	MUT	H697Y	Advanced Solid Tumor	Imatinib	decreased response	Preclinical	19861435	Other	Therapeutic	D
KIT	MUT	H697Y	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	19861435	Other	Therapeutic	D
KIT	MUT	H697Y	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	H697Y	Thymic	Sunitinib	Responsive	Pre-clinical	19861435	Thymus	Therapeutic	D
KIT	MUT	I571_D579dup	Advanced Solid Tumor	Flumatinib	predicted - resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	I571_D579dup	Advanced Solid Tumor	Imatinib	predicted - resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	I571_D579dup	Advanced Solid Tumor	Sunitinib	predicted - resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	416_422del	Acute myeloid leukemia	Imatinib	Responsive	Pre-clinical	15618474	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	577_579del	Thymic	Sorafenib	Responsive	Case report	20970876	Thymus	Therapeutic	D
KIT	MUT	560_560del	Thymic	Imatinib	Responsive	Case report	15201427	Thymus	Therapeutic	D
KIT	MUT	inframe insertion 416-422	Acute myeloid leukemia	Imatinib	Responsive	Pre-clinical	15618474	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	484_487del	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	18955451	Stomach	Therapeutic	C
KIT	MUT	550_558del	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	550_557del	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	550_557del	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	550_557del	Advanced Solid Tumor	Regorafenib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	550_557del	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	550_557del	Gastrointestinal Stromal Tumor	Sunitinib,Regorafenib,Ponatinib,Imatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	K558delinsKNP	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	K558delinsKNP	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	K558delinsKNP	Advanced Solid Tumor	Regorafenib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	K558delinsKNP	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	K558delinsKR	gastrointestinal stromal tumor	Cabozantinib	sensitive	Preclinical - Pdx	27777285	Stomach	Therapeutic	D
KIT	MUT	K558delinsKR	gastrointestinal stromal tumor	Imatinib	sensitive	Preclinical - Pdx	27777285	Stomach	Therapeutic	D
KIT	MUT	K558NP	Gastrointestinal Stromal Tumor	Regorafenib,Sunitinib,Ponatinib,Imatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	558_559del	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	K642E	gastrointestinal stromal tumor	Axitinib	sensitive	Preclinical - Patient cell culture	31205508	Stomach	Therapeutic	D
KIT	MUT	K642E	gastrointestinal stromal tumor	BGJ398 + Imatinib	sensitive	Preclinical - Cell culture	25673643	Stomach	Therapeutic	D
KIT	MUT	K642E	gastrointestinal stromal tumor	Ponatinib	sensitive	Preclinical	25239608	Stomach	Therapeutic	D
KIT	MUT	K642E	gastrointestinal stromal tumor	Regorafenib	sensitive	Preclinical - Cell culture	21170960	Stomach	Therapeutic	D
KIT	MUT	K642E	Gastrointestinal Stromal Tumor	Sunitinib,Ponatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	K642E	gastrointestinal stromal tumor	Sunitinib	sensitive	Preclinical - Patient cell culture	31205508	Stomach	Therapeutic	D
KIT	MUT	K642E	Melanoma		Better Outcome	C	18510589	Skin	Prognostic	C
KIT	MUT	K642E	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	K642E	vulvar melanoma	Imatinib	predicted - sensitive	Case Reports/Case Series	20372153	Other	Therapeutic	D
KIT	MUT	L576P	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	L576P	Cancer	Dasatinib,Imatinib	Sensitivity/Response	D	25317746	Cancer	Therapeutic	D
KIT	MUT	L576P	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	L576P	Lung Non-small Cell Carcinoma	Dasatinib,Imatinib,Nilotinib	Sensitivity/Response	D	17372901	Lung	Therapeutic	D
KIT	MUT	L576P	melanoma	Bevacizumab + Sorafenib	predicted - sensitive	Case Reports/Case Series	25363205	Skin	Therapeutic	D
KIT	MUT	L576P	melanoma	Dasatinib	sensitive	Case Reports/Case Series	19671763	Skin	Therapeutic	D
KIT	MUT	L576P	melanoma	Dasatinib	sensitive	Preclinical - Cell culture	29035277	Skin	Therapeutic	D
KIT	MUT	L576P	Melanoma	Dasatinib	Sensitivity/Response	D	19671763	Skin	Therapeutic	D
KIT	MUT	L576P	Melanoma	Imatinib,Nilotinib,Sorafenib	Resistance	D	19671763	Skin	Therapeutic	D
KIT	MUT	L576P	melanoma	Imatinib	unknown	Case Reports/Case Series	20372153	Skin	Therapeutic	D
KIT	MUT	L576P	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	L576P	melanoma	SEL201	sensitive	Preclinical - Cell line xenograft	29035277	Skin	Therapeutic	D
KIT	MUT	M541L	chronic leukemia	Imatinib	sensitive	Phase I	25015329;18795925	Blood;Bone_Marrow	Therapeutic	C
KIT	MUT	M541L	Chronic Leukemia	Imatinib	Sensitivity/Response	C	25015329	Blood;Bone_Marrow	Therapeutic	C
KIT	MUT	552_558del	gastrointestinal stromal tumor	Ponatinib	predicted - resistant	Case Reports/Case Series	25239608	Stomach	Therapeutic	D
KIT	MUT	552_559del	Advanced Solid Tumor	Motesanib	sensitive	Preclinical - Cell culture	20633291	Other	Therapeutic	D
KIT	MUT	mutant	gastrointestinal stromal tumor	Avapritinib	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	mutant	gastrointestinal stromal tumor	BGJ398 + Imatinib	sensitive	Preclinical - Pdx	25673643	Stomach	Therapeutic	D
KIT	MUT	mutant	gastrointestinal stromal tumor	DCC-2618	predicted - sensitive	Phase I	;	Stomach	Therapeutic	C
KIT	MUT	mutant	gastrointestinal stromal tumor	HQP1351	sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
KIT	MUT	mutant	gastrointestinal stromal tumor	N/A	not applicable	Clinical Study	25193432;26276366;25729899	Stomach	Diagnostic	C
KIT	MUT	mutant	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	mutant	melanoma	Nilotinib	sensitive	Phase II	28843487	Skin	Therapeutic	C
KIT	MUT	mutation	breast cancer	Imatinib + Letrozole	predicted - sensitive	Phase 0	18248884	Breast	Therapeutic	C
KIT	MUT	mutation	gastrointestinal stromal tumor	Imatinib	sensitive	FDA approved	12374669;	Stomach	Therapeutic	A
KIT	MUT	mutation	Gastrointestinal Stromal Tumor	Pictilisib,Imatinib	Sensitivity/Response	D	23231951	Stomach	Therapeutic	D
KIT	MUT	mutation	germ cell cancer	Imatinib	resistant	Phase II	16462496	Ovary;Testis	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	[HSP90 inhibitor]	Responsive	Early trials	22898035	Stomach	Therapeutic	C
KIT	MUT	exon(s) 11 missense	Gastrointestinal stromal	Sunitinib	Resistant	Late trials	18955458	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 missense	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23840364	Stomach	Therapeutic	D
KIT	MUT	exon(s) 17 missense	Gastrointestinal stromal	Nilotinib	Responsive	Early trials	22119758;21456006	Stomach	Therapeutic	C
KIT	MUT	exon(s) 17 missense	Gastrointestinal stromal	Sorafenib	Responsive	Pre-clinical	23840364	Stomach	Therapeutic	D
KIT	MUT	exon(s) 17 missense	Gastrointestinal stromal	Sunitinib	Resistant	Pre-clinical	23840364	Stomach	Therapeutic	D
KIT	MUT	exon(s) 17, 18 missense	Cutaneous melanoma	Imatinib	Resistant	Early trials	21690468;21642685	Skin	Therapeutic	C
KIT	MUT	exon(s) 9 missense	Cutaneous melanoma	Dasatinib	Responsive	Case report	19671763	Skin	Therapeutic	D
KIT	MUT	exon(s) 9 missense	Cutaneous melanoma	Imatinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 9 missense	Cutaneous melanoma	Imatinib	Responsive	NCCN guidelines	NCCN	Skin	Therapeutic	A
KIT	MUT	exon(s) 9 missense	Cutaneous melanoma	Nilotinib	Responsive	Early trials	22068222;25695690	Skin	Therapeutic	C
KIT	MUT	exon(s) 9 missense	Cutaneous melanoma	Sunitinib	Responsive	Late trials	18421059;21642685;21690468;22261812	Skin	Therapeutic	C
KIT	MUT	exon(s) 9 missense	Gastrointestinal stromal	Imatinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 9 missense	Gastrointestinal stromal	Regorafenib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 9 missense	Gastrointestinal stromal	Sunitinib	Responsive	FDA guidelines	FDA	Stomach	Therapeutic	A
KIT	MUT	exon(s) 9, 11 missense	Gastrointestinal stromal	Sorafenib	Responsive	Early trials	22270258	Stomach	Therapeutic	C
KIT	MUT	exon(s) 9, 17 missense	Gastrointestinal stromal	[HSP90 inhibitor]	Responsive	Pre-clinical	21737509	Stomach	Therapeutic	D
KIT	MUT	mutation	Melanoma	Imatinib	Sensitivity/Response	B	21690468	Skin	Therapeutic	B
KIT	MUT	mutation	prostate neuroendocrine neoplasm	Imatinib	no benefit	Preclinical	27980106	Prostate	Therapeutic	D
KIT	MUT	N505I	melanoma	Imatinib	predicted - sensitive	Preclinical	24317392	Skin	Therapeutic	D
KIT	MUT	N505I	melanoma	Sorafenib	sensitive	Preclinical	24317392	Skin	Therapeutic	D
KIT	MUT	N822	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	N822I	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical - Cell culture	21689725	Other	Therapeutic	D
KIT	MUT	N822I	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	21689725	Other	Therapeutic	D
KIT	MUT	N822K	acute myeloid leukemia	Avapritinib	sensitive	Preclinical - Cell culture	29093181	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	acute myeloid leukemia	BPR1J373	sensitive	Preclinical - Cell line xenograft	27512117	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	Acute myeloid leukemia	Dasatinib	Responsive	Pre-clinical	23149070	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	acute myeloid leukemia	DCC-2618	sensitive	Preclinical - Pdx	;	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	Acute Myeloid Leukemia	Ponatinib	Sensitivity/Response	D	21482694	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	acute myeloid leukemia	Sunitinib	predicted - sensitive	Preclinical - Cell culture	31217744	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	Advanced Solid Tumor	Flumatinib	predicted - sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	N822K	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	N822K	Advanced Solid Tumor	Sunitinib	predicted - sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	N822K	gastrointestinal stromal tumor	Imatinib	predicted - resistant	Case Reports/Case Series	26316776	Stomach	Therapeutic	D
KIT	MUT	N822K	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	N822K	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	N822K	Gastrointestinal Stromal Tumor	Regorafenib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	N822K	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	C	22614970	Stomach	Therapeutic	C
KIT	MUT	N822K	leukemia	Ponatinib	sensitive	Preclinical - Cell culture	21482694	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	N822K	Melanoma in Anus			1	16908931,18980976,19718013,28779754	Other	Therapeutic	B
KIT	MUT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Regorafenib, Imatinib, Sunitinib	Response	1	28196207, 18955451, 18235122, 12181401, 17046465, 23177515	Stomach	Therapeutic	A
KIT	MUT	Oncogenic Mutations	Melanoma	Imatinib	Response	2A	23775962, 21642685	Skin	Therapeutic	B
KIT	MUT	Oncogenic Mutations	Thymic Tumor	Sunitinib, Sorafenib	Response	2A	14991904, 25592632, 19461405, 20571495	Thymus	Therapeutic	B
KIT	MUT	551_554del	Advanced Solid Tumor	Imatinib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	551_554del	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	551_554del	Advanced Solid Tumor	Regorafenib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	551_554del	Advanced Solid Tumor	Sunitinib	resistant	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	551_554del	Gastrointestinal Stromal Tumor	Ponatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	551_555del	gastrointestinal stromal tumor	Sorafenib	sensitive	Preclinical - Pdx	19139124	Stomach	Therapeutic	D
KIT	MUT	P551delinsPTL	gastrointestinal stromal tumor	Sorafenib	sensitive	Preclinical - Pdx	19139124	Stomach	Therapeutic	D
KIT	MUT	P551delinsPL	gastrointestinal stromal tumor	Ponatinib	predicted - sensitive	Case Reports/Case Series	25239608	Stomach	Therapeutic	D
KIT	MUT	577_579del	thymic carcinoma	Sorafenib	predicted - sensitive	Case Reports/Case Series	20970876	Thymus	Therapeutic	D
KIT	MUT	S476I	mast-cell leukemia	Midostaurin	predicted - sensitive	Preclinical - Patient cell culture	25209843	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	S476I	mast-cell leukemia	Nilotinib	predicted - sensitive	Preclinical - Patient cell culture	25209843	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	S628N	Cancer	Dasatinib,Imatinib	Sensitivity/Response	D	25317746	Cancer	Therapeutic	D
KIT	MUT	seven-codon duplication in exon 11	Malignant Anus Melanoma	Imatinib	Sensitivity/Response	C	18421059	Skin	Therapeutic	C
KIT	MUT	T417delinsTI	Advanced Solid Tumor	Flumatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	T417delinsTI	Advanced Solid Tumor	Imatinib	conflicting	Preclinical - Cell culture	16015387	Other	Therapeutic	D
KIT	MUT	T417delinsTI	Advanced Solid Tumor	Imatinib	conflicting	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	T417delinsTI	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	T417delinsTY	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	18955451	Stomach	Therapeutic	C
KIT	MUT	T632I	melanoma	Imatinib	predicted - resistant	Case Reports/Case Series	31043947	Skin	Therapeutic	D
KIT	MUT	T670	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	T670I	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	T670I	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	T670I	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	T670I	Gastrointestinal stromal	Imatinib	Resistant	Case report	24687822	Stomach	Therapeutic	D
KIT	MUT	T670I	Gastrointestinal stromal	Ponatinib	Responsive	Pre-clinical	25239608	Stomach	Therapeutic	D
KIT	MUT	T670I	gastrointestinal stromal tumor	Imatinib	predicted - sensitive	Case Reports/Case Series	15236194	Stomach	Therapeutic	D
KIT	MUT	T670I	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KIT	MUT	T670I	Gastrointestinal Stromal Tumor	Imatinib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	T670I	Gastrointestinal Stromal Tumor	Imatinib	Resistant	R2	16551858, 17545544, 23840364, 1675110, 16954519, 17699867	Stomach	Therapeutic	C
KIT	MUT	T670I	Gastrointestinal Stromal Tumor	Regorafenib	Resistance	D	25239608	Stomach	Therapeutic	D
KIT	MUT	T670I	Gastrointestinal Stromal Tumor	Regorafenib, Sunitinib	Response	1	17046465, 17699867, 23177515	Stomach	Therapeutic	A
KIT	MUT	T670I	melanoma	Dasatinib	resistant	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	T670I	melanoma	Imatinib	resistant	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	T670I	Melanoma	Imatinib	Response	2A	23775962, 21642685	Skin	Therapeutic	B
KIT	MUT	T670I	melanoma	Nilotinib	resistant	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	T670I	melanoma	Sunitinib	sensitive	Preclinical	23582185;25594040	Skin	Therapeutic	D
KIT	MUT	T670I	Thymic Tumor	Sunitinib, Sorafenib	Response	2A	14991904, 25592632, 19461405, 20571495	Thymus	Therapeutic	B
KIT	MUT	555_559del	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	V559A	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	V559A	gastrointestinal stromal tumor	Imatinib	predicted - resistant	Case Reports/Case Series	18488160	Stomach	Therapeutic	D
KIT	MUT	V559A	melanoma	Imatinib	predicted - sensitive	Case Reports/Case Series	19812602	Skin	Therapeutic	D
KIT	MUT	V559A	Melanoma in Skin			1	16908931,18980976,28779754	Skin	Therapeutic	B
KIT	MUT	V559A	melanoma	Nilotinib	sensitive	Case Reports/Case Series	28327988	Skin	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical - Cell culture	21689725	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Flumatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21689725	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V559D	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	V559D	Cancer	PD-180970,BMS-354825,Imatinib,SU11248,MLN518	Sensitivity/Response	D	16046538	Cancer	Therapeutic	D
KIT	MUT	559_559del	gastrointestinal stromal tumor	G007-LK + Imatinib	sensitive	Preclinical	28611108	Stomach	Therapeutic	D
KIT	MUT	V559D	gastrointestinal stromal tumor	Axitinib	sensitive	Preclinical - Patient cell culture	31205508	Stomach	Therapeutic	D
KIT	MUT	V559D	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	22114577	Stomach	Therapeutic	C
KIT	MUT	V559D	Gastrointestinal Stromal Tumor	Regorafenib,Imatinib,Ponatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	V559D	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	V559G	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	V559I	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	559_560del	Advanced Solid Tumor	Flumatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	559_560del	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	559_560del	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	24205792	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical	16397263	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Motesanib	sensitive	Preclinical - Cell culture	20633291	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Regorafenib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	22665524	Other	Therapeutic	D
KIT	MUT	V560D	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V560D	Cancer	Imatinib Mesylate	Sensitivity/Response	D	18955458	Cancer	Therapeutic	D
KIT	MUT	560_560del	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	19861435	Other	Therapeutic	D
KIT	MUT	560_560del	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	19861435	Other	Therapeutic	D
KIT	MUT	560_560del	Thymic Carcinoma	Imatinib	Sensitivity/Response	C	15201427	Thymus	Therapeutic	C
KIT	MUT	V560D	Gastrointestinal Stromal Tumor in Stomach/Small Intestine			1	24093165,PharmGKB,23127174,26040420	Other;Stomach	Therapeutic	B
KIT	MUT	V560D	Gastrointestinal Stromal Tumor	Regorafenib,Sunitinib,Ponatinib,Imatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	V560D	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	V560D	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	V560G	Advanced Solid Tumor	Nilotinib	sensitive	Preclinical	20442311	Other	Therapeutic	D
KIT	MUT	V560G	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V560G	Gastrointestinal Stromal Tumor	Regorafenib,Imatinib,Ponatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	V560G	mast-cell leukemia	Avapritinib	sensitive	Preclinical - Cell culture	29093181	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	560_576del	gastrointestinal stromal tumor	Imatinib	sensitive	Preclinical - Pdxcell culture	25239608	Stomach	Therapeutic	D
KIT	MUT	560_576del	gastrointestinal stromal tumor	Ponatinib	sensitive	Preclinical - Pdxcell culture	25239608	Stomach	Therapeutic	D
KIT	MUT	560_576del	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	560_578del	gastrointestinal stromal tumor	Axitinib	sensitive	Preclinical - Cell line xenograft	31205508	Stomach	Therapeutic	D
KIT	MUT	560_578del	gastrointestinal stromal tumor	BGJ398 + Imatinib	sensitive	Preclinical - Cell culture	25673643	Stomach	Therapeutic	D
KIT	MUT	560_578del	gastrointestinal stromal tumor	Imatinib	sensitive	Preclinical	25239608	Stomach	Therapeutic	D
KIT	MUT	560_578del	gastrointestinal stromal tumor	Ponatinib	sensitive	Preclinical - Patient cell culture	25239608	Stomach	Therapeutic	D
KIT	MUT	560_578del	gastrointestinal stromal tumor	Sunitinib	sensitive	Preclinical - Cell culture	31205508	Stomach	Therapeutic	D
KIT	MUT	569_576del	Gastrointestinal Stromal Tumor	Sunitinib	Sensitivity/Response	B	26772734	Stomach	Therapeutic	B
KIT	MUT	V654A	Advanced Solid Tumor	Axitinib	sensitive	Preclinical - Cell line xenograft	31205508	Other	Therapeutic	D
KIT	MUT	V654A	Advanced Solid Tumor	Imatinib	resistant	Preclinical	16751810	Other	Therapeutic	D
KIT	MUT	V654A	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	V654A	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	31205508	Other	Therapeutic	D
KIT	MUT	V654A	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	V654A	Gastrointestinal stromal	Ponatinib	Responsive	Pre-clinical	25239608	Stomach	Therapeutic	D
KIT	MUT	V654A	gastrointestinal stromal tumor	AZD3229	predicted - sensitive	Preclinical - Pdx	;	Stomach	Therapeutic	D
KIT	MUT	V654A	Gastrointestinal Stromal Tumor	Imatinib	Resistance	D	16954519	Stomach	Therapeutic	D
KIT	MUT	V654A	Gastrointestinal Stromal Tumor	Imatinib	Resistant	R2	16551858, 23840364, 18955458, 16954519	Stomach	Therapeutic	C
KIT	MUT	V654A	Gastrointestinal Stromal Tumor	Regorafenib, Sunitinib	Response	1	17046465, 23177515	Stomach	Therapeutic	A
KIT	MUT	V654A	Gastrointestinal Stromal Tumor	Sunitinib	Sensitivity/Response	B	16638875	Stomach	Therapeutic	B
KIT	MUT	V654A	Melanoma	Imatinib	Response	2A	23775962, 21642685	Skin	Therapeutic	B
KIT	MUT	V654A	Thymic Tumor	Sunitinib, Sorafenib	Response	2A	14991904, 25592632, 19461405, 20571495	Thymus	Therapeutic	B
KIT	MUT	W557G	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	23567324	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Dasatinib	sensitive	Preclinical - Cell culture	17699867	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Nilotinib	sensitive	Preclinical - Cell culture	17699867	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell line xenograft	25239608	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Regorafenib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	557_558del	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical	25239608	Other	Therapeutic	D
KIT	MUT	557_558del	gastrointestinal stromal tumor	PD-0325901	sensitive	Preclinical - Cell culture	26936919	Stomach	Therapeutic	D
KIT	MUT	557_558del	Gastrointestinal Stromal Tumor	Ponatinib,Imatinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	557_558del	Gastrointestinal Stromal Tumor	Regorafenib,Sunitinib	Sensitivity/Response	D	25239608	Stomach	Therapeutic	D
KIT	MUT	557_558del	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
KIT	MUT	W557R	melanoma	Nilotinib	sensitive	Phase II	28327988	Skin	Therapeutic	C
KIT	MUT	W557delinsWF	gastrointestinal stromal tumor	Avapritinib	sensitive	Preclinical - Pdx	29093181	Stomach	Therapeutic	D
KIT	MUT	WILDTYPE	acute myeloid leukemia	BPR1J373	sensitive	Preclinical - Cell culture	27512117	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	WILDTYPE	Gastrointestinal stromal	Dasatinib	Responsive	Pre-clinical	16397263	Stomach	Therapeutic	D
KIT	MUT	WILDTYPE	Gastrointestinal stromal	Imatinib	Resistant	Late trials	18955458	Stomach	Therapeutic	C
KIT	MUT	WILDTYPE	Gastrointestinal stromal	Sorafenib	Responsive	Early trials	ASCO 2011 (abstr 10009)	Stomach	Therapeutic	C
KIT	MUT	WILDTYPE	Gastrointestinal stromal	Sunitinib	Responsive	Late trials	18955458	Stomach	Therapeutic	C
KIT	MUT	WILDTYPE	Gastrointestinal Stromal Tumor	Regorafenib	Sensitivity/Response	B	27371698	Stomach	Therapeutic	B
KIT	MUT	WILDTYPE	megakaryocytic leukemia	Avapritinib	decreased response	Preclinical - Cell culture	29093181	Blood;Bone_Marrow	Therapeutic	D
KIT	MUT	Y553N	thymic carcinoma	Imatinib	sensitive	Case Reports/Case Series	21969494	Thymus	Therapeutic	D
KIT	MUT	Y553N	Thymic	Imatinib	Responsive	Case report	21969494	Thymus	Therapeutic	D
KIT	MUT	Y553N	Thymic	Sunitinib	Responsive	Case report	23375402	Thymus	Therapeutic	D
KIT	MUT	Y578C	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	23567324	Other	Therapeutic	D
KIT	MUT	Y823D	Advanced Solid Tumor	Motesanib	sensitive	Preclinical - Cell culture	20633291	Other	Therapeutic	D
KIT	MUT	Y823D	Gastrointestinal stromal	Imatinib	Resistant	Pre-clinical	23582185;21689725;17259998	Stomach	Therapeutic	D
KIT	MUT	Y823D	gastrointestinal stromal tumor	AZD3229	predicted - sensitive	Preclinical - Pdx	;	Stomach	Therapeutic	D
KIT	MUT	Y823D	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	16954519	Stomach	Therapeutic	C
KLF2	MUT	any frameshift	Marginal Zone B Cell Lymphoma in Spleen			2	25428260	Other	Therapeutic	C
KLF2	MUT	any missense	Marginal Zone B Cell Lymphoma in Spleen			2	25428260	Other	Therapeutic	C
KLF2	MUT	any nonsense	Marginal Zone B Cell Lymphoma in Spleen			2	25428260	Other	Therapeutic	C
KMT2A-AFF1	FUS		acute lymphocytic leukemia	AZD5153	predicted - sensitive	Preclinical - Cell line xenograft	27573426	Blood;Bone_Marrow	Therapeutic	D
KMT2A-AFF1	FUS		acute myeloid leukemia	AZD5153	predicted - sensitive	Preclinical - Cell line xenograft	27573426	Blood;Bone_Marrow	Therapeutic	D
KMT2A-AFF1	FUS		acute myeloid leukemia	Dinaciclib	sensitive	Preclinical	26627013	Blood;Bone_Marrow	Therapeutic	D
KMT2A-AFF1	FUS		acute myeloid leukemia	MI-503	sensitive	Preclinical - Cell line xenograft	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A-AFF1	FUS		leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2A-AFF1	FUS		leukemia	IRAK1/4	sensitive	Preclinical - Cell culture	28065413	Blood;Bone_Marrow	Therapeutic	D
KMT2A-ELL	FUS		acute myeloid leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Patient cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2A	FUS	- EP300	acute myeloid leukemia	MI-503	sensitive	Preclinical - Patient cell culture	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A	FUS	fusion	acute myeloid leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Patient cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2A	FUS	fusion	acute myeloid leukemia	MI-503	predicted - sensitive	Preclinical - Cell culture	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A	FUS	MLL-MLLT3	Acute Myeloid Leukemia		Positive	A	19357394	Blood;Bone_Marrow	Diagnostic	A
KMT2A-GAS7	FUS		leukemia	AMI-408	sensitive	Preclinical - Cell line xenograft	26766589	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT10	FUS		acute myeloid leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Patient cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT10	FUS		leukemia	EPZ004777	sensitive	Preclinical	23138183	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT1	FUS		acute myeloid leukemia	MI-503	sensitive	Preclinical - Cell culture	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT1	FUS	NRAS G12D	acute myeloid leukemia	AZ20	predicted - sensitive	Preclinical	27625305	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT1	FUS	NRAS G12D	acute myeloid leukemia	AZD0156	predicted - sensitive	Preclinical	27625305	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT1	FUS	NRAS G12D	acute myeloid leukemia	Dinaciclib	sensitive	Preclinical	26627013	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS		acute myeloid leukemia	Dinaciclib	sensitive	Preclinical	26627013	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS		acute myeloid leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Patient cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS		acute myeloid leukemia	MI-503	sensitive	Preclinical - Patient cell culture	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS		leukemia	IRAK1/4	sensitive	Preclinical	28065413	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS		leukemia	MI-503	sensitive	Preclinical	25817203	Blood;Bone_Marrow	Therapeutic	D
KMT2A-MLLT3	FUS	SRSF2 P95H	acute myeloid leukemia	H3B-8800	sensitive	Preclinical	;	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute leukemia	Pinometostat	predicted - sensitive	Case Reports/Case Series	29724899	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Cytarabine + Dacinostat	sensitive	Preclinical - Cell culture	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Cytarabine + Mocetinostat	sensitive	Preclinical - Cell culture	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Cytarabine + Panobinostat	sensitive	Preclinical - Cell culture	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Cytarabine + Romidepsin	sensitive	Preclinical - Cell line xenograft	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Cytarabine	sensitive	Preclinical - Cell line xenograft	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute lymphocytic leukemia	Romidepsin	decreased response	Preclinical - Cell line xenograft	27443263	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute myeloid leukemia	KO-539	predicted - sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	acute myeloid leukemia	N/A	not applicable	Clinical Study	21881046;24487413;22417203;22915647	Blood;Bone_Marrow	Prognostic	C
KMT2A	MUT	rearrange	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
KMT2A	MUT	rearrange	leukemia	Doxorubicin + I-CBP112	predicted - sensitive	Preclinical	26552700	Blood;Bone_Marrow	Therapeutic	D
KMT2A	MUT	rearrange	leukemia	I-CBP112 + JQ1	predicted - sensitive	Preclinical	26552700	Blood;Bone_Marrow	Therapeutic	D
KMT2A-SEPTIN6	FUS		acute myeloid leukemia	I-BET151 + SGC0946	sensitive	Preclinical - Patient cell culture	27294782	Blood;Bone_Marrow	Therapeutic	D
KMT2C	MUT	mutation	Skin Squamous Cell Carcinoma		Poor Outcome	B	25303977	Skin	Prognostic	B
KMT2D	MUT	LOSS-OF-FUNCTION	Follicular Lymphoma		Positive	B	21796119	Lymph_Nodes	Diagnostic	B
KRAS	CNV	amplification	Colorectal adenocarcinoma	[BRAF inhibitor;EGFR mAb inhibitor]	Resistant	Case report	ENA 2014 (abstr 428)	Colorectal	Therapeutic	D
KRAS	CNV	amplification	Colorectal adenocarcinoma	[BRAF inhibitor;MEK inhibitor]	Resistant	Case report	ENA 2014 (abstr 428)	Colorectal	Therapeutic	D
KRAS	CNV	AMPLIFICATION	Endometrial Cancer		Poor Outcome	B	23099803	Uterus	Prognostic	B
KRAS	CNV	AMPLIFICATION	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
KRAS	CNV	AMPLIFICATION	Skin Melanoma	Docetaxel,Carboplatin,Sorafenib	Sensitivity/Response	B	26307133	Skin	Therapeutic	B
KRAS	MUT	codon(s) 117 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 12 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 12 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 13 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 13 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 146 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 59 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	codon(s) 61 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
KRAS	MUT	A11V	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	A11V	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	A146P	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	A146P	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	A146P	Colorectal Cancer	Cetuximab	Resistance	B	19603018	Colorectal	Therapeutic	B
KRAS	MUT	A146T	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	A146T	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	A146T	Colorectal Cancer	Cetuximab,FOLFOX4	Resistance	B	25666295	Colorectal	Therapeutic	B
KRAS	MUT	A146T	Colorectal Cancer	Cetuximab	Resistance	D	20570890	Colorectal	Therapeutic	D
KRAS	MUT	A146T	Colorectal Cancer	Selumetinib,Dactolisib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	A146V	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	A146V	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	A146V	Colorectal Cancer	Dactolisib,Selumetinib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	A146V	Lung Non-small Cell Carcinoma	LY2835219	Sensitivity/Response	C	24836576	Lung	Therapeutic	C
KRAS	MUT	any mutation	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24166518,24105326,22615103,19075190,2407301,12518368,24569456	Blood;Bone_Marrow	Therapeutic	B
KRAS	MUT	any mutation	Adenocarcinoma/Carcinoma in Esophagus/Gastroesophageal Junction			2	27107065,23158210,18316791,20570890,24024839	Esophagus	Therapeutic	C
KRAS	MUT	any mutation	Adenocarcinoma/Cholangiocarcinoma in Ampulla (Pancreaticobiliary Duct)/Liver			2	25332972,25536104,24867389,24563076	Liver;Pancreas	Therapeutic	C
KRAS	MUT	any mutation	Adenocarcinoma in Appendix			2	24560515,21443421,23199549	Other	Therapeutic	C
KRAS	MUT	any mutation	Adenocarcinoma in Endometrium			2	23851676,23219661,25709969,19261849,26489445	Uterus	Therapeutic	C
KRAS	MUT	any mutation	Adenocarcinoma in Prostate			2	16721785,26299074,22140652	Prostate	Therapeutic	C
KRAS	MUT	any mutation	Mucinous Cystic Neoplasms of Pancreas in Ampulla (Pancreaticobiliary Duct)/Pancreas			2	18515410,16858545,9351717,21775669,19412570	Pancreas	Therapeutic	C
KRAS	MUT	any mutation	Papillary Carcinoma/Follicular Carcinoma in Thyroid			2	22515291,22328910,25132659	Thyroid	Therapeutic	C
KRAS	MUT	any mutation	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	any mutation	Urothelial Carcinoma in Bladder			2	23640097,21072204,22820081	Bladder	Therapeutic	C
KRAS	MUT	any mutation	Urothelial Carcinoma in Kidney/Ureter			2	26278805,23640097,21072204,22820081	Bladder;Kidney	Therapeutic	C
KRAS	MUT	codon(s) 12, 13, 61, 117, 146 any	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24166518,24105326,22615103,19075190,2407301,12518368,24569456	Blood;Bone_Marrow	Therapeutic	B
KRAS	MUT	codon(s) 12, 13, 61, 117, 146 any	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	codon(s) 12, 13, 61, 117, 146 any	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	codon(s) 12, 13, 61, 117, 146 any	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	codon(s) 12, 13, 61, 117, 146 any	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	codon(s) 12 any	Adenocarcinoma in Gall Bladder			2	24508317,25536104	Bladder	Therapeutic	C
KRAS	MUT	exon(s) 2 mutation	Colorectal Cancer	Cetuximab	Resistance	A	18946061	Colorectal	Therapeutic	A
KRAS	MUT	exon(s) 2 mutation	Colorectal Cancer	Cetuximab	Resistance	B	16618717	Colorectal	Therapeutic	B
KRAS	MUT	exon(s) 2 mutation	Colorectal Cancer	EGFR Inhibitor	Resistance	B	27037411	Colorectal	Therapeutic	B
KRAS	MUT	exon(s) 2 mutation	Colorectal Cancer	Irinotecan,Selumetinib	Sensitivity/Response	B	25322874	Colorectal	Therapeutic	B
KRAS	MUT	exon(s) 2 mutation	Pancreatic Cancer	Erlotinib,Gemcitabine	Resistance	B	21862683	Pancreas	Therapeutic	B
KRAS	MUT	exon(s) 2 mutation	Pancreatic Carcinoma		Poor Outcome	B	23435671	Pancreas	Prognostic	B
KRAS	MUT	G12A	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12A	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12A	Adenocarcinoma in Ovary			2	24549645,22930283,28129591	Ovary	Therapeutic	C
KRAS	MUT	G12A	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12A	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	G12A	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12A	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12	Acute Leukemia		Positive	B	24571676	Blood;Bone_Marrow	Diagnostic	B
KRAS	MUT	G12	Acute lymphoblastic leukemia	[MEK inhibitor]	Responsive	Pre-clinical	18701506	Blood;Bone_Marrow	Therapeutic	D
KRAS	MUT	G12A	Lung Adenocarcinoma	Gefitinib,Erlotinib	Resistance	B	19794967	Lung	Therapeutic	B
KRAS	MUT	G12A	Lung Cancer	Gefitinib	Resistance	B	17409929	Lung	Therapeutic	B
KRAS	MUT	G12A	Multiple Myeloma	Melphalan	Resistance	B	19284554	Bone_Marrow	Therapeutic	B
KRAS	MUT	G12A	Multiple Myeloma	Melphalan	Resistance	D	11050000	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12A	Multiple Myeloma	Melphalan	Resistance	D	12483530	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12A	Multiple Myeloma	Melphalan	Resistance	D	16497971	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12A	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G12C	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12C	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12C	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12C	Cancer	EGFR Inhibitor,ARS-853	Sensitivity/Response	D	26739882	Cancer	Therapeutic	D
KRAS	MUT	G12C	Colorectal Cancer	Dactolisib,Selumetinib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	G12C	Colorectal Cancer	Erlotinib,Gefitinib	Resistance	B	23313110	Colorectal	Therapeutic	B
KRAS	MUT	G12C	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12C	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12C	Lung Cancer	Gefitinib	Resistance	B	17409929	Lung	Therapeutic	B
KRAS	MUT	G12C	Lung Cancer		Positive	B	23014527	Lung	Diagnostic	B
KRAS	MUT	G12C	Lung Non-small Cell Carcinoma		Poor Outcome	B	22247021	Lung	Prognostic	B
KRAS	MUT	G12C	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Sensitivity/Response	B	26125448	Lung	Therapeutic	B
KRAS	MUT	G12C	Multiple Myeloma	Melphalan	Resistance	B	19284554	Bone_Marrow	Therapeutic	B
KRAS	MUT	G12C	Multiple Myeloma	Melphalan	Resistance	D	11050000	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12C	Multiple Myeloma	Melphalan	Resistance	D	12483530	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12C	Multiple Myeloma	Melphalan	Resistance	D	16497971	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12C	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G12D	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12D	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12D	Adenocarcinoma in Gall Bladder			2	24508317,25536104	Bladder	Therapeutic	C
KRAS	MUT	G12D	Adenocarcinoma in Ovary			2	24549645,22930283,28129591	Ovary	Therapeutic	C
KRAS	MUT	G12D	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12D	Colorectal Cancer	Dactolisib,Selumetinib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	G12D	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	G12D	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12D	Colorectal Cancer		Positive	B	22948721	Colorectal	Prognostic	B
KRAS	MUT	G12D	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12D	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes	Sensitivity/Response	C	27959684	Colorectal	Therapeutic	C
KRAS	MUT	G12D	Hairy Cell Leukemia	Vemurafenib	Resistance	C	26352686	Blood;Bone_Marrow	Therapeutic	C
KRAS	MUT	G12D	Lung Cancer	Gefitinib	Resistance	B	17409929	Lung	Therapeutic	B
KRAS	MUT	G12D	Lung Cancer		Positive	B	23014527	Lung	Diagnostic	B
KRAS	MUT	G12D	Lung Non-small Cell Carcinoma	Dactolisib,ARRY-142886	Sensitivity/Response	D	19029981	Lung	Therapeutic	D
KRAS	MUT	G12D	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
KRAS	MUT	G12D	Multiple Myeloma	Melphalan	Resistance	B	19284554	Bone_Marrow	Therapeutic	B
KRAS	MUT	G12D	Multiple Myeloma	Melphalan	Resistance	D	11050000	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12D	Multiple Myeloma	Melphalan	Resistance	D	12483530	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12D	Multiple Myeloma	Melphalan	Resistance	D	16497971	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12D	Ovarian Cancer	Cetuximab	Resistance	D	22246397	Ovary	Therapeutic	D
KRAS	MUT	G12D	Pancreatic Cancer		Poor Outcome	B	27010960	Pancreas	Prognostic	B
KRAS	MUT	G12D	Pancreatic Carcinoma	MK-2206	Sensitivity/Response	C	22025163	Pancreas	Therapeutic	C
KRAS	MUT	G12D	Pancreatic Ductal Carcinoma		Poor Outcome	B	27010960	Pancreas	Prognostic	B
KRAS	MUT	G12D	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G12D	Tumor Of Exocrine Pancreas		Poor Outcome	B	23565280	Pancreas	Prognostic	B
KRAS	MUT	G12	Colorectal Cancer	Cetuximab	Resistance	B	19603024	Colorectal	Therapeutic	B
KRAS	MUT	G13	Colorectal Cancer	Cetuximab	Resistance	B	19603024	Colorectal	Therapeutic	B
KRAS	MUT	G12	Colorectal Cancer	Cetuximab	Resistance	B	20619739	Colorectal	Therapeutic	B
KRAS	MUT	G13	Colorectal Cancer	Cetuximab	Resistance	B	20619739	Colorectal	Therapeutic	B
KRAS	MUT	G12	Colorectal Cancer	Cetuximab	Resistance	D	18202412	Colorectal	Therapeutic	D
KRAS	MUT	G13	Colorectal Cancer	Cetuximab	Resistance	D	18202412	Colorectal	Therapeutic	D
KRAS	MUT	G12	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	19223544	Colorectal	Therapeutic	B
KRAS	MUT	G13	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	19223544	Colorectal	Therapeutic	B
KRAS	MUT	G12	Colorectal Cancer		Poor Outcome	D	18202412	Colorectal	Prognostic	D
KRAS	MUT	G13	Colorectal Cancer		Poor Outcome	D	18202412	Colorectal	Prognostic	D
KRAS	MUT	G12	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Resistance	B	15696205	Lung	Therapeutic	B
KRAS	MUT	G13	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Resistance	B	15696205	Lung	Therapeutic	B
KRAS	MUT	G12	Pancreatic Adenocarcinoma	Gemcitabine,Trametinib	Resistance	B	24915778	Pancreas	Therapeutic	B
KRAS	MUT	G13	Pancreatic Adenocarcinoma	Gemcitabine,Trametinib	Resistance	B	24915778	Pancreas	Therapeutic	B
KRAS	MUT	G12	Gastrointestinal stromal	Imatinib	Resistant	Case report	24687822	Stomach	Therapeutic	D
KRAS	MUT	G12	Lung Non-small Cell Carcinoma		Poor Outcome	B	15597105	Lung	Prognostic	B
KRAS	MUT	G12	Multiple Myeloma		Poor Outcome	B	18528420	Bone_Marrow	Prognostic	B
KRAS	MUT	G12R	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12R	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12R	Adenocarcinoma in Ovary			2	24549645,22930283,28129591	Ovary	Therapeutic	C
KRAS	MUT	G12R	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12R	Colorectal Cancer	Cetuximab	Resistance	D	22722830	Colorectal	Therapeutic	D
KRAS	MUT	G12R	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12R	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12R	Pancreatic Cancer		Poor Outcome	B	22983505	Pancreas	Prognostic	B
KRAS	MUT	G12R	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G12S	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12S	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12S	Adenocarcinoma in Ovary			2	24549645,22930283,28129591	Ovary	Therapeutic	C
KRAS	MUT	G12S	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12S	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	G12S	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12S	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12S	Lung Cancer	Gefitinib	Resistance	B	17409929	Lung	Therapeutic	B
KRAS	MUT	G12S	Multiple Myeloma	Melphalan	Resistance	B	19284554	Bone_Marrow	Therapeutic	B
KRAS	MUT	G12S	Multiple Myeloma	Melphalan	Resistance	D	11050000	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12S	Multiple Myeloma	Melphalan	Resistance	D	12483530	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12S	Multiple Myeloma	Melphalan	Resistance	D	16497971	Bone_Marrow	Therapeutic	D
KRAS	MUT	G12S	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G12V	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G12V	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G12V	Adenocarcinoma in Ovary			2	24549645,22930283,28129591	Ovary	Therapeutic	C
KRAS	MUT	G12V	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G12V	Colorectal Cancer	Cetuximab	Resistance	D	20978259	Colorectal	Therapeutic	D
KRAS	MUT	G12V	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	G12V	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G12V	Colorectal Cancer	Regorafenib	Resistance	D	26161928	Colorectal	Therapeutic	D
KRAS	MUT	G12V	Colorectal Cancer	Selumetinib,Dactolisib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	G12V	Lung Cancer	Gefitinib	Resistance	C	17409929	Lung	Therapeutic	C
KRAS	MUT	G12V	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Sensitivity/Response	B	26125448	Lung	Therapeutic	B
KRAS	MUT	G12V	Lung Non-small Cell Carcinoma	PD0332991	Sensitivity/Response	D	20609353	Lung	Therapeutic	D
KRAS	MUT	G12V	Lung Non-small Cell Carcinoma		Poor Outcome	B	26372703	Lung	Prognostic	B
KRAS	MUT	G12V	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G13C	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G13C	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G13C	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G13C	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G13D	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G13D	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G13D	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Resistance	B	25666295	Colorectal	Therapeutic	B
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Resistance	B	26371285	Colorectal	Therapeutic	B
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Resistance	B	26812186	Colorectal	Therapeutic	B
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Resistance	D	22722830	Colorectal	Therapeutic	D
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	20978259	Colorectal	Therapeutic	B
KRAS	MUT	G13D	Colorectal Cancer	Cetuximab	Sensitivity/Response	D	20978259	Colorectal	Therapeutic	D
KRAS	MUT	G13D	Colorectal Cancer	Dactolisib,Selumetinib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
KRAS	MUT	G13D	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	G13D	Colorectal Cancer	Panitumumab	Resistance	C	18316791	Colorectal	Therapeutic	C
KRAS	MUT	G13D	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G13	Multiple Myeloma		Poor Outcome	B	18528420	Bone_Marrow	Prognostic	B
KRAS	MUT	G13R	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G13R	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G13R	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G13R	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G13S	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	G13S	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	G13S	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	G13S	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	G13V	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
KRAS	MUT	mutation	Cancer	AZD5438	Sensitivity/Response	D	26881434	Cancer	Therapeutic	D
KRAS	MUT	mutation	Cancer	G-573,GDC-0623	Sensitivity/Response	D	23934108	Cancer	Therapeutic	D
KRAS	MUT	mutation	Cancer	Trametinib	Sensitivity/Response	D	22169769	Cancer	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Bevacizumab,Chemotherapy	Resistance	B	23828442	Colorectal	Therapeutic	B
KRAS	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	D	22586653	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Dasatinib,Cetuximab	Sensitivity/Response	D	20956938	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	EGFR Inhibitor,IMO	Sensitivity/Response	D	21890455	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Ixazomib	Resistance	D	26709701	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Palbociclib,Binimetinib	Sensitivity/Response	D	27167191	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	A	28275037	Colorectal	Therapeutic	A
KRAS	MUT	mutation	Colorectal Cancer	R1507,Selumetinib	Sensitivity/Response	D	21985784	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	RAF265,Selumetinib	Sensitivity/Response	D	25199829	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Colorectal Cancer	Trametinib,Afatinib	Sensitivity/Response	D	24685132	Colorectal	Therapeutic	D
KRAS	MUT	mutation	Hepatocellular Carcinoma	Sorafenib,Refametinib	Sensitivity/Response	B	25294897	Liver	Therapeutic	B
KRAS	MUT	mutation	Lung Adenocarcinoma		Poor Outcome	B	22810899	Lung	Prognostic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Abemaciclib	Sensitivity/Response	B	27217383	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Afatinib,Trametinib	Sensitivity/Response	D	24685132	Lung	Therapeutic	D
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Atezolizumab,Nivolumab	Sensitivity/Response	B	28525386	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Resistance	A	28492898	Lung	Therapeutic	A
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Sensitivity/Response	B	23200175	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Resistance	B	21258250	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Erlotinib	Resistance	B	21969500	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Pemetrexed,Docetaxel,Trametinib	Sensitivity/Response	B	27876675	Lung	Therapeutic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma		Poor Outcome	B	21969500	Lung	Prognostic	B
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	RAF265,Selumetinib	Sensitivity/Response	D	25199829	Lung	Therapeutic	D
KRAS	MUT	mutation	Lung Non-small Cell Carcinoma	Trametinib	Sensitivity/Response	B	22805291	Lung	Therapeutic	B
KRAS	MUT	mutation	Melanoma	Dabrafenib,Vemurafenib	Resistance	B	24265155	Skin	Therapeutic	B
KRAS	MUT	mutation	Ovarian Cancer	Decitabine	Sensitivity/Response	D	25968887	Ovary	Therapeutic	D
KRAS	MUT	mutation	Pancreatic Adenocarcinoma	SCH772984,AZD8186	Sensitivity/Response	D	26725216	Pancreas	Therapeutic	D
KRAS	MUT	mutation	Pseudomyxoma Peritonei		Poor Outcome	B	27502722	Other	Prognostic	B
KRAS	MUT	oncogenic mutation	Acute myeloid leukemia;Cervix;Ovary	[MEK inhibitor]	Responsive	Pre-clinical	22507781;22169769;19018267	Blood;Bone_Marrow;Cervix;Ovary	Therapeutic	D
KRAS	MUT	oncogenic mutation	Any cancer type	[EZH2 inhibitor]	Resistant	Pre-clinical	26552009	Cancer	Therapeutic	D
KRAS	MUT	oncogenic mutation	Cervix squamous cell	[CDK4/6 inhibitor;MEK inhibitor]	Responsive	Pre-clinical	27167191	Cervix	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	NCCN guidelines	Colorectal	Therapeutic	A
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[EGFR mAb inhibitor;MEK inhibitor]	Responsive	Pre-clinical	24553387	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[MEK inhibitor;BCL-XL inhibitor]	Responsive	Pre-clinical	23245996	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[MEK inhibitor;IGF1R inhibitor]	Responsive	Pre-clinical	24045180	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[MEK inhibitor;PI3K pathway inhibitor]	Responsive	Pre-clinical	22392911	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[MTOR inhibitor;BH3 mimetics]	Responsive	Pre-clinical	24163374	Colorectal	Therapeutic	D
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	Panitumumab	Resistant	NCCN guidelines	NCCN guidelines	Colorectal	Therapeutic	A
KRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	Trastuzumab;Lapatinib	Resistant	Late trials	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	Colorectal	Therapeutic	C
KRAS	MUT	oncogenic mutation	Endometrium	[pan-RAF inhibitor]	Responsive	Case report	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)	Uterus	Therapeutic	D
KRAS	MUT	oncogenic mutation	Endometrium	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	21984976;22662154	Uterus	Therapeutic	D
KRAS	MUT	oncogenic mutation	Endometrium	[PI3K pathway inhibitor]	Resistant	Pre-clinical	22662154	Uterus	Therapeutic	D
KRAS	MUT	oncogenic mutation	Hepatic carcinoma	Sorafenib;MEK inhibitor	Responsive	Early Trials,Case Report	25294897	Liver	Therapeutic	C
KRAS	MUT	oncogenic mutation	Lung	Abemaciclib	Responsive	Early trials	27217383	Lung	Therapeutic	C
KRAS	MUT	oncogenic mutation	Lung adenocarcinoma	Trametinib;Ponatinib	Responsive	Pre-clinical	27338794	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[BET inhibitor]	Responsive	Pre-clinical	23129625;24045185	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung;Billiary tract	[MEK inhibitor]	Responsive	Early trials	23200175;24947927;25667274;25722381;23391555	Lung;Other	Therapeutic	C
KRAS	MUT	oncogenic mutation	Lung	[CDK4/6 inhibitor;MEK inhibitor]	Responsive	Early trials	AACR 2017 (CT046)	Lung	Therapeutic	C
KRAS	MUT	oncogenic mutation	Lung	[CDK4 inhibitor]	Responsive	Pre-clinical	20609353	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[EGFR inhibitor]	Resistant	NCCN guidelines	NCCN guidelines	Lung	Therapeutic	A
KRAS	MUT	oncogenic mutation	Lung	[FAK inhibitor]	Responsive	Pre-clinical	23358651	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[FAS inhibitor]	Responsive	Case report	AACR 2016, abstr LB214	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[FAS inhibitor]	Responsive	Case report	AACR 2016;abstr	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[HSP90 inhibitor (in combination)]	Responsive	Pre-clinical	23012248;21907929	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[JAK/TBK1/IKKÎµ inhibitor]	Responsive	Pre-clinical	24444711	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Lung	[pan-RAF inhibitor]	Responsive	Early trials	AACR 2017 (abstr  CT002)	Lung	Therapeutic	C
KRAS	MUT	oncogenic mutation	Lung	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Early trials	25516890	Lung	Therapeutic	C
KRAS	MUT	oncogenic mutation	Non-small cell lung	[EGFR inhibitor]	Resistant	Pre-clinical	19238210	Lung	Therapeutic	D
KRAS	MUT	oncogenic mutation	Non-small cell lung	Selumetinib	Responsive	Early trials	NCT00890825	Lung	Therapeutic	C
KRAS	MUT	oncogenic mutation	Ovary	Decitabine;BCL2 inhibitor	Responsive	Pre-clinical	25968887	Ovary	Therapeutic	D
KRAS	MUT	oncogenic mutation	Pancreas	Gemcitabine;MEK inhibitor	Responsive	Early trials	23583440	Pancreas	Therapeutic	C
KRAS	MUT	Oncogenic Mutations	All Tumors	Cobimetinib, Binimetinib, Trametinib	Response	4	29247021, 28783719	Cancer	Therapeutic	D
KRAS	MUT	Oncogenic Mutations	Colorectal Cancer	Panitumumab, Cetuximab	Resistant	R1	21228335, 20619739, 18316791, 20921465, 24024839	Colorectal	Therapeutic	A
KRAS	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib	Response	3A	29236635, 30867592	Lymph_Nodes	Therapeutic	C
KRAS	MUT	oncogenic mutation	Stomach	[EGFR mAb inhibitor]	Resistant	Pre-clinical	22614881;22290393	Stomach	Therapeutic	D
KRAS	MUT	Q22X	Colon Mucinous Adenocarcinoma	Panitumumab	Resistance	C	19661358	Colorectal	Therapeutic	C
KRAS	MUT	Q22K	Adenocarcinoma in Lung			2	26018876,25964588,26284123,17056636	Lung	Therapeutic	C
KRAS	MUT	Q61H	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	Q61H	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	Q61H	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	Q61H	Colorectal Cancer	Cetuximab	Resistance	C	22722830	Colorectal	Therapeutic	C
KRAS	MUT	Q61H	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	Q61K	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	Q61K	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	Q61K	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	Q61K	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	Q61L	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	Q61L	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	Q61L	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	Q61L	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	Q61	Multiple Myeloma		Poor Outcome	B	18528420	Bone_Marrow	Prognostic	B
KRAS	MUT	Q61R	Adenocarcinoma/Carcinoma in Pancreas			1	18515410	Pancreas	Therapeutic	B
KRAS	MUT	Q61R	Adenocarcinoma in Colon/Rectum			1	18202412,18316791,28716728,21573178,20570890,24024839	Colorectal	Therapeutic	B
KRAS	MUT	Q61R	Adenocarcinoma/Pleomorphic Carcinoma in Lung			2	26018876	Lung	Therapeutic	C
KRAS	MUT	Q61R	Squamous Cell Carcinoma in Lung			2	24158231,26018876	Lung	Therapeutic	C
KRAS	MUT	V14I	Adenocarcinoma in Colon			2	18316791,26315110,20736745,20949621,19075190	Colorectal	Therapeutic	C
KRAS	MUT	WILDTYPE	Colorectal Cancer	Regorafenib, Panitumumab, Cetuximab	Response	1	31268481, 20921462, 24739896, 20921465, 19339720, 15677699, 23177514	Colorectal	Therapeutic	A
KRT18	EXP	UNDEREXPRESSION	Prostate Cancer		Poor Outcome	D	26892177	Prostate	Prognostic	D
LEPR	EXP	UNDEREXPRESSION	Meningioma		Poor Outcome	B	26894859	Nervous_System	Prognostic	B
LRP1B	CNV	deletion	Ovary	Liposomal Doxorubicin	Resistant	Early trials	22896685	Ovary	Therapeutic	C
LRP1B	CNV	deletion	Glioblastoma Multiforme		Poor Outcome	B	26428308	Brain	Prognostic	B
LRP1B	MUT	exon(s) 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 deletion	Ovarian Cancer	Doxorubicin	Resistance	D	22896685	Ovary	Therapeutic	D
LRP1B	MUT	oncogenic mutation	Ovary	Liposomal Doxorubicin	Resistant	Early trials	22896685	Ovary	Therapeutic	C
LUC7L2	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			2	24220272,23708642,22323480	Blood;Bone_Marrow	Therapeutic	C
MAGEH1	EXP	EXPRESSION	Bile Duct Adenocarcinoma	Gemcitabine	Resistance	D	20088962	Bile_Duct	Therapeutic	D
MAP2K1	MUT	any mutation	Hairy Cell Leukemia in Blood/Bone Marrow			1	24241536	Blood;Bone_Marrow	Therapeutic	B
MAP2K1	MUT	C121S	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	C121S	colorectal cancer	Cetuximab	resistant	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
MAP2K1	MUT	C121S	colorectal cancer	Cetuximab + Trametinib	sensitive	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
MAP2K1	MUT	C121S	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144;23444215;21383288	Skin	Therapeutic	D
MAP2K1	MUT	C121S	Cutaneous melanoma	[novel MEK inhibitor]	Responsive	Pre-clinical	24448821	Skin	Therapeutic	D
MAP2K1	MUT	C121S	Melanoma	Vemurafenib	Resistance	C	21383288	Skin	Therapeutic	C
MAP2K1	MUT	D67N	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	E120D	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	E203K	Cutaneous melanoma	Vemurafenib	Resistant	Case report	23569304	Skin	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F129L	Any cancer type	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Cancer	Therapeutic	D
MAP2K1	MUT	F129L	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	F129L	colorectal cancer	RO4927350	sensitive	Preclinical - Cell line xenograft	21705440	Colorectal	Therapeutic	D
MAP2K1	MUT	F133L	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	F53L	colorectal cancer	Cetuximab	resistant	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
MAP2K1	MUT	F53L	colorectal cancer	Cetuximab + Trametinib	sensitive	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
MAP2K1	MUT	F53L	colorectal cancer	Trametinib	sensitive	Preclinical	26582713	Colorectal	Therapeutic	D
MAP2K1	MUT	F53S	Advanced Solid Tumor	CI-1040	sensitive	Preclinical - Cell culture	12370306	Other	Therapeutic	D
MAP2K1	MUT	G128D	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	H119P	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	I103N	Advanced Solid Tumor	CI-1040	decreased response	Preclinical - Cell culture	12370306	Other	Therapeutic	D
MAP2K1	MUT	I103N	Any cancer type	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Cancer	Therapeutic	D
MAP2K1	MUT	I103N	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	I103N	melanoma	CI-1040	resistant	Preclinical - Cell culture	19915144	Skin	Therapeutic	D
MAP2K1	MUT	I103N	melanoma	Selumetinib	resistant	Preclinical - Cell culture	19915144	Skin	Therapeutic	D
MAP2K1	MUT	I111N	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I111S	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	I99T	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	56_60del	Ovary	Selumetinib	Responsive	Case report	26324360	Ovary	Therapeutic	D
MAP2K1	MUT	K104N	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	K57E	Cutaneous melanoma	Vemurafenib	Resistant	Case report	23569304	Skin	Therapeutic	D
MAP2K1	MUT	K57E	melanoma	Dabrafenib	resistant	Preclinical	24463458	Skin	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	K57N	colorectal cancer	Cetuximab	resistant	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57N	colorectal cancer	Cetuximab + Trametinib	sensitive	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57N	colorectal cancer	Panitumumab	resistant	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57N	colorectal cancer	Panitumumab + Trametinib	sensitive	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57N	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144;23444215;21383288	Skin	Therapeutic	D
MAP2K1	MUT	K57N	Lung Adenocarcinoma		Positive	C	25351745	Lung	Diagnostic	C
MAP2K1	MUT	K57N	lung adenocarcinoma	Selumetinib	sensitive	Preclinical	18632602	Lung	Therapeutic	D
MAP2K1	MUT	K57N	Lung Adenocarcinoma	Selumetinib	Sensitivity/Response	D	18632602	Lung	Therapeutic	D
MAP2K1	MUT	K57N	lymphatic system cancer	Trametinib	sensitive	Case Reports/Case Series	26566875	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	K57T	Colorectal adenocarcinoma	Panitumumab;Trametinib	Responsive	Case report	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57T	colorectal cancer	Cetuximab	predicted - resistant	Case Reports/Case Series	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57T	colorectal cancer	Cetuximab + Trametinib	sensitive	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57T	colorectal cancer	Panitumumab	resistant	Preclinical	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	K57T	colorectal cancer	Panitumumab + Trametinib	sensitive	Case Reports/Case Series	26644315	Colorectal	Therapeutic	D
MAP2K1	MUT	L115A	Advanced Solid Tumor	CI-1040	decreased response	Preclinical - Cell culture	12370306	Other	Therapeutic	D
MAP2K1	MUT	L115	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	L115P	Advanced Solid Tumor	CI-1040	resistant	Preclinical - Cell culture	12370306	Other	Therapeutic	D
MAP2K1	MUT	L115P	melanoma	CI-1040	resistant	Preclinical - Cell culture	19915144	Skin	Therapeutic	D
MAP2K1	MUT	L115P	melanoma	Selumetinib	resistant	Preclinical - Cell culture	19915144	Skin	Therapeutic	D
MAP2K1	MUT	L215P	Any cancer type	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Cancer	Therapeutic	D
MAP2K1	MUT	L215P	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	oncogenic mutation	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Case report	26030179	Colorectal	Therapeutic	D
MAP2K1	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib	Response	3A	25351745, 26324360, 26566875, 25370473	Lymph_Nodes	Therapeutic	C
MAP2K1	MUT	Oncogenic Mutations	Low-Grade Serous Ovarian Cancer	Cobimetinib, Trametinib	Response	3A	25351745, 26324360, 26566875, 25370473	Ovary	Therapeutic	C
MAP2K1	MUT	Oncogenic Mutations	Melanoma	Cobimetinib, Trametinib	Response	3A	25351745, 26324360, 26566875, 25370473	Skin	Therapeutic	C
MAP2K1	MUT	Oncogenic Mutations	Non-Small Cell Lung Cancer	Cobimetinib, Trametinib	Response	3A	25351745, 26324360, 26566875, 25370473	Lung	Therapeutic	C
MAP2K1	MUT	105_107del	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	P124	Any cancer type	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Cancer	Therapeutic	D
MAP2K1	MUT	P124	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	P124	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Early trials	25370473	Skin	Therapeutic	C
MAP2K1	MUT	P124	Cutaneous melanoma	[ERK inhibitor]	Responsive	Pre-clinical	25370473	Skin	Therapeutic	D
MAP2K1	MUT	P124L	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	19915144;21383288	Skin	Therapeutic	D
MAP2K1	MUT	C121S	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	19915144;21383288	Skin	Therapeutic	D
MAP2K1	MUT	P124L	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144;23444215;21383288	Skin	Therapeutic	D
MAP2K1	MUT	P124L	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144	Skin	Therapeutic	D
MAP2K1	MUT	P124L	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	P124L	melanoma	Selumetinib	resistant	Preclinical	19915144	Skin	Therapeutic	D
MAP2K1	MUT	P124Q	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	P124S	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	19915144;21383288	Skin	Therapeutic	D
MAP2K1	MUT	P124S	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144	Skin	Therapeutic	D
MAP2K1	MUT	P124S	Melanoma	Selumetinib	Resistance	D	19915144	Skin	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	Q56P	Any cancer type	Trametinib	Responsive	Pre-clinical	26582713	Cancer	Therapeutic	D
MAP2K1	MUT	Q56P	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	19915144;21383288	Skin	Therapeutic	D
MAP2K1	MUT	Q56P	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	19915144	Skin	Therapeutic	D
MAP2K1	MUT	Q56P	Cutaneous melanoma	Vemurafenib	Resistant	Case report	23569304	Skin	Therapeutic	D
MAP2K1	MUT	Q56P	lung adenocarcinoma	PD-0325901	sensitive	Preclinical	26582713	Lung	Therapeutic	D
MAP2K1	MUT	Q56P	lung adenocarcinoma	Refametinib	sensitive	Preclinical	26582713	Lung	Therapeutic	D
MAP2K1	MUT	Q56P	lung adenocarcinoma	Selumetinib	sensitive	Preclinical	26582713	Lung	Therapeutic	D
MAP2K1	MUT	Q56P	lung adenocarcinoma	Trametinib	sensitive	Preclinical	26582713	Lung	Therapeutic	D
MAP2K1	MUT	Q56P	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	26566875	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	Q56P	lymphatic system cancer	Cobimetinib	predicted - sensitive	Case Reports/Case Series	30867592	Lymph_Nodes	Therapeutic	D
MAP2K1	MUT	Q56P	Melanoma	Selumetinib	Resistance	D	19915144	Skin	Therapeutic	D
MAP2K1	MUT	Q56P	stomach cancer	Selumetinib	sensitive	Preclinical	22327936	Stomach	Therapeutic	D
MAP2K1	MUT	Q56P	stomach cancer	Trametinib	sensitive	Preclinical	26582713	Stomach	Therapeutic	D
MAP2K1	MUT	56_60del	Ovarian Serous Carcinoma	Selumetinib	Sensitivity/Response	C	26324360	Ovary	Therapeutic	C
MAP2K1	MUT	V211D	Advanced Solid Tumor	AZD8330	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	Binimetinib	predicted - resistant	Preclinical	31227518	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	Cobimetinib	predicted - resistant	Preclinical	31227518	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	GDC0879	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	PD98059	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	PLX4720	sensitive	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	Regorafenib	resistant	Preclinical - Cell culture	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Advanced Solid Tumor	Selumetinib	resistant	Preclinical	29753091	Other	Therapeutic	D
MAP2K1	MUT	V211D	Any cancer type	[MEK inhibitor]	Resistant	Pre-clinical	19915144	Cancer	Therapeutic	D
MAP2K1	MUT	V60E	melanoma	Dabrafenib	resistant	Preclinical	24265153	Skin	Therapeutic	D
MAP2K1	MUT	V60E	melanoma	Trametinib	resistant	Preclinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	C125S	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	C125S	Cutaneous melanoma	[MEK inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	L46F	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	L46F	Cutaneous melanoma	[MEK inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	N126D	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	N126D	Cutaneous melanoma	[MEK inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib	Response	3A	29236635, 30867592	Lymph_Nodes	Therapeutic	C
MAP2K2	MUT	Q60P	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	24265154	Skin	Therapeutic	D
MAP2K2	MUT	Q60P	Cutaneous melanoma	[MEK inhibitor]	Resistant	Case report	24265154	Skin	Therapeutic	D
MAP2K2	MUT	V35M	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K2	MUT	V35M	Cutaneous melanoma	[MEK inhibitor]	Resistant	Pre-clinical	24265153	Skin	Therapeutic	D
MAP2K7	MUT	E116K	Lung Cancer		Poor Outcome	B	27028764	Lung	Prognostic	B
MAPK1	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	WZ4002	Resistance	D	22961667	Lung	Therapeutic	D
MAPK1	MUT	E322K	Head And Neck Squamous Cell Carcinoma	Erlotinib	Sensitivity/Response	C	26181029	Head_and_Neck	Therapeutic	C
MCL1	CNV	amplification	Any cancer type	[Tubulin inhibitor]	Resistant	Pre-clinical	21368834	Cancer	Therapeutic	D
MDM2	CNV	amplification	Liposarcoma	[MDM2 inhibitor]	Responsive	Early trials	23084521;ASCO 2015 (abstr 10564)	Soft_Tissue	Therapeutic	C
MDM2	CNV	amplification	Male germ cell tumor	Cisplatin	Resistant	Early trials	27646943	Testis	Therapeutic	C
MDM2	EXP	EXPRESSION	Malignant Pleural Mesothelioma	Cisplatin,Pemetrexed	Resistance	B	25668009	Other	Therapeutic	B
MDM2	EXP	EXPRESSION	Malignant Pleural Mesothelioma		Poor Outcome	B	25668009	Other	Prognostic	B
MDM2	CNV	Amplification	Liposarcoma	Milademetan Tosylate, RO5045337	Response	3A	23400593, 23084521	Soft_Tissue	Therapeutic	C
MDM2	CNV	copy number gain	Urothelial Carcinoma in Bladder			1	26475335,16160477,18500263,12409668,19737942,25121597,11971182,23593348	Bladder	Therapeutic	B
MDM2	MUT	SNP309	Head And Neck Cancer		Poor Outcome	B	26916894	Head_and_Neck	Prognostic	B
MDM4	CNV	amplification	Sarcoma	[MDM2/MDMX inhibitor]	Responsive	Pre-clinical	24336067	Other	Therapeutic	D
MEF2B	MUT	any mutation	Mantle Cell Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma in Blood/Bone Marrow/Lymph Node			2	24145436,22343534,21796119	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
MEN1	MUT	any frameshift	Thyroid Hurthle Cell Carcinoma		Positive	C	25625803	Thyroid	Diagnostic	C
MERTK	EXP	OVEREXPRESSION	Melanoma	UNC1062	Sensitivity/Response	D	23585477	Skin	Therapeutic	D
MET	CNV	amplification	Colorectal adenocarcinoma	[BCL2 inhibitor]	Responsive	Pre-clinical	27397505	Colorectal	Therapeutic	D
MET	CNV	amplification	Colorectal adenocarcinoma	Cabozantinib;Panitumumab	Responsive	Case report	ENA 2015 (abstr A52)	Colorectal	Therapeutic	D
MET	CNV	amplification	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Early trials	23729478	Colorectal	Therapeutic	C
MET	CNV	amplification	Glioma	Crizotinib	Responsive	Case report	22162573	Nervous_System	Therapeutic	D
MET	CNV	amplification	Hepatic carcinoma	[MET inhibitor]	Responsive	Case report	ENA 2015 (abstract A55)	Liver	Therapeutic	D
MET	CNV	amplification	Lung adenocarcinoma	Osimertinib	Resistant	Case report	27252416	Lung	Therapeutic	D
MET	CNV	amplification	Lung adenocarcinoma	Rociletinib	Resistant	Case report	27252416	Lung	Therapeutic	D
MET	CNV	amplification	Lung adenocarcinoma;Stomach	Crizotinib	Responsive	Early trials	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	Lung;Stomach	Therapeutic	C
MET	CNV	amplification	Non-small cell lung;Colorectal adenocarcinoma	[EGFR inhibitor 1st gen]	Resistant	Early trials	22189054;23729478	Colorectal;Lung	Therapeutic	C
MET	CNV	amplification	Non-small cell lung	Crizotinib	Responsive	Early trials	NCT02499614;ASCO 2015 (abstr 2595)	Lung	Therapeutic	C
MET	CNV	amplification	Renal	[MET inhibitor]	Responsive	Early trials	23213094;AACR 2016 (abstr CT2006)	Kidney	Therapeutic	C
MET	CNV	amplification	Stomach	[MET inhibitor]	Responsive	Pre-clinical	22729845;23327903	Stomach	Therapeutic	D
MET	CNV	amp	Advanced Solid Tumor	ABT-700	sensitive	Phase I	;	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	AMG 337	conflicting	Clinical Study - Cohort	25326232	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	AMG 337	conflicting	Phase I	30425090	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	Capmatinib	predicted - sensitive	Phase I	;	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	EMD 1204831	decreased response	Clinical Study - Cohort	25326232	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	Emibetuzumab	sensitive	Preclinical	25231402	Other	Therapeutic	D
MET	CNV	amp	Advanced Solid Tumor	SAR125844	predicted - sensitive	Phase I	;29145039	Other	Therapeutic	C
MET	CNV	amp	Advanced Solid Tumor	SYM015	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
MET	CNV	amp	Advanced Solid Tumor	Tepotinib	sensitive	Phase I	;	Other	Therapeutic	C
MET	CNV	amp	colorectal cancer	Cetuximab	resistant	Case Reports/Case Series	23729478	Colorectal	Therapeutic	D
MET	CNV	amp	colorectal cancer	JNJ 38877605	sensitive	Preclinical - Pdx	23729478	Colorectal	Therapeutic	D
MET	CNV	amp	esophagus adenocarcinoma	AMG 337	predicted - sensitive	Case Reports/Case Series	26432108	Esophagus	Therapeutic	D
MET	CNV	amp	esophagus adenocarcinoma	AMG 337	predicted - sensitive	Case Reports/Case Series	30425090	Esophagus	Therapeutic	D
MET	CNV	amp	gastroesophageal adenocarcinoma	AMG 337	predicted - sensitive	Phase II	30366938	Esophagus	Therapeutic	C
MET	CNV	amp	gastroesophageal cancer	AMG 337	predicted - sensitive	Phase I	;	Esophagus	Therapeutic	C
MET	CNV	amp	hepatocellular carcinoma	AMG 337	sensitive	Preclinical - Pdxcell culture	27196749	Liver	Therapeutic	D
MET	CNV	amp	hepatocellular carcinoma	TPX-0022	predicted - sensitive	Preclinical - Pdx	;	Liver	Therapeutic	D
MET	CNV	AMPLIFICATION	Cancer	Crizotinib	Sensitivity/Response	C	25232318	Cancer	Therapeutic	C
MET	CNV	AMPLIFICATION	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	Resistance	D	23729478	Colorectal	Therapeutic	D
MET	CNV	AMPLIFICATION	Colorectal Cancer	Cetuximab,Crizotinib	Sensitivity/Response	D	23729478	Colorectal	Therapeutic	D
MET	CNV	AMPLIFICATION	Colorectal Cancer	Vemurafenib,Crizotinib	Sensitivity/Response	C	27325282	Colorectal	Therapeutic	C
MET	CNV	AMPLIFICATION	Gastric Adenocarcinoma	Onartuzumab	Sensitivity/Response	C	22389872	Stomach	Therapeutic	C
MET	CNV	AMPLIFICATION	Glioblastoma Multiforme	Crizotinib	Sensitivity/Response	C	22162573	Brain	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	25922291	Lung	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	26724472	Lung	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Adenocarcinoma	Erlotinib,Gefitinib	Resistance	C	23470965	Lung	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	21623265	Lung	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	C	27664533	Lung	Therapeutic	C
MET	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	D	21716144	Lung	Therapeutic	D
MET	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	D	17463250	Lung	Therapeutic	D
MET	CNV	AMPLIFICATION	Lung Squamous Cell Carcinoma	Crizotinib	Sensitivity/Response	C	24192513	Lung	Therapeutic	C
MET	CNV	amp	liver cancer	Crizotinib	sensitive	Preclinical - Pdx	26483207	Liver	Therapeutic	D
MET	CNV	amp	lung cancer	AMG 337	sensitive	Preclinical - Cell culture	27196782	Lung	Therapeutic	D
MET	CNV	amp	lung cancer	Glesatinib	sensitive	Preclinical - Cell culture	28765324	Lung	Therapeutic	D
MET	CNV	amp	lung cancer	Golvatinib	sensitive	Preclinical - Cell line xenograft	19832844	Lung	Therapeutic	D
MET	CNV	amp	lung cancer	SAR125844	sensitive	Preclinical - Cell culture	25504634	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Alvespimycin	predicted - sensitive	Preclinical - Cell line xenograft	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	AMG 337	predicted - sensitive	Case Reports/Case Series	30366938	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	AMG 337	predicted - sensitive	Case Reports/Case Series	30425090	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	BEZ235 + Selumetinib	sensitive	Preclinical - Cell line xenograft	24939055	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	BEZ235	sensitive	Preclinical	24939055	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Capmatinib	sensitive	Phase I	;	Lung	Therapeutic	C
MET	CNV	amp	lung non-small cell carcinoma	Crizotinib	sensitive	Case Reports/Case Series	31156053	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	;	Lung	Therapeutic	A
MET	CNV	amp	lung non-small cell carcinoma	Crizotinib	sensitive	Preclinical - Pdx	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Dasatinib	predicted - sensitive	Preclinical - Cell culture	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	EMD 1214063	sensitive	Preclinical - Cell line xenograft	23553846	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Ganetespib	predicted - sensitive	Preclinical - Cell culture	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	KTN0073-IgG2	sensitive	Preclinical - Cell culture	27550450	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Merestinib	predicted - sensitive	Preclinical - Pdx	;	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	MTI-31	sensitive	Preclinical - Cell line xenograft	30796032	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Osimertinib	predicted - resistant	Case Reports/Case Series	30268451	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	PP-121	predicted - sensitive	Preclinical - Cell culture	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	SCC244	sensitive	Preclinical - Pdx	29237805	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	Selumetinib	sensitive	Preclinical	24939055	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	SGX523	sensitive	Preclinical - Cell culture	26483207	Lung	Therapeutic	D
MET	CNV	amp	lung non-small cell carcinoma	TAE226	sensitive	Preclinical	26090892	Lung	Therapeutic	D
MET	CNV	amp	lung squamous cell carcinoma	SCC244	sensitive	Preclinical - Cell line xenograft	29237805	Lung	Therapeutic	D
MET	CNV	amp	papillary renal cell carcinoma	Savolitinib	sensitive	Case Reports/Case Series	30952639	Kidney	Therapeutic	D
MET	CNV	amp	papillary renal cell carcinoma	Savolitinib	sensitive	Phase II	28644771	Kidney	Therapeutic	C
MET	CNV	amp	papillary renal cell carcinoma	Savolitinib	sensitive	Preclinical - Pdx	25779944	Kidney	Therapeutic	D
MET	CNV	amp	stomach cancer	AMG 337	sensitive	Preclinical - Cell line xenograft	27196782	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	ARGX-111	sensitive	Phase I	;	Stomach	Therapeutic	C
MET	CNV	amp	stomach cancer	Debio 1347	no benefit	Preclinical - Cell line xenograft	26438159	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	Glesatinib	sensitive	Preclinical - Cell line xenograft	28765324	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	Golvatinib	sensitive	Preclinical - Cell line xenograft	19832844	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	KTN0073-IgG2	sensitive	Preclinical - Cell line xenograft	27550450	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	M-COPA	sensitive	Preclinical - Cell line xenograft	27197184	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	SAR125844	sensitive	Preclinical - Cell line xenograft	25504634	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	SCC244	sensitive	Preclinical - Cell line xenograft	29237805	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	SGX523	sensitive	Preclinical - Cell line xenograft	19934279	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	TAE226	sensitive	Preclinical	26090892	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	TAS-115	sensitive	Preclinical	24140932	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	Telisotuzumab vedotin	sensitive	Preclinical - Cell line xenograft	27573171	Stomach	Therapeutic	D
MET	CNV	amp	stomach cancer	TPX-0022	predicted - sensitive	Preclinical - Cell line xenograft	;	Stomach	Therapeutic	D
MET	CNV	amp	stomach carcinoma	EMD 1214063	sensitive	Preclinical - Cell line xenograft	23553846	Stomach	Therapeutic	D
MET	CNV	amp	triple-receptor negative breast cancer	Crizotinib	predicted - sensitive	Case Reports/Case Series	;	Breast	Therapeutic	D
MET	CNV	del exon(s) 14 any	Advanced Solid Tumor	Capmatinib	sensitive	Preclinical - Cell culture	28765324	Other	Therapeutic	D
MET	CNV	del exon(s) 14 any	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	28765324	Other	Therapeutic	D
MET	CNV	del exon(s) 14 any	Advanced Solid Tumor	Glesatinib	sensitive	Preclinical - Cell culture	28765324	Other	Therapeutic	D
MET	CNV	del exon(s) 14 any	Advanced Solid Tumor	SYM015	sensitive	Preclinical - Pdxcell culture	;	Other	Therapeutic	D
MET	CNV	del exon(s) 14 any	colorectal cancer	Cabozantinib	sensitive	Preclinical - Patient cell culture	26375439	Colorectal	Therapeutic	D
MET	CNV	del exon(s) 14 any	colorectal cancer	Crizotinib	sensitive	Preclinical - Patient cell culture	26375439	Colorectal	Therapeutic	D
MET	CNV	del exon(s) 14 any	colorectal cancer	PHA-665752	sensitive	Preclinical - Patient cell culture	26375439	Colorectal	Therapeutic	D
MET	CNV	del exon(s) 14 any	colorectal cancer	SAIT301	sensitive	Preclinical - Patient cell culture	26375439	Colorectal	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung adenocarcinoma	Crizotinib	predicted - sensitive	Case Reports/Case Series	25971939	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung adenocarcinoma	Crizotinib	predicted - sensitive	Case Reports/Case Series	31312453	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung adenocarcinoma	Glesatinib	predicted - sensitive	Case Reports/Case Series	28765324	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung cancer	Emibetuzumab	decreased response	Preclinical - Pdx	28679766	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung cancer	Glesatinib	sensitive	Preclinical - Cell culture	28765324	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung cancer	SYM015	sensitive	Preclinical - Pdx	28679766	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung non-small cell carcinoma	KTN0073-IgG1	sensitive	Preclinical - Cell culture	27550450	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung non-small cell carcinoma	Onartuzumab	sensitive	Preclinical - Cell line xenograft	23882082	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	lung non-small cell carcinoma	Savolitinib	predicted - sensitive	Phase II	;	Lung	Therapeutic	C
MET	CNV	del exon(s) 14 any	lung squamous cell carcinoma	Capmatinib	predicted - sensitive	Case Reports/Case Series	25971938	Lung	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach cancer	Emibetuzumab	decreased response	Preclinical - Cell line xenograft	28679766	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach cancer	Glesatinib	sensitive	Preclinical - Cell line xenograft	28765324	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach cancer	SYM015	sensitive	Preclinical - Cell line xenograft	28679766	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach carcinoma	Cabozantinib	sensitive	Preclinical - Cell culture	26375439	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach carcinoma	Crizotinib	sensitive	Preclinical - Patient cell culture	26375439	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach carcinoma	PHA-665752	sensitive	Preclinical - Patient cell culture	26375439	Stomach	Therapeutic	D
MET	CNV	del exon(s) 14 any	stomach carcinoma	SAIT301	sensitive	Preclinical - Patient cell culture	26375439	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	breast cancer	Crizotinib + Rucaparib	sensitive	Preclinical - Cell line xenograft	26779812	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	cholangiocarcinoma	Cabozantinib	predicted - sensitive	Phase II	28192597	Bile_Duct	Therapeutic	C
MET	EXP	OVEREXPRESSION	colorectal cancer	Cetuximab + JNJ 38877605	sensitive	Preclinical - Cell culture	23729478	Colorectal	Therapeutic	D
MET	EXP	OVEREXPRESSION	colorectal cancer	Cetuximab	resistant	Preclinical - Cell culture	23729478	Colorectal	Therapeutic	D
MET	EXP	OVEREXPRESSION	colorectal cancer	JNJ 38877605 + Panitumumab	sensitive	Preclinical - Cell culture	23729478	Colorectal	Therapeutic	D
MET	EXP	OVEREXPRESSION	colorectal cancer	Panitumumab	resistant	Preclinical - Cell culture	23729478	Colorectal	Therapeutic	D
MET	EXP	OVEREXPRESSION	glioblastoma multiforme	Altiratinib	predicted - sensitive	Preclinical - Cell line xenograft	26965451	Brain	Therapeutic	D
MET	EXP	OVEREXPRESSION	hepatocellular carcinoma	SCC244	sensitive	Preclinical - Pdx	29237805	Liver	Therapeutic	D
MET	EXP	OVEREXPRESSION	hepatocellular carcinoma	Tepotinib	sensitive	Preclinical - Pdx	25256830	Liver	Therapeutic	D
MET	EXP	OVEREXPRESSION	hepatocellular carcinoma	Tivantinib	no benefit	Phase III	29625879	Liver	Therapeutic	C
MET	EXP	OVEREXPRESSION	lung adenocarcinoma	Merestinib	sensitive	Preclinical - Cell line xenograft	23275061	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung adenocarcinoma	Telisotuzumab vedotin	predicted - sensitive	Preclinical - Pdx	27573171	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung cancer	Crizotinib + Rucaparib	sensitive	Preclinical - Cell line xenograft	26779812	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung cancer	SYM015	sensitive	Preclinical - Pdxcell culture	28679766	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung non-small cell carcinoma	Erlotinib + Telisotuzumab vedotin	sensitive	Phase I	;	Lung	Therapeutic	C
MET	EXP	OVEREXPRESSION	lung non-small cell carcinoma	SCC244	sensitive	Preclinical - Pdx	29237805	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung non-small cell carcinoma	Telisotuzumab vedotin	sensitive	Phase I	;30285518	Lung	Therapeutic	C
MET	EXP	OVEREXPRESSION	lung non-small cell carcinoma	Telisotuzumab vedotin	sensitive	Preclinical - Cell culture	27573171	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung papillary adenocarcinoma	Telisotuzumab vedotin	sensitive	Preclinical - Cell culture	27573171	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung small cell carcinoma	Ponatinib	sensitive	Preclinical	25122427	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	lung squamous cell carcinoma	EMD 1214063	sensitive	Preclinical - Cell culture	26358474	Lung	Therapeutic	D
MET	EXP	OVEREXPRESSION	malignant mesothelioma	AMG 337	predicted - sensitive	Case Reports/Case Series	30425090	Other	Therapeutic	D
MET	EXP	OVEREXPRESSION	melanoma	XL147	sensitive	Preclinical	25637314	Skin	Therapeutic	D
MET	EXP	OVEREXPRESSION	Skin Melanoma	Vemurafenib	Resistance	B	26359985	Skin	Therapeutic	B
MET	EXP	OVEREXPRESSION	stomach cancer	Crizotinib	sensitive	Preclinical - Cell culture	26432108	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	stomach cancer	KRC-00509	sensitive	Preclinical	26801760	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	stomach cancer	KRC-00715	sensitive	Preclinical	26801760	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	stomach cancer	Merestinib	sensitive	Preclinical - Cell line xenograft	23275061	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	stomach cancer	SYM015	sensitive	Preclinical - Pdxcell culture	28679766	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	stomach carcinoma	EMD 1214063	sensitive	Preclinical - Cell culture	26358474	Stomach	Therapeutic	D
MET	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	Buparlisib + Crizotinib	unknown	Preclinical - Cell line xenograft	29203461	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	Crizotinib + Rucaparib	sensitive	Preclinical - Cell line xenograft	26779812	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	Foretinib + Rucaparib	sensitive	Preclinical - Cell culture	26779812	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	Foretinib + Veliparib	sensitive	Preclinical - Cell line xenograft	26779812	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	triple-receptor negative breast cancer	Rucaparib	decreased response	Preclinical - Cell culture	26779812	Breast	Therapeutic	D
MET	EXP	OVEREXPRESSION	Uveal Melanoma	Crizotinib	Sensitivity/Response	D	24140933	Eye	Therapeutic	D
MET	EXP	OVEREXPRESSION	Uveal Melanoma	Selumetinib,Trametinib	Resistance	D	25952648	Eye	Therapeutic	D
MET	EXP	UNDEREXPRESSION	triple-receptor negative breast cancer	Olaparib	sensitive	Preclinical	26779812	Breast	Therapeutic	D
MET	EXP	UNDEREXPRESSION	triple-receptor negative breast cancer	Rucaparib	sensitive	Preclinical - Cell culture	26779812	Breast	Therapeutic	D
MET	EXP	UNDEREXPRESSION	triple-receptor negative breast cancer	Veliparib	sensitive	Preclinical - Cell culture	26779812	Breast	Therapeutic	D
MET	CNV	Amplification	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	CNV	Amplification	Non-Small Cell Lung Cancer	Erlotinib, Osimertinib, Gefitinib	Resistant	R2	30073261, 30676858, 18093943, 17463250	Lung	Therapeutic	C
MET	CNV	Amplification	Renal Cell Carcinoma	Cabozantinib	Response	2A	27279544, 27462141	Kidney	Therapeutic	B
MET	MUT	D1010H	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	D1010H	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	D1010N	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	D1010N	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	D1010Y	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	D1010Y	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	D1228H	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	D1228H	papillary renal cell carcinoma	Crizotinib	predicted - sensitive	Phase II	29149761	Kidney	Therapeutic	C
MET	MUT	D1228N	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	BMS-777607	predicted - sensitive	Preclinical - Cell culture	28396313	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	Cabozantinib	predicted - sensitive	Preclinical	28396313	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	Capmatinib	predicted - resistant	Preclinical	28396313	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	Crizotinib	predicted - resistant	Preclinical	28396313	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	Merestinib	sensitive	Preclinical - Cell culture	23275061	Other	Therapeutic	D
MET	MUT	D1228N	Advanced Solid Tumor	Savolitinib	predicted - resistant	Preclinical - Cell culture	28396313	Other	Therapeutic	D
MET	MUT	D1228N	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	27343442	Lung	Therapeutic	C
MET	MUT	D1228N	Non-Small Cell Lung Cancer	Crizotinib, Cabozantinib, Capmatinib	Resistant	R2	28396313, 27987579, 28522754, 27343442, 29128427	Lung	Therapeutic	C
MET	MUT	D1228V	Advanced Solid Tumor	Cabozantinib	sensitive	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Advanced Solid Tumor	Capmatinib	resistant	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Advanced Solid Tumor	Glesatinib	sensitive	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Advanced Solid Tumor	Merestinib	sensitive	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Advanced Solid Tumor	Savolitinib	resistant	Preclinical - Cell culture	27694386	Other	Therapeutic	D
MET	MUT	D1228V	Lung Non-small Cell Carcinoma	Cabozantinib	Sensitivity/Response	C	27694386	Lung	Therapeutic	C
MET	MUT	D1228V	Lung Non-small Cell Carcinoma	Savolitinib	Resistance	C	27694386	Lung	Therapeutic	C
MET	MUT	D1246V	Lung adenocarcinoma	[MET inhibitor]	Resistant	Case report	27694386	Lung	Therapeutic	D
MET	MUT	E168D	Adenocarcinoma in Lung			2	19723643,16397241,22973954,15765445,18999102	Lung	Therapeutic	C
MET	MUT	E168D	Advanced Solid Tumor	SU11274	sensitive	Preclinical	19723643	Other	Therapeutic	D
MET	MUT	exon(s) 14 deletion	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	exon(s) 14 deletion	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Atezolizumab	unknown	Clinical Study	30165371	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Capmatinib	sensitive	Phase I	;	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	;	Lung	Therapeutic	A
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Durvalumab	unknown	Clinical Study	30165371	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Ipilimumab + Nivolumab	unknown	Clinical Study	30165371	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Nivolumab	unknown	Clinical Study	30165371	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Pembrolizumab	unknown	Clinical Study	30165371	Lung	Therapeutic	C
MET	MUT	exon(s) 14 any	lung non-small cell carcinoma	Tepotinib	predicted - sensitive	Phase II	;	Lung	Therapeutic	C
MET	MUT	exon(s) 14 SKIPPING	Cancer	Crizotinib	Sensitivity/Response	D	26547802	Cancer	Therapeutic	D
MET	MUT	exon(s) 14 SKIPPING	Lung Adenocarcinoma	Capmatinib	Sensitivity/Response	C	25971938	Lung	Therapeutic	C
MET	MUT	exon(s) 14 SKIPPING	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	25769807	Lung	Therapeutic	C
MET	MUT	exon(s) 14 SKIPPING	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	25971939	Lung	Therapeutic	C
MET	MUT	exon(s) 14 SKIPPING	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	26729443	Lung	Therapeutic	C
MET	MUT	exon(s) 14 SKIPPING	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	26845194	Lung	Therapeutic	C
MET	MUT	exon(s) 14 splice	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	exon(s) 14 splice	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	F1200I	papillary renal cell carcinoma	Crizotinib	predicted - sensitive	Phase II	29149761	Kidney	Therapeutic	C
MET	FUS	Fusions	All Tumors	Crizotinib	Response	4	29102694, 29527595, 29284707	Cancer	Therapeutic	D
MET	MUT	Gain-of-Function	Advanced Solid Tumor	Altiratinib	sensitive	Preclinical - Cell culture	26285778	Other	Therapeutic	D
MET	MUT	Gain-of-Function	Advanced Solid Tumor	Emibetuzumab	sensitive	Preclinical	25231402	Other	Therapeutic	D
MET	MUT	Gain-of-Function	Advanced Solid Tumor	Glesatinib	sensitive	Preclinical	;	Other	Therapeutic	D
MET	MUT	Gain-of-Function	hepatocellular carcinoma	Tepotinib	sensitive	Preclinical	;	Liver	Therapeutic	D
MET	MUT	Gain-of-Function	lung non-small cell carcinoma	Crizotinib	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
MET	MUT	Gain-of-Function	malignant glioma	Merestinib	sensitive	Preclinical - Cell line xenograft	23275061	Nervous_System	Therapeutic	D
MET	MUT	Gain-of-Function	papillary renal cell carcinoma	Savolitinib	predicted - sensitive	Phase II	28644771	Kidney	Therapeutic	C
MET	MUT	Gain-of-Function	sarcoma	BMS-777607	sensitive	Preclinical	22286523	Soft_Tissue	Therapeutic	D
MET	MUT	Gain-of-Function	stomach carcinoma	S-49076	sensitive	Preclinical - Cell line xenograft	23804704	Stomach	Therapeutic	D
MET	MUT	H1112L	Any cancer type	[Crizotinib]	Responsive	Pre-clinical	AACR 2012 (abstr 1786)	Cancer	Therapeutic	D
MET	MUT	H1112L	cancer	SU11274	sensitive	Preclinical	19783361	Cancer	Therapeutic	D
MET	MUT	H1112R	Any cancer type	Crizotinib	Responsive	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	H1112R	Renal	[MET inhibitor]	Responsive	Early trials	23213094	Kidney	Therapeutic	C
MET	MUT	H1112Y	Adenocarcinoma in Lung			2	19723643,16397241,22973954,15765445,18999102	Lung	Therapeutic	C
MET	MUT	H1112Y	cancer	SU11274	sensitive	Preclinical	15064724	Cancer	Therapeutic	D
MET	MUT	kinase domain mutation	Renal	Savolitinib	Responsive	Early trials	28644771	Kidney	Therapeutic	C
MET	MUT	L1195V	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	L1213F	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	L1213V	cancer	SU11274	resistant	Preclinical	15064724	Cancer	Therapeutic	D
MET	MUT	M1131T	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	M1149T	papillary renal cell carcinoma	Crizotinib	predicted - sensitive	Phase II	29149761	Kidney	Therapeutic	C
MET	MUT	M1149T	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	M1250T	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	M1268T	Any cancer type	Crizotinib	Responsive	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	M1268T	cancer	K252a	sensitive	Preclinical	12118367	Cancer	Therapeutic	D
MET	MUT	M1268T	cancer	SU11274	sensitive	Preclinical	15064724	Cancer	Therapeutic	D
MET	MUT	M1268T	Renal	[MET inhibitor]	Responsive	Case report	23610116	Kidney	Therapeutic	D
MET	MUT	mutation	Advanced Solid Tumor	AMG208	no benefit	Phase I	26155941	Other	Therapeutic	C
MET	MUT	mutation	Advanced Solid Tumor	ARGX-111	sensitive	Phase I	;	Other	Therapeutic	C
MET	MUT	mutation	Advanced Solid Tumor	Emibetuzumab	sensitive	Phase I	;	Other	Therapeutic	C
MET	MUT	mutation	Advanced Solid Tumor	INCB028060	sensitive	Phase I	;	Other	Therapeutic	C
MET	MUT	mutation	Advanced Solid Tumor	Merestinib	predicted - sensitive	Preclinical - Pdx	;	Other	Therapeutic	D
MET	MUT	mutation	clear cell sarcoma	Crizotinib	predicted - sensitive	Phase II	28950372	Soft_Tissue	Therapeutic	C
MET	MUT	mutation	glioblastoma multiforme	Altiratinib + Bevacizumab	sensitive	Preclinical - Cell line xenograft	26965451	Brain	Therapeutic	D
MET	MUT	mutation	glioblastoma multiforme	Altiratinib	predicted - sensitive	Preclinical - Cell line xenograft	26965451	Brain	Therapeutic	D
MET	MUT	mutation	glioblastoma multiforme	Ningetinib	sensitive	Preclinical - Cell line xenograft	;	Brain	Therapeutic	D
MET	MUT	exon(s) 16, 17, 18, 19 missense	Renal	Crizotinib	Responsive	Early trials	AACR 2016 (abstr CT2006)	Kidney	Therapeutic	C
MET	MUT	mutation	lung non-small cell carcinoma	Capmatinib	sensitive	Phase I	;	Lung	Therapeutic	C
MET	MUT	mutation	lung non-small cell carcinoma	Emibetuzumab + Erlotinib	sensitive	Phase I	27803065	Lung	Therapeutic	C
MET	MUT	mutation	lung non-small cell carcinoma	Emibetuzumab + Erlotinib	sensitive	Phase I	;	Lung	Therapeutic	C
MET	MUT	mutation	lung non-small cell carcinoma	Erlotinib + Onartuzumab	conflicting	Phase III	24101053;	Lung	Therapeutic	C
MET	MUT	mutation	lung non-small cell carcinoma	Telisotuzumab vedotin	sensitive	Phase I	;	Lung	Therapeutic	C
MET	MUT	mutation	multiple myeloma	Ficlatuzumab	predicted - sensitive	Phase I	24901237	Bone_Marrow	Therapeutic	C
MET	MUT	mutation	myeloid neoplasm	Amuvatinib	predicted - sensitive	Preclinical - Cell culture	24326130	Blood;Bone_Marrow	Therapeutic	D
MET	MUT	mutation	ovarian cancer	Altiratinib	predicted - sensitive	Preclinical - Cell line xenograft	24362531	Ovary	Therapeutic	D
MET	MUT	mutation	Papillary Renal Cell Carcinoma	Foretinib	Sensitivity/Response	B	23213094	Kidney	Therapeutic	B
MET	MUT	mutation	triple-receptor negative breast cancer	Cabozantinib	sensitive	Preclinical - Cell line xenograft	26432786	Breast	Therapeutic	D
MET	MUT	N375S	Advanced Solid Tumor	SU11274	decreased response	Preclinical	19723643	Other	Therapeutic	D
MET	MUT	N375S	oral cavity cancer	Crizotinib	no benefit	Case Reports/Case Series	28514312	Esophagus	Therapeutic	D
MET	MUT	N375S	ovarian carcinoma	Bevacizumab + Sorafenib	predicted - sensitive	Case Reports/Case Series	25363205	Ovary	Therapeutic	D
MET	MUT	R1004G	oral squamous cell carcinoma	Crizotinib	predicted - sensitive	Case Reports/Case Series	31391294	Esophagus	Therapeutic	D
MET	MUT	R988C	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	17483355	Other	Therapeutic	D
MET	MUT	R988C	Any cancer type	Crizotinib	Responsive	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	T1010I	Adenocarcinoma in Lung			2	19723643,16397241,22973954,15765445,18999102	Lung	Therapeutic	C
MET	MUT	T1010I	Any cancer type	Crizotinib	Responsive	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	T1010I	lung carcinoma	Crizotinib	sensitive	Preclinical - Cell culture	17483355	Lung	Therapeutic	D
MET	MUT	V1110I	Any cancer type	Crizotinib	Responsive	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	V1110I	cancer	SU11274	sensitive	Preclinical	19783361	Cancer	Therapeutic	D
MET	MUT	V1110I	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	V1188L	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	V1206L	cancer	SU11274	sensitive	Preclinical	19783361	Cancer	Therapeutic	D
MET	MUT	V12201	Papillary Renal Cell Carcinoma in Kidney			2	15765445,26536169	Kidney	Therapeutic	C
MET	MUT	V1238I	cancer	SU11274	sensitive	Preclinical	19783361	Cancer	Therapeutic	D
MET	MUT	WILDTYPE	Advanced Solid Tumor	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Other	Therapeutic	D
MET	MUT	WILDTYPE	bladder carcinoma	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Bladder	Therapeutic	D
MET	MUT	WILDTYPE	breast cancer	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Breast	Therapeutic	D
MET	MUT	WILDTYPE	cholangiocarcinoma	Merestinib	sensitive	Preclinical - Pdxcell culture	26757360	Bile_Duct	Therapeutic	D
MET	MUT	WILDTYPE	colorectal cancer	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Colorectal	Therapeutic	D
MET	MUT	WILDTYPE	pancreatic cancer	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Pancreas	Therapeutic	D
MET	MUT	WILDTYPE	prostate cancer	BMS-777607	sensitive	Preclinical	20515943	Prostate	Therapeutic	D
MET	MUT	WILDTYPE	prostate cancer	Glesatinib	decreased response	Preclinical - Cell line xenograft	28765324	Prostate	Therapeutic	D
MET	MUT	Y1003C	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	Y1003C	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	Y1003F	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	Y1003F	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	Y1003N	Non-Small Cell Lung Cancer	Cabozantinib, Capmatinib	Response	3A	21918175, 25971939, 25971938, 27693535	Lung	Therapeutic	C
MET	MUT	Y1003N	Non-Small Cell Lung Cancer	Crizotinib	Response	2A	21623265, 25971939, 26729443	Lung	Therapeutic	B
MET	MUT	Y1230C	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	Y1230C	Advanced Solid Tumor	Glesatinib	sensitive	Preclinical - Cell line xenograft	28765324	Other	Therapeutic	D
MET	MUT	Y1230C	Advanced Solid Tumor	Merestinib	sensitive	Preclinical - Cell culture	23275061	Other	Therapeutic	D
MET	MUT	Y1230C	stomach cancer	Capmatinib	resistant	Preclinical - Cell culture	15494073;28765324	Stomach	Therapeutic	D
MET	MUT	Y1230C	stomach cancer	Crizotinib	resistant	Preclinical - Cell culture	15494073;28765324	Stomach	Therapeutic	D
MET	MUT	Y1230C	stomach cancer	Glesatinib	sensitive	Preclinical - Cell culture	28765324;15494073	Stomach	Therapeutic	D
MET	MUT	Y1230C	Any cancer type	Crizotinib	Resistant	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	Y1235D	Any cancer type	Crizotinib	Resistant	Pre-clinical	17483355	Cancer	Therapeutic	D
MET	MUT	Y1230D	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	Altiratinib	predicted - sensitive	Preclinical	26285778	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	BMS-777607	predicted - sensitive	Preclinical - Cell culture	28396313	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	Cabozantinib	predicted - sensitive	Preclinical	28396313	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	Capmatinib	predicted - resistant	Preclinical	28396313	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	Crizotinib	predicted - resistant	Preclinical - Cell line xenograft	28396313	Other	Therapeutic	D
MET	MUT	Y1230H	Advanced Solid Tumor	Savolitinib	predicted - resistant	Preclinical - Cell culture	28396313	Other	Therapeutic	D
MET	MUT	Y1230H	Non-Small Cell Lung Cancer	Crizotinib, Capmatinib	Resistant	R2	27666659, 28396313, 27987579, 28522754, 29128427	Lung	Therapeutic	C
MET	MUT	Y1248H	cancer	SU11274	resistant	Preclinical	15064724	Cancer	Therapeutic	D
MGMT	EXP	UNDEREXPRESSION	Glioblastoma Multiforme	Temozolomide	Sensitivity/Response	B	17442989	Brain	Therapeutic	B
MGMT	EXP	UNDEREXPRESSION	Glioblastoma Multiforme	Temozolomide	Sensitivity/Response	B	21331613	Brain	Therapeutic	B
MGMT	EXP	UNDEREXPRESSION	Malignant Glioma	Temozolomide	Sensitivity/Response	B	21365007	Nervous_System	Therapeutic	B
MGMT	EXP	UNDEREXPRESSION	Neuroendocrine Tumor	Temozolomide	Sensitivity/Response	B	19118063	Nervous_System	Therapeutic	B
MGMT	EXP	UNDEREXPRESSION	Oligodendroglioma	Temozolomide	Sensitivity/Response	B	16541434	Nervous_System	Therapeutic	B
MGMT	MUT	PROMOTER METHYLATION	Anaplastic Oligodendroglioma		Better Outcome	B	19901104	Brain	Prognostic	B
MGMT	MUT	PROMOTER METHYLATION	Glioblastoma Multiforme		Better Outcome	B	11070098	Brain	Prognostic	B
MGMT	MUT	PROMOTER METHYLATION	Glioblastoma Multiforme		Better Outcome	B	15758010	Brain	Prognostic	B
MGMT	MUT	PROMOTER METHYLATION	Glioblastoma Multiforme	Carmustine	Sensitivity/Response	B	11070098	Brain	Therapeutic	B
MGMT	MUT	PROMOTER METHYLATION	Glioblastoma Multiforme	O(6)-benzylguanine	Sensitivity/Response	E	11070098	Brain	Therapeutic	D
MGMT	MUT	PROMOTER METHYLATION	Glioblastoma Multiforme	Temozolomide	Sensitivity/Response	A	15758010	Brain	Therapeutic	A
MIR218-1	EXP	EXPRESSION	Colorectal Cancer		Better Outcome	B	26442524	Colorectal	Prognostic	B
MIR218-1	EXP	UNDEREXPRESSION	Pancreatic Cancer		Poor Outcome	D	26662432	Pancreas	Prognostic	D
MITF	CNV	amplification	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	24265153	Skin	Therapeutic	D
MKI67	EXP	EXPRESSION	Breast Cancer		Poor Outcome	B	26341751	Breast	Prognostic	B
MKI67	EXP	EXPRESSION	Prostate Cancer		Poor Outcome	B	23329234	Prostate	Prognostic	B
MKI67	EXP	overexpression	Renal	Sunitinib	Responsive	Pre-clinical	24086736	Kidney	Therapeutic	D
MLH1	CNV	loss	colon cancer	KU60648	sensitive	Preclinical - Cell culture	28224663	Colorectal	Therapeutic	D
MLH1	EXP	EXPRESSION	Stomach Carcinoma		Poor Outcome	B	27313181	Stomach	Prognostic	B
MLH1	OTH	METHYLATION	Stomach Carcinoma	Oxaliplatin	Resistance	B	24748501	Stomach	Therapeutic	B
MLL2	MUT	oncogenic mutation	Lung squamous cell	Bicalutamide	Responsive	Pre-clinical	27397505	Lung	Therapeutic	D
MMP2	MUT	SERUM LEVELS	Brain Glioma	Bevacizumab	Sensitivity/Response	B	24327581	Brain	Therapeutic	B
MMP2	MUT	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab	Sensitivity/Response	B	26921265	Inflammatory;Breast	Therapeutic	B
MMP9	MUT	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab	Resistance	B	26921265	Inflammatory;Breast	Therapeutic	B
MPL	MUT	codon(s) 515 missense	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis in Blood/Bone Marrow			1	16834459,14764528,16868251,19194467	Blood;Bone_Marrow	Therapeutic	B
MPL	MUT	W515F	Myelodisplasic proliferative syndrome	[JAK inhibitor]	Responsive	Pre-clinical	16834459	Bone_Marrow	Therapeutic	D
MPL	MUT	W515K	myelofibrosis	Everolimus	sensitive	Phase II	21725052	Bone_Marrow	Therapeutic	C
MPL	MUT	W515K	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
MPL	MUT	W515K	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis in Blood/Bone Marrow			1	16834459,14764528,16868251,19194467	Blood;Bone_Marrow	Therapeutic	B
MPL	MUT	W515L	Advanced Solid Tumor	BEZ235 + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
MPL	MUT	W515L	Advanced Solid Tumor	Pictilisib + Ruxolitinib	sensitive	Preclinical	24251790	Other	Therapeutic	D
MPL	MUT	W515L	Advanced Solid Tumor	Ruxolitinib + TGX-221	sensitive	Preclinical	24251790	Other	Therapeutic	D
MPL	MUT	W515L	Advanced Solid Tumor	Ruxolitinib + ZSTK474	sensitive	Preclinical	24251790	Other	Therapeutic	D
MPL	MUT	W515L	hematologic cancer	BMS-911543	sensitive	Preclinical - Cell culture	22015772	Blood	Therapeutic	D
MPL	MUT	W515L	hematologic cancer	CHZ868	sensitive	Preclinical	26175413	Blood	Therapeutic	D
MPL	MUT	W515L	hematologic cancer	NS-018	sensitive	Preclinical - Cell culture	22829185	Blood	Therapeutic	D
MPL	MUT	W515L	myelofibrosis	CHZ868	sensitive	Preclinical	26175413	Bone_Marrow	Therapeutic	D
MPL	MUT	W515L	myelofibrosis	Everolimus	sensitive	Phase II	21725052	Bone_Marrow	Therapeutic	C
MPL	MUT	W515L	myelofibrosis	MK2206	sensitive	Preclinical	23748344	Bone_Marrow	Therapeutic	D
MPL	MUT	W515L	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
MPL	MUT	W515L	myeloproliferative neoplasm	BMS-911543	sensitive	Preclinical - Cell culture	22015772	Blood;Bone_Marrow	Therapeutic	D
MPL	MUT	W515L	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis in Blood/Bone Marrow			1	16834459,14764528,16868251,19194467	Blood;Bone_Marrow	Therapeutic	B
MRE11	CNV	LOSS	Endometrial Cancer	BMN-673	Sensitivity/Response	D	24927325	Uterus	Therapeutic	D
MRE11	MUT	frameshift	Prostate Cancer	Olaparib	Sensitivity/Response	B	26510020	Prostate	Therapeutic	B
MSH2	CNV	LOSS	Urothelial Carcinoma	MEDI4736,MEDI0680	Sensitivity/Response	C	26674132	Bladder	Therapeutic	C
MSH3	MUT	oncogenic mutation	Any cancer type	[DNA-PKc inhibitor]	Responsive	Pre-clinical	24556366	Cancer	Therapeutic	D
MSH6	CNV	loss	colon cancer	KU60648	no benefit	Preclinical - Cell culture	28224663	Colorectal	Therapeutic	D
MSH6	CNV	LOSS	Urothelial Carcinoma	MEDI4736,MEDI0680	Sensitivity/Response	C	26674132	Bladder	Therapeutic	C
MSH6	MUT	mutant	colorectal cancer	N/A	not applicable	Clinical Study	26582061;19125127	Colorectal	Diagnostic	C
MSH6	MUT	T1219I	glioblastoma multiforme	Temozolomide	resistant	Preclinical	19584161	Brain	Therapeutic	D
MTAP	CNV	deletion	Breast Cancer	5-Fluoropyrimidine	Sensitivity/Response	D	26751376	Breast	Therapeutic	D
MTHFR	MUT	A222V	Pancreatic Cancer		Better Outcome	B	27819322	Pancreas	Prognostic	B
MTHFR	MUT	A222V	Rectum Cancer	5-fluorouracil	Sensitivity/Response	B	26693073	Colorectal	Therapeutic	B
MTHFR	MUT	A222V	Stomach Cancer	5-fluorouracil	Sensitivity/Response	B	18704422	Stomach	Therapeutic	B
MTOR	MUT	A2034V	Breast Cancer	Rapamycin (Sirolimus)	Resistance	D	27279227	Breast	Therapeutic	D
MTOR	MUT	C1483Y	T-cell Acute Lymphoblastic Leukemia	Rapamycin (Sirolimus)	Sensitivity/Response	D	24631838	Blood;Bone_Marrow	Therapeutic	D
MTOR	MUT	E1799K	Clear Cell Renal Cell Carcinoma	Rapamycin (Sirolimus)	Sensitivity/Response	D	24631838	Kidney	Therapeutic	D
MTOR	MUT	E2014K	Bladder Cancer	Everolimus	Response	3A	24625776, 23551593	Bladder	Therapeutic	C
MTOR	MUT	E2014K	Bladder	Everolimus	Responsive	Case report	24625776	Bladder	Therapeutic	D
MTOR	MUT	E2419K	Bladder Cancer	Everolimus	Response	3A	24625776, 23551593	Bladder	Therapeutic	C
MTOR	MUT	E2419K	Bladder	Everolimus	Responsive	Case report	24625776	Bladder	Therapeutic	D
MTOR	MUT	F2108L	Any cancer type	[MTOR kinase inhibitor]	Responsive	Pre-clinical	25295501	Cancer	Therapeutic	D
MTOR	MUT	F2108L	Breast Cancer	Rapamycin (Sirolimus)	Resistance	D	27279227	Breast	Therapeutic	D
MTOR	MUT	F2108L	Thyroid carcinoma	Everolimus	Resistant	Case report	25295501	Thyroid	Therapeutic	D
MTOR	MUT	F2108L	Thyroid Gland Carcinoma	Everolimus	Resistance	C	25295501	Thyroid	Therapeutic	C
MTOR	MUT	H1968Y	Melanoma	LY294002,AZD5363	Sensitivity/Response	D	26490311	Skin	Therapeutic	D
MTOR	MUT	I1973F	Angiosarcoma;Renal	Everolimus	Responsive	Case report	ASCO 2015 (abstr 11010);26859683	Kidney;Soft_Tissue	Therapeutic	D
MTOR	MUT	K1771R	Stomach;Anaplastic oligodendroglioma	Everolimus	Responsive	Case report	ASCO 2015 (abstr 11010);26859683	Brain;Stomach	Therapeutic	D
MTOR	MUT	L1460P	Any cancer type	Sirolimus	Responsive	Pre-clinical	24631838	Cancer	Therapeutic	D
MTOR	MUT	L1460P	Renal Cell Carcinoma	Temsirolimus	Response	3A	26831717	Kidney	Therapeutic	C
MTOR	MUT	L2209V	Renal Cell Carcinoma	Temsirolimus	Response	3A	26831717	Kidney	Therapeutic	C
MTOR	MUT	L2427Q	Renal Cell Carcinoma	Temsirolimus	Response	3A	26831717	Kidney	Therapeutic	C
MTOR	MUT	M2327I	Breast Cancer	AZD8055	Resistance	D	27279227	Breast	Therapeutic	D
MTOR	MUT	mutation	Bladder Carcinoma	Everolimus,Pazopanib	Sensitivity/Response	C	24625776	Bladder	Therapeutic	C
MTOR	MUT	mutation	Melanoma		Poor Outcome	B	26490311	Skin	Prognostic	B
MTOR	MUT	N1421D	Bladder	Everolimus	Responsive	Case report	24625776	Bladder	Therapeutic	D
MTOR	MUT	N1421D	Stomach	Everolimus	Responsive	Case report	26859683	Stomach	Therapeutic	D
MTOR	MUT	Oncogenic Mutations	All Solid Tumors	Temsirolimus, Everolimus	Response	4	24631838, 27482884, 30327302, 26831717, 24622468	Other	Therapeutic	D
MTOR	MUT	P2213S	Melanoma	AZD5363,LY294002	Sensitivity/Response	D	26490311	Skin	Therapeutic	D
MTOR	MUT	Q2223K	Renal Cell Carcinoma	Everolimus	Response	3A	24622468	Kidney	Therapeutic	C
MTOR	MUT	Q2223K	Renal	Everolimus	Responsive	Case report	24622468	Kidney	Therapeutic	D
MTOR	MUT	R2505P	Any cancer type	Sirolimus	Responsive	Pre-clinical	24631838	Cancer	Therapeutic	D
MTOR	MUT	S2215Y	Any cancer type	Sirolimus	Responsive	Pre-clinical	24631838	Cancer	Therapeutic	D
MTOR	MUT	S2215Y	Endometrial Adenocarcinoma	Rapamycin (Sirolimus)	Sensitivity/Response	D	24631838	Uterus	Therapeutic	D
MYC	CNV	amplification	Colorectal adenocarcinoma	Temozolomide	Responsive	Pre-clinical	27397505	Colorectal	Therapeutic	D
MYC	CNV	amplification	Myeloma;Neuroblastoma	[BET inhibitor]	Responsive	Pre-clinical	21889194;23430699	Adrenal_Gland;Bone_Marrow;Nervous_System	Therapeutic	D
MYC	CNV	amplification	Neuroblastoma	[CDK7 inhibitor]	Responsive	Pre-clinical	25416950	Adrenal_Gland;Nervous_System	Therapeutic	D
MYC	CNV	amplification	Neuroblastoma	[FACT inhibitor]	Responsive	Pre-clinical	26537256	Adrenal_Gland;Nervous_System	Therapeutic	D
MYC	CNV	amplification	Prostate adenocarcinoma	[PIM inhibitor]	Responsive	Pre-clinical	25505253	Prostate	Therapeutic	D
MYC	EXP	OVEREXPRESSION	Lung Small Cell Carcinoma	Prexasertib,Olaparib,Cisplatin	Sensitivity/Response	D	28490518	Lung	Therapeutic	D
MYC	EXP	OVEREXPRESSION	Multiple Myeloma	JQ-1	Sensitivity/Response	D	21889194	Bone_Marrow	Therapeutic	D
MYCL	EXP	EXPRESSION	Multiple Myeloma	I-BET151,JQ1	Sensitivity/Response	D	27276402	Bone_Marrow	Therapeutic	D
MYCN	CNV	amplification	Medulloblastoma	[SMO inhibitor]	Resistant	Pre-clinical	24951114	Nervous_System	Therapeutic	D
MYCN	CNV	AMPLIFICATION	Neuroblastoma	CBL0137	Sensitivity/Response	D	26537256	Adrenal_Gland;Nervous_System	Therapeutic	D
MYCN	CNV	AMPLIFICATION	Neuroblastoma		Poor Outcome	A	25517749	Adrenal_Gland;Nervous_System	Prognostic	A
MYD88	EXP	OVEREXPRESSION	Breast Cancer	Paclitaxel	Resistance	D	26596839	Breast	Therapeutic	D
MYD88	MUT	any mutation	Lymphoplasmacytic Lymphoma in Blood/Bone Marrow			1	21179087,22931316,21642962,23560587,24224040,23215570,22150006,21519346,21991928,2199192,23285191,24782504,25853747	Blood;Bone_Marrow	Therapeutic	B
MYD88	MUT	Gain-of-Function	diffuse large B-cell lymphoma	Tomivosertib	predicted - sensitive	Preclinical - Cell line xenograft	;	Lymph_Nodes	Therapeutic	D
MYD88	MUT	L265P	B-cell lymphoma	IMO-8400	sensitive	Preclinical - Cell line xenograft	;	Lymph_Nodes	Therapeutic	D
MYD88	MUT	L265P	central nervous system lymphoma	Ibrutinib	sensitive	Phase I	28619981	Lymph_Nodes	Therapeutic	C
MYD88	MUT	L265P	Chronic Lymphocytic Leukemia		Better Outcome	B	24943832	Blood;Bone_Marrow	Prognostic	B
MYD88	MUT	L265P	diffuse large B-cell lymphoma	Ibrutinib	resistant	Phase II	;	Lymph_Nodes	Therapeutic	C
MYD88	MUT	L265P	diffuse large B-cell lymphoma	N/A	not applicable	Clinical Study	26792260;24903481;25055137	Lymph_Nodes	Prognostic	C
MYD88	MUT	L265P	diffuse large B-cell lymphoma	Vorinostat	sensitive	Preclinical - Cell culture	27733371	Lymph_Nodes	Therapeutic	D
MYD88	MUT	L265P	Lymphoplasmacytic Lymphoma in Blood/Bone Marrow			1	21179087,22931316,21642962,23560587,24224040,23215570,22150006,21519346,21991928,2199192,23285191,24782504,25853747	Blood;Bone_Marrow	Therapeutic	B
MYD88	MUT	L265P	non-Hodgkin lymphoma	Ibrutinib	no benefit	Preclinical - Pdx	;	Lymph_Nodes	Therapeutic	D
MYD88	MUT	L265P	WaldenstrÃ¶m macroglobulinemia	Ibrutinib	Responsive	FDA guidelines	25853747	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	A
MYD88	MUT	L265P	WaldenstrÃ¶m's Macroglobulinemia	Ibrutinib	Sensitivity/Response	B	25853747	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
MYD88	MUT	L265P	WaldenstrÃ¶m's Macroglobulinemia	IRAK-1/4 Inhibitor,IMG-2005-5	Sensitivity/Response	D	22931316	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	D
MYD88	MUT	L265P	Waldenstroems macroglobulinemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow;Lymph_Nodes	Diagnostic	A
MYD88	MUT	mutant	lymphoplasmacytic lymphoma	N/A	not applicable	Clinical Study	26230596;22944768	Lymph_Nodes	Diagnostic	C
MYD88	MUT	mutant	marginal zone B-cell lymphoma	N/A	not applicable	Guideline	;	Lymph_Nodes	Diagnostic	A
MYD88	MUT	mutant	Waldenstroems macroglobulinemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow;Lymph_Nodes	Diagnostic	A
MYD88	MUT	WILDTYPE	diffuse large B-cell lymphoma	ST2825	predicted - sensitive	Preclinical	;	Lymph_Nodes	Therapeutic	D
NAPRT	MUT	PROMOTER HYPERMETHYLATION	Cancer	GNE-617	Sensitivity/Response	D	24097869	Cancer	Therapeutic	D
NCOA2	FUS	HEY1-NCOA2	Mesenchymal Chondrosarcoma		Positive	B	22034177	Bone	Diagnostic	B
NCOA2	FUS	HEY1-NCOA2	Mesenchymal Chondrosarcoma		Positive	B	23252872	Bone	Diagnostic	B
NCOA2	FUS	HEY1-NCOA2	Mesenchymal Chondrosarcoma		Positive	B	24124145	Bone	Diagnostic	B
NCOA2	FUS	HEY1-NCOA2	Mesenchymal Chondrosarcoma		Positive	B	26146478	Bone	Diagnostic	B
NCOA2	MUT	any missense	Adenocarcinoma in Prostate			1	20579941,23759327,26799514	Prostate	Therapeutic	B
NCOA2	CNV	copy number gain	Adenocarcinoma in Prostate			1	20579941,23759327,26799514	Prostate	Therapeutic	B
NCOA3	CNV	AMPLIFICATION	Breast Cancer		Poor Outcome	B	23322234	Breast	Prognostic	B
NCOA3	EXP	OVEREXPRESSION	Breast Cancer		Poor Outcome	B	23322234	Breast	Prognostic	B
NEDD9	EXP	EXPRESSION	Hepatocellular Carcinoma		Poor Outcome	B	26893853	Liver	Prognostic	B
NF1	CNV	deletion	Cutaneous melanoma	[Pan-RAF inhibitor;MEK inhibitor]	Responsive	Pre-clinical	26351322	Skin	Therapeutic	D
NF1	CNV	deletion	Cutaneous melanoma	[PD1 Ab inhibitor]	Responsive	Early trials	ASCO 2016 (abstr 105)	Skin	Therapeutic	C
NF1	CNV	deletion	Cutaneous melanoma	Trametinib	Responsive	Pre-clinical	24576830;2524381	Skin	Therapeutic	D
NF1	CNV	deletion	Glioma	Bevacizumab	Responsive	Case report	24232489;2485933	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma;Leukemia	[MEK inhibitor]	Responsive	Pre-clinical	22573716;19727076	Blood;Bone_Marrow;Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma;Malignant peripheral nerve sheat tumor;Leukemia	[MTOR inhibitor]	Responsive	Pre-clinical	19573811;18483311;20505189;24509877	Blood;Bone_Marrow;Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma	Sirolimus;Erlotinib	Responsive	Case report	22434731	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma	Trametinib	Responsive	Case report	26936308	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma	Vinblastine;Nilotinib	Responsive	Case report	ASCO 2016 (abstr 10555)	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Glioma	Vinblastine	Responsive	Early trials	ASCO 2016 (abstr 2019)	Nervous_System	Therapeutic	C
NF1	CNV	deletion	Head an neck;Salivary glands	Everolimus	Responsive	Case report	26859683;ASCO 2016 (abstr e17557)	Esophagus;Head_and_Neck	Therapeutic	D
NF1	CNV	deletion	Lung	Dasatinib	Resistant	Pre-clinical	24296828	Lung	Therapeutic	D
NF1	CNV	deletion	Lung	Erlotinib	Resistant	Pre-clinical	24535670	Lung	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	[AURK inhibitor]	Responsive	Pre-clinical	24373973	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	[BRD4 inhibitor]	Responsive	Pre-clinical	24373973	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	[KIT inhibitor;MTOR inhibitor]	Responsive	Pre-clinical	24718867	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	[MEK inhibitor]	Responsive	Pre-clinical	23221341	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	[MTOR inhibitor;HSP90 inhibitor]	Responsive	Pre-clinical	21907929	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	Sorafenib;Sirolimus	Responsive	Pre-clinical	25810463	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Malignant peripheral nerve sheat tumor	Tamoxifen	Responsive	Pre-clinical	21075781	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Neuroblastoma	[Retinoic Acid]	Resistant	Pre-clinical	20655465	Adrenal_Gland;Nervous_System	Therapeutic	D
NF1	CNV	deletion	Plexiform neurofibroma	Imatinib	Responsive	Early trials	23099009	Nervous_System	Therapeutic	C
NF1	CNV	deletion	Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	Nilotinib	Responsive	Pre-clinical	24173684	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Plexiform neurofibroma	PLX3397	Responsive	Pre-clinical	23099891	Nervous_System	Therapeutic	D
NF1	CNV	deletion	Plexiform neurofibroma	Selumetinib	Responsive	Early trials	ASCO 2014 (abstr 10018)	Nervous_System	Therapeutic	C
NF1	CNV	deletion	Plexiform neurofibroma	Sirolimus	Responsive	Early trials	25314964	Nervous_System	Therapeutic	C
NF1	CNV	LOSS	Malignant Peripheral Nerve Sheath Tumor	JQ1 Compound	Sensitivity/Response	D	24373973	Nervous_System	Therapeutic	D
NF1	MUT	D1644A	Head an neck	Everolimus	Responsive	Case report	ASCO 2015 (abstr 11010);26859683	Head_and_Neck	Therapeutic	D
NF1	MUT	mutation	Plexiform Neurofibroma	Selumetinib	Sensitivity/Response	B	28029918	Nervous_System	Therapeutic	B
NF1	MUT	mutation	Skin Melanoma	AZ628,VTX-11e	Sensitivity/Response	D	23288408	Skin	Therapeutic	D
NF1	MUT	mutation	Skin Melanoma	Rapamycin (Sirolimus),PD0325901	Sensitivity/Response	D	23171796	Skin	Therapeutic	D
NF1	MUT	mutation	Skin Melanoma	Vemurafenib	Resistance	C	23288408	Skin	Therapeutic	C
NF1	MUT	mutation	Skin Melanoma	Vemurafenib	Resistance	D	23171796	Skin	Therapeutic	D
NF1	MUT	oncogenic mutation	Cutaneous melanoma	[Pan-RAF inhibitor;MEK inhibitor]	Responsive	Pre-clinical	26351322	Skin	Therapeutic	D
NF1	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 Ab inhibitor]	Responsive	Early trials	ASCO 2016 (abstr 105)	Skin	Therapeutic	C
NF1	MUT	oncogenic mutation	Cutaneous melanoma	Trametinib	Responsive	Pre-clinical	24576830;2524381	Skin	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma	Bevacizumab	Responsive	Case report	24232489;2485933	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma;Leukemia	[MEK inhibitor]	Responsive	Pre-clinical	22573716;19727076	Blood;Bone_Marrow;Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma;Malignant peripheral nerve sheat tumor;Leukemia	[MTOR inhibitor]	Responsive	Pre-clinical	19573811;18483311;20505189;24509877	Blood;Bone_Marrow;Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma	Sirolimus;Erlotinib	Responsive	Case report	22434731	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma	Trametinib	Responsive	Case report	26936308	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma	Vinblastine;Nilotinib	Responsive	Case report	ASCO 2016 (abstr 10555)	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Glioma	Vinblastine	Responsive	Early trials	ASCO 2016 (abstr 2019)	Nervous_System	Therapeutic	C
NF1	MUT	oncogenic mutation	Head an neck;Salivary glands	Everolimus	Responsive	Case report	26859683;ASCO 2016 (abstr e17557)	Esophagus;Head_and_Neck	Therapeutic	D
NF1	MUT	oncogenic mutation	Hepatic carcinoma	Everolimus;Pazopanib	Responsive	Case report	24931142	Liver	Therapeutic	D
NF1	MUT	oncogenic mutation	Lung	Dasatinib	Resistant	Pre-clinical	24296828	Lung	Therapeutic	D
NF1	MUT	oncogenic mutation	Lung	Erlotinib	Resistant	Pre-clinical	24535670	Lung	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	[AURK inhibitor]	Responsive	Pre-clinical	24373973	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	[BRD4 inhibitor]	Responsive	Pre-clinical	24373973	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	[KIT inhibitor;MTOR inhibitor]	Responsive	Pre-clinical	24718867	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	[MEK inhibitor]	Responsive	Pre-clinical	23221341	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	[MTOR inhibitor;HSP90 inhibitor]	Responsive	Pre-clinical	21907929	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	Sorafenib;Sirolimus	Responsive	Pre-clinical	25810463	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Malignant peripheral nerve sheat tumor	Tamoxifen	Responsive	Pre-clinical	21075781	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Neuroblastoma	[Retinoic Acid]	Resistant	Pre-clinical	20655465	Adrenal_Gland;Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Neurofibroma	Everolimus	Responsive	Late trials	NCT01365468	Nervous_System	Therapeutic	C
NF1	MUT	oncogenic mutation	Plexiform neurofibroma	Imatinib	Responsive	Early trials	23099009	Nervous_System	Therapeutic	C
NF1	MUT	oncogenic mutation	Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	Nilotinib	Responsive	Pre-clinical	24173684	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Plexiform neurofibroma	PLX3397	Responsive	Pre-clinical	23099891	Nervous_System	Therapeutic	D
NF1	MUT	oncogenic mutation	Plexiform neurofibroma	Selumetinib	Responsive	Early trials	ASCO 2014 (abstr 10018)	Nervous_System	Therapeutic	C
NF1	MUT	oncogenic mutation	Plexiform neurofibroma	Sirolimus	Responsive	Early trials	25314964	Nervous_System	Therapeutic	C
NF1	MUT	Oncogenic Mutations	All Solid Tumors	Cobimetinib, Trametinib	Response	4	24576830, 26936308, 24535670	Other	Therapeutic	D
NF2	CNV	deletion	Breast adenocarcinoma	Tensirolimus;Chemotherapy	Responsive	Case report	25878190	Breast	Therapeutic	D
NF2	CNV	deletion	Meningioma	AR42	Responsive	Early trials	ASCO 2016 (abstr 2558)	Nervous_System	Therapeutic	C
NF2	CNV	deletion	Meningioma	Everolimus;Octreotide	Responsive	Pre-clinical	26015296	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Meningioma	[HSP90 inhibitor]	Responsive	Pre-clinical	23714726	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Meningioma	[MTOR inhibitor]	Responsive	Pre-clinical	19451225;2242646	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Mesothelioma	[FAK inhibitor]	Responsive	Early trials	ENA 2012 (abstr 610)	Pleura	Therapeutic	C
NF2	CNV	deletion	Mesothelioma;Ovary	[FAK inhibitor]	Responsive	Pre-clinical	24848258;24786638	Ovary;Pleura	Therapeutic	D
NF2	CNV	deletion	Schwannoma	AR42	Responsive	Pre-clinical	21778190	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Schwannoma	Bevacizumab	Responsive	Early trials	19587327;22805104;26022982	Nervous_System	Therapeutic	C
NF2	CNV	deletion	Schwannoma	Everolimus	Responsive	Early trials	24311643;2556735	Nervous_System	Therapeutic	C
NF2	CNV	deletion	Schwannoma	Imatinib	Responsive	Pre-clinical	19509233;2290085	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Schwannoma;Meningioma	[PAK inhibitor]	Responsive	Pre-clinical	23960073;25596744	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Schwannoma;Neurofibroma	Lapatinib	Responsive	Early trials	22844108;NCT00973739	Nervous_System	Therapeutic	C
NF2	CNV	deletion	Schwannoma	[PDK1 inhibitor]	Responsive	Pre-clinical	19359162	Nervous_System	Therapeutic	D
NF2	CNV	deletion	Thyroid	[MEK inhibitor]	Responsive	Pre-clinical	26359368	Thyroid	Therapeutic	D
NF2	CNV	LOSS	Thyroid Gland Carcinoma	Selumetinib	Sensitivity/Response	D	26359368	Thyroid	Therapeutic	D
NF2	MUT	K159fs	Breast Cancer	Temsirolimus	Sensitivity/Response	C	25878190	Breast	Therapeutic	C
NF2	MUT	mutation	Acoustic Neuroma	Everolimus	N/A	B	25567352	Other	Therapeutic	B
NF2	MUT	oncogenic mutation	Breast adenocarcinoma	Tensirolimus;Chemotherapy	Responsive	Case report	25878190	Breast	Therapeutic	D
NF2	MUT	oncogenic mutation	Meningioma	AR42	Responsive	Early trials	ASCO 2016 (abstr 2558)	Nervous_System	Therapeutic	C
NF2	MUT	oncogenic mutation	Meningioma	Everolimus;Octreotide	Responsive	Pre-clinical	26015296	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Meningioma	[HSP90 inhibitor]	Responsive	Pre-clinical	23714726	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Meningioma	[MTOR inhibitor]	Responsive	Pre-clinical	19451225;2242646	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Mesothelioma	[FAK inhibitor]	Responsive	Early trials	ENA 2012 (abstr 610)	Pleura	Therapeutic	C
NF2	MUT	oncogenic mutation	Mesothelioma;Ovary	[FAK inhibitor]	Responsive	Pre-clinical	24848258;24786638	Ovary;Pleura	Therapeutic	D
NF2	MUT	oncogenic mutation	Schwannoma	AR42	Responsive	Pre-clinical	21778190	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Schwannoma	Bevacizumab	Responsive	Early trials	19587327;22805104;26022982	Nervous_System	Therapeutic	C
NF2	MUT	oncogenic mutation	Schwannoma	Everolimus	Responsive	Early trials	24311643;2556735	Nervous_System	Therapeutic	C
NF2	MUT	oncogenic mutation	Schwannoma	Imatinib	Responsive	Pre-clinical	19509233;2290085	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Schwannoma;Meningioma	[PAK inhibitor]	Responsive	Pre-clinical	23960073;25596744	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Schwannoma;Neurofibroma	Lapatinib	Responsive	Early trials	22844108;NCT00973739	Nervous_System	Therapeutic	C
NF2	MUT	oncogenic mutation	Schwannoma	[PDK1 inhibitor]	Responsive	Pre-clinical	19359162	Nervous_System	Therapeutic	D
NF2	MUT	oncogenic mutation	Thyroid	[MEK inhibitor]	Responsive	Pre-clinical	26359368	Thyroid	Therapeutic	D
NF2	MUT	Y177fs	Peritoneal Mesothelioma	Carboplatin,Cisplatin	Resistance	C	25798586	Other	Therapeutic	C
NKX2-1	CNV	copy number gain	Adenocarcinoma in Lung			2	17982442,23763999,21471965	Lung	Therapeutic	C
NOTCH1	CNV	AMPLIFICATION	Colorectal Cancer	NOTCH1 Antibody	Sensitivity/Response	D	26152787	Colorectal	Therapeutic	D
NOTCH1	CNV	AMPLIFICATION	Colorectal Cancer		Poor Outcome	B	26152787	Colorectal	Prognostic	B
NOTCH1	EXP	OVEREXPRESSION	Advanced Solid Tumor	Brontictuzumab	sensitive	Phase I	;	Other	Therapeutic	C
NOTCH1	MUT	A1552G	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	A1552V	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	A1570G	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	A1707T	Advanced Solid Tumor	MRK-003	sensitive	Preclinical	25104330	Other	Therapeutic	D
NOTCH1	MUT	A1707T	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Acute lymphoblastic leukemia	[Gamma secretase inhibitor;CDK4 inhibitor]	Responsive	Pre-clinical	19318552	Blood;Bone_Marrow	Therapeutic	D
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Acute lymphoblastic leukemia	[Gamma secretase inhibitor;MTOR inhibitor]	Responsive	Pre-clinical	19246562	Blood;Bone_Marrow	Therapeutic	D
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Acute lymphoblastic leukemia	[Gamma secretase inhibitor]	Responsive	Early trials	ASCO 2006 (abstr 6585)	Blood;Bone_Marrow	Therapeutic	C
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Acute lymphoblastic leukemia	[Gamma secretase inhibitor]	Responsive	Pre-clinical	15472075;19778842;22510873;23001755	Blood;Bone_Marrow	Therapeutic	D
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Any cancer type	OMP-52M51	Responsive	Early trials	NCT01703572;NCT01778439	Cancer	Therapeutic	C
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Any cancer type	[Ro4929097,Pf-03084014,Mk-0752]	Responsive	Early trials	NCT01703572;NCT01778439; NCT01098344; NCT01981551	Cancer	Therapeutic	C
NOTCH1	MUT	activating mutation in Cterm-PEST domain	Breast adenocarcinoma	[Gamma secretase inhibitor]	Responsive	Pre-clinical	25564152	Breast	Therapeutic	D
NOTCH1	MUT	C478F	head and neck squamous cell carcinoma	LGK974	sensitive	Preclinical	24277854	Head_and_Neck	Therapeutic	D
NOTCH1	MUT	D1642H	Lung Non-small Cell Carcinoma		Poor Outcome	B	20007775	Lung	Prognostic	B
NOTCH1	MUT	E1567K	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	exon(s) 26 deletion	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 26 insertion	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 26 missense	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 27 deletion	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 27 insertion	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 27 missense	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 frameshift	Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 frameshift	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 missense	Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 missense	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 nonsense	Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	exon(s) 34 nonsense	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	15472075,24652989,23860447,21642962,24652989,24943832	Blood;Bone_Marrow	Therapeutic	B
NOTCH1	MUT	frameshift variant 2245-2536	Adenoid cystic carcinoma	[NOTCH1 inhibitor]	Responsive	Case report	27870570	Bladder	Therapeutic	D
NOTCH1	MUT	Gain-of-Function	acute lymphocytic leukemia	Brontictuzumab	sensitive	Preclinical - Pdx	23774673	Blood;Bone_Marrow	Therapeutic	D
NOTCH1	MUT	Gain-of-Function	breast cancer	Brontictuzumab	sensitive	Preclinical - Pdx	;	Breast	Therapeutic	D
NOTCH1	MUT	Gain-of-Function	colorectal cancer	PF-03084014	sensitive	Preclinical - Cell culture	23868008	Colorectal	Therapeutic	D
NOTCH1	MUT	Gain-of-Function	T-cell adult acute lymphocytic leukemia	Dexamethasone + Ribociclib	predicted - sensitive	Preclinical - Pdx	28151717	Blood;Bone_Marrow	Therapeutic	D
NOTCH1	MUT	I1680S	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	LOSS-OF-FUNCTION	Head And Neck Squamous Cell Carcinoma	LGK974	Sensitivity/Response	D	24277854	Head_and_Neck	Therapeutic	D
NOTCH1	MUT	mutant	mantle cell lymphoma	Ibrutinib + Venetoclax	predicted - resistant	Phase II	30455436	Lymph_Nodes	Therapeutic	C
NOTCH1	MUT	mutant	triple-receptor negative breast cancer	PF-03084014	sensitive	Preclinical - Pdx	25564152	Breast	Therapeutic	D
NOTCH1	MUT	mutation	breast cancer	LY3039478	sensitive	Preclinical	;	Breast	Therapeutic	D
NOTCH1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	A	26837699	Blood;Bone_Marrow	Prognostic	A
NOTCH1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	23086750	Blood;Bone_Marrow	Prognostic	B
NOTCH1	MUT	mutation	colon cancer	LY3039478	sensitive	Preclinical	;	Colorectal	Therapeutic	D
NOTCH1	MUT	mutation	glioblastoma multiforme	LY3039478	sensitive	Preclinical	;	Brain	Therapeutic	D
NOTCH1	MUT	mutation	glioblastoma multiforme	Radiotherapy + RO4929097 + Temozolomide	sensitive	Phase I	27154916	Brain	Therapeutic	C
NOTCH1	MUT	mutation	lung cancer	LY3039478	sensitive	Preclinical	;	Lung	Therapeutic	D
NOTCH1	MUT	mutation	Mantle Cell Lymphoma		Poor Outcome	B	22210878	Lymph_Nodes	Prognostic	B
NOTCH1	MUT	mutation	ovarian cancer	LY3039478	sensitive	Preclinical	;	Ovary	Therapeutic	D
NOTCH1	MUT	mutation	prostate cancer	Docetaxel + PF-03084014	predicted - sensitive	Preclinical - Cell line xenograft	26202948	Prostate	Therapeutic	D
NOTCH1	MUT	mutation	stomach cancer	LY3039478	sensitive	Preclinical	;	Stomach	Therapeutic	D
NOTCH1	MUT	oncogenic mutation	Mantle cell lymphoma	[Gamma secretase inhibitor]	Responsive	Pre-clinical	22210878	Lymph_Nodes	Therapeutic	D
NOTCH1	MUT	P2514fs	Chronic Lymphocytic Leukemia		Poor Outcome	B	21670202	Blood;Bone_Marrow	Prognostic	B
NOTCH1	MUT	P2514fs	Chronic Lymphocytic Leukemia		Poor Outcome	B	22077063	Blood;Bone_Marrow	Prognostic	B
NOTCH1	MUT	R1683W	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	R2327W	Lung Non-small Cell Carcinoma		Poor Outcome	B	20007775	Lung	Prognostic	B
NOTCH1	MUT	rearrange	triple-receptor negative breast cancer	MRK-003 + Paclitaxel	sensitive	Preclinical	25104330	Breast	Therapeutic	D
NOTCH1	MUT	rearrange	triple-receptor negative breast cancer	MRK-003 + SCH772984	no benefit	Preclinical	25104330	Breast	Therapeutic	D
NOTCH1	MUT	rearrange	triple-receptor negative breast cancer	MRK-003	sensitive	Preclinical	25104330	Breast	Therapeutic	D
NOTCH1	MUT	S2275fs	Lung Non-small Cell Carcinoma		Poor Outcome	B	20007775	Lung	Prognostic	B
NOTCH1	MUT	S2449fs	triple-receptor negative breast cancer	PF-03084014	sensitive	Preclinical - Pdx	25564152	Breast	Therapeutic	D
NOTCH1	MUT	splice acceptor variant 2245-2536	Adenoid cystic carcinoma	[NOTCH1 inhibitor]	Responsive	Case report	27870570	Bladder	Therapeutic	D
NOTCH1	MUT	splice donor variant 2245-2536	Adenoid cystic carcinoma	[NOTCH1 inhibitor]	Responsive	Case report	27870570	Bladder	Therapeutic	D
NOTCH1	MUT	stop gained 2245-2536	Adenoid cystic carcinoma	[NOTCH1 inhibitor]	Responsive	Case report	27870570	Bladder	Therapeutic	D
NOTCH1	MUT	stop lost 2245-2536	Adenoid cystic carcinoma	[NOTCH1 inhibitor]	Responsive	Case report	27870570	Bladder	Therapeutic	D
NOTCH1	MUT	V1575A	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	V1599M	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	V1676I	osteosarcoma	MRK-003	sensitive	Preclinical	25104330	Bone	Therapeutic	D
NOTCH1	MUT	V2444fs	Lung Non-small Cell Carcinoma		Poor Outcome	B	20007775	Lung	Prognostic	B
NOTCH1	MUT	WILDTYPE	triple-receptor negative breast cancer	MRK-003	decreased response	Preclinical	25104330	Breast	Therapeutic	D
NOTCH1	MUT	WILDTYPE	triple-receptor negative breast cancer	MRK-003 + Paclitaxel	no benefit	Preclinical	25104330	Breast	Therapeutic	D
NOTCH2	MUT	activating mutation missense in TAD, truncating in Cterm-PEST domain	Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia	Mk-0752	Responsive	Early trials	25564152	Blood;Bone_Marrow;Breast	Therapeutic	C
NOTCH2	MUT	activating mutation missense in TAD, truncating in Cterm-PEST domain	Solid tumors	OMP-59R5	Responsive	Early trials	NCT01859741;NCT01277146	Other	Therapeutic	C
NOTCH2	MUT	any mutation	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	19445024,22891276	Blood;Bone_Marrow	Therapeutic	B
NOTCH2	MUT	exon(s) 34 frameshift	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	19445024,22891276	Blood;Bone_Marrow	Therapeutic	B
NOTCH2	MUT	exon(s) 34 frameshift	Marginal Zone B Cell Lymphoma in Spleen			1	22891276,19445024	Other	Therapeutic	B
NOTCH2	MUT	I2304fs	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma in Blood/Bone Marrow			1	19445024,22891276	Blood;Bone_Marrow	Therapeutic	B
NOTCH2	MUT	I2304fs	Marginal Zone B Cell Lymphoma in Spleen			1	22891276,19445024	Other	Therapeutic	B
NPM1-ALK	CNV	amp	anaplastic large cell lymphoma	Alectinib	decreased response	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	CNV	amp	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	CNV	amp	anaplastic large cell lymphoma	Brigatinib	resistant	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	CNV	amp	anaplastic large cell lymphoma	Ceritinib	resistant	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	CNV	amp	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS		Advanced Solid Tumor	TAE684	sensitive	Preclinical - Cell culture	20207848	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156F	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK C1156Y	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK E1210K	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	Advanced Solid Tumor	Lorlatinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174I	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	AZD3463	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174L	anaplastic large cell lymphoma	Ceritinib	resistant	Preclinical - Cell culture	27009859	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Alectinib	decreased response	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174V	Advanced Solid Tumor	ASP3026	predicted - sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK F1174V	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1128S	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1202R	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1202R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	ASP3026	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	ASP3026	conflicting	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK G1269A	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	27009859	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171N	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	AZD3463	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171S	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	27009859	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK I1171T	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	24509625	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK L1122V	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1122V	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1122V	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1122V	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1152R	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1152R	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Alectinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Brigatinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Ceritinib	conflicting	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1196Q	anaplastic large cell lymphoma	ASP3026	sensitive	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK L1196Q	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1198F	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK L1198F	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	ASP3026	decreased response	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	Advanced Solid Tumor	Lorlatinib	resistant	Preclinical - Cell culture	25749034	Other	Therapeutic	D
NPM1-ALK	FUS	ALK N1178H	anaplastic large cell lymphoma	ASP3026	resistant	Preclinical - Cell culture	25749034	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK P1139S	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK P1139S	Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK P1139S	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK P1139S	Advanced Solid Tumor	Ceritinib	decreased response	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK P1139S	Advanced Solid Tumor	Crizotinib	sensitive	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	AZD3463	decreased response	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK R1192P	anaplastic large cell lymphoma	Crizotinib	resistant	Preclinical - Cell culture	27009859	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	Advanced Solid Tumor	Ceritinib	decreased response	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	Advanced Solid Tumor	Crizotinib	decreased response	Preclinical - Cell culture	25421750	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206C	anaplastic large cell lymphoma	Brigatinib	resistant	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Alectinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	ASP3026	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Ceritinib	sensitive	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK S1206Y	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	25727400	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Alectinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	ASP3026	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	AZD3463	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Brigatinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Ceritinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	Advanced Solid Tumor	Crizotinib	resistant	Preclinical - Cell culture	27009859	Other	Therapeutic	D
NPM1-ALK	FUS	ALK T1151M	anaplastic large cell lymphoma	Ceritinib	resistant	Preclinical - Cell culture	27009859	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	Alectinib	sensitive	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	ASP3026	sensitive	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	Brigatinib	sensitive	Preclinical - Cell line xenograft	27780853	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	CEP-28122	sensitive	Preclinical - Pdxcell culture	22203728	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	Ceritinib	sensitive	Preclinical - Cell culture	25421750	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	Crizotinib	sensitive	Phase Ib/II	28787259	Lymph_Nodes	Therapeutic	C
NPM1-ALK	FUS		anaplastic large cell lymphoma	Crizotinib	sensitive	Preclinical - Cell line xenograft	18089725	Lymph_Nodes	Therapeutic	D
NPM1-ALK	FUS		anaplastic large cell lymphoma	Entrectinib	sensitive	Preclinical - Cell line xenograft	26939704	Lymph_Nodes	Therapeutic	D
NPM1	MUT	codon(s) 288 frameshift	Acute Myeloid Leukemia in Blood/Bone Marrow			1	15659725,15994285,24487413,22417203	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	codon(s) 290 frameshift	Acute Myeloid Leukemia in Blood/Bone Marrow			1	15659725,15994285,24487413,22417203	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	exon(s) 12 any	acute myeloid leukemia	Deguelin	sensitive	Preclinical	25242579;25348016	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 any	acute myeloid leukemia	Ixazomib	predicted - sensitive	Case Reports/Case Series	26634271	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 any	acute myeloid leukemia	Ixazomib + Vorinostat	sensitive	Preclinical - Cell culture	26634271	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	All-trans Retinoic Acid,NSC348884	Sensitivity/Response	D	21719597	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	All-trans Retinoic Acid	Resistance	B	19965647	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	All-trans Retinoic Acid	Sensitivity/Response	B	19059939	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	Anti-CD33,Anti-CD123	Sensitivity/Response	E	24927407	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	Anti-CD33	Sensitivity/Response	E	24927407	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	15659725	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	16051734	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	16076867	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	16455956	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	17957027	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	18450602	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	19047294	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	19059939	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	20026798	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	22417203	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	22430270	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Better Outcome	B	24855211	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	Daunorubicin	Sensitivity/Response	B	22417203	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Negative	B	16076867	Blood;Bone_Marrow	Diagnostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Poor Outcome	B	19587375	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Poor Outcome	B	24859829	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Poor Outcome	B	26789727	Blood;Bone_Marrow	Prognostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Positive	A	19357394	Blood;Bone_Marrow	Diagnostic	A
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Positive	B	16076867	Blood;Bone_Marrow	Diagnostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Positive	B	16455956	Blood;Bone_Marrow	Diagnostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Positive	B	17957027	Blood;Bone_Marrow	Diagnostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia		Positive	B	19059939	Blood;Bone_Marrow	Diagnostic	B
NPM1	MUT	exon(s) 12 mutation	Acute Myeloid Leukemia	Valproic Acid	Sensitivity/Response	B	24797300	Blood;Bone_Marrow	Therapeutic	B
NPM1	MUT	mutant	acute myeloid leukemia	Cytarabine + Venetoclax	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
NPM1	MUT	mutant	acute myeloid leukemia	ENMD-2076	sensitive	Phase I	27406088	Blood;Bone_Marrow	Therapeutic	C
NPM1	MUT	mutant	acute myeloid leukemia	Entospletinib	predicted - sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	mutant	acute myeloid leukemia	EPZ004777	predicted - sensitive	Preclinical - Patient cell culture	27535106	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	mutant	acute myeloid leukemia	Ibrutinib	predicted - sensitive	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	mutant	acute myeloid leukemia	MI-503	predicted - sensitive	Preclinical - Cell line xenograft	27535106	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	25713434;19047294;24573385	Blood;Bone_Marrow	Prognostic	C
NPM1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	26239249;26676635;16109776;26586702	Blood;Bone_Marrow	Prognostic	C
NPM1	MUT	mutant	acute myeloid leukemia	NSC348884	sensitive	Preclinical	21719597	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	mutant	leukemia	EPZ004777	predicted - sensitive	Preclinical	27535106	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	oncogenic mutation	Acute myeloid leukemia	Daunorubicin	Responsive	FDA guidelines	22417203	Blood;Bone_Marrow	Therapeutic	A
NPM1	MUT	oncogenic mutation	Acute myeloid leukemia	[DOT1L inhibitors;MLL1 inhibitors]	Responsive	Pre-clinical	27535106	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	W288fs	Acute Myeloid Leukemia	Induction Therapy	Sensitivity/Response	E	15659725	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	W288fs	Acute Myeloid Leukemia	NSC348884	Sensitivity/Response	D	21719597	Blood;Bone_Marrow	Therapeutic	D
NPM1	MUT	W288fs	Acute Myeloid Leukemia		Positive	B	21067377	Blood;Bone_Marrow	Diagnostic	B
NQO1	EXP	EXPRESSION	Lung Cancer	Amrubicin	Resistance	D	21964527	Lung	Therapeutic	D
NQO1	MUT	P187S	Lung Cancer	Amrubicin	Sensitivity/Response	D	21964527	Lung	Therapeutic	D
NRAS	CNV	amp	melanoma	Binimetinib	predicted - sensitive	Preclinical - Pdx	29245078	Skin	Therapeutic	D
NRAS	EXP	OVEREXPRESSION	melanoma	Binimetinib	predicted - sensitive	Preclinical - Cell culture	29245078	Skin	Therapeutic	D
NRAS	MUT	codon(s) 117 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 117 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 12 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 12 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 13 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 13 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 146 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 146 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 59 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 59 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 61 missense	Colorectal adenocarcinoma	Cetuximab	Resistant	NCCN guidelines	24024839;20619739;23325582	Colorectal	Therapeutic	A
NRAS	MUT	codon(s) 61 missense	Colorectal adenocarcinoma	Panitumumab	Resistant	FDA guidelines	FDA guidelines	Colorectal	Therapeutic	A
NRAS	MUT	A146X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	A146X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	A59X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	A59X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	any mutation	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/MDS/MPN in Blood/Bone Marrow			1	24178622,23708912,21714648,17550846,10846828,20371679,19075190,12518368,PharmGKB	Blood;Bone_Marrow	Therapeutic	B
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	codon(s) 12, 13, 61, 146 any	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	exon(s) 2 any	colon cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 2 any	colon cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 2 any	rectum cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 2 any	rectum cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 3 any	colon cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 3 any	colon cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 3 any	rectum cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 3 any	rectum cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 4 any	colon cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 4 any	colon cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 4 any	rectum cancer	Cetuximab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	exon(s) 4 any	rectum cancer	Panitumumab	resistant	Guideline	;	Colorectal	Therapeutic	A
NRAS	MUT	G12A	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12A	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12A	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12A	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12A	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12A	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12C	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12C	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12C	Any cancer type	[ERK inhibitor]	Responsive	Pre-clinical	23614898	Cancer	Therapeutic	D
NRAS	MUT	G12C	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12C	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12C	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12C	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12D	acute myeloid leukemia	Alpelisib + Binimetinib	sensitive	Preclinical - Cell line xenograft	24569456	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	G12D	acute myeloid leukemia	Binimetinib	sensitive	Preclinical	24569456;11238126	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	G12D	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12D	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12D	Advanced Solid Tumor	N-Arachidonoyl Dopamine	sensitive	Preclinical - Cell culture	27760835	Other	Therapeutic	D
NRAS	MUT	G12D	Cholangiocarcinoma in Liver			2	23391413,21303542,24563076,24889489	Liver	Therapeutic	C
NRAS	MUT	G12D	Colorectal Cancer	Cetuximab	Resistance	B	25666295	Colorectal	Therapeutic	B
NRAS	MUT	G12D	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12D	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12D	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12D	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
NRAS	MUT	G13	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
NRAS	MUT	G12R	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12R	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12R	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12R	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12R	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12R	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12S	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12S	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12S	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12S	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12S	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12S	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12V	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G12V	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G12V	colorectal cancer	Cetuximab	resistant	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
NRAS	MUT	G12V	colorectal cancer	Cetuximab + Trametinib	sensitive	Preclinical - Cell culture	28179366	Colorectal	Therapeutic	D
NRAS	MUT	G12V	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G12V	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G12V	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G12V	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G12X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	G12X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	G12X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
NRAS	MUT	G13A	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13A	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13A	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13A	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13A	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13A	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13C	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13C	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13C	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13C	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13C	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13C	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13D	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13D	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13D	adult T-cell leukemia	3144	sensitive	Preclinical - Cell culture	28235199	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	G13D	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13D	Melanoma	17-AAG	Sensitivity/Response	C	18375819	Skin	Therapeutic	C
NRAS	MUT	G13D	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13D	melanoma	LY3009120	sensitive	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	G13D	melanoma	Selumetinib	sensitive	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	G13D	melanoma	Vemurafenib	resistant	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	G13D	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13D	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13R	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13R	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13R	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13R	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13R	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13R	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13S	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13S	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13S	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13S	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13S	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13S	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13V	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	G13V	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	G13V	adult T-cell leukemia	3144	sensitive	Preclinical - Pdxcell culture	28235199	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	G13V	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	19949014,20731249,20619739,22515291,16291983	Thyroid	Therapeutic	B
NRAS	MUT	G13V	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	G13V	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	G13V	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	G13X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	G13X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	G13X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
NRAS	MUT	Gain-of-Function	lung non-small cell carcinoma	RAF709	sensitive	Preclinical - Pdx	29343524	Lung	Therapeutic	D
NRAS	MUT	K117X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	K117X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	mutant	acute myeloid leukemia	AZD5153	predicted - sensitive	Preclinical - Cell line xenograft	27573426	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	acute myeloid leukemia	LY3009120	sensitive	Preclinical	26343583	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	acute myeloid leukemia	Pazopanib	predicted - resistant	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	acute myeloid leukemia	Tivozanib	predicted - resistant	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	acute myeloid leukemia	Trametinib	sensitive	Preclinical	26343583	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	acute myeloid leukemia	Vemurafenib	predicted - resistant	Preclinical - Patient cell culture	30333627	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	Advanced Solid Tumor	BGB-283	predicted - sensitive	Phase I	;	Other	Therapeutic	C
NRAS	MUT	mutant	Advanced Solid Tumor	CC-90003	no benefit	Phase I	;	Other	Therapeutic	C
NRAS	MUT	mutant	Advanced Solid Tumor	KO-947	predicted - sensitive	Preclinical - Pdx	;	Other	Therapeutic	D
NRAS	MUT	mutant	Advanced Solid Tumor	NS1	no benefit	Preclinical - Cell culture	27820802	Other	Therapeutic	D
NRAS	MUT	mutant	Advanced Solid Tumor	Obatoclax	sensitive	Preclinical	22460902	Other	Therapeutic	D
NRAS	MUT	mutant	Advanced Solid Tumor	RAF709	sensitive	Preclinical - Cell culture	29343524	Other	Therapeutic	D
NRAS	MUT	mutant	autonomic nervous system neoplasm	Trametinib	sensitive	Preclinical	26343583	Nervous_System	Therapeutic	D
NRAS	MUT	mutant	biliary tract cancer	Binimetinib	predicted - sensitive	Phase I	28152546	Bile_Duct	Therapeutic	C
NRAS	MUT	mutant	central nervous system cancer	Trametinib	sensitive	Preclinical	26343583	Nervous_System	Therapeutic	D
NRAS	MUT	mutant	cervix carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Cervix	Therapeutic	D
NRAS	MUT	mutant	colon cancer	GDC0879	resistant	Preclinical - Cell culture	19276360	Colorectal	Therapeutic	D
NRAS	MUT	mutant	colorectal cancer	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	no benefit	Phase III	25605843	Colorectal	Therapeutic	C
NRAS	MUT	mutant	colorectal cancer	KO-947	predicted - sensitive	Preclinical - Pdx	;	Colorectal	Therapeutic	D
NRAS	MUT	mutant	colorectal cancer	Regorafenib	no benefit	Phase II	30120161	Colorectal	Therapeutic	C
NRAS	MUT	mutant	colorectal cancer	SYM004	predicted - resistant	Preclinical - Pdx	29423521	Colorectal	Therapeutic	D
NRAS	MUT	mutant	hematologic cancer	SHP099	predicted - resistant	Preclinical	27362227	Blood	Therapeutic	D
NRAS	MUT	mutant	hepatocellular carcinoma	Refametinib + Sorafenib	sensitive	Phase II	29950351	Liver	Therapeutic	C
NRAS	MUT	mutant	leukemia	Alpelisib + Binimetinib	sensitive	Preclinical - Cell culture	29437705	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	leukemia	Belvarafenib	sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	leukemia	Trametinib	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
NRAS	MUT	mutant	liver cancer	Trametinib	sensitive	Preclinical	26343583	Liver	Therapeutic	D
NRAS	MUT	mutant	lung adenocarcinoma	Trametinib	resistant	Preclinical	26343583	Lung	Therapeutic	D
NRAS	MUT	mutant	lung non-small cell carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Lung	Therapeutic	D
NRAS	MUT	mutant	lymphoma	Trametinib	sensitive	Preclinical	26343583	Lymph_Nodes	Therapeutic	D
NRAS	MUT	mutant	melanoma	Adavosertib	sensitive	Preclinical	24791855	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Belvarafenib	predicted - sensitive	Case Reports/Case Series	;	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Belvarafenib	predicted - sensitive	Phase I	;	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	BI-69A11	sensitive	Preclinical	26603897	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Binimetinib + Buparlisib	sensitive	Preclinical - Cell culture	27307593	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Binimetinib	conflicting	Phase II	23414587	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Binimetinib	conflicting	Phase III	28284557	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Binimetinib + Ribociclib	sensitive	Phase Ib/II	;	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Buparlisib	sensitive	Preclinical - Cell line xenograft	27307593	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	CCT196969	sensitive	Preclinical	25500121	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	CCT241161	sensitive	Preclinical	25500121	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	LY3009120	sensitive	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Nivolumab	predicted - sensitive	Clinical Study - Cohort	29973670	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Palbociclib	conflicting	Preclinical - Cell culture	30819666	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Palbociclib	conflicting	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Palbociclib + PD-0325901	sensitive	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Palbociclib + Trametinib	predicted - sensitive	Preclinical - Cell culture	30819666	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	PD-0325901	no benefit	Preclinical - Cell line xenograft	27488531	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Pembrolizumab	predicted - sensitive	Clinical Study - Cohort	29973670	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	S63845 + Trametinib	sensitive	Preclinical - Cell culture	27760111	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	SBI-0640726	sensitive	Preclinical	26603897	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	SBI-0640756	sensitive	Preclinical	26603897	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Trametinib	sensitive	Phase I	22805292	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Trametinib	sensitive	Preclinical - Cell culture	30819666	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Tubastatin A	sensitive	Preclinical	25957812	Skin	Therapeutic	D
NRAS	MUT	mutant	melanoma	Ulixertinib	predicted - sensitive	Phase I	29247021	Skin	Therapeutic	C
NRAS	MUT	mutant	melanoma	Vemurafenib	resistant	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	mutant	multiple myeloma	Trametinib	sensitive	Preclinical	26343583	Bone_Marrow	Therapeutic	D
NRAS	MUT	mutant	neuroblastoma	Alpelisib + Binimetinib	sensitive	Preclinical - Cell culture	29437705	Adrenal_Gland;Nervous_System	Therapeutic	D
NRAS	MUT	mutant	non-Hodgkin lymphoma	Trametinib	resistant	Preclinical	26343583	Lymph_Nodes	Therapeutic	D
NRAS	MUT	mutant	ovarian cancer	Trametinib	sensitive	Preclinical	26343583	Ovary	Therapeutic	D
NRAS	MUT	mutant	pancreatic cancer	KO-947	predicted - sensitive	Preclinical - Pdx	;	Pancreas	Therapeutic	D
NRAS	MUT	mutant	sarcoma	Trametinib	resistant	Preclinical	26343583	Soft_Tissue	Therapeutic	D
NRAS	MUT	mutant	skin melanoma	Binimetinib	sensitive	Phase III	;	Skin	Therapeutic	C
NRAS	MUT	mutant	stomach carcinoma	KO-947	predicted - sensitive	Preclinical - Pdx	;	Stomach	Therapeutic	D
NRAS	MUT	mutant	thyroid cancer	Selumetinib	sensitive	Phase I	23406027	Thyroid	Therapeutic	C
NRAS	MUT	mutant	transitional cell carcinoma	Trametinib	decreased response	Preclinical	26343583	Bladder	Therapeutic	D
NRAS	MUT	mutation	Cancer	Trametinib,Metformin	Sensitivity/Response	D	25504439	Cancer	Therapeutic	D
NRAS	MUT	mutation	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	A	28275037	Colorectal	Therapeutic	A
NRAS	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	D	22586653	Colorectal	Therapeutic	D
NRAS	MUT	mutation	Colorectal Cancer		Poor Outcome	B	24666267	Colorectal	Prognostic	B
NRAS	MUT	mutation	Melanoma	Binimetinib (MEK162)	Sensitivity/Response	D	24588908	Skin	Therapeutic	D
NRAS	MUT	mutation	Melanoma	Omipalisib (GSK2126458),Trametinib	Sensitivity/Response	D	23431193	Skin	Therapeutic	D
NRAS	MUT	mutation	Melanoma		Poor Outcome	B	22180178	Skin	Prognostic	B
NRAS	MUT	mutation	Melanoma	RO4987655	Sensitivity/Response	B	24947927	Skin	Therapeutic	B
NRAS	MUT	mutation	Melanoma	Vemurafenib,Dabrafenib	Resistance	B	24265155	Skin	Therapeutic	B
NRAS	MUT	mutation	Multiple Myeloma		N/A	B	18528420	Bone_Marrow	Prognostic	B
NRAS	MUT	mutation	Skin Melanoma	Amuvatinib	Sensitivity/Response	D	24950457	Skin	Therapeutic	D
NRAS	MUT	mutation	Skin Melanoma	Binimetinib (MEK162)	Sensitivity/Response	B	23414587	Skin	Therapeutic	B
NRAS	MUT	mutation	Skin Melanoma	Binimetinib	Sensitivity/Response	B	28284557	Skin	Therapeutic	B
NRAS	MUT	mutation	Skin Melanoma	Docetaxel,Trametinib	Sensitivity/Response	B	25542057	Skin	Therapeutic	B
NRAS	MUT	mutation	Skin Melanoma	Ribociclib,Binimetinib	Sensitivity/Response	B	26987942	Skin	Therapeutic	B
NRAS	MUT	oncogenic mutation	Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia	[MEK inhibitor]	Responsive	Pre-clinical	22507781;23515407;18701506	Blood;Bone_Marrow;Lung	Therapeutic	D
NRAS	MUT	oncogenic mutation	Colorectal adenocarcinoma	[MEK inhibitor +/- PI3K pathway inhibitor]	Responsive	Pre-clinical	23274911;22392911	Colorectal	Therapeutic	D
NRAS	MUT	oncogenic mutation	Cutaneous melanoma	[CDK4/6 inhibitor;MEK inhibitor]	Responsive	Early trials	26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	Skin	Therapeutic	C
NRAS	MUT	oncogenic mutation	Cutaneous melanoma	[ERK inhibitor]	Responsive	Case report	ASCO 2017 (abstr 2508)	Skin	Therapeutic	D
NRAS	MUT	oncogenic mutation	Cutaneous melanoma	[HSP90 inhibitor]	Responsive	Pre-clinical	23538902	Skin	Therapeutic	D
NRAS	MUT	oncogenic mutation	Cutaneous melanoma	[Pan-RAF inhibitor]	Responsive	Case report	ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)	Skin	Therapeutic	D
NRAS	MUT	oncogenic mutation	Cutaneous melanoma	Vemurafenib	Resistant	Pre-clinical	20179705	Skin	Therapeutic	D
NRAS	MUT	oncogenic mutation	Hepatic carcinoma	Sorafenib;MEK inhibitor	Responsive	Early Trials,Case Report	25294897	Liver	Therapeutic	C
NRAS	MUT	oncogenic mutation	Myeloma	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	22985491	Bone_Marrow	Therapeutic	D
NRAS	MUT	Oncogenic Mutations	Colorectal Cancer	Panitumumab, Cetuximab	Resistant	R1	20619739, 24024844, 25110411, 24024839	Colorectal	Therapeutic	A
NRAS	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib	Response	3A	29236635, 30867592	Lymph_Nodes	Therapeutic	C
NRAS	MUT	Oncogenic Mutations	Melanoma	Binimetinib, Binimetinib + Ribociclib	Response	3A	16273091, 28284557, 22983396	Skin	Therapeutic	C
NRAS	MUT	Oncogenic Mutations	Thyroid Cancer	Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol + Selumetinib	Response	3A	22105174, 23406027	Thyroid	Therapeutic	C
NRAS	MUT	Q179X	Colorectal Cancer	Cetuximab	Resistance	B	25666295	Colorectal	Therapeutic	B
NRAS	MUT	Q61	Colorectal Cancer	Cetuximab	Resistance	B	20619739	Colorectal	Therapeutic	B
NRAS	MUT	Q61	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Early trials	23569304;24265153	Skin	Therapeutic	C
NRAS	MUT	Q61	Cutaneous melanoma	[MEK inhibitor]	Responsive	Late trials	23414587,ASCO 2016 (abstr 9500)	Skin	Therapeutic	C
NRAS	MUT	Q61	Follicular Thyroid Carcinoma		N/A	B	22650231	Thyroid	Prognostic	B
NRAS	MUT	Q61H	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	Q61H	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	Q61H	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	22515291,25254041,21779504,25132659	Thyroid	Therapeutic	B
NRAS	MUT	Q61H	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	Q61H	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	Q61H	rhabdomyosarcoma	Alpelisib + Binimetinib	sensitive	Preclinical - Cell culture	29437705	Other	Therapeutic	D
NRAS	MUT	Q61H	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	Q61K	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	Q61K	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	Q61K	Colorectal Cancer	Selumetinib,Dactolisib	Sensitivity/Response	D	22392911	Colorectal	Therapeutic	D
NRAS	MUT	Q61K	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	22515291,25254041,21779504,25132659	Thyroid	Therapeutic	B
NRAS	MUT	Q61K	lung cancer	RAF709	sensitive	Preclinical - Cell line xenograft	29343524	Lung	Therapeutic	D
NRAS	MUT	Q61K	lung non-small cell carcinoma	Everolimus + Pimasertib	sensitive	Preclinical - Cell culture	23629727	Lung	Therapeutic	D
NRAS	MUT	Q61K	lung non-small cell carcinoma	Gedatolisib	decreased response	Preclinical	21325073;12068308	Lung	Therapeutic	D
NRAS	MUT	Q61K	lung non-small cell carcinoma	Pimasertib + Regorafenib	sensitive	Preclinical - Cell culture	23629727	Lung	Therapeutic	D
NRAS	MUT	Q61K	lung non-small cell carcinoma	Pimasertib	sensitive	Preclinical - Cell culture	23629727	Lung	Therapeutic	D
NRAS	MUT	Q61K	lung non-small cell carcinoma	Pimasertib + Sorafenib	sensitive	Preclinical - Cell culture	23629727	Lung	Therapeutic	D
NRAS	MUT	Q61K	Lung Non-small Cell Carcinoma	Selumetinib,Trametinib	Sensitivity/Response	D	23515407	Lung	Therapeutic	D
NRAS	MUT	Q61K	melanoma	Binimetinib	sensitive	Phase II	23414587	Skin	Therapeutic	C
NRAS	MUT	Q61K	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	Q61K	melanoma	LY3009120	sensitive	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61K	melanoma	RAF709	predicted - sensitive	Preclinical - Cell culture	29343524	Skin	Therapeutic	D
NRAS	MUT	Q61K	melanoma	Selumetinib	sensitive	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61K	melanoma	Vemurafenib	resistant	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61K	Neuroblastoma	Binimetinib (MEK162),Everolimus	Sensitivity/Response	D	26821351	Adrenal_Gland;Nervous_System	Therapeutic	D
NRAS	MUT	Q61K	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	Q61K	Skin Melanoma	Selumetinib	Sensitivity/Response	D	22194965	Skin	Therapeutic	D
NRAS	MUT	Q61K	Skin Melanoma	Vemurafenib	Resistance	D	22194965	Skin	Therapeutic	D
NRAS	MUT	Q61K	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	Q61L	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	Q61L	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	Q61L	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	22515291,25254041,21779504,25132659	Thyroid	Therapeutic	B
NRAS	MUT	Q61L	melanoma	Binimetinib	sensitive	Phase II	23414587	Skin	Therapeutic	C
NRAS	MUT	Q61L	melanoma	CCT196969	sensitive	Preclinical - Cell line xenograft	25500121;23431193	Skin	Therapeutic	D
NRAS	MUT	Q61L	melanoma	CCT241161	sensitive	Preclinical - Cell line xenograft	25500121;23431193	Skin	Therapeutic	D
NRAS	MUT	Q61L	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	Q61L	melanoma	LY3009120	decreased response	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61L	melanoma	PLX4720	resistant	Preclinical - Cell line xenograft	25500121;23431193	Skin	Therapeutic	D
NRAS	MUT	Q61L	melanoma	RAF709	sensitive	Preclinical - Cell culture	29343524	Skin	Therapeutic	D
NRAS	MUT	Q61L	melanoma	Selumetinib	decreased response	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61L	Melanoma	Temozolomide	Sensitivity/Response	C	21576590	Skin	Therapeutic	C
NRAS	MUT	Q61L	melanoma	Vemurafenib	resistant	Preclinical	26343583	Skin	Therapeutic	D
NRAS	MUT	Q61L	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	Q61L	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	Q61	Melanoma		Positive	B	23861977	Skin	Diagnostic	B
NRAS	MUT	Q61	Melanoma	Vemurafenib	Resistance	B	23569304	Skin	Therapeutic	B
NRAS	MUT	Q61R	Adenocarcinoma in Colon/Rectum			1	19949014,20731249,20619739,22515291,16291983	Colorectal	Therapeutic	B
NRAS	MUT	Q61R	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	23515407,25277205,25738220,26301800	Lung	Therapeutic	C
NRAS	MUT	Q61R	Cholangiocarcinoma in Liver			2	23391413,21303542,24563076,24889489	Liver	Therapeutic	C
NRAS	MUT	Q61R	Follicular Carcinoma/Papillary Carcinoma in Thyroid			1	22515291,25254041,21779504,25132659	Thyroid	Therapeutic	B
NRAS	MUT	Q61R	melanoma	Binimetinib	sensitive	Phase II	23414587	Skin	Therapeutic	C
NRAS	MUT	Q61R	Melanoma in Skin			1	19949014,20731249,20619739,22515291,16291983	Skin	Therapeutic	B
NRAS	MUT	Q61R	Melanoma	Temozolomide	Sensitivity/Response	C	21576590	Skin	Therapeutic	C
NRAS	MUT	Q61R	Other Tumor Type in Thyroid			1	23895130,16772343	Thyroid	Therapeutic	B
NRAS	MUT	Q61R	thyroid cancer	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
NRAS	MUT	Q61R	Urothelial Carcinoma in Bladder			2	21072204,24122582	Bladder	Therapeutic	C
NRAS	MUT	Q61	Skin Melanoma	Binimetinib (MEK162)	Sensitivity/Response	B	23414587	Skin	Therapeutic	B
NRAS	MUT	Q61	Skin Melanoma	Selumetinib	Sensitivity/Response	C	18390968	Skin	Therapeutic	C
NRAS	MUT	Q61X	colorectal cancer	Cetuximab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	Q61X	colorectal cancer	Panitumumab	resistant	FDA contraindicated	;	Colorectal	Therapeutic	A
NRAS	MUT	Q61X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
NRAS	MUT	WILDTYPE	colorectal cancer	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	predicted - sensitive	Phase III	25605843	Colorectal	Therapeutic	C
NRAS	MUT	WILDTYPE	colorectal cancer	Panitumumab	predicted - sensitive	FDA approved - On Companion Diagnostic	;;	Colorectal	Therapeutic	A
NRAS	MUT	WILDTYPE	colorectal cancer	Panitumumab	predicted - sensitive	Phase III	26341920	Colorectal	Therapeutic	C
NRAS	MUT	WILDTYPE	melanoma	E6201	sensitive	Preclinical	23039341	Skin	Therapeutic	D
NRAS	MUT	WILDTYPE	melanoma	Palbociclib	sensitive	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
NRAS	MUT	WILDTYPE	melanoma	Palbociclib + Trametinib	decreased response	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
NRAS	MUT	WILDTYPE	melanoma	Trametinib	sensitive	Preclinical - Cell culture	27488531	Skin	Therapeutic	D
NRG1	EXP	EXPRESSION	Cancer	AV-203	Sensitivity/Response	D	25542901	Cancer	Therapeutic	D
NRG1	EXP	EXPRESSION	Colorectal Cancer	Cetuximab	Resistance	D	21900593	Colorectal	Therapeutic	D
NRG1	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Lapatinib	Sensitivity/Response	D	21840482	Head_and_Neck	Therapeutic	D
NRG1	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Carboplatin,Gemcitabine,Cisplatin,Paclitaxel	Sensitivity/Response	D	23390248	Lung	Therapeutic	D
NRG1	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Patritumab	Sensitivity/Response	B	26137564	Lung	Therapeutic	B
NRG1	EXP	EXPRESSION	Ovarian Cancer	Seribantumab	Sensitivity/Response	D	20227043	Ovary	Therapeutic	D
NRG1	FUS	ATP1B1-NRG1 fusion	Cholangiocarcinoma	Afatinib	Sensitivity/Response	C	28950338	Bile_Duct	Therapeutic	C
NRG1	FUS	NRG1 fusion	Pancreatic Adenocarcinoma	Afatinib	Sensitivity/Response	C	29802158	Pancreas	Therapeutic	C
NRG1	FUS	SDC4-NRG1	Lung Adenocarcinoma	Afatinib	Sensitivity/Response	C	28950338	Lung	Therapeutic	C
NT5C2	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	PharmGKB,23377183	Blood;Bone_Marrow	Therapeutic	B
NT5C2	MUT	D407A	T-cell Acute Lymphoblastic Leukemia	6-thioguanine,6-mercaptopurine	Resistance	D	23377281	Blood;Bone_Marrow	Therapeutic	D
NT5C2	MUT	K359Q	Acute Lymphocytic Leukemia		Poor Outcome	B	23377281	Blood;Bone_Marrow	Prognostic	B
NT5C2	MUT	K359Q	T-cell Acute Lymphoblastic Leukemia	6-mercaptopurine,6-thioguanine	Resistance	D	23377281	Blood;Bone_Marrow	Therapeutic	D
NT5C2	MUT	R367Q	T-cell Acute Lymphoblastic Leukemia	6-mercaptopurine,6-thioguanine	Resistance	D	23377281	Blood;Bone_Marrow	Therapeutic	D
NT5E	EXP	OVEREXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	B	25520391	Colorectal	Therapeutic	B
NTRK1	CNV	AMPLIFICATION	Cancer	Entrectinib	Resistance	B	28183697	Cancer	Therapeutic	B
NTRK1	EXP	EXPRESSION	Neuroblastoma		Positive	B	8441429	Adrenal_Gland;Nervous_System	Prognostic	B
NTRK1	FUS	LMNA-NTRK1	Colorectal Adenocarcinoma	Entrectinib	Sensitivity/Response	C	26546295	Colorectal	Therapeutic	C
NTRK1	FUS	LMNA-NTRK1 G595R AND G667C	Colorectal Adenocarcinoma	Entrectinib	Resistance	C	26546295	Colorectal	Therapeutic	C
NTRK1	FUS	LMNA-NTRK1	Sarcoma	Larotrectinib (LOXO-101)	Sensitivity/Response	C	26216294	Soft_Tissue	Therapeutic	C
NTRK1	FUS	LMNA-NTRK1	Sarcoma	Larotrectinib	Sensitivity/Response	C	29606586	Soft_Tissue	Therapeutic	C
NTRK1	FUS	NTRK1-DDR2	Melanoma	Larotrectinib	Sensitivity/Response	E	29683819	Skin	Therapeutic	D
NTRK1	FUS	NTRK1 FUSIONS	Cancer	Entrectinib	Sensitivity/Response	B	28183697	Cancer	Therapeutic	B
NTRK1	FUS	NTRK1 FUSIONS	Cancer	Larotrectinib	Sensitivity/Response	B	29466156	Cancer	Therapeutic	B
NTRK1	FUS	NTRK1 FUSIONS	Cancer	Larotrectinib	Sensitivity/Response	B	29606586	Cancer	Therapeutic	B
NTRK1	FUS	NTRK1 FUSIONS	Colorectal Cancer	Larotrectinib	Sensitivity/Response	D	26716414	Colorectal	Therapeutic	D
NTRK1	FUS	NTRK1 FUSIONS	Lung Adenocarcinoma	ARRY-470,Crizotinib,Lestaurtinib (CEP-701)	Sensitivity/Response	D	24162815	Lung	Therapeutic	D
NTRK1	FUS	NTRK1 FUSIONS	Lung Non-small Cell Carcinoma	Entrectinib	Sensitivity/Response	C	26565381	Lung	Therapeutic	C
NTRK1	FUS	NTRK1 FUSIONS	Sarcoma	Larotrectinib (LOXO-101)	Sensitivity/Response	C	26216294	Soft_Tissue	Therapeutic	C
NTRK1	FUS	NTRK1-GON4L	Melanoma	Larotrectinib	Sensitivity/Response	E	29683819	Skin	Therapeutic	D
NTRK1	FUS	NTRK1-TRIM63	Melanoma	Larotrectinib	Sensitivity/Response	E	29683819	Skin	Therapeutic	D
NTRK1	FUS	PDE4DIP-NTRK1	Sarcoma	Larotrectinib	Sensitivity/Response	C	29606586	Soft_Tissue	Therapeutic	C
NTRK1	FUS	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib	Sensitivity/Response	C	26565381	Lung	Therapeutic	C
NTRK1	FUS	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib	Sensitivity/Response	C	28183697	Lung	Therapeutic	C
NTRK1	FUS	SQSTM1-NTRK1	Pediatric Fibrosarcoma	Larotrectinib	Sensitivity/Response	C	29606586	Soft_Tissue	Therapeutic	C
NTRK1	FUS	TMP3-NTRK1	Sarcoma	Larotrectinib	Sensitivity/Response	C	29606586	Soft_Tissue	Therapeutic	C
NTRK1	FUS	Fusions	All Solid Tumors	Entrectinib	Response	3A	28183697	Other	Therapeutic	C
NTRK1	FUS	Fusions	All Solid Tumors	Larotrectinib	Response	1	26216294, 29466156	Other	Therapeutic	A
NTRK1	MUT	G595R	All Solid Tumors	Larotrectinib	Resistant	R2	29466156	Other	Therapeutic	C
NTRK1	MUT	G595R	Any cancer type	Larotrectinib	Resistant	Pre-clinical	28578312	Cancer	Therapeutic	D
NTRK1	MUT	G595R	Colorectal adenocarcinoma	[Entrectinib]	Resistant	Case report	26546295	Colorectal	Therapeutic	D
NTRK1	MUT	G667C	Colorectal adenocarcinoma	[Entrectinib]	Resistant	Case report	26546295	Colorectal	Therapeutic	D
NTRK2	FUS	ETV6-NTRK2	Hematologic Cancer	Larotrectinib	Sensitivity/Response	C	29920189	Blood	Therapeutic	C
NTRK2	FUS	NTRK2-STRN fusion	Sarcoma	Larotrectinib	Sensitivity/Response	C	29606586	Soft_Tissue	Therapeutic	C
NTRK2	FUS	Fusions	All Solid Tumors	Entrectinib	Response	3A	28183697	Other	Therapeutic	C
NTRK2	FUS	Fusions	All Solid Tumors	Larotrectinib	Response	1	26216294, 29466156	Other	Therapeutic	A
NTRK3	CNV	AMPLIFICATION	Cancer	Entrectinib	Resistance	B	28183697	Cancer	Therapeutic	B
NTRK3	FUS	ETV6-NTRK3	Breast Secretory Carcinoma	Larotrectinib,LOXO-101	Sensitivity/Response	C	29623306	Breast	Therapeutic	C
NTRK3	FUS	ETV6-NTRK3 FUSION	Congenital Fibrosarcoma	Larotrectinib	Sensitivity/Response	C	27093299	Soft_Tissue	Therapeutic	C
NTRK3	FUS	ETV6-NTRK3 G623R	Breast Cancer	Entrectinib	Resistance	C	26884591	Breast	Therapeutic	C
NTRK3	FUS	ETV6-NTRK3	Pediatric B-lymphoblastic Leukemia	Larotrectinib,PLX7486	Sensitivity/Response	D	29880614	Blood;Bone_Marrow	Therapeutic	D
NTRK3	FUS	ETV6-NTRK3	Pediatric Fibrosarcoma	Larotrectinib	Sensitivity/Response	B	29606586	Soft_Tissue	Therapeutic	B
NTRK3	FUS	ETV6-NTRK3	Salivary Gland Carcinoma	Entrectinib	Sensitivity/Response	C	26884591	Esophagus	Therapeutic	C
NTRK3	FUS	ETV6-NTRK3	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	26784937	Thyroid	Prognostic	B
NTRK3	FUS	NTRK3 FUSIONS	Cancer	Entrectinib	Sensitivity/Response	B	28183697	Cancer	Therapeutic	B
NTRK3	FUS	NTRK3 FUSIONS	Cancer	Larotrectinib	Sensitivity/Response	B	29466156	Cancer	Therapeutic	B
NTRK3	FUS	Fusions	All Solid Tumors	Entrectinib	Response	3A	28183697	Other	Therapeutic	C
NTRK3	FUS	Fusions	All Solid Tumors	Larotrectinib	Response	1	26216294, 29466156	Other	Therapeutic	A
NTRK3	MUT	G623R	All Solid Tumors	Larotrectinib	Resistant	R2	29466156, 28578312	Other	Therapeutic	C
NTRK3	MUT	G623R	Any cancer type	Larotrectinib	Resistant	Pre-clinical	28578312	Cancer	Therapeutic	D
NTRK3	MUT	G623R	Any cancer type	[novel TRK inhibitor]	Responsive	Case report	28578312	Cancer	Therapeutic	D
Other Biomarkers	MUT	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab	Response	1	30589920, 28596308, 26028255	Other	Therapeutic	A
Other Biomarkers	MUT	Microsatellite Instability-High	Colorectal Cancer	Nivolumab	Response	1	28734759	Colorectal	Therapeutic	A
PAK1	CNV	amplification	Cutaneous melanoma	[PAK inhibitor]	Responsive	Pre-clinical	23535073	Skin	Therapeutic	D
PALB2	BIA	BIALLELIC INACTIVATION	Pancreatic Cancer	Mitomycin C	Sensitivity/Response	C	21135251	Pancreas	Therapeutic	C
PALB2	BIA	BIALLELIC INACTIVATION	Prostate Cancer	Olaparib	Sensitivity/Response	C	26510020	Prostate	Therapeutic	C
PALB2	CNV	deletion	Pancreas	Mytomycin C	Responsive	Case report	21135251	Pancreas	Therapeutic	D
PALB2	CNV	deletion	Pancreas	[PARP inhibitor]	Responsive	Pre-clinical	25263539;NCT01585805	Pancreas	Therapeutic	D
PALB2	CNV	deletion	Pancreas	Platinum Agent	Responsive	Case report	25719666	Pancreas	Therapeutic	D
PALB2	CNV	deletion	Prostate adenocarcinoma	[PARP inhibitor]	Responsive	Early trials	AACR 2015 (abstr CT322);26510020	Prostate	Therapeutic	C
PALB2	MUT	L531fs	Breast Cancer		Positive	B	18628482	Breast	Diagnostic	B
PALB2	MUT	oncogenic mutation	Pancreas	Mytomycin C	Responsive	Case report	21135251	Pancreas	Therapeutic	D
PALB2	MUT	oncogenic mutation	Pancreas	[PARP inhibitor]	Responsive	Pre-clinical	25263539;NCT01585805	Pancreas	Therapeutic	D
PALB2	MUT	oncogenic mutation	Pancreas	Platinum Agent	Responsive	Case report	25719666	Pancreas	Therapeutic	D
PALB2	MUT	oncogenic mutation	Prostate adenocarcinoma	[PARP inhibitor]	Responsive	Early trials	AACR 2015 (abstr CT322);26510020	Prostate	Therapeutic	C
PAX5	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24013638,24939936	Blood;Bone_Marrow	Therapeutic	B
PAX8	EXP	EXPRESSION	Female Reproductive Organ Cancer		Positive	A	24800185	Cervix	Diagnostic	A
PAX8	FUS	PAX8-PPARG	Follicular Thyroid Carcinoma		Positive	B	12727991	Thyroid	Diagnostic	B
PBK	EXP	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Resistance	D	26745678	Lung	Therapeutic	D
PBK	MUT	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Poor Outcome	B	26894977	Stomach	Prognostic	B
PBRM1	CNV	deletion	Any cancer type	[EZH2 inhibitor]	Responsive	Pre-clinical	26552009	Cancer	Therapeutic	D
PBRM1	EXP	undexpression	Renal	Everolimus	Responsive	Pre-clinical	25997916	Kidney	Therapeutic	D
PBRM1	MUT	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma in Kidney			2	23036577,24166983,25873528,25365943	Kidney	Therapeutic	C
PBRM1	MUT	mutation	Clear Cell Renal Cell Carcinoma		N/A	B	23620406	Kidney	Prognostic	B
PBRM1	MUT	mutation	Renal Cell Carcinoma		Better Outcome	B	23333114	Kidney	Prognostic	B
PBRM1	MUT	oncogenic mutation	Any cancer type	[EZH2 inhibitor]	Responsive	Pre-clinical	26552009	Cancer	Therapeutic	D
PDCD4	EXP	EXPRESSION	Lung Cancer	Paclitaxel	Sensitivity/Response	B	25928036	Lung	Therapeutic	B
PDGFA	MUT	Y273F	Ductal Carcinoma in Breast			2	18955451,15545668	Breast	Therapeutic	C
PDGFB	FUS	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	Imatinib	Response	1	20439456, 21128251, 15503291, 15746584, 18451237, 15681532, 19620561	Soft_Tissue	Therapeutic	A
PDGFRA	CNV	AMPLIFICATION	Lung Non-small Cell Carcinoma	Sunitinib	Sensitivity/Response	D	19366796	Lung	Therapeutic	D
PDGFRA	CNV	amp	lung non-small cell carcinoma	Sunitinib	sensitive	Preclinical	19366796	Lung	Therapeutic	D
PDGFRA	CNV	amp	lung small cell carcinoma	Ponatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
PDGFRA	CNV	amp	lung squamous cell carcinoma	Dasatinib	sensitive	Preclinical - Cell line xenograft	22328973	Lung	Therapeutic	D
PDGFRA	CNV	amp	lung squamous cell carcinoma	Imatinib	sensitive	Preclinical	22328973	Lung	Therapeutic	D
PDGFRA	CNV	amp	malignant peripheral nerve sheath tumor	Imatinib	sensitive	Preclinical	16357008	Nervous_System	Therapeutic	D
PDGFRA	EXP	overexpression	Renal	Sunitinib	Responsive	Pre-clinical	24086736	Kidney	Therapeutic	D
PDGFRA	FUS	DI842-843VM	Gastrointestinal Stromal Tumor	Crenolanib	Sensitivity/Response	D	22745105	Stomach	Therapeutic	D
PDGFRA	FUS	FIP1L1-PDGFRA	Acute Myeloid Leukemia	Sorafenib,Sunitinib	Sensitivity/Response	D	21482694	Blood;Bone_Marrow	Therapeutic	D
PDGFRA	FUS	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Sensitivity/Response	A	12660384	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	A
PDGFRA	FUS	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Sensitivity/Response	B	14504092	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
PDGFRA	FUS	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Sensitivity/Response	C	24456122	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
PDGFRA	FUS	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib	Sensitivity/Response	D	24407160	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	D
PDGFRA	FUS	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Resistance	C	12660384	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
PDGFRA	FUS	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Resistance	C	21818111	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
PDGFRA	FUS	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib	Sensitivity/Response	D	24407160	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	D
PDGFRA	FUS	PDGFRA FUSIONS	Chronic Myelomonocytic Leukemia		Negative	A	27069254	Blood;Bone_Marrow	Diagnostic	A
PDGFRA	FUS	PDGFRA FUSIONS	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1		Positive	A	27069254	Blood;Bone_Marrow;Lymph_Nodes	Diagnostic	A
PDGFRA	FUS	TNKS2-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Sensitivity/Response	C	25658984	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	C
PDGFRA	MUT	exon(s) 12 missense	Gastrointestinal stromal	Imatinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 12 missense	Gastrointestinal stromal	Regorafenib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 12 missense	Gastrointestinal stromal	Sunitinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 14 missense	Gastrointestinal stromal	Imatinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 14 missense	Gastrointestinal stromal	Regorafenib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 14 missense	Gastrointestinal stromal	Sunitinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 18 missense	Gastrointestinal stromal	Imatinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 18 missense	Gastrointestinal stromal	Regorafenib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	exon(s) 18 missense	Gastrointestinal stromal	Sunitinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	codon(s) 842 any	Gastrointestinal Stromal Tumor in Stomach/Small Intestine			1	15928335	Other;Stomach	Therapeutic	B
PDGFRA	MUT	D842delinsDIM	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	D842I	Gastrointestinal Stromal Tumor	Crenolanib	Sensitivity/Response	D	22745105	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Avapritinib	sensitive	Preclinical - Cell culture	29093181	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical - Cell culture	22745105	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	GSK2126458	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Imatinib	resistant	Preclinical	15928335	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Nilotinib	resistant	Preclinical - Cell culture	18794084	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Nilotinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Sunitinib	resistant	Preclinical - Cell culture	18955458	Other	Therapeutic	D
PDGFRA	MUT	D842V	Advanced Solid Tumor	Sunitinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	D842V	Cancer	Imatinib Mesylate	Resistance	D	18955458	Cancer	Therapeutic	D
PDGFRA	MUT	D842V	Cancer	Imatinib	Resistance	D	14645423	Cancer	Therapeutic	D
PDGFRA	MUT	D842V	Cancer	Sunitinib	Resistance	D	18955458	Cancer	Therapeutic	D
PDGFRA	MUT	D842V	Gastrointestinal stromal	Crenolanib	Responsive	Early trials	ASCO 2016 (abstr 11010)	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Gastrointestinal stromal	Dasatinib	Responsive	Pre-clinical	18794084	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	Gastrointestinal stromal	[HSP90 inhibitor]	Responsive	Pre-clinical	18794084	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	Gastrointestinal stromal	Imatinib	Resistant	Late trials,Pre-clinical	22718859;16638875	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	Gastrointestinal stromal	Sunitinib	Resistant	Late trials,Pre-clinical	22718859;16638875	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Avapritinib	sensitive	Phase I	29093181	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Crenolanib	sensitive	Phase Ib/II	;	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Crenolanib	Sensitivity/Response	D	22745105	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Dasatinib	Response	2A		Stomach	Therapeutic	B
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Dasatinib	sensitive	Guideline	;	Stomach	Therapeutic	A
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Dasatinib	sensitive	Phase 0	29710216	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistance	B	15928335	Stomach	Therapeutic	B
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistance	B	16954519	Stomach	Therapeutic	B
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistance	B	26130666	Stomach	Therapeutic	B
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistance	C	14645423	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistance	D	12949711	Stomach	Therapeutic	D
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Imatinib	resistant	Guideline	;	Stomach	Therapeutic	A
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Imatinib	Resistant	R1	25905001, 17087936, 12949711, 24963404, 22718859, 15928335, 18955458, 23752188, 22745105, 15685537, 18794084	Stomach	Therapeutic	A
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor in Stomach/Small Intestine			1	15928335	Other;Stomach	Therapeutic	B
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor		Negative	B	15146165	Stomach	Diagnostic	B
PDGFRA	MUT	D842V	gastrointestinal stromal tumor	Regorafenib	predicted - sensitive	Clinical Study - Cohort	25905001	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Gastrointestinal Stromal Tumor	Sunitinib	Resistance	C	18955458	Stomach	Therapeutic	C
PDGFRA	MUT	D842V	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRA	MUT	D842X	gastrointestinal stromal tumor	Avapritinib	sensitive	Phase I	;	Stomach	Therapeutic	C
PDGFRA	MUT	D842Y	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	D842Y	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	D842Y	Gastrointestinal Stromal Tumor	Crenolanib	Sensitivity/Response	D	22745105	Stomach	Therapeutic	D
PDGFRA	MUT	D846V	gastrointestinal stromal tumor	Imatinib	predicted - resistant	Case Reports/Case Series	16624552	Stomach	Therapeutic	D
PDGFRA	MUT	D846V	osteosarcoma	Sorafenib	predicted - sensitive	Case Reports/Case Series	30318721	Bone	Therapeutic	D
PDGFRA	MUT	D846Y	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	FUS	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	Imatinib	Response	1	18950453	Blood;Bone_Marrow	Therapeutic	A
PDGFRA	FUS	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib	Response	1	12944919, 17555450, 12660384, 16498388, 14504092, 16845659, 18950453, 15034867	Bone_Marrow	Therapeutic	A
PDGFRA	MUT	G853D	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	G853D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	G853D	Cutaneous melanoma	Crenolanib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	G853D	Cutaneous melanoma	Imatinib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	G853D	Melanoma	Crenolanib,Imatinib	Sensitivity/Response	D	24132921	Skin	Therapeutic	D
PDGFRA	MUT	Gain-of-Function	gastrointestinal stromal tumor	N/A	not applicable	Guideline	;	Stomach	Diagnostic	A
PDGFRA	MUT	Gain-of-Function	pancreatic cancer	Vistusertib	predicted - sensitive	Phase I	25805799	Pancreas	Therapeutic	C
PDGFRA	MUT	H650Q	leukemia	Imatinib	sensitive	Preclinical	21224473	Blood;Bone_Marrow	Therapeutic	D
PDGFRA	MUT	H650Q	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRA	MUT	H845delinsHP	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	H845delinsHP	gastrointestinal stromal tumor	Imatinib	predicted - sensitive	Case Reports/Case Series	30778083	Stomach	Therapeutic	D
PDGFRA	MUT	H845Y	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	H845Y	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	H845Y	Cutaneous melanoma	Crenolanib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	H845Y	Cutaneous melanoma	Imatinib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	H845Y	Melanoma	Crenolanib,Imatinib	Sensitivity/Response	D	24132921	Skin	Therapeutic	D
PDGFRA	MUT	843_843del	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	14645423	Other	Therapeutic	D
PDGFRA	MUT	843_843del	Gastrointestinal Stromal Tumor	Crenolanib	Sensitivity/Response	D	22745105	Stomach	Therapeutic	D
PDGFRA	MUT	843_843del	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	D	14645423	Stomach	Therapeutic	D
PDGFRA	MUT	843_843del	Gastrointestinal stromal	Imatinib	Responsive	NCCN guidelines	NCCN guidelines	Stomach	Therapeutic	A
PDGFRA	MUT	L221F	gastrointestinal stromal tumor	Imatinib	sensitive	Phase I	22718859	Stomach	Therapeutic	C
PDGFRA	MUT	mutant	gastrointestinal stromal tumor	Imatinib	sensitive	Guideline	;	Stomach	Therapeutic	A
PDGFRA	MUT	mutant	gastrointestinal stromal tumor	N/A	not applicable	Clinical Study	25729899;26276366	Stomach	Diagnostic	C
PDGFRA	MUT	N659K	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	22745105	Other	Therapeutic	D
PDGFRA	MUT	N659K	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	22745105	Other	Therapeutic	D
PDGFRA	MUT	N659S	myeloid leukemia	Imatinib	decreased response	Preclinical - Cell culture	21224473	Blood;Bone_Marrow	Therapeutic	D
PDGFRA	MUT	N659S	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRA	MUT	N848K	lung non-small cell carcinoma	Imatinib	predicted - sensitive	Case Reports/Case Series	30268485	Lung	Therapeutic	D
PDGFRA	MUT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Imatinib	Response	2A	22718859	Stomach	Therapeutic	B
PDGFRA	MUT	P577S	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	P577S	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	P577S	Cutaneous melanoma	Crenolanib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	P577S	Cutaneous melanoma	Imatinib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	P577S	Melanoma	Imatinib,Crenolanib	Sensitivity/Response	D	24132921	Skin	Therapeutic	D
PDGFRA	MUT	R748G	myeloid leukemia	Imatinib	sensitive	Preclinical - Cell line xenograft	21224473	Blood;Bone_Marrow	Therapeutic	D
PDGFRA	MUT	R748G	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRA	MUT	R841delinsRKI	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	R841K	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	R841K	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	R841K	Cutaneous melanoma	Crenolanib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	R841K	Cutaneous melanoma	Imatinib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	R841K	Melanoma	Imatinib,Crenolanib	Sensitivity/Response	D	24132921	Skin	Therapeutic	D
PDGFRA	MUT	S566delinsSR	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	T674I	Hyper eosinophilic advanced snydrome	Imatinib	Resistant	Case report	12660384	Blood	Therapeutic	D
PDGFRA	MUT	T674I	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRA	MUT	V561A	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	D	12949711	Stomach	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Avapritinib	sensitive	Preclinical - Cell culture	29093181	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	GSK2126458	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	15928335	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Nilotinib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	V561D	Advanced Solid Tumor	Sunitinib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	V561D	Gastrointestinal Stromal Tumor	Imatinib	Sensitivity/Response	C	18955451	Stomach	Therapeutic	C
PDGFRA	MUT	V561delinsVER	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	V658A	Advanced Solid Tumor	Crenolanib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	V658A	Advanced Solid Tumor	Imatinib	sensitive	Preclinical	24132921	Other	Therapeutic	D
PDGFRA	MUT	V658A	Cutaneous melanoma	Crenolanib	Responsive	Pre-clinical	24132921	Skin	Therapeutic	D
PDGFRA	MUT	WILDTYPE	Gastrointestinal stromal	Dasatinib	Responsive	Pre-clinical	16397263	Stomach	Therapeutic	D
PDGFRA	MUT	WILDTYPE	Gastrointestinal stromal	Imatinib	Resistant	Late trials	14645423;18955458	Stomach	Therapeutic	C
PDGFRA	MUT	WILDTYPE	Gastrointestinal stromal	Sorafenib	Responsive	Early trials	ASCO 2011 (abstr 10009)	Stomach	Therapeutic	C
PDGFRA	MUT	WILDTYPE	Gastrointestinal stromal	Sunitinib	Responsive	Late trials	18955458	Stomach	Therapeutic	C
PDGFRA	MUT	Y288C	Advanced Solid Tumor	AZD9150	no benefit	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	Crenolanib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	GSK2126458	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	Imatinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	Nilotinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	Sunitinib	resistant	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y288C	Advanced Solid Tumor	Trametinib	sensitive	Preclinical - Cell culture	30389923	Other	Therapeutic	D
PDGFRA	MUT	Y849S	Advanced Solid Tumor	Imatinib	sensitive	Preclinical - Cell culture	21224473	Other	Therapeutic	D
PDGFRA	MUT	Y849S	myeloid leukemia	Imatinib	sensitive	Preclinical - Cell culture	21224473	Blood;Bone_Marrow	Therapeutic	D
PDGFRA	MUT	Y849S	Myeloproliferative Neoplasm in Blood/Bone Marrow			1	23752188,24057647,21224473,12660384,16645167,22301675	Blood;Bone_Marrow	Therapeutic	B
PDGFRB	FUS	EBF1-PDGFRB	Acute Lymphocytic Leukemia	Imatinib	Sensitivity/Response	C	23835704	Blood;Bone_Marrow	Therapeutic	C
PDGFRB	FUS	EBF1-PDGFRB	Pediatric B-cell Acute Lymphoblastic Leukemia	Imatinib	Sensitivity/Response	C	24186319	Blood;Bone_Marrow	Therapeutic	C
PDGFRB	FUS	EBF1-PDGFRB	Pediatric B-cell Acute Lymphoblastic Leukemia	Imatinib	Sensitivity/Response	C	26872634	Blood;Bone_Marrow	Therapeutic	C
PDGFRB	FUS	PDGFRB FUSIONS	Chronic Myelomonocytic Leukemia		Negative	A	27069254	Blood;Bone_Marrow	Diagnostic	A
PDGFRB	FUS	PDGFRB FUSIONS	Chronic Myeloproliferative Disease	Imatinib	Sensitivity/Response	A	16960151	Blood;Bone_Marrow	Therapeutic	A
PDGFRB	FUS	PDGFRB FUSIONS	Hematologic Cancer		Positive	A	27069254	Blood	Diagnostic	A
PDGFRB	FUS	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib	Response	1	16960151, 12676775, 12181402, 14504092, 18950453, 24687085, 22897847, 26355392, 1516603	Bone_Marrow	Therapeutic	A
PDPK1	CNV	amplification	Breast adenocarcinoma	[PI3K pathway inhibitor]	Responsive	Pre-clinical	19602588	Breast	Therapeutic	D
PDS5B	MUT	any mutation	Myelodysplastic Syndrome in Blood/Bone Marrow			2	23955599	Blood;Bone_Marrow	Therapeutic	C
PGR	EXP	EXPRESSION	Breast Cancer		Better Outcome	B	16497822	Breast	Prognostic	B
PGR	EXP	EXPRESSION	Breast Cancer		Poor Outcome	B	21422407	Breast	Prognostic	B
PHF6	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23354995,22928734,22417203,21880637,21736506,21030981,20228800	Blood;Bone_Marrow	Therapeutic	B
PIGA	MUT	any mutation	Other Tumor Type in Blood/Bone Marrow			1	19686268	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	CNV	amplification	Breast adenocarcinoma	[PI3K pathway inhibitor]	Resistant	Pre-clinical	24366379	Breast	Therapeutic	D
PIK3CA	CNV	amp	head and neck squamous cell carcinoma	AZD8055	predicted - sensitive	Preclinical - Cell culture	28446642	Head_and_Neck	Therapeutic	D
PIK3CA	CNV	amp	head and neck squamous cell carcinoma	BEZ235	sensitive	Preclinical - Cell culture	28446642	Head_and_Neck	Therapeutic	D
PIK3CA	CNV	amp	head and neck squamous cell carcinoma	Radiotherapy + Taselisib	sensitive	Preclinical - Cell line xenograft	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	CNV	AMPLIFICATION	Epithelial Ovarian Cancer	Pictilisib	Sensitivity/Response	C	25370471	Ovary	Therapeutic	C
PIK3CA	CNV	AMPLIFICATION	Gastric Adenocarcinoma		Poor Outcome	B	22292935	Stomach	Prognostic	B
PIK3CA	CNV	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	Taselisib (GDC-0032)	Sensitivity/Response	D	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	CNV	AMPLIFICATION	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PIK3CA	CNV	AMPLIFICATION	Stomach Carcinoma	BYL719 (Alpelisib)	Sensitivity/Response	D	24608574	Stomach	Therapeutic	D
PIK3CA	CNV	amp	lung squamous cell carcinoma	Buparlisib	no benefit	Preclinical - Pdx	30093452	Lung	Therapeutic	D
PIK3CA	CNV	amp	nasopharynx carcinoma	MK2206	sensitive	Phase II	26084990	Head_and_Neck	Therapeutic	C
PIK3CA	CNV	amp	ovarian cancer	Panulisib	sensitive	Preclinical	25700704	Ovary	Therapeutic	D
PIK3CA	CNV	amp	ovarian cancer	SAR245409	sensitive	Preclinical - Cell line xenograft	24634413	Ovary	Therapeutic	D
PIK3CA	CNV	amp	ovarian cancer	XL147	sensitive	Preclinical - Cell line xenograft	25637314	Ovary	Therapeutic	D
PIK3CA	CNV	amp	triple-receptor negative breast cancer	Linsitinib + Pictilisib	sensitive	Preclinical - Cell culture	27196766	Breast	Therapeutic	D
PIK3CA	CNV	amp	triple-receptor negative breast cancer	NVP-AEW541 + Pictilisib	sensitive	Preclinical - Cell culture	27196766	Breast	Therapeutic	D
PIK3CA	CNV	amp	urinary bladder cancer	Gemcitabine + Pictilisib	sensitive	Preclinical - Pdx	28808038	Bladder	Therapeutic	D
PIK3CA	EXP	OVEREXPRESSION	glioblastoma multiforme	YM-024	sensitive	Preclinical	24718026	Brain	Therapeutic	D
PIK3CA	EXP	OVEREXPRESSION	head and neck squamous cell carcinoma	Gedatolisib	sensitive	Preclinical - Cell culture	25977343	Head_and_Neck	Therapeutic	D
PIK3CA	EXP	OVEREXPRESSION	lung squamous cell carcinoma	Alpelisib	sensitive	Preclinical - Cell line xenograft	26013318	Lung	Therapeutic	D
PIK3CA	EXP	OVEREXPRESSION	lung squamous cell carcinoma	BEZ235	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	EXP	OVEREXPRESSION	lung squamous cell carcinoma	Buparlisib	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	any mutation	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma in Liver/Pancreas/Stomach			2	15467468,15608678,15994075,24185509,25855536	Liver;Pancreas;Stomach	Therapeutic	C
PIK3CA	MUT	any mutation	Medulloblastoma in Brain			2	22722829,11351043,17050665,15289301,25934342,24806303	Brain	Therapeutic	C
PIK3CA	MUT	any mutation	Squamous Cell Carcinoma in Anus/Oral Cavity/Pharynx			2	21798893,25631445,27219019,26498363,24767105	Esophagus;Other	Therapeutic	C
PIK3CA	MUT	C420R	Advanced Solid Tumor	Sirolimus	sensitive	Preclinical	17376864	Other	Therapeutic	D
PIK3CA	MUT	C420R	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	;;31091374	Breast	Therapeutic	A
PIK3CA	MUT	C420R	ovarian clear cell adenocarcinoma	DS-7423	sensitive	Preclinical - Cell culture	24504419	Ovary	Therapeutic	D
PIK3CA	MUT	codon(s) 542, 545, 1047 any	Adenocarcinoma in Breast			1	20619739,28726194,22722201	Breast	Therapeutic	B
PIK3CA	MUT	codon(s) 542, 545, 1047 any	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	17657213,19330652,22675565,24440717,16764926	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	MUT	codon(s) 542, 545, 1047 any	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma in Liver/Pancreas/Stomach			2	15467468,15608678,15994075,24185509,25855536	Liver;Pancreas;Stomach	Therapeutic	C
PIK3CA	MUT	codon(s) 542, 545, 1047 any	Squamous Cell Carcinoma in Anus/Oral Cavity/Pharynx			2	21798893,25631445,27219019,26498363,24767105	Esophagus;Other	Therapeutic	C
PIK3CA	MUT	D350G	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PIK3CA	MUT	D549Y	urinary bladder cancer	Pictilisib	decreased response	Preclinical - Pdx	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	E39K	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	E453K	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	E453K	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	E542K	Adenocarcinoma in Breast			1	20619739,28726194,22722201	Breast	Therapeutic	B
PIK3CA	MUT	E542K	Advanced Solid Tumor	Sirolimus	sensitive	Preclinical	15647370	Other	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	CH5132799	sensitive	Preclinical	21558396	Breast	Therapeutic	D
PIK3CA	MUT	E542K	Breast Cancer	CH5132799	Sensitivity/Response	D	21558396	Breast	Therapeutic	D
PIK3CA	MUT	E542K	Breast Cancer	Fulvestrant,Alpelisib	Sensitivity/Response	A	31091374	Breast	Therapeutic	A
PIK3CA	MUT	E542K	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	Miransertib	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	Breast Cancer	Rapamycin (Sirolimus)	Sensitivity/Response	D	15647370	Breast	Therapeutic	D
PIK3CA	MUT	E542K	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E542K	cervical squamous cell carcinoma	Gemcitabine + LY2780301	sensitive	Phase Ib/II	28750271	Cervix	Therapeutic	C
PIK3CA	MUT	E542K	colon adenocarcinoma	VS-5584	sensitive	Preclinical	23270925	Colorectal	Therapeutic	D
PIK3CA	MUT	E542K	colorectal cancer	Cetuximab + Fluorouracil	resistant	Preclinical - Cell culture	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	E542K	colorectal cancer	Cetuximab + Irinotecan	predicted - sensitive	Case Reports/Case Series	25714871	Colorectal	Therapeutic	D
PIK3CA	MUT	E542K	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	B	19223544	Colorectal	Therapeutic	B
PIK3CA	MUT	E542K	colorectal cancer	PD-0325901 + Pictilisib	sensitive	Preclinical - Cell line xenograft	24339963	Colorectal	Therapeutic	D
PIK3CA	MUT	E542K	Colorectal Cancer		Poor Outcome	B	19223544	Colorectal	Prognostic	B
PIK3CA	MUT	E542K	Colorectal Cancer		Poor Outcome	E	22357840	Colorectal	Prognostic	D
PIK3CA	MUT	E542K	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	17657213,19330652,16573740,22675565,24440717,16764926	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	MUT	E542K	gastrointestinal system cancer	Capivasertib	sensitive	Preclinical	24088382	Stomach	Therapeutic	D
PIK3CA	MUT	E542K	Head And Neck Squamous Cell Carcinoma	Apitolisib	Sensitivity/Response	C	26787751	Head_and_Neck	Therapeutic	C
PIK3CA	MUT	E542K	head and neck squamous cell carcinoma	GDC-0980	sensitive	Phase I	26787751	Head_and_Neck	Therapeutic	C
PIK3CA	MUT	E542K	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma in Liver/Pancreas/Stomach			2	16449998,15608678,15994075,24185509,25855536	Liver;Pancreas;Stomach	Therapeutic	C
PIK3CA	MUT	E542K	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	;;31091374	Breast	Therapeutic	A
PIK3CA	MUT	E542K	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	E542K	papillary thyroid carcinoma	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PIK3CA	MUT	E542K	papillary thyroid carcinoma	MK2206 + Temsirolimus	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PIK3CA	MUT	E542K	Squamous Cell Carcinoma in Anus/Oral Cavity/Pharynx			2	21798893,25631445,27219019,26498363,24767105	Esophagus;Other	Therapeutic	C
PIK3CA	MUT	E542K	Thyroid Cancer	Temsirolimus,Perifosine	Sensitivity/Response	D	19706758	Thyroid	Therapeutic	D
PIK3CA	MUT	E542V	colorectal cancer	Cetuximab	predicted - sensitive	Case Reports/Case Series	25714871	Colorectal	Therapeutic	D
PIK3CA	MUT	E545A	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	E545X	Cutaneous melanoma	[BRAF inhibitor]	Resistant	Case report	PMC3936420	Skin	Therapeutic	D
PIK3CA	MUT	E545D	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	E545G	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	E545G	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PIK3CA	MUT	E545K	Adenocarcinoma in Breast			1	20619739,19366826,22722201	Breast	Therapeutic	B
PIK3CA	MUT	E545K	Adenocarcinoma in Colon/Rectum			1	PharmGKB,24666267,23786770,23792451	Colorectal	Therapeutic	B
PIK3CA	MUT	E545K	Advanced Solid Tumor	A66	resistant	Preclinical	21668414	Other	Therapeutic	D
PIK3CA	MUT	E545K	Advanced Solid Tumor	Alpelisib	sensitive	Preclinical - Pdx	24608574	Other	Therapeutic	D
PIK3CA	MUT	E545K	Advanced Solid Tumor	GDC-0980	sensitive	Phase I	26787751	Other	Therapeutic	C
PIK3CA	MUT	E545K	Advanced Solid Tumor	Rigosertib	sensitive	Preclinical - Cell culture	27104980	Other	Therapeutic	D
PIK3CA	MUT	E545K	Advanced Solid Tumor	Sirolimus	sensitive	Preclinical	15647370	Other	Therapeutic	D
PIK3CA	MUT	E545K	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	26627007	Other	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	ARQ 751	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	BAY1125976	sensitive	Preclinical - Cell line xenograft	27699769	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	BEZ235 + Venetoclax	no benefit	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	BEZ235 + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	CH5132799	sensitive	Preclinical	21558396	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Everolimus	sensitive	Preclinical	20664172	Breast	Therapeutic	D
PIK3CA	MUT	E545K	Breast Cancer	GDC-0941	Sensitivity/Response	D	20453058	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Gedatolisib	sensitive	Preclinical	17314276;21325073	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Miransertib	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	E545K	Breast Cancer	MK-2206,Pictilisib	Sensitivity/Response	D	23888070	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	PKI-402	sensitive	Preclinical - Cell line xenograft	20371716	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	SAR245409	sensitive	Preclinical - Cell line xenograft	24634413	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast cancer	WYE-125132	sensitive	Preclinical	20068177	Breast	Therapeutic	D
PIK3CA	MUT	E545K	breast carcinoma	XL147	sensitive	Preclinical - Cell line xenograft	25637314	Breast	Therapeutic	D
PIK3CA	MUT	E545K	Cancer	Apitolisib	Sensitivity/Response	C	26787751	Cancer	Therapeutic	C
PIK3CA	MUT	E545K	cervical cancer	PW12	sensitive	Preclinical	22391131	Cervix	Therapeutic	D
PIK3CA	MUT	E545K	colon cancer	LY2780301	sensitive	Phase I	25902900	Colorectal	Therapeutic	C
PIK3CA	MUT	E545K	colorectal cancer	BEZ235	sensitive	Preclinical	21966435	Colorectal	Therapeutic	D
PIK3CA	MUT	E545K	colorectal cancer	Cetuximab + Fluorouracil	resistant	Preclinical - Cell culture	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	E545K	colorectal cancer	Cetuximab + Irinotecan	sensitive	Case Reports/Case Series	25714871	Colorectal	Therapeutic	D
PIK3CA	MUT	E545K	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	C	19223544	Colorectal	Therapeutic	C
PIK3CA	MUT	E545K	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	17657213,19330652,16573740,22675565,24440717,16764926	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	MUT	E545K	esophagus squamous cell carcinoma	LY294002	sensitive	Preclinical	18262558	Esophagus	Therapeutic	D
PIK3CA	MUT	E545K	estrogen-receptor mutation breast cancer	AZD8835	sensitive	Preclinical	26839307	Breast	Therapeutic	D
PIK3CA	MUT	E545K	gastrointestinal system cancer	Capivasertib	sensitive	Preclinical	24088382	Stomach	Therapeutic	D
PIK3CA	MUT	E545K	head and neck squamous cell carcinoma	Carboplatin + Paclitaxel + Temsirolimus	predicted - sensitive	Phase II	28961834	Head_and_Neck	Therapeutic	C
PIK3CA	MUT	E545K	head and neck squamous cell carcinoma	Rigosertib	sensitive	Preclinical - Pdx	23873848	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	E545K	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma in Liver/Pancreas/Stomach			2	15467468,15608678,15994075,24185509,25855536	Liver;Pancreas;Stomach	Therapeutic	C
PIK3CA	MUT	E545K	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	E545K	Her2-receptor Positive Breast Cancer	Ado-trastuzumab Emtansine	Sensitivity/Response	B	26920887	Breast	Therapeutic	B
PIK3CA	MUT	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	D	18829560	Breast	Therapeutic	D
PIK3CA	MUT	E545K	Klatskins tumor	Sirolimus	unknown	Phase 0	28685070	Bile_Duct	Therapeutic	C
PIK3CA	MUT	E545K	leukemia	LY3023414	sensitive	Preclinical	27439478	Blood;Bone_Marrow	Therapeutic	D
PIK3CA	MUT	E545K	Lung Adenocarcinoma	Afatinib,Erlotinib,Gefitinib	Resistance	B	27304188	Lung	Therapeutic	B
PIK3CA	MUT	E545K	Lung Adenocarcinoma	Gefitinib	Resistance	D	16906227	Lung	Therapeutic	D
PIK3CA	MUT	E545K	lung non-small cell carcinoma	Copanlisib + Paclitaxel	sensitive	Preclinical - Pdx	24170767	Lung	Therapeutic	D
PIK3CA	MUT	E545K	Lung Non-small Cell Carcinoma	PI103	Sensitivity/Response	D	19513541	Lung	Therapeutic	D
PIK3CA	MUT	E545K	lung squamous cell carcinoma	Alpelisib	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	E545K	lung squamous cell carcinoma	BEZ235	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	E545K	lung squamous cell carcinoma	Buparlisib	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	E545K	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	E545K	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PIK3CA	MUT	E545K	ovarian cancer	CH5132799	sensitive	Preclinical	21558396	Ovary	Therapeutic	D
PIK3CA	MUT	E545K	Squamous Cell Carcinoma in Anus/Oral Cavity/Pharynx			2	21798893,25631445,27219019,26498363,24767105	Esophagus;Other	Therapeutic	C
PIK3CA	MUT	E545K	thyroid cancer	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PIK3CA	MUT	E545K	urinary bladder cancer	Cisplatin + Pictilisib	sensitive	Preclinical - Cell culture	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	E545K	urinary bladder cancer	Gemcitabine + Pictilisib	sensitive	Preclinical - Cell culture	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	E545K	urinary bladder cancer	Pictilisib	sensitive	Preclinical - Cell culture	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	E545K	urinary bladder cancer	Pictilisib + Sorafenib	sensitive	Preclinical - Cell culture	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	E545V	ovarian clear cell adenocarcinoma	DS-7423	sensitive	Preclinical - Cell culture	24504419	Ovary	Therapeutic	D
PIK3CA	MUT	exon(s) 20 mutation	Breast Cancer		Better Outcome	B	17947469	Breast	Prognostic	B
PIK3CA	MUT	exon(s) 21 mutation	Colorectal Cancer	Cetuximab	Resistance	B	20619739	Colorectal	Therapeutic	B
PIK3CA	MUT	exon(s) 9 mutation	Breast Cancer		Poor Outcome	B	17947469	Breast	Prognostic	B
PIK3CA	MUT	exon(s) 10, 20, 21 any	Adenocarcinoma in Colon/Rectum			2	22357840,PharmGKB,23792451	Colorectal	Therapeutic	C
PIK3CA	MUT	exon(s) 10, 20, 21 any	Adenocarcinoma/Squamous Cell Carcinoma in Lung			2	PharmGKB,16930767	Lung	Therapeutic	C
PIK3CA	MUT	exon(s) 10, 20, 21 any	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	17657213,19330652,16573740,22675565,24440717,16764926	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	MUT	exon(s) 10, 20, 21 any	Glial Neoplasm in Brain			2	11351043,17050665,15289301,25934342,24806303	Brain	Therapeutic	C
PIK3CA	MUT	exon(s) 10, 20, 21 any	Papillary Carcinoma/Carcinoma in Thyroid			2	23979959,16288007,19487299,17317825,23933154	Thyroid	Therapeutic	C
PIK3CA	MUT	F930S	colorectal cancer	Cetuximab + Fluorouracil	resistant	Case Reports/Case Series	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	G1049R	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	26627007	Other	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	Alpelisib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	G1049R	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	G118D	lung non-small cell carcinoma	LY3023414	sensitive	Preclinical - Cell line xenograft	27439478	Lung	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Afuresertib	sensitive	Preclinical	24978597	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	BAY1125976	sensitive	Preclinical	;	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Everolimus	sensitive	Preclinical - Cell line xenograft	20664172	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	GSK1059615	sensitive	Preclinical	;	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Ipatasertib + Paclitaxel	sensitive	Phase Ib/II	;	Other	Therapeutic	C
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Metformin	sensitive	Preclinical	23986086	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Taselisib	conflicting	Phase II	;	Other	Therapeutic	C
PIK3CA	MUT	Gain-of-Function	Advanced Solid Tumor	Taselisib	conflicting	Preclinical - Cell line xenograft	23662903	Other	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Alpelisib + WEHI-539	no benefit	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	BEZ235 + Venetoclax	no benefit	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	BEZ235 + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Buparlisib + WEHI-539	no benefit	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Copanlisib	sensitive	Phase I	27672108	Breast	Therapeutic	C
PIK3CA	MUT	Gain-of-Function	breast cancer	Copanlisib	sensitive	Preclinical	24170767	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	MK2206 + Ridaforolimus	predicted - sensitive	Phase I	26187616	Breast	Therapeutic	C
PIK3CA	MUT	Gain-of-Function	breast cancer	MK2206	sensitive	Preclinical	22932669	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Sapanisertib + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Torin 1 + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	breast cancer	Vistusertib + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	estrogen-receptor mutation breast cancer	Capivasertib + Tamoxifen	predicted - sensitive	Preclinical - Cell culture	26116361	Breast	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	head and neck squamous cell carcinoma	AZD8055 + Cetuximab	predicted - sensitive	Preclinical - Pdx	28446642	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	head and neck squamous cell carcinoma	Gedatolisib	sensitive	Preclinical	24823695	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	lung non-small cell carcinoma	Pictilisib	sensitive	Preclinical - Cell line xenograft	23136191	Lung	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	lung small cell carcinoma	Navitoclax + Pictilisib	predicted - sensitive	Preclinical - Cell line xenograft	27197306	Lung	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	lung squamous cell carcinoma	Alpelisib	predicted - sensitive	Preclinical - Pdx	30093452	Lung	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	lung squamous cell carcinoma	Buparlisib	predicted - sensitive	Preclinical - Pdx	30093452	Lung	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	ovarian clear cell adenocarcinoma	BEZ235	sensitive	Preclinical	24927217	Ovary	Therapeutic	D
PIK3CA	MUT	Gain-of-Function	triple-receptor negative breast cancer	Bevacizumab + Doxorubicin + Everolimus	predicted - sensitive	Phase I	27893038	Breast	Therapeutic	C
PIK3CA	MUT	Gain-of-Function	triple-receptor negative breast cancer	Bevacizumab + Doxorubicin + Temsirolimus	predicted - sensitive	Phase I	27893038	Breast	Therapeutic	C
PIK3CA	MUT	H1047L	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047L	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	;31091374;	Breast	Therapeutic	A
PIK3CA	MUT	H1047R	Adenocarcinoma in Breast			1	20619739,28726194,22722201	Breast	Therapeutic	B
PIK3CA	MUT	H1047R	Advanced Solid Tumor	A66	sensitive	Preclinical	21668414	Other	Therapeutic	D
PIK3CA	MUT	H1047R	Advanced Solid Tumor	Rigosertib	sensitive	Preclinical - Cell culture	27104980	Other	Therapeutic	D
PIK3CA	MUT	H1047R	Advanced Solid Tumor	Sirolimus	sensitive	Preclinical	15647370	Other	Therapeutic	D
PIK3CA	MUT	H1047R	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	26627007	Other	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Alpelisib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	ARQ 751	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	BAY1125976	sensitive	Preclinical - Cell line xenograft	27699769	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	Breast Cancer		Better Outcome	B	17202311	Breast	Prognostic	B
PIK3CA	MUT	H1047R	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Buparlisib	sensitive	Preclinical - Cell line xenograft	28539475	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	CH5132799	sensitive	Preclinical	21558396	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	Breast Cancer	CH5132799	Sensitivity/Response	D	21558396	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Gedatolisib	sensitive	Preclinical	17314276;21325073	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	M2698	sensitive	Preclinical - Cell line xenograft	27186432	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Metformin	sensitive	Preclinical - Cell line xenograft	23986086	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Miransertib	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast cancer	Taselisib	sensitive	Phase I	28331003	Breast	Therapeutic	C
PIK3CA	MUT	H1047R	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	Breast Cancer	Trastuzumab	Resistance	D	20453058	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	breast metaplastic carcinoma	Buparlisib + Paclitaxel	predicted - sensitive	Case Reports/Case Series	30577988	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	colorectal cancer	Cetuximab + Fluorouracil	resistant	Preclinical - Cell culture	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	H1047R	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	C	19223544	Colorectal	Therapeutic	C
PIK3CA	MUT	H1047R	colorectal cancer	Cetuximab	sensitive	Case Reports/Case Series	25714871	Colorectal	Therapeutic	D
PIK3CA	MUT	H1047R	colorectal cancer	Metformin	sensitive	Preclinical - Cell line xenograft	23986086	Colorectal	Therapeutic	D
PIK3CA	MUT	H1047R	Colorectal Cancer		Poor Outcome	B	17590872	Colorectal	Prognostic	B
PIK3CA	MUT	H1047R	Colorectal Cancer		Poor Outcome	B	19903786	Colorectal	Prognostic	B
PIK3CA	MUT	H1047R	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	17657213,19330652,16573740,22675565,24440717,16764926	Blood;Bone_Marrow	Therapeutic	B
PIK3CA	MUT	H1047R	estrogen-receptor mutation breast cancer	Everolimus	predicted - sensitive	Clinical Study - Cohort	31088410	Breast	Therapeutic	C
PIK3CA	MUT	H1047R	Head And Neck Cancer	BYL719 (Alpelisib)	Sensitivity/Response	D	25550549	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	Head And Neck Cancer	Cetuximab,Dactolisib	Sensitivity/Response	D	23619167	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	Head And Neck Cancer	Dactolisib	Sensitivity/Response	D	23619167	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	Head And Neck Cancer	Dactolisib	Sensitivity/Response	D	25855885	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	head and neck squamous cell carcinoma	Cetuximab	resistant	Preclinical - Cell culture	30962319	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	head and neck squamous cell carcinoma	Gedatolisib	sensitive	Preclinical - Cell culture	25977343	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	head and neck squamous cell carcinoma	Radiotherapy + Taselisib	sensitive	Preclinical	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	head and neck squamous cell carcinoma	SHR-A1307	predicted - sensitive	Preclinical - Cell culture	30962319	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	head and neck squamous cell carcinoma	Sirolimus + Trametinib	sensitive	Preclinical - Cell line xenograft	26882569	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	Head And Neck Squamous Cell Carcinoma	Taselisib (GDC-0032)	Sensitivity/Response	D	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	H1047R	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma in Liver/Pancreas/Stomach			2	15467468,15608678,15994075,24185509,25855536	Liver;Pancreas;Stomach	Therapeutic	C
PIK3CA	MUT	H1047R	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	H1047R	Her2-receptor Positive Breast Cancer	Ado-trastuzumab Emtansine	Sensitivity/Response	B	26920887	Breast	Therapeutic	B
PIK3CA	MUT	H1047R	Her2-receptor Positive Breast Cancer	Fulvestrant,Everolimus	Sensitivity/Response	C	27445490	Breast	Therapeutic	C
PIK3CA	MUT	H1047R	Her2-receptor Positive Breast Cancer	Lapatinib,AZD5363	Sensitivity/Response	D	22294718	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	Her2-receptor Positive Breast Cancer	Trastuzumab,AZD5363	Sensitivity/Response	D	22294718	Breast	Therapeutic	D
PIK3CA	MUT	H1047R	lung adenocarcinoma	BEZ235	sensitive	Preclinical	19029981	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	Lung Adenocarcinoma	Dactolisib	Sensitivity/Response	D	19029981	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung adenocarcinoma	Sirolimus	no benefit	Preclinical	19029981	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung cancer	BEZ235	sensitive	Preclinical	19029981	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung cancer	Sirolimus	no benefit	Preclinical	19029981	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	Lung Non-small Cell Carcinoma	PI103	Sensitivity/Response	D	19513541	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung squamous cell carcinoma	Alpelisib	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung squamous cell carcinoma	BEZ235	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung squamous cell carcinoma	Buparlisib	sensitive	Preclinical - Cell culture	26013318	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	H1047R	ovarian cancer	A66	sensitive	Preclinical - Cell line xenograft	21668414	Ovary	Therapeutic	D
PIK3CA	MUT	H1047R	ovarian cancer	AZD8835	sensitive	Preclinical	;	Ovary	Therapeutic	D
PIK3CA	MUT	H1047R	ovarian cancer	CH5132799	sensitive	Phase I	25231405	Ovary	Therapeutic	C
PIK3CA	MUT	H1047R	ovarian cancer	PF-04691502	sensitive	Preclinical - Cell line xenograft	21750219	Ovary	Therapeutic	D
PIK3CA	MUT	H1047R	progesterone-receptor mutation breast cancer	Everolimus	predicted - sensitive	Clinical Study - Cohort	31088410	Breast	Therapeutic	C
PIK3CA	MUT	H1047R	Squamous Cell Carcinoma in Anus/Oral Cavity/Pharynx			2	21798893,25631445,27219019,26498363,24767105	Esophagus;Other	Therapeutic	C
PIK3CA	MUT	H1047R	stomach cancer	Capivasertib	sensitive	Preclinical - Pdx	24088382	Stomach	Therapeutic	D
PIK3CA	MUT	H1047R	thyroid cancer	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PIK3CA	MUT	H1047R	thyroid cancer	MK2206 + Temsirolimus	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PIK3CA	MUT	H1047R	Thyroid Cancer	Temsirolimus,Perifosine	Sensitivity/Response	D	19706758	Thyroid	Therapeutic	D
PIK3CA	MUT	H1047R	urinary bladder cancer	BEZ235	sensitive	Preclinical - Pdx	26270481	Bladder	Therapeutic	D
PIK3CA	MUT	H1047R	urinary bladder cancer	Cisplatin + Pictilisib	sensitive	Preclinical - Pdx	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	H1047R	urinary bladder cancer	Pictilisib	sensitive	Preclinical - Pdx	28808038	Bladder	Therapeutic	D
PIK3CA	MUT	H1047X	colorectal cancer	Bevacizumab + Temsirolimus	predicted - resistant	Case Reports/Case Series	21216929	Colorectal	Therapeutic	D
PIK3CA	MUT	H1047X	endometrial adenocarcinoma	Temsirolimus	predicted - sensitive	Case Reports/Case Series	21216929	Uterus	Therapeutic	D
PIK3CA	MUT	H1047X	lung non-small cell carcinoma	Taselisib	sensitive	Phase I	28331003	Lung	Therapeutic	C
PIK3CA	MUT	H1047X	small intestine adenocarcinoma	Bortezomib + Temsirolimus + Topotecan	predicted - resistant	Case Reports/Case Series	21216929	Other	Therapeutic	D
PIK3CA	MUT	H1047Y	endometrial cancer	CH5132799	sensitive	Preclinical - Cell line xenograft	21558396	Uterus	Therapeutic	D
PIK3CA	MUT	H1047Y	glioblastoma multiforme	YM-024	sensitive	Preclinical	24718026	Brain	Therapeutic	D
PIK3CA	MUT	H1047Y	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	;31091374;	Breast	Therapeutic	A
PIK3CA	MUT	450_458del	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	29284706	Breast	Therapeutic	D
PIK3CA	MUT	I391M	uterine cancer	Sirolimus	predicted - sensitive	Case Reports/Case Series	28514312	Uterus	Therapeutic	D
PIK3CA	MUT	K111N	breast cancer	ARQ 751	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	K111N	breast cancer	BAY1125976	sensitive	Preclinical - Cell culture	27699769	Breast	Therapeutic	D
PIK3CA	MUT	K111N	breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PIK3CA	MUT	K111N	breast cancer	Miransertib	sensitive	Preclinical - Cell culture	26469692	Breast	Therapeutic	D
PIK3CA	MUT	K111N	estrogen-receptor mutation breast cancer	AZD8835	sensitive	Preclinical	26839307	Breast	Therapeutic	D
PIK3CA	MUT	K944N	colorectal cancer	Cetuximab + Fluorouracil	resistant	Case Reports/Case Series	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	K966E	colorectal cancer	Cetuximab + Fluorouracil	resistant	Clinical Study - Cohort	28424201	Colorectal	Therapeutic	C
PIK3CA	MUT	M1043I	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	M1043V	Advanced Solid Tumor	Sirolimus	sensitive	Preclinical	17376864	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	A-443654	sensitive	Preclinical	19208828	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	Alpelisib	sensitive	Phase I	29401002	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	Alpelisib	sensitive	Preclinical - Cell line xenograft	24608574	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	AT-7867	sensitive	Preclinical	20423992	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	AZD8835	sensitive	Preclinical	26839307	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	BAY1082439	sensitive	Preclinical	;	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus	sensitive	Clinical Study	21216929	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	Carboxyamidotriazole Orotate	sensitive	Phase I	;	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	CC-223	sensitive	Phase I	26177599;	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	CUDC-907	sensitive	Preclinical - Cell line xenograft	22693356	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	GDC-0980	sensitive	Phase I	26787751	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	M2698	sensitive	Preclinical	;	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	MLN1117	sensitive	Phase I	;	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	MLN1117	sensitive	Preclinical	;	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	PX-866	sensitive	Phase I	22693357	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	Sapanisertib	sensitive	Preclinical	25261369	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	Taselisib	sensitive	Phase I	;	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	Uprosertib	predicted - sensitive	Phase I	;	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	VS-5584	sensitive	Preclinical	23270925	Other	Therapeutic	D
PIK3CA	MUT	mutant	Advanced Solid Tumor	XL147	sensitive	Phase I	24166903	Other	Therapeutic	C
PIK3CA	MUT	mutant	Advanced Solid Tumor	XL147	sensitive	Preclinical	25637314	Other	Therapeutic	D
PIK3CA	MUT	mutant	breast adenocarcinoma	GS-9820	sensitive	Preclinical - Cell line xenograft	;	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	Alpelisib + GSK2334470	sensitive	Preclinical - Cell line xenograft	27451907	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	AT13148	sensitive	Preclinical - Cell line xenograft	22781553	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	AZD8835	sensitive	Preclinical	;	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	Capivasertib	predicted - sensitive	Phase I	29066505	Breast	Therapeutic	C
PIK3CA	MUT	mutant	breast cancer	Capivasertib	predicted - sensitive	Preclinical	22294718	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	CH5132799	sensitive	Preclinical	21558396	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	CUDC-907	sensitive	Preclinical	22693356	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	GDC-0077	predicted - sensitive	Preclinical - Pdxcell culture	;	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	GSK2126458	no benefit	Phase I	26603258	Breast	Therapeutic	C
PIK3CA	MUT	mutant	breast cancer	Letrozole + Taselisib	sensitive	Phase Ib/II	;	Breast	Therapeutic	C
PIK3CA	MUT	mutant	breast cancer	MK2206	no benefit	Phase II	31277699	Breast	Therapeutic	C
PIK3CA	MUT	mutant	breast cancer	MLN1117	predicted - sensitive	Case Reports/Case Series	28490463	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	OSI-027	sensitive	Preclinical - Cell line xenograft	21673091	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	Pictilisib	sensitive	Preclinical	24601221	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	Sapanisertib	sensitive	Preclinical	23085766	Breast	Therapeutic	D
PIK3CA	MUT	mutant	breast cancer	Temsirolimus	no benefit	Phase II	22245973	Breast	Therapeutic	C
PIK3CA	MUT	mutant	breast cancer	VS-5584	sensitive	Preclinical	23270925	Breast	Therapeutic	D
PIK3CA	MUT	mutant	cervical cancer	Alpelisib	predicted - sensitive	Phase I	29401002	Cervix	Therapeutic	C
PIK3CA	MUT	mutant	cervical cancer	Cetuximab	decreased response	Phase II	25724520	Cervix	Therapeutic	C
PIK3CA	MUT	mutant	colon cancer	BEZ235	sensitive	Preclinical	22543857	Colorectal	Therapeutic	D
PIK3CA	MUT	mutant	colon cancer	PWT33597	sensitive	Preclinical	;	Colorectal	Therapeutic	D
PIK3CA	MUT	mutant	colorectal cancer	Alpelisib	sensitive	Phase I	29401002	Colorectal	Therapeutic	C
PIK3CA	MUT	mutant	colorectal cancer	MS417 + Pictilisib	predicted - sensitive	Preclinical - Cell culture	26058079	Colorectal	Therapeutic	D
PIK3CA	MUT	mutant	endometrial cancer	Alpelisib	sensitive	Phase I	29401002	Uterus	Therapeutic	C
PIK3CA	MUT	mutant	endometrial cancer	CH5132799	sensitive	Preclinical	21558396	Uterus	Therapeutic	D
PIK3CA	MUT	mutant	endometrial cancer	GDC-0980	sensitive	Phase II	;	Uterus	Therapeutic	C
PIK3CA	MUT	mutant	endometrial cancer	Pictilisib	sensitive	Preclinical	23674493	Uterus	Therapeutic	D
PIK3CA	MUT	mutant	endometrial cancer	Temsirolimus	no benefit	Phase II	27016228	Uterus	Therapeutic	C
PIK3CA	MUT	mutant	endometrioid ovary carcinoma	Capivasertib	sensitive	Phase I	;	Ovary	Therapeutic	C
PIK3CA	MUT	mutant	estrogen-receptor mutation breast cancer	AZD8835	sensitive	Preclinical	26839307	Breast	Therapeutic	D
PIK3CA	MUT	mutant	estrogen-receptor mutation breast cancer	Fulvestrant	no benefit	Phase II	27174596	Breast	Therapeutic	C
PIK3CA	MUT	mutant	estrogen-receptor mutation breast cancer	Fulvestrant + Pictilisib	no benefit	Phase II	27174596	Breast	Therapeutic	C
PIK3CA	MUT	mutant	estrogen-receptor mutation breast cancer	Letrozole	predicted - sensitive	Phase III	29902286	Breast	Therapeutic	C
PIK3CA	MUT	mutant	female reproductive organ cancer	Capivasertib	predicted - sensitive	Phase I	29066505	Cervix	Therapeutic	C
PIK3CA	MUT	mutant	gastric adenocarcinoma	Fluorouracil + PI-103	sensitive	Preclinical	22336586	Stomach	Therapeutic	D
PIK3CA	MUT	mutant	head and neck cancer	Alpelisib	sensitive	Phase I	29401002	Head_and_Neck	Therapeutic	C
PIK3CA	MUT	mutant	head and neck squamous cell carcinoma	Carboplatin + Paclitaxel + Temsirolimus	predicted - sensitive	Phase II	28961834	Head_and_Neck	Therapeutic	C
PIK3CA	MUT	mutant	head and neck squamous cell carcinoma	Radiotherapy + Taselisib	sensitive	Preclinical - Pdxcell culture	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	mutant	hematologic cancer	CUDC-907	sensitive	Preclinical - Cell line xenograft	22693356	Blood	Therapeutic	D
PIK3CA	MUT	mutant	hepatocellular carcinoma	Sorafenib	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
PIK3CA	MUT	mutant	Her2-receptor mutation breast cancer	CCT128930	sensitive	Preclinical - Cell line xenograft	21191045	Breast	Therapeutic	D
PIK3CA	MUT	mutant	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - Has Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	mutant	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	Phase III	;	Breast	Therapeutic	C
PIK3CA	MUT	mutant	Her2-receptor negative breast cancer	Alpelisib	sensitive	Phase I	29401002	Breast	Therapeutic	C
PIK3CA	MUT	mutant	Her2-receptor negative breast cancer	Capivasertib + Paclitaxel	no benefit	Phase II	30860570	Breast	Therapeutic	C
PIK3CA	MUT	mutant	invasive bladder transitional cell carcinoma	Cisplatin + Gemcitabine + Sorafenib	predicted - resistant	Phase II	;	Bladder	Therapeutic	C
PIK3CA	MUT	mutant	lung non-small cell carcinoma	PF-04691502	sensitive	Preclinical - Cell line xenograft	21750219	Lung	Therapeutic	D
PIK3CA	MUT	mutant	lung non-small cell carcinoma	PWT33597	sensitive	Preclinical	;	Lung	Therapeutic	D
PIK3CA	MUT	mutant	lung squamous cell carcinoma	Taselisib	no benefit	Phase I	31158500	Lung	Therapeutic	C
PIK3CA	MUT	mutant	ovarian cancer	Buparlisib + Olaparib	sensitive	Preclinical - Cell line xenograft	26909613	Ovary	Therapeutic	D
PIK3CA	MUT	mutant	ovarian cancer	CH5132799	sensitive	Preclinical	21558396	Ovary	Therapeutic	D
PIK3CA	MUT	mutant	ovarian cancer	OSI-027	sensitive	Preclinical - Cell line xenograft	21673091	Ovary	Therapeutic	D
PIK3CA	MUT	mutant	ovarian cancer	Temsirolimus	sensitive	Case Reports/Case Series	21216929	Ovary	Therapeutic	D
PIK3CA	MUT	mutant	ovarian cancer	Temsirolimus	sensitive	Phase I	22271473	Ovary	Therapeutic	C
PIK3CA	MUT	mutant	prostate cancer	CH5132799	sensitive	Preclinical	21558396	Prostate	Therapeutic	D
PIK3CA	MUT	mutant	squamous cell carcinoma	Carboxyamidotriazole Orotate	sensitive	Phase I	;	Skin	Therapeutic	C
PIK3CA	MUT	mutant	stomach cancer	BAY1082439	sensitive	Preclinical	;	Stomach	Therapeutic	D
PIK3CA	MUT	mutant	stomach cancer	BEZ235	sensitive	Preclinical	22543857	Stomach	Therapeutic	D
PIK3CA	MUT	mutant	stomach cancer	MLN1117	predicted - sensitive	Case Reports/Case Series	28490463	Stomach	Therapeutic	D
PIK3CA	MUT	mutant	triple-receptor negative breast cancer	Capivasertib + Paclitaxel	predicted - sensitive	Phase II	30715161	Breast	Therapeutic	C
PIK3CA	MUT	mutant	triple-receptor negative breast cancer	Ipatasertib + Paclitaxel	predicted - sensitive	Phase II	;	Breast	Therapeutic	C
PIK3CA	MUT	mutant	triple-receptor negative breast cancer	Palbociclib + Pictilisib	sensitive	Preclinical	27020857	Breast	Therapeutic	D
PIK3CA	MUT	mutant	triple-receptor negative breast cancer	Pictilisib	sensitive	Preclinical - Cell culture	27196766	Breast	Therapeutic	D
PIK3CA	MUT	mutation	Breast Cancer		Better Outcome	B	17575221	Breast	Prognostic	B
PIK3CA	MUT	mutation	Breast Cancer	Everolimus,PP242	Sensitivity/Response	D	21358673	Breast	Therapeutic	D
PIK3CA	MUT	mutation	Breast Cancer	PI3K Inhibitor,Palbociclib (PD0332991)	Sensitivity/Response	D	25002028	Breast	Therapeutic	D
PIK3CA	MUT	mutation	Breast Cancer	PI3K Inhibitor,Ribociclib	Sensitivity/Response	D	25002028	Breast	Therapeutic	D
PIK3CA	MUT	mutation	Breast Cancer	Trastuzumab	Resistance	B	21594665	Breast	Therapeutic	B
PIK3CA	MUT	mutation	Cancer	AZD5363	Sensitivity/Response	B	28489509	Cancer	Therapeutic	B
PIK3CA	MUT	mutation	Cancer	AZD5363	Sensitivity/Response	D	22294718	Cancer	Therapeutic	D
PIK3CA	MUT	mutation	Cancer	BYL719 (Alpelisib)	Sensitivity/Response	D	24608574	Cancer	Therapeutic	D
PIK3CA	MUT	mutation	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	Resistance	B	23435830	Colorectal	Therapeutic	B
PIK3CA	MUT	mutation	Colorectal Cancer	Aspirin	Sensitivity/Response	B	23094721	Colorectal	Therapeutic	B
PIK3CA	MUT	mutation	Colorectal Cancer	Cabozantinib	Sensitivity/Response	D	25242168	Colorectal	Therapeutic	D
PIK3CA	MUT	mutation	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	B	19223544	Colorectal	Therapeutic	B
PIK3CA	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	B	19603024	Colorectal	Therapeutic	B
PIK3CA	MUT	mutation	Colorectal Cancer	Cetuximab	Resistance	D	22586653	Colorectal	Therapeutic	D
PIK3CA	MUT	mutation	Endometrial Cancer	Pictilisib	Sensitivity/Response	D	23674493	Uterus	Therapeutic	D
PIK3CA	MUT	mutation	Head And Neck Cancer	Dactolisib	Sensitivity/Response	D	23619167	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	mutation	Head And Neck Squamous Cell Carcinoma	Radiation,Taselisib (GDC-0032)	Sensitivity/Response	D	26589432	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	mutation	Her2-receptor Positive Breast Cancer	AZD5363	Sensitivity/Response	D	22294718	Breast	Therapeutic	D
PIK3CA	MUT	mutation	Her2-receptor Positive Breast Cancer	Everolimus	Sensitivity/Response	B	27091708	Breast	Therapeutic	B
PIK3CA	MUT	mutation	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	B	17936563	Breast	Therapeutic	B
PIK3CA	MUT	mutation	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	B	21594665	Breast	Therapeutic	B
PIK3CA	MUT	mutation	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Resistance	B	21258250	Lung	Therapeutic	B
PIK3CA	MUT	mutation	Stomach Cancer	AZD5363	Sensitivity/Response	D	24088382	Stomach	Therapeutic	D
PIK3CA	MUT	N345I	breast cancer	Buparlisib	resistant	Preclinical - Cell culture	29636477	Breast	Therapeutic	D
PIK3CA	MUT	N345K	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	26627007	Other	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	N345K	lung squamous cell carcinoma	Taselisib	no benefit	Case Reports/Case Series	31158500	Lung	Therapeutic	D
PIK3CA	MUT	oncogenic mutation	Bladder;Head an neck;Lung	[PI3K pathway inhibitor]	Responsive	Case report	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	Bladder;Head_and_Neck;Lung	Therapeutic	D
PIK3CA	MUT	oncogenic mutation	Breast adenocarcinoma	[AKT inhibitor]	Responsive	Early trials	ASCO 2015 (abstr 2500)	Breast	Therapeutic	C
PIK3CA	MUT	oncogenic mutation	Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium	[PI3K pathway inhibitor]	Responsive	Early trials	22271473;27672108;AACR 2013 (abstr LB-66);25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	Breast;Cervix;Ovary;Uterus	Therapeutic	C
PIK3CA	MUT	oncogenic mutation	Breast adenocarcinoma	[PIK3CA inhibitor]	Responsive	Early trials	28331003	Breast	Therapeutic	C
PIK3CA	MUT	oncogenic mutation	Colorectal adenocarcinoma	Cetuximab	Resistant	Late trials	19223544;20619739	Colorectal	Therapeutic	C
PIK3CA	MUT	oncogenic mutation	Glioma;Thyroid carcinoma	[PI3K pathway inhibitor]	Responsive	Pre-clinical	19671762;21289267	Nervous_System;Thyroid	Therapeutic	D
PIK3CA	MUT	oncogenic mutation	Head an neck squamous	[PI3K pathway inhibitor]	Responsive	Case report	26787751;26763254	Head_and_Neck	Therapeutic	D
PIK3CA	MUT	oncogenic mutation	Lung;Colorectal adenocarcinoma	[PI3K pathway inhibitor (alone, in combination)]	Responsive	Pre-clinical	23136191;23475782;22392911	Colorectal;Lung	Therapeutic	D
PIK3CA	MUT	Oncogenic Mutations	Breast Cancer	Alpelisib + Fulvestrant	Response	1	25877889, 30543347, 31091374	Breast	Therapeutic	A
PIK3CA	MUT	Oncogenic Mutations	Breast Cancer	Buparlisib, Serabelisib, Copanlisib, GDC-0077, Taselisib + Fulvestrant, Alpelisib, Buparlisib + Fulvestrant, Taselisib	Response	3A	22049316, 25877889, 29401002, 28490463, 29793946, 24652201, 30715997, 24608574, 23662903, 22188813, 27672108, 25172762	Breast	Therapeutic	C
PIK3CA	MUT	oncogenic mutation	Stomach	[PIK3CA inhibitor]	Responsive	Case report	ASCO 2015 (abstr 2501)	Stomach	Therapeutic	D
PIK3CA	MUT	447_455del	estrogen-receptor mutation breast cancer	Alpelisib + Letrozole	predicted - sensitive	Case Reports/Case Series	29284706	Breast	Therapeutic	D
PIK3CA	MUT	P471L	Merkel Cell Carcinoma	Idelalisib	Sensitivity/Response	C	26466009	Skin	Therapeutic	C
PIK3CA	MUT	P539R	breast cancer	BAY1125976	sensitive	Preclinical - Cell culture	27699769	Breast	Therapeutic	D
PIK3CA	MUT	Q546E	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	;31091374;	Breast	Therapeutic	A
PIK3CA	MUT	Q546K	Advanced Solid Tumor	Trametinib	sensitive	Preclinical	26627007	Other	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	Alpelisib	sensitive	Preclinical - Cell culture	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	BEZ235	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	Lapatinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	MK2206	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	Neratinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546K	breast cancer	Trametinib	sensitive	Preclinical	26627007	Breast	Therapeutic	D
PIK3CA	MUT	Q546R	Her2-receptor negative breast cancer	Alpelisib + Fulvestrant	sensitive	FDA approved - On Companion Diagnostic	31091374;;	Breast	Therapeutic	A
PIK3CA	MUT	Q546R	prostate cancer	CH5132799	sensitive	Preclinical	21558396	Prostate	Therapeutic	D
PIK3CA	MUT	R88Q	colorectal cancer	Cetuximab + Floxuridine + Fluorouracil + Irinotecan	predicted - sensitive	Case Reports/Case Series	25714871	Colorectal	Therapeutic	D
PIK3CA	MUT	R88Q	malignant pleural mesothelioma	GDC-0980	sensitive	Phase I	26787751	Blood	Therapeutic	C
PIK3CA	MUT	V344G	glioblastoma multiforme	YM-024	no benefit	Preclinical	24718026	Brain	Therapeutic	D
PIK3CA	MUT	V952A	colorectal cancer	Cetuximab + Fluorouracil	resistant	Case Reports/Case Series	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	V955G	colorectal cancer	Cetuximab + Fluorouracil	resistant	Case Reports/Case Series	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	V955I	colorectal cancer	Cetuximab + Fluorouracil	resistant	Case Reports/Case Series	28424201	Colorectal	Therapeutic	D
PIK3CA	MUT	WILDTYPE	Advanced Solid Tumor	PX-866	sensitive	Phase I	22693357	Other	Therapeutic	C
PIK3CA	MUT	WILDTYPE	breast cancer	A-1210477 + WEHI-539	predicted - sensitive	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	WILDTYPE	breast cancer	BEZ235 + WEHI-539	no benefit	Preclinical - Cell culture	27974663	Breast	Therapeutic	D
PIK3CA	MUT	WILDTYPE	Her2-receptor mutation breast cancer	Lapatinib + Paclitaxel + Trastuzumab	sensitive	Phase II	26245675	Breast	Therapeutic	C
PIK3CA	MUT	WILDTYPE	Her2-receptor negative breast cancer	Alpelisib	no benefit	Phase I	29401002	Breast	Therapeutic	C
PIK3CA	MUT	WILDTYPE	triple-receptor negative breast cancer	Palbociclib + Pictilisib	no benefit	Preclinical	27020857	Breast	Therapeutic	D
PIK3CB	MUT	D1067Y	Breast adenocarcinoma	[AKT inhibitor]	Responsive	Pre-clinical	26759240	Breast	Therapeutic	D
PIK3CB	MUT	D1067Y	Breast adenocarcinoma	[MTORC1/2 inhibitor]	Responsive	Pre-clinical	26759240	Breast	Therapeutic	D
PIK3CB	MUT	D1067Y	Breast adenocarcinoma	[PI3K pathway inhibitor]	Resistant	Case report	26759240	Breast	Therapeutic	D
PIK3CB	MUT	oncogenic mutation	Head an neck squamous	[AKT inhibitor]	Responsive	Pre-clinical	23619167	Head_and_Neck	Therapeutic	D
PIK3CB	MUT	oncogenic mutation	Head an neck squamous	[MTORC1/2 inhibitor]	Responsive	Pre-clinical	23619167	Head_and_Neck	Therapeutic	D
PIK3CB	MUT	oncogenic mutation	Head an neck squamous	[PI3K pathway inhibitor]	Responsive	Pre-clinical	23619167	Head_and_Neck	Therapeutic	D
PIK3R1	MUT	mutation	Breast Cancer	PP242	Sensitivity/Response	D	21358673	Breast	Therapeutic	D
PIK3R1	MUT	oncogenic mutation	Endometrium	[PI3K pathway inhibitor]	Responsive	Case report	ASCO 2015 (abstr 11075)	Uterus	Therapeutic	D
PIK3R1	MUT	oncogenic mutation	Glioma	[AKT inhibitor]	Responsive	Pre-clinical	23166678	Nervous_System	Therapeutic	D
PIK3R2	MUT	A171V	Endometrium	[MTOR inhibitor]	Responsive	Pre-clinical	21984976;19962665	Uterus	Therapeutic	D
PIK3R2	MUT	N561D	Endometrium	[MTOR inhibitor]	Responsive	Pre-clinical	21984976;19962665	Uterus	Therapeutic	D
PIK3R2	MUT	N561D	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PIM1	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			2	21802138,21628411	Blood;Bone_Marrow	Therapeutic	C
PIM1	MUT	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	26918046	Lung	Prognostic	B
PLCG2	MUT	L845F	Chronic lymphocytic leukemia	Ibrutinib	Resistant	Early trials	24869598	Blood;Bone_Marrow	Therapeutic	C
PLCG2	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	24869598	Blood;Bone_Marrow	Prognostic	B
PLCG2	MUT	R665W	Chronic lymphocytic leukemia	Ibrutinib	Resistant	Early trials	24869598	Blood;Bone_Marrow	Therapeutic	C
PML	FUS	PML-RARA A216V	Acute Promyelocytic Leukemia	All-trans Retinoic Acid	Resistance	C	21613260	Blood;Bone_Marrow	Therapeutic	C
PML	FUS	PML-RARA	Acute Promyelocytic Leukemia	All-trans Retinoic Acid,Arsenic Trioxide	Sensitivity/Response	A	11704842	Blood;Bone_Marrow	Therapeutic	A
PML	FUS	PML-RARA	Acute Promyelocytic Leukemia	All-trans Retinoic Acid	Sensitivity/Response	B	8674046	Blood;Bone_Marrow	Therapeutic	B
PML	FUS	PML-RARA	Acute Promyelocytic Leukemia	All-trans Retinoic Acid	Sensitivity/Response	C	21505136	Blood;Bone_Marrow	Therapeutic	C
PML	FUS	PML-RARA	Acute Promyelocytic Leukemia		Positive	A	7628753	Blood;Bone_Marrow	Diagnostic	A
PML	FUS	PML-RARA L218P	Acute Promyelocytic Leukemia	All-trans Retinoic Acid	Resistance	C	21613260	Blood;Bone_Marrow	Therapeutic	C
PML	MUT	B2 DOMAIN mutation	Acute Promyelocytic Leukemia	All-trans Retinoic Acid	Resistance	B	23670176	Blood;Bone_Marrow	Therapeutic	B
PMS2	MUT	K706fs	Glioblastoma Multiforme	Nivolumab	Sensitivity/Response	C	27001570	Brain	Therapeutic	C
POLD1	MUT	C284Y	Lung Adenocarcinoma	Pembrolizumab	Sensitivity/Response	C	25765070	Lung	Therapeutic	C
POLD1	MUT	E374K	Lung Non-small Cell Carcinoma	Pembrolizumab	Sensitivity/Response	C	25765070	Lung	Therapeutic	C
POLE	MUT	codon(s) 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 47 missense	Glioma;Endometrium	[PD1 Ab inhibitor]	Responsive	Case report	27001570;27683556;27159395	Nervous_System;Uterus	Therapeutic	D
POLE	MUT	mutation	Endometrial Cancer	Pembrolizumab	Sensitivity/Response	C	27159395	Uterus	Therapeutic	C
POLE	MUT	mutation	Glioblastoma Multiforme	Pembrolizumab	Sensitivity/Response	C	27683556	Brain	Therapeutic	C
POLE	MUT	oncogenic mutation	Colorectal adenocarcinoma	[PD1 Ab inhibitor]	Responsive	Case report	28188185	Colorectal	Therapeutic	D
POLE	MUT	P286R	Colorectal Cancer		Better Outcome	B	28404093	Colorectal	Prognostic	B
POLE	MUT	S459F	Colorectal Cancer		Better Outcome	B	28404093	Colorectal	Prognostic	B
POLE	MUT	V411L	Colorectal Cancer		Better Outcome	B	28404093	Colorectal	Prognostic	B
POT1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	27226433	Blood;Bone_Marrow	Prognostic	B
POU5F1	EXP	EXPRESSION	Colon Cancer	Oxaliplatin	Resistance	D	26398480	Colorectal	Therapeutic	D
PRDM1	MUT	mutation	Diffuse Large B-cell Lymphoma		Poor Outcome	B	27568520	Lymph_Nodes	Prognostic	B
PREX2	MUT	R172I	Melanoma	Vemurafenib	Resistance	C	24265155	Skin	Therapeutic	C
PRKAA2	MUT	T172 PHOSPHORYLATION	Cancer	ACLY SiRNA	Sensitivity/Response	E	23506848	Cancer	Therapeutic	D
PRKACA	FUS	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma		Positive	B	24578576	Liver	Diagnostic	B
PRKACA	FUS	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma		Positive	B	25557953	Liver	Diagnostic	B
PRKACA	FUS	DNAJB1-PRKACA	Hepatocellular Fibrolamellar Carcinoma		Positive	B	25698061	Liver	Diagnostic	B
PRKACA	FUS	DNAJB1-PRKACA	Hepatocellular Mixed Fibrolamellar Carcinoma		Positive	C	27029710	Liver	Diagnostic	C
PRKCB	MUT	D427N	Adult T-cell Leukemia		Positive	D	26437031	Blood;Bone_Marrow	Diagnostic	D
PROM1	EXP	EXPRESSION	Hepatocellular Carcinoma	Sorafenib	Resistance	B	22596232	Liver	Therapeutic	B
PRPF40B	MUT	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	21909114	Blood;Bone_Marrow	Therapeutic	B
PRPF8	MUT	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia in Blood/Bone Marrow			1	24220272,22323480	Blood;Bone_Marrow	Therapeutic	B
PSMB8	MUT	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Poor Outcome	B	26894977	Stomach	Prognostic	B
PTCH1	MUT	LOH	Brain Medulloblastoma	Vismodegib	Sensitivity/Response	B	26169613	Brain	Therapeutic	B
PTCH1	MUT	mutation	Brain Medulloblastoma	Sonidegib	Sensitivity/Response	B	24651015	Brain	Therapeutic	B
PTCH1	MUT	mutation	Cancer	Vismodegib	Sensitivity/Response	B	29320312	Cancer	Therapeutic	B
PTCH1	MUT	oncogenic mutation	Basal cell carcinoma;Medulloblastoma	Vismodegib	Responsive	FDA guidelines	19726763;19726761	Nervous_System;Skin	Therapeutic	A
PTCH1	MUT	oncogenic mutation	Medulloblastoma	Foretinib	Responsive	Pre-clinical	25391241	Nervous_System	Therapeutic	D
PTCH1	MUT	oncogenic mutation	Medulloblastoma	[SMO inhibitor]	Responsive	Pre-clinical	24651015 	Nervous_System	Therapeutic	D
PTCH1	MUT	Truncating Mutations	Embryonal Tumor	Sonidegib	Response	3A	24900187, 24523439	Nervous_System	Therapeutic	C
PTCH1	MUT	Truncating Mutations	Skin Cancer, Non-Melanoma	Sonidegib, Vismodegib	Response	3A	29320312, 24900187, 22670903, 22670904, 24523439	Skin	Therapeutic	C
PTEN	CNV	deletion	Any cancer type	Sirolimus	Responsive	Early trials	ASCO 2013 (abstr 2532)	Cancer	Therapeutic	C
PTEN	CNV	deletion	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Late trials	21163703;19398573	Colorectal	Therapeutic	C
PTEN	CNV	deletion	Cutaneous melanoma	[PD1 Ab inhibitor]	Responsive	Early trials	26645196	Skin	Therapeutic	C
PTEN	CNV	deletion	Endometrium	[PARP inhibitor]	Responsive	Case report	21468130;20944090	Uterus	Therapeutic	D
PTEN	CNV	deletion	Ovary	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	21632463	Ovary	Therapeutic	D
PTEN	CNV	deletion	Pancreas	[AKT inhibitor]	Responsive	Case report	22025163	Pancreas	Therapeutic	D
PTEN	CNV	deletion	Prostate adenocarcinoma	Everolimus	Responsive	Early trials	23582881	Prostate	Therapeutic	C
PTEN	CNV	deletion	Prostate adenocarcinoma	[PI3K pathway inhibitor;AR antagonist]	Responsive	Pre-clinical	21575859	Prostate	Therapeutic	D
PTEN	CNV	deletion	Prostate adenocarcinoma	[PIK3CB inhibitor]	Responsive	Case report	ASCO 2014 (abstr 2514)	Prostate	Therapeutic	D
PTEN	CNV	deletion	Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium	[PI3K pathway inhibitor]	Responsive	Pre-clinical	21289267;21325073;21191045;17804702;23136191;21632463;21673091;23287563;21998291;22662154;23085766;22932669	Breast;Cancer;Lung;Nervous_System;Ovary;Thyroid;Uterus	Therapeutic	D
PTEN	CNV	del	Advanced Solid Tumor	CC-223	sensitive	Phase I	26177599	Other	Therapeutic	C
PTEN	CNV	del	Advanced Solid Tumor	GSK2636771	no benefit	Phase I	26117819	Other	Therapeutic	C
PTEN	CNV	del	breast cancer	CUDC-907	sensitive	Preclinical - Cell culture	22693356	Breast	Therapeutic	D
PTEN	CNV	deletion	Prostate Adenocarcinoma		Poor Outcome	B	17700571	Prostate	Prognostic	B
PTEN	CNV	deletion	Prostate Cancer	Everolimus	Sensitivity/Response	B	23582881	Prostate	Therapeutic	B
PTEN	CNV	deletion	Prostate Cancer		Poor Outcome	B	27470558	Prostate	Prognostic	B
PTEN	CNV	del	head and neck squamous cell carcinoma	Taselisib	resistant	Preclinical	26589432	Head_and_Neck	Therapeutic	D
PTEN	CNV	del	lung non-small cell carcinoma	PF-04691502	predicted - sensitive	Preclinical - Cell line xenograft	21750219	Lung	Therapeutic	D
PTEN	CNV	del	prostate cancer	Alpelisib + AZD8186 + Enzalutamide	sensitive	Preclinical	25544636	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	Alpelisib + AZD8186	sensitive	Preclinical	25544636	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	AZD8186 + Enzalutamide	sensitive	Preclinical	25544636	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	AZD8186	predicted - sensitive	Phase I	;	Prostate	Therapeutic	C
PTEN	CNV	del	prostate cancer	CH5132799	sensitive	Preclinical - Cell line xenograft	21558396	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	Gedatolisib	sensitive	Preclinical	14737113;21325073	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	Ipatasertib	sensitive	Preclinical - Cell line xenograft	24141624	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	Pictilisib + Vorinostat	sensitive	Preclinical	22693356;9661880	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	Rucaparib	sensitive	Preclinical - Cell culture	23565244	Prostate	Therapeutic	D
PTEN	CNV	del	prostate cancer	VS-5584	sensitive	Preclinical - Cell line xenograft	23270925	Prostate	Therapeutic	D
PTEN	CNV	del	stomach cancer	CH5132799	sensitive	Preclinical - Cell line xenograft	21558396	Stomach	Therapeutic	D
PTEN	CNV	del	urinary bladder cancer	Metformin	sensitive	Preclinical	26921394	Bladder	Therapeutic	D
PTEN	CNV	loss	acute lymphocytic leukemia	BGT226	sensitive	Preclinical - Cell culture	23705826	Blood;Bone_Marrow	Therapeutic	D
PTEN	CNV	loss	Advanced Solid Tumor	BAY1125976	sensitive	Preclinical	;	Other	Therapeutic	D
PTEN	CNV	loss	Advanced Solid Tumor	Capivasertib	sensitive	Preclinical - Cell culture	22294718	Other	Therapeutic	D
PTEN	CNV	loss	Advanced Solid Tumor	Everolimus	no benefit	Phase II	28330462	Other	Therapeutic	C
PTEN	CNV	loss	Advanced Solid Tumor	SAR260301	no benefit	Phase I	;	Other	Therapeutic	C
PTEN	CNV	LOSS	Bladder Carcinoma	Everolimus	Resistance	B	23989949	Bladder	Therapeutic	B
PTEN	CNV	loss	brain glioma	Gedatolisib	sensitive	Preclinical	21325073	Brain	Therapeutic	D
PTEN	CNV	loss	breast adenocarcinoma	Gemcitabine + LY2780301	sensitive	Phase Ib/II	28750271	Breast	Therapeutic	C
PTEN	CNV	loss	breast adenocarcinoma	SAR245409	sensitive	Preclinical - Cell culture	24634413	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	Alpelisib	resistant	Preclinical - Cell culture	27604488	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	AZD6482	sensitive	Preclinical	23674493	Breast	Therapeutic	D
PTEN	CNV	LOSS	Breast Cancer	AZD8186	Sensitivity/Response	D	25398829	Breast	Therapeutic	D
PTEN	CNV	LOSS	Breast Cancer	BYL719 (Alpelisib)	Resistance	D	25409150	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	Everolimus	resistant	Preclinical - Cell culture	21358673	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	GSK2636771	sensitive	Preclinical	23674493	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	MK2206	no benefit	Phase II	31277699	Breast	Therapeutic	C
PTEN	CNV	loss	breast cancer	OSI-027	sensitive	Preclinical - Cell line xenograft	21673091	Breast	Therapeutic	D
PTEN	CNV	loss	breast cancer	Torkinib	resistant	Preclinical - Cell culture	21358673	Breast	Therapeutic	D
PTEN	CNV	LOSS	Breast Cancer	Trastuzumab	Resistance	B	21594665	Breast	Therapeutic	B
PTEN	CNV	LOSS	Breast Cancer	Trastuzumab	Resistance	B	24387334	Breast	Therapeutic	B
PTEN	CNV	LOSS	Cancer	AZD5363	Sensitivity/Response	D	22294718	Cancer	Therapeutic	D
PTEN	CNV	LOSS	Cancer	Buparlisib,Carboplatin,Paclitaxel	Sensitivity/Response	B	25672916	Cancer	Therapeutic	B
PTEN	CNV	loss	colon cancer	KU-55933	sensitive	Preclinical	25870146	Colorectal	Therapeutic	D
PTEN	CNV	loss	colorectal cancer	AZD8186 + Vistusertib	sensitive	Phase I	;	Colorectal	Therapeutic	C
PTEN	CNV	LOSS	Colorectal Cancer	Cetuximab,Panitumumab	Resistance	B	19223544	Colorectal	Therapeutic	B
PTEN	CNV	LOSS	Colorectal Cancer	Cetuximab	Resistance	B	21163703	Colorectal	Therapeutic	B
PTEN	CNV	loss	diffuse large B-cell lymphoma	GSK2334470 + Idelalisib	predicted - sensitive	Preclinical - Cell culture	28178345	Lymph_Nodes	Therapeutic	D
PTEN	CNV	loss	diffuse large B-cell lymphoma	Idelalisib + MK2206	predicted - sensitive	Preclinical - Cell culture	28178345	Lymph_Nodes	Therapeutic	D
PTEN	CNV	LOSS	Endometrial Cancer	Temsirolimus	Sensitivity/Response	D	23674493	Uterus	Therapeutic	D
PTEN	CNV	LOSS	Gastric Adenocarcinoma	Trastuzumab,Lapatinib	Resistance	B	25300346	Stomach	Therapeutic	B
PTEN	CNV	loss	glioblastoma multiforme	A66	resistant	Preclinical - Cell line xenograft	21668414	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	BLZ945	no benefit	Preclinical	27199435	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	CCT128930	sensitive	Preclinical - Cell line xenograft	21191045	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	GDC-0084	sensitive	Preclinical - Cell line xenograft	27638506	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	LY3023414	sensitive	Preclinical - Cell line xenograft	27439478	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	PF-04691502	sensitive	Preclinical - Cell line xenograft	21750219	Brain	Therapeutic	D
PTEN	CNV	loss	glioblastoma multiforme	PKI-402	sensitive	Preclinical - Cell line xenograft	20371716	Brain	Therapeutic	D
PTEN	CNV	loss	head and neck squamous cell carcinoma	AZD8055	predicted - sensitive	Preclinical - Cell culture	28446642	Head_and_Neck	Therapeutic	D
PTEN	CNV	loss	head and neck squamous cell carcinoma	BEZ235	predicted - sensitive	Preclinical - Cell culture	28446642	Head_and_Neck	Therapeutic	D
PTEN	CNV	loss	head and neck squamous cell carcinoma	Rigosertib	predicted - sensitive	Phase I	;	Head_and_Neck	Therapeutic	C
PTEN	CNV	LOSS	Her2-receptor Positive Breast Cancer	Everolimus	Sensitivity/Response	B	27091708	Breast	Therapeutic	B
PTEN	CNV	LOSS	Her2-receptor Positive Breast Cancer	LY294002,Trastuzumab	Sensitivity/Response	D	15324695	Breast	Therapeutic	D
PTEN	CNV	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	B	20813970	Breast	Therapeutic	B
PTEN	CNV	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	B	21594665	Breast	Therapeutic	B
PTEN	CNV	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab	Resistance	D	17936563	Breast	Therapeutic	D
PTEN	CNV	loss	lung non-small cell carcinoma	Pictilisib	sensitive	Preclinical - Cell line xenograft	23136191	Lung	Therapeutic	D
PTEN	CNV	loss	lung squamous cell carcinoma	AZD8186	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
PTEN	CNV	loss	lung squamous cell carcinoma	Buparlisib	no benefit	Preclinical - Pdxcell culture	30093452	Lung	Therapeutic	D
PTEN	CNV	loss	melanoma	DETD-35	sensitive	Preclinical - Cell line xenograft	27048951	Skin	Therapeutic	D
PTEN	CNV	loss	melanoma	DETD-35 + Vemurafenib	sensitive	Preclinical - Cell line xenograft	27048951	Skin	Therapeutic	D
PTEN	CNV	LOSS	Melanoma	GSK2141795	Sensitivity/Response	D	24735930	Skin	Therapeutic	D
PTEN	CNV	loss	melanoma	GSK2636771	sensitive	Preclinical	26645196	Skin	Therapeutic	D
PTEN	CNV	LOSS	Melanoma	Vemurafenib	Resistance	D	24265155	Skin	Therapeutic	D
PTEN	CNV	LOSS	Ovarian Cancer	Cisplatin	Resistance	D	15790433	Ovary	Therapeutic	D
PTEN	CNV	loss	ovarian cancer	OSI-027	sensitive	Preclinical - Cell line xenograft	21673091	Ovary	Therapeutic	D
PTEN	CNV	loss	ovarian mucinous neoplasm	KX2-391	decreased response	Preclinical	24100628	Ovary	Therapeutic	D
PTEN	CNV	loss	ovarian mucinous neoplasm	KX2-391 + Oxaliplatin	no benefit	Preclinical	24100628	Ovary	Therapeutic	D
PTEN	CNV	LOSS	Pancreatic Carcinoma	MK-2206	Sensitivity/Response	C	22025163	Pancreas	Therapeutic	C
PTEN	CNV	loss	prostate cancer	Abiraterone + Ipatasertib	sensitive	Phase II	30037818;	Prostate	Therapeutic	C
PTEN	CNV	loss	prostate cancer	AR-mTOR-26	predicted - sensitive	Preclinical - Cell line xenograft	;	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	AT13148	sensitive	Preclinical - Cell line xenograft	22781553	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	AZD6482	sensitive	Preclinical	23674493	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	AZD8186	sensitive	Preclinical	25514658	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	Capivasertib	sensitive	Preclinical	26910118	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	CX-5461 + CX-6258	predicted - sensitive	Preclinical	27486174	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	CX-5461	no benefit	Preclinical	27486174	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	CX-6258	predicted - sensitive	Preclinical	27486174	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	GS-9820	sensitive	Preclinical - Cell line xenograft	;	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	GSK2636771	sensitive	Preclinical	23674493	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	Ipatasertib	sensitive	Phase I	27872130	Prostate	Therapeutic	C
PTEN	CNV	loss	prostate cancer	KU-60019	sensitive	Preclinical	25870146	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	MK2206	no benefit	Phase I	26187616	Prostate	Therapeutic	C
PTEN	CNV	loss	prostate cancer	OP449	sensitive	Preclinical	26563471	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	Panulisib	sensitive	Preclinical - Cell line xenograft	25700704	Prostate	Therapeutic	D
PTEN	CNV	LOSS	Prostate Cancer		Poor Outcome	B	17700571	Prostate	Prognostic	B
PTEN	CNV	loss	prostate cancer	SAR245409	sensitive	Preclinical - Cell line xenograft	24634413	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate cancer	SF1126	sensitive	Preclinical - Cell line xenograft	18172313;24634413	Prostate	Therapeutic	D
PTEN	CNV	LOSS	Prostate Cancer	Temsirolimus	Sensitivity/Response	D	11504908	Prostate	Therapeutic	D
PTEN	CNV	loss	prostate carcinoma	SAR260301	decreased response	Preclinical - Cell line xenograft	27196754	Prostate	Therapeutic	D
PTEN	CNV	loss	renal carcinoma	Capivasertib	sensitive	Preclinical - Pdx	22294718	Kidney	Therapeutic	D
PTEN	CNV	loss	renal carcinoma	Gedatolisib	decreased response	Preclinical	21325073	Kidney	Therapeutic	D
PTEN	CNV	loss	renal cell carcinoma	Everolimus	predicted - sensitive	Clinical Study - Cohort	30327302	Kidney	Therapeutic	C
PTEN	CNV	loss	sarcoma	YU238259	sensitive	Preclinical	26116172	Soft_Tissue	Therapeutic	D
PTEN	CNV	LOSS	Stomach Cancer	Docetaxel,AZD5363	Sensitivity/Response	D	24088382	Stomach	Therapeutic	D
PTEN	CNV	LOSS	Stomach Carcinoma	Chemotherapy	Resistance	B	15900596	Stomach	Therapeutic	B
PTEN	CNV	loss	transitional cell carcinoma	Everolimus	resistant	Phase II	22473592	Bladder	Therapeutic	C
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD6482 + Niraparib	sensitive	Preclinical - Cell culture	;	Breast	Therapeutic	D
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD6482 + Olaparib	sensitive	Preclinical - Cell culture	;	Breast	Therapeutic	D
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD6482 + Rucaparib	sensitive	Preclinical - Cell culture	;	Breast	Therapeutic	D
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD6482 + Talazoparib	sensitive	Preclinical	;	Breast	Therapeutic	D
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD6482 + Veliparib	sensitive	Preclinical - Cell culture	;	Breast	Therapeutic	D
PTEN	CNV	loss	triple-receptor negative breast cancer	AZD8186	predicted - sensitive	Phase I	;	Breast	Therapeutic	C
PTEN	CNV	loss	triple-receptor negative breast cancer	M2698	sensitive	Preclinical - Cell line xenograft	27186432	Breast	Therapeutic	D
PTEN	CNV	loss	uterine corpus sarcoma	AT13148	sensitive	Preclinical - Cell line xenograft	22781553	Uterus	Therapeutic	D
PTEN	EXP	EXPRESSION	Breast Cancer	Trastuzumab	Sensitivity/Response	B	16404430	Breast	Therapeutic	B
PTEN	EXP	EXPRESSION	Glioblastoma Multiforme	Dacomitinib	Sensitivity/Response	D	25939761	Brain	Therapeutic	D
PTEN	EXP	EXPRESSION	Glioblastoma Multiforme	EGFR Inhibitor	Sensitivity/Response	B	16282176	Brain	Therapeutic	B
PTEN	EXP	EXPRESSION	Glioblastoma Multiforme	Gefitinib,Erlotinib	Sensitivity/Response	B	16282176	Brain	Therapeutic	B
PTEN	EXP	EXPRESSION	Her2-receptor Positive Breast Cancer	Fulvestrant,Everolimus	Resistance	C	27445490	Breast	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	Advanced Solid Tumor	GSK2636771	sensitive	Phase Ib/II	;	Other	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	Advanced Solid Tumor	Pemetrexed + Sorafenib	predicted - sensitive	Phase I	27213589	Other	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	melanoma	Nivolumab	decreased response	Clinical Study - Cohort	26645196	Skin	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	melanoma	Pembrolizumab	decreased response	Clinical Study - Cohort	26645196	Skin	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	melanoma	SAR260301	sensitive	Preclinical - Cell line xenograft	24387221	Skin	Therapeutic	D
PTEN	EXP	UNDEREXPRESSION	renal cell carcinoma	Everolimus	no benefit	Phase II	26951309	Kidney	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	renal cell carcinoma	GDC-0980	no benefit	Phase II	26951309	Kidney	Therapeutic	C
PTEN	EXP	UNDEREXPRESSION	triple-receptor negative breast cancer	Ipatasertib + Paclitaxel	predicted - sensitive	Phase II	;	Breast	Therapeutic	C
PTEN	MUT	A126G	prostate cancer	Alpelisib	sensitive	Preclinical - Cell culture	26504226	Prostate	Therapeutic	D
PTEN	MUT	A126G	prostate cancer	AZD6482	sensitive	Preclinical	26504226	Prostate	Therapeutic	D
PTEN	MUT	A72fs	breast cancer	Gedatolisib	sensitive	Preclinical	17314276;21325073	Breast	Therapeutic	D
PTEN	MUT	A72fs	triple-receptor negative breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PTEN	MUT	any deletion	Adenocarcinoma in Colon/Rectum			2	21129603,19884556	Colorectal	Therapeutic	C
PTEN	MUT	any deletion	Adenocarcinoma in Lung			2	10817513,19351834,21430697	Lung	Therapeutic	C
PTEN	MUT	any deletion	Adenocarcinoma in Prostate			2	25726356,26000489	Prostate	Therapeutic	C
PTEN	MUT	any deletion	Follicular Carcinoma/Papillary Carcinoma in Thyroid			2	15650451,26531219,27617518,18794882,26878173	Thyroid	Therapeutic	C
PTEN	MUT	any deletion	Glioblastoma/Glial Neoplasm in Brain			2	12845540,18794882,22443084	Brain	Therapeutic	C
PTEN	MUT	any deletion	Invasive Ductal Carcinoma/Adenocarcinoma in Breast			2	18794882,22443084,PharmGKB,17452630,22252256	Breast	Therapeutic	C
PTEN	MUT	any frameshift	Adenocarcinoma in Lung			2	10817513,19351834,21430697	Lung	Therapeutic	C
PTEN	MUT	any frameshift	Follicular Carcinoma/Papillary Carcinoma in Thyroid			2	15650451,26531219,27617518,18794882,26878173	Thyroid	Therapeutic	C
PTEN	MUT	any frameshift	Invasive Ductal Carcinoma/Adenocarcinoma in Breast			2	18794882,22443084,PharmGKB,17452630,22252256	Breast	Therapeutic	C
PTEN	MUT	any missense	Adenocarcinoma in Prostate			2	25726356,26000489	Prostate	Therapeutic	C
PTEN	MUT	any missense	Invasive Ductal Carcinoma/Adenocarcinoma in Breast			2	18794882,22443084,PharmGKB,17452630,22252256	Breast	Therapeutic	C
PTEN	MUT	any mutation	Adenocarcinoma in Endometrium			2	22301702,18632658	Uterus	Therapeutic	C
PTEN	MUT	any mutation	Carcinoma in Parathyroid			2	26210223,10866302,12864795,23616356	Other	Therapeutic	C
PTEN	MUT	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma in Kidney			2	24704020,28384121	Kidney	Therapeutic	C
PTEN	MUT	any mutation	Follicular Carcinoma/Papillary Carcinoma in Thyroid			2	15650451,26531219,27617518,18794882,26878173	Thyroid	Therapeutic	C
PTEN	MUT	any mutation	Glioblastoma/Glial Neoplasm in Brain			2	12845540,18794882,22443084	Brain	Therapeutic	C
PTEN	MUT	any mutation	Invasive Ductal Carcinoma/Adenocarcinoma in Breast			2	18794882,22443084,PharmGKB,17452630,22252256	Breast	Therapeutic	C
PTEN	MUT	any mutation	Melanoma in Skin			2	18794882,23875803,16912270	Skin	Therapeutic	C
PTEN	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24166518,22491738	Blood;Bone_Marrow	Therapeutic	B
PTEN	MUT	C136Y	breast cancer	Alpelisib	resistant	Preclinical - Cell culture	27604488	Breast	Therapeutic	D
PTEN	MUT	G129R	ovarian mucinous neoplasm	KX2-391	decreased response	Preclinical	24100628	Ovary	Therapeutic	D
PTEN	MUT	G165R	Carcinoma in Parathyroid			2	26210223,10866302,12864795,23616356	Other	Therapeutic	C
PTEN	MUT	L108R	breast cancer	BAY1125976	sensitive	Preclinical - Cell culture	27699769	Breast	Therapeutic	D
PTEN	MUT	L108R	breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Capivasertib	sensitive	Preclinical - Cell culture	22294718	Other	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	estrogen-receptor mutation breast cancer	Fulvestrant + Pictilisib	sensitive	Preclinical - Cell culture	26733612	Breast	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	estrogen-receptor mutation breast cancer	Pictilisib	sensitive	Preclinical - Cell culture	26733612	Breast	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	glioblastoma multiforme	SAR245409	sensitive	Preclinical - Cell line xenograft	24634413	Brain	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	glioblastoma multiforme	SF1126	sensitive	Preclinical - Cell line xenograft	18172313;24634413	Brain	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	kidney cancer	LY3023414	sensitive	Preclinical - Cell line xenograft	27439478	Kidney	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	prostate adenocarcinoma	Paclitaxel + XL147	sensitive	Preclinical - Cell line xenograft	25637314	Prostate	Therapeutic	D
PTEN	MUT	LOSS-OF-FUNCTION	prostate adenocarcinoma	XL147	sensitive	Preclinical - Cell line xenograft	25637314	Prostate	Therapeutic	D
PTEN	MUT	mutant	breast cancer	CUDC-907	sensitive	Preclinical - Cell culture	22693356	Breast	Therapeutic	D
PTEN	MUT	mutant	breast cancer	MS417 + Pictilisib	predicted - sensitive	Preclinical - Cell culture	26058079	Breast	Therapeutic	D
PTEN	MUT	mutant	breast cancer	Sapanisertib	sensitive	Preclinical	25261369	Breast	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	A66 + AZD6482	sensitive	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	A66 + GSK2636771	sensitive	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	A66	resistant	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	AZD6482	resistant	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	BEZ235	sensitive	Preclinical	22662154	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	Everolimus	sensitive	Preclinical - Cell line xenograft	22662154	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	GDC-0980	sensitive	Phase II	;	Uterus	Therapeutic	C
PTEN	MUT	mutant	endometrial cancer	GSK2636771	resistant	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	endometrial cancer	Temsirolimus	no benefit	Phase II	27016228	Uterus	Therapeutic	C
PTEN	MUT	mutant	endometrial cancer	TGX-221	resistant	Preclinical	23674493	Uterus	Therapeutic	D
PTEN	MUT	mutant	head and neck squamous cell carcinoma	Taselisib	resistant	Preclinical - Cell line xenograft	26589432	Head_and_Neck	Therapeutic	D
PTEN	MUT	mutant	hepatocellular carcinoma	Sorafenib	decreased response	Clinical Study - Cohort	30373752	Liver	Therapeutic	C
PTEN	MUT	mutant	melanoma	BI-69A11	sensitive	Preclinical - Cell line xenograft	19175524	Skin	Therapeutic	D
PTEN	MUT	mutant	triple-receptor negative breast cancer	Capivasertib + Paclitaxel	predicted - sensitive	Phase II	30715161	Breast	Therapeutic	C
PTEN	MUT	mutant	triple-receptor negative breast cancer	Ipatasertib + Paclitaxel	predicted - sensitive	Phase II	;	Breast	Therapeutic	C
PTEN	MUT	mutant	uterine cancer	GSK2256098 + Paclitaxel	sensitive	Preclinical	25833835	Uterus	Therapeutic	D
PTEN	MUT	mutant	uterine cancer	GSK2256098	sensitive	Preclinical	25833835	Uterus	Therapeutic	D
PTEN	MUT	mutant	uterine cancer	GSK2256098 + Topotecan	sensitive	Preclinical	25833835	Uterus	Therapeutic	D
PTEN	MUT	mutation	Cancer	Ipatasertib	Sensitivity/Response	D	23287563	Cancer	Therapeutic	D
PTEN	MUT	mutation	Glioblastoma Multiforme		Positive	C	9331072	Brain	Diagnostic	C
PTEN	MUT	mutation	head and neck squamous cell carcinoma	Cetuximab	predicted - sensitive	Clinical Study - Cohort	30926065	Head_and_Neck	Therapeutic	C
PTEN	MUT	mutation	Head And Neck Squamous Cell Carcinoma	Taselisib (GDC-0032)	Resistance	D	26589432	Head_and_Neck	Therapeutic	D
PTEN	MUT	mutation	melanoma	Nivolumab	sensitive	Clinical Study - Cohort	26645196	Skin	Therapeutic	C
PTEN	MUT	mutation	melanoma	Pembrolizumab	sensitive	Clinical Study - Cohort	26645196	Skin	Therapeutic	C
PTEN	MUT	mutation	Prostate Cancer	BYL719 (Alpelisib),AZD8186,Enzalutamide	Sensitivity/Response	D	25544636	Prostate	Therapeutic	D
PTEN	MUT	N48I	urinary bladder cancer	Pictilisib	decreased response	Preclinical - Cell culture	28808038	Bladder	Therapeutic	D
PTEN	MUT	oncogenic mutation	Any cancer type	Sirolimus	Responsive	Early trials	ASCO 2013 (abstr 2532)	Cancer	Therapeutic	C
PTEN	MUT	oncogenic mutation	Breast adenocarcinoma	[ATM inhibitor]	Responsive	Pre-clinical	27397505	Breast	Therapeutic	D
PTEN	MUT	oncogenic mutation	Colorectal adenocarcinoma	[EGFR mAb inhibitor]	Resistant	Late trials	21163703;19398573	Colorectal	Therapeutic	C
PTEN	MUT	oncogenic mutation	Cutaneous melanoma	[PD1 Ab inhibitor]	Responsive	Early trials	26645196	Skin	Therapeutic	C
PTEN	MUT	oncogenic mutation	Endometrium	[PARP inhibitor]	Responsive	Case report	21468130;20944090	Uterus	Therapeutic	D
PTEN	MUT	oncogenic mutation	Ovary	[PI3K pathway inhibitor;MEK inhibitor]	Responsive	Pre-clinical	21632463	Ovary	Therapeutic	D
PTEN	MUT	oncogenic mutation	Pancreas	[AKT inhibitor]	Responsive	Case report	22025163	Pancreas	Therapeutic	D
PTEN	MUT	oncogenic mutation	Prostate adenocarcinoma	Everolimus	Responsive	Early trials	23582881	Prostate	Therapeutic	C
PTEN	MUT	oncogenic mutation	Prostate adenocarcinoma	[PI3K pathway inhibitor;AR antagonist]	Responsive	Pre-clinical	21575859	Prostate	Therapeutic	D
PTEN	MUT	oncogenic mutation	Prostate adenocarcinoma	[PIK3CB inhibitor]	Responsive	Case report	ASCO 2014 (abstr 2514)	Prostate	Therapeutic	D
PTEN	MUT	Oncogenic Mutations	All Tumors	GSK2636771, AZD8186	Response	4	28645941	Cancer	Therapeutic	D
PTEN	MUT	oncogenic mutation	Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium	[PI3K pathway inhibitor]	Responsive	Pre-clinical	21289267;21325073;21191045;17804702;23136191;21632463;21673091;23287563;21998291;22662154;23085766;22932669	Breast;Cancer;Lung;Nervous_System;Ovary;Thyroid;Uterus	Therapeutic	D
PTEN	MUT	R130X	follicular thyroid carcinoma	MK2206	sensitive	Preclinical - Cell culture	21289267	Thyroid	Therapeutic	D
PTEN	MUT	R130Q	head and neck squamous cell carcinoma	Carboplatin + Paclitaxel + Temsirolimus	predicted - sensitive	Phase II	28961834	Head_and_Neck	Therapeutic	C
PTEN	MUT	R130X	Thyroid Cancer	Temsirolimus,Perifosine	Sensitivity/Response	D	19706758	Thyroid	Therapeutic	D
PTEN	MUT	R233X	Breast Cancer	MTOR Inhibitors	Sensitivity/Response	D	20085938	Breast	Therapeutic	D
PTEN	MUT	T319fs	breast cancer	BAY1125976	sensitive	Preclinical - Cell culture	27699769	Breast	Therapeutic	D
PTEN	MUT	V275X	triple-receptor negative breast cancer	DHM25	sensitive	Preclinical - Cell culture	26237138	Breast	Therapeutic	D
PTEN	MUT	V317fs	Skin Melanoma	PD184352,MK-2206	Sensitivity/Response	D	24504448	Skin	Therapeutic	D
PTEN	MUT	V54fs	glioblastoma multiforme	XL147	sensitive	Preclinical - Cell line xenograft	25637314	Brain	Therapeutic	D
PTEN	MUT	WILDTYPE	glioblastoma multiforme	2-Methoxyestradiol	sensitive	Preclinical	24162827	Brain	Therapeutic	D
PTEN	MUT	WILDTYPE	melanoma	E6201	sensitive	Preclinical	23039341	Skin	Therapeutic	D
PTEN	MUT	WILDTYPE	ovarian mucinous neoplasm	KX2-391 + Oxaliplatin	sensitive	Preclinical	24100628	Ovary	Therapeutic	D
PTEN	MUT	WILDTYPE	ovarian mucinous neoplasm	KX2-391	sensitive	Preclinical	24100628	Ovary	Therapeutic	D
PTEN	MUT	WILDTYPE	uterine cancer	GSK2256098	decreased response	Preclinical	25833835	Uterus	Therapeutic	D
PTGS2	EXP	OVEREXPRESSION	Colorectal Cancer	Aspirin	Sensitivity/Response	B	17522398	Colorectal	Therapeutic	B
PTP4A3	EXP	OVEREXPRESSION	Colorectal Cancer	Cetuximab	Sensitivity/Response	D	23867504	Colorectal	Therapeutic	D
PTPN11	EXP	EXPRESSION	Laryngeal Carcinoma		Poor Outcome	B	24297342	Esophagus	Prognostic	B
PTPN11	EXP	UNDEREXPRESSION	myeloid leukemia	SHP099	resistant	Preclinical - Cell culture	29568093	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	A72V	myeloid leukemia	SHP099	resistant	Preclinical - Cell culture	29568093	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	12717436,23825065,24067137,19776760,17330262,16115145,15951301,15749679,15725481,15009076,PharmGKB	Blood;Bone_Marrow	Therapeutic	B
PTPN11	MUT	D61Y	myeloid leukemia	SHP099	resistant	Preclinical - Cell culture	29568093	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	E69K	myeloid leukemia	SHP099	sensitive	Preclinical - Cell culture	29568093	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	E76K	hematologic cancer	II-B08	sensitive	Preclinical	20170098	Blood	Therapeutic	D
PTPN11	MUT	E76K	juvenile myelomonocytic leukemia	Cryptotanshinone	sensitive	Preclinical	23957426	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	E76K	leukemia	PD98059	sensitive	Preclinical	17942397	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	E76K	leukemia	U0126	sensitive	Preclinical	17942397	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	E76K	myeloid leukemia	SHP099	resistant	Preclinical - Cell culture	29568093	Blood;Bone_Marrow	Therapeutic	D
PTPN11	MUT	Gain-of-Function	lung non-small cell carcinoma	Refametinib	sensitive	Preclinical	;	Lung	Therapeutic	D
PTPRB	MUT	LOSS-OF-FUNCTION	Angiosarcoma	Sunitinib	Sensitivity/Response	D	24633157	Soft_Tissue	Therapeutic	D
PTPRD	MUT	mutation	Head And Neck Carcinoma	JSI-124	Sensitivity/Response	D	26267899	Head_and_Neck	Therapeutic	D
PTPRD	MUT	oncogenic mutation	Sarcoma	[IGF1R inhibitor]	Responsive	Case report	23800680	Other	Therapeutic	D
PTPRD	MUT	V253I	Ewing Sarcoma Of Bone	Cixutumumab,R1507	Sensitivity/Response	C	23800680	Bone	Therapeutic	C
PTPRT	MUT	PROMOTER HYPERMETHYLATION	Head And Neck Squamous Cell Carcinoma	JSI-124,Stattic	Sensitivity/Response	D	25982282	Head_and_Neck	Therapeutic	D
PTTG1	EXP	OVEREXPRESSION	Meningioma		Poor Outcome	B	26894859	Nervous_System	Prognostic	B
RAC1	MUT	P29S	Melanoma	Dabrafenib,Vemurafenib	Resistance	D	25056119	Skin	Therapeutic	D
RAD21	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myeloid Leukemia in Blood/Bone Marrow			1	24335498,23955599	Blood;Bone_Marrow	Therapeutic	B
RAD23B	EXP	EXPRESSION	Sarcoma	Vorinostat	Sensitivity/Response	D	27499916	Soft_Tissue	Therapeutic	D
RAD50	MUT	L1237F	Ureter Small Cell Carcinoma	Irinotecan,AZD7762	Sensitivity/Response	C	24934408	Bladder	Therapeutic	C
RAD51C	MUT	oncogenic mutation	Ovary	[PARP inhibitor]	Responsive	Early trials	ASCO 2015 (abstr 5508)	Ovary	Therapeutic	C
RAF1	CNV	AMPLIFICATION	Skin Melanoma	Sorafenib,Paclitaxel,Carboplatin	Sensitivity/Response	B	26307133	Skin	Therapeutic	B
RAF1	EXP	overexpression	Osteosarcoma	Sorafenib	Responsive	Pre-clinical	24375110	Other	Therapeutic	D
RAF1	MUT	Oncogenic Mutations	Histiocytosis	Cobimetinib	Response	3A	29236635, 30867592	Lymph_Nodes	Therapeutic	C
RASA1	MUT	LOSS-OF-FUNCTION	Lung Non-small Cell Carcinoma	Trametinib	Sensitivity/Response	D	29127119	Lung	Therapeutic	D
RB1	CNV	deletion	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
RB1	CNV	deletion	Retinoblastoma	[HDAC inhibitor]	Responsive	Pre-clinical	18483379	Eye	Therapeutic	D
RB1	CNV	deletion	Retinoblastoma	[MDM2/MDMX inhibitor]	Responsive	Pre-clinical	17080083;21515735	Eye	Therapeutic	D
RB1	CNV	loss	Advanced Solid Tumor	Palbociclib	no benefit	Preclinical	26649278	Other	Therapeutic	D
RB1	CNV	loss	estrogen-receptor mutation breast cancer	Palbociclib	resistant	Preclinical - Cell culture	27020857	Breast	Therapeutic	D
RB1	CNV	loss	lung small cell carcinoma	Topotecan + Trilaciclib	sensitive	Preclinical - Cell line xenograft	26826116	Lung	Therapeutic	D
RB1	CNV	loss	lung small cell carcinoma	Trilaciclib	resistant	Preclinical - Cell line xenograft	26826116	Lung	Therapeutic	D
RB1	CNV	loss	neuroendocrine tumor	Sirolimus	sensitive	Preclinical	23454836	Nervous_System	Therapeutic	D
RB1	CNV	loss	retinoblastoma	Entinostat	sensitive	Preclinical - Cell line xenograft	23498719;18483379	Eye	Therapeutic	D
RB1	CNV	loss	retinoblastoma	Sirolimus	sensitive	Preclinical	21468343;1689463	Eye	Therapeutic	D
RB1	CNV	loss	retinoblastoma	Trichostatin A	sensitive	Preclinical - Cell culture	23498719;18483379	Eye	Therapeutic	D
RB1	CNV	loss	retinoblastoma	Vorinostat	sensitive	Preclinical - Cell culture	23498719;18483379	Eye	Therapeutic	D
RB1	EXP	EXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	22619677	Lung	Prognostic	B
RB1	EXP	OVEREXPRESSION	Pancreatic Adenocarcinoma	Gemcitabine,5-fluorouracil,Mitomycin C,Doxorubicin	Resistance	D	11792751	Pancreas	Therapeutic	D
RB1	EXP	overexpression	Prostate adenocarcinoma	Palbociclib	Responsive	Pre-clinical	23708653	Prostate	Therapeutic	D
RB1	MUT	any mutation	Glioblastoma in Brain			2	18772890,19058223,26649278	Brain	Therapeutic	C
RB1	MUT	H483Y	Her2-receptor negative breast cancer	Letrozole + Ribociclib	predicted - resistant	Case Reports/Case Series	29236940	Breast	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	Breast Cancer	Palbociclib (PD0332991)	Resistance	D	20473330	Breast	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	Glioblastoma Multiforme	Palbociclib (PD0332991)	Resistance	D	20354191	Brain	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	glioblastoma multiforme	Palbociclib	resistant	Preclinical - Cell line xenograft	20354191	Brain	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	retinoblastoma	BAY 61-3606	sensitive	Preclinical	22237022	Eye	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	retinoblastoma	Fostamatinib	sensitive	Preclinical	22237022	Eye	Therapeutic	D
RB1	MUT	LOSS-OF-FUNCTION	retinoblastoma	Nutlin-3	sensitive	Preclinical	21515735	Eye	Therapeutic	D
RB1	MUT	M695fs	Estrogen-receptor Positive Breast Cancer	Palbociclib (PD0332991)	Resistance	D	27020857	Breast	Therapeutic	D
RB1	MUT	mutant	estrogen-receptor mutation breast cancer	Palbociclib	predicted - resistant	Phase III	30206110	Breast	Therapeutic	C
RB1	MUT	mutant	osteosarcoma	VCN-01	sensitive	Preclinical - Cell line xenograft	26603261	Bone	Therapeutic	D
RB1	MUT	mutation	Advanced Solid Tumor	Ribociclib	predicted - sensitive	Phase I	24795392;27542767	Other	Therapeutic	C
RB1	MUT	mutation	breast cancer	Paclitaxel + Palbociclib	predicted - sensitive	Phase I	30635336	Breast	Therapeutic	C
RB1	MUT	mutation	glioblastoma multiforme	Palbociclib	predicted - sensitive	Preclinical - Cell line xenograft	20354191	Brain	Therapeutic	D
RB1	MUT	mutation	Lung Small Cell Carcinoma	Chemotherapy	Sensitivity/Response	B	26802149	Lung	Therapeutic	B
RB1	MUT	mutation	medulloblastoma	Palbociclib	sensitive	Preclinical - Pdx	27012813	Nervous_System	Therapeutic	D
RB1	MUT	oncogenic mutation	Bladder	Cisplatin	Responsive	Early trials	26238431	Bladder	Therapeutic	C
RB1	MUT	oncogenic mutation	Retinoblastoma	[HDAC inhibitor]	Responsive	Pre-clinical	18483379	Eye	Therapeutic	D
RB1	MUT	oncogenic mutation	Retinoblastoma	[MDM2/MDMX inhibitor]	Responsive	Pre-clinical	17080083;21515735	Eye	Therapeutic	D
RB1	MUT	PHOSPHORYLATION	Breast Cancer	Alpelisib	Resistance	B	25002028	Breast	Therapeutic	B
REL	CNV	AMPLIFICATION	Diffuse Large B-cell Lymphoma		Positive	B	12075054	Lymph_Nodes	Diagnostic	B
RET	EXP	EXPRESSION	Breast Cancer	Vandetanib	Sensitivity/Response	D	26686064	Breast	Therapeutic	D
RET	EXP	EXPRESSION	Lung Adenocarcinoma		Poor Outcome	B	24037524	Lung	Prognostic	B
RET	EXP	OVEREXPRESSION	breast cancer	Y078-DM1	sensitive	Preclinical - Cell line xenograft	26240273	Breast	Therapeutic	D
RET	EXP	OVEREXPRESSION	Papillary Adenocarcinoma	Sunitinib	Sensitivity/Response	C	20696054	Lung	Therapeutic	C
RET	FUS	CCDC6-RET	Lung Non-small Cell Carcinoma	Nintedanib	Sensitivity/Response	C	26787234	Lung	Therapeutic	C
RET	FUS	FUSION	Lung Non-small Cell Carcinoma	Alectinib	Sensitivity/Response	B	27544060	Lung	Therapeutic	B
RET	FUS	FUSION	Lung Non-small Cell Carcinoma	Cabozantinib	Sensitivity/Response	B	27825636	Lung	Therapeutic	B
RET	FUS	fusion	lung non-small cell carcinoma	LOXO-292	sensitive	Phase I	;	Lung	Therapeutic	C
RET	FUS	fusion	lung non-small cell carcinoma	Vandetanib	sensitive	Phase II	;	Lung	Therapeutic	C
RET	FUS	FUSION	Lung Non-small Cell Carcinoma	Vandetanib	Sensitivity/Response	B	27803005	Lung	Therapeutic	B
RET	FUS	FUSION	Lung Non-small Cell Carcinoma	Vandetanib	Sensitivity/Response	B	27825616	Lung	Therapeutic	B
RET	FUS	fusion	papillary thyroid carcinoma	LOXO-292	sensitive	Phase I	;	Thyroid	Therapeutic	C
RET	FUS	KIF5B-RET	Lung Adenocarcinoma	Everolimus,Vandetanib	Sensitivity/Response	C	25982012	Lung	Therapeutic	C
RET	FUS	KIF5B-RET	Lung Adenocarcinoma	Vandetanib	Sensitivity/Response	C	23584301	Lung	Therapeutic	C
RET	MUT	codon(s) 618 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 620 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 634 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 768 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 791 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 891 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	codon(s) 918 missense	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	A883F	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	A883F	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	C618R	thyroid medullary carcinoma	Sorafenib	predicted - sensitive	Phase II	20368568	Thyroid	Therapeutic	C
RET	MUT	C620R	thyroid medullary carcinoma	Everolimus	sensitive	Phase II	26294908	Thyroid	Therapeutic	C
RET	MUT	C634F	thyroid medullary carcinoma	Sorafenib	predicted - sensitive	Phase II	20368568	Thyroid	Therapeutic	C
RET	MUT	C634R	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23811235	Other	Therapeutic	D
RET	MUT	C634R	Advanced Solid Tumor	Pz-1	sensitive	Preclinical - Cell line xenograft	26126987	Other	Therapeutic	D
RET	MUT	C634R	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	16507829	Other	Therapeutic	D
RET	MUT	C634R	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	17664273	Other	Therapeutic	D
RET	MUT	C634R	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	C634R	thyroid medullary carcinoma	Sorafenib	predicted - sensitive	Phase II	20368568	Thyroid	Therapeutic	C
RET	MUT	C634W	Thyroid	Cabozantinib	Responsive	Pre-clinical	21470995	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid cancer	AZD1480	sensitive	Preclinical - Cell culture	23056499	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid cancer	Lenvatinib	sensitive	Preclinical	25295214	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid cancer	Regorafenib	sensitive	Preclinical - Cell culture	21170960	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid carcinoma	Cabozantinib	sensitive	Preclinical - Cell line xenograft	23705946	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid carcinoma	Ponatinib	sensitive	Preclinical - Cell line xenograft	23526464	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid carcinoma	Sorafenib	sensitive	Preclinical	17664273	Thyroid	Therapeutic	D
RET	MUT	C634W	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	C634W	Thyroid Gland Medullary Carcinoma	Motesanib	Resistance	D	21422803	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	ALW-II-41-27	sensitive	Preclinical - Cell culture	26046350	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	BLU-667	sensitive	Preclinical - Cell line xenograft	;29657135	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	HG-6-63-01	sensitive	Preclinical	26046350	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	LOXO-292	sensitive	Preclinical - Cell line xenograft	29912274	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	RXDX-105	sensitive	Preclinical - Cell culture	28011461	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	Sorafenib	sensitive	Preclinical - Cell line xenograft	16507829	Thyroid	Therapeutic	D
RET	MUT	C634W	thyroid medullary carcinoma	XMD15-44	sensitive	Preclinical	26046350	Thyroid	Therapeutic	D
RET	MUT	C634W	Thyroid	[RET inhibitor]	Responsive	Pre-clinical	23056499	Thyroid	Therapeutic	D
RET	MUT	C634W	Thyroid	Sunitinib	Responsive	Pre-clinical	21470995	Thyroid	Therapeutic	D
RET	MUT	C634Y	Advanced Solid Tumor	ALW-II-41-27	sensitive	Preclinical - Cell culture	26046350	Other	Therapeutic	D
RET	MUT	C634Y	Advanced Solid Tumor	HG-6-63-01	sensitive	Preclinical	26046350	Other	Therapeutic	D
RET	MUT	C634Y	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	C634Y	Advanced Solid Tumor	XMD15-44	sensitive	Preclinical	26046350	Other	Therapeutic	D
RET	MUT	C634Y	thyroid medullary carcinoma	Sorafenib	predicted - sensitive	Phase II	20368568	Thyroid	Therapeutic	C
RET	MUT	D898V	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	E768D	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	E768D	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	E884K	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	FUS	Fusions	Non-Small Cell Lung Cancer	Cabozantinib, Vandetanib	Response	2A	27803005, 28447912, 27825636, 23533264	Lung	Therapeutic	B
RET	FUS	Fusions	Non-Small Cell Lung Cancer	LOXO-292, BLU-667	Response	3A	29912274, 29657135	Lung	Therapeutic	C
RET	MUT	G691S	Advanced Solid Tumor	Dovitinib	sensitive	Phase I	25103625	Other	Therapeutic	C
RET	MUT	Gain-of-Function	lung non-small cell carcinoma	Ponatinib	sensitive	Preclinical - Cell culture	;	Lung	Therapeutic	D
RET	MUT	I788N	Lung adenocarcinoma	Ponatinib	Resistant	Pre-clinical	28615362	Lung	Therapeutic	D
RET	MUT	L790F	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	L790F	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	ALW-II-41-27	sensitive	Preclinical - Cell culture	26046350	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	HG-6-63-01	sensitive	Preclinical	26046350	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	LOXO-292	sensitive	Preclinical - Cell culture	29912274	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	Pz-1	predicted - sensitive	Preclinical	26126987	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	17664273	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	M918T	Advanced Solid Tumor	XMD15-44	sensitive	Preclinical	26046350	Other	Therapeutic	D
RET	MUT	M918T	colorectal cancer	Sorafenib	sensitive	Preclinical	17664273	Colorectal	Therapeutic	D
RET	MUT	M918T	lung small cell carcinoma	Ponatinib	sensitive	Preclinical	25122427	Lung	Therapeutic	D
RET	MUT	M918T	lung small cell carcinoma	Vandetanib	sensitive	Preclinical	25122427	Lung	Therapeutic	D
RET	MUT	M918T	Thyroid	Cabozantinib	Responsive	Pre-clinical	21470995	Thyroid	Therapeutic	D
RET	MUT	M918T	thyroid carcinoma	Ponatinib	sensitive	Preclinical	23526464	Thyroid	Therapeutic	D
RET	MUT	M918T	Thyroid carcinoma	Vandetanib	Responsive	FDA guidelines	20065189;22025146	Thyroid	Therapeutic	A
RET	MUT	M918T	Thyroid Gland Medullary Carcinoma	AZD1480	Sensitivity/Response	D	23056499	Thyroid	Therapeutic	D
RET	MUT	M918T	Thyroid Gland Medullary Carcinoma	Motesanib	Resistance	D	21422803	Thyroid	Therapeutic	D
RET	MUT	M918T	Thyroid Gland Medullary Carcinoma		Poor Outcome	B	9839497	Thyroid	Prognostic	B
RET	MUT	M918T	Thyroid Gland Medullary Carcinoma		Positive	B	18073307	Thyroid	Diagnostic	B
RET	MUT	M918T	Thyroid Gland Medullary Carcinoma	Sorafenib	Sensitivity/Response	B	20368568	Thyroid	Therapeutic	B
RET	MUT	M918T	thyroid medullary carcinoma	ALW-II-41-27	sensitive	Preclinical - Cell culture	26046350	Thyroid	Therapeutic	D
RET	MUT	M918T	thyroid medullary carcinoma	AZD1480	sensitive	Preclinical - Cell culture	23056499	Thyroid	Therapeutic	D
RET	MUT	M918T	thyroid medullary carcinoma	BLU-667	predicted - sensitive	Phase I	29657135	Thyroid	Therapeutic	C
RET	MUT	M918T	thyroid medullary carcinoma	Cabozantinib	sensitive	Phase III	27525386	Thyroid	Therapeutic	C
RET	MUT	M918T	thyroid medullary carcinoma	Cabozantinib	sensitive	Phase III	;	Thyroid	Therapeutic	C
RET	MUT	M918T	thyroid medullary carcinoma	Everolimus	sensitive	Phase II	26294908	Thyroid	Therapeutic	C
RET	MUT	M918T	thyroid medullary carcinoma	HG-6-63-01	sensitive	Preclinical	26046350	Thyroid	Therapeutic	D
RET	MUT	M918T	thyroid medullary carcinoma	LOXO-292	sensitive	Preclinical - Cell culture	29912274	Thyroid	Therapeutic	D
RET	MUT	M918T	thyroid medullary carcinoma	Sorafenib	predicted - sensitive	Phase II	20368568	Thyroid	Therapeutic	C
RET	MUT	M918T	thyroid medullary carcinoma	XMD15-44	sensitive	Preclinical	26046350	Thyroid	Therapeutic	D
RET	MUT	M918T	Thyroid	[RET inhibitor]	Responsive	Pre-clinical	23056499	Thyroid	Therapeutic	D
RET	MUT	M918T	Thyroid	Sunitinib	Responsive	Pre-clinical	21470995	Thyroid	Therapeutic	D
RET	MUT	mutant	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical - Cell line xenograft	23526464	Other	Therapeutic	D
RET	MUT	mutant	cancer	Sorafenib	sensitive	Preclinical	17664273	Cancer	Therapeutic	D
RET	MUT	mutant	colorectal cancer	Ponatinib	sensitive	Preclinical	23811235	Colorectal	Therapeutic	D
RET	MUT	mutant	thyroid medullary carcinoma	Cabozantinib	sensitive	Phase III	27525386	Thyroid	Therapeutic	C
RET	MUT	mutant	thyroid medullary carcinoma	Everolimus	sensitive	Phase II	26294908	Thyroid	Therapeutic	C
RET	MUT	mutant	thyroid medullary carcinoma	LOXO-292	sensitive	Phase I	;	Thyroid	Therapeutic	C
RET	MUT	mutation	breast cancer	Y078-DM4	sensitive	Preclinical - Cell line xenograft	26240273	Breast	Therapeutic	D
RET	MUT	mutation	thyroid medullary carcinoma	Y078-DM4	sensitive	Preclinical	26240273	Thyroid	Therapeutic	D
RET	MUT	Oncogenic Mutations	Medullary Thyroid Cancer	LOXO-292, BLU-667	Response	3A	29912274, 29657135	Thyroid	Therapeutic	C
RET	MUT	rearrange	Advanced Solid Tumor	RXDX-105	sensitive	Preclinical - Pdx	;	Other	Therapeutic	D
RET	MUT	rearrange	lung cancer	Alectinib	predicted - sensitive	Clinical Study - Cohort	30017832	Lung	Therapeutic	C
RET	MUT	rearrange	lung cancer	Cabozantinib	conflicting	Clinical Study - Cohort	30017832	Lung	Therapeutic	C
RET	MUT	rearrange	lung cancer	Cabozantinib	conflicting	Phase II	27825636	Lung	Therapeutic	C
RET	MUT	rearrange	lung cancer	Ponatinib	no benefit	Clinical Study - Cohort	30017832	Lung	Therapeutic	C
RET	MUT	rearrange	lung non-small cell carcinoma	Alectinib	predicted - sensitive	Case Reports/Case Series	27544060	Lung	Therapeutic	D
RET	MUT	rearrange	lung non-small cell carcinoma	Cabozantinib	sensitive	Clinical Study	28447912	Lung	Therapeutic	C
RET	MUT	rearrange	lung non-small cell carcinoma	Cabozantinib	sensitive	Guideline	;	Lung	Therapeutic	A
RET	MUT	rearrange	lung non-small cell carcinoma	RXDX-105	predicted - sensitive	Case Reports/Case Series	28011461	Lung	Therapeutic	D
RET	MUT	rearrange	lung non-small cell carcinoma	RXDX-105	predicted - sensitive	Phase I	30487236	Lung	Therapeutic	C
RET	MUT	rearrange	lung non-small cell carcinoma	Sunitinib	predicted - sensitive	Clinical Study	28447912	Lung	Therapeutic	C
RET	MUT	rearrange	lung non-small cell carcinoma	Vandetanib	sensitive	Clinical Study	28447912	Lung	Therapeutic	C
RET	MUT	rearrange	lung non-small cell carcinoma	Vandetanib	sensitive	Guideline	;	Lung	Therapeutic	A
RET	MUT	rearrange	papillary thyroid carcinoma	Ponatinib	sensitive	Preclinical	23526464	Thyroid	Therapeutic	D
RET	MUT	rearrange	papillary thyroid carcinoma	Sorafenib	sensitive	Preclinical	17664273	Thyroid	Therapeutic	D
RET	MUT	S891A	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	S891A	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	17664273	Other	Therapeutic	D
RET	MUT	S891A	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	V804L	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23811235	Other	Therapeutic	D
RET	MUT	V804L	Advanced Solid Tumor	Pz-1	predicted - sensitive	Preclinical	26126987	Other	Therapeutic	D
RET	MUT	V804L	Advanced Solid Tumor	Vandetanib	resistant	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	V804M	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23811235	Other	Therapeutic	D
RET	MUT	V804M	Advanced Solid Tumor	Pz-1	predicted - sensitive	Preclinical	26126987	Other	Therapeutic	D
RET	MUT	V804M	Advanced Solid Tumor	Sorafenib	sensitive	Preclinical	16507829	Other	Therapeutic	D
RET	MUT	V804M	Advanced Solid Tumor	Vandetanib	resistant	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	V804M	thyroid medullary carcinoma	LOXO-292	sensitive	Phase I	;	Thyroid	Therapeutic	C
RET	MUT	WILDTYPE	lung small cell carcinoma	Ponatinib	sensitive	Preclinical	25122427	Lung	Therapeutic	D
RET	MUT	WILDTYPE	lung small cell carcinoma	Vandetanib	sensitive	Preclinical	25122427	Lung	Therapeutic	D
RET	MUT	Y791F	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RET	MUT	Y791F	Advanced Solid Tumor	Vandetanib	sensitive	Preclinical	15184865	Other	Therapeutic	D
RET	MUT	Y806C	Advanced Solid Tumor	Ponatinib	sensitive	Preclinical	23526464	Other	Therapeutic	D
RHOA	MUT	mutation	Stomach Carcinoma		Poor Outcome	E	27313181	Stomach	Prognostic	D
RICTOR	CNV	amplification	Lung	[MTORC1/2 inhibitor]	Responsive	Case report	26370156	Lung	Therapeutic	D
RICTOR	CNV	AMPLIFICATION	Lung Adenocarcinoma	MLN0128,Cc-223	Sensitivity/Response	C	26370156	Lung	Therapeutic	C
RIT1	EXP	OVEREXPRESSION	Endometrial Cancer		Poor Outcome	B	26617739	Uterus	Prognostic	B
RIT1	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	23765226	Blood;Bone_Marrow	Therapeutic	B
RIT1	MUT	mutation	Lung Adenocarcinoma	Selumetinib,Pictilisib	Sensitivity/Response	D	24469055	Lung	Therapeutic	D
RNF43	MUT	oncogenic mutation	Colorectal adenocarcinoma	[Porcupine inhibitor]	Responsive	Case report	ENA 2015 (abstr C45)	Colorectal	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2032R	Lung Adenocarcinoma	Crizotinib	Resistance	C	23724914	Lung	Therapeutic	C
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	AZD3463,Ceritinib,Brigatinib,Crizotinib	Resistance	D	26372962	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Cabozantinib	Sensitivity/Response	D	25351743	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	C	25688157	Lung	Therapeutic	C
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Foretinib,Cabozantinib	Sensitivity/Response	D	26372962	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Foretinib	Sensitivity/Response	D	25688157	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Lorlatinib	Sensitivity/Response	D	25733882	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	25688157	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	Foretinib	Sensitivity/Response	D	25688157	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	25688157	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib	Resistance	D	25733882	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Foretinib	Sensitivity/Response	D	25688157	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Lorlatinib	Sensitivity/Response	D	25733882	Lung	Therapeutic	D
ROS1	FUS	CD74-ROS1 L2155S	Lung Non-small Cell Carcinoma	TAE684,Foretinib,Crizotinib	Resistance	D	25688157	Lung	Therapeutic	D
ROS1	FUS	fusion	Advanced Solid Tumor	Brigatinib	sensitive	Preclinical - Cell culture	27780853	Other	Therapeutic	D
ROS1	FUS	fusion	Advanced Solid Tumor	Repotrectinib	predicted - sensitive	Phase I	;	Other	Therapeutic	C
ROS1	FUS	fusion	lung non-small cell carcinoma	Crizotinib	sensitive	FDA approved	;25264305	Lung	Therapeutic	A
ROS1	FUS	fusion	lung non-small cell carcinoma	DS6051b	predicted - sensitive	Phase I	;	Lung	Therapeutic	C
ROS1	FUS	fusion	lung non-small cell carcinoma	Entrectinib	sensitive	FDA approved	;;	Lung	Therapeutic	A
ROS1	FUS	fusion	lung non-small cell carcinoma	Lorlatinib	sensitive	Phase I	;	Lung	Therapeutic	C
ROS1	FUS	TFG-ROS1	Inflammatory Myofibroblastic Tumor	Crizotinib	Sensitivity/Response	C	24875859	Soft_Tissue	Therapeutic	C
ROS1	FUS	Fusions	Non-Small Cell Lung Cancer	Crizotinib	Response	1	25264305, 29596029	Lung	Therapeutic	A
ROS1	MUT	G2032R	Lung adenocarcinoma	Cabozantinib	Responsive	Pre-clinical	25351743	Lung	Therapeutic	D
ROS1	MUT	G2032R	Lung Adenocarcinoma	Crizotinib	Resistance	C	23724914	Lung	Therapeutic	C
ROS1	MUT	G2032R	Lung adenocarcinoma	Crizotinib	Resistant	Case report	23724914;25688157	Lung	Therapeutic	D
ROS1	MUT	mutation	lung non-small cell carcinoma	Entrectinib	sensitive	FDA approved	;;	Lung	Therapeutic	A
ROS1	MUT	mutation	lung non-small cell carcinoma	Lorlatinib	sensitive	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	mutation	pancreatic cancer	Entrectinib	predicted - sensitive	Case Reports/Case Series	;	Pancreas	Therapeutic	D
ROS1	MUT	rearrange	Advanced Solid Tumor	Entrectinib	sensitive	Phase I	28183697	Other	Therapeutic	C
ROS1	MUT	rearrange	Advanced Solid Tumor	Entrectinib	sensitive	Phase I	;	Other	Therapeutic	C
ROS1	MUT	rearrange	lung adenocarcinoma	Crizotinib	sensitive	Phase I	25667280	Lung	Therapeutic	C
ROS1	MUT	rearrange	lung non-small cell carcinoma	Afatinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Alectinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Brigatinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Ceritinib	sensitive	Phase II	28520527	Lung	Therapeutic	C
ROS1	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	FDA approved	25264305;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	30285222;30715168	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Crizotinib	sensitive	Phase II	30978502	Lung	Therapeutic	C
ROS1	MUT	rearrange	lung non-small cell carcinoma	Entrectinib	sensitive	Phase I	28183697	Lung	Therapeutic	C
ROS1	MUT	rearrange	lung non-small cell carcinoma	Erlotinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Gefitinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	rearrange	lung non-small cell carcinoma	Lorlatinib	sensitive	Phase I	29074098	Lung	Therapeutic	C
ROS1	MUT	rearrange	lung non-small cell carcinoma	NPS-1034	sensitive	Preclinical - Cell culture	24165158	Lung	Therapeutic	D
ROS1	MUT	rearrange	lung non-small cell carcinoma	Osimertinib	no benefit	Guideline	;	Lung	Therapeutic	A
ROS1	MUT	REARRANGEMENT	Bronchiolo-alveolar Adenocarcinoma	Crizotinib	Sensitivity/Response	C	22215748	Lung	Therapeutic	C
ROS1	MUT	REARRANGEMENT	Cancer	Entrectinib	Sensitivity/Response	B	28183697	Cancer	Therapeutic	B
ROS1	MUT	REARRANGEMENT	Colorectal Adenocarcinoma	Crizotinib	Sensitivity/Response	E	24296758	Colorectal	Therapeutic	D
ROS1	MUT	REARRANGEMENT	Lung Adenocarcinoma	Ceritinib	Sensitivity/Response	C	26917690	Lung	Therapeutic	C
ROS1	MUT	REARRANGEMENT	Lung Adenocarcinoma	Crizotinib	Sensitivity/Response	C	25922291	Lung	Therapeutic	C
ROS1	MUT	REARRANGEMENT	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	25264305	Lung	Therapeutic	B
ROS1	MUT	REARRANGEMENT	Lung Non-small Cell Carcinoma	Crizotinib	Sensitivity/Response	B	25667280	Lung	Therapeutic	B
ROS1	MUT	S1986F	Lung adenocarcinoma	Ceritinib	Resistant	Case report	27401242	Lung	Therapeutic	D
ROS1	MUT	S1986F	Lung adenocarcinoma	Crizotinib	Resistant	Case report	27401242	Lung	Therapeutic	D
ROS1	MUT	S1986F	Lung adenocarcinoma	Lorlatinib	Responsive	Case report	27401242	Lung	Therapeutic	D
ROS1	MUT	S1986Y	Lung adenocarcinoma	Ceritinib	Resistant	Case report	27401242	Lung	Therapeutic	D
ROS1	MUT	S1986Y	Lung adenocarcinoma	Crizotinib	Resistant	Case report	27401242	Lung	Therapeutic	D
ROS1	MUT	S1986Y	Lung adenocarcinoma	Lorlatinib	Responsive	Case report	27401242	Lung	Therapeutic	D
RPL10	MUT	any mutation	T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	23263491	Blood;Bone_Marrow	Therapeutic	B
RPS6	MUT	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	Sensitivity/Response	D	22343617	Stomach	Therapeutic	D
RRM1	EXP	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine	Resistance	D	17224927	Pancreas	Therapeutic	D
RRM1	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin,Gemcitabine	Sensitivity/Response	B	24595080	Lung	Therapeutic	B
RRM1	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Vinorelbine,Docetaxel,Gemcitabine	Sensitivity/Response	B	24647522	Lung	Therapeutic	B
RRM1	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Vinorelbine,Gemcitabine,Paclitaxel	Sensitivity/Response	B	23038758	Lung	Therapeutic	B
RRM1	EXP	UNDEREXPRESSION	Pancreatic Cancer	Gemcitabine	Sensitivity/Response	B	17131328	Pancreas	Therapeutic	B
RRM1	EXP	UNDEREXPRESSION	Pancreatic Cancer	Gemcitabine	Sensitivity/Response	B	19543324	Pancreas	Therapeutic	B
RRM2	EXP	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine	Resistance	D	17224927	Pancreas	Therapeutic	D
RSF1	CNV	AMPLIFICATION	Breast Cancer	Tamoxifen	Resistance	B	24367492	Breast	Therapeutic	B
RUNX1	MUT	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	21714648,22150309,24487413,24220272,11986246,24136165,24792891,22237106	Blood;Bone_Marrow	Therapeutic	B
RUNX1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	21343560;25652455;22689681;22753902	Blood;Bone_Marrow	Prognostic	C
RUNX1	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
RUNX1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	22869879;21714648	Bone_Marrow	Prognostic	C
RUNX1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
RUNX1	MUT	mutation	Acute Lymphocytic Leukemia		Poor Outcome	B	23341344	Blood;Bone_Marrow	Prognostic	B
RUNX1	MUT	mutation	Acute Myeloid Leukemia	Cytarabine	Resistance	B	21343560	Blood;Bone_Marrow	Therapeutic	B
RUNX1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	21343560	Blood;Bone_Marrow	Prognostic	B
RUNX1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	22753902	Blood;Bone_Marrow	Prognostic	B
RUNX1	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	27137476	Blood;Bone_Marrow	Prognostic	B
RUNX1-RUNX1T1	FUS		acute myeloid leukemia	GSK690	sensitive	Preclinical - Cell culture	26837761	Blood;Bone_Marrow	Therapeutic	D
RUNX1-RUNX1T1	FUS		acute myeloid leukemia	N/A	not applicable	Clinical Study	9746770;25111512;22180162	Blood;Bone_Marrow	Prognostic	C
RUNX1-RUNX1T1	FUS		acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
RUNX1-RUNX1T1	FUS		acute myeloid leukemia	RN-1	sensitive	Preclinical - Cell line xenograft	26837761	Blood;Bone_Marrow	Therapeutic	D
RUNX1-RUNX1T1	FUS	KIT mut	acute myeloid leukemia	N/A	not applicable	Clinical Study	25111512;16384925;18648004	Blood;Bone_Marrow	Prognostic	C
RUNX1-RUNX1T1	FUS		leukemia	Doxorubicin + I-CBP112	sensitive	Preclinical	26552700	Blood;Bone_Marrow	Therapeutic	D
RUNX1-RUNX1T1	FUS		leukemia	I-CBP112 + JQ1	sensitive	Preclinical	26552700	Blood;Bone_Marrow	Therapeutic	D
RUNX1-RUNX1T1	FUS		leukemia	I-CBP112	sensitive	Preclinical	26552700	Blood;Bone_Marrow	Therapeutic	D
SERPINB3	MUT	oncogenic mutation	Cutaneous melanoma	[CTLA4 inhibitor]	Responsive	Early trials	27668655	Skin	Therapeutic	C
SETBP1	MUT	any mutation	Atypical Chronic Myeloid Leukemia/Chronic Neutrophilic Leukemia/MDS/MPN/Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	23222956,23443343,23832012	Blood;Bone_Marrow	Therapeutic	B
SETBP1	MUT	exon(s) 4 mutation	Chronic Myeloid Leukemia		Poor Outcome	B	23222956	Blood;Bone_Marrow	Prognostic	B
SETBP1	MUT	G870S	Chronic Myeloid Leukemia		Poor Outcome	D	23222956	Blood;Bone_Marrow	Prognostic	D
SETBP1	MUT	mutant	chronic myelomonocytic leukemia	N/A	not applicable	Clinical Study	29225884;28209919;23832012;23558523;28158286	Blood;Bone_Marrow	Prognostic	C
SETBP1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	23889083;24127063;28447248;23832012;28158286	Bone_Marrow	Prognostic	C
SETD2	CNV	deletion	Any cancer type	[WEE1 inhibitor]	Responsive	Pre-clinical	ENA 2014 (abstr 211)	Cancer	Therapeutic	D
SETD2	MUT	any frameshift	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24509477,24662245,22237106	Blood;Bone_Marrow	Therapeutic	B
SETD2	MUT	any missense	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24509477,24662245,22237106	Blood;Bone_Marrow	Therapeutic	B
SETD2	MUT	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma in Kidney			2	23036577,24166983,25873528,25365943,23792563,23797736	Kidney	Therapeutic	C
SETD2	MUT	any nonsense	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24509477,24662245,22237106	Blood;Bone_Marrow	Therapeutic	B
SETD2	MUT	oncogenic mutation	Any cancer type	[WEE1 inhibitor]	Responsive	Pre-clinical	ENA 2014 (abstr 211)	Cancer	Therapeutic	D
SF1	MUT	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	21909114	Blood;Bone_Marrow	Therapeutic	B
SF3A1	MUT	any mutation	Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			2	23645565,21909114	Blood;Bone_Marrow	Therapeutic	C
SF3B1	MUT	codon(s) 700, 666, 662, 625, 622 missense	Myeloproliferative Neoplasm/Chronic Lymphocytic Leukemia/MDS with Ring Sideroblasts/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Primary Myelofibrosis/Essential Thrombocythemia in Blood/Bone Marrow			1	24113472,21909114,22343920,22150006,22064353,21995386,24652989,24943832,21886174,22064355	Blood;Bone_Marrow	Therapeutic	B
SF3B1	MUT	D781X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	E622X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	exon(s) 13, 14, 15, 16 missense	Myeloproliferative Neoplasm/Chronic Lymphocytic Leukemia/MDS with Ring Sideroblasts/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Primary Myelofibrosis/Essential Thrombocythemia in Blood/Bone Marrow			1	24113472,21909114,22343920,22150006,22064353,21995386,24652989,24943832,21886174,22064355	Blood;Bone_Marrow	Therapeutic	B
SF3B1	MUT	G740X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	G742X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	H662X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	I704X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	K666N	Any cancer type	[Spliceosome inhibitor]	Responsive	Pre-clinical	ENA 2014 (abstr 456);ENA 2014 (abstr 575);25424858	Cancer	Therapeutic	D
SF3B1	MUT	K666N	Breast Cancer	Spliceostatin A	Sensitivity/Response	D	25424858	Breast	Therapeutic	D
SF3B1	MUT	K666N	endometrial cancer	Spliceostatin A	sensitive	Preclinical	25424858	Uterus	Therapeutic	D
SF3B1	MUT	K666X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	K700E	acute myeloid leukemia	H3B-8800	sensitive	Preclinical - Cell culture	;	Blood;Bone_Marrow	Therapeutic	D
SF3B1	MUT	K700E	Any cancer type	[Spliceosome inhibitor]	Responsive	Pre-clinical	ENA 2014 (abstr 456);ENA 2014 (abstr 575);25424858	Cancer	Therapeutic	D
SF3B1	MUT	K700E	Breast Cancer	Spliceostatin A	Sensitivity/Response	D	25424858	Breast	Therapeutic	D
SF3B1	MUT	K700E	chronic myeloid leukemia	H3B-8800	sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
SF3B1	MUT	K700E	hematologic cancer	E7107	sensitive	Preclinical - Cell culture	27622333	Blood	Therapeutic	D
SF3B1	MUT	K700E	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	K700E	pancreatic cancer	Spliceostatin A	sensitive	Preclinical	25424858	Pancreas	Therapeutic	D
SF3B1	MUT	mutant	essential thrombocythemia	N/A	not applicable	Guideline	;	Blood	Prognostic	A
SF3B1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	22096241;21998214;24220272	Bone_Marrow	Prognostic	C
SF3B1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	A	26837699	Blood;Bone_Marrow	Prognostic	A
SF3B1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	23086750	Blood;Bone_Marrow	Prognostic	B
SF3B1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	23568491	Blood;Bone_Marrow	Prognostic	B
SF3B1	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	24943832	Blood;Bone_Marrow	Prognostic	B
SF3B1	MUT	mutation	Myelodysplastic Syndrome		Better Outcome	B	21995386	Bone_Marrow	Prognostic	B
SF3B1	MUT	N626X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
SF3B1	MUT	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
SF3B1	MUT	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800	Response	4	29457796	Bone_Marrow	Therapeutic	D
SF3B1	MUT	R1074H	Advanced Solid Tumor	H3B-8800	resistant	Preclinical - Cell culture	;	Other	Therapeutic	D
SF3B1	MUT	R625X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	T663X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SF3B1	MUT	Y623X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SGK1	EXP	OVEREXPRESSION	Breast Cancer	Alpelisib	Resistance	B	27451907	Breast	Therapeutic	B
SGK1	EXP	OVEREXPRESSION	Breast Cancer	Alpelisib	Resistance	D	27451907	Breast	Therapeutic	D
SGK1	EXP	OVEREXPRESSION	Breast Cancer	SGK1-Inh,Alpelisib	Sensitivity/Response	D	27451907	Breast	Therapeutic	D
SH2B3	CNV	deletion	Myelodisplasic proliferative syndrome	[JAK inhibitor]	Responsive	Pre-clinical	20404132	Bone_Marrow	Therapeutic	D
SH2B3	MUT	any mutation	Myeloproliferative Neoplasm/T Lymphoblastic Leukemia/Lymphoma/B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24482502,23908464,22897847,22237106,20404132,18566540	Blood;Bone_Marrow	Therapeutic	B
SH2B3	MUT	oncogenic mutation	Myelodisplasic proliferative syndrome	[JAK inhibitor]	Responsive	Pre-clinical	20404132	Bone_Marrow	Therapeutic	D
SIRT1	EXP	OVEREXPRESSION	Pancreatic Cancer	Nicotinamide	Resistance	D	24088390	Pancreas	Therapeutic	D
SIRT1	EXP	OVEREXPRESSION	Pancreatic Ductal Carcinoma		Poor Outcome	B	24088390	Pancreas	Prognostic	B
SLC29A1	MUT	oncogenic mutation	Bladder	Gemcitabine	Resistant	Pre-clinical	21166756	Bladder	Therapeutic	D
SLC44A4	EXP	overexpression	Prostate adenocarcinoma;Pancreas adenocarcinoma	[SLC44A4 inhibitor]	Responsive	Pre-clinical	27550944 	Pancreas;Prostate	Therapeutic	D
SLCO1B1	MUT	N130D	Cancer	Methotrexate	Adverse Response	B	23652803	Cancer	Therapeutic	B
SLFN11	EXP	EXPRESSION	Colorectal Cancer	SN-38	Sensitivity/Response	D	25089570	Colorectal	Therapeutic	D
SMAD4	CNV	deletion	Colorectal Cancer	5-fluorouracil	Resistance	B	12237773	Colorectal	Therapeutic	B
SMAD4	CNV	del	pancreatic cancer	Cisplatin	sensitive	Preclinical	22753594	Pancreas	Therapeutic	D
SMAD4	CNV	del	pancreatic cancer	Gemcitabine	decreased response	Preclinical	22753594	Pancreas	Therapeutic	D
SMAD4	CNV	del	pancreatic cancer	Irinotecan	sensitive	Preclinical	22753594	Pancreas	Therapeutic	D
SMAD4	CNV	LOSS	Pancreatic Cancer		Poor Outcome	B	19273710	Pancreas	Prognostic	B
SMAD4	CNV	loss	pancreatic carcinoma	SD-093	sensitive	Preclinical	15289325	Pancreas	Therapeutic	D
SMAD4	EXP	EXPRESSION	Pancreatic Ductal Adenocarcinoma		Better Outcome	B	11751510	Pancreas	Prognostic	B
SMAD4	EXP	UNDEREXPRESSION	colorectal cancer	N/A	not applicable	Clinical Study	25749173;19478385;26861460;25681512	Colorectal	Prognostic	C
SMAD4	EXP	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab	Resistance	D	26046389	Head_and_Neck	Therapeutic	D
SMAD4	EXP	UNDEREXPRESSION	head and neck squamous cell carcinoma	Cetuximab	resistant	Clinical Study - Cohort	28522603	Head_and_Neck	Therapeutic	C
SMAD4	EXP	UNDEREXPRESSION	head and neck squamous cell carcinoma	Cetuximab + SP600125	sensitive	Preclinical - Cell culture	28522603	Head_and_Neck	Therapeutic	D
SMAD4	EXP	UNDEREXPRESSION	head and neck squamous cell carcinoma	Cetuximab + U0126	sensitive	Preclinical - Cell culture	28522603	Head_and_Neck	Therapeutic	D
SMAD4	EXP	UNDEREXPRESSION	head and neck squamous cell carcinoma	SP600125	decreased response	Preclinical - Cell culture	28522603	Head_and_Neck	Therapeutic	D
SMAD4	EXP	UNDEREXPRESSION	head and neck squamous cell carcinoma	U0126	decreased response	Preclinical - Cell culture	28522603	Head_and_Neck	Therapeutic	D
SMAD4	EXP	UNDEREXPRESSION	pancreatic cancer	N/A	not applicable	Clinical Study	22504380;19584151;25760429;26947875	Pancreas	Prognostic	C
SMAD4	MUT	any mutation	Adenocarcinoma in Pancreas			2	24625091	Pancreas	Therapeutic	C
SMAD4	MUT	LOSS-OF-FUNCTION	pancreatic cancer	Irinotecan	sensitive	Preclinical	22753594	Pancreas	Therapeutic	D
SMAD4	MUT	mutant	colorectal cancer	Cetuximab	no benefit	Clinical Study - Cohort	29703253	Colorectal	Therapeutic	C
SMAD4	MUT	mutation	Colorectal Cancer	Panitumumab,Cetuximab	Resistance	B	26508446	Colorectal	Therapeutic	B
SMAD4	MUT	mutation	Pancreatic Adenocarcinoma		Poor Outcome	B	19584151	Pancreas	Prognostic	B
SMARCA1	MUT	oncogenic mutation	Any cancer type	[EZH2 inhibitor]	Responsive	Pre-clinical	26552009	Cancer	Therapeutic	D
SMARCA4	CNV	deletion	Ovary	[EZH2 inhibitor]	Responsive	Case report	ESMO 2015 (abstract 302)	Ovary	Therapeutic	D
SMARCA4	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin,Vinorelbine	Sensitivity/Response	B	26671993	Lung	Therapeutic	B
SMARCA4	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma		Poor Outcome	B	26671993	Lung	Prognostic	B
SMARCA4	MUT	INACTIVATING mutation	Lung Adenocarcinoma		Poor Outcome	B	24658004	Lung	Prognostic	B
SMARCA4	MUT	mutation	Small Cell Carcinoma Of The Ovary Hypercalcemic Type		Positive	B	24658004	Ovary	Diagnostic	B
SMARCA4	MUT	oncogenic mutation	Ovary	[EZH2 inhibitor]	Responsive	Case report	ESMO 2015 (abstract 302)	Ovary	Therapeutic	D
SMARCB1	CNV	deletion	Malignant rhabdoid tumor	[EZH2 inhibitor]	Responsive	Case report	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	Kidney	Therapeutic	D
SMARCB1	CNV	deletion	Malignant rhabdoid tumor	[EZH2 inhibitor]	Responsive	Early trials	ESMO 2015 (abstract 302)	Kidney	Therapeutic	C
SMARCB1	CNV	del	epithelioid sarcoma	N/A	not applicable	Guideline	;	Soft_Tissue	Diagnostic	A
SMARCB1	CNV	deletion	Rhabdoid Cancer	EPZ-6438	Sensitivity/Response	D	23620515	Eye	Therapeutic	D
SMARCB1	CNV	loss	atypical teratoid rhabdoid tumor	CFI-400945	sensitive	Preclinical - Cell culture	28398638	Eye	Therapeutic	D
SMARCB1	CNV	loss	rhabdoid cancer	Tazemetostat	sensitive	Preclinical - Cell line xenograft	23620515	Kidney	Therapeutic	D
SMARCB1	EXP	UNDEREXPRESSION	Synovial Sarcoma	EPZ-6438	Sensitivity/Response	D	27391784	Soft_Tissue	Therapeutic	D
SMARCB1	MUT	LOSS-OF-FUNCTION	epithelioid sarcoma	N/A	not applicable	Guideline	;	Soft_Tissue	Diagnostic	A
SMARCB1	MUT	oncogenic mutation	Malignant rhabdoid tumor	[EZH2 inhibitor]	Responsive	Case report	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)	Kidney	Therapeutic	D
SMARCB1	MUT	oncogenic mutation	Malignant rhabdoid tumor	[HDAC inhibitor]	Responsive	Pre-clinical	26920892	Kidney	Therapeutic	D
SMARCB1	MUT	Oncogenic Mutations	All Tumors	Tazemetostat	Response	4	29650362, 23620515, 20951942, 27391784	Cancer	Therapeutic	D
SMC1A	MUT	any mutation	Acute Myeloid Leukemia/Chronic Myeloid Leukemia in Blood/Bone Marrow			1	24335498,23955599	Blood;Bone_Marrow	Therapeutic	B
SMC3	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	24335498,23955599	Blood;Bone_Marrow	Therapeutic	B
SMO	EXP	UNDEREXPRESSION	osteosarcoma	SANT1	predicted - sensitive	Preclinical	26781311	Bone	Therapeutic	D
SMO	MUT	A327P	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	A459V	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	A459V	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	A459V	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	A459V	Advanced Solid Tumor	Vismodegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	any mutation	Basal Cell Carcinoma in Skin			1	26950094,26546616	Skin	Therapeutic	B
SMO	MUT	C390R	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	C469Y	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	C469Y	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	C469Y	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	C469Y	Advanced Solid Tumor	Vismodegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	D384A	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	D384N	Advanced Solid Tumor	Arsenic trioxide + Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D384N	Advanced Solid Tumor	Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D384N	Advanced Solid Tumor	Sonidegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D384N	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D384N	sarcoma	Vismodegib	decreased response	Preclinical	25759019	Soft_Tissue	Therapeutic	D
SMO	MUT	D473G	Advanced Solid Tumor	Arsenic trioxide + Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D473G	Advanced Solid Tumor	Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D473G	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	D473G	Advanced Solid Tumor	Vismodegib	resistant	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	D473G	basal cell carcinoma	Sonidegib	resistant	Phase I	26546616	Skin	Therapeutic	C
SMO	MUT	D473G	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	D473G	basal cell carcinoma	Vismodegib	resistant	Preclinical	25759020	Skin	Therapeutic	D
SMO	MUT	D473H	Advanced Solid Tumor	TAK-441	predicted - sensitive	Preclinical	24291104	Other	Therapeutic	D
SMO	MUT	D473H	Advanced Solid Tumor	Taladegib	sensitive	Preclinical	;	Other	Therapeutic	D
SMO	MUT	D473H	basal cell carcinoma	Sonidegib	resistant	Phase I	26546616	Skin	Therapeutic	C
SMO	MUT	D473H	Basal Cell Carcinoma	Vismodegib	Resistance	D	25759020	Skin	Therapeutic	D
SMO	MUT	D473H	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	D473H	Brain Medulloblastoma	Saridegib	Sensitivity/Response	D	22550175	Brain	Therapeutic	D
SMO	MUT	D473H	Brain Medulloblastoma	Vismodegib	Resistance	C	19726788	Brain	Therapeutic	C
SMO	MUT	D473H	Medulloblastoma	Vismodegib	Resistant	Case report	19726788;25759019	Nervous_System	Therapeutic	D
SMO	MUT	D473Y	basal cell carcinoma	Vismodegib	predicted - resistant	Case Reports/Case Series	25306392	Skin	Therapeutic	D
SMO	MUT	D506N	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	E181K	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	E481G	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	E518K	Advanced Solid Tumor	Arsenic trioxide + Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	E518K	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	E518K	Advanced Solid Tumor	Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	E518K	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	E518K	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	F460L	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	25759020	Other	Therapeutic	D
SMO	MUT	F605L	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	G453D	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	G497W	basal cell carcinoma	Vismodegib	predicted - resistant	Case Reports/Case Series	25306392	Skin	Therapeutic	D
SMO	MUT	G497W	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	H231R	basal cell carcinoma	Vismodegib	resistant	Preclinical	25759020	Skin	Therapeutic	D
SMO	MUT	I408V	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	I408V	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	I408V	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	I408V	Advanced Solid Tumor	Vismodegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	K519R	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	K564E	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	L221P	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	L325F	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	L353F	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	L412F	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	25759020	Other	Therapeutic	D
SMO	MUT	L412F	Basal Cell Carcinoma	Vismodegib	Resistance	C	26822128	Skin	Therapeutic	C
SMO	MUT	L412F	Basal Cell Carcinoma	Vismodegib	Resistance	D	25759020	Skin	Therapeutic	D
SMO	MUT	L412F	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	M525G	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	mutation	Basal Cell Carcinoma	Arsenic Trioxide,PSI	Sensitivity/Response	D	25759020	Skin	Therapeutic	D
SMO	MUT	mutation	Basal Cell Carcinoma	Vismodegib,LDE225	Resistance	B	26546616	Skin	Therapeutic	B
SMO	MUT	mutation	Basal Cell Carcinoma	Vismodegib	Resistance	B	25759020	Skin	Therapeutic	B
SMO	MUT	N219D	Advanced Solid Tumor	Arsenic trioxide + Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	N219D	Advanced Solid Tumor	Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	N219D	Advanced Solid Tumor	Sonidegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	N219D	sarcoma	Vismodegib	decreased response	Preclinical	25759019	Soft_Tissue	Therapeutic	D
SMO	MUT	N476K	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	P513L	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	P641A	Lung	Vismodegib	Responsive	Case report	ASCO 2017 (abstr 9062)	Lung	Therapeutic	D
SMO	MUT	P698T	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	P739L	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	P739S	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	Q477E	basal cell carcinoma	Sonidegib	no benefit	Phase I	26546616	Skin	Therapeutic	C
SMO	MUT	Q477E	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	Q477E	basal cell carcinoma	Vismodegib	resistant	Preclinical	25759020	Skin	Therapeutic	D
SMO	MUT	R168H	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	R199Q	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	R400A	Advanced Solid Tumor	MRT-92	predicted - sensitive	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	S387N	Advanced Solid Tumor	Arsenic trioxide + Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	S387N	Advanced Solid Tumor	Posaconazole	sensitive	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	S387N	Advanced Solid Tumor	Sonidegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	S387N	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	S387N	sarcoma	Vismodegib	decreased response	Preclinical	25759019	Soft_Tissue	Therapeutic	D
SMO	MUT	S533N	basal cell carcinoma	Sonidegib	resistant	Phase I	26546616	Skin	Therapeutic	C
SMO	MUT	T241M	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	T241M	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	T241M	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	T241M	Advanced Solid Tumor	Vismodegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	T336I	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	T349I	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	T349P	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	T466F	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	T534I	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	T548I	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	T640A	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	V321M	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	V321M	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	V321M	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	V321M	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	25759020	Other	Therapeutic	D
SMO	MUT	V321M	basal cell carcinoma	Vismodegib	predicted - resistant	Case Reports/Case Series	25199678	Skin	Therapeutic	D
SMO	MUT	V329F	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SMO	MUT	V386A	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	V404M	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	V414A	Advanced Solid Tumor	Vismodegib	no benefit	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	W281C	Advanced Solid Tumor	JQ1	sensitive	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	W281C	Advanced Solid Tumor	Sonidegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	W281C	Advanced Solid Tumor	Taladegib	decreased response	Preclinical	25759019	Other	Therapeutic	D
SMO	MUT	W281C	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	W281C	basal cell carcinoma	Vismodegib	resistant	Preclinical	25759020	Skin	Therapeutic	D
SMO	MUT	W281L	basal cell carcinoma	Vismodegib	predicted - resistant	Case Reports/Case Series	25199678	Skin	Therapeutic	D
SMO	MUT	W535L	Advanced Solid Tumor	Posaconazole	resistant	Preclinical	26823493	Other	Therapeutic	D
SMO	MUT	W535L	Advanced Solid Tumor	Vismodegib	resistant	Preclinical	25759020	Other	Therapeutic	D
SMO	MUT	W535L	Advanced Solid Tumor	Vismodegib	resistant	Preclinical - Cell culture	25801792	Other	Therapeutic	D
SMO	MUT	W535L	basal cell carcinoma	Sonidegib	predicted - sensitive	Phase I	26546616	Skin	Therapeutic	C
SMO	MUT	W535L	Basal cell carcinoma	Vismodegib	Resistant	Case report	25759020;25306392	Skin	Therapeutic	D
SMO	MUT	W535L	medulloblastoma	Arsenic trioxide	sensitive	Preclinical	21183792	Nervous_System	Therapeutic	D
SMO	MUT	WILDTYPE	medulloblastoma	Taladegib	sensitive	Preclinical	;	Nervous_System	Therapeutic	D
SMO	MUT	WILDTYPE	stomach cancer	Vismodegib	predicted - sensitive	Preclinical	26676867	Stomach	Therapeutic	D
SMO	MUT	Y394A	Advanced Solid Tumor	MRT-92	predicted - resistant	Preclinical	25636740	Other	Therapeutic	D
SOX10	CNV	LOSS	Melanoma	Vemurafenib	Resistance	D	24670642	Skin	Therapeutic	D
SPHK1	EXP	OVEREXPRESSION	Cervical Cancer		Poor Outcome	B	26311741	Cervix	Prognostic	B
SPOP	MUT	any mutation	Adenocarcinoma in Prostate			2	25726356,23759327,18538735,21368222,22610119	Prostate	Therapeutic	C
SRC	CNV	amp	lung non-small cell carcinoma	Derazantinib	sensitive	Case Reports/Case Series	28972963;	Lung	Therapeutic	D
SRC	EXP	OVEREXPRESSION	clear cell renal cell carcinoma	Cediranib + Saracatinib	no benefit	Phase II	26802156	Kidney	Therapeutic	C
SRC	MUT	mutation	Advanced Solid Tumor	Bosutinib	predicted - sensitive	Preclinical - Cell culture	18483306	Other	Therapeutic	D
SRC	MUT	mutation	biliary tract cancer	Bosutinib + Cisplatin	sensitive	Preclinical - Cell line xenograft	27196758	Bile_Duct	Therapeutic	D
SRC	MUT	mutation	biliary tract cancer	Bosutinib + Gemcitabine	sensitive	Preclinical - Cell line xenograft	27196758	Bile_Duct	Therapeutic	D
SRC	MUT	mutation	biliary tract cancer	Bosutinib	sensitive	Preclinical - Cell line xenograft	27196758	Bile_Duct	Therapeutic	D
SRC	MUT	mutation	glioblastoma multiforme	Dasatinib	sensitive	Preclinical - Cell culture	19098899	Brain	Therapeutic	D
SRC	MUT	mutation	glioblastoma multiforme	Radiotherapy + Si306	sensitive	Preclinical - Cell line xenograft	27196762	Brain	Therapeutic	D
SRC	MUT	mutation	glioblastoma multiforme	Si306	sensitive	Preclinical - Cell line xenograft	27196762	Brain	Therapeutic	D
SRC	MUT	mutation	lung non-small cell carcinoma	AC-93253 iodide	predicted - sensitive	Preclinical - Cell line xenograft	29132432	Lung	Therapeutic	D
SRC	MUT	mutation	triple-receptor negative breast cancer	BIRB-796 + Dasatinib	sensitive	Preclinical - Cell culture	27154914	Breast	Therapeutic	D
SRC	MUT	mutation	triple-receptor negative breast cancer	KX2-391 + Paclitaxel	sensitive	Preclinical - Cell line xenograft	22784709	Breast	Therapeutic	D
SRC	MUT	mutation	triple-receptor negative breast cancer	KX2-391	sensitive	Preclinical - Cell line xenograft	22784709	Breast	Therapeutic	D
SRC	MUT	mutation	triple-receptor negative breast cancer	UM-164	predicted - sensitive	Preclinical - Cell line xenograft	27154914	Breast	Therapeutic	D
SRSF2	MUT	codon(s) 95 missense	Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Primary Myelofibrosis in Blood/Bone Marrow			1	24549259,25729726,24220272,24668493,23335386,22389253	Blood;Bone_Marrow	Therapeutic	B
SRSF2	MUT	mutant	acute myeloid leukemia	CG-806	predicted - sensitive	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
SRSF2	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Clinical Study	26508027;26769228	Bone_Marrow	Prognostic	C
SRSF2	MUT	mutant	myelofibrosis	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SRSF2	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	27276561	Blood;Bone_Marrow	Prognostic	B
SRSF2	MUT	oncogenic mutation	Acute myeloid leukemia	[Spliceosome inhibitor]	Responsive	Pre-clinical	27135740	Blood;Bone_Marrow	Therapeutic	D
SRSF2	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
SRSF2	MUT	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
SRSF2	MUT	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800	Response	4	29457796	Bone_Marrow	Therapeutic	D
SRSF2	MUT	P95X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
SSX1	FUS	SS18-SSX1	Malignant Peripheral Nerve Sheath Tumor		Positive	B	11144931	Nervous_System	Diagnostic	B
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Poor Outcome	B	11782370	Soft_Tissue	Prognostic	B
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Poor Outcome	B	9428816	Soft_Tissue	Prognostic	B
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Positive	A	11607825	Soft_Tissue	Diagnostic	A
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Positive	B	11122430	Soft_Tissue	Diagnostic	B
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Positive	B	11144931	Soft_Tissue	Diagnostic	B
SSX1	FUS	SS18-SSX1	Synovial Sarcoma		Positive	B	9428816	Soft_Tissue	Diagnostic	B
SSX2	FUS	SS18-SSX2	Synovial Sarcoma		Better Outcome	B	11782370	Soft_Tissue	Prognostic	B
SSX2	FUS	SS18-SSX2	Synovial Sarcoma		Better Outcome	B	9428816	Soft_Tissue	Prognostic	B
SSX2	FUS	SS18-SSX2	Synovial Sarcoma		Positive	A	11607825	Soft_Tissue	Diagnostic	A
SSX2	FUS	SS18-SSX2	Synovial Sarcoma		Positive	B	9428816	Soft_Tissue	Diagnostic	B
SSX4	FUS	SS18-SSX4	Synovial Sarcoma		Positive	C	10359553	Soft_Tissue	Diagnostic	C
STAG2	EXP	UNDEREXPRESSION	Bladder Carcinoma		Better Outcome	B	26838030	Bladder	Prognostic	B
STAG2	EXP	UNDEREXPRESSION	colorectal cancer	Olaparib	sensitive	Preclinical	24356817	Colorectal	Therapeutic	D
STAG2	EXP	UNDEREXPRESSION	Melanoma	Vemurafenib	Resistance	D	27500726	Skin	Therapeutic	D
STAG2	MUT	any mutation	Myeloproliferative Neoplasm/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Chronic Myeloid Leukemia in Blood/Bone Marrow			1	24335498,23955599,21852505	Blood;Bone_Marrow	Therapeutic	B
STAG2	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
STAG2	MUT	mutation	Ewing Sarcoma Of Bone		Poor Outcome	B	25186949	Bone	Prognostic	B
STAG2	MUT	N357fs	glioblastoma multiforme	Camptothecin + Olaparib	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG2	MUT	N357fs	glioblastoma multiforme	Olaparib	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG2	MUT	N357fs	glioblastoma multiforme	Olaparib + Temozolomide	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG2	MUT	N357fs	glioblastoma multiforme	Rucaparib	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG2	MUT	N357fs	glioblastoma multiforme	Veliparib	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG2	MUT	oncogenic mutation	Glioma	[PARP inhibitor]	Responsive	Pre-clinical	24356817	Nervous_System	Therapeutic	D
STAG2	MUT	S653X	glioblastoma multiforme	Camptothecin	sensitive	Preclinical - Cell culture	24356817;21852505	Brain	Therapeutic	D
STAG2	MUT	S653X	glioblastoma multiforme	Olaparib	sensitive	Preclinical - Cell culture	21852505;24356817	Brain	Therapeutic	D
STAG3	EXP	UNDEREXPRESSION	Melanoma	Vemurafenib	Resistance	D	27500726	Skin	Therapeutic	D
STAT3	MUT	any mutation	T-Cell LGL Leukemia/T Cell Lymphoproliferative Disorder/NK Cell Lymphoproliferative Disorder in Blood/Bone Marrow/Lymph Node			1	24705981,22591296,22859607,23926297	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
STAT3	MUT	SH2 DOMAIN mutation	T-cell Large Granular Lymphocyte Leukemia		Positive	B	22591296	Blood;Bone_Marrow	Diagnostic	B
STK11	CNV	deletion	Any cancer type	[MTOR inhibitor]	Responsive	Pre-clinical	19541609	Cancer	Therapeutic	D
STK11	CNV	deletion	Lung adenocarcinoma	[MEK inhibitor]	Responsive	Pre-clinical	19165201	Lung	Therapeutic	D
STK11	CNV	deletion	Lung adenocarcinoma	Phenformin	Responsive	Pre-clinical	23352126	Lung	Therapeutic	D
STK11	CNV	deletion	Lung adenocarcinoma	[SRC inhibitor;PI3K/MEK inhibitor]	Responsive	Pre-clinical	20541700	Lung	Therapeutic	D
STK11	CNV	loss	Advanced Solid Tumor	Metformin	no benefit	Preclinical - Cell culture	18006825;17062558	Other	Therapeutic	D
STK11	CNV	loss	lung cancer	unspecified PD-1 antibody	resistant	Preclinical	26833127	Lung	Therapeutic	D
STK11	CNV	LOSS	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Resistance	D	22425996	Lung	Therapeutic	D
STK11	CNV	LOSS	Peutz-Jeghers Syndrome	Rapamycin (Sirolimus)	Sensitivity/Response	D	18281551	Esophagus	Therapeutic	D
STK11	CNV	LOSS	Peutz-Jeghers Syndrome	Rapamycin (Sirolimus)	Sensitivity/Response	D	19541609	Esophagus	Therapeutic	D
STK11	EXP	UNDEREXPRESSION	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell line xenograft	27821489	Lung	Therapeutic	D
STK11	EXP	UNDEREXPRESSION	Prostate Cancer	SB202190	Sensitivity/Response	D	26391455	Prostate	Therapeutic	D
STK11	MUT	D194E	Pancreas	Everolimus	Responsive	Case report	21189378	Pancreas	Therapeutic	D
STK11	MUT	D194E	Pancreatic Cancer	Everolimus	Sensitivity/Response	C	21189378	Pancreas	Therapeutic	C
STK11	MUT	E199X	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	E57fs	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	exon(s) 1, 2 mutation	Lung Non-small Cell Carcinoma		Poor Outcome	B	26625312	Lung	Prognostic	B
STK11	MUT	F298L	pituitary carcinoma	Everolimus + Radiotherapy	predicted - sensitive	Case Reports/Case Series	27615706	Other	Therapeutic	D
STK11	MUT	F354L	triple-receptor negative breast cancer	Everolimus + Exemestane	predicted - sensitive	Case Reports/Case Series	28550065	Breast	Therapeutic	D
STK11	MUT	K48fs	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	CI-1040	sensitive	Preclinical - Cell culture	27821489	Other	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	PD-0325901	sensitive	Preclinical - Cell culture	27821489	Other	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	RDEA119	sensitive	Preclinical - Cell culture	27821489	Other	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Selumetinib	sensitive	Preclinical - Cell culture	27821489	Other	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	Advanced Solid Tumor	Trametinib	sensitive	Preclinical - Cell culture	27821489	Other	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	endometrial cancer	Sirolimus	sensitive	Preclinical	20142330	Uterus	Therapeutic	D
STK11	MUT	LOSS-OF-FUNCTION	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	mutant	lung non-small cell carcinoma	Gedatolisib	sensitive	Preclinical	21325073	Lung	Therapeutic	D
STK11	MUT	mutant	lung non-small cell carcinoma	unspecified PD-1 antibody	decreased response	Clinical Study - Cohort	;	Lung	Therapeutic	C
STK11	MUT	mutant	lung non-small cell carcinoma	unspecified PD-L1 antibody	decreased response	Clinical Study - Cohort	;	Lung	Therapeutic	C
STK11	MUT	mutation	Lung Adenocarcinoma	Atezolizumab,Pembrolizumab,Nivolumab	Resistance	B	29773717	Lung	Therapeutic	B
STK11	MUT	oncogenic mutation	Any cancer type	[MTOR inhibitor]	Responsive	Pre-clinical	19541609	Cancer	Therapeutic	D
STK11	MUT	oncogenic mutation	Lung adenocarcinoma	[MEK inhibitor]	Responsive	Pre-clinical	19165201	Lung	Therapeutic	D
STK11	MUT	oncogenic mutation	Lung adenocarcinoma	Phenformin	Responsive	Pre-clinical	23352126	Lung	Therapeutic	D
STK11	MUT	oncogenic mutation	Lung adenocarcinoma	[SRC inhibitor;PI3K/MEK inhibitor]	Responsive	Pre-clinical	20541700	Lung	Therapeutic	D
STK11	MUT	oncogenic mutation	Lung	[BET inhibitor]	Resistant	Pre-clinical	23129625;24045185	Lung	Therapeutic	D
STK11	MUT	Q37X	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	W332X	lung non-small cell carcinoma	Trametinib	sensitive	Preclinical - Cell culture	27821489	Lung	Therapeutic	D
STK11	MUT	WILDTYPE	Advanced Solid Tumor	Metformin	sensitive	Preclinical - Cell culture	18006825;17062558	Other	Therapeutic	D
STK11	MUT	Y60fs	Adenocarcinoma/Non-Small Cell Lung Carcinoma in Lung			2	12097271,17599048,26477306,22980975,25695224	Lung	Therapeutic	C
STMN1	EXP	EXPRESSION	Endometrial Carcinoma	Paclitaxel	Resistance	B	24587245	Uterus	Therapeutic	B
SUZ12	CNV	deletion	Any cancer type	[BET inhibitor]	Responsive	Pre-clinical	25119042	Cancer	Therapeutic	D
SUZ12	MUT	oncogenic mutation	Any cancer type	[BET inhibitor]	Responsive	Pre-clinical	25119042	Cancer	Therapeutic	D
SYK	CNV	amplification	Mantle cell lymphoma;Chronic lymphocytic leukemia	[SYK inhibitor]	Responsive	Pre-clinical	16409295;19549911	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	D
SYK	EXP	OVEREXPRESSION	Ovarian Cancer	Paclitaxel	Resistance	D	26096845	Ovary	Therapeutic	D
TBK1	EXP	OVEREXPRESSION	Melanoma	AZ909,Selumetinib	Sensitivity/Response	D	24962318	Skin	Therapeutic	D
TERT	CNV	AMPLIFICATION	Acral Lentiginous Melanoma		Poor Outcome	B	25219713	Skin	Prognostic	B
TERT	MUT	C228T	Thyroid Cancer		Positive	B	25121551	Thyroid	Diagnostic	B
TERT	MUT	C228T	Thyroid Gland Papillary Carcinoma		Poor Outcome	B	25024077	Thyroid	Prognostic	B
TERT	MUT	PROMOTER mutation	Brain Glioma		Positive	B	26765760	Brain	Diagnostic	B
TERT	MUT	PROMOTER mutation	Glioblastoma Multiforme		Poor Outcome	B	23955565	Brain	Prognostic	B
TERT	MUT	PROMOTER mutation	Skin Melanoma		Poor Outcome	B	25217772	Skin	Prognostic	B
TERT	MUT	PROMOTER mutation	Thyroid Cancer		Poor Outcome	B	23766237	Thyroid	Prognostic	B
TERT	MUT	PROMOTER mutation	Thyroid Cancer		Positive	B	23766237	Thyroid	Diagnostic	B
TERT	MUT	promoters core	Glioblastoma multiforme	Eribulin	Responsive	Pre-clinical	25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	Brain	Therapeutic	D
TET2	MUT	any mutation	Myeloproliferative Neoplasm/Mast Cell Neoplasm/Acute Myeloid Leukemia/Primary Myelofibrosis/Myelodysplastic Syndrome/Angioimmunoblastic T-Cell Lymphoma/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	19262599,19295549,19797729,19474426	Blood;Bone_Marrow	Therapeutic	B
TET2	MUT	mutant	acute myeloid leukemia	Azacitidine	predicted - sensitive	Phase I	21494260	Blood;Bone_Marrow	Therapeutic	C
TET2	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Clinical Study	24524305;25412851;24994606	Blood;Bone_Marrow	Prognostic	C
TET2	MUT	mutation	Acute Myeloid Leukemia		Better Outcome	B	22430270	Blood;Bone_Marrow	Prognostic	B
TET2	MUT	mutation	Acute Myeloid Leukemia		N/A	B	21343549	Blood;Bone_Marrow	Prognostic	B
TET2	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	21343549	Blood;Bone_Marrow	Prognostic	B
TET2	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	21828143	Blood;Bone_Marrow	Prognostic	B
TET2	MUT	mutation	Myelodysplastic Syndrome		Better Outcome	B	19666869	Bone_Marrow	Prognostic	B
TFF3	EXP	EXPRESSION	Breast Cancer	Aminoglutethimide,Tamoxifen	Sensitivity/Response	B	25900183	Breast	Therapeutic	B
TGFA	EXP	EXPRESSION	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	9625170	Head_and_Neck	Prognostic	B
THBS2	EXP	UNDEREXPRESSION	Colorectal Cancer		Poor Outcome	B	26807188	Colorectal	Prognostic	B
TIMP1	EXP	OVEREXPRESSION	Breast Cancer	Fulvestrant	Resistance	D	23881388	Breast	Therapeutic	D
TIMP1	EXP	OVEREXPRESSION	Breast Cancer	Paclitaxel	Resistance	B	22544540	Breast	Therapeutic	B
TLK2	CNV	AMPLIFICATION	Breast Cancer	GF109203X,Go6983	Sensitivity/Response	D	27694828	Breast	Therapeutic	D
TOP1	CNV	AMPLIFICATION	Colorectal Cancer	Irinotecan	Sensitivity/Response	B	24256029	Colorectal	Therapeutic	B
TOP1	EXP	EXPRESSION	Colorectal Cancer	Irinotecan	Sensitivity/Response	B	19775480	Colorectal	Therapeutic	B
TOP1	EXP	EXPRESSION	Ovarian Cancer	Cyclophosphamide,Carboplatin,Topotecan	Sensitivity/Response	B	19648970	Ovary	Therapeutic	B
TOP2A	CNV	amplification	Breast adenocarcinoma	Anthracyclines	Responsive	Late trials	22864769	Breast	Therapeutic	C
TOP2A	EXP	EXPRESSION	Breast Cancer	Doxorubicin	Sensitivity/Response	B	15486187	Breast	Therapeutic	B
TP53	CNV	deletion	B cell lymphoma	AZD6738	Responsive	Early trials	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Lymph_Nodes	Therapeutic	C
TP53	CNV	deletion	Thymic	Pramlintide	Responsive	Pre-clinical	25409149	Thymus	Therapeutic	D
TP53	CNV	del	colorectal cancer	Doxorubicin + Seliciclib	predicted - sensitive	Preclinical - Cell culture	26826118	Colorectal	Therapeutic	D
TP53	CNV	del	colorectal cancer	Tanespimycin	decreased response	Preclinical	30107178	Colorectal	Therapeutic	D
TP53	CNV	del	colorectal cancer	TC-A2317	predicted - sensitive	Preclinical - Cell culture	22293494	Colorectal	Therapeutic	D
TP53	CNV	del	ovarian cancer	Cisplatin + Nutlin-3	sensitive	Preclinical	25964101	Ovary	Therapeutic	D
TP53	CNV	del	ovarian cancer	Etoposide + Nutlin-3	sensitive	Preclinical	25964101	Ovary	Therapeutic	D
TP53	CNV	del	ovarian cancer	Nutlin-3	no benefit	Preclinical	25964101	Ovary	Therapeutic	D
TP53	CNV	del	ovarian clear cell carcinoma	thioureidobutyronitrile	predicted - sensitive	Preclinical - Cell line xenograft	;	Ovary	Therapeutic	D
TP53	CNV	loss	acute myeloid leukemia	ALRN-6924	resistant	Preclinical - Cell culture	29643228	Blood;Bone_Marrow	Therapeutic	D
TP53	CNV	loss	Advanced Solid Tumor	Adavosertib	sensitive	Preclinical	19887545	Other	Therapeutic	D
TP53	CNV	loss	Advanced Solid Tumor	CTX-1	decreased response	Preclinical	26883273	Other	Therapeutic	D
TP53	CNV	loss	CLL/SLL	Ibrutinib	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	CNV	loss	CLL/SLL	Idelalisib + Rituximab	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	CNV	loss	CLL/SLL	Rituximab + Venetoclax	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	CNV	loss	CLL/SLL	Venetoclax	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	CNV	loss	colon cancer	CHIR-124 + SN-38	sensitive	Preclinical - Cell culture	17255282	Colorectal	Therapeutic	D
TP53	CNV	loss	colon cancer	CPUY201112	decreased response	Preclinical	26743233	Colorectal	Therapeutic	D
TP53	CNV	loss	colon carcinoma	MPI-0479605	sensitive	Preclinical	21980130	Colorectal	Therapeutic	D
TP53	CNV	loss	colon carcinoma	SP600125	sensitive	Preclinical	22438244	Colorectal	Therapeutic	D
TP53	CNV	loss	colorectal cancer	Ad5CMV-p53 gene	predicted - sensitive	Preclinical	15608394	Colorectal	Therapeutic	D
TP53	CNV	loss	colorectal cancer	AZD6738 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	28062704	Colorectal	Therapeutic	D
TP53	CNV	loss	colorectal cancer	PHA-680632 + Radiotherapy	sensitive	Preclinical - Pdx	18026198	Colorectal	Therapeutic	D
TP53	CNV	loss	colorectal cancer	Prodigiosin	sensitive	Preclinical	26759239	Colorectal	Therapeutic	D
TP53	CNV	loss	glioblastoma multiforme	BLZ945	sensitive	Preclinical	27199435	Brain	Therapeutic	D
TP53	CNV	loss	lung cancer	AMG 232 + Radiotherapy	resistant	Preclinical - Cell line xenograft	26162687	Lung	Therapeutic	D
TP53	CNV	loss	lung cancer	AMG 232	resistant	Preclinical - Cell culture	26162687	Lung	Therapeutic	D
TP53	CNV	loss	mantle cell lymphoma	Bendamustine + Rituximab	predicted - resistant	Case Reports/Case Series	30559058	Lymph_Nodes	Therapeutic	D
TP53	CNV	loss	mantle cell lymphoma	Ibrutinib + Rituximab	predicted - sensitive	Case Reports/Case Series	30559058	Lymph_Nodes	Therapeutic	D
TP53	CNV	loss	osteosarcoma	CPUY201112	decreased response	Preclinical	26743233	Bone	Therapeutic	D
TP53	CNV	loss	ovarian cancer	Cisplatin + LB-100	sensitive	Preclinical	25376608	Ovary	Therapeutic	D
TP53	CNV	loss	ovarian cancer	ReACp53	no benefit	Preclinical	26748848	Ovary	Therapeutic	D
TP53	CNV	loss	pancreatic cancer	Adavosertib + Gemcitabine	sensitive	Preclinical - Pdx	21389100	Pancreas	Therapeutic	D
TP53	CNV	loss	thymoma	Selinexor	predicted - resistant	Preclinical - Cell culture	28819023	Thymus	Therapeutic	D
TP53	EXP	OVEREXPRESSION	Ovarian Cancer	Cisplatin,Carboplatin	Resistance	B	11595686	Ovary	Therapeutic	B
TP53	EXP	OVEREXPRESSION	ovarian cancer	HLA-A2 p53:264-272 vaccine	predicted - sensitive	Phase I	21927947	Ovary	Therapeutic	C
TP53	EXP	OVEREXPRESSION	Ovarian Cancer		Poor Outcome	B	11595686	Ovary	Prognostic	B
TP53	EXP	OVEREXPRESSION	Stomach Cancer	Etoposide,Mitomycin,Cisplatin	Sensitivity/Response	B	14514923	Stomach	Therapeutic	B
TP53	MUT	A159V	lung non-small cell carcinoma	Seliciclib	decreased response	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	ALTERATION	Ovarian Cancer	Carboplatin,Cisplatin	Resistance	B	11595686	Ovary	Therapeutic	B
TP53	MUT	ALTERATION	Ovarian Cancer		Poor Outcome	B	11595686	Ovary	Prognostic	B
TP53	MUT	any deletion	Adenocarcinoma in Prostate			2	22722839	Prostate	Therapeutic	C
TP53	MUT	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	24725250,24652989,24487413,23297687,24619868,23334668,23403321,24943832	Blood;Bone_Marrow	Therapeutic	B
TP53	MUT	any mutation	Adenocarcinoma in Breast/Unknown			2	20182602	Breast;Other	Therapeutic	C
TP53	MUT	any mutation	Adenocarcinoma in Colon/Rectum/Appendix			2	20182602	Colorectal;Other	Therapeutic	C
TP53	MUT	any mutation	Adenocarcinoma in Prostate			2	22722839	Prostate	Therapeutic	C
TP53	MUT	any mutation	Adenocarcinoma/Squamous Cell Carcinoma in Lung/Pancreas			2	20182602	Lung;Pancreas	Therapeutic	C
TP53	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24487413,23297687,24619868,23334668,23403321	Blood;Bone_Marrow	Therapeutic	B
TP53	MUT	any mutation	Chronic Lymphocytic Leukemia in Blood/Bone Marrow/Lymph Node			1	24725250,24652989,24487413,23297687,24619868,23334668,23403321,24943832	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
TP53	MUT	any mutation	Glial Neoplasm/Glioblastoma in Brain			2	20182602	Brain	Therapeutic	C
TP53	MUT	any mutation	Langerhans Cell Histiocytosis in Skin			2	20182602	Skin	Therapeutic	C
TP53	MUT	any mutation	Melanoma in Skin			2	20182602	Skin	Therapeutic	C
TP53	MUT	C135Y	peritoneum cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Other	Therapeutic	D
TP53	MUT	C238F	fallopian tube cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	CONSERVED DOMAIN MUT	Ovarian Cancer		Poor Outcome	B	11595686	Ovary	Prognostic	B
TP53	CNV	copy number loss	Acute Myeloid Leukemia/Myelodysplastic Syndrome in Blood/Bone Marrow			1	24725250,24652989,24487413,23297687,24619868,23334668,23403321,24943832	Blood;Bone_Marrow	Therapeutic	B
TP53	CNV	copy number loss	Adenocarcinoma in Prostate			2	22722839	Prostate	Therapeutic	C
TP53	CNV	copy number loss	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24487413,23297687,24619868,23334668,23403321	Blood;Bone_Marrow	Therapeutic	B
TP53	CNV	copy number loss	Chronic Lymphocytic Leukemia in Blood/Bone Marrow/Lymph Node			1	24725250,24652989,24487413,23297687,24619868,23334668,23403321,24943832	Blood;Bone_Marrow;Lymph_Nodes	Therapeutic	B
TP53	MUT	D259Y	melanoma	LY3009120	sensitive	Preclinical	26343583	Skin	Therapeutic	D
TP53	MUT	D259Y	melanoma	Selumetinib	sensitive	Preclinical	26343583	Skin	Therapeutic	D
TP53	MUT	D259Y	melanoma	Vemurafenib	sensitive	Preclinical	26343583	Skin	Therapeutic	D
TP53	MUT	DELETERIOUS mutation	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	DELETERIOUS mutation	Cancer	Nutlin-3a	Resistance	D	17671205	Cancer	Therapeutic	D
TP53	MUT	DELETERIOUS mutation	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	22090360	Head_and_Neck	Prognostic	B
TP53	MUT	DELETERIOUS mutation	Leukemia	RG7112	Resistance	B	26459177	Blood;Bone_Marrow	Therapeutic	B
TP53	MUT	DELETERIOUS mutation	Sarcoma	Pazopanib	Sensitivity/Response	B	26646755	Soft_Tissue	Therapeutic	B
TP53	MUT	DNA BINDING DOMAIN mutation	Breast Cancer	Tamoxifen	Resistance	B	10786679	Breast	Therapeutic	B
TP53	MUT	DNA BINDING DOMAIN mutation	Oral Squamous Cell Carcinoma		Poor Outcome	B	12509970	Esophagus	Prognostic	B
TP53	MUT	E204X	Adenocarcinoma/Squamous Cell Carcinoma in Lung/Pancreas			2	20182602	Lung;Pancreas	Therapeutic	C
TP53	MUT	E258Q	osteosarcoma	Nutlin-3	resistant	Preclinical	21643018	Bone	Therapeutic	D
TP53	MUT	G244S	mantle cell lymphoma	Ibrutinib + Rituximab	predicted - sensitive	Case Reports/Case Series	30559058	Lymph_Nodes	Therapeutic	D
TP53	MUT	G245C	Adenocarcinoma/Squamous Cell Carcinoma in Lung/Pancreas			2	20182602	Lung;Pancreas	Therapeutic	C
TP53	MUT	G245S	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	I232S	osteosarcoma	Nutlin-3	resistant	Preclinical	21643018	Bone	Therapeutic	D
TP53	MUT	L111Q	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	L194F	breast cancer	Ganetespib	sensitive	Preclinical - Cell culture	26009011	Breast	Therapeutic	D
TP53	MUT	L194F	breast cancer	Tanespimycin	sensitive	Preclinical - Cell line xenograft	26009011	Breast	Therapeutic	D
TP53	MUT	L194F	breast cancer	Tanespimycin + Vorinostat	sensitive	Preclinical - Cell line xenograft	26009011	Breast	Therapeutic	D
TP53	MUT	L194F	breast cancer	Vorinostat	sensitive	Preclinical - Cell line xenograft	26009011	Breast	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	breast cancer	Adavosertib + Radiotherapy	sensitive	Preclinical	21799033	Breast	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	breast cancer	AMG 900	sensitive	Preclinical	24091768	Breast	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	breast carcinoma	CHIR-124 + Irinotecan	predicted - sensitive	Preclinical - Cell line xenograft	17255282	Breast	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	breast carcinoma	CHIR-124 + SN-38	predicted - sensitive	Preclinical - Cell culture	17255282	Breast	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	chronic lymphocytic leukemia	AZD6482	predicted - sensitive	Preclinical	26563132	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	chronic lymphocytic leukemia	AZD6738 + Ibrutinib	sensitive	Preclinical	26563132	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	lung small cell carcinoma	APR-246	sensitive	Preclinical - Cell line xenograft	21415220	Lung	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	ovarian cancer	Adavosertib + Carboplatin + Paclitaxel	sensitive	Phase I	;	Ovary	Therapeutic	C
TP53	MUT	LOSS-OF-FUNCTION	ovarian cancer	Cisplatin + LB-100	sensitive	Preclinical	25376608	Ovary	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	ovarian cancer	Cisplatin + Nutlin-3	sensitive	Preclinical	25964101	Ovary	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	ovarian carcinoma	ReACp53	sensitive	Preclinical	26748848	Ovary	Therapeutic	D
TP53	MUT	LOSS-OF-FUNCTION	prostate cancer	Abiraterone	no benefit	Clinical Study - Cohort	30209161	Prostate	Therapeutic	C
TP53	MUT	LOSS-OF-FUNCTION	prostate cancer	Enzalutamide	no benefit	Clinical Study - Cohort	30209161	Prostate	Therapeutic	C
TP53	MUT	M237I	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	mutant	acute myeloid leukemia	CG-806	predicted - sensitive	Preclinical - Patient cell culture	;	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	mutant	acute myeloid leukemia	Cytarabine + Venetoclax	predicted - sensitive	Phase Ib/II	;	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	mutant	acute myeloid leukemia	Decitabine	sensitive	Guideline	;	Blood;Bone_Marrow	Therapeutic	A
TP53	MUT	mutant	acute myeloid leukemia	N/A	not applicable	Guideline	;	Blood;Bone_Marrow	Prognostic	A
TP53	MUT	mutant	Advanced Solid Tumor	Adavosertib	sensitive	Phase I	27601554	Other	Therapeutic	C
TP53	MUT	mutant	Advanced Solid Tumor	AMG 232	resistant	Preclinical - Cell culture	25567130	Other	Therapeutic	D
TP53	MUT	mutant	Advanced Solid Tumor	Bevacizumab	sensitive	Clinical Study - Cohort	23670029	Other	Therapeutic	C
TP53	MUT	mutant	Advanced Solid Tumor	CTX-1	sensitive	Preclinical	26883273	Other	Therapeutic	D
TP53	MUT	mutant	Advanced Solid Tumor	Pazopanib + Vorinostat	sensitive	Phase I	25669829	Other	Therapeutic	C
TP53	MUT	mutant	Advanced Solid Tumor	Unspecified VEGFR inhibitor	sensitive	Clinical Study - Cohort	27466356	Other	Therapeutic	C
TP53	MUT	mutant	breast cancer	PK11007	sensitive	Preclinical - Cell culture	;	Breast	Therapeutic	D
TP53	MUT	mutant	breast carcinoma	Camptothecin + CHIR-124	predicted - sensitive	Preclinical - Cell culture	17255282	Breast	Therapeutic	D
TP53	MUT	mutant	chronic lymphocytic leukemia	Duvelisib	predicted - sensitive	Phase I	;	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	mutant	chronic lymphocytic leukemia	Ibrutinib + Venetoclax	predicted - sensitive	Phase II	;	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	mutant	CLL/SLL	Ibrutinib	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	MUT	mutant	CLL/SLL	Idelalisib + Rituximab	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	MUT	mutant	CLL/SLL	Rituximab + Venetoclax	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	MUT	mutant	CLL/SLL	Venetoclax	sensitive	Guideline	;	Blood	Therapeutic	A
TP53	MUT	mutant	colon carcinoma	Camptothecin + CHIR-124	predicted - sensitive	Preclinical - Cell culture	17255282	Colorectal	Therapeutic	D
TP53	MUT	mutant	colorectal cancer	Bevacizumab	sensitive	Phase III	17145525	Colorectal	Therapeutic	C
TP53	MUT	mutant	colorectal cancer	NSC59984	predicted - sensitive	Preclinical - Cell line xenograft	26294215	Colorectal	Therapeutic	D
TP53	MUT	mutant	colorectal cancer	Pazopanib + Vorinostat	sensitive	Phase I	25669829	Colorectal	Therapeutic	C
TP53	MUT	mutant	colorectal cancer	PD0166285	sensitive	Preclinical	11719452	Colorectal	Therapeutic	D
TP53	MUT	mutant	colorectal cancer	Prodigiosin	sensitive	Preclinical - Cell line xenograft	26759239	Colorectal	Therapeutic	D
TP53	MUT	mutant	essential thrombocythemia	N/A	not applicable	Guideline	;	Blood	Prognostic	A
TP53	MUT	mutant	fibrous histiocytoma	GDC-0575 + Gemcitabine	predicted - sensitive	Preclinical - Pdx	29409053	Soft_Tissue	Therapeutic	D
TP53	MUT	mutant	glioblastoma multiforme	Adavosertib + Radiotherapy	sensitive	Preclinical - Cell line xenograft	21992793	Brain	Therapeutic	D
TP53	MUT	mutant	glioblastoma multiforme	Adavosertib	sensitive	Preclinical - Pdx	27196784	Brain	Therapeutic	D
TP53	MUT	mutant	glioblastoma multiforme	AZD1390	sensitive	Preclinical - Cell culture	;	Brain	Therapeutic	D
TP53	MUT	mutant	head and neck squamous cell carcinoma	AZD7762 + Cisplatin	sensitive	Preclinical	23839309	Head_and_Neck	Therapeutic	D
TP53	MUT	mutant	head and neck squamous cell carcinoma	Buparlisib + Paclitaxel	predicted - sensitive	Phase II	29490986	Head_and_Neck	Therapeutic	C
TP53	MUT	mutant	hypopharynx cancer	unspecified EGFR antibody	resistant	Preclinical - Cell culture	27196767	Esophagus	Therapeutic	D
TP53	MUT	mutant	hypopharynx cancer	unspecified EGFR antibody + unspecified ERBB3 antibody	predicted - sensitive	Preclinical - Cell culture	27196767	Esophagus	Therapeutic	D
TP53	MUT	mutant	hypopharynx cancer	unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody	predicted - sensitive	Preclinical - Cell culture	27196767	Esophagus	Therapeutic	D
TP53	MUT	mutant	hypopharynx cancer	unspecified EGFR antibody + unspecified IGF-1R antibody	predicted - sensitive	Preclinical - Cell culture	27196767	Esophagus	Therapeutic	D
TP53	MUT	mutant	leukemia	RG7112	decreased response	Phase I	26459177	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	mutant	lung non-small cell carcinoma	CEP-8983 + Cisplatin	sensitive	Preclinical	23428903	Lung	Therapeutic	D
TP53	MUT	mutant	lung non-small cell carcinoma	Ipilimumab + Nivolumab	predicted - sensitive	Clinical Study - Cohort	31097096	Lung	Therapeutic	C
TP53	MUT	mutant	lung non-small cell carcinoma	Nivolumab	predicted - sensitive	Clinical Study - Cohort	31097096	Lung	Therapeutic	C
TP53	MUT	mutant	lung non-small cell carcinoma	Pembrolizumab	predicted - sensitive	Clinical Study - Cohort	31097096	Lung	Therapeutic	C
TP53	MUT	mutant	lung non-small cell carcinoma	Pembrolizumab	predicted - sensitive	Phase I	28039262	Lung	Therapeutic	C
TP53	MUT	mutant	medulloblastoma	JQ1	decreased response	Preclinical	24231268	Nervous_System	Therapeutic	D
TP53	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
TP53	MUT	mutant	neuroblastoma	GSK2830371	resistant	Preclinical	25658463	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	mutant	neuroblastoma	MI-63	resistant	Preclinical	21725357	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	mutant	neuroblastoma	Nutlin-3	resistant	Preclinical	21725357	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	mutant	ovarian cancer	Adavosertib + Carboplatin	predicted - sensitive	Phase II	27998224	Ovary	Therapeutic	C
TP53	MUT	mutant	ovarian cancer	Etoposide + Nutlin-3	sensitive	Preclinical	25964101	Ovary	Therapeutic	D
TP53	MUT	mutant	ovarian cancer	Nutlin-3	no benefit	Preclinical	25964101	Ovary	Therapeutic	D
TP53	MUT	mutant	ovarian clear cell adenocarcinoma	DS-7423	decreased response	Preclinical	24504419	Ovary	Therapeutic	D
TP53	MUT	mutant	ovarian serous carcinoma	thioureidobutyronitrile	sensitive	Preclinical - Cell culture	;	Ovary	Therapeutic	D
TP53	MUT	mutant	pharynx squamous cell carcinoma	AZD6738 + Radiotherapy	sensitive	Preclinical - Cell culture	28062704	Esophagus	Therapeutic	D
TP53	MUT	mutant	sarcoma	GDC-0575 + Gemcitabine	predicted - sensitive	Phase I	29409053	Soft_Tissue	Therapeutic	C
TP53	MUT	mutant	sarcoma	Pazopanib	sensitive	Clinical Study - Cohort	26646755	Soft_Tissue	Therapeutic	C
TP53	MUT	mutant	sarcoma	Pazopanib + Vorinostat	sensitive	Phase I	25669829	Soft_Tissue	Therapeutic	C
TP53	MUT	mutant	tongue squamous cell carcinoma	AZD6738 + Radiotherapy	sensitive	Preclinical - Cell culture	28062704	Esophagus	Therapeutic	D
TP53	MUT	mutant	triple-receptor negative breast cancer	Carboplatin + Nutlin-3	predicted - sensitive	Preclinical - Cell culture	26494859	Breast	Therapeutic	D
TP53	MUT	mutant	triple-receptor negative breast cancer	Doxorubicin + Seliciclib	predicted - sensitive	Preclinical - Cell line xenograft	26826118	Breast	Therapeutic	D
TP53	MUT	mutant	triple-receptor negative breast cancer	GDC-0425 + Gemcitabine	predicted - sensitive	Phase I	27815358	Breast	Therapeutic	C
TP53	MUT	mutation	Acute Myeloid Leukemia		Poor Outcome	B	26771088	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Adrenocortical Carcinoma		Poor Outcome	B	15922892	Adrenal_Gland	Prognostic	B
TP53	MUT	mutation	Advanced Solid Tumor	MVAp53	sensitive	Phase I	;	Other	Therapeutic	C
TP53	MUT	mutation	Advanced Solid Tumor	p28	predicted - sensitive	Phase I	23449360	Other	Therapeutic	C
TP53	MUT	mutation	Advanced Solid Tumor	Serdemetan	sensitive	Phase I	21831953	Other	Therapeutic	C
TP53	MUT	mutation	Breast Cancer	Doxorubicin	Sensitivity/Response	D	22698404	Breast	Therapeutic	D
TP53	MUT	mutation	breast cancer	Serdemetan	sensitive	Phase I	21831953	Breast	Therapeutic	C
TP53	MUT	mutation	Breast Cancer	Tamoxifen	Resistance	C	10786679	Breast	Therapeutic	C
TP53	MUT	mutation	Chronic Lymphocytic Leukemia	Alemtuzumab	Sensitivity/Response	B	14726385	Blood;Bone_Marrow	Therapeutic	B
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	A	26837699	Blood;Bone_Marrow	Prognostic	A
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	18689542	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	20697090	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	21483000	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	24943832	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Chronic Lymphocytic Leukemia		Poor Outcome	B	8241511	Blood;Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Esophagus Squamous Cell Carcinoma		Poor Outcome	B	19941080	Esophagus	Prognostic	B
TP53	MUT	mutation	Gastric Adenocarcinoma	Chemotherapy	Sensitivity/Response	B	24740294	Stomach	Therapeutic	B
TP53	MUT	mutation	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	11325447	Head_and_Neck	Prognostic	B
TP53	MUT	mutation	Lung Non-small Cell Carcinoma	Docetaxel	Resistance	D	22425996	Lung	Therapeutic	D
TP53	MUT	mutation	Lung Non-small Cell Carcinoma		N/A	B	28453411	Lung	Prognostic	B
TP53	MUT	mutation	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Sensitivity/Response	D	22425996	Lung	Therapeutic	D
TP53	MUT	mutation	Myelodysplastic Syndrome		Poor Outcome	B	24836762	Bone_Marrow	Prognostic	B
TP53	MUT	mutation	Myeloma		Poor Outcome	B	17215851	Bone_Marrow	Prognostic	B
TP53	MUT	mutation	ovarian cancer	NU6027 + Temozolomide	predicted - sensitive	Preclinical - Cell culture	21730979	Ovary	Therapeutic	D
TP53	MUT	mutation	Precursor B Lymphoblastic Lymphoma/leukemia		Poor Outcome	B	21747090	Blood;Bone_Marrow;Lymph_Nodes	Prognostic	B
TP53	MUT	mutation	Precursor B Lymphoblastic Lymphoma/leukemia		Poor Outcome	B	22699455	Blood;Bone_Marrow;Lymph_Nodes	Prognostic	B
TP53	MUT	mutation	Stomach Carcinoma	Etoposide,Cisplatin,Doxorubicin	Sensitivity/Response	C	14514923	Stomach	Therapeutic	C
TP53	MUT	oncogenic mutation	Acute myeloid leukemia;Myelodisplasic proliferative syndrome	Decitabine	Responsive	Early trials	27959731	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	oncogenic mutation	B cell lymphoma	AZD6738	Responsive	Early trials	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Lymph_Nodes	Therapeutic	C
TP53	MUT	oncogenic mutation	Bladder	Doxorubicin	Responsive	Pre-clinical	27397505	Bladder	Therapeutic	D
TP53	MUT	oncogenic mutation	Bladder	Gemcitabine	Responsive	Pre-clinical	27397505	Bladder	Therapeutic	D
TP53	MUT	oncogenic mutation	Bladder	Mitomycin C	Responsive	Pre-clinical	27397505	Bladder	Therapeutic	D
TP53	MUT	oncogenic mutation	Breast adenocarcinoma	Abemaciclib	Resistant	Early trials	27217383	Breast	Therapeutic	C
TP53	MUT	oncogenic mutation	Female germ cell tumor;Male germ cell tumor	Cisplatin	Resistant	Early trials	27646943	Ovary;Testis	Therapeutic	C
TP53	MUT	oncogenic mutation	Head an neck	[WEE1 inhibitor]	Responsive	Pre-clinical	25125259	Head_and_Neck	Therapeutic	D
TP53	MUT	oncogenic mutation	Liposarcoma	[MDM2 inhibitor]	Resistant	Early trials	23084521;ASCO 2015 (abstr 10564)	Soft_Tissue	Therapeutic	C
TP53	MUT	oncogenic mutation	Ovary	[WEE1 inhibitor]	Responsive	Early trials	27998224	Ovary	Therapeutic	C
TP53	MUT	oncogenic mutation	Thymic	Pramlintide	Responsive	Pre-clinical	25409149	Thymus	Therapeutic	D
TP53	MUT	P151H	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	P177T	osteosarcoma	Nutlin-3	resistant	Preclinical	21643018	Bone	Therapeutic	D
TP53	MUT	P278R	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	P47S	Cancer	Cisplatin	Resistance	E	27034505	Cancer	Therapeutic	D
TP53	MUT	P72R	breast cancer	Daunorubicin	predicted - sensitive	Phase I	16243804	Breast	Therapeutic	C
TP53	MUT	P72R	breast cancer	Daunoxome	predicted - sensitive	Phase I	16243804	Breast	Therapeutic	C
TP53	MUT	P72R	breast cancer	Epirubicin	sensitive	Phase I	22903472	Breast	Therapeutic	C
TP53	MUT	P72R	breast cancer	Pegylated liposomal-doxorubicin	predicted - sensitive	Phase I	16243804	Breast	Therapeutic	C
TP53	MUT	P72R	estrogen-receptor negative breast cancer	Cyclophosphamide + Doxorubicin + Fluorouracil	sensitive	Phase I	16243804	Breast	Therapeutic	C
TP53	MUT	P72R	lung non-small cell carcinoma	Cisplatin + Irinotecan	sensitive	Phase I	18618574	Lung	Therapeutic	C
TP53	MUT	P72R	sarcoma	Doxorubicin + Ifosfamide	sensitive	Phase I	23165797	Soft_Tissue	Therapeutic	C
TP53	MUT	P98A	lung non-small cell carcinoma	Seliciclib	decreased response	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	R158G	lung non-small cell carcinoma	Gedatolisib	sensitive	Preclinical	21325073;23980093	Lung	Therapeutic	D
TP53	MUT	R158H	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R158L	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R175H	Advanced Solid Tumor	Alvespimycin + Vorinostat	sensitive	Preclinical	26009011	Other	Therapeutic	D
TP53	MUT	R175H	Advanced Solid Tumor	ReACp53	sensitive	Preclinical	26748848	Other	Therapeutic	D
TP53	MUT	R175H	Any cancer type	[HSP90 inhibitor]	Responsive	Pre-clinical	26009011	Cancer	Therapeutic	D
TP53	MUT	R175H	Breast Cancer	Doxorubicin	Sensitivity/Response	D	22698404	Breast	Therapeutic	D
TP53	MUT	R175H	breast cancer	Ganetespib	sensitive	Preclinical - Cell culture	26009011	Breast	Therapeutic	D
TP53	MUT	R175H	breast cancer	NSC319726	sensitive	Preclinical - Cell culture	22624712	Breast	Therapeutic	D
TP53	MUT	R175H	Breast Cancer		Poor Outcome	B	16489069	Breast	Prognostic	B
TP53	MUT	R175H	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R175H	colorectal cancer	NSC59984	sensitive	Preclinical - Cell culture	26294215	Colorectal	Therapeutic	D
TP53	MUT	R175H	head and neck cancer	ReACp53	sensitive	Preclinical	26748848	Head_and_Neck	Therapeutic	D
TP53	MUT	R175H	lung non-small cell carcinoma	Seliciclib	resistant	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	R175H	ovarian cancer	NSC319726	sensitive	Preclinical - Cell culture	22624712	Ovary	Therapeutic	D
TP53	MUT	R175H	ovarian clear cell adenocarcinoma	DS-7423	decreased response	Preclinical - Cell culture	24504419	Ovary	Therapeutic	D
TP53	MUT	R175H	Stomach Carcinoma	EAP Protocol	Sensitivity/Response	C	14514923	Stomach	Therapeutic	C
TP53	MUT	R175L	colorectal cancer	NSC59984	sensitive	Preclinical - Cell culture	26294215	Colorectal	Therapeutic	D
TP53	MUT	R175L	lung large cell carcinoma	NSC319726	sensitive	Preclinical - Cell culture	22624712	Lung	Therapeutic	D
TP53	MUT	R213P	Stomach Carcinoma	EAP Protocol	Sensitivity/Response	C	14514923	Stomach	Therapeutic	C
TP53	MUT	R248Q	acute myeloid leukemia	ALRN-6924	resistant	Preclinical - Cell culture	29643228	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	R248Q	Advanced Solid Tumor	Ganetespib	sensitive	Preclinical	26009011	Other	Therapeutic	D
TP53	MUT	R248Q	Any cancer type	[HSP90 inhibitor]	Responsive	Pre-clinical	26009011	Cancer	Therapeutic	D
TP53	MUT	R248Q	Breast Cancer		Poor Outcome	B	16489069	Breast	Prognostic	B
TP53	MUT	R248Q	Breast Cancer		Poor Outcome	B	9569050	Breast	Prognostic	B
TP53	MUT	R248Q	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R248Q	colorectal cancer	Napabucasin	predicted - sensitive	Preclinical - Cell culture	30107178	Colorectal	Therapeutic	D
TP53	MUT	R248Q	colorectal cancer	Tanespimycin	sensitive	Preclinical	30107178	Colorectal	Therapeutic	D
TP53	MUT	R248Q	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical	26086967	Ovary	Therapeutic	D
TP53	MUT	R248Q	ovarian cancer	ReACp53	sensitive	Preclinical - Pdxcell culture	26748848	Ovary	Therapeutic	D
TP53	MUT	R248W	Breast Cancer		Poor Outcome	B	16489069	Breast	Prognostic	B
TP53	MUT	R248W	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R248W	lung non-small cell carcinoma	APR-246 + Cisplatin	sensitive	Preclinical	26086967	Lung	Therapeutic	D
TP53	MUT	R249	Breast Cancer	Doxorubicin	Sensitivity/Response	B	9569050	Breast	Therapeutic	B
TP53	MUT	R249	Breast Cancer		Poor Outcome	B	9569050	Breast	Prognostic	B
TP53	MUT	R249S	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R249S	hepatocellular carcinoma	CP-31398	sensitive	Preclinical - Cell line xenograft	26250460	Liver	Therapeutic	D
TP53	MUT	R273C	Breast Cancer		Poor Outcome	B	16489069	Breast	Prognostic	B
TP53	MUT	R273C	Breast Cancer		Poor Outcome	B	9569050	Breast	Prognostic	B
TP53	MUT	R273C	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R273H	Breast Cancer		Poor Outcome	B	16489069	Breast	Prognostic	B
TP53	MUT	R273H	Breast Cancer		Poor Outcome	B	9569050	Breast	Prognostic	B
TP53	MUT	R273H	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R273H	lung non-small cell carcinoma	APR-246 + Cisplatin	sensitive	Preclinical	26086967	Lung	Therapeutic	D
TP53	MUT	R273L	lung small cell carcinoma	APR-246	sensitive	Preclinical - Cell line xenograft	21415220	Lung	Therapeutic	D
TP53	MUT	R273L	Ovarian Cancer	Cisplatin,Carboplatin	Resistance	C	11595686	Ovary	Therapeutic	C
TP53	MUT	R273W	breast cancer	NSC319726	resistant	Preclinical - Cell culture	22624712	Breast	Therapeutic	D
TP53	MUT	R280K	breast cancer	Ganetespib	sensitive	Preclinical	26009011	Breast	Therapeutic	D
TP53	MUT	R280K	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R280K	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	R280K	triple-receptor negative breast cancer	YW3-56	sensitive	Preclinical - Cell line xenograft	25612620	Breast	Therapeutic	D
TP53	MUT	R280M	osteosarcoma	Nutlin-3	resistant	Preclinical	21643018	Bone	Therapeutic	D
TP53	MUT	R280T	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	R282L	Stomach Carcinoma	EAP Protocol	Sensitivity/Response	C	14514923	Stomach	Therapeutic	C
TP53	MUT	S215G	lung non-small cell carcinoma	Seliciclib	resistant	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	S241F	lung small cell carcinoma	APR-246	sensitive	Preclinical - Cell line xenograft	21415220	Lung	Therapeutic	D
TP53	MUT	S241F	ovarian cancer	Ganetespib	sensitive	Preclinical	26009011	Ovary	Therapeutic	D
TP53	MUT	S241F	ovarian clear cell adenocarcinoma	DS-7423	decreased response	Preclinical - Cell culture	24504419	Ovary	Therapeutic	D
TP53	MUT	TRUNCATING mutation	Head And Neck Squamous Cell Carcinoma		Poor Outcome	B	21467160	Head_and_Neck	Prognostic	B
TP53	MUT	V157F	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	V173M	acute myeloid leukemia	APR-246	predicted - sensitive	Phase I	22965953	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	WILDTYPE	acute leukemia	SAR405838	sensitive	Preclinical - Cell line xenograft	25145672	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	acute myeloid leukemia	ALRN-6924	sensitive	Preclinical - Patient cell culture	29643228	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	acute myeloid leukemia	CTX-1 + Nutlin-3	sensitive	Preclinical	26883273	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	acute myeloid leukemia	CTX-1	sensitive	Preclinical	26883273	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	acute myeloid leukemia	Cytarabine + RO6839921	sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	Acute myeloid leukemia	[HDM2 inhibitor]	Responsive	Early trials	AACR 2017 (abstr CT152)	Blood;Bone_Marrow	Therapeutic	C
TP53	MUT	WILDTYPE	acute myeloid leukemia	RO6839921	sensitive	Preclinical - Cell line xenograft	;	Blood;Bone_Marrow	Therapeutic	D
TP53	MUT	WILDTYPE	Advanced Solid Tumor	ALRN-6924	predicted - sensitive	Phase I	;	Other	Therapeutic	C
TP53	MUT	WILDTYPE	Advanced Solid Tumor	AMG 232	sensitive	Phase I	31359240	Other	Therapeutic	C
TP53	MUT	WILDTYPE	Advanced Solid Tumor	AMG 232	sensitive	Preclinical - Cell line xenograft	25567130	Other	Therapeutic	D
TP53	MUT	WILDTYPE	Advanced Solid Tumor	CTX-1 + Nutlin-3	sensitive	Preclinical	26883273	Other	Therapeutic	D
TP53	MUT	WILDTYPE	Advanced Solid Tumor	CTX-1	sensitive	Preclinical	26883273	Other	Therapeutic	D
TP53	MUT	WILDTYPE	Advanced Solid Tumor	HDM201	sensitive	Preclinical - Cell line xenograft	;	Other	Therapeutic	D
TP53	MUT	WILDTYPE	Advanced Solid Tumor	MK-8242	unknown	Phase I	28240971	Other	Therapeutic	C
TP53	MUT	WILDTYPE	Advanced Solid Tumor	Pazopanib + Vorinostat	decreased response	Phase I	;	Other	Therapeutic	C
TP53	MUT	WILDTYPE	breast cancer	AMG 232 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	26162687	Breast	Therapeutic	D
TP53	MUT	WILDTYPE	breast cancer	AMG 232	sensitive	Preclinical - Cell culture	26162687	Breast	Therapeutic	D
TP53	MUT	WILDTYPE	breast cancer	SAR405838	predicted - sensitive	Preclinical - Pdx	27765850	Breast	Therapeutic	D
TP53	MUT	WILDTYPE	Cancer	AMGMDS3	Sensitivity/Response	D	25730903	Cancer	Therapeutic	D
TP53	MUT	WILDTYPE	Cancer	Nutlin-3a	Sensitivity/Response	D	17671205	Cancer	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	Adavosertib + PF-00477736	sensitive	Preclinical	22713237	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	AMG 232 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	26162687	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	AMG 232	sensitive	Preclinical - Cell culture	26162687	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	CPUY201112	sensitive	Preclinical	26743233	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	SAR405838	sensitive	Preclinical - Cell line xenograft	25145672	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon cancer	Trifluridine	sensitive	Preclinical - Cell culture	25700705	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colon carcinoma	MPI-0479605	sensitive	Preclinical	21980130	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colorectal cancer	ALRN-6924	sensitive	Phase I	;	Colorectal	Therapeutic	C
TP53	MUT	WILDTYPE	Colorectal Cancer	Cetuximab,Capecitabine,Oxaliplatin	Sensitivity/Response	B	24957073	Colorectal	Therapeutic	B
TP53	MUT	WILDTYPE	colorectal cancer	MK-8745	predicted - sensitive	Preclinical - Cell culture	22293494	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colorectal cancer	PD-0325901 + Sapanisertib	predicted - sensitive	Preclinical - Pdxcell culture	26272063	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	colorectal cancer	Prodigiosin	sensitive	Preclinical	26759239	Colorectal	Therapeutic	D
TP53	MUT	WILDTYPE	endometrioid ovary carcinoma	thioureidobutyronitrile	sensitive	Preclinical - Cell line xenograft	;	Ovary	Therapeutic	D
TP53	MUT	WILDTYPE	Esophageal Carcinoma	Chemotherapy	Sensitivity/Response	B	23515910	Esophagus	Therapeutic	B
TP53	MUT	WILDTYPE	fibrosarcoma	Pegylated liposomal-doxorubicin + RO6839921	sensitive	Preclinical - Cell line xenograft	;	Soft_Tissue	Therapeutic	D
TP53	MUT	WILDTYPE	Leukemia	RG7112	Sensitivity/Response	B	26459177	Blood;Bone_Marrow	Therapeutic	B
TP53	MUT	WILDTYPE	liposarcoma	ALRN-6924	sensitive	Phase I	;	Soft_Tissue	Therapeutic	C
TP53	MUT	WILDTYPE	liposarcoma	MK-8242	predicted - sensitive	Phase I	28240971	Soft_Tissue	Therapeutic	C
TP53	MUT	WILDTYPE	lung cancer	AMG 232 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	26162687	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung cancer	AMG 232	sensitive	Preclinical - Cell culture	26162687	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung carcinoma	AZD6738 + Radiotherapy	sensitive	Preclinical - Cell culture	28062704	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung large cell carcinoma	NSC319726	resistant	Preclinical - Cell line xenograft	22624712	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy	Sensitivity/Response	B	26899019	Lung	Therapeutic	B
TP53	MUT	WILDTYPE	lung non-small cell carcinoma	AMG 232 + Carboplatin	sensitive	Preclinical - Cell line xenograft	25567130	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung non-small cell carcinoma	AMG 232 + Cisplatin	sensitive	Preclinical - Cell line xenograft	25567130	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung non-small cell carcinoma	AMG 232	sensitive	Preclinical - Cell line xenograft	25567130	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung non-small cell carcinoma	CEP-8983 + Cisplatin	sensitive	Preclinical	23428903	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lung non-small cell carcinoma	Seliciclib	sensitive	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	WILDTYPE	lymphoma	ALRN-6924	predicted - sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
TP53	MUT	WILDTYPE	medulloblastoma	JQ1	sensitive	Preclinical	24231268	Nervous_System	Therapeutic	D
TP53	MUT	WILDTYPE	melanoma	AMG 232 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	26162687	Skin	Therapeutic	D
TP53	MUT	WILDTYPE	melanoma	AMG 232	sensitive	Preclinical - Cell culture	26162687	Skin	Therapeutic	D
TP53	MUT	WILDTYPE	melanoma	APR-246	sensitive	Preclinical - Cell line xenograft	21239882	Skin	Therapeutic	D
TP53	MUT	WILDTYPE	Merkel cell carcinoma	ALRN-6924	sensitive	Phase I	;	Skin	Therapeutic	C
TP53	MUT	WILDTYPE	neuroblastoma	Carboplatin + GSK2830371	predicted - sensitive	Preclinical	25658463	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	WILDTYPE	neuroblastoma	Doxorubicin + GSK2830371	predicted - sensitive	Preclinical	25658463	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	WILDTYPE	neuroblastoma	GSK2830371	predicted - sensitive	Preclinical	25658463	Adrenal_Gland;Nervous_System	Therapeutic	D
TP53	MUT	WILDTYPE	osteosarcoma	AMG 232 + Radiotherapy	sensitive	Preclinical - Cell line xenograft	26162687	Bone	Therapeutic	D
TP53	MUT	WILDTYPE	osteosarcoma	AMG 232	sensitive	Preclinical - Cell culture	26162687	Bone	Therapeutic	D
TP53	MUT	WILDTYPE	osteosarcoma	CPUY201112	sensitive	Preclinical	26743233	Bone	Therapeutic	D
TP53	MUT	WILDTYPE	ovarian cancer	Ad.p53-DC vaccine	predicted - sensitive	Phase I	12082455;19621448;21927947;15297186;12082456	Ovary	Therapeutic	C
TP53	MUT	WILDTYPE	ovarian cancer	p53-SLP vaccine	no benefit	Phase II	21328579;19621448	Ovary	Therapeutic	C
TP53	MUT	WILDTYPE	papillary thyroid carcinoma	APG-115	sensitive	Preclinical - Cell line xenograft	28498808	Thyroid	Therapeutic	D
TP53	MUT	WILDTYPE	peripheral T-cell lymphoma	ALRN-6924	sensitive	Phase I	;	Lymph_Nodes	Therapeutic	C
TP53	MUT	WILDTYPE	prostate cancer	SAR405838	sensitive	Preclinical - Cell line xenograft	25145672	Prostate	Therapeutic	D
TP53	MUT	WILDTYPE	salivary gland adenoid cystic carcinoma	Cisplatin + SAR405838	predicted - sensitive	Preclinical - Pdx	27550999	Esophagus	Therapeutic	D
TP53	MUT	WILDTYPE	salivary gland adenoid cystic carcinoma	SAR405838	predicted - sensitive	Preclinical - Pdx	26936915	Esophagus	Therapeutic	D
TP53	MUT	WILDTYPE	sarcoma	Adavosertib + Gemcitabine	sensitive	Preclinical - Pdxcell culture	23520471	Soft_Tissue	Therapeutic	D
TP53	MUT	Y163C	lung small cell carcinoma	APR-246 + Cisplatin	sensitive	Preclinical	26086967	Lung	Therapeutic	D
TP53	MUT	Y163H	ovarian cancer	APR-246 + Cisplatin	sensitive	Preclinical - Patient cell culture	27179933	Ovary	Therapeutic	D
TP53	MUT	Y163X	ovarian cancer	Adavosertib + Carboplatin	predicted - sensitive	Phase II	27998224	Ovary	Therapeutic	C
TP53	MUT	Y220C	Cancer	AMGMDS3	Resistance	D	25730903	Cancer	Therapeutic	D
TP53	MUT	Y220C	hepatocellular carcinoma	CP-31398	sensitive	Preclinical - Cell culture	26250460	Liver	Therapeutic	D
TP53	MUT	Y220C	lung non-small cell carcinoma	Seliciclib	resistant	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	Y220C	Stomach Carcinoma	Cisplatin,Etoposide,Mitomycin	Sensitivity/Response	C	14514923	Stomach	Therapeutic	C
TP53	MUT	Y234C	lung non-small cell carcinoma	Seliciclib	decreased response	Preclinical - Cell culture	22862161	Lung	Therapeutic	D
TP53	MUT	Y234C	Ovarian Cancer	Cisplatin,Carboplatin	Resistance	C	11595686	Ovary	Therapeutic	C
TP53	MUT	Y234C	ovarian carcinoma	ReACp53	sensitive	Preclinical	26748848	Ovary	Therapeutic	D
TP53	MUT	Y327L	ovarian carcinoma	ReACp53	sensitive	Preclinical	26748848	Ovary	Therapeutic	D
TSC1	CNV	deletion	Renal	Everolimus	Responsive	Case report	24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	Kidney	Therapeutic	D
TSC1	MUT	any missense	Adenocarcinoma/Urothelial Carcinoma/Renal Cell Carcinoma/Clear Cell Renal Cell Carcinoma in Lung/Kidney/Bladder			2	19602587,22923433,21533174,21533174,24593867	Bladder;Kidney;Lung	Therapeutic	C
TSC1	MUT	any frameshift	Invasive Bladder Transitional Cell Carcinoma	Everolimus	Sensitivity/Response	B	22923433	Bladder	Therapeutic	B
TSC1	MUT	any frameshift	Lung Non-small Cell Carcinoma	Rapamycin (Sirolimus)	Sensitivity/Response	D	19966866	Lung	Therapeutic	D
TSC1	MUT	LOSS-OF-FUNCTION	Bladder Carcinoma	Everolimus	Sensitivity/Response	B	22923433	Bladder	Therapeutic	B
TSC1	MUT	oncogenic mutation	Bladder	Everolimus	Responsive	Early trials	22923433	Bladder	Therapeutic	C
TSC1	MUT	oncogenic mutation	Giant cell astrocytoma	Everolimus	Responsive	FDA guidelines	FDA	Brain	Therapeutic	A
TSC1	MUT	oncogenic mutation	Renal angiomyolipoma	Everolimus	Responsive	FDA guidelines	FDA	Kidney	Therapeutic	A
TSC1	MUT	oncogenic mutation	Renal angiomyolipoma	[MTOR inhibitor]	Responsive	Early trials	23312829;21525172;20048174	Kidney	Therapeutic	C
TSC1	MUT	oncogenic mutation	Renal	Everolimus	Responsive	Case report	24622468;26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	Kidney	Therapeutic	D
TSC1	MUT	oncogenic mutation	Sarcoma;Stomach	Everolimus	Responsive	Case report	26859683	Other;Stomach	Therapeutic	D
TSC1	MUT	Oncogenic Mutations	CNS Cancer	Everolimus	Response	1	23158522	Nervous_System	Therapeutic	A
TSC1	MUT	Oncogenic Mutations	Renal Cell Carcinoma	Everolimus	Response	2A	30327302, 26831717	Kidney	Therapeutic	B
TSC2	CNV	deletion	Lymphangioleiomyomatosis	[SRC inhibitor]	Responsive	Pre-clinical	24691995	Other	Therapeutic	D
TSC2	MUT	any missense	Adenocarcinoma/Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma/Urothelial Carcinoma in Lung/Kidney/Bladder			2	19602587,22923433,21533174,21533174,24593867	Bladder;Kidney;Lung	Therapeutic	C
TSC2	MUT	E66K	Endometrium	Tensirolimus	Responsive	Case report	27016228	Uterus	Therapeutic	D
TSC2	MUT	oncogenic mutation	Bladder	Everolimus	Responsive	Early trials	22923433	Bladder	Therapeutic	C
TSC2	MUT	oncogenic mutation	Lymphangioleiomyomatosis	[SRC inhibitor]	Responsive	Pre-clinical	24691995	Other	Therapeutic	D
TSC2	MUT	oncogenic mutation	Renal angiomyolipoma;Giant cell astrocytoma	Everolimus	Responsive	FDA guidelines	FDA	Brain;Kidney	Therapeutic	A
TSC2	MUT	oncogenic mutation	Renal angiomyolipoma	[MTOR inhibitor]	Responsive	Early trials	23312829;21525172;20048174	Kidney	Therapeutic	C
TSC2	MUT	Oncogenic Mutations	CNS Cancer	Everolimus	Response	1	23158522	Nervous_System	Therapeutic	A
TSC2	MUT	Oncogenic Mutations	Renal Cell Carcinoma	Everolimus	Response	2A	30327302, 26831717	Kidney	Therapeutic	B
TSC2	MUT	Q1178X	Thyroid carcinoma	Everolimus	Responsive	Case report	25295501	Thyroid	Therapeutic	D
TSC2	MUT	Q1178X	Thyroid Gland Carcinoma	Everolimus	Sensitivity/Response	C	25295501	Thyroid	Therapeutic	C
TUBB3	EXP	EXPRESSION	Breast Cancer	Taxane	Sensitivity/Response	B	23218766	Breast	Therapeutic	B
TUBB3	EXP	EXPRESSION	Cancer	Paclitaxel	Resistance	D	21576762	Cancer	Therapeutic	D
TUBB3	EXP	overexpression	Bladder	Paclitaxel	Resistant	Pre-clinical	23184177	Bladder	Therapeutic	D
TYMS	CNV	AMPLIFICATION	Lung Adenocarcinoma	Pemetrexed	Resistance	B	23645741	Lung	Therapeutic	B
TYMS	EXP	EXPRESSION	Gastric Adenocarcinoma	Raltitrexed	Resistance	B	22422354	Stomach	Therapeutic	B
TYMS	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed	Resistance	B	23060591	Lung	Therapeutic	B
TYMS	EXP	EXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed	Resistance	B	26502926	Lung	Therapeutic	B
TYMS	EXP	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed	Sensitivity/Response	B	21367480	Lung	Therapeutic	B
TYMS	EXP	UNDEREXPRESSION	Prostate Cancer	Pemetrexed	Sensitivity/Response	C	24782778	Prostate	Therapeutic	C
TYMS	OTH	5' TANDEM REPEAT	Colorectal Cancer	5-fluorouracil,Irinotecan	Resistance	B	20628391	Colorectal	Therapeutic	B
U2AF1	MUT	codon(s) 157 missense	Myeloproliferative Neoplasm/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23861105,23335386,22389253,22158538,21909114,23645565	Blood;Bone_Marrow	Therapeutic	B
U2AF1	MUT	codon(s) 34 missense	Myeloproliferative Neoplasm/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia in Blood/Bone Marrow			1	23861105,23335386,22389253,22158538,21909114,23645565	Blood;Bone_Marrow	Therapeutic	B
U2AF1	MUT	mutant	essential thrombocythemia	N/A	not applicable	Guideline	;	Blood	Prognostic	A
U2AF1	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
U2AF1	MUT	mutation	Myelofibrosis		Poor Outcome	B	27058230	Bone_Marrow	Prognostic	B
U2AF1	MUT	oncogenic mutation	Any cancer type	[FLT3 inhibitor]	Responsive	Pre-clinical	27397505	Cancer	Therapeutic	D
U2AF1	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
U2AF1	MUT	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
U2AF1	MUT	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800	Response	4	29457796	Bone_Marrow	Therapeutic	D
U2AF1	MUT	Q157P	Myelodysplastic Syndrome		Poor Outcome	B	23861105	Bone_Marrow	Prognostic	B
U2AF1	MUT	Q157R	Myelodysplastic Syndrome		Poor Outcome	B	23861105	Bone_Marrow	Prognostic	B
U2AF1	MUT	Q157X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
U2AF1	MUT	S34F	lung cancer	H3B-8800	sensitive	Preclinical - Cell line xenograft	;	Lung	Therapeutic	D
U2AF1	MUT	S34X	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
U2AF1	MUT	S34Y	Myelodysplastic Syndrome		Poor Outcome	B	23861105	Bone_Marrow	Prognostic	B
U2AF1	MUT	S34F	Myelodysplastic Syndrome		Poor Outcome	B	23861105	Bone_Marrow	Prognostic	B
U2AF2	MUT	any mutation	Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			2	23645565	Blood;Bone_Marrow	Therapeutic	C
UGT1A1	MUT	UGT1A1*28	Cancer	Belinostat	Adverse Response	A	26313268	Cancer	Therapeutic	A
UGT1A1	MUT	UGT1A1*60	Cancer	Belinostat	Adverse Response	B	26313268	Cancer	Therapeutic	B
UGT1A	EXP	EXPRESSION	Colorectal Cancer	Ganetespib	Resistance	D	25210794	Colorectal	Therapeutic	D
VEGFA	CNV	amplification	Hepatic carcinoma	Sorafenib	Responsive	Early trials	24687604	Liver	Therapeutic	C
VEGFA	EXP	UNDEREXPRESSION	Colorectal Cancer	L-Folinic Acid,Bevacizumab,Irinotecan,5-fluorouracil	Sensitivity/Response	B	25973082	Colorectal	Therapeutic	B
VHL	CNV	3p26.3-25.3 11Mb del	Von Hippel-Lindau Disease		Positive	C	26365017	Other	Diagnostic	C
VHL	CNV	del	renal cell carcinoma	Regorafenib	predicted - sensitive	Preclinical - Cell line xenograft	21170960	Kidney	Therapeutic	D
VHL	CNV	LOSS	Renal Carcinoma	Temsirolimus	Sensitivity/Response	D	16341243	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	Bevacizumab	sensitive	Preclinical	22931246	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	BPTES + Olaparib	sensitive	Preclinical - Cell culture	28346230	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	BPTES	sensitive	Preclinical - Cell culture	28346230	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	CB-839 + Olaparib	sensitive	Preclinical - Cell line xenograft	28346230	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	CB-839	sensitive	Preclinical - Cell culture	28346230	Kidney	Therapeutic	D
VHL	CNV	loss	renal cell carcinoma	ELR510444	sensitive	Preclinical - Cell line xenograft	22295124	Kidney	Therapeutic	D
VHL	EXP	OVEREXPRESSION	clear cell renal cell carcinoma	Cediranib + Saracatinib	no benefit	Phase II	26802156	Kidney	Therapeutic	C
VHL	MUT	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma in Kidney			1	23036577,24166983,25365943,24359990	Kidney	Therapeutic	B
VHL	MUT	E70K 	Von Hippel-Lindau Disease		Positive	C	25715769	Other	Diagnostic	C
VHL	MUT	LOSS-OF-FUNCTION	Clear Cell Renal Cell Carcinoma		Poor Outcome	B	11793370	Kidney	Prognostic	B
VHL	MUT	LOSS-OF-FUNCTION	clear cell renal cell carcinoma	PT2399	conflicting	Preclinical - Pdx	27595393	Kidney	Therapeutic	D
VHL	MUT	LOSS-OF-FUNCTION	renal cell carcinoma	Alpha 2 Interferon + Bevacizumab	predicted - sensitive	Clinical Study - Cohort	16827904	Kidney	Therapeutic	C
VHL	MUT	LOSS-OF-FUNCTION	renal cell carcinoma	Everolimus	predicted - sensitive	Phase II	26951309	Kidney	Therapeutic	C
VHL	MUT	LOSS-OF-FUNCTION	renal cell carcinoma	GDC-0980	no benefit	Phase II	26951309	Kidney	Therapeutic	C
VHL	MUT	mutant	renal cell carcinoma	Everolimus	sensitive	Phase I	;	Kidney	Therapeutic	C
VHL	MUT	mutant	renal cell carcinoma	N/A	no benefit	Clinical Study	28103578	Kidney	Prognostic	C
VHL	MUT	mutant	renal cell carcinoma	Sunitinib	predicted - sensitive	Phase I	22105611	Kidney	Therapeutic	C
VHL	MUT	mutation	Clear Cell Renal Cell Carcinoma		Better Outcome	B	18464292	Kidney	Prognostic	B
VHL	MUT	mutation	Clear Cell Renal Cell Carcinoma		N/A	B	23620406	Kidney	Prognostic	B
VHL	MUT	mutation	Renal Cell Carcinoma	Everolimus	Sensitivity/Response	B	26951309	Kidney	Therapeutic	B
VHL	MUT	mutation	Renal Cell Carcinoma	VEGF Inhibition	Resistance	B	28103578	Kidney	Therapeutic	B
VHL	MUT	oncogenic mutation	Renal	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	Responsive	Pre-clinical	18635227	Kidney	Therapeutic	D
VHL	MUT	R167Q 	Von Hippel-Lindau Disease		Positive	C	29396065	Other	Diagnostic	C
VHL	MUT	R200W 	Chuvash Polycythemia	Ruxolitinib	Sensitivity/Response	C	27518686	Blood	Therapeutic	C
VHL	MUT	V155fs	kidney cancer	Sunitinib + Trametinib	predicted - sensitive	Preclinical - Pdx	26487278	Kidney	Therapeutic	D
VPS37A	EXP	UNDEREXPRESSION	Ovarian Cancer	Cetuximab	Resistance	D	22016507	Ovary	Therapeutic	D
WHSC1	MUT	any mutation	B Lymphoblastic Leukemia/Lymphoma in Blood/Bone Marrow			1	24076604,23823660	Blood;Bone_Marrow	Therapeutic	B
WT1	MUT	any mutation	Acute Myeloid Leukemia in Blood/Bone Marrow			1	18559874,23929217,19221039,23697841	Blood;Bone_Marrow	Therapeutic	B
WT1	MUT	exon(s) 7 mutation	Acute Myeloid Leukemia	Daunorubicin,Cytarabine	Resistance	B	18591546	Blood;Bone_Marrow	Therapeutic	B
WT1	MUT	exon(s) 7 mutation	Acute Myeloid Leukemia		Poor Outcome	B	18559874	Blood;Bone_Marrow	Prognostic	B
WT1	MUT	exon(s) 7 mutation	Acute Myeloid Leukemia		Poor Outcome	B	18591546	Blood;Bone_Marrow	Prognostic	B
WT1	MUT	exon(s) 7 mutation	Acute Myeloid Leukemia		Poor Outcome	B	19221039	Blood;Bone_Marrow	Prognostic	B
WT1	MUT	exon(s) 7 mutation	Acute Myeloid Leukemia		Poor Outcome	B	19536888	Blood;Bone_Marrow	Prognostic	B
WT1	MUT	exon(s) 9 mutation	Acute Myeloid Leukemia		Poor Outcome	B	18559874	Blood;Bone_Marrow	Prognostic	B
WWTR1	FUS	WWTR1-CAMTA1	Epithelioid Hemangioendothelioma		Positive	B	21584898	Soft_Tissue	Diagnostic	B
XPO1	MUT	any mutation	Chronic Lymphocytic Leukemia in Blood/Bone Marrow			1	24113472,23034282,21642962	Blood;Bone_Marrow	Therapeutic	B
XRCC1	MUT	Q399R	Cervical Cancer	Cisplatin,Carboplatin	Sensitivity/Response	B	16875718	Cervix	Therapeutic	B
XRCC1	MUT	Q399R	Lung Non-small Cell Carcinoma		Better Outcome	B	22551904	Lung	Prognostic	B
XRCC1	MUT	R194W	Lung Non-small Cell Carcinoma	Gemcitabine,Vinorelbine,Docetaxel	Sensitivity/Response	B	19157633	Lung	Therapeutic	B
ZBTB16	EXP	undexpression	Prostate adenocarcinoma	[LHRH analogues, antagonist]	Resistant	Pre-clinical	16637071	Prostate	Therapeutic	D
ZEB1	EXP	EXPRESSION	Mantle Cell Lymphoma	Doxorubicin,Cytarabine,Gemcitabine	Resistance	D	24013721	Lymph_Nodes	Therapeutic	D
ZEB1	EXP	EXPRESSION	Mantle Cell Lymphoma	Doxorubicin,Salinomycin	Sensitivity/Response	D	24013721	Lymph_Nodes	Therapeutic	D
ZNRF3	MUT	oncogenic mutation	Colorectal adenocarcinoma	[Porcupine inhibitor]	Responsive	Pre-clinical	26023187	Colorectal	Therapeutic	D
ZRSR2	MUT	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia in Blood/Bone Marrow			1	21909114,23645565,22389253,22343920	Blood;Bone_Marrow	Therapeutic	B
ZRSR2	MUT	mutant	myelodysplastic syndrome	N/A	not applicable	Guideline	;	Bone_Marrow	Prognostic	A
ZRSR2	MUT	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
ZRSR2	MUT	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800	Response	4	29457796	Blood;Bone_Marrow	Therapeutic	D
ZRSR2	MUT	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800	Response	4	29457796	Bone_Marrow	Therapeutic	D
